CA2893359A1 - Protein expression enhancing polypeptides - Google Patents
Protein expression enhancing polypeptides Download PDFInfo
- Publication number
- CA2893359A1 CA2893359A1 CA2893359A CA2893359A CA2893359A1 CA 2893359 A1 CA2893359 A1 CA 2893359A1 CA 2893359 A CA2893359 A CA 2893359A CA 2893359 A CA2893359 A CA 2893359A CA 2893359 A1 CA2893359 A1 CA 2893359A1
- Authority
- CA
- Canada
- Prior art keywords
- protein
- domain
- seq
- expression
- fusion protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 1014
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 943
- 230000014509 gene expression Effects 0.000 title claims abstract description 440
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 247
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 240
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 234
- 230000002708 enhancing effect Effects 0.000 title claims abstract description 164
- 108020001507 fusion proteins Proteins 0.000 claims abstract description 555
- 102000037865 fusion proteins Human genes 0.000 claims abstract description 536
- 230000027455 binding Effects 0.000 claims abstract description 146
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 94
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 91
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 91
- 230000004927 fusion Effects 0.000 claims abstract description 77
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 40
- 201000010099 disease Diseases 0.000 claims abstract description 34
- 235000018102 proteins Nutrition 0.000 claims description 461
- 239000013604 expression vector Substances 0.000 claims description 94
- 102000012605 Cystic Fibrosis Transmembrane Conductance Regulator Human genes 0.000 claims description 77
- 108010079245 Cystic Fibrosis Transmembrane Conductance Regulator Proteins 0.000 claims description 77
- 238000000034 method Methods 0.000 claims description 73
- 239000013598 vector Substances 0.000 claims description 65
- 150000001413 amino acids Chemical group 0.000 claims description 60
- 101710101803 DNA-binding protein J Proteins 0.000 claims description 54
- 235000001014 amino acid Nutrition 0.000 claims description 48
- 229940024606 amino acid Drugs 0.000 claims description 48
- 102000005962 receptors Human genes 0.000 claims description 48
- 108020003175 receptors Proteins 0.000 claims description 48
- 239000012634 fragment Substances 0.000 claims description 45
- 230000004186 co-expression Effects 0.000 claims description 42
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 33
- 230000028327 secretion Effects 0.000 claims description 24
- 239000003446 ligand Substances 0.000 claims description 23
- 239000002753 trypsin inhibitor Substances 0.000 claims description 23
- 230000002950 deficient Effects 0.000 claims description 20
- 102000036639 antigens Human genes 0.000 claims description 18
- 108091007433 antigens Proteins 0.000 claims description 18
- 239000000427 antigen Substances 0.000 claims description 17
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 claims description 15
- 102100031675 DnaJ homolog subfamily C member 5 Human genes 0.000 claims description 14
- 238000012258 culturing Methods 0.000 claims description 14
- 230000004853 protein function Effects 0.000 claims description 14
- 108010016626 Dipeptides Proteins 0.000 claims description 12
- 230000007812 deficiency Effects 0.000 claims description 11
- 238000003259 recombinant expression Methods 0.000 claims description 11
- 108091008324 binding proteins Proteins 0.000 claims description 10
- 102000004127 Cytokines Human genes 0.000 claims description 9
- 108090000695 Cytokines Proteins 0.000 claims description 9
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 9
- 208000024827 Alzheimer disease Diseases 0.000 claims description 8
- 208000023105 Huntington disease Diseases 0.000 claims description 8
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 8
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 8
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 8
- 102000000470 PDZ domains Human genes 0.000 claims description 8
- 108050008994 PDZ domains Proteins 0.000 claims description 8
- 208000018737 Parkinson disease Diseases 0.000 claims description 8
- 208000014675 Prion-associated disease Diseases 0.000 claims description 8
- 235000004279 alanine Nutrition 0.000 claims description 8
- 108020001756 ligand binding domains Proteins 0.000 claims description 8
- 108010026228 mRNA guanylyltransferase Proteins 0.000 claims description 8
- 101710128836 Large T antigen Proteins 0.000 claims description 7
- 101710120037 Toxin CcdB Proteins 0.000 claims description 7
- 108010059354 cysteine string protein Proteins 0.000 claims description 7
- 229930182817 methionine Natural products 0.000 claims description 7
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 7
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 6
- 230000002103 transcriptional effect Effects 0.000 claims description 6
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 6
- 239000004475 Arginine Substances 0.000 claims description 5
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 5
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 5
- 239000004472 Lysine Substances 0.000 claims description 5
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 5
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 5
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 5
- 229960000310 isoleucine Drugs 0.000 claims description 5
- 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 claims description 5
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 5
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 4
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 4
- 108010057085 cytokine receptors Proteins 0.000 claims description 4
- 102000003675 cytokine receptors Human genes 0.000 claims description 4
- 239000004474 valine Substances 0.000 claims description 4
- 102000023732 binding proteins Human genes 0.000 claims 6
- 239000002253 acid Substances 0.000 claims 1
- 208000006682 alpha 1-Antitrypsin Deficiency Diseases 0.000 claims 1
- 230000006870 function Effects 0.000 abstract description 32
- 210000004027 cell Anatomy 0.000 description 355
- 125000003275 alpha amino acid group Chemical group 0.000 description 156
- 239000013612 plasmid Substances 0.000 description 69
- 239000001963 growth medium Substances 0.000 description 45
- 108020004414 DNA Proteins 0.000 description 44
- 238000002474 experimental method Methods 0.000 description 38
- 102000004447 HSP40 Heat-Shock Proteins Human genes 0.000 description 36
- 108010042283 HSP40 Heat-Shock Proteins Proteins 0.000 description 35
- 230000000694 effects Effects 0.000 description 35
- 238000004458 analytical method Methods 0.000 description 34
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 31
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 31
- 239000002299 complementary DNA Substances 0.000 description 27
- 238000003556 assay Methods 0.000 description 26
- 238000000326 densiometry Methods 0.000 description 25
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 24
- 102000003816 Interleukin-13 Human genes 0.000 description 23
- 108090000176 Interleukin-13 Proteins 0.000 description 23
- 238000001262 western blot Methods 0.000 description 23
- 239000002609 medium Substances 0.000 description 21
- 101100507655 Canis lupus familiaris HSPA1 gene Proteins 0.000 description 19
- 102000053602 DNA Human genes 0.000 description 19
- 102000035195 Peptidases Human genes 0.000 description 19
- 108091005804 Peptidases Proteins 0.000 description 19
- 102000001708 Protein Isoforms Human genes 0.000 description 19
- 108010029485 Protein Isoforms Proteins 0.000 description 19
- 238000001415 gene therapy Methods 0.000 description 19
- 239000013592 cell lysate Substances 0.000 description 18
- 239000005090 green fluorescent protein Substances 0.000 description 18
- 239000000203 mixture Substances 0.000 description 17
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 16
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 16
- 108060003951 Immunoglobulin Proteins 0.000 description 16
- 239000004365 Protease Substances 0.000 description 16
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 16
- 238000010586 diagram Methods 0.000 description 16
- 102000018358 immunoglobulin Human genes 0.000 description 16
- 238000010367 cloning Methods 0.000 description 15
- 102100027954 BAG family molecular chaperone regulator 3 Human genes 0.000 description 14
- 241000196324 Embryophyta Species 0.000 description 14
- 101000697871 Homo sapiens BAG family molecular chaperone regulator 3 Proteins 0.000 description 14
- 230000001413 cellular effect Effects 0.000 description 14
- 102000003390 tumor necrosis factor Human genes 0.000 description 14
- 101710081722 Antitrypsin Proteins 0.000 description 12
- 108010006519 Molecular Chaperones Proteins 0.000 description 12
- 230000001475 anti-trypsic effect Effects 0.000 description 12
- 230000003190 augmentative effect Effects 0.000 description 12
- 230000001965 increasing effect Effects 0.000 description 12
- 238000003780 insertion Methods 0.000 description 12
- 230000037431 insertion Effects 0.000 description 12
- 238000001890 transfection Methods 0.000 description 12
- 238000003119 immunoblot Methods 0.000 description 11
- 239000012528 membrane Substances 0.000 description 11
- 230000003834 intracellular effect Effects 0.000 description 10
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- -1 1 to 10 amino acids Chemical class 0.000 description 9
- 238000001514 detection method Methods 0.000 description 9
- 101150115114 dnaJ gene Proteins 0.000 description 9
- 230000035772 mutation Effects 0.000 description 9
- 230000012846 protein folding Effects 0.000 description 9
- 108091026890 Coding region Proteins 0.000 description 8
- 102000008300 Mutant Proteins Human genes 0.000 description 8
- 108010021466 Mutant Proteins Proteins 0.000 description 8
- 102100029447 Na(+)/H(+) exchange regulatory cofactor NHE-RF1 Human genes 0.000 description 8
- 230000006872 improvement Effects 0.000 description 8
- 241000894007 species Species 0.000 description 8
- 230000009261 transgenic effect Effects 0.000 description 8
- 102100027955 BAG family molecular chaperone regulator 4 Human genes 0.000 description 7
- 101000697866 Homo sapiens BAG family molecular chaperone regulator 4 Proteins 0.000 description 7
- 102000005431 Molecular Chaperones Human genes 0.000 description 7
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 7
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 7
- 210000004899 c-terminal region Anatomy 0.000 description 7
- 239000006143 cell culture medium Substances 0.000 description 7
- 230000001086 cytosolic effect Effects 0.000 description 7
- 238000012217 deletion Methods 0.000 description 7
- 230000037430 deletion Effects 0.000 description 7
- 230000002538 fungal effect Effects 0.000 description 7
- 210000003734 kidney Anatomy 0.000 description 7
- 230000001575 pathological effect Effects 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 101710082261 Competence-stimulating peptide Proteins 0.000 description 6
- 101710138858 DnaJ homolog subfamily C member 5 Proteins 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 108091006020 Fc-tagged proteins Proteins 0.000 description 6
- 101000697493 Homo sapiens Large proline-rich protein BAG6 Proteins 0.000 description 6
- 102100028047 Large proline-rich protein BAG6 Human genes 0.000 description 6
- 102100029448 Na(+)/H(+) exchange regulatory cofactor NHE-RF2 Human genes 0.000 description 6
- 241000235648 Pichia Species 0.000 description 6
- 241000235070 Saccharomyces Species 0.000 description 6
- 108700019146 Transgenes Proteins 0.000 description 6
- 241000700605 Viruses Species 0.000 description 6
- 230000009286 beneficial effect Effects 0.000 description 6
- 238000003776 cleavage reaction Methods 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- 238000002955 isolation Methods 0.000 description 6
- 239000002773 nucleotide Substances 0.000 description 6
- 125000003729 nucleotide group Chemical group 0.000 description 6
- 238000003752 polymerase chain reaction Methods 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- 230000007017 scission Effects 0.000 description 6
- 210000001082 somatic cell Anatomy 0.000 description 6
- 102100037927 DnaJ homolog subfamily B member 11 Human genes 0.000 description 5
- 108010008165 Etanercept Proteins 0.000 description 5
- 241000238631 Hexapoda Species 0.000 description 5
- 102100029467 Na(+)/H(+) exchange regulatory cofactor NHE-RF3 Human genes 0.000 description 5
- 208000024777 Prion disease Diseases 0.000 description 5
- 108010076504 Protein Sorting Signals Proteins 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 229960000403 etanercept Drugs 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 238000010561 standard procedure Methods 0.000 description 5
- 102000014914 Carrier Proteins Human genes 0.000 description 4
- 102100035420 DnaJ homolog subfamily C member 1 Human genes 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- XZWYTXMRWQJBGX-VXBMVYAYSA-N FLAG peptide Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(O)=O)CC1=CC=C(O)C=C1 XZWYTXMRWQJBGX-VXBMVYAYSA-N 0.000 description 4
- 101001125322 Homo sapiens Na(+)/H(+) exchange regulatory cofactor NHE-RF2 Proteins 0.000 description 4
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 4
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 4
- 102000018697 Membrane Proteins Human genes 0.000 description 4
- 108010052285 Membrane Proteins Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 238000000137 annealing Methods 0.000 description 4
- RASZIXQTZOARSV-BDPUVYQTSA-N astacin Chemical compound CC=1C(=O)C(=O)CC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)C(=O)CC1(C)C RASZIXQTZOARSV-BDPUVYQTSA-N 0.000 description 4
- 208000006673 asthma Diseases 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 210000003527 eukaryotic cell Anatomy 0.000 description 4
- 208000010544 human prion disease Diseases 0.000 description 4
- 230000005847 immunogenicity Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 101150086595 lat gene Proteins 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 4
- 230000010076 replication Effects 0.000 description 4
- 238000012552 review Methods 0.000 description 4
- 108010046571 sodium-hydrogen exchanger regulatory factor Proteins 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 239000013603 viral vector Substances 0.000 description 4
- 108091006112 ATPases Proteins 0.000 description 3
- 241000251468 Actinopterygii Species 0.000 description 3
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 3
- 241000228212 Aspergillus Species 0.000 description 3
- 102100028046 BAG family molecular chaperone regulator 5 Human genes 0.000 description 3
- 101150029409 CFTR gene Proteins 0.000 description 3
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 3
- 241000699800 Cricetinae Species 0.000 description 3
- 241000699802 Cricetulus griseus Species 0.000 description 3
- 101710081891 DnaJ homolog subfamily B member 11 Proteins 0.000 description 3
- 102100023317 DnaJ homolog subfamily C member 10 Human genes 0.000 description 3
- 102100031681 DnaJ homolog subfamily C member 3 Human genes 0.000 description 3
- 101000697498 Homo sapiens BAG family molecular chaperone regulator 5 Proteins 0.000 description 3
- 101000845898 Homo sapiens DnaJ homolog subfamily C member 3 Proteins 0.000 description 3
- 101001055222 Homo sapiens Interleukin-8 Proteins 0.000 description 3
- 101001125417 Homo sapiens Na(+)/H(+) exchange regulatory cofactor NHE-RF3 Proteins 0.000 description 3
- 102000015696 Interleukins Human genes 0.000 description 3
- 108010063738 Interleukins Proteins 0.000 description 3
- 241000235649 Kluyveromyces Species 0.000 description 3
- 241000244206 Nematoda Species 0.000 description 3
- 241000221960 Neurospora Species 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 3
- 241000235346 Schizosaccharomyces Species 0.000 description 3
- 108090000190 Thrombin Proteins 0.000 description 3
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 3
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 3
- 241000723792 Tobacco etch virus Species 0.000 description 3
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 3
- 241000235013 Yarrowia Species 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 239000013613 expression plasmid Substances 0.000 description 3
- 102000052624 human CXCL8 Human genes 0.000 description 3
- 210000005260 human cell Anatomy 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 230000028709 inflammatory response Effects 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 235000018977 lysine Nutrition 0.000 description 3
- 239000012139 lysis buffer Substances 0.000 description 3
- 201000000050 myeloid neoplasm Diseases 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 210000001672 ovary Anatomy 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 102000040430 polynucleotide Human genes 0.000 description 3
- 108091033319 polynucleotide Proteins 0.000 description 3
- 239000002157 polynucleotide Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 210000001236 prokaryotic cell Anatomy 0.000 description 3
- 230000002797 proteolythic effect Effects 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 230000000717 retained effect Effects 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 229960004072 thrombin Drugs 0.000 description 3
- 229960000187 tissue plasminogen activator Drugs 0.000 description 3
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 3
- 241000701161 unidentified adenovirus Species 0.000 description 3
- 210000003501 vero cell Anatomy 0.000 description 3
- 108030001653 Adamalysin Proteins 0.000 description 2
- 102000034473 Adamalysin Human genes 0.000 description 2
- ORILYTVJVMAKLC-UHFFFAOYSA-N Adamantane Natural products C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 2
- 108090000658 Astacin Proteins 0.000 description 2
- 102000034498 Astacin Human genes 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 102000007590 Calpain Human genes 0.000 description 2
- 108010032088 Calpain Proteins 0.000 description 2
- 108010076667 Caspases Proteins 0.000 description 2
- 102000011727 Caspases Human genes 0.000 description 2
- 108091006146 Channels Proteins 0.000 description 2
- 102000011045 Chloride Channels Human genes 0.000 description 2
- 108010062745 Chloride Channels Proteins 0.000 description 2
- 102100022641 Coagulation factor IX Human genes 0.000 description 2
- 102100023804 Coagulation factor VII Human genes 0.000 description 2
- FMKGDHLSXFDSOU-BDPUVYQTSA-N Dienon-Astacin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)C(=O)C(=CC1(C)C)O)C=CC=C(/C)C=CC2=C(C)C(=O)C(=CC2(C)C)O FMKGDHLSXFDSOU-BDPUVYQTSA-N 0.000 description 2
- 101800001224 Disintegrin Proteins 0.000 description 2
- 102100035419 DnaJ homolog subfamily B member 9 Human genes 0.000 description 2
- 101710086702 DnaJ homolog subfamily C member 10 Proteins 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 102100029727 Enteropeptidase Human genes 0.000 description 2
- 108010013369 Enteropeptidase Proteins 0.000 description 2
- 241000206602 Eukaryota Species 0.000 description 2
- 108010076282 Factor IX Proteins 0.000 description 2
- 108010023321 Factor VII Proteins 0.000 description 2
- 108010054218 Factor VIII Proteins 0.000 description 2
- 102000001690 Factor VIII Human genes 0.000 description 2
- 101710154606 Hemagglutinin Proteins 0.000 description 2
- 108010093488 His-His-His-His-His-His Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000805858 Homo sapiens DnaJ homolog subfamily B member 11 Proteins 0.000 description 2
- 101000804119 Homo sapiens DnaJ homolog subfamily B member 9 Proteins 0.000 description 2
- 101000804122 Homo sapiens DnaJ homolog subfamily C member 1 Proteins 0.000 description 2
- 101000908042 Homo sapiens DnaJ homolog subfamily C member 10 Proteins 0.000 description 2
- 101000845893 Homo sapiens DnaJ homolog subfamily C member 5 Proteins 0.000 description 2
- 101100286681 Homo sapiens IL13 gene Proteins 0.000 description 2
- 101001125327 Homo sapiens Na(+)/H(+) exchange regulatory cofactor NHE-RF1 Proteins 0.000 description 2
- 101000843497 Homo sapiens Probable ATP-dependent DNA helicase HFM1 Proteins 0.000 description 2
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 2
- 241000713666 Lentivirus Species 0.000 description 2
- 101710143582 Na(+)/H(+) exchange regulatory cofactor NHE-RF1 Proteins 0.000 description 2
- 108091061960 Naked DNA Proteins 0.000 description 2
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 2
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 2
- 239000002033 PVDF binder Substances 0.000 description 2
- 101150114533 Pdzk1 gene Proteins 0.000 description 2
- 102100030730 Probable ATP-dependent DNA helicase HFM1 Human genes 0.000 description 2
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 2
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 2
- 101710176177 Protein A56 Proteins 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 239000012722 SDS sample buffer Substances 0.000 description 2
- 108091006629 SLC13A2 Proteins 0.000 description 2
- 108090000899 Serralysin Proteins 0.000 description 2
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 2
- 108020004682 Single-Stranded DNA Proteins 0.000 description 2
- 101150031256 Slc9a3r2 gene Proteins 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 108091006982 Zinc-dependent endopeptidases Proteins 0.000 description 2
- 102000036861 Zinc-dependent endopeptidases Human genes 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 108091005764 adaptor proteins Proteins 0.000 description 2
- 102000035181 adaptor proteins Human genes 0.000 description 2
- 230000009285 allergic inflammation Effects 0.000 description 2
- 235000003676 astacin Nutrition 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 230000001627 detrimental effect Effects 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 210000001723 extracellular space Anatomy 0.000 description 2
- 229960004222 factor ix Drugs 0.000 description 2
- 229940012413 factor vii Drugs 0.000 description 2
- 229960000301 factor viii Drugs 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 239000000185 hemagglutinin Substances 0.000 description 2
- 102000058223 human VEGFA Human genes 0.000 description 2
- 210000003000 inclusion body Anatomy 0.000 description 2
- 108091006086 inhibitor proteins Proteins 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 102000006240 membrane receptors Human genes 0.000 description 2
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 2
- OMNKZBIFPJNNIO-UHFFFAOYSA-N n-(2-methyl-4-oxopentan-2-yl)prop-2-enamide Chemical compound CC(=O)CC(C)(C)NC(=O)C=C OMNKZBIFPJNNIO-UHFFFAOYSA-N 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 238000002515 oligonucleotide synthesis Methods 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000013600 plasmid vector Substances 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 235000004252 protein component Nutrition 0.000 description 2
- 108020001580 protein domains Proteins 0.000 description 2
- 108060006633 protein kinase Proteins 0.000 description 2
- 230000006337 proteolytic cleavage Effects 0.000 description 2
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 2
- 108700015048 receptor decoy activity proteins Proteins 0.000 description 2
- 238000004064 recycling Methods 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 238000000527 sonication Methods 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000005030 transcription termination Effects 0.000 description 2
- 230000002463 transducing effect Effects 0.000 description 2
- 239000012096 transfection reagent Substances 0.000 description 2
- 102000035160 transmembrane proteins Human genes 0.000 description 2
- 108091005703 transmembrane proteins Proteins 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- XSYUPRQVAHJETO-WPMUBMLPSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-amino-3-(1h-imidazol-5-yl)propanoyl]amino]-3-(1h-imidazol-5-yl)propanoyl]amino]-3-(1h-imidazol-5-yl)propanoyl]amino]-3-(1h-imidazol-5-yl)propanoyl]amino]-3-(1h-imidazol-5-yl)propanoyl]amino]-3-(1h-imidaz Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(O)=O)C1=CN=CN1 XSYUPRQVAHJETO-WPMUBMLPSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 102100022712 Alpha-1-antitrypsin Human genes 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 101100063076 Arabidopsis thaliana DEGP1 gene Proteins 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 101710103210 Capsid protein F Proteins 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 102000008169 Co-Repressor Proteins Human genes 0.000 description 1
- 108010060434 Co-Repressor Proteins Proteins 0.000 description 1
- 101710116312 Co-chaperone protein HscB Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 101000916289 Ctenocephalides felis Salivary antigen 1 Proteins 0.000 description 1
- 101710138829 DnaJ homolog subfamily C member 1 Proteins 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 240000002989 Euphorbia neriifolia Species 0.000 description 1
- 108010074860 Factor Xa Proteins 0.000 description 1
- 101710112780 Gene 1 protein Proteins 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 208000031448 Genomic Instability Diseases 0.000 description 1
- HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 description 1
- 102000018932 HSP70 Heat-Shock Proteins Human genes 0.000 description 1
- 108010027992 HSP70 Heat-Shock Proteins Proteins 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 101100010026 Homo sapiens DNAJC1 gene Proteins 0.000 description 1
- 101000926535 Homo sapiens Interferon-induced, double-stranded RNA-activated protein kinase Proteins 0.000 description 1
- 101001077298 Homo sapiens Retinoblastoma-binding protein 5 Proteins 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 102100034170 Interferon-induced, double-stranded RNA-activated protein kinase Human genes 0.000 description 1
- 102000007482 Interleukin-13 Receptor alpha2 Subunit Human genes 0.000 description 1
- 108010085418 Interleukin-13 Receptor alpha2 Subunit Proteins 0.000 description 1
- 102000004559 Interleukin-13 Receptors Human genes 0.000 description 1
- 108010017511 Interleukin-13 Receptors Proteins 0.000 description 1
- 102100027530 Iron-sulfur cluster co-chaperone protein HscB Human genes 0.000 description 1
- 208000003456 Juvenile Arthritis Diseases 0.000 description 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 108010059881 Lactase Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 101710167839 Morphogenetic protein Proteins 0.000 description 1
- 101000908071 Mus musculus DnaJ homolog subfamily C member 10 Proteins 0.000 description 1
- 101100117262 Mus musculus Dnajc5 gene Proteins 0.000 description 1
- 101100523604 Mus musculus Rassf5 gene Proteins 0.000 description 1
- 101100309443 Mus musculus Sacs gene Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000037062 Polyps Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 102100037097 Protein disulfide-isomerase A3 Human genes 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102100025192 Retinoblastoma-binding protein 5 Human genes 0.000 description 1
- 241000282849 Ruminantia Species 0.000 description 1
- DFPOZTRSOAQFIK-UHFFFAOYSA-N S,S-dimethyl-beta-propiothetin Chemical compound C[S+](C)CCC([O-])=O DFPOZTRSOAQFIK-UHFFFAOYSA-N 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 108010076818 TEV protease Proteins 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 108010000499 Thromboplastin Proteins 0.000 description 1
- 102000002262 Thromboplastin Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 206010049644 Williams syndrome Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 229960002964 adalimumab Drugs 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 description 1
- 229940024142 alpha 1-antitrypsin Drugs 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000006800 cellular catabolic process Effects 0.000 description 1
- 230000007248 cellular mechanism Effects 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000012761 co-transfection Methods 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000006353 environmental stress Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229940048921 humira Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000002998 immunogenetic effect Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 229940116108 lactase Drugs 0.000 description 1
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 102000034288 naturally occurring fusion proteins Human genes 0.000 description 1
- 108091006048 naturally occurring fusion proteins Proteins 0.000 description 1
- 238000001821 nucleic acid purification Methods 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 208000019764 polyarticular juvenile idiopathic arthritis Diseases 0.000 description 1
- 229920002704 polyhistidine Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- IEMCJUJOHAEFFW-UHFFFAOYSA-M potassium 2-[(2-acetyloxybenzoyl)amino]ethanesulfonate Chemical compound CC(=O)OC1=CC=CC=C1C(=O)NCCS(=O)(=O)[O-].[K+] IEMCJUJOHAEFFW-UHFFFAOYSA-M 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000012743 protein tagging Effects 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 238000012289 standard assay Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 210000002105 tongue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 238000011426 transformation method Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
- C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5437—IL-13
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
- C07K14/8121—Serpins
- C07K14/8125—Alpha-1-antitrypsin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6437—Coagulation factor VIIa (3.4.21.21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/644—Coagulation factor IXa (3.4.21.22)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
- C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/705—Fusion polypeptide containing domain for protein-protein interaction containing a protein-A fusion
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Wood Science & Technology (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Virology (AREA)
- Psychology (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pulmonology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Fusion proteins comprising a protein expression enhancing polypeptide linked to a target protein binding domain and nucleic acid molecules encoding such fusion proteins are described for use in enhancing expression and/or location of a targeted protein of interest, for restoring lost functions in cells, and for treating disease. Additional fusion proteins comprising a target protein of interest modified with a fusion partner comprising a protein expression enhancing polypeptide are also disclosed.
Description
Protein Expression Enhancing Polypeptides Cross-Reference to Related Applications This application claims the benefit of priority to U.S. Provisional Application No. 61/733,884, filed December 5, 2012, and to U.S. Provisional Application No. 61/733,743, filed December 5, 2012.
Field of the Invention This invention is in the field of engineered proteins. In particular, the invention is directed to polypeptides for enhancing expression of proteins and nucleic acid molecules encoding such protein expression enhancing polypeptides. Methods of increasing production levels of a protein of interest are also provided.
Background of the Invention Expressing a protein of interest in a culture of genetically engineered cells at levels that permit easy isolation in quantities sufficient for research, development, or commercial use requires the optimization of a variety of recombinant techniques and cell culture methodologies. Such techniques include in vitro methods of isolating and recombining nucleic acid molecules to encode a desired protein molecule, operably linking the desired coding sequences with appropriate transcriptional and translational elements, inserting the engineered genetic material into an appropriate expression vector, introducing the resulting recombinant expression vector into compatible host cells, and culturing the host cells containing the recombinant expression vector under conditions that permit expression of the desired recombinant protein. Proper selection and optimization of such methods has permitted expression and use of a variety of recombinant proteins from a wide variety of host cells, including bacterial, fungal, insect, plant, and mammalian host cells.
Despite many advances in recombinant and cell culture methodologies, the problem of ensuring proper protein folding can still thwart the most extensive efforts to produce useful amounts of a desired recombinant protein. All proteins must achieve a proper two- and three-dimensional conformation in order to function properly at their intended location. Proper conformation ensures that a protein will provide a cell or multi-cell organism with its intended function (for example, enzymatic activity, signal transduction, or structural feature) at its intended location (for example, cytoplasm, nucleus, intracellular structure, organelle, cell membrane, or extracellular (secreted) location). Although the information for the proper structure and conformation resides in a protein's amino acid sequence, the general intracellular environment and a variety of stimuli and environmental stresses, including oxidative stress, nutrient deprivation, and high temperature, can make proper folding of even endogenously produced proteins more difficult to the point that many protein molecules take on an undesired structure and thus fail to provide a cell with their intended function.
To deal with the continual risk of not attaining or maintaining proper functional conformations, cells possess a system of proteins that serve as molecular chaperones to assist in the folding and refolding of nascent and mature proteins into their proper conformations. The heat shock 70 kDa proteins (referred herein as "Hsp7Os") constitute one of the most ubiquitous classes of chaperone proteins in the cells of a wide variety of species. The Hsp70 machinery includes the participation of co-factor (or co-chaperone) proteins, such as J proteins, and nucleotide exchange factors (NEFs).
In a current model of the Hsp70 chaperone machinery for folding proteins, Hsp70 cycles between ATP- and ADP-bound states. In this model, a J protein binds to a protein in need of folding or refolding (referred to as a "client protein") and interacts with an ATP-bound state of Hsp70 (Hsp70-ATP). Binding by the J protein-client complex to Hsp70-ATP stimulates ATP hydrolysis, which causes a conformational change in the Hsp70 protein that closes a helical lid, thereby stabilizing the interaction between the client protein with the Hsp70-ADP, and release of the J protein, which is then free to bind another client protein. While bound to the Hsp70-ADP, the client protein is provided with an environment that permits folding or refolding into a proper conformation. Next, a nucleotide exchange factor (NEF) binds to Hsp70-ADP resulting in release of ADP and binding of ATP. The client protein is then released because of its low affinity (in the absence of J protein) for Hsp70-ATP. If the client protein has not achieved a proper conformation, it may be rebound by a J
protein and enter the cycle again. See, Kampinga et al., Nat. Rev., 11: 579-592 (2010). Thus, according to this model, J proteins play a critical role in the Hsp70 machinery by associating with individual client proteins and also with the Hsp70 chaperone protein to provide a bridging function that facilitates the capture and submission of a wide variety of client proteins into the Hsp70 machinery to promote folding or refolding into proper conformations. When attempts by the Hsp70 chaperone machinery fail to fold or refold a protein into proper functional conformations, the Hsp70 chaperone machinery also can facilitate the transfer of the improperly folded protein to the cell's proteolytic system (e.g., the proteasome) for degradation and recycling of amino acids. For a review of the Hsp70 chaperone machinery, including the critical role of J proteins, see, Kampinga et al, Nature Rev., 11: 579-592 (2010) and Voisine et al., Neurobiol. Dis., 40: 12-20 (2010).
Expressed proteins are thus subjected to a strict quality control system of the Hsp70 machinery for maintaining proper conformations. The problem of proper protein folding is of particular concern in the case of producing useful quantities of functional exogenous (recombinant) proteins expressed in various recombinant host cells. The problem can arise in both eukaryotic and prokaryotic host cells. The failure to properly fold exogenous proteins expressed in bacterial host cells frequently can result in the formation within the cells of large, potentially toxic, aggregates of inactive molecules of the exogenous protein. Such aggregates are referred to as "inclusion bodies"
and are considered to be the result of ineffective protein folding that leads to non-functional conformations with exposed hydrophobic domains that in turn promote association and aggregation with other improperly folded protein molecules.
When a wild-type gene encoding a protein undergoes a mutation, the encoded mutant form of the protein may still be expressed in the cell. Such expressed mutant proteins usually fail to achieve a
Field of the Invention This invention is in the field of engineered proteins. In particular, the invention is directed to polypeptides for enhancing expression of proteins and nucleic acid molecules encoding such protein expression enhancing polypeptides. Methods of increasing production levels of a protein of interest are also provided.
Background of the Invention Expressing a protein of interest in a culture of genetically engineered cells at levels that permit easy isolation in quantities sufficient for research, development, or commercial use requires the optimization of a variety of recombinant techniques and cell culture methodologies. Such techniques include in vitro methods of isolating and recombining nucleic acid molecules to encode a desired protein molecule, operably linking the desired coding sequences with appropriate transcriptional and translational elements, inserting the engineered genetic material into an appropriate expression vector, introducing the resulting recombinant expression vector into compatible host cells, and culturing the host cells containing the recombinant expression vector under conditions that permit expression of the desired recombinant protein. Proper selection and optimization of such methods has permitted expression and use of a variety of recombinant proteins from a wide variety of host cells, including bacterial, fungal, insect, plant, and mammalian host cells.
Despite many advances in recombinant and cell culture methodologies, the problem of ensuring proper protein folding can still thwart the most extensive efforts to produce useful amounts of a desired recombinant protein. All proteins must achieve a proper two- and three-dimensional conformation in order to function properly at their intended location. Proper conformation ensures that a protein will provide a cell or multi-cell organism with its intended function (for example, enzymatic activity, signal transduction, or structural feature) at its intended location (for example, cytoplasm, nucleus, intracellular structure, organelle, cell membrane, or extracellular (secreted) location). Although the information for the proper structure and conformation resides in a protein's amino acid sequence, the general intracellular environment and a variety of stimuli and environmental stresses, including oxidative stress, nutrient deprivation, and high temperature, can make proper folding of even endogenously produced proteins more difficult to the point that many protein molecules take on an undesired structure and thus fail to provide a cell with their intended function.
To deal with the continual risk of not attaining or maintaining proper functional conformations, cells possess a system of proteins that serve as molecular chaperones to assist in the folding and refolding of nascent and mature proteins into their proper conformations. The heat shock 70 kDa proteins (referred herein as "Hsp7Os") constitute one of the most ubiquitous classes of chaperone proteins in the cells of a wide variety of species. The Hsp70 machinery includes the participation of co-factor (or co-chaperone) proteins, such as J proteins, and nucleotide exchange factors (NEFs).
In a current model of the Hsp70 chaperone machinery for folding proteins, Hsp70 cycles between ATP- and ADP-bound states. In this model, a J protein binds to a protein in need of folding or refolding (referred to as a "client protein") and interacts with an ATP-bound state of Hsp70 (Hsp70-ATP). Binding by the J protein-client complex to Hsp70-ATP stimulates ATP hydrolysis, which causes a conformational change in the Hsp70 protein that closes a helical lid, thereby stabilizing the interaction between the client protein with the Hsp70-ADP, and release of the J protein, which is then free to bind another client protein. While bound to the Hsp70-ADP, the client protein is provided with an environment that permits folding or refolding into a proper conformation. Next, a nucleotide exchange factor (NEF) binds to Hsp70-ADP resulting in release of ADP and binding of ATP. The client protein is then released because of its low affinity (in the absence of J protein) for Hsp70-ATP. If the client protein has not achieved a proper conformation, it may be rebound by a J
protein and enter the cycle again. See, Kampinga et al., Nat. Rev., 11: 579-592 (2010). Thus, according to this model, J proteins play a critical role in the Hsp70 machinery by associating with individual client proteins and also with the Hsp70 chaperone protein to provide a bridging function that facilitates the capture and submission of a wide variety of client proteins into the Hsp70 machinery to promote folding or refolding into proper conformations. When attempts by the Hsp70 chaperone machinery fail to fold or refold a protein into proper functional conformations, the Hsp70 chaperone machinery also can facilitate the transfer of the improperly folded protein to the cell's proteolytic system (e.g., the proteasome) for degradation and recycling of amino acids. For a review of the Hsp70 chaperone machinery, including the critical role of J proteins, see, Kampinga et al, Nature Rev., 11: 579-592 (2010) and Voisine et al., Neurobiol. Dis., 40: 12-20 (2010).
Expressed proteins are thus subjected to a strict quality control system of the Hsp70 machinery for maintaining proper conformations. The problem of proper protein folding is of particular concern in the case of producing useful quantities of functional exogenous (recombinant) proteins expressed in various recombinant host cells. The problem can arise in both eukaryotic and prokaryotic host cells. The failure to properly fold exogenous proteins expressed in bacterial host cells frequently can result in the formation within the cells of large, potentially toxic, aggregates of inactive molecules of the exogenous protein. Such aggregates are referred to as "inclusion bodies"
and are considered to be the result of ineffective protein folding that leads to non-functional conformations with exposed hydrophobic domains that in turn promote association and aggregation with other improperly folded protein molecules.
When a wild-type gene encoding a protein undergoes a mutation, the encoded mutant form of the protein may still be expressed in the cell. Such expressed mutant proteins usually fail to achieve a
2 proper functional conformation of the wild-type protein and may form inactive aggregates. Such improperly folded mutant protein species are typically ushered by the Hsp70 machinery into the cells proteolytic system for degradation and recycling of amino acids. Elimination of the improperly folded mutant protein still, of course, leaves the cell with a loss of functional protein and the consequence of such loss of function can be debilitating or even fatal to the cell. In fact, loss of properly folded functional protein species has been demonstrated or is implicated in a number of diseases, including prion-associated diseases (transmissible spongiform encephalopathies), Alzheimer's disease, Parkinson's disease, Huntington's disease, and cystic fibrosis.
Members of the BAG family of proteins found in eukaryotes are nucleotide exchange factors (NEFs) that possess diverse N-terminal domains and a conserved C-terminal Hsp70-binding domain (the BAG domain) that can interact with the ATPase domain of Hsp70. See, for example, Kampinga et al., Nat. Rev. Biol., 11:579-592 (2010). Thus, BAG proteins have a topology, binding domains, and binding specificities that are consistent with a protein designed to participate in recruiting the Hsp70 chaperone machinery. Although a BAG protein might participate as a NEF in the Hsp70 machinery, many studies suggest that BAG proteins may predominantly be involved in regulatory mechanisms to control a variety of activities, including promoting cell growth, quiescence, or apoptosis; regulating transcription complex formation; and modulating signal transduction. See, for example, the review by Takayama et al., Nat. Cell Biol., 3: E237-E241 (2001). Recently, it has been reported that when desired recombinant proteins are linked to a BAG domain, the resulting fusion proteins are expressed at levels that are greater than those of the protein alone. See, International Publication No.
WO 2012/087835 A2.
In general, with an increasing level of expression of a protein in a cell (as can easily occur in recombinant gene expression systems), there is an increasing risk that such proteins may fail to fold or refold into proper functional conformations. Accordingly, along with a constant desire for increasing expression of desired exogenous or endogenous proteins, needs remain for means for enhancing the proper folding of exogenous and endogenous proteins expressed in cells, i.e., to increase the yield of properly conformed, functional proteins.
Summary of the Invention The present invention provides compositions and methods for enhancing the level of expression of a target protein of interest produced by a cell. In particular, the invention provides protein expression enhancing polypeptides that can be incorporated into genetically engineered fusion proteins, which when expressed by a host cell are able to enhance the level of expression of a specific target protein of interest at its intended location.
In one embodiment, a protein expression enhancing polypeptide of the invention is selected from the group consisting of:
Members of the BAG family of proteins found in eukaryotes are nucleotide exchange factors (NEFs) that possess diverse N-terminal domains and a conserved C-terminal Hsp70-binding domain (the BAG domain) that can interact with the ATPase domain of Hsp70. See, for example, Kampinga et al., Nat. Rev. Biol., 11:579-592 (2010). Thus, BAG proteins have a topology, binding domains, and binding specificities that are consistent with a protein designed to participate in recruiting the Hsp70 chaperone machinery. Although a BAG protein might participate as a NEF in the Hsp70 machinery, many studies suggest that BAG proteins may predominantly be involved in regulatory mechanisms to control a variety of activities, including promoting cell growth, quiescence, or apoptosis; regulating transcription complex formation; and modulating signal transduction. See, for example, the review by Takayama et al., Nat. Cell Biol., 3: E237-E241 (2001). Recently, it has been reported that when desired recombinant proteins are linked to a BAG domain, the resulting fusion proteins are expressed at levels that are greater than those of the protein alone. See, International Publication No.
WO 2012/087835 A2.
In general, with an increasing level of expression of a protein in a cell (as can easily occur in recombinant gene expression systems), there is an increasing risk that such proteins may fail to fold or refold into proper functional conformations. Accordingly, along with a constant desire for increasing expression of desired exogenous or endogenous proteins, needs remain for means for enhancing the proper folding of exogenous and endogenous proteins expressed in cells, i.e., to increase the yield of properly conformed, functional proteins.
Summary of the Invention The present invention provides compositions and methods for enhancing the level of expression of a target protein of interest produced by a cell. In particular, the invention provides protein expression enhancing polypeptides that can be incorporated into genetically engineered fusion proteins, which when expressed by a host cell are able to enhance the level of expression of a specific target protein of interest at its intended location.
In one embodiment, a protein expression enhancing polypeptide of the invention is selected from the group consisting of:
3 (a) an isolated J domain of a J protein;
(b) an isolated protein expression enhancing polypeptide fragment of a J
domain;
(c) an isolated protein expression enhancing polypeptide analog of a J domain, said J
domain analog polypeptide comprises the amino acid sequence of formula I:
(1) X1-X2-X3-X4-X5-X6-X7-X8-X9 (SEQ ID NO:47), wherein:
X1 is isoleucine (I), leucine (L), valine (V), alanine (A), or methionine (M);
X2 and X3 are each independently any amino acid with the proviso that one or both are K or R;
X4 is any amino acid or X4 may be absent when X1 through X3 are present and X5 through X9 are present;
X5 is tyrosine (Y), tryptophan (W), or phenylalanine (F);
X6 and X7 are each independently any amino acid with the proviso that one or both are lysine (K) or arginine (R); or either one of X6 and X7 may be absent when the other is K or R and when X1 through X5 are present and X8 and X9 are present; and X8 and X9 are any amino acid with the proviso that one or both are leucine (L) or alanine (A); or one of X8 and X9 may be absent when the other is L or A and when X1 through X7 are present; and (d) an isolated protein expression enhancing polypeptide selected from the group of decapeptides consisting of:
IKKAYKLALQ (SEQ ID NO:49), IKKAYRLALQ (SEQ ID NO:50), IKKAYRKALQ (SEQ ID NO:51), or IKKAYRKLLQ (SEQ ID NO:52).
In accordance with the invention, a protein expression enhancing polypeptide enhances the level of expression of a target protein of interest expressed in a host cell as compared to the level of expression of the target protein of interest in the absence of the protein expression enhancing polypeptide. Use of the polypeptides of the present invention provides a means for increasing the amount of a desired recombinant protein in the desired location (compartment) with respect to the producing cell.
In a particular embodiment, a protein expression enhancing polypeptide of the invention is an isolated J domain that has an amino acid sequence selected from any of the J
domain sequences set forth in Table 1, infra.
Preferably, a protein expressing enhancing polypeptide of the invention is an isolated J
domain of an Erdj protein, a large T antigen of 5V40, or a mammalian cysteine string protein alpha (CSP-a). A preferred isolated J domain of an Erdj protein of the invention is an isolated J domain of
(b) an isolated protein expression enhancing polypeptide fragment of a J
domain;
(c) an isolated protein expression enhancing polypeptide analog of a J domain, said J
domain analog polypeptide comprises the amino acid sequence of formula I:
(1) X1-X2-X3-X4-X5-X6-X7-X8-X9 (SEQ ID NO:47), wherein:
X1 is isoleucine (I), leucine (L), valine (V), alanine (A), or methionine (M);
X2 and X3 are each independently any amino acid with the proviso that one or both are K or R;
X4 is any amino acid or X4 may be absent when X1 through X3 are present and X5 through X9 are present;
X5 is tyrosine (Y), tryptophan (W), or phenylalanine (F);
X6 and X7 are each independently any amino acid with the proviso that one or both are lysine (K) or arginine (R); or either one of X6 and X7 may be absent when the other is K or R and when X1 through X5 are present and X8 and X9 are present; and X8 and X9 are any amino acid with the proviso that one or both are leucine (L) or alanine (A); or one of X8 and X9 may be absent when the other is L or A and when X1 through X7 are present; and (d) an isolated protein expression enhancing polypeptide selected from the group of decapeptides consisting of:
IKKAYKLALQ (SEQ ID NO:49), IKKAYRLALQ (SEQ ID NO:50), IKKAYRKALQ (SEQ ID NO:51), or IKKAYRKLLQ (SEQ ID NO:52).
In accordance with the invention, a protein expression enhancing polypeptide enhances the level of expression of a target protein of interest expressed in a host cell as compared to the level of expression of the target protein of interest in the absence of the protein expression enhancing polypeptide. Use of the polypeptides of the present invention provides a means for increasing the amount of a desired recombinant protein in the desired location (compartment) with respect to the producing cell.
In a particular embodiment, a protein expression enhancing polypeptide of the invention is an isolated J domain that has an amino acid sequence selected from any of the J
domain sequences set forth in Table 1, infra.
Preferably, a protein expressing enhancing polypeptide of the invention is an isolated J
domain of an Erdj protein, a large T antigen of 5V40, or a mammalian cysteine string protein alpha (CSP-a). A preferred isolated J domain of an Erdj protein of the invention is an isolated J domain of
4 PCT/US2013/073442 08.04.2015 Erdjl, Erdj2, Erdj3, Erdj4, Erdj5, Erdj6 or Erdj7. Particularly preferred is an isolated J domain of Erdj3.
In another embodiment, a protein expression enhancing polypeptide of the invention is a polypeptide fragment of a J domain that has an amino acid sequence that is selected from any of the following:
I-K-K-A-Y-R-K-L-A (SEQ ID NO:48), I-R-K-A-Y-R-K-L-S-L-T-L (SEQ ID NO:83), I-K-K-Q-Y-R-L-L-S-L-K-Y (SEQ ID NO:84), I-K-K-A-F-H-K-L-A-M-K-Y (SEQ ID NO:85), I-R-Q-A-F-K-K-L-A-L-K-L (SEQ NO:86), I-I-K-A-Y-R-K-L-A-L-Q-W (SEQ ID NO:87), I-A-R-A-Y-R-Q-L-A-R-R-Y (SEQ ID NO:88), I-K-R-A-Y-R-R-Q-A-L-R-Y (SEQ ID NO:89), I-K-K-S-Y-R-K-L-A-L-K-Y (SEQ ID NO:90), and I-K-K-A-Y-K-R-L-A-M-K-Y (SEQ ID NO:91).
In another embodiment, a protein expression enhancing polypeptide is a J
domain analog polypeptide having the amino acid sequence of formula I, supra. In particular embodiments, a protein enhancing polypeptide of the invention comprises a polypeptide having the sequence: X1-X2-X3-X4-X5-X6-X7-X8-X9 (SEQ ID NO:326), wherein:
X1 is I, L, V, A, or M;
the dipeptide X2-X3 is selected from the group consisting of: KR, la, RK, RR, AK, AR, =
ICA, IK, NK, KQ, RQ, and RD;
X4 is A, S, T, R, S, Q, E, F, C, or 1;
X5 is Y or F;
the dipeptide X6-X7 is selected from the group consisting of: KR, la, RK, RR, RQ, FR, RL, KL, IIK, LK, QK, and KV; and the dipeptide X8-X9 is selected from the group consisting of: LA, LL, AL, AA, LC, LV, QA, KA, LS, IA LY, and RA.
In particular embodiments, a J domain analog polypeptide of the invention comprises one of the following amino acid sequences:
Sequence Identifier Amino Acid Sequence SEQ ID NO:48 IKKAYRKLA
SEQ ID NO:49 IKKAYKLALQ
SEQ ID NO:50 IKKAYRLALQ
SEQ ID NO:51 IKKAYRKALQ
SEQ ID NO:52 IKKAYRKLLQ
SEQ ID NO:53 IKKYRKLA
In another embodiment, a protein expression enhancing polypeptide of the invention is a polypeptide fragment of a J domain that has an amino acid sequence that is selected from any of the following:
I-K-K-A-Y-R-K-L-A (SEQ ID NO:48), I-R-K-A-Y-R-K-L-S-L-T-L (SEQ ID NO:83), I-K-K-Q-Y-R-L-L-S-L-K-Y (SEQ ID NO:84), I-K-K-A-F-H-K-L-A-M-K-Y (SEQ ID NO:85), I-R-Q-A-F-K-K-L-A-L-K-L (SEQ NO:86), I-I-K-A-Y-R-K-L-A-L-Q-W (SEQ ID NO:87), I-A-R-A-Y-R-Q-L-A-R-R-Y (SEQ ID NO:88), I-K-R-A-Y-R-R-Q-A-L-R-Y (SEQ ID NO:89), I-K-K-S-Y-R-K-L-A-L-K-Y (SEQ ID NO:90), and I-K-K-A-Y-K-R-L-A-M-K-Y (SEQ ID NO:91).
In another embodiment, a protein expression enhancing polypeptide is a J
domain analog polypeptide having the amino acid sequence of formula I, supra. In particular embodiments, a protein enhancing polypeptide of the invention comprises a polypeptide having the sequence: X1-X2-X3-X4-X5-X6-X7-X8-X9 (SEQ ID NO:326), wherein:
X1 is I, L, V, A, or M;
the dipeptide X2-X3 is selected from the group consisting of: KR, la, RK, RR, AK, AR, =
ICA, IK, NK, KQ, RQ, and RD;
X4 is A, S, T, R, S, Q, E, F, C, or 1;
X5 is Y or F;
the dipeptide X6-X7 is selected from the group consisting of: KR, la, RK, RR, RQ, FR, RL, KL, IIK, LK, QK, and KV; and the dipeptide X8-X9 is selected from the group consisting of: LA, LL, AL, AA, LC, LV, QA, KA, LS, IA LY, and RA.
In particular embodiments, a J domain analog polypeptide of the invention comprises one of the following amino acid sequences:
Sequence Identifier Amino Acid Sequence SEQ ID NO:48 IKKAYRKLA
SEQ ID NO:49 IKKAYKLALQ
SEQ ID NO:50 IKKAYRLALQ
SEQ ID NO:51 IKKAYRKALQ
SEQ ID NO:52 IKKAYRKLLQ
SEQ ID NO:53 IKKYRKLA
5 AMENDED SHEET - IPEA/US
Sequence Identifier Amino Acid Sequence SEQ ID NO:54 I KKAYKLA
SEQ ID NO:55 I KKAYRLA
SEQ ID NO:56 I KKAYRKA
SEQ ID NO:57 LKKAYRKLA
SEQ ID NO:58 VKKAYRKLA
SEQ ID NO:59 MKKAYRKLA
SEQ ID NO:60 AKKAYRKLA
SEQ ID NO:61 IAKAYRKLA
SEQ ID NO:62 I KAAYRKLA
SEQ ID NO:63 I KKRYRKLA
SEQ ID NO:64 IKKSYRKLA
SEQ ID NO:65 I KKQYRKLA
SEQ ID NO:66 I KKEYRKLA
SEQ ID NO:67 I KKFYRKLA
SEQ ID NO:68 IKKCYRKLA
SEQ ID NO:69 I KKAFRKLA
SEQ ID NO:70 I KKAWRKLA
SEQ ID NO:71 I KKAYRKQA
SEQ ID NO:72 I KKAYRKMA
SEQ ID NO:73 I KKAYRK IA
SEQ ID NO:74 I KKAYRKAA
SEQ ID NO:75 I KKAYRKVA
SEQ ID NO:76 I KKAYRKRA
SEQ ID NO:77 I KKAYRKLM
SEQ ID NO:78 I KKAYRKL I
SEQ ID NO:79 I KKAYRKLV
SEQ ID NO:80 I KKAYRKL C
SEQ ID NO:81 I KKAYRKL S
SEQ ID NO:82 I KKAYRKL Y
SEQ ID NO:83 IRKAYRKL SLTL
SEQ ID NO:84 IKKQYRLL S LKY
SEQ ID NO:85 I KKAFHKLAMKY
SEQ ID NO:86 I RQAFKKLALKL
SEQ ID NO:87 IIKAYRKLALQW
SEQ ID NO:88 IARAYRQLARRY
SEQ ID NO:89 I KRAYRRQALRY
SEQ ID NO:90 IKKSYRKLALKY
SEQ ID NO:91 I KKAYKRLAMKY
In a further embodiment, the invention provides a fusion protein comprising a protein expression enhancing polypeptide fused to a target protein of interest, wherein the protein expression enhancing polypeptide fusion partner is a J domain of a J protein, a J domain fragment having the ability to enhance expression of the protein of interest fusion partner, or a J domain analog polypeptide having the amino acid sequence of formula I (SEQ ID NO:47) as described above.
Expression of this fusion protein leads to increased expression of the fused target protein of interest, as compared with expression of the target protein of interest without the use of the protein expression
Sequence Identifier Amino Acid Sequence SEQ ID NO:54 I KKAYKLA
SEQ ID NO:55 I KKAYRLA
SEQ ID NO:56 I KKAYRKA
SEQ ID NO:57 LKKAYRKLA
SEQ ID NO:58 VKKAYRKLA
SEQ ID NO:59 MKKAYRKLA
SEQ ID NO:60 AKKAYRKLA
SEQ ID NO:61 IAKAYRKLA
SEQ ID NO:62 I KAAYRKLA
SEQ ID NO:63 I KKRYRKLA
SEQ ID NO:64 IKKSYRKLA
SEQ ID NO:65 I KKQYRKLA
SEQ ID NO:66 I KKEYRKLA
SEQ ID NO:67 I KKFYRKLA
SEQ ID NO:68 IKKCYRKLA
SEQ ID NO:69 I KKAFRKLA
SEQ ID NO:70 I KKAWRKLA
SEQ ID NO:71 I KKAYRKQA
SEQ ID NO:72 I KKAYRKMA
SEQ ID NO:73 I KKAYRK IA
SEQ ID NO:74 I KKAYRKAA
SEQ ID NO:75 I KKAYRKVA
SEQ ID NO:76 I KKAYRKRA
SEQ ID NO:77 I KKAYRKLM
SEQ ID NO:78 I KKAYRKL I
SEQ ID NO:79 I KKAYRKLV
SEQ ID NO:80 I KKAYRKL C
SEQ ID NO:81 I KKAYRKL S
SEQ ID NO:82 I KKAYRKL Y
SEQ ID NO:83 IRKAYRKL SLTL
SEQ ID NO:84 IKKQYRLL S LKY
SEQ ID NO:85 I KKAFHKLAMKY
SEQ ID NO:86 I RQAFKKLALKL
SEQ ID NO:87 IIKAYRKLALQW
SEQ ID NO:88 IARAYRQLARRY
SEQ ID NO:89 I KRAYRRQALRY
SEQ ID NO:90 IKKSYRKLALKY
SEQ ID NO:91 I KKAYKRLAMKY
In a further embodiment, the invention provides a fusion protein comprising a protein expression enhancing polypeptide fused to a target protein of interest, wherein the protein expression enhancing polypeptide fusion partner is a J domain of a J protein, a J domain fragment having the ability to enhance expression of the protein of interest fusion partner, or a J domain analog polypeptide having the amino acid sequence of formula I (SEQ ID NO:47) as described above.
Expression of this fusion protein leads to increased expression of the fused target protein of interest, as compared with expression of the target protein of interest without the use of the protein expression
6 enhancing polypeptide fusion partner. Removal of the protein expression enhancing polypeptide portion of the fusion protein by standard methods results in increased recovery of the target protein of interest.
A fusion protein of the invention comprising a protein expression enhancing polypeptide described herein linked to a target protein of interest may be used in a method to restore a protein function in cells of a mammalian subject that are deficient in the secretion of a native secreted protein that provides the protein function comprising the steps of inserting into cells of the mammalian subject (such as a human, non-human primate, rodent, or livestock) an exogenous nucleic acid molecule encoding a fusion protein comprising a protein expression enhancing polypeptide as described above linked to the secreted protein, wherein expression of the fusion protein provides the function of the native secreted protein whose secretion is deficient in cells of the subject in the absence of the exogenous nucleic acid.
In a preferred embodiment, the above method for restoring a protein function in cells of a mammalian subject is used to treat a subject that has a disease associated with the deficient secretion of a native secreted protein in the subject. Such diseases include, but are not limited to, prion-associated disease, Alzheimer's disease, Parkinson's disease, Huntington's disease, cystic fibrosis (CF), and al-antitrypsin deficiency. In a particularly preferred embodiment, a method for restoring a protein function is used to treat a human subject deficient in the secretion of cystic fibrosis transmembrane conductance regulator protein (CETR) and the disease is cystic fibrosis. In this embodiment, an exogenous nucleic acid molecule that is inserted into cells of the human subject encodes a fusion protein comprising a protein expression enhancing polypeptide described above linked to CFTR. Expression of the fusion protein in the cells of the human subject restores the deficiency of CETR function.
In a further embodiment, the invention provides a fusion protein comprising a protein expression enhancing polypeptide linked to a target protein binding domain, wherein the protein expression enhancing polypeptide element is a J domain of a J protein, a J
domain fragment having the ability to enhance expression of the protein of interest fusion partner, or a J domain analog polypeptide having the amino acid sequence of formula I (SEQ ID NO:47) as described above, and the target protein binding domain is a polypeptide capable of binding to a target protein of interest when the fusion protein and the target protein of interest are co-expressed in the same host cell. A
fusion protein that binds a target protein of interest enhances the level of expression of the target protein and/or enhances the level of the target protein at its proper cellular or extracellular location.
Accordingly, fusion proteins described herein may be used to enhance the level of expression of a target protein of interest that is not expressed in adequate amounts or at the proper cellular or extracellular location for a given purpose. Such situations in which a fusion protein described herein is useful include, without limitation, failure to express desired quantities of an endogenous or
A fusion protein of the invention comprising a protein expression enhancing polypeptide described herein linked to a target protein of interest may be used in a method to restore a protein function in cells of a mammalian subject that are deficient in the secretion of a native secreted protein that provides the protein function comprising the steps of inserting into cells of the mammalian subject (such as a human, non-human primate, rodent, or livestock) an exogenous nucleic acid molecule encoding a fusion protein comprising a protein expression enhancing polypeptide as described above linked to the secreted protein, wherein expression of the fusion protein provides the function of the native secreted protein whose secretion is deficient in cells of the subject in the absence of the exogenous nucleic acid.
In a preferred embodiment, the above method for restoring a protein function in cells of a mammalian subject is used to treat a subject that has a disease associated with the deficient secretion of a native secreted protein in the subject. Such diseases include, but are not limited to, prion-associated disease, Alzheimer's disease, Parkinson's disease, Huntington's disease, cystic fibrosis (CF), and al-antitrypsin deficiency. In a particularly preferred embodiment, a method for restoring a protein function is used to treat a human subject deficient in the secretion of cystic fibrosis transmembrane conductance regulator protein (CETR) and the disease is cystic fibrosis. In this embodiment, an exogenous nucleic acid molecule that is inserted into cells of the human subject encodes a fusion protein comprising a protein expression enhancing polypeptide described above linked to CFTR. Expression of the fusion protein in the cells of the human subject restores the deficiency of CETR function.
In a further embodiment, the invention provides a fusion protein comprising a protein expression enhancing polypeptide linked to a target protein binding domain, wherein the protein expression enhancing polypeptide element is a J domain of a J protein, a J
domain fragment having the ability to enhance expression of the protein of interest fusion partner, or a J domain analog polypeptide having the amino acid sequence of formula I (SEQ ID NO:47) as described above, and the target protein binding domain is a polypeptide capable of binding to a target protein of interest when the fusion protein and the target protein of interest are co-expressed in the same host cell. A
fusion protein that binds a target protein of interest enhances the level of expression of the target protein and/or enhances the level of the target protein at its proper cellular or extracellular location.
Accordingly, fusion proteins described herein may be used to enhance the level of expression of a target protein of interest that is not expressed in adequate amounts or at the proper cellular or extracellular location for a given purpose. Such situations in which a fusion protein described herein is useful include, without limitation, failure to express desired quantities of an endogenous or
7 heterologous (recombinant) protein of interest in cell culture and failure to express sufficient levels of a protein in vivo where inadequate expression of one or more functional proteins leads to a pathological state (such as, without limitation, a prion-associated disease (a transmissible spongiform encephalopathy); Alzheimer's disease; Parkinson's disease; Huntington's disease; cystic fibrosis; iii-antitrypsin deficiency).
A protein that is targeted by a fusion protein of the invention for an enhanced level of expression and/or enhanced expression at a desired cellular or extracellular location may be a soluble protein, a membrane-associated protein, or a secreted protein.
A target protein binding domain of a fusion protein of the invention is a polypeptide that binds a target protein. Preferably, the target binding domain has a binding affinity for a target protein that is sufficiently specific as to exclude other proteins from interfering with the enhancement in the level of expression of the target protein. Examples of polypeptides that may be used as a target binding domain of the invention include, but are not limited to, an antibody or antigen binding portion thereof that binds a target protein, an immunoglobulin-specific binding protein (such as Protein A, Protein L, and Protein G) that binds a target immunoglobulin or fragment thereof, an Fc binding protein (such as Protein A and Protein G) that binds an Fc domain of a target protein, an Fc binding peptide that binds an Fc domain of a target protein, a ligand binding domain of a receptor protein that binds the target protein of interest, a protein hg and of the target protein (such as a protein ligand of a receptor), a PDZ domain of a PDZ protein that binds a PDZ binding domain of a target protein, and the like.
In an embodiment of the invention, when the target protein is a cytokine, the target binding domain of a fusion protein of the invention may comprise a ligand binding domain of a cytokine receptor protein that binds the target cytokine protein.
In another embodiment, when the target protein is a receptor protein or ligand binding portion thereof, then the target binding domain of a fusion protein of the invention may comprise a protein ligand which is bound by the receptor or the ligand binding portion thereof.
In a preferred embodiment, when the target protein is a cytokine receptor protein or cytokine binding portion thereof, the target binding domain comprises the cytokine that is bound by the cytokine receptor or cytokine binding portion of such receptor.
In an embodiment wherein the target protein, such as the cystic fibrosis transmembrane conductance regulator (CFTR) protein, possesses a PDZ-binding domain, then the target binding domain of a fusion protein of the invention may comprise a PDZ domain from any of a variety of proteins that possess a PDZ domain. In a preferred embodiment, when a target protein possesses a PDZ-binding domain, a target binding domain of a fusion protein of the invention comprises a PDZ
domain from any of the members of the NHERF family of PDZ adapter proteins including, but not
A protein that is targeted by a fusion protein of the invention for an enhanced level of expression and/or enhanced expression at a desired cellular or extracellular location may be a soluble protein, a membrane-associated protein, or a secreted protein.
A target protein binding domain of a fusion protein of the invention is a polypeptide that binds a target protein. Preferably, the target binding domain has a binding affinity for a target protein that is sufficiently specific as to exclude other proteins from interfering with the enhancement in the level of expression of the target protein. Examples of polypeptides that may be used as a target binding domain of the invention include, but are not limited to, an antibody or antigen binding portion thereof that binds a target protein, an immunoglobulin-specific binding protein (such as Protein A, Protein L, and Protein G) that binds a target immunoglobulin or fragment thereof, an Fc binding protein (such as Protein A and Protein G) that binds an Fc domain of a target protein, an Fc binding peptide that binds an Fc domain of a target protein, a ligand binding domain of a receptor protein that binds the target protein of interest, a protein hg and of the target protein (such as a protein ligand of a receptor), a PDZ domain of a PDZ protein that binds a PDZ binding domain of a target protein, and the like.
In an embodiment of the invention, when the target protein is a cytokine, the target binding domain of a fusion protein of the invention may comprise a ligand binding domain of a cytokine receptor protein that binds the target cytokine protein.
In another embodiment, when the target protein is a receptor protein or ligand binding portion thereof, then the target binding domain of a fusion protein of the invention may comprise a protein ligand which is bound by the receptor or the ligand binding portion thereof.
In a preferred embodiment, when the target protein is a cytokine receptor protein or cytokine binding portion thereof, the target binding domain comprises the cytokine that is bound by the cytokine receptor or cytokine binding portion of such receptor.
In an embodiment wherein the target protein, such as the cystic fibrosis transmembrane conductance regulator (CFTR) protein, possesses a PDZ-binding domain, then the target binding domain of a fusion protein of the invention may comprise a PDZ domain from any of a variety of proteins that possess a PDZ domain. In a preferred embodiment, when a target protein possesses a PDZ-binding domain, a target binding domain of a fusion protein of the invention comprises a PDZ
domain from any of the members of the NHERF family of PDZ adapter proteins including, but not
8 PCT/US2013/073442 08.04.2015 limited to, of NHERF1 (also known as NHERF, EBP50, or SLC9A3R1), NHERF2 (also known as E3KARP or SLC9A3R2), and PDZK I (also known as CAP70 or NHERF3).
Particular embodiments of a target protein-binding fusion protein of the invention comprise a J domain of a J protein, or an active (expression enhancing) fragment thereof, or a protein expression enhancing polypeptide of formula I, fused to a target protein binding domain with or without a linker peptide. When a linker peptide is present in a target protein-binding fusion protein of the invention, the linker may be one or more amino acids, including 1 to 10 amino acids, 1 to 20 amino acids, and even 1 to 50 amino acids. Typically, a linker will not be more than 20 amino acids and will be selected or designed so that linker does not interfere with (and hopefully enhances) the function of either the target protein binding domain or the protein expression enhancement polypeptide. The linker, if present, preferably is selected to optimize the contribution of both elements of the fusion protein and thereby increase the level of expression and/or proper location of a target protein of interest. The linker may be omitted if direct attachment of a protein expression enhancement polypcptide to a target protein binding domain does not unacceptably diminish the function of either element or does not unacceptably diminish the desired enhancement in the level of expression and/or location of the target protein.
A linker useful in a fusion protein of the invention may include an enzymatically cleavable peptide, i.e., a cleavage site for an enzyme such as an enterokinase, the light chain of enterolcinase, thrombin, urolcinase, tobacco etch virus protease (TEV), tissue plasminogen activator, a zinc-dependent endopeptidase, a matrix metalloproteinase (MMP), a serralysin, an astacin, an adamalysin, a disintegrin, an ADAM, a caspase, a cathespsin, a calpain, and the like. Use of a cleavable linker in a fusion protein described herein may be advantageous to halt or slow the function of the fusion protein or to eliminate its presence in a cell or presence in a population of target protein molecules. Some cells possess one or more intracellular proteases that can cleave polypeptide linker molecules that contain a corresponding proteolytic recognition site. Accordingly, a cleavable linker used in a fusion protein of the invention may be selected that permits an intracellular protease to cleave the fusion protein after expression in the cell.
A fusion protein of the invention may further comprise an epitope tag to assist in detecting or isolating the fusion protein. An epitope tag useful in the invention includes, but is not limited to, a polyhistidine tag (such as hexaHis, SEQ ID NO:112), a V5 epitope tag, a Myc epitope tag, a Flag epitope tag, and an HA (human influenza hemagglutinin) epitope tag.
Fusion proteins of the present invention are demonstrated to enhance the level of expression of target proteins compared to the level of expression of the target proteins alone, i.e., in the absence of a fusion protein. The level of expression of a target protein of interest can be increased at least about 1.5-fold and up to 2-fold, 4-fold, 6-fold, 8-fold, 10-fold, 25-fold or more by following the
Particular embodiments of a target protein-binding fusion protein of the invention comprise a J domain of a J protein, or an active (expression enhancing) fragment thereof, or a protein expression enhancing polypeptide of formula I, fused to a target protein binding domain with or without a linker peptide. When a linker peptide is present in a target protein-binding fusion protein of the invention, the linker may be one or more amino acids, including 1 to 10 amino acids, 1 to 20 amino acids, and even 1 to 50 amino acids. Typically, a linker will not be more than 20 amino acids and will be selected or designed so that linker does not interfere with (and hopefully enhances) the function of either the target protein binding domain or the protein expression enhancement polypeptide. The linker, if present, preferably is selected to optimize the contribution of both elements of the fusion protein and thereby increase the level of expression and/or proper location of a target protein of interest. The linker may be omitted if direct attachment of a protein expression enhancement polypcptide to a target protein binding domain does not unacceptably diminish the function of either element or does not unacceptably diminish the desired enhancement in the level of expression and/or location of the target protein.
A linker useful in a fusion protein of the invention may include an enzymatically cleavable peptide, i.e., a cleavage site for an enzyme such as an enterokinase, the light chain of enterolcinase, thrombin, urolcinase, tobacco etch virus protease (TEV), tissue plasminogen activator, a zinc-dependent endopeptidase, a matrix metalloproteinase (MMP), a serralysin, an astacin, an adamalysin, a disintegrin, an ADAM, a caspase, a cathespsin, a calpain, and the like. Use of a cleavable linker in a fusion protein described herein may be advantageous to halt or slow the function of the fusion protein or to eliminate its presence in a cell or presence in a population of target protein molecules. Some cells possess one or more intracellular proteases that can cleave polypeptide linker molecules that contain a corresponding proteolytic recognition site. Accordingly, a cleavable linker used in a fusion protein of the invention may be selected that permits an intracellular protease to cleave the fusion protein after expression in the cell.
A fusion protein of the invention may further comprise an epitope tag to assist in detecting or isolating the fusion protein. An epitope tag useful in the invention includes, but is not limited to, a polyhistidine tag (such as hexaHis, SEQ ID NO:112), a V5 epitope tag, a Myc epitope tag, a Flag epitope tag, and an HA (human influenza hemagglutinin) epitope tag.
Fusion proteins of the present invention are demonstrated to enhance the level of expression of target proteins compared to the level of expression of the target proteins alone, i.e., in the absence of a fusion protein. The level of expression of a target protein of interest can be increased at least about 1.5-fold and up to 2-fold, 4-fold, 6-fold, 8-fold, 10-fold, 25-fold or more by following the
9 methods described herein. Moreover, fusion proteins of the invention also enhance the level of target proteins at their proper cellular or extracellular locations.
In another embodiment, the invention provides compositions comprising a fusion protein useful for providing the fusion protein to an individual to enhance expression of a target protein.
Compositions of the invention also include pharmaceutical compositions comprising a fusion protein and a pharmaceutically acceptable carrier for use in treating a disease or disorder in an individual, including in a human individual. Pharmaceutical compositions comprising a fusion protein as described herein may further comprise one or more other therapeutically active compounds.
Examples of such additional therapeutically active compounds that may be incorporated into a pharmaceutical composition of the invention include, but are not limited to, an antibiotic, an anti-viral compound, an anti-cancer compound, a sedative, a stimulant, a local anesthetic, a corticosteroid, an analgesic, an anti-histamine, a non-steroid anti-inflammatory drug (NSAID), and appropriate combinations thereof.
The invention also provides methods of treating a human or animal subject for a disease state characterized by a loss or diminution of a function or property that can be provided by a target protein of interest whose expression is enhanced by one of the types of fusion proteins described herein.
Such methods may include administering a fusion protein as described herein to a patient in need of treatment.
The invention also provides isolated nucleic acids encoding a protein expression enhancing polypeptide selected from the group consisting of an isolated J domain of a J
protein, an isolated J
domain fragment having the ability to enhance expression of a target protein of interest, or an isolated J domain analog polypeptide having the amino acid sequence of formula I (SEQ
ID NO:47) as described above.
The invention also provides nucleic acid vectors comprising an isolated nucleic acid described above.
In another embodiment, the invention comprises a host cell comprising an isolated nucleic acid or a nucleic acid vector described above.
The invention provides isolated nucleic acid molecules encoding a fusion protein described herein. Also provided are recombinant vector molecules into which has been inserted an isolated nucleic acid molecule encoding a fusion protein of the invention. Such recombinant vector molecules include cloning vectors to replicate the inserted nucleic acid in a transfected host cell and also expression vectors for expressing the encoded fusion protein in a compatible transfected host cell.
Any of a variety of expression vectors available in the art may be used to produce a fusion protein of the invention. Examples of expression vectors useful for expressing a fusion of the invention include, but are not limited to, plasmid pcDNA, pcDNA3.3 TOPO (Life Technologies, New York), plasmid pTT3, plasmid pEF-BOS, and the like.
The invention also provides expression vector molecules into which has been inserted an isolated nucleic acid encoding an isolated J domain, an active J domain fragment, or a J domain analog of formula I, for use in expressing a fusion protein of the invention in vitro in a compatible host cell.
Expression vectors of the invention also include gene therapy vectors for expressing a fusion protein of the invention in vivo in a gene therapy to restore a lost or deficient target protein function in a plant or animal (including mammals, such as humans, non-human primates, rodents, and livestock).
In another aspect, the invention provides a host cell comprising an expression vector for expressing a protein expression enhancing polypeptide described here or a fusion protein described herein. Host cells useful in the invention include, without limitation, eukaryotic host cells. Preferred eukaryotic host cells include, without limitation, a mammalian host cell, an insect host cell, a plant host cell, a fungal host cell, a eukaryotic algal host cell, a nematode host cell, a protozoan host cell, and a fish host cell. Preferably, a mammalian host cell is a Chinese Hamster Ovary (CHO) cell, a COS cell, a Vero cell, an SP2/0 cell, an NS/0 myeloma cell, a human embryonic kidney (HEK293) cell, a baby hamster kidney (BHK) cell, a HeLa cell, a human B cell, a CV-1/EBNA cell, an L cell, a 3T3 cell, an HEPG2 cell, a PerC6 cell, or an MDCK cell. Preferred fungal host cells include Aspergillus, Neurospora, Saccharomyces, Pichia, Hansenula, Schizosaccharomyces, Kluyveromyces, Yarrowia, and Candida. More preferably, a Saccharomyces host cell is a Saccharomyces cerevisiae cell.
The invention provides a method of expressing a fusion protein comprising a J
domain of a J
protein, a protein expression enhancing fragment thereof, or a J domain analog of formula I linked to a target protein of interest comprising culturing a host cell comprising a vector molecule comprising an isolated nucleic acid molecule encoding the fusion protein under conditions sufficient to produce the fusion protein.
In another embodiment, the invention provides a method of expressing a fusion protein comprising a J domain of a J protein, a protein expression enhancing fragment thereof, or a J domain analog of formula I as described above linked to a target protein of interest comprising transfecting a host cell with an expression vector comprising a structural gene encoding the fusion protein and culturing the transfected host cell under conditions causing the expression of the fusion protein.
The invention also provides a method of expressing a fusion protein comprising a protein expression enhancing polypeptide described herein linked to a target protein of interest comprising the steps of:
1) constructing a recombinant gene sequence encoding the fusion protein;
2) inserting the recombinant gene sequence into an expression vector to form a recombinant expression vector wherein said recombinant gene sequence is operably linked to a transcriptional promoter sequence;
3) transfecting said recombinant expression vector into host cells that are compatible with said promoter sequence; and 4) culturing said transfected host cells under conditions that permit expression said fusion protein.
The invention also provides a method of expressing a fusion protein comprising an isolated expression enhancing polypeptide described herein linked to a target protein binding domain comprising culturing a host cell comprising a vector comprising an isolated nucleic acid encoding the fusion protein under conditions sufficient to produce the fusion protein.
In another embodiment, the invention provides a method of enhancing the expression of a target protein of interest expressed by a host cell comprising transfecting the host cell with an expression vector comprising a structural gene encoding a fusion protein comprising an isolated J
domain of a J protein, an isolated J domain fragment having the ability to enhance expression of a target protein of interest, or an isolated J domain analog polypeptide having the amino acid sequence of formula I (SEQ ID NO:47) as described above linked to the target protein binding domain, and culturing said transfected host cell under conditions causing the co-expression of said fusion protein encoded by said structural gene and of said target protein of interest.
The invention provides a method of enhancing the expression of a target protein of interest comprising (a) transfecting a host cell with an expression vector comprising a structural gene encoding a fusion protein, wherein the fusion protein comprises a J domain of a J protein, an active fragment thereof, or a J domain analog of formula I linked to a target protein binding domain and wherein the fusion protein binds the target protein of interest, and (b) culturing said transfected host cell under conditions causing the expression of the fusion protein encoded on the structural gene.
Said structural gene may also include optional segments encoding a linker peptide connecting the J
domaina domain fragmenta domain analog element and the target protein binding domain element, and may also include segments encoding epitope tags, enzyme cleavage sites, and the like. The method may advantageously be carried out by following the steps:
1) constructing a recombinant gene sequence encoding a fusion protein comprising a protein expression enhancing polypeptide linked to a target binding domain;
2) inserting the recombinant gene sequence into an expression vector to form a recombinant expression vector wherein said recombinant gene sequence is operably linked to a transcriptional promoter sequence;
3) transfecting suitable host cells that are compatible with said promoter sequence with said recombinant expression vector; and 4) culturing said transfected host cells under conditions that lead to expression of said fusion protein.
PCT/US2013/073442 08.04.2015 In an embodiment of the invention, a nucleic acid encoding a fusion protein of the invention is inserted into the cells of a plant or non-human animal to express the fusion protein and enhance the level of expression of a target protein to provide a missing or desired function to the plant or non-human animal. Such methods include producing transgenic plants and transgenic non-human animals in which a nucleic acid encoding a fusion protein is permanently incorporated into the genome as a functional gene (transgene) such that the plant or non-human animal not only expresses the fusion protein, but also passes a copy of the expressible transgene on to progeny.
In another embodiment, the invention provides a method of restoring a function provided by a target protein in cells of a subject that are deficient in the expression of the target protein comprising inserting into cells of the subject an exogenous nucleic acid molecule encoding a fusion protein according to the invention, wherein after inserting the exogenous nucleic acid molecule into the cells, the fusion protein is expressed and enhances the level expression of the target protein (which enhancement may be the result of stabilizing the endogenous target protein, increasing the amount of properly folded target protein, improving the localization of the target protein to the desired cellular or extracellular compartment (e.g., improving secretion of a secreted protein), etc.), to provide the function of the target protein whose expression is deficient in the cells of the subject in the absence of the exogenous nucleic acid. Such a method is particularly useful in treating a subject that has a disease associated with the deficient expression of a protein in the subject.
Such diseases include, but are not limited to, a prion-associated disease (a transmissible spongiform encephalopathy), Alzheimer's disease, Parkinson's disease, Huntington's disease, cystic fibrosis, and al-antitrypsin (AAT) deficiency. Particularly preferred, are embodiments of the method wherein the subject is a human subject that is deficient in the expression of cystic fibrosis transmembrane conductance regulator (MR) protein and the disease is cystic fibrosis or wherein the subject is a human subject that is deficient in al -antitrypsin and the disease is al-antitrypsin (AAT) deficiency.
Brief Description of the Drawinzs Figures lA ¨ IC illustrate a series of experiments described in Example 2 that demonstrate improvement in the level of expression of a target protein of interest (the IL13Ra2 receptor protein) in = a modified arrangement in which the target protein is linked to a J
domain (from Hsp40, SV40, or CSP J proteins) in comparison to the protein alone (IL13Ra2WT) or expressed as a fusion protein with a BAG domain (from BAG3, BAG4, BAGS, or BAG6 proteins). Figure IA depicts diagrams of the structural genes for insertion into an expression vector plasmid used to transfect host cells. A
cDNA encoding an IL13Ra2 protein (wild-type protein, "WT") was augmented with a segment encoding a V5 epitope tag at the 3' end for the ''IL13Ra2W1" expression product. For BAG domain fusion proteins, a cDNA encoding IL13Ra2 was linked in frame to a segment encoding a BAG
domain, which was linked in turn to a segment encoding a V5 epitope tag to provide BAG domain fusion protein expression products. For J domain fusion proteins of the invention, a cllNA encoding AMENDED SHEET - IPEA/US
PCT/US2013/073442 08.04.2015 =
IL13Ra2 was linked in frame to a segment encoding a J domain, which was linked in turn to a segment encoding a V5 epitope tag to provide J domain fusion protein expression products. Figure 1B shows x-ray film images of chemiluminescent signals of a Western blot (immunoblot) analysis of cell lysates indicating relative levels of expression of the tagged IL13Ra2 wild-type (WT) protein or fusion protein counterparts in transfected cells. It can be seen that employing a J domain of J proteins Hsp40, SV40, or CSP as a fusion partner for the IL13Ra2 protein of interest resulted in significantly greater protein expression compared to the wild-type IL13Ra2 protein (WT) or any of the BAG
domain fusion counterparts comprising a BAG domain of BAG proteins BAG3, BAG4, BAGS, or BAG6. All transfectants were co-transfected with a reporter plasmid expressing green fluorescent protein (GFP) to show successful transfection and operability of the transfectants. See, lower panel of Figure I B. Figure IC provides the results of a densitometry analysis of the chemiluminescent signals in the immunoblot of Figure 1B using the NIB ImageJ image processing program.
The bar graphs in Figure 1C clearly show a significantly higher level of expression of all three secreted IL13Ra2-J
domain fusion proteins compared to that for any of the four IL13Ra2-BAG domain fusion proteins or the wild-type IL131262. protein (IL13a2WT expression = 100%).
Figures 2A and 2B show the results of an experiment described in Example 2 that examined improvement in the level of expression of a secreted target protein of interest in a modified arrangement in which a truncated form ("TF") of the ILl3Ra2 receptor protein (which is the extracellular portion of the IL13Ra2 receptor protein containing the ligand binding domain) is linked to a J domain (J-IL13Ra2TF) in comparison to the truncated receptor protein alone (IL13Ra2TF).
Figure 2A depicts diagrams of the structural gene constructs for insertion into an expression vector plasmid used to transfect host cells. A cDNA encoding IL13Rct2TF was augmented with a segment encoding a V5 epitope tag at the 3' end for the IL13Ra2TF expression product.
A cDNA encoding IL13Ra2TF was augmented at the 3' end with a segment encoding a V5 epitope tag and linked at the 5' end with a segment encoding a J domain (from J protein Erdj3) for a J
domain fusion protein expression product of the invention (J-IL13Ra2TF). Figure 2B shows x-ray film images of chemiluminescent signals in a Western blot indicating relative levels of expression in cells (cell lysates) and secreted into culture medium (medium) of the V5-tagged ILI 3Ra2TF
protein and J
domain fusion protein counterpart. It can be seen that employing a J domain as a fusion partner for the IL13Ra2TF protein of interest resulted in significantly greater level of protein expression compared to 1L13Ra2TF protein without a J domain. All transfectants were co-transfected with a reporter plasmid expressing green fluorescent protein (GFP) to show successful transfection and operability of the transfectants. See, lower panel of Figure 2B. Mock cultures contained cells = transfected with an "empty" vector, i.e., an expression vector lacking a structural gene for expressing any protein.
AMENDED SHEET -IPEA/US
=
PCT/US2013/073442 08.04.2015 Figures 3A and 3B show results of an experiment an experiment described in Example 2 comparing relative levels of expression of protein secreted into the culture medium of host cells transfected with an expression vector for expressing a truncated receptor protein (IL13Ra2TF), a BAG domain-IL!3Ra2TF fusion protein (BAG-IL13Ra2TF), and a J domain-1L13Ra2TF
fusion protein (J-IL13Ra2 IF). Figure 3A shows x-ray film images of chemiluminescent signals of a dot blot analysis of IL13Ra2TF, BAG domain-IL!3Ra2TF fusion protein, and J domain-IL!3Ra2TF fusion protein secreted into culture medium of transfected cells. All proteins carried a V5 epitope tag for immunodetection with anti-V5 antibody. Figure 3B provides the results of a densitometry analysis of the chemiluminescent signals in Figure 3A using the NIH ImageJ image processing program. The bar graphs in Figure 3B clearly show the significantly higher level of expression of secreted J domain-IL13Ra2TF fusion protein (bar graph 4) compared to either the 11,13Ra2TF (bar graph 2) or the BAG
domain- IL13Ra2TF fusion protein (bar graph 3). Mock cultures (bar graph 1) contained cells transfected with expression vector lacking a structural gene for expressing any protein.
Figures 4A ¨ 4C show results of an experiment described in Example 2 to examine =
improvement in the level of expression of a secreted al anti-trypsin (alAT) in a modified arrangement in which alAT is linked to (fused with) a J domain fusion partner in comparison to the protein alone or expressed as a fusion with a BAG domain. Figure 4A depicts diagrams of the structural gene constructs for insertion into an expression vector plasmid used to transfect host cells.
A cDNA encoding al AT was augmented with a segment encoding ,a V5 epitope tag at the 3' end for the alAT expression product. A cDNA encoding alAT was linked in frame to a segment encoding a BAG domain, which was linked in turn to a segment encoding a V5 epitope tag for a BAG domain fusion protein (alAT-BAG) expression product. A cDNA encoding alAT was linked in frame to a segment encoding a J domain, which was linked in turn to a segment encoding a V5 epitope tag for a J
domain fusion protein (al AT-J) expression product of the invention. Figure 4B
shows x-ray film images of chemiluminescent signals of a dot blot analysis indicating relative levels of expression of secreted alAT protein or secreted fusion protein counterparts secreted into culture media. It can be seen that employing a J domain as a fusion partner for the alAT protein of interest (al AT-J) resulted in significantly greater expression of the secreted protein (al AT-J) compared to the al AT protein alone or BAG domain fusion counterpart (al AT-BAG). Mock cultures contained cells transfected with expression vector lacking a structural gene for expressing any protein.
Figure 4C provides the results of a densitometry analysis of the chemiluminescent signals in Figure 4B using the NIH ImageJ
image processing program. The bar graphs in Figure 4C clearly show the significantly higher level of expression of secreted al AT-J fusion protein (bar graph 4) compared to either the (unfused) alAT
(bar graph 2) or the BAG domain-alAT fusion protein (bar graph 3).
Figures 5A ¨5C show results of an experiment described in Example 2 that demonstrate improvement in the level of expression of a secreted truncated form of a TNF-a receptorl protein =
AMENDED SHEET - IPEA/US
PCT/US13/73442 03-10-2014 PCT/US2013/073442 08.04.2015 (TNFIUTF) in a modified arrangement in which TNFR1TF is linked to a J domain fusion partner in comparison to the protein alone (TNFR1TF). Figure 5A depicts diagrams of the structural gene constructs for insertion into an expression vector plasmid used to transfect host cells. A cDNA
encoding TNFRITF was augmented with a segment encoding a V5 epitope tag at the 3' end for the TNFRITF expression product. A cDNA encoding TNFRITF was linked in frame to a segment encoding a J domain, which was linked in turn to a segment encoding a V5 epitope tag to provide a J
domain fusion protein expression product of the invention. Figure 5B shows x-ray film images of chemiluminescent signals of dot blots indicating relative levels of TNFRITF
and TNFR1TF-J domain fusion protein secreted into culture media. It can be seen that employing a J
domain as a fusion partner for the TNFRITF protein of interest (TNFR1TF-J) resulted in significantly greater expression of the secreted protein than for the (unfused) TNFRITF protein. Figure 5C
provides the results of a densitometry analysis of the chemiluminescent signals in the dot blots of Figure 5B using the ImageJ image processing program. The bar graphs in Figure 5C clearly show the significantly higher level of expression of secreted TNFR1TF-J domain fusion protein (bar graph 3) compared to TNFRITF (bar graph 2). Mock cultures contained cells transfected with expression vector lacking a structural gene for expressing any protein.
Figures 6A ¨ 6C-3 show results of a series of experiments described in Example 2 that demonstrate improvement in the level of expression of target Fe fusion proteins of interest in a modified arrangement in which each of three target proteins of interest is linked to a J domain fusion =
partner. Figure 6A depicts diagrams of structural gene constructs used in this example. For the Fe fusion proteins, a cDNA encoding each protein of interest (TNFRITF, IL13Ra2TF, or alAT) was augmented with a segment encoding a V5 epitope tag at the 3' end, which was linked in turn to a segment ("Fe") encoding constant domains of an immunoglobulin Fe region. For J
domain fusions, a cDNA encoding a J domain was linked in frame between the cDNA encoding each protein of interest and the segment encoding a V5 epitope tag. See, Figure 6A. Figures 6B-1 ¨ 6B-3 show dot blot analysis for secreted proteins in media from cultures of transfected cells.
Each of the Fe fusion proteins (TNFR1-V5-Fc, IL13Ra2TF-Fc, and alAT-Fc) were expressed in culture media as shown in the dot blots in the middle lane of each panel in Figures 6B-1 ¨ 6B-3. This level of expression of the Fe fusion proteins was greater than that for each of the proteins of interest alone (i.e., without fusion to an Fe domain; data not shown). Significantly higher levels of expression were obtained in each case when a J domain was linked to the protein of interest segment within the Fe fusion proteins as shown in the dot blots in the right lane of each panel in Figures 6B-1 ¨ 6B-3.
The results of a densitometry analysis of the chemilutninescent signals of the dot blots in Figures 6B-1 ¨ 6B-3 are shown in the corresponding panels of Figures 6C-1 ¨ 6C-3, where the significantly higher level of expression of the J domain fusion proteins is clearly evident by comparing bar graph 2 (protein of interest-Fe fusion proteins) with bar graph 3 (protein of AMENDED SHEET -IPEA/US
PCT/US2013/073442 08.04.2015 interest-J domain-Fe fusion proteins) in each of the panels of Figures 6C-1 ¨
6C-3. Mock cultures contained cells transfected with expression vector lacking a structural gene for expressing any protein.
Figures 7A and 7B show results of an experiment described in Example 2 that demonstrates improvement in the level of expression of the cytoplasmic p53 protein in a modified arrangement in which p53 is linked to (fused with) a J domain fusion partner in comparison to the p53 protein alone.
Figure 7A depicts diagrams of the constructs used in this experiment. A cDNA
encoding p53 was augmented at its 5' end with a segment encoding a V5 epitope tag for the p53 expression product. A
cDNA encoding p53 was linked in frame at its 5 end to a segment encoding a J
domain of an SV40 J
protein, which was in turn linked at its 5' end to a segment encoding a V5 epitope tag for a J domain fusion protein (J-p53) expression product of the invention. Figure 7B shows x-ray film images of chemiluminescent signals of a Western blot of cell lysates indicating relative levels of expression in cells of the tagged p53 protein and the J domain fusion protein counterpart (J-p53). It can be seen that employing a J domain as a fusion partner for the p53 protein of interest (J-p53) resulted in a significantly greater level of expression in transfected cells compared to the level of expression in transfected cells of the p53 protein without a J domain (p53). Mock cultures contained cells transfected with expression vector lacking a structural gene for expressing any protein.
Figures 8A and 8B show results of a series of experiments described in Example 2 that demonstrate improvement in the levels of expression of two target proteins of interest, i.e., a wild-type CFTR protein and the corresponding CFTR 6,508F mutant protein (deletion at position 508 of a phenylalanine residue results in defective folding and rapid degradation of the CFTR 6,508F mutant protein), in a modified arrangement in which each of the proteins is linked to (fused with) a J domain fusion partner in comparison to each of the proteins alone or each of the proteins expressed as a fusion with a BAG domain. Figure 8A depicts diagrams of constructs for insertion into an expression vector plasmid used to transfect host cells. A cDNA encoding each protein of interest, i.e., the wild-type CFTR protein (CFTR WT) or the CFTR 6,508F mutant protein (6,508F), was augmented at the 5' end with a segment encoding a V5 epitope tag. For BAG domain fusions, a cDNA
encoding a BAG
domain was linked in frame between the cllNA encoding each protein of interest and the 5' segment encoding a V5 epitope tag. For J domain fusion protein expression products of the invention, a cDNA
encoding an SV40 J domain was linked in frame between the cDNA encoding each protein of interest and a 5' segment encoding a V5 epitope tag for the J domain. See, Figure 8A.
Figure 8B shows x-ray film images of chemilurninescent signals of a Western blot analysis of cell lysates indicating relative levels of expression in cells of the tagged proteins of interest (CFTR WT and CFTR 6,508F), BAG
domain fusion proteins (BAG-CFTR WT and BAG-CFTR 6,508F), and J domain fusion proteins (J-CFTR WT and J-CFTR 6,508F). It can be seen that employing a J domain as a fusion partner for both CFTR WT and CFTR 6508F proteins resulted in a significantly greater level of expression in transfected cells as compared to the levels of expression of (unfused) CFTR WT
and mutant CFTR
AMENDED SHEET - IPEA/US
PCT/US2013/073442 08.04.2015 =
.6,508F proteins or of the BAG domain fusion counterparts. All transfectants were co-transfected with a reporter plasmid expressing green fluorescent protein (GFP) to show successful transfection and operability of the transfectants (lower panel of Figure 8B).
Figure 9A depicts a diagram of a general scheme of an unmodified arrangement for enhancing expression of a target protein on interest in which co-expression of a fusion protein of the invention enhances expression of a target protein of interest as described in Example 4. In the scheme, a fusion protein of the invention comprises a protein expression enhancing polypeptide (PEEP) domain linked to a target protein binding domain, wherein the target protein binding domain binds a target protein of interest thereby bringing the target protein into close proximity with the PEEP domain, which in turn results in an elevation of the level of expression of the target protein in its proper cellular or extracellular location.
Figure 913 is a diagram of a structural gene encoding an IL13Ra2TF fusion protein (target protein) for insertion into an expression vector plasmid, which was used to transfect host cells as described in Example 4, below. A cDNA encoding a truncated form of the IL13Ra2 receptor protein (IL13Ra2TF), which comprises the extracellular IL13 ligand binding domain of IL13Ra2, was augmented with a segment encoding a V5 epitope tag at the 3' end.
Figure 9C depicts a construct for expressing a fusion protein of the invention to enhance expression of the V5-tagged IL13Ra2TF target protein depicted in Figure 9B and as described in Example 4. A cDNA encoding a J domain of an Erdj3 J protein (protein expression enhancing polypeptide domain) was linked to a segment encoding the IL13 protein (target protein binding domain). A segment encoding a Flag epitope tag was linked to the 3' end of the segment encoding the IL13 target protein binding domain.
Figure 10 shows x-ray film images of chemiluminescent signals of a Western blot analysis of culture medium (upper panel) and cell lysates (middle panel) of transfected cells expressing a truncated form of the IL13Ra2 receptor protein (IL13Ra2TF) when expressed alone (lane 2 from the left), when co-expressed with its IL13 ligand (IL13 Only, lane 3 from the left), and when co-expressed in an unmodified arrangement with a J domain-1L13 fusion protein of the invention (J-1L13, lane 4 from the left), as described in Example 4. A properly folded ILI
3Ra2TF protein (target protein) is expected to be secreted from the transfected host cells. It can be seen that co-expression of the IL13Ra2TF protein with the J domain-1L13 fusion protein significantly enhanced the level of expression of secreted 1L13Ra2TF protein (top panel, lane 4 from the left) as compared to expression of IL13Ra2TF protein alone (top panel, lane 2 from the left) or co-expression of IL13Ra2TF protein with its IL13 ligand (top panel, lane 3 from the left). Moreover, co-expression of the 1L13Ra2TF
protein with the J domain-IL13 fusion protein significantly enhanced the level of expression of intracellular IL13Ra2TF protein (middle panel, lane 4 from the left) as compared to the level expression of IL13Ra2TF protein alone (middle panel, lane 2 from the left) or co-expression of AMENDED SHEET - IPEA/US
=
=
PCT/US2013/073442 08.04.2015 1L13Ra2TF protein with its 1L13 ligand (middle panel, lane 3 from the left).
All transfectants were co-transfected with a reporter plasmid expressing green fluorescent protein (GFP) to show successful transfection and operability of the transfeetants. See, lower panel of Figure
In another embodiment, the invention provides compositions comprising a fusion protein useful for providing the fusion protein to an individual to enhance expression of a target protein.
Compositions of the invention also include pharmaceutical compositions comprising a fusion protein and a pharmaceutically acceptable carrier for use in treating a disease or disorder in an individual, including in a human individual. Pharmaceutical compositions comprising a fusion protein as described herein may further comprise one or more other therapeutically active compounds.
Examples of such additional therapeutically active compounds that may be incorporated into a pharmaceutical composition of the invention include, but are not limited to, an antibiotic, an anti-viral compound, an anti-cancer compound, a sedative, a stimulant, a local anesthetic, a corticosteroid, an analgesic, an anti-histamine, a non-steroid anti-inflammatory drug (NSAID), and appropriate combinations thereof.
The invention also provides methods of treating a human or animal subject for a disease state characterized by a loss or diminution of a function or property that can be provided by a target protein of interest whose expression is enhanced by one of the types of fusion proteins described herein.
Such methods may include administering a fusion protein as described herein to a patient in need of treatment.
The invention also provides isolated nucleic acids encoding a protein expression enhancing polypeptide selected from the group consisting of an isolated J domain of a J
protein, an isolated J
domain fragment having the ability to enhance expression of a target protein of interest, or an isolated J domain analog polypeptide having the amino acid sequence of formula I (SEQ
ID NO:47) as described above.
The invention also provides nucleic acid vectors comprising an isolated nucleic acid described above.
In another embodiment, the invention comprises a host cell comprising an isolated nucleic acid or a nucleic acid vector described above.
The invention provides isolated nucleic acid molecules encoding a fusion protein described herein. Also provided are recombinant vector molecules into which has been inserted an isolated nucleic acid molecule encoding a fusion protein of the invention. Such recombinant vector molecules include cloning vectors to replicate the inserted nucleic acid in a transfected host cell and also expression vectors for expressing the encoded fusion protein in a compatible transfected host cell.
Any of a variety of expression vectors available in the art may be used to produce a fusion protein of the invention. Examples of expression vectors useful for expressing a fusion of the invention include, but are not limited to, plasmid pcDNA, pcDNA3.3 TOPO (Life Technologies, New York), plasmid pTT3, plasmid pEF-BOS, and the like.
The invention also provides expression vector molecules into which has been inserted an isolated nucleic acid encoding an isolated J domain, an active J domain fragment, or a J domain analog of formula I, for use in expressing a fusion protein of the invention in vitro in a compatible host cell.
Expression vectors of the invention also include gene therapy vectors for expressing a fusion protein of the invention in vivo in a gene therapy to restore a lost or deficient target protein function in a plant or animal (including mammals, such as humans, non-human primates, rodents, and livestock).
In another aspect, the invention provides a host cell comprising an expression vector for expressing a protein expression enhancing polypeptide described here or a fusion protein described herein. Host cells useful in the invention include, without limitation, eukaryotic host cells. Preferred eukaryotic host cells include, without limitation, a mammalian host cell, an insect host cell, a plant host cell, a fungal host cell, a eukaryotic algal host cell, a nematode host cell, a protozoan host cell, and a fish host cell. Preferably, a mammalian host cell is a Chinese Hamster Ovary (CHO) cell, a COS cell, a Vero cell, an SP2/0 cell, an NS/0 myeloma cell, a human embryonic kidney (HEK293) cell, a baby hamster kidney (BHK) cell, a HeLa cell, a human B cell, a CV-1/EBNA cell, an L cell, a 3T3 cell, an HEPG2 cell, a PerC6 cell, or an MDCK cell. Preferred fungal host cells include Aspergillus, Neurospora, Saccharomyces, Pichia, Hansenula, Schizosaccharomyces, Kluyveromyces, Yarrowia, and Candida. More preferably, a Saccharomyces host cell is a Saccharomyces cerevisiae cell.
The invention provides a method of expressing a fusion protein comprising a J
domain of a J
protein, a protein expression enhancing fragment thereof, or a J domain analog of formula I linked to a target protein of interest comprising culturing a host cell comprising a vector molecule comprising an isolated nucleic acid molecule encoding the fusion protein under conditions sufficient to produce the fusion protein.
In another embodiment, the invention provides a method of expressing a fusion protein comprising a J domain of a J protein, a protein expression enhancing fragment thereof, or a J domain analog of formula I as described above linked to a target protein of interest comprising transfecting a host cell with an expression vector comprising a structural gene encoding the fusion protein and culturing the transfected host cell under conditions causing the expression of the fusion protein.
The invention also provides a method of expressing a fusion protein comprising a protein expression enhancing polypeptide described herein linked to a target protein of interest comprising the steps of:
1) constructing a recombinant gene sequence encoding the fusion protein;
2) inserting the recombinant gene sequence into an expression vector to form a recombinant expression vector wherein said recombinant gene sequence is operably linked to a transcriptional promoter sequence;
3) transfecting said recombinant expression vector into host cells that are compatible with said promoter sequence; and 4) culturing said transfected host cells under conditions that permit expression said fusion protein.
The invention also provides a method of expressing a fusion protein comprising an isolated expression enhancing polypeptide described herein linked to a target protein binding domain comprising culturing a host cell comprising a vector comprising an isolated nucleic acid encoding the fusion protein under conditions sufficient to produce the fusion protein.
In another embodiment, the invention provides a method of enhancing the expression of a target protein of interest expressed by a host cell comprising transfecting the host cell with an expression vector comprising a structural gene encoding a fusion protein comprising an isolated J
domain of a J protein, an isolated J domain fragment having the ability to enhance expression of a target protein of interest, or an isolated J domain analog polypeptide having the amino acid sequence of formula I (SEQ ID NO:47) as described above linked to the target protein binding domain, and culturing said transfected host cell under conditions causing the co-expression of said fusion protein encoded by said structural gene and of said target protein of interest.
The invention provides a method of enhancing the expression of a target protein of interest comprising (a) transfecting a host cell with an expression vector comprising a structural gene encoding a fusion protein, wherein the fusion protein comprises a J domain of a J protein, an active fragment thereof, or a J domain analog of formula I linked to a target protein binding domain and wherein the fusion protein binds the target protein of interest, and (b) culturing said transfected host cell under conditions causing the expression of the fusion protein encoded on the structural gene.
Said structural gene may also include optional segments encoding a linker peptide connecting the J
domaina domain fragmenta domain analog element and the target protein binding domain element, and may also include segments encoding epitope tags, enzyme cleavage sites, and the like. The method may advantageously be carried out by following the steps:
1) constructing a recombinant gene sequence encoding a fusion protein comprising a protein expression enhancing polypeptide linked to a target binding domain;
2) inserting the recombinant gene sequence into an expression vector to form a recombinant expression vector wherein said recombinant gene sequence is operably linked to a transcriptional promoter sequence;
3) transfecting suitable host cells that are compatible with said promoter sequence with said recombinant expression vector; and 4) culturing said transfected host cells under conditions that lead to expression of said fusion protein.
PCT/US2013/073442 08.04.2015 In an embodiment of the invention, a nucleic acid encoding a fusion protein of the invention is inserted into the cells of a plant or non-human animal to express the fusion protein and enhance the level of expression of a target protein to provide a missing or desired function to the plant or non-human animal. Such methods include producing transgenic plants and transgenic non-human animals in which a nucleic acid encoding a fusion protein is permanently incorporated into the genome as a functional gene (transgene) such that the plant or non-human animal not only expresses the fusion protein, but also passes a copy of the expressible transgene on to progeny.
In another embodiment, the invention provides a method of restoring a function provided by a target protein in cells of a subject that are deficient in the expression of the target protein comprising inserting into cells of the subject an exogenous nucleic acid molecule encoding a fusion protein according to the invention, wherein after inserting the exogenous nucleic acid molecule into the cells, the fusion protein is expressed and enhances the level expression of the target protein (which enhancement may be the result of stabilizing the endogenous target protein, increasing the amount of properly folded target protein, improving the localization of the target protein to the desired cellular or extracellular compartment (e.g., improving secretion of a secreted protein), etc.), to provide the function of the target protein whose expression is deficient in the cells of the subject in the absence of the exogenous nucleic acid. Such a method is particularly useful in treating a subject that has a disease associated with the deficient expression of a protein in the subject.
Such diseases include, but are not limited to, a prion-associated disease (a transmissible spongiform encephalopathy), Alzheimer's disease, Parkinson's disease, Huntington's disease, cystic fibrosis, and al-antitrypsin (AAT) deficiency. Particularly preferred, are embodiments of the method wherein the subject is a human subject that is deficient in the expression of cystic fibrosis transmembrane conductance regulator (MR) protein and the disease is cystic fibrosis or wherein the subject is a human subject that is deficient in al -antitrypsin and the disease is al-antitrypsin (AAT) deficiency.
Brief Description of the Drawinzs Figures lA ¨ IC illustrate a series of experiments described in Example 2 that demonstrate improvement in the level of expression of a target protein of interest (the IL13Ra2 receptor protein) in = a modified arrangement in which the target protein is linked to a J
domain (from Hsp40, SV40, or CSP J proteins) in comparison to the protein alone (IL13Ra2WT) or expressed as a fusion protein with a BAG domain (from BAG3, BAG4, BAGS, or BAG6 proteins). Figure IA depicts diagrams of the structural genes for insertion into an expression vector plasmid used to transfect host cells. A
cDNA encoding an IL13Ra2 protein (wild-type protein, "WT") was augmented with a segment encoding a V5 epitope tag at the 3' end for the ''IL13Ra2W1" expression product. For BAG domain fusion proteins, a cDNA encoding IL13Ra2 was linked in frame to a segment encoding a BAG
domain, which was linked in turn to a segment encoding a V5 epitope tag to provide BAG domain fusion protein expression products. For J domain fusion proteins of the invention, a cllNA encoding AMENDED SHEET - IPEA/US
PCT/US2013/073442 08.04.2015 =
IL13Ra2 was linked in frame to a segment encoding a J domain, which was linked in turn to a segment encoding a V5 epitope tag to provide J domain fusion protein expression products. Figure 1B shows x-ray film images of chemiluminescent signals of a Western blot (immunoblot) analysis of cell lysates indicating relative levels of expression of the tagged IL13Ra2 wild-type (WT) protein or fusion protein counterparts in transfected cells. It can be seen that employing a J domain of J proteins Hsp40, SV40, or CSP as a fusion partner for the IL13Ra2 protein of interest resulted in significantly greater protein expression compared to the wild-type IL13Ra2 protein (WT) or any of the BAG
domain fusion counterparts comprising a BAG domain of BAG proteins BAG3, BAG4, BAGS, or BAG6. All transfectants were co-transfected with a reporter plasmid expressing green fluorescent protein (GFP) to show successful transfection and operability of the transfectants. See, lower panel of Figure I B. Figure IC provides the results of a densitometry analysis of the chemiluminescent signals in the immunoblot of Figure 1B using the NIB ImageJ image processing program.
The bar graphs in Figure 1C clearly show a significantly higher level of expression of all three secreted IL13Ra2-J
domain fusion proteins compared to that for any of the four IL13Ra2-BAG domain fusion proteins or the wild-type IL131262. protein (IL13a2WT expression = 100%).
Figures 2A and 2B show the results of an experiment described in Example 2 that examined improvement in the level of expression of a secreted target protein of interest in a modified arrangement in which a truncated form ("TF") of the ILl3Ra2 receptor protein (which is the extracellular portion of the IL13Ra2 receptor protein containing the ligand binding domain) is linked to a J domain (J-IL13Ra2TF) in comparison to the truncated receptor protein alone (IL13Ra2TF).
Figure 2A depicts diagrams of the structural gene constructs for insertion into an expression vector plasmid used to transfect host cells. A cDNA encoding IL13Rct2TF was augmented with a segment encoding a V5 epitope tag at the 3' end for the IL13Ra2TF expression product.
A cDNA encoding IL13Ra2TF was augmented at the 3' end with a segment encoding a V5 epitope tag and linked at the 5' end with a segment encoding a J domain (from J protein Erdj3) for a J
domain fusion protein expression product of the invention (J-IL13Ra2TF). Figure 2B shows x-ray film images of chemiluminescent signals in a Western blot indicating relative levels of expression in cells (cell lysates) and secreted into culture medium (medium) of the V5-tagged ILI 3Ra2TF
protein and J
domain fusion protein counterpart. It can be seen that employing a J domain as a fusion partner for the IL13Ra2TF protein of interest resulted in significantly greater level of protein expression compared to 1L13Ra2TF protein without a J domain. All transfectants were co-transfected with a reporter plasmid expressing green fluorescent protein (GFP) to show successful transfection and operability of the transfectants. See, lower panel of Figure 2B. Mock cultures contained cells = transfected with an "empty" vector, i.e., an expression vector lacking a structural gene for expressing any protein.
AMENDED SHEET -IPEA/US
=
PCT/US2013/073442 08.04.2015 Figures 3A and 3B show results of an experiment an experiment described in Example 2 comparing relative levels of expression of protein secreted into the culture medium of host cells transfected with an expression vector for expressing a truncated receptor protein (IL13Ra2TF), a BAG domain-IL!3Ra2TF fusion protein (BAG-IL13Ra2TF), and a J domain-1L13Ra2TF
fusion protein (J-IL13Ra2 IF). Figure 3A shows x-ray film images of chemiluminescent signals of a dot blot analysis of IL13Ra2TF, BAG domain-IL!3Ra2TF fusion protein, and J domain-IL!3Ra2TF fusion protein secreted into culture medium of transfected cells. All proteins carried a V5 epitope tag for immunodetection with anti-V5 antibody. Figure 3B provides the results of a densitometry analysis of the chemiluminescent signals in Figure 3A using the NIH ImageJ image processing program. The bar graphs in Figure 3B clearly show the significantly higher level of expression of secreted J domain-IL13Ra2TF fusion protein (bar graph 4) compared to either the 11,13Ra2TF (bar graph 2) or the BAG
domain- IL13Ra2TF fusion protein (bar graph 3). Mock cultures (bar graph 1) contained cells transfected with expression vector lacking a structural gene for expressing any protein.
Figures 4A ¨ 4C show results of an experiment described in Example 2 to examine =
improvement in the level of expression of a secreted al anti-trypsin (alAT) in a modified arrangement in which alAT is linked to (fused with) a J domain fusion partner in comparison to the protein alone or expressed as a fusion with a BAG domain. Figure 4A depicts diagrams of the structural gene constructs for insertion into an expression vector plasmid used to transfect host cells.
A cDNA encoding al AT was augmented with a segment encoding ,a V5 epitope tag at the 3' end for the alAT expression product. A cDNA encoding alAT was linked in frame to a segment encoding a BAG domain, which was linked in turn to a segment encoding a V5 epitope tag for a BAG domain fusion protein (alAT-BAG) expression product. A cDNA encoding alAT was linked in frame to a segment encoding a J domain, which was linked in turn to a segment encoding a V5 epitope tag for a J
domain fusion protein (al AT-J) expression product of the invention. Figure 4B
shows x-ray film images of chemiluminescent signals of a dot blot analysis indicating relative levels of expression of secreted alAT protein or secreted fusion protein counterparts secreted into culture media. It can be seen that employing a J domain as a fusion partner for the alAT protein of interest (al AT-J) resulted in significantly greater expression of the secreted protein (al AT-J) compared to the al AT protein alone or BAG domain fusion counterpart (al AT-BAG). Mock cultures contained cells transfected with expression vector lacking a structural gene for expressing any protein.
Figure 4C provides the results of a densitometry analysis of the chemiluminescent signals in Figure 4B using the NIH ImageJ
image processing program. The bar graphs in Figure 4C clearly show the significantly higher level of expression of secreted al AT-J fusion protein (bar graph 4) compared to either the (unfused) alAT
(bar graph 2) or the BAG domain-alAT fusion protein (bar graph 3).
Figures 5A ¨5C show results of an experiment described in Example 2 that demonstrate improvement in the level of expression of a secreted truncated form of a TNF-a receptorl protein =
AMENDED SHEET - IPEA/US
PCT/US13/73442 03-10-2014 PCT/US2013/073442 08.04.2015 (TNFIUTF) in a modified arrangement in which TNFR1TF is linked to a J domain fusion partner in comparison to the protein alone (TNFR1TF). Figure 5A depicts diagrams of the structural gene constructs for insertion into an expression vector plasmid used to transfect host cells. A cDNA
encoding TNFRITF was augmented with a segment encoding a V5 epitope tag at the 3' end for the TNFRITF expression product. A cDNA encoding TNFRITF was linked in frame to a segment encoding a J domain, which was linked in turn to a segment encoding a V5 epitope tag to provide a J
domain fusion protein expression product of the invention. Figure 5B shows x-ray film images of chemiluminescent signals of dot blots indicating relative levels of TNFRITF
and TNFR1TF-J domain fusion protein secreted into culture media. It can be seen that employing a J
domain as a fusion partner for the TNFRITF protein of interest (TNFR1TF-J) resulted in significantly greater expression of the secreted protein than for the (unfused) TNFRITF protein. Figure 5C
provides the results of a densitometry analysis of the chemiluminescent signals in the dot blots of Figure 5B using the ImageJ image processing program. The bar graphs in Figure 5C clearly show the significantly higher level of expression of secreted TNFR1TF-J domain fusion protein (bar graph 3) compared to TNFRITF (bar graph 2). Mock cultures contained cells transfected with expression vector lacking a structural gene for expressing any protein.
Figures 6A ¨ 6C-3 show results of a series of experiments described in Example 2 that demonstrate improvement in the level of expression of target Fe fusion proteins of interest in a modified arrangement in which each of three target proteins of interest is linked to a J domain fusion =
partner. Figure 6A depicts diagrams of structural gene constructs used in this example. For the Fe fusion proteins, a cDNA encoding each protein of interest (TNFRITF, IL13Ra2TF, or alAT) was augmented with a segment encoding a V5 epitope tag at the 3' end, which was linked in turn to a segment ("Fe") encoding constant domains of an immunoglobulin Fe region. For J
domain fusions, a cDNA encoding a J domain was linked in frame between the cDNA encoding each protein of interest and the segment encoding a V5 epitope tag. See, Figure 6A. Figures 6B-1 ¨ 6B-3 show dot blot analysis for secreted proteins in media from cultures of transfected cells.
Each of the Fe fusion proteins (TNFR1-V5-Fc, IL13Ra2TF-Fc, and alAT-Fc) were expressed in culture media as shown in the dot blots in the middle lane of each panel in Figures 6B-1 ¨ 6B-3. This level of expression of the Fe fusion proteins was greater than that for each of the proteins of interest alone (i.e., without fusion to an Fe domain; data not shown). Significantly higher levels of expression were obtained in each case when a J domain was linked to the protein of interest segment within the Fe fusion proteins as shown in the dot blots in the right lane of each panel in Figures 6B-1 ¨ 6B-3.
The results of a densitometry analysis of the chemilutninescent signals of the dot blots in Figures 6B-1 ¨ 6B-3 are shown in the corresponding panels of Figures 6C-1 ¨ 6C-3, where the significantly higher level of expression of the J domain fusion proteins is clearly evident by comparing bar graph 2 (protein of interest-Fe fusion proteins) with bar graph 3 (protein of AMENDED SHEET -IPEA/US
PCT/US2013/073442 08.04.2015 interest-J domain-Fe fusion proteins) in each of the panels of Figures 6C-1 ¨
6C-3. Mock cultures contained cells transfected with expression vector lacking a structural gene for expressing any protein.
Figures 7A and 7B show results of an experiment described in Example 2 that demonstrates improvement in the level of expression of the cytoplasmic p53 protein in a modified arrangement in which p53 is linked to (fused with) a J domain fusion partner in comparison to the p53 protein alone.
Figure 7A depicts diagrams of the constructs used in this experiment. A cDNA
encoding p53 was augmented at its 5' end with a segment encoding a V5 epitope tag for the p53 expression product. A
cDNA encoding p53 was linked in frame at its 5 end to a segment encoding a J
domain of an SV40 J
protein, which was in turn linked at its 5' end to a segment encoding a V5 epitope tag for a J domain fusion protein (J-p53) expression product of the invention. Figure 7B shows x-ray film images of chemiluminescent signals of a Western blot of cell lysates indicating relative levels of expression in cells of the tagged p53 protein and the J domain fusion protein counterpart (J-p53). It can be seen that employing a J domain as a fusion partner for the p53 protein of interest (J-p53) resulted in a significantly greater level of expression in transfected cells compared to the level of expression in transfected cells of the p53 protein without a J domain (p53). Mock cultures contained cells transfected with expression vector lacking a structural gene for expressing any protein.
Figures 8A and 8B show results of a series of experiments described in Example 2 that demonstrate improvement in the levels of expression of two target proteins of interest, i.e., a wild-type CFTR protein and the corresponding CFTR 6,508F mutant protein (deletion at position 508 of a phenylalanine residue results in defective folding and rapid degradation of the CFTR 6,508F mutant protein), in a modified arrangement in which each of the proteins is linked to (fused with) a J domain fusion partner in comparison to each of the proteins alone or each of the proteins expressed as a fusion with a BAG domain. Figure 8A depicts diagrams of constructs for insertion into an expression vector plasmid used to transfect host cells. A cDNA encoding each protein of interest, i.e., the wild-type CFTR protein (CFTR WT) or the CFTR 6,508F mutant protein (6,508F), was augmented at the 5' end with a segment encoding a V5 epitope tag. For BAG domain fusions, a cDNA
encoding a BAG
domain was linked in frame between the cllNA encoding each protein of interest and the 5' segment encoding a V5 epitope tag. For J domain fusion protein expression products of the invention, a cDNA
encoding an SV40 J domain was linked in frame between the cDNA encoding each protein of interest and a 5' segment encoding a V5 epitope tag for the J domain. See, Figure 8A.
Figure 8B shows x-ray film images of chemilurninescent signals of a Western blot analysis of cell lysates indicating relative levels of expression in cells of the tagged proteins of interest (CFTR WT and CFTR 6,508F), BAG
domain fusion proteins (BAG-CFTR WT and BAG-CFTR 6,508F), and J domain fusion proteins (J-CFTR WT and J-CFTR 6,508F). It can be seen that employing a J domain as a fusion partner for both CFTR WT and CFTR 6508F proteins resulted in a significantly greater level of expression in transfected cells as compared to the levels of expression of (unfused) CFTR WT
and mutant CFTR
AMENDED SHEET - IPEA/US
PCT/US2013/073442 08.04.2015 =
.6,508F proteins or of the BAG domain fusion counterparts. All transfectants were co-transfected with a reporter plasmid expressing green fluorescent protein (GFP) to show successful transfection and operability of the transfectants (lower panel of Figure 8B).
Figure 9A depicts a diagram of a general scheme of an unmodified arrangement for enhancing expression of a target protein on interest in which co-expression of a fusion protein of the invention enhances expression of a target protein of interest as described in Example 4. In the scheme, a fusion protein of the invention comprises a protein expression enhancing polypeptide (PEEP) domain linked to a target protein binding domain, wherein the target protein binding domain binds a target protein of interest thereby bringing the target protein into close proximity with the PEEP domain, which in turn results in an elevation of the level of expression of the target protein in its proper cellular or extracellular location.
Figure 913 is a diagram of a structural gene encoding an IL13Ra2TF fusion protein (target protein) for insertion into an expression vector plasmid, which was used to transfect host cells as described in Example 4, below. A cDNA encoding a truncated form of the IL13Ra2 receptor protein (IL13Ra2TF), which comprises the extracellular IL13 ligand binding domain of IL13Ra2, was augmented with a segment encoding a V5 epitope tag at the 3' end.
Figure 9C depicts a construct for expressing a fusion protein of the invention to enhance expression of the V5-tagged IL13Ra2TF target protein depicted in Figure 9B and as described in Example 4. A cDNA encoding a J domain of an Erdj3 J protein (protein expression enhancing polypeptide domain) was linked to a segment encoding the IL13 protein (target protein binding domain). A segment encoding a Flag epitope tag was linked to the 3' end of the segment encoding the IL13 target protein binding domain.
Figure 10 shows x-ray film images of chemiluminescent signals of a Western blot analysis of culture medium (upper panel) and cell lysates (middle panel) of transfected cells expressing a truncated form of the IL13Ra2 receptor protein (IL13Ra2TF) when expressed alone (lane 2 from the left), when co-expressed with its IL13 ligand (IL13 Only, lane 3 from the left), and when co-expressed in an unmodified arrangement with a J domain-1L13 fusion protein of the invention (J-1L13, lane 4 from the left), as described in Example 4. A properly folded ILI
3Ra2TF protein (target protein) is expected to be secreted from the transfected host cells. It can be seen that co-expression of the IL13Ra2TF protein with the J domain-1L13 fusion protein significantly enhanced the level of expression of secreted 1L13Ra2TF protein (top panel, lane 4 from the left) as compared to expression of IL13Ra2TF protein alone (top panel, lane 2 from the left) or co-expression of IL13Ra2TF protein with its IL13 ligand (top panel, lane 3 from the left). Moreover, co-expression of the 1L13Ra2TF
protein with the J domain-IL13 fusion protein significantly enhanced the level of expression of intracellular IL13Ra2TF protein (middle panel, lane 4 from the left) as compared to the level expression of IL13Ra2TF protein alone (middle panel, lane 2 from the left) or co-expression of AMENDED SHEET - IPEA/US
=
=
PCT/US2013/073442 08.04.2015 1L13Ra2TF protein with its 1L13 ligand (middle panel, lane 3 from the left).
All transfectants were co-transfected with a reporter plasmid expressing green fluorescent protein (GFP) to show successful transfection and operability of the transfeetants. See, lower panel of Figure
10. Mock cultures contained cells transfected with "empty vector", i.e., an expression vector lacking a structural gene for expressing any protein (no IL13Ra2TF protein, no co-expression; "none" in lane 1 from the left of the blot). The empty vector transfectants were, however, co-transfected with the GFP vector, and successful co-transfection is shown by GPF expression detected in the lower panel of Figure 10.
Figures llA and 11B show schematic diagrams of nucleic acid constructs encoding proteins for insertion into expression vector plasmids used to transfect host cells for the experiments described iri Example 5 below. Figure 11A depicts a DNA construct encoding an Fe fusion protein (target protein) comprising a cDNA encoding a protein of interest augmented at its 3' end with a segment encoding a VS epitope tag, which in turn was linked to a segment encoding the constant domains of an immunoglobulin Fc domain. For Example 5 below, the Fc fusion protein target comprised a truncated form of the IL13Ra2 receptor protein (IL13Ra2TF), which was linked to a VS epitope tag, which in turn was linked to an Fc domain to yield the desired IL13Ra2TF-Fc fusion protein. Figure 11B depicts a DNA construct encoding a fusion protein of the invention in which a protein expression enhancing polypeptide (PEEP) domain (such as a J domain of a J protein) is linked to a target protein binding domain (such as Protein A, which is known to bind Fc domains). The construct was further augmented at the 3' end with a coding segment for a Flag epitope tag for easy identification and isolation with a standard anti-Flag antibody.
Figures 12A ¨ 12D show results of an experiment described in Example 5 that demonstrate significant enhancement in the expression of an 1L13Ra2TF-Fc fusion protein (target protein) in an unmodified arrangement in which the target protein is co-expressed with a J
domain-Protein A fusion protein but not when the target protein is co-expressed with Protein A alone.
Figure 12A shows x-ray film images of chemiluminescent signals of a Western blot analysis of media from cultures of transfected cells expressing the IL13Ra2TF-Fc fusion protein (target protein) when expressed alone (lane 2, none), when co-expressed with Protein A
alone (lane 3, Protein A Only), when co-expressed with an Erdj3 J domain-Protein A fusion protein (lane 4, J-Protein A), and when co-expressed with an Erdj5 J domain-Protein A fusion protein (lane 5, J2-Protein A), as described in Example 5. Mock cultures contained cells transfected with expression vector lacking a structural gene for expressing any protein (lane 1 from the left). It can be seen that co-expression of the IL13Ra2TF-Fc fusion target protein and either J domain-Protein A fusion protein (lanes 4 and 5 from the left) resulted in a significantly greater level of expression of the IL13Ra2TF-Fc fusion target protein secreted into culture medium as compared to the level of expression in transfectant cells expressing the 1L13Ra2TF-Fc fusion target protein alone (lane 2 from the left) or co-expressing the IL13Ra2TF-Fc fusion target protein with unfused Protein A
(lane 3 from the left).
AMENDED SHEET - IPEA/US
PCT/US2013/073442 08.04.2015 = Figure 12B shows results of a densitometry analysis of the chemiluminescent signals in Figure 12A using the NTH ImageJ image processing program. Bar graphs 1-5 of Figure 12B
correspond to signals in lanes 1-5 in Figure 12A. The bar graphs in Figure 12B
clearly show that co-expression of the IL13Ra2TF-Fc target protein with either J domain-Protein A
fusion protein (bar graphs 4 and 5) significantly enhanced the level of expression of secreted IL13Ra2TF-Fc as compared to expression of IL13Ra2TF-Fc alone (bar graph 2) or co-expression of IL13Ra2TF-Fc with (unfused) Protein A alone (bar graph 3).
Figure 12C shows x-ray film images of chemiluminescent signals of a Western blot analysis of media from cultures of transfected cells expressing the IL13Ro2TF (no Pc domain) protein alone (lane 1, none), when co-expressed with an Erdj3 J domain-Protein A fusion protein (lane 2, J-Protein A), and when co-expressed with Protein A alone (lane 3, Protein A Only), as described in Example 5.
The results show that little if any expression of secreted IL13Ra2TF protein was observed, as expected if the enhanced level of the secreted IL13Ra2TF-Fc fusion target protein in Figures 12A and 12B was dependent on the specificity of the target protein binding domain of the J domain-Protein A
fusion protein for the Fc domain of 1L13Ra2TF-Fc target protein. Figure 12D
provides the results of a densitometry analysis of the chemiluminescent signals in Figure 12C using the NIH ImageJ image processing program: Figures 12C and 12D thus show a control experimental result in that the IL13Ra2TF protein was not recognized by the J domain-Protein A fusion (the Fe ligand for the target binding domain (Protein A) being absent), and thus the enhancement in the level of expression that could be provided by the J domain (a protein expression enhancing polypeptide domain) was not . targeted to the IL13Ra2TF, as the results indicate.
Figures 13A-1 ¨ 13C-2 provide results of a series of experiments that demonstrate significant = enhancement of the level of expression of three different Fe fusion target proteins when co-expressed with a corresponding fusion protein of the invention as described in Example 6 below. Figure 13A-1 shows x-ray film images of chemiluminescent signals of a Western blot assay for expression of an IL13Ra2TE-Fc fusion protein (target protein) secreted into the media of cultures of transfected cells expressing the 1L13Ra2TF-Fc fusion protein alone (lane 1 from the left) and of transfected cells co-expressing the IL13Ra2TF-Fc fusion protein and the J domain-Protein A fusion protein (lane 2 from -the left) as described in Example 6.1 below and similar to the experiment described in Example 5.
30, Figure 13A-2 provides the results of a densitometry analysis of the chemiluminescent signals in Figure 13A-1 using the N1H ImageJ image processing program. Bar graphs 1 and 2 (from left to right) in Figure 13A-2 correspond to the signals in lanes 1 and 2 (from left to right) in Figure 13A-1.
The results show that co-expression of the J domain-Protein A fusion protein of the invention significantly elevated (8-fold) the level of expression of the IL13Ra2TF-Fc target protein secreted into the culture AMENDED SHEET - IPEA/US
PCT/US2013/073442 08.04.2015 medium as compared to the level of expression of the target protein in the absence of the J domain-Protein A fusion protein. Results are consistent with those described in Example 5 and Figure 12.
Figure 13B-1 shows x-ray film images of chemiluminescent signals of a Western blot assay for expression of a TNFR1TF-Fc fusion protein (target protein) secreted into the media of cultures of transfected cells expressing the TNFRITF-Fc fusion target protein alone (lane I from the left) and of transfected cells co-expressing the TNFRITF-Fc fusion protein and the J domain-Protein A fusion (lane 2 from the left) .as described in Example 6.2 below. Figure 13B-2 provides the results of a densitometry analysis of the chemiluminescent signals in Figure 13B-1 using the NIN ImageJ image processing program. Bar graphs 1 and 2 (from left to right) in Figure 13B-2 correspond to the signals in lanes 1 and 2 (from left to right) in Figure 13B-1. The results show that co-expression of J domain-Protein A fusion protein significantly elevated (6-fold) the level of expression of the TNFR1TF-Fc target protein secreted into the culture medium as compared to the level of expression of the target protein in the absence of the J domain-Protein A fusion protein.
Figure 13C-1 shows x-ray film images of chemiluminescent signals of a Western blot assay for expression of an at anti-trypsin (alAT)-Fc fusion protein (target protein) secreted into the media of cultures of transfected cells expressing the alAT-Fc fusion target protein alone (lane 1 from the left) and of transfected cells co-expressing the alAT-Fc fusion target protein and the J domain-Protein A fusion protein. (lane 2 from the left) as described in Example,6.3. Figure 13C-2 provides the results of a densitometry analysis of the chemiluminescent signals in Figure 13C-1 using the NIH ImageJ
image processing program. Bar graphs 1 and 2 (from left to right) in Figure 13C-2 correspond to the signals in lanes 1 and 2 (from left to right) in Figure 13C-1. The results show that co-expression of J
domain-Protein A fusion protein significantly elevated (3-fold) the level of expression of the al AT-Fe fusion target protein secreted into the culture medium as compared to the level of expression of the target protein in the absence of the J domain-Protein A fusion protein.
Figures 14A and 14B provide results from a series of experiments that test the enhancement in the level of expression of a secreted humanized anti-1L8 IgG1 antibody in an unmodified arrangement described in Example 7 below. Figure 14A shows x-ray film images of chemiluminescent signals of a dot blot assay for expression of the anti-1L8 antibody (target protein) secreted into the media of cultures of transfected cells expressing the anti-IL8 antibody alone (lane 2), co-expressing anti-1L8 antibody and Protein A (lane 3, Protein A Only), co-expressing anti-[L8 antibody and an Erdj3 J domain-Protein A fusion protein of the invention (lane 4, J-Protein A), co-expressing anti-1L8 antibody and Protein L (lane 5, Protein L Only), co-expressing anti-1L8 antibody and an Erdj3 J domain-Protein L fusion protein of the invention (lane 6, J-Protein L), co-expressing anti-1L8 antibody and its IL8 ligand (lane 7, IL8), co-expressing an Erdj3 J
domain-1L8 ligand fusion protein = AMENDED SHEET - IPEA/US
PCT/US2013/073442 08.04.2015 "
of the invention (lane 8, J-1L8), expressing the Erdj3 J-Protein A fusion protein alone (lane 9, J-Protein A), expressing the Erdj3 J domain-Protein L fusion protein alone (lane 10, J-Protein L), and expressing the Erdj3 J domain-1L8 ligand fusion protein (lane 11, J-1L8). Mock cultures contained cells transfected with expression vector lacking a structural gene for expressing any protein (no anti-IL8 antibody, lane 1). Expression of the anti -1L8 antibody in culture media was analyzed in the dot blot assay using an anti-human IgG antibody ("anti-huIgG Ab") (catalog no.
AP112P, Millipore). It can be seen that co-expression in transfected cells of the anti-1L8 antibody with a J domain-Protein A
fusion protein (lane 4), with a J domain-Protein L fusion protein (lane 6), or with a J domain-1L8 fusion protein (lane 8) significantly enhanced the level of expression of anti-1L8 antibody secreted into the culture medium as compared to the level of the antibody expressed in transfected cells expressing the anti-1L8 antibody alone (lane 2), co-expressing with Protein A
alone (lane 3, Protein A
Only), co-expressing Protein L alone (lane 5, Protein L Only), or co-expressing IL8 ligand protein alone (lane 7). No signal was.detected in culture media of transfected cells expressing the J domain-Protein A fusion protein alone (lane 9, 1-Protein A), of transfected cells expressing the J domain-Protein L fusion protein alone (lane 10, J-Protein L), or of transfected cells expressing the J domain-1L8 fusion protein alone (lane 10, J-1L8), indicating that all three fusion proteins specifically targeted and enhanced expression of the co-expressed anti-1L8 antibody target protein.
Figure 14B shows the results of a densitometry analysis of the chethiluminescent signals in each of the lanes in Figure 14A using the NIH ImageJ image processing program.
The bar graphs of Figure 14B are numbered to correspond to the lane numbers of Figure 14A. The results of this series of experiments clearly show that co-expression of the targeted anti-1L8 antibody with a fusion protein of the invention comprising a protein expression enhancing polypeptide (here, an Erdj3 J domain) linked to a target protein binding domain (here, Protein A, Protein L, or 1L8) significantly enhanced the expression of secreted anti-1L8 antibody as compared to co-expression of the antibody with the unfused target protein binding domain protein alone (Protein G only, Protein L
only, or IL8 only).
Figures 15A and 15B provide results that demonstrate that a fusion protein according to the invention can be used to enhance the level of expression of a target protein that is already stably produced in an established commercially relevant cell line as described in Example 8 below. Figure 15A shows x-ray film images of chemiluminescent signals of a dot blot assay for expression of the anti-1L8 antibody (target protein) secreted into the media of cultures of cells of a CHO-DP12 cell line (accession no. CRL-124444, American Type Culture Collection, Manassas, Virginia) expressing the anti-IL8 antibody alone (lane 2) and in transfected cells co-expressing anti-1L8 antibody and an Erdj3 J domain-Protein A fusion protein (lane 3, J-Protein A). Expression of the anti-IL8 antibody in culture media was analyzed in the dot blot assay using an anti-human IgG
antibody ("anti-huIgG
Ab"). It can be seen that co-expression of the antibody with the J domain-Protein A fusion protein AMENDED SHEET - IPEA/US
PCT/US2013/073442 08.04.2015 significantly enhanced the level of expression of the antibody secreted into the culture medium (lane 3) as =
=
PCT/US2013/073442 08.04.2015 compared to the level of the antibody expressed in the absence of the J domain-Protein A fusion protein (lane 2, none). Lane 1 is control (Medium Only). Figure 15B shows the results of a densitometry analysis of the chemiluminescent signals in the dot blots in the lanes in Figure I5A
using the NIII IrnageJ image processing program is shown in the respective bar graphs in Figure 15B.
The results indicate that co-expression of the antibody with the J domain-Protein A fusion protein (bar graph 3) significantly enhanced expression of the secreted antibody, providing an approximately four-to five-fold greater enhancement in the level of expression, as compared to that obtained when the antibody was expressed in the absence of the J domain-Protein A fusion protein (bar graph 2). The results indicate that a fusion protein of the invention can be employed to significantly enhance the level of production of a target protein that is already stably expressed in an established production cell line.
Figures 16A and 16B provide results from a series of experiments that tested various fusion proteins comprising a J domain (as a protein expression enhancing polypeptide domain) of a J protein linked to any of a variety of proteins, as described in Example 9.1 below. The various J domain fusion proteins and other proteins were then tested and compared for their ability to enhance levels of expression of the IL13Ra2TF-Fc fusion protein (target protein) secreted into media of cultures of transfected HEK293 cells. Figure 16A shows x-ray film images of chemiluminescent signals of a Western blot analysis of samples of media from cultures of transfected cells expressing the IL13Ra2TF-Fc fusion protein (target protein) alone (lane 1), co-expressing IL13Ra2TF-Fc with a J
domain-Protein A fusion protein (lane 2), co-expressing IL13Ra2TF-Fc with Protein A alone (lane 3, Protein A Only), co-expressing IL13Ra2TF-Fc with a J domain-Protein G fusion protein (lane 4), co-expressing IL13Ra2TF-Fc with a J domain-hFcR fusion protein (lane 5, J-hFcR), co-expressing 1L13Ra2TF-Fc with a J domain-vFcR fusion protein (lane 6, J-vFeR), co-expressing IL13Ra2TF-Fc with a J domain-gI fusion protein (lane 7, J-g[), co-expressing IL13Ra2TF-Fc with a J domain-gE
fusion protein (lane 8, J-gE), and co-expressing IL13Ra2TF-Fc with both J
domain-gI fusion protein and J domain-gE fusion protein (lane 9, J-gI + J-gE). The results of a densitometry analysis of the chemiluminescent signals in the Western blot in Figure 16A using the N1HImageJ
image processing program are shown in the respective bar graphs in Figure 16B. See, Example 9.1 for details.
Figures 17A-1 and 17B provide results from a series of experiments that tested various fusion proteins comprising a J domain (as a protein expression enhancing polypeptide domain) of a J protein linked to each of six Fe-binding peptides (FcBP1 through FcBP6) for use in enhancing the level of expression of proteins that possess an Fc domain as described in Example 9.2 below. The amino acid sequences of the Pc binding peptides are given in Figure 17A-2 (SEQ ID NOS:240-245, respectively).
Figure 17A-1 shows x-ray film images of chemiluminescent signals of a Western blot assay of samples of media of cultures of transfected cells expressing the IL13Ra2TF-Fc fusion protein (target AMENDED SHEET - IPEA/US
=
PCT/US2013/073442 08.04.2015 protein) alone (lanes 1 and 3), co-expressing IL13Ra2TF-Fc with a J domain-Protein A fusion protein (lane 2, J-Protein A), co-=
AMENDED SHEET -IPEA/US
PCT/US2013/073442 08.04.2015 expressing IL13Ra2TF-Fc with a J domain-FcBP1 fusion protein (lane 4, J-FcBP1), co-expressing ILI3Ra2TF-Fc with a J domain-FcBP2 fusion protein (lane 5, J-FcBP2), co-expressing IL13Ra2TF-Fc with a J domain-FcBP3 fusion protein (lane 6, J-FcBP3), co-expressing IL13Ra2TF-Fc with a J
=domain-FcBP4 fusion protein (lane 7, J-FcBP4), co-expressing IL13Ra2TF-Fc with a J domain-FcBP5 fusion protein (lane 8, J-FcBP5), co-expressing IL13Ra2TF-Fc with a J
domain-FcBP6 fusion protein (lane 9, J-FcBP6), and co-expressing IL13Ra2TF-Fc with a J domain-Protein G fusion protein (lane 10, J-Protein G),. As shown in Figure 17A-1, co-expression of the IL13Ra2TF-Fc fusion protein with each of the six J domain-peptide fusion proteins in HEK293 transfectants significantly enhanced the level of expression of secreted IL13Ra2TF-Fc fusion protein (lanes 4-9) as compared to the level of expression of 1L13Ra2TF-Fc fusion protein alone (lanes 1 and 3).
The experiment also included for comparison the effect of co-expression of IL13Ra2TF-Fclusion protein with a J domain-Protein A fusion protein (lane 2) or with a J domain-Protein G fusion protein (lane 10) on the expression of secreted IL13Ra2TF-Fc fusion protein. As shown in Figure 17A-1, co-expression of IL13Ra2TF-Fc fusion protein with either J domain-Protein A fusion protein (lane 2) or the J domain-Protein G fusion protein (lane 10) significantly enhanced the level of expression of secreted the IL13Ra2TF-Fc fusion protein as also observed in Examples 5 (Figures 12A and 12B), 6.1 (Figures 13A-1 and 13A-2), and 9.1 (Figures 16A and 16B). The results of a densitometry analysis of the chemiluminescent signals in the Western blot in Figure 17A-1 using the NIH
ImageJ image processing program are shown in the respective bar graphs in Figure 17B.
Figure 18 shows x-ray film images of chemiluminescent signals of a dot blot assay showing examples of relative levels of target protein expression enhancing activity of three polyp" eptides used in an unmodified arrangement described in Example 10. The levels of expression indicated in the dot blot, i.e., High Activity (HA), Activity (A), and No Activity (NA), were determined for polypeptides designated "3 (J domain)", "3-45", and "3-72" (see Table 58, infra.). Each polypeptide was linked to Protein A to form a fusion protein that was co-expressed with a V5-tagged IL13Ra2-Fc target protein in transfected cells. The level of expression of the VS-tagged IL13Ra2-Fe target protein in culture media was determined in the dot blot using an anti-V5 antibody. The dot blot shows expression of the V5-tagged IL13Ra2-Fc target protein in the media of cultures of transfected cells expressing the target protein alone (lane 2 from left), of transfected cells co-expressing the target protein and the polypeptide 3-Protein A fusion protein (lane 3 from left), of transfected cells co-expressing the target protein and the polypeptide 3-45-Protein A fusion protein (lane 4 from left), and of transfected cells co-expressing the target protein and the polypeptide 3-72-Protein A fusion protein (lane 5 from left).
The high activity (HA) of a polypeptide for enhancing expression of a target protein in an unmodified arrangement is represented by the level of expression shown in lane 3 (from the left) of the dot blot.
Improved activity compared to negative control (A) of a polypeptide for enhancing expression of a AMENDED SHEET - IPEA/US
PCT/US2013/073442 08.04.2015 target protein is represented by the level of expression shown in lane 4 (from the left) of the dot blot.
No activity (NA) of a polypeptide for enhancing expression of a target protein is shown in lane 5 =
=
=
AMENDED SHEET - IPEA/US
PCT/US2013/073442 08.04.2015 (from the left) of the dot blot. Lane 1 (from the left) of the dot blot shows no target protein was expressed in the medium of a mock culture of cells that did not express the target protein or any polypeptide-Fc fusion protein.
Figure 19 shows an alignment of the amino acid sequence of the J domain of Erdj3 with the amino acid sequences of a series of polypeptides that were generated as N- and C-terminal deletion mutations of the full-length J domain as described in Example 11. The alpha helices and loop domains of the J domain are indicated by brackets. Also shown are a designation number, length (amino acid residues), protein expression enhancing activity (HA, NA), and sequence identification number for each of the polypeptides. (See, Figure 18 and Example 10 for a description of high activity (HA), improved activity (A), and no activity (NA) for enhancing target protein expression.) As shown in the alignment, the J domain is designated polypeptide 3, is 61 amino acids in length, and has high activity (HA) for enhancing expression of a target protein in an unmodified arrangement.
Figures 20A and 20B show results of a series of experiments described in Example 12 that compares the target protein expression enhancing activity of two polypeptides used in a modified arrangement. Figure 20A shows diagrams of nucleic acid constructs for insertion into an expression vector used to transfect cells. The IL13Ra2TF construct encodes a fusion polypeptide comprising a truncated form of 11,13Ra2 that contains the extracellular IL13 binding domain fused to a C-terminal V5 epitope tag. The IL13Ra2TF-BSC1 construct encodes a fusion polypeptide comprising the truncated form of IL13Ra2 fused to the BSC1 sequence (polypeptide 3-29, IKKAYRKLA, SEQ ID
NO:48), which is fused to a C-tenninal V5 epitope tag. The IL13Ra2TF-BSC1MT
construct encodes the truncated from of IL13Ra2 fused to the BSC1MT sequence (polypeptide 3-55, IAQAYRKLA, SEQ ID NO:298), which is fused to a C-terminal V5 epitopc tag. The amino acid sequence of polypeptide 3-55 differs from that of polypeptide 3-29 at two positions as shown at the bottom of Figure 20A. Cells transfected with a vector containing the IL13Ra2TF construct were taken as the _25 control (no fusion with a BSC I or BSC1MT polypeptide).
Figure 20B shows X-ray film images of chemiluminescent signals of a dot blot analysis of the media of cultures of transfected cells expressing the IL13Ra2TF, IL13Ra2TF-BSC1, and IL13Ra2TF-BSC I MT proteins using an anti-V5 antibody. Lane 2 (from the left) of Fig. 208 shows that only a very low level of IL13Ra2TF fusion protein was detected in medium of a culture of control cells. Lane 3 (from the left) in Fig. 20B shows that a significant level of the IL13Ra2TF-BSCI fusion protein was expressed in the medium of a culture of cells transfected with a vector containing the IL13Ra2TF-BSC I construct. Lane 4 (from the left) in Fig. 208 shows that only a very low level of the IL13Ra2TF-BSC1MT fusion protein was expressed in the medium of culture of cells transfected with a vector containing the IL13Ra2TF-BSCIMT construct. The results indicate that polypeptide 3-29 has "high activity" for enhancing expression of a target protein in a modified AMENDED SHEET - IPEA/US
PCT/US2013/073442 08.04.2015 arrangement, whereas polypeptide 3-55 is considered to have "no activity" for enhancing expression of a target protein in a modified arrangement.
Figure 21 is a bar graph showing IL13 binding activity of 11,13Ra2TF-Fc target protein co expressed in an unmodified arrangement with a BSC1-Protein A in HEK293 cells as described in Example 13. The BSC1-Protein A protein if a fusion protein comprising the polypeptide 3-29 (IKKAYRKLA, SEQ ID NO:48) linked to Protein A as shown in Example 13. The assay used for determining IL13 binding activity is a sandwich ELISA in which detection of human IL13 decreases when the IL13 is trapped by the IL13Ra2TF-Fc protein. The first bar graph (from the left) in Fig. 21 shows no IL13 binding activity was present in medium from a culture of control cells that did not =
express either IL13Ra2TF-Fc or the BSC1-Protein A fusion protein. Bar 2 (middle) in Fig. 21 shows that some low level of IL13 binding activity was detected in medium from a culture of cells expressing only the IL13Ra2TF-Fc protein. In contrast, as shown in Bar 3 (far right) in Fig. 21, a significant level of human IL13 binding activity was present in the medium of a culture of cells co-expressing IL13Ra2TF-Fc and the BSC1-Protein A fusion protein. The results shown that the = 15 IL13Ra2TF-Fc target protein expressed at enhanced levels in culture medium in an unmodified arrangement retains its IL13 binding activity.
Figures 22A and 22B show results of an experiment that demonstrates significant enhancement in the level of expression of a Factor VII (FVII)-Fc fusion protein (target protein) secreted into culture medium when co-expressed in an unmodified arrangement with a BSC1-Protein G fusion protein comprising polypeptide 3-29 (IKKAYRKLA, SEQ 1D NO:48) linked to Protein G as described in Example 14. Figure 22A shows X-ray film images of chemiluminescent signals of a Western blot assay for expression of an FV1I-Fc fusion protein (top panel) secreted into the media of cultures of transfected cells expressing the FV1.1-Fc fusion protein alone (lane 2) and of transfected cells co-expressing the FVII-Fc fusion protein and the BSC1-Protein G fusion protein (lane 3). Lane I shows non-expressing cell culture medium as a control. Anti-Flag antibody was used to detect BSC1-Protein G in cell lysate (middle panel) and secreted BSC1-Protein G
(bottom panel), respectively. Figure 22B provides the results of a densitometry analysis of the chemiluminescent signals in the top panel of Figure 22A using the NIH ImageJ image processing program. Bar graphs 1, 2, and 3 in Figure 228 correspond to the signals in lanes 1, 2, and 3 in the top panel of Figure 22A.
The results show that co-expression of the FVH-Fc target protein and the BSC1-Protein G fusion protein significantly elevated the level of expression of the FV1.1-Fc target protein secreted into the culture medium as compared to the level of expression of the target protein expressed in the absence of the BSC1-Protein G fusion protein. In addition, the BSC1-Protein G fusion protein was not secreted but remained in the cells. Compare expression of BSC1-Protein G
fusion protein cell lysates (middle panel of Fig. 22A) with that in medium (bottom panel of Fig. 22A).
AMENDED SHEET -IPEA/US
PCT/US2013/073442 08.04.2015 Figures 23A and 23B show results of an experiment to demonstrate improvement in the level of expression of a Factor IX (FIX)-Fc fusion protein (FIX-Pc) target protein in the presence of a =
BSC 1-Protein A fusion protein comprising polypeptide 3-29 (HUCAYRKLA, SEQ ID
NO:48) linked to Protein A as described in Example 15. Figure 23A shows X-ray film images of chemiluminescent signals of a Western blot assay for expression of an FIX-Fe fusion protein secreted into the media of cultures of transfected cells expressing the FIX-Fc fusion protein alone (row 2) and of transfected cells co-expressing the FIX-Pc fusion protein and the BSC1-Protein A fusion protein (row 3). Row 1 shows non-expressing cell culture medium as a control. Figure 23B provides the results of a densitometry analysis of the chemiluminescent signals in the top panel of Figure 23A using the NI11 Imagel image processing program. Bar graphs 1, 2, and 3 in Figure 23B
correspond to the signals in rows 1, 2, and 3 in Figure 23A. The results show that co-expression of the FIX-Fe target protein and the BSC1-Protein A fusion protein significantly elevated the level of expression of the FIX-Fe target = protein secreted into the culture medium as compared to the level of expression of the target protein in the absence of the BSC1-Protein A fusion Protein.
Figure 24 provides results of a series of experiments that demonstrate significant enhancement of the level of expression of a Factor VIII (FV111)-Fc fusion protein (FVBI-Fc) when co-expressed in an unmodified arrangement with a BSC1-Protein G fusion protein comprising polypeptide 3-29 (LICKAYRKLA, SEQ ID NO:48) linked to Protein G as described in Example 16.
Media was harvested from cultures of transfected HEK293 cells co-expressing the FVIH-Fc fusion protein (target protein) with BSC I-Protein G fusion protein or cells expressing the FVIII-Fc fusion protein alone. The media was assayed for WM activity by ELISA (VisuLizemi FVHI
Antigen Kit, Affinity Biologicals Inc.). Cell culture medium in which empty vector was transfected was used for a negative control (first bar from the left). Second bar from the left shows no FV1.11 was detected in medium from cells expressing the FVIII-Fc target protein alone. Third bar from the left shows that = 25 significant level of FVIII-Fc target protein was secreted into the medium of cells co-expressing the = FVHI-Fe target protein and the BSC 1-Protein G fusion protein. Human serum was used as a positive control (last bar from left). The results show that co-expression of the FV111-Fc target protein and the BSCI -Protein G fusion protein significantly elevated the level of expression of the FVIII-Fc target , protein secreted into the culture medium as compared to the level of expression of the target protein in the absence of the BSC1-Protein G fusion protein.
Figures 25A ¨ 25C show results of an experiment demonstrating improved levels of expression of an anti-1L8 antibody (target protein) secreted into the culture medium when co-expressed in an unmodified arrangement with a BSC1-Protein A comprising the 3-29 polypeptide (IKKAYRICLA, SEQ ID NO:48) linked to Protein A as described in Example 17.
Figure 25A shows X-ray film images of chemiluminescent signals of a dot blot assay for expression of the anti-1L8 AMENDED SHEET - IPEA/US
PCT/US2013/073442 08.04.2015 antibody (target protein) secreted into the media of cultures of transfected cells expressing the anti-1L8 antibody alone AMENDED SHEET - IPEA/US
PCT/US2013/073442 08.04.2015 (row 2) and of cells co-expressing the anti-1L8 antibody and a BSC1-Protein A
fusion protein (row 3, BSC1-Protein A). Expression of the anti-1L8 antibody in culture media was analyzed in the dot blot assay using an anti-human IgG antibody. Mock cultures contained cells transfected with expression vector lacking a structural gene for expressing any protein (no anti-1L8 antibody, row 1). It can be seen that co-expression in transfected cells of the anti-1L8 antibody with a BSC1-Protein A fusion protein (row 3) significantly enhanced the level of expression of anti-1L8 antibody secreted into the culture medium as compared to the level of the antibody expressed in transfected cells expressing the anti-1L8 antibody alone (row 2).
Figure 25B shows the results of a densitometry analysis of the chemiluminescent signals in each of the rows in Figure 25A using the N1H hnageJ image processing program.
The bars of Figure 25B are numbered to correspond to the row numbers of Figure 25A. The results of this series of experiments clearly show that co-expression of the targeted anti-1L8 antibody with a BSC1-Protein A
fusion protein significantly enhanced the expression of secreted anti-1L8 antibody compared to the level of expression of the antibody in the absence of the BSC1-Protein A
fusion protein.
Figure 25C shows a bar graph of the results of an ELISA to detect IL8 binding activity by the expressed anti-1L8 antibody (target protein). A 96-well plate was coated with recombinant purified human IL8, and incubated with the anti-1L8 antibody (target protein) secreted into the media of cultures of transfected cells expressing the anti-1L8 antibody alone (bar graph 2) or co-expressing the anti-1L8 antibody with the BSC1-Protein A fusion protein (bar graph 3, BSC I -Protein A). Mock cultures contained cells transfected with expression vector lacking a structural gene for expressing any protein (no anti-1L8 antibody, bar graph 1). The results of this series of experiments clearly show that the anti-1L8 antibody expressed at enhanced levels and secreted into the culture medium retains its binding activity for human 1L8, indicating proper conformation of the antibody.
Figures 26A ¨ 26C show results of a series of experiments demonstrating significant enhancement in the level of expression of the anti-VEGF antibody, bevacizumab, when co-expressed with a BSC1-Protein A fusion comprising the 3-29 polypeptide (IKKAYRICLA, SEQ
ID NO:48) linked to Protein A as described in Example 18. Figure 26A shows X-ray film images of chemiluminescent signals of a dot blot assay for expression of the anti-VEGF
antibody secreted into the media of cultures of transfected cells expressing the anti-VEGF antibody alone (row 2) or co-expressing the anti-VEGF antibody and a BSC 1-Protein A fusion protein (row 3). Mock cultures contained cells transfected with expression vector lacking a structural gene for expressing any protein (no anti-VEGF antibody, row 1). Expression of the anti-VEGF antibody in culture media was analyzed in the dot blot assay using an anti-human IgG antibody. It can be seen that co-expression in transfected cells of the anti-VEGF antibody with the BSC1-Protein A fusion protein (row 3) significantly enhanced the level of expression of anti-VEGF antibody secreted into the culture PCT/US2013/073442 08.04.2015 medium as compared to the level of the antibody expressed in transfeeted cells expressing the anti-VEGF antibody alone (row 2).
AMENDED SHEET - IPEA/US
PCT/US13/73442 03-10-2014PCT/US2013/073442 08.04.2015 =
Figure 26B shows the results of a densitometry analysis of the chemiluminescent signals in each of the rows in Figure 26A using the NIH ImageJ image processing program.
The bar graphs in Figure 26B are numbered to correspond to the row numbers in Figure 26A. The results clearly show that co-expression of the anti-VEGF antibody with a BSC1-Protein A fusion protein significantly enhanced the expression of secreted anti-VEGF antibody compared to the level of the antibody expressed alone.
Figure 26C shows the results of an ELISA to detect VEGF binding by the anti-VEGF
antibody expressed in the media of cultures of transfected cells. A 96-well plate was coated with recombinant purified human VEGF-A, and incubated with the anti-VEGF antibody (target protein) secreted into the media of cultures of transfected cells expressing the anti-VEGF antibody alone (bar graph 2) or co-expressing anti-VEGF antibody and the BSC1-Protein A fusion protein of the invention (bar graph 3). Mock cultures contained cells transfected with expression vector lacking a structural gene for expressing any protein (no anti-VEGF antibody, bar graph 1). The results of this series of experiments clearly show that the anti-VEGF antibody expressed at enhanced levels and secreted into the culture medium retains its binding activity for human VEGF-A, indicating proper conformation of the secreted antibody.
Figures 27A ¨ 27C show results from a series of experiments demonstrating significant enhancement in the level of expression the therapeutic anti-TNFa antibody, adalimumab (Humira , AbbVie), when co-expressed with a BSC1-Protein A fusion comprising the 3-29 polypeptide (IKKAYRKLA, SEQ ID NO:48) linked to Protein A as described in Example 19.
Figure 27A shows X-ray film images of chemiluminescent signals of a dot blot assay for expression of the anti-TNFa antibody secreted into the media of cultures of transfected cells expressing the anti-TNFa antibody alone (row 2) or co-expressing the anti-TNFa antibody and the BSC1-Protein A
fusion (row 3).
Mock cultures contained cells transfected with expression vector lacking a structural gene for expressing any protein (row 1, no anti-TNFa antibody). Expression of the anti-TNFa antibody in culture media was analyzed in the dot blot assay using an anti-human IgG
antibody. It can be seen that co-expression in transfected cells of the anti-TNFa antibody with a BSCI-Protein A fusion protein (bottom row) significantly enhanced the level of expression of anti-TNFa antibody secreted into the culture medium as compared to the level of the antibody expressed in transfected cells expressing the anti-TNFa antibody alone (middle).
Figure 27B shows the results of a densitometry analysis of the chemiluminescent signals in each of the rows in Figure 27A using the NIH ImageJ image processing program.
The bar graphs of Figure 27B are numbered to correspond to the row numbers of Figure 27A. The results of this series of experiments clearly show that co-expression of the anti-TNFa antibody (target protein) with the BSC1-Protein A fusion protein significantly enhanced the expression of secreted anti-TNFa antibody.
AMENDED SHEET - IPEA/US
PCT/US2013/073442 08.04.2015 Figure 27C shows the results of an ELBA to detect TNFa binding activity by the anti- TNFa antibody expressed in the media of cultures of transfected cells. A 96-well plate was coated with =
AMENDED SHEET - IPEA/US
PCT/US2013/073442 08.04.2015 recombinant purified human TNFa and incubated with the anti-TNFa antibody (target protein) secreted into the media of cultures of transfected cells expressing the anti-TNFa antibody alone (bar graph 2) or cells co-expressing the anti-TNFa antibody and the BSC1-Protein A
fusion protein (bar graph 3). Mock cultures contained cells transfected with expression vector lacking a structural gene =
for expressing any protein (bar graph 1). The results of this series of experiments clearly show that the anti-TNFa antibody expressed at enhanced levels and secreted into the culture medium retains its binding activity for human TNFa, indicating proper conformation of the secreted antibody.
Figures 28A ¨ 28C provide results that demonstrate that the level of expression of a protein that is already stably produced in an established commercially relevant cell line can be enhanced when co-expressed with as BSC1-Protein A fusion comprising the 3-29 polypeptide (11KKAYRKLA, SEQ ID NO:48) linked to Protein A as described in Example 20. Figure 28A shows X-ray film images of chemiluminescent signals of a dot blot assay for expression of the anti-1L8 antibody (target protein) secreted into the media of cultures of cells of a CHO-DP12 cell line (accession no. CRL-124444, American Type Culture Collection, Manassas, Virginia) expressing the anti-1L8 antibody alone (row 2) and of transfected cells co-expressing the anti-1L8 antibody and the BSC1-Protein A
fusion protein (row 3). It can be seen that co-expression of the antibody with the BSC1-Protein A
fusion protein significantly enhanced the level of expression of the antibody secreted into the culture medium (row 3) as compared to the level of the antibody expressed in the absence of the BSC1-Protein A fusion protein (row 2). Row 1 is control (Medium Only). Figure 28B
shows the results of a densitometry analysis of the chemiluminescent signals in the dot blots in the rows in Figure 28A using the NIB ImageJ image processing program are shown in the respective bar graphs in Figure 28B. The results indicate that co-expression of the antibody with the BSC1-Protein A
fusion molecule (bar graph 3) significantly enhanced expression of the secreted antibody, providing an approximately four to five-fold greater enhancement in the level of expression, as compared to that obtained when the antibody was expressed in the absence of the BSC1-Protein A fusion molecule (bar graph 2).
Figure 28C shows the results of an ELISA to detect IL8 binding activity by the anti-1L8 antibody expressed in the media of cultures of transfected cells. A 96-well plate was coated with recombinant purified human IL8 and incubated with the anti-1L8 antibody (target protein) secreted into the media of cultures stably expressing the anti-1L8 antibody (bar graph 2) or co-expressing the antibody and the BSC1-Protein A fusion protein (bar graph 3). Culture medium was used as a negative control (bar graph 1, no IL8 binding activity). The results of this series of experiments clearly show that the anti-1L8 antibody secreted at enhanced levels into the culture medium retains its binding activity for human IL8, indicating proper conformation of the secreted antibody.
Figure 29 provides results of an experiment described in Example 21 that indicate that protein expression enhancing polypeptides of the invention may be used to treat a disease caused by a mutant protein that does not fold into its proper conformation. Figure 29 shows X-ray film images of AMENDED SHEET - IPEA/US
=
chemiluminescent signals of a Western blot assay for expression of fusion proteins comprising wild type alphal-antitrypsin (AAT) or the mutant alphal-antitrypsin containing the Z mutation (AATZ, wherein Glu is replaced by Lys at codon 342) linked to the Fc domain from human IgG with or without co-expression of a BSC1-Protein A comprising the 3-29 polypeptide (IKKAYRKLA, SEQ ID
NO:48) linked to Protein A. The top panel of Figure 29 shows expression of Fc fusion proteins in the media of cultures of transfected cells expressing the AAT-Fc fusion protein alone (lane 2, from the left), of transfected cells expressing the AATZ-Fc fusion protein alone (lane 3, from the left), and of transfected cells co-expressing the AATZ-Fc fusion protein and the BSC1-Protein A fusion protein (lane 4, from the left). Lane 1 shows non-expressing cell culture medium as a control. Clearly, no AATZ-Fc fusion protein was secreted into media of cultures of cells expressing AATZ-Fc fusion protein alone (lane 3, from the left). As shown in the middle panel (Cell Lysate) of Figure 29, for cells expressing the AATZ-Fc fusion protein alone, the AATZ-Fc fusion protein remained in the cells (lane 3, from the left), presumably lodged in the endoplasmic reticulum as is known for the unfused AATZ protein. In contrast, co-expression of the AATZ-Fc fusion protein and the BSC1-Protein A
fusion protein significantly enhanced the level of AATZ-Fc fusion protein secreted into the culture medium as shown in lane 4 (from the left) in the top panel (medium) of Figure 29. Moreover, as shown in lane 4 (from the left) in the middle panel (Cell Lysate) of Figure 29, virtually no AATZ-Fc fusion protein was retained in the cells. The same membrane was blotted with anti-Tubulin antibody for a loading control (lower panel) in Figure 29. The results show that co-expression of the BSC1-Protein A fusion protein significantly elevated the level the AATZ-Fc target protein secreted into the culture medium as compared to the level of expression of the target protein in the absence of the BSC1-Protein A fusion protein with virtually no AATZ-Fc retained in the cells.
Detailed Description of the Invention The invention provides a new family of polypeptides for enhancing the level of expression of a target protein of interest. The invention is based on the discovery that a target protein of interest can be expressed at a significantly higher level and in the proper cellular or extracellular location when co-expressed in either of two arrangements in a host cell with a protein expression enhancing polypeptide comprising:
an isolated J domain of a J protein, a protein expression enhancing polypeptide fragment of a J domain, or a protein expression enhancing J domain analog polypeptide comprising the formula:
X1-X2-X3-X4-X5-X6-X7-X8-X9 (SEQ ID NO:47), wherein:
X1 is isoleucine (I), leucine (L), valine (V), alanine (A), or methionine (M);
X2 and X3 are each independently any amino acid with the proviso that at least one is lysine (K) or arginine (R);
X4 is any amino acid; or X4 may be absent when X1 through X3 are present and through X9 are present;
X5 is tyrosine (Y), tryptophan (W), or phenylalanine (F);
X6 and X7 are each independently any amino acid with the proviso at least one is lysine (K) or arginine (R); or one of X6 and X7 may be absent when the other is K or R and when X1 through X5 are present and X8 and X9 are present; and X8 and X9 are any amino acid with the proviso that at least one is leucine (L) or alanine (A); or one of X8 and X9 may be absent when the other is L or A and when X1 through X7 are present.
A protein expression enhancing polypeptide of the invention may be employed in either of two arrangements for enhancing expression of a target protein of interest by a host cell. In a "modified" arrangement, a fusion protein comprises a protein expression enhancing polypeptide linked (fused) to a target protein of interest. The fusion protein is thus a "modified" target protein that acts as a functional surrogate for the target protein of interest and is expressed at an enhanced level by a host cell compared to the level of expression of the unmodified target protein alone. In an "unmodified" arrangement, a fusion protein comprises a protein expression enhancing polypeptide of the invention linked to a target protein binding domain that has an affinity for and binds the regular "unmodified" target protein of interest, wherein co-expression of the fusion protein and the target protein of interest in a host cell enhances the expression of the unmodified target protein as compared to the level of expression in the absence of the target protein-binding fusion protein according to the invention. In accordance with the invention, the enhanced level of protein expression in the modified and unmodified arrangements includes expression of the respective modified or unmodified target protein of interest in the proper location (cellular or extracellular) of the target protein of interest.
Accordingly, the invention provides a technical solution when there is a failure to express desired quantities of an endogenous or heterologous (recombinant) protein of interest in cells. The present invention also provides compositions and methods for treating individuals for a disease or disorder in which there is a failure to express sufficient levels of a functional protein in vivo, where inadequate expression of the protein or a functional version thereof leads to a pathological state.
Examples of diseases in which an improperly folded protein species has been demonstrated or implicated include, but are not limited to, prion-associated disease (transmissible spongiform encephalopathy), Alzheimer's disease; Parkinson's disease; Huntington's disease; and cystic fibrosis (CF).
In order to more clearly describe the invention the following comments and definitions of terms apply.
Unless otherwise defined herein, scientific and technical terms used in connection with the present invention shall have the meanings that are commonly understood by those of ordinary skill in the art. The meaning and scope of the terms should be clear; however, in the event of any latent ambiguity, definitions provided herein take precedent over any dictionary or extrinsic definition.
Further, unless otherwise required by context, singular terms shall include pluralities and plural terms shall include the singular. In this application, the use of the term "or"
means "and/or," unless stated otherwise. Furthermore, the use of the term "including", as well as other forms, such as "includes"
and "included", is not limiting.
Generally, nomenclatures used in connection with and techniques of protein and nucleic acid chemistry (including methods of recombinant nucleic acid and polymerase chain reaction (PCR)), cell and tissue culture, molecular biology, genetics, microbiology, biochemistry, proteomics, pharmacology, and pharmaceutical science described herein are those well-known and commonly used in the art. The methods and techniques of the present invention are generally performed according to conventional methods in the art and as described in various general and more specific references available in the art. Assays and purification techniques are performed according to protocols available in the art, including in manuals of laboratory techniques and manufacturer's specifications, as commonly accomplished in the art or as described herein.
Unless indicated otherwise, when the terms "about" and "approximately" are used in combination with an amount, number, or value, then that combination describes the recited amount, number, or value alone as well as the amount, number, or value plus or minus 10% of that amount, number, or value. By way of example, the phrases "about 40%" and "approximately 40%" disclose both "40%" and "from 36% to 44%, inclusive".
The term "target protein of interest", "target protein", or "protein of interest" refers to any protein for which there is a need or desire to enhance the level of expression in its intended cellular (including intracellular and membrane-associated) or extracellular (secreted) location.
The term "isolated" as in an "isolated molecule" (e.g., "isolated protein" or "isolated nucleic acid") is a molecule that by virtue of its origin or source of derivation: is not associated with naturally associated components that accompany it in its native state; is substantially free of other kinds of molecules from the same species; is expressed by a cell from a different species; or does not occur in nature. Thus, a protein or nucleic acid molecule that is chemically synthesized or synthesized in a cellular system different from the cell from which it naturally originates will be "isolated" from its naturally associated components. A protein or nucleic acid molecule may also be rendered substantially free of naturally associated components by isolation, using respectively protein or nucleic acid purification techniques well known in the art.
The term "vector", as used herein, is intended to refer to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. One type of vector is a "plasmid", which refers to a circular double stranded nucleic acid (typically, DNA) loop into which additional nucleic acid segments may be inserted. Another type of vector is a viral vector, wherein additional DNA segments may be inserted into the viral genome. Certain vectors are capable of autonomous replication in a host cell into which they are introduced (e.g., bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). Other vectors (e.g., non-episomal mammalian vectors) can be integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome. Moreover, certain vectors are capable of directing the expression of genes to which they are operatively linked. Such vectors are referred to herein as "recombinant expression vectors" (or simply, "expression vectors").
In general, expression vectors of utility in recombinant DNA techniques are often in the form of plasmids. In the present specification, "plasmid" and "vector" may be used interchangeably as the plasmid is the most commonly used form of vector. However, the invention is intended to include other forms of expression vectors, such as viral vectors (e.g., replication defective retroviruses, lentivirus-derived vectors, and adenovirus-derived viruses), which serve equivalent or comparable functions.
The term "operably linked" refers to a juxtaposition of described components wherein the components are in a relationship permitting them to function in their intended manner. A control sequence "operably linked" to a coding sequence is ligated in such a way that expression of the coding sequence is achieved under conditions compatible with the control sequences.
"Operably linked"
sequences may include both expression control sequences that are contiguous with the gene of interest and expression control sequences that act in trans or at a distance to control the gene of interest. The term "expression control sequence" refers to polynucleotide sequences that are necessary to effect the expression and processing of coding sequences to which they are ligated.
Expression control sequences include appropriate transcription initiation, termination, promoter and enhancer sequences;
efficient RNA processing signals such as splicing and polyadenylation signals;
sequences that stabilize cytoplasmic mRNA; sequences that enhance translation efficiency (such as, a Kozak consensus sequence); sequences that enhance protein stability; and when desired, sequences that enhance protein secretion. The nature of such control sequences differs depending upon the host organism; in prokaryotes, such control sequences generally include promoter, ribosomal binding site, and transcription termination sequence; in eukaryotes, generally, such control sequences include promoters and transcription termination sequence. The term "control sequences"
is intended to include components whose presence is essential for expression and processing, and can also include additional components whose presence is advantageous, for example, leader sequences and fusion partner sequences. Unless stated otherwise, a description or statement herein of inserting a nucleic acid molecule encoding a fusion protein of the invention into an expression vector means that the inserted nucleic acid has also been operably linked within the vector to a functional promoter and other transcriptional and translational control elements required for expression of the encoded fusion protein when the expression vector containing the inserted nucleic acid molecule is introduced into compatible host cells or compatible cells of an organism.
As used herein, the term "recombinant" when used as an adjective describes non-naturally altered or manipulated nucleic acids, host cells transfected with exogenous nucleic acids, or polypeptides expressed non-naturally, through manipulation of isolated nucleic acid (typically DNA) and transfection of host cells or through manipulation of endogenous nucleic acid to alternative expression by introduction of non-endogenous nucleic acid. "Recombinant" is a term that specifically encompasses DNA molecules that have been constructed in vitro using genetic engineering techniques, and use of the term "recombinant" as an adjective to describe a molecule, construct, vector, cell, protein, polypeptide, peptide, or polynucleotide specifically excludes naturally occurring ("endogenous") such molecules, constructs, vectors, cells, proteins, polypeptides, peptides, and polynucleotides in their respective, unisolated, native locations (for example, intracellular, tissue, or organ locations).
The term "recombinant host cell" (or simply, in context, "host cell"), as used herein, is intended to refer to a cell into which exogenous nucleic acid has been introduced. It should be understood that such terms are intended to refer not only to the particular subject cell but to the progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term "host cell" as used herein. Host cells useful in various aspects of the invention may be prokaryotic and eukaryotic cells.
Preferred prokaryotic host cells include various bacterial cells, including Escherichia coli. While some manipulations, constructions, expressions, or replications of nucleic acids or encoded polypeptides related to the invention may be conducted using prokaryotic or eukaryotic host cells, the preferred host cells for enhanced expression of a target protein of interest, whether in the modified or unmodified arrangements described herein, are eukaryotic host cells. Preferred eukaryotic host cells include, without limitation, a mammalian host cell, an insect host cell, a plant host cell, a fungal host cell, a eukaryotic algal host cell, a nematode host cell, a protozoan host cell, and a fish host cell. Preferably, a mammalian host cell is a Chinese Hamster Ovary (CHO) cell, a COS cell, a Vero cell, an SP2/0 cell, an NS/0 myeloma cell, a human embryonic kidney (HEK293) cell, a baby hamster kidney (BHK) cell, a HeLa cell, a human B cell, a CV-1/EBNA cell, an L cell, a 3T3 cell, an HEPG2 cell, a PerC6 cell, or an MDCK cell. Preferred fungal host cells include Aspergillus, Neurospora, Saccharomyces, Pichia, Hansenula, Schizosaccharomyces, Kluyveromyces, Yarrowia, and Candida. A
particularly preferred Saccharomyces host cell is a Saccharomyces cerevisiae cell. A particularly preferred insect host cell is an Sf9 cell.
The terms "heterologous" and "exogenous" are synonymous and are used broadly as adjectives to describe any molecule (e.g., protein, polypeptide, nucleic acid) that is not native to a host cell containing or expressing the molecule. Accordingly, "heterologous" and "exogenous" encompass the term "recombinant" as defined above.
"Transgenic organism", as known in the art and as used herein, refers to an organism having cells that contain a transgene, wherein the transgene introduced into the organism (or an ancestor of the organism) expresses a polypeptide not naturally expressed in the organism or not naturally expressed at the normal or proper level to provide the intended function of the polypeptide to the organism. A "transgene" is a nucleic acid construct, which is stably and operably integrated into the genome of a cell from which a transgenic organism develops, directing the expression of an encoded gene product in one or more cell types or tissues of the transgenic organism.
The terms "disease" and "disorder" are used interchangeably to indicate a pathological state identified according to acceptable medical standards and practices in the art.
As used herein, the term "effective amount" refers to the amount of a therapy that is sufficient to reduce or ameliorate the severity and/or duration of a disease or one or more symptoms thereof; to prevent the advancement of a detrimental or pathological state; to cause regression of a pathological state; to prevent recurrence, development, onset, or progression of one or more symptoms associated with a pathological state; to detect a disorder; or to enhance or improve the prophylactic or therapeutic effect(s) of a therapy (e.g. , the administration of another prophylactic or therapeutic agent).
A "biological sample," as used herein, includes, but is not limited to, any quantity of a substance from a living organism or formerly living organism. Such organisms include, but are not limited to, humans, non-human primates, mice, rats, monkeys, dogs, rabbits, ruminants, and other animals. Such substances of a biological sample may include, but are not limited to, blood, serum, plasma, urine, saliva, sputum, mucus, synovial fluid, milk, semen, cells, organs (for example, heart, spleen, lung, kidney, breast, brain, eye, tongue, stomach, pancreas, intestines, gall bladder, reproductive organs, appendix), tissues (for example, bone, cartilage, muscle, skin), bone marrow, and lymph nodes.
A composition or method described herein as "comprising" (or which "comprises") one or more named elements or steps is open-ended, meaning that the named elements or steps are essential, but other elements or steps may be added within the scope of the composition or method. To avoid prolixity, it is also understood that any composition or method described as "comprising" (or which "comprises") one or more named elements or steps also describes the corresponding, more limited, composition or method "consisting essentially of" (or which "consists essentially of") the same named elements or steps, meaning that the composition or method includes the named essential elements or steps and may also include additional elements or steps that do not materially affect the basic and novel characteristic(s) of the composition or method. It is also understood that any composition or method described herein as "comprising" or "consisting essentially of" one or more named elements or steps also describes the corresponding, more limited, and close-ended composition or method "consisting of' (or which "consists of") the named elements or steps to the exclusion of any other unnamed element or step.
The term "J domain analog" as used herein refers to a target protein expression enhancing polypeptide (or PEEP) that comprises the sequence of amino acids of formula I
(SEQ ID NO:47).
Such polypeptides, where incorporated into a target protein sequence to make a modified target protein or when used to construct a protein expression enhancing polypeptide-target protein binding domain fusion protein, are useful for effecting an increase in expression of a target protein of interest.
The terms "J domain active fragment" or "active fragment of a J domain" refer to a fragment of a J domain of a J protein which retains the ability to increase the level of expression of a target protein when used in the two types of fusion proteins (PEEP/target protein fusion or PEEP/target protein binding domain fusion) described herein. The Examples below indicate that J domain active fragments will commonly retain the region of a J domain at the C-terminal extremity of a helix II.
Larger portions of a J domain may be active as well, but excision of all or part of the C-terminal nine amino acids of a helix II invariably leads to loss of protein expression enhancement activity.
In any composition or method disclosed herein, known or disclosed equivalents of any named essential element or step may be substituted for that element or step.
Unless specifically indicated, a composition or method is not limited by any particular order of the listed elements or steps, unless a particular method step requires the prior performance of another step.
It is also understood that an element or step "selected from the group consisting of" or "any of' (or equivalent phrase) refers to one or more of the elements or steps in the list that follows, including combinations of any two or more of the listed elements or steps.
J Domains Useful in the Invention The J domains of a variety of J proteins have been determined. See, for example, Kampinga et al., Nat. Rev., 11: 579-592 (2010); Hennessy et al., Protein Science, 14:1697-1709 (2005). A J
domain useful in preparing a fusion protein of the invention (whether in the modified or unmodified arrangement) has the key defining features of a J domain of any member of the J protein family.
Accordingly, an isolated J domain useful in the invention comprises a polypeptide domain from a J
protein, which is characterized by four a-helices (I, II, III, IV) and usually having the highly conserved tripeptide sequence of histidine, proline, and aspartic acid (referred to as the "HPD motif") between helices II and III. Typically, the J domain of a J protein is between fifty and seventy amino acids in length, and the site of interaction (binding) of a J domain with an Hsp7O-ATP chaperone protein is believed to be a region extending from within helix II and including the HPD motif.
Representative J domains include, but are not limited, a J domain of an ERdj protein (for example, a J
domain of ERdj3 or ERdj5), a J domain of a large T antigen of 5V40, and a J
domain of a mammalian cysteine string protein (CSP-a). The amino acid sequences for these and other J domains that may be used in fusion proteins of the invention are provided in Table 1.
Table 1. Amino acid sequences of representative isolated J domains.
J Protein Source of J Domain SEQ ID J Domain Amino Acid Sequence NO:
human Hsp40 1 KID YYQ 7A.P. GAS D.E.E K RAYR H
(NP_006136; Heat Shock Protein PDKNKEPGAEEKFKEIAEAYDVLSDPRK
40) human ErdJ1 2 LNFY0FLTIQUAS SAD I RKAYRKL SLILH
(NM_022365; DnaJC1, HTJ1, PDKNKDENAETQFKI,V7kIYEVI,KDDEP.
MTJ1, DnaJ homolog subfamily C
member 1 protein, DNAJL1) human ErdJ2 3 YNPYFVLNLDPGATVA.EIKQYPLLSLKYH
(NM_001017975; HFM1, PDKGGDEVMFMRIAR:AYAAL I' DEES
5EC63 domain containing 1 protein, MER3, hHFM1) human ErdJ3 4 RDL.YKiLGVPRSASIKDIKKAYRKLALQLH
(NM_016306; DNAJB11, DnaJ PDP.1%.=PDD1-:,QAQEKFQDLGAAYEVISDSEK
(Hsp40) homolog, subfamily B, member 11, ERj3p, HEDJ, ERj3, ABBP2, ER-associated DNAJ
protein 3) human ErdJ4 5 .1.T.SYYDTT,GyPK :A3ERQIKK7F.LIKLANK:zi.-I
(NM_012328; DNAJB9, PDKNKSPDAEAKE'RE IAEAYETLSDANR
microvascular differentiation gene 1 protein, MDG1, endothelial Mdgl) human ErdJ5 6 QD.FYS (3`,TSJ:: TAS S RE Pc.).AFKK L.7E:K
(NM_018981; DNAJC10, ER- PDKNPNNPNAHGDFLKINPAYEVI,KDEDI, resident protein ERdj5, JPD1, J-domain-containing protein disulfide isomerase-like protein, DnaJ (Hsp40) homolog, subfamily C, member 10, hMTHr protein) human ErdJ6 7 RDYYKiLGV-KRNAKKQEIIKAYRKLALQWH
(NM_006260; DNAJC3, PONE' Q.NE E E KKKAE KKE' ID I Als,A.KENIL
SDP
DnaJ (Hsp40) EM
homolog, subfamily C, member 3 protein, protein-kinase, interferon-inducible double stranded RNA
dependent inhibitor protein, P58IPK protein, PRKRI, 58 kDa cellular inhibitor protein, p58 inhibitor of protein kinase) human CSP 8 E.SLY:HVLGLDKNi-VISDDIKKSYRKLALK"YE
(NP_079495; cysteine string PliK1:4P1)1\111).EAADRTKEINNAHAI LTDATK
protein alpha, CSPalpha protein, DNAJC5 protein, cysteine string protein, DnaJ (Hsp40) homolog, subfamily C, member 5 protein, CSP protein) J Protein Source of J Domain SEQ ID J Domain Amino Acid Sequence NO:
SV40 large T antigen 9 DDLMDLI,GLERSAWGNIPI,PIRKAYLKKCIsTE
(YP_003708382; large tumor FHPDKGGDEEKTAKKNINTLYKKMEDGVK
antigen T-ag [Simian virus 40]) DnaJ 10 QDYYEILGVSKTAEEREIKKAYKRLAMKIE
PDRNQGDKEAEAKFKE KEAYEVLT DS QK
human dnaJ homolog subfamily C, 11 NPFEVLQIDPEVTDEEIKKRFRQLSILVHP
member 8 DKNQDDADRAQKAFEAVDKAYKLLLDQEQK
KRAL DVI Q
human dnaJ homolog subfamily C, 12 F2J%i .Y7 T3,,C31_,Iii--:.GASNEETKKTYP.K.LALEHt-i member 5B PL)KNPDDPAATEKFREINNAHAILTDISK
human dnaJ homolog subfamily C, 13 LNPFHVY_,GVL;ATASENELKKAYRQLAVMVE
member 14 PliBINHHPRAEEAFKVERAAWD I V SNAEK
human dnaJ homolog subfamily C, 14 RDCYEVLGAISRSAGKAEIARAYROLARRYE
member 25 precursor P DRY RPQP G DEGP GRTPQ SAE EAF INATA
T LKDEE T
human dnaJ homolog subfamily B, 15 71\SYYFILDvPRSASADDIKNAYRRRALQwH
member 2, isoform a DKNPDNKEFAEKKFKEVAEAYEVL S D I-1K
human dnaJ homolog subfamily B, 16 ASYYETLIWPRSASADDIKKAYRRKALQWH
member 2, isoform b PDKNDNKEFAEKKFKEVAEAYEVLSDKHK
Chain A, 17 TTYYDVI,GVKPNATaTEELKKAYRKLALKYI-i nmr structure of Bc008182 protein, PL)KNPNEGEKFKQI SQAYEVLSDAKK
a human Dnaj-like domain Chain A, 18 7A.SYYE L DVPIR SAS AD I) I KKAYRRKAL (2Toq H
solution structure of J Domain of DKNPDNKEFAEKKFKEVAEAYEVL S D K
Hsjla Chain A, 19 KD SWD1',1L GYKE) GASRDEVisaAYRKLAVL LH
solution structure of a Dnaj-like PDKOVAPGSEDAFKAVVNARTALLKNIK
domain from human ras-associated protein Rapl Chain A, 20 VDIYEVLDVE'RQAS SEAI KFAYRKLALKWH
solution structure of Dnaj domain PDKNPENKEEAERRFNQVAEAYEVLSDARK
of human protein Hcg3, a hypothetical protein Tmp_locus_21 Chain A, 21 GDYYQT.LGVPRNASQKE I KJ.'AYYQLAKKYH
solution structure of J domain from PDTNKDDPKAREKFSQLAEAYEVLSDEVK
Dnaj homolog, human Tidl protein Chain A, 22 C-;SYYD L GVK. SA. E RQ K
solution structure of J domain from PDKNKSPDAEAKFRE 1AF:22:YETI, ST)13,NR.
human Dnaj subfamily B, member Chain A, 23 GDYYEILGVSRGASDEDLKKIYRLAJKFH:
solution structure of J domain fromD KN HAP GAT EAF"..f2k I G TA YAW., SNPE
human Dnaj subfamily B, member J Protein Source of J Domain SEQ ID J Domain Amino Acid Sequence NO:
Chain A, 24 KDYYQTLGLARGASDFFIKRAYRRQA.LRH
human Hsp40 (HDJ-1), nmr PDKNKEPGAEEKFKE I AEAYDVL S DPRK
Chain A, solution structure of Dnaj 25 T2LYDLLGVPSTATQAQIKAAYYRQCF Y H
domain from human Williams- I-1'DR.NSGSAEAAERFTRI SOAYVVL GS AT I, Beuren syndrome chromosome region 18 protein Chain A, solution structure of J 26 ANYYEVI, GVOASASP ED I KNAYRKLALP.WH
domain of Dnaj homolog PDKNPDNKEEAEKKFKLVSEAfEVLSDSKK
subfamily B, member 8 Chain A, solution structure of J 27 EDYYTI,T,GCDET
.SSVEQII,A.EFKVR.ALECH
domain of Dnaj homolog DKHPENPKAVE TFQKLQKAKE I L TNEE S
subfamily C, member 12 Chain A, Dnaj domain of human 28 S LKEVTSVVEQAWKLPESERKKI I RRLYL
Kiaa0730 protein KWHPDKNPENHD IANEVFKHLQNE I NR
human dnaJ homolog, subfamily 29 v 1) YEVL GVQRHASE)E D KKA Y RK AL KWH
B, PDKNPENREEAERKFRQVAEAYEVLSDARR
member 6, isoform a human dnaJ homolog, subfamily 30 -,,,T)YYEVL GVQRHA.3 P ED KKAYRKLALKWH
B, P DKNP EN KEEAF. RKF KQVAEAYEVL S DAKK
member 6, isoform b human dnaJ homolog, subfamily 31 IsT.S YY F) 1- ,C-;-\IPKSASERQ I KKTIF
FIKLAT.4KY1.5:
B, PDKNKSPDAEAKFREIAEAYETLSDANR
member 9 precursor human DnaJ (Hsp40) homolog, 32 LNPFEVLQI DPIEVT DEE I KKPEI-ZOL S I LVE-i subfamily C, PDKNQDDADRAQKAFEAVDKAYKLLLDQEC, member 8, isoform CRA_c human DnaJ (Hsp40) homolog, 33 DDAYEVLNLPQGQGP FIDE SK I RKAYFRLAQ
subfamily C, .1.<:Yf1P1) KNFEGRDMF E MTN YEFLCTKS
member 13, isoform CRA_b human DnaJ (Hsp40) homolog, 34 RALiLGVSPT7NKGKIRD7J-TRRI.MLLNH
subfamily C, P DKGK
member 19, isoform CRA_e human DnaJ (Hsp40) homolog, 35 ESLYi-1\71C-;LDKNATSDD IKKSYRKLA.LKH
subfamily C, PDKNDNPEPADKFKEI.NNAHAi L T DA T K
member 5, isoform CRA_b human DnaJ (Hsp40) homolog, 36 i GV.H.P GA.3 TEEVKR.%%17F SK SKELLI
subfamily C, P DRDP GNP SLHSRFVELSEAYRVLSREQS
member 4, isoform CRA _f human zinc finger, CSL-type 37 .1.<:DwY S GADP SAN :I SDI,KQKYQKI, I
I,M7y71.-I
containing 3, isoform CRA_c PDKQSTDVPAGTVEECVQKF E I DQAWK L
E E
J Protein Source of J Domain SEQ ID J Domain Amino Acid Sequence NO:
human DnaJ (Hsp40) homolog, 38 MD I, YALLGIEE KAAD KEVEIKAI I-Z K AL
SC H
subfamily C, P DKNP DNPRAAE LE HQL S Q.7k EVI:77 DAAA
member 17, isoform CRA_a human DnaJ (Hsp40) homolog, 39 KS YY D IiGVPKSASERIKKAFBKLAMKYH
subfamily B, P D KNK S P DA.EAKF RE I 7-1E GA SVPAA
SSE
member 9, isoform CRA_a human DnaJ (Hsp40) homolog, 40 T :CY C-;7s.S SKSKEJH
SKE
subfamily C, PDRDGNPSLI-iSFVELSEAYRVLSREQS
member 4, isoform CRA_g human DnaJ (Hsp40) homolog, 41 3TI{YELLGVH.PGAST.EVKRFSKSKELH
subfamily C, PDRDGNPSLI-iSFVELSEAYRVLSREQS
member 4, isoform CRA_a human DnaJ (Hsp40) homolog, 42 ED :(YS Li_,NVRREA.3 S EE I, KAAYRRI,CML7y71.-I
subfamily C, PDKHRDPELKSQ2-1,ERISNLVHQAYEVL SDP
member 11, QT
isoform CRA_c human zinc finger, CSL-type 43 .T.ungYS GADP SAN S D I,K.QK 'N.M., T.
I,M7y71.-I
containing 3, isoform CRA_b PDKQS TDVPAGTVEECVQKIF E DQAcIK L
Gis,EET
human J-type co-chaperone 44 RDT{FSLMDCNR3FRVDTARLQHRT{QQLQRL
HSC20, isoform CRA_c VI-IPDFFSQRSQTEKDFSEKFISTLAMDKYKT
lii3LP I, S
human hCG1994888, isoform 45 RDCY FAIL GV S R S AG A.E I A RAY P.
c.). LAR R Y H
CRA_d I-1'DRYRPOP GDE GP GP. TPQSAEEAFT., LVATA
E T KDE: E T
human DnaJ (Hsp40) homolog, 46 ' 'I H
subfamily A, P DKNPNE GEKVKML YISS
member 1, isoform CRA_a J Domain Fragments and Analogs with Protein Expression Enhancing Activity Further study of J domains using sequence analysis, including amino and carboxy terminal deletion analysis, revealed that only a relatively small portion of a J domain is required to provide protein expression enhancement activity. Surprisingly, the analysis determined that protein expression enhancement activity according to the invention can be provided by a polypeptide fragment isolated from within a J domain and that consists of as little as 9 or 10 amino acids. See, Examples 10 and 11, infra. As with isolated J domains, such J domain polypeptide fragments may be used in the methods and compositions described herein to enhance expression of a target protein of interest in its intended cellular (intracellular, membrane-associated) or extracellular (secreted) location. The individual J domain polypeptide fragments are not all identical in amino acid sequence, but may share some sequence homology and structural features in addition to providing a protein expression enhancement activity in either a modified or an unmodified arrangement described herein.
Further deletion and substitution mutation analysis of the above-mentioned J
domain polypeptide fragments provided the basis for defining a structural formula for a new family of J
domain analog polypeptides that possess target protein expression enhancement activity. The members of this family of analog polypeptides comprise 8 to 9 amino acids and include some J
domain polypeptide fragments as well as polypeptides that have not been previously identified in the current library of J domains. See, Example 11.
The smaller size of J domain polypeptide fragments and of J domain analog polypeptides compared to complete (full-length) J domains reduces the size of fusion proteins that can be constructed and expressed in the modified and unmodified arrangements of the invention for enhancing expression of a target protein of interest. Thus, the size of recombinant nucleic acid molecules encoding such fusion proteins can be correspondingly smaller than nucleic acid molecules that encode fusion proteins comprising a complete J domain. The relatively small size of J domain polypeptide fragments and J domain analog polypeptides of the invention may be particularly beneficial in reducing the immunogenicity of fusion proteins of the modified arrangement in which a protein expression enhancing polypeptide is linked (fused) to a target protein of interest to form a modified (fusion) target protein that is expressed in or administered to a subject in place of the (unlinked) target protein of interest. The less immunogenic the fusion protein is, the more likely the fusion protein can persist in the subject in order to provide the subject with the beneficial property or effect of the fusion protein without being rapidly eliminated or inhibited by an immune response directed to the fusion protein.
Fusion Proteins Comprising a Protein Expression Enhancing Polypeptide According to the invention, a protein expression enhancing polypeptide described herein is used as a component of a fusion protein that enhances expression of a target protein of interest for which there is a need to improve expression in a host cell. The protein expression enhancing polypeptide is used to enhance expression of a target protein of interest in either of two arrangements that describe the primary structure (amino acid sequence) of the expressed target protein of interest.
In the "modified" arrangement for enhancing protein expression, a protein expression enhancing polypeptide is linked to a target protein of interest to form a fusion protein, i.e., a "modified" target protein of interest, which is expressed at an enhanced level compared to that of the unmodified target protein that is poorly expressed in the absence of a protein expression enhancing polypeptide. Thus, the fusion protein in the modified arrangement is a modified form of the target protein of interest that is expressed and employed as a surrogate in place of the poorly expressed, unmodified target protein.
In the "unmodified" arrangement for enhancing protein expression, the primary structure of the target protein of interest remains unaltered ("unmodified") in that it is not fused to a protein expression enhancing polypeptide. A protein expression enhancing polypeptide of the invention is linked to a target protein binding domain that has an affinity for and binds to a target protein of interest. Co-expression of the fusion protein and the unmodified target protein of interest in a host cell results in an enhanced level of expression of the target protein of interest as compared to the level of expression in the absence of the target protein-binding fusion protein.
As the primary structure (amino acid sequence) of a target protein of interest remains unaltered (not linked in a fusion protein) in the unmodified arrangement, it is likely that for many applications, the unmodified arrangement for enhancing protein expression will be preferred over the modified arrangement. However, as explained below, it is also possible to engineer the fusion protein of a modified arrangement so that the protein expression enhancing polypeptide component of the fusion protein is easily cleaved to liberate the target protein component comprising the original amino acid sequence of the target protein with no or only a few additional remnant amino acids from the fusion protein. Such a fusion protein may be more suitable than the unmodified target protein for certain applications.
While it is possible to synthesize a fusion protein in either arrangement using direct synthesis (for example, solid-phase peptide synthesis, solution-phase synthesis, etc.), it is likely that in most cases a fusion protein described herein will be more economically produced using standard recombinant nucleic acid techniques, including polymerase chain reaction (PCR) techniques, in concert with cell culture methods or transgenic methods.
Standard techniques may be used for recombinant DNA, oligonucleotide synthesis, transfection of cells (for example, without limitation, electroporation, liposome-mediated transfection, transformation methods), and cell and tissue culture methods to express a fusion protein of the invention. Enzymatic reactions and purification techniques may be performed as commonly accomplished in the art, as described in a manufacturer's specifications, or as described herein. The foregoing techniques and procedures may be generally performed according to conventional methods well known in the art and as described in various general and more specific references that are cited and discussed throughout the present specification. See e.g., Sambrook et al., eds., Molecular Cloning: A Laboratory Manual, Second Edition (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1989) and Ausubel et al. (eds.), Current Protocols in Molecular Biology (John Wiley & Sons, New York, 2012), which are incorporated herein by reference.
As noted above, the terms "modified" and "unmodified" refer to whether or not a target protein of interest is linked to a protein expression enhancing polypeptide.
It is understood that in some embodiments of both the modified and unmodified arrangements, it may be beneficial to link one or more additional domains may to a fusion protein or target protein of interest. For example, any of the well-known epitope tag peptides (epitope tags) may be incorporated into a protein to facilitate detection and/or purification of the expressed protein. Such epitope tags include, but are not limited to, a V5 epitope tag (GKPIPNPLLGLDST (SEQ ID NO:110)), a Flag epitope tag (DYKDDDDK
(SEQ ID NO:111)), a hexa-histidine epitope tag (HHHHHH (SEQ ID NO:112)), a hemagglutinin epitope tag (YPYDVPDYA (SEQ ID NO:113)), a c-myc epitope tag (EQKLISEEDL (SEQ
ID
NO:114)), a VSV-G epitope tag (YTDIEMNRLGK (SEQ ID NO:115)), and a HSV epitope tag (QPELAPEDPED (SEQ ID NO:116)). As explained below, it is also possible to link a protein with such an epitope tag using a linker that can be cleaved by a proteolytic enzyme and thereby removed (or substantially removed) from the protein.
Linkers Any domain may be linked to another domain within a fusion protein of the invention by methods known in the art. For example, in the modified arrangement of the invention, a fusion protein comprises a protein expression enhancing polypeptide linked to a target protein of interest.
The expressed fusion protein is therefore a modified target protein that can be used as a surrogate for the unfused and poorly expressed target protein of interest. The protein expression enhancing polypeptide may be linked directly to the target protein of interest or linked indirectly via a linker molecule. In the unmodified arrangement of the invention, a fusion protein comprises a protein expression enhancing polypeptide linked to a target protein binding domain that has an affinity for and binds to a target protein of interest. Co-expression of the fusion protein with the target protein of interest enhances the level of expression of the unmodified (unfused) target protein of interest compared to the level of expression in the absence of the fusion protein. The protein expression enhancing polypeptide may be linked directly to the target protein binding domain or linked indirectly via a linker molecule. Other domains may also be linked to a fusion protein or unfused protein in either the modified and unmodified arrangements to provide one or more additional features. For example, an epitope tag may be linked to a fusion protein or unfused protein to facilitate detection or purification of the tagged protein.
At the amino acid level, a linker may be one or more amino acids, including 1 to 10 amino acids, 1 to 20 amino acids, and even 1 to 50 amino acids. Typically, with respect to linking a protein expression enhancing polypeptide to a target protein of interest (in the modified arrangement) or to a target protein binding domain (in the unmodified arrangement), it is not necessary to use a linker that is more than 20 amino acids because linking a protein expression enhancing polypeptide directly to a target protein of interest or to a target protein binding domain does not appear to significantly diminish the necessary biochemical and functional properties of the protein of interest or the target protein binding domain (data not shown).
Selecting one or more linkers to produce a fusion protein according to the invention is within the knowledge and skill of the art. See, for example, Arai et al., Protein Eng., 14(8): 529-532 (2001);
Crasto et al., Protein Eng., 13(5): 309-314 (2000); George et al., Protein Eng., 15(11): 871-879 (2003); Robinson et al., Proc. Natl. Acad. Sci. USA, 95: 5929-5934 (1998).
General considerations for using a particular linker to link a protein expression enhancing polypeptide to a target protein of interest or to a target protein binding domain may include those in making other fusion proteins in which one functional domain is linked to another functional domain, for example, as may be considered in linking immunoglobulin variable and/or constant domains in a wide variety of formats for producing engineered functional binding proteins. Clearly, a linker should not interfere with the folding of a target protein of interest or a target protein binding domain that is linked to a protein expression enhancing polypeptide. A linker, if present in a fusion protein, is selected to optimize the contribution of the protein expression enhancing polypeptide to increase levels of expression or yield of the fusion protein in the modified arrangement or the (unfused) target protein of interest in the in the unmodified arrangement, and it may be omitted if direct attachment of a protein expression enhancement polypeptide to the target protein of interest or target protein binding domain achieves a desired enhanced level of expression. Linker molecules present in a fusion protein of the invention may comprise one or more amino acids encoded by a nucleotide sequence present on a segment of nucleic acid in or around a cloning site of an expression vector into which is inserted in frame a nucleic acid segment encoding a protein domain (e.g., protein expression enhancing polypeptide, protein of interest, target protein binding domain) or an entire fusion protein.
Linker molecules, especially those that are four amino acids and longer, preferably possess a flexibility that permits the protein of interest to fold into its proper conformation. A variety of relatively flexible linkers are known in the field for linking functional domains. A linker may also be used to link one or more additional domains, such as an epitope tag, to the protein expression enhancing polypeptide or protein of interest of a fusion protein of the invention. Linkers that may be used in preparing a fusion protein according to the invention, include, by are not limited to, DIAAA
(SEQ ID NO:117); DIAAALE (SEQ ID NO:118); GTGSEF (SEQ ID NO:119); AS; TVA;
ASTK
(SEQ ID NO:120); GGGSGGSGGSGG (SEQ ID NO:121); DIGGGSGGSGGSGGAAA (SEQ ID
NO:122); AKTTPKLEEGEFSEAR (SEQ ID NO:123); AKTTPKLEEGEFSEARV (SEQ ID
NO:124); AKTTPKLGG (SEQ ID NO:125); SAKTTPKLGG (SEQ ID NO:126); SAKTTP (SEQ ID
NO:127); RADAAP (SEQ ID NO:128); RADAAPTVS (SEQ ID NO:129); RADAAAAGGPGS
(SEQ ID NO:130); RADAAAA(G45)4 (SEQ ID NO:131); SAKTTPKLEEGEFSEARV (SEQ ID
NO:132); ADAAP (SEQ ID NO:133); ADAAPTVSIFPP (SEQ ID NO:134); TVAAP (SEQ ID
NO:135); TVAAPSVFIFPP (SEQ ID NO:136); QPKAAP (SEQ ID NO:137); QPKAAPSVTLFPP
(SEQ ID NO:138); AKTTPP (SEQ ID NO:139); AKTTPPSVTPLAP (SEQ ID NO:140); AKTTAP
(SEQ ID NO:141); AKTTAPSVYPLAP (SEQ ID NO:142); ASTKGP (SEQ ID NO:143);
ASTKGPSVFPLAP (SEQ ID NO:144), GGGGSGGGGSGGGGS (SEQ ID NO:145);
GENKVEYAPALMALS (SEQ ID NO:146); GPAKELTPLKEAKVS (SEQ ID NO:147);
GHEAAAVMQVQYPAS (SEQ ID NO:148); GGGGGGGP (SEQ ID NO:149); GGGGGGGGP
(SEQ ID NO:150); PAPNLLGGP (SEQ ID NO:151); PNLLGGP (SEQ ID NO:152); GGGGGGP
(SEQ ID NO:153); PAPELLGGP (SEQ ID NO:154); PTISPAPNLLGGP (SEQ ID NO:155);
TVAADDDDKSVFIVPP (SEQ ID NO:156); TVDDDDKAAP (SEQ ID NO:157); LVPRGSAAP
(SEQ ID NO:158); ASTKGPSV (SEQ ID NO:159); ASTKGPSVFP (SEQ ID NO:160); TVAAPSV
(SEQ ID NO:161); TVAAPSVFI (SEQ ID NO:162); and the like.
In some embodiments, a fusion protein may contain one or more linkers that can be cleaved by one or more proteases. Such linkers possess an amino acid sequence that is recognized by a protease for cleavage of the protein at or near the recognition sequence.
Incorporating one or more cleavable linker molecules into a fusion protein provides the option of removing one or more domains from the expressed fusion protein. By way of non-limiting examples, in some applications or preparations, it may be desirable to remove the polypeptide expression enhancing polypeptide linked to the protein of interest (for example, to reduce potential immunogenicity) and/or to remove an epitope tag that had been incorporated into a fusion protein to facilitate detection or purification of the expressed fusion protein. In another example, if the fusion protein is secreted, a polypeptide expression enhancing polypeptide (or other domain) linked by a cleavable linker to the protein of interest may be removed by adding the appropriate protease directly to the medium of cultures expressing the fusion protein. Alternatively, the protein expression enhancing polypeptide (or other domain) linked by the cleavable linker may be removed after performing one or more steps to purify the fusion protein from the culture medium.
It may be useful in some situations to remove a domain or epitope tag linked to a protein.
This can be accomplished, for example, by expressing the protein comprising the additional domain or tag in cells in which the expression of a protease that can cleave a linker of the protein is regulated, such as incorporating into the cell a recombinant gene for the appropriate protease under the control of a promoter that can be regulated by a signal (e.g., temperature shift) or agent (ion change) that can be applied to a culture after the cells have expressed the fusion protein. A
variety of promoters are available in the art for regulating gene expression in prokaryotic or eukaryotic cells. In addition, some cells express one or more proteases that can cleave a linker molecule containing a corresponding cleavage site. It is within the skill of a practitioner in the art to determine whether use of a protease that may be expressed by a host cell may be useful to cleave a linker in a fusion protein expressed by the same host cell. Alternatively, it is possible to add an appropriate protease to a sample, such as culture medium or cell lysate, containing a protein linked to an additional domain or tag via a protease-cleavable linker.
A variety of linker molecules containing proteolytic cleavage sites are known and available in the art for linking one protein or protein domain to another. Such linkers include, but are not limited to, one of more of the following examples, where the asterisk (*) indicates the proteolytic cleavage site: DYKDDDDK* (SEQ ID NO:163); ASDDDDK*GGP (SEQ ID NO:164); ALVPR*GSGP (SEQ
ID NO:165 ); ASTDDDDK*SVFPLAP (SEQ ID NO:166 ); TVALVPR*GSVFIFPP (SEQ ID
NO:167 ); ASTLVPR*GSVFPLAP (SEQ ID NO: 168); TVAADDDK*SVFIVPP (SEQ ID NO:169);
ASTDDDK*SVFPLAP (SEQ ID NO:170); LEVLFQ*GP (SEQ ID NO:171);
TVAALEVLFQ*GPAP (SEQ ID NO:172); ASTLEVLFQ*GPLAP (SEQ ID NO:173);
PAPLEVLFQ*GP (SEQ ID NO:174); TAENLYFQ*GAP (SEQ ID NO:175); AENLYFQ*GA (SEQ
ID NO:176); PGPFGR*SAGGP (SEQ ID NO:177); PGPFGR*SAGG (SEQ ID NO:178);
PQRGR*SAG (SEQ ID NO:179); PHYGR*SGG (SEQ ID NO:180); GPFGR*SAGP (SEQ ID
NO:181); GDDDDK*GGP (SEQ ID NO:182); AGDDDDK*GGP (SEQ ID NO:183);
GGDDDDK*GGP (SEQ ID NO:184); ENLYFQ*G (SEQ ID NO:185); ENLYFQ*S (SEQ ID
NO:186); and the like.
A variety of proteolytic enzymes are known in the art that may be used to cleave a cleavable linker employed in a protein of the invention. Clearly, a protease that is selected to cleave a cleavable linker in a fusion protein comprising a target protein of interest should not also cleave the target protein of interest or any other domain that is desired to be retained after cleavage of the linker.
Proteolytic enzymes that may be used to cleave a fusion protein at a site in a linker within the fusion protein include, but are not limited to, enterokinase, factor Xa, thrombin, PreScission, tobacco etch virus (TEV) protease, tissue plasminogen activator (tPA), a zinc-dependent endopeptidase, a matrix metalloproteinase (MMP), a serralysin, an astacin, an adamalysin, a disintegrin, an ADAM, a caspase, a cathespsin, a calpain, and the like.
Nucleic Acids Encoding Fusion Proteins Using standard methods available in the art, a nucleic acid (typically DNA) molecule is constructed that encodes a fusion protein employed in a modified or unmodified arrangement for enhancing expression of a target protein of interest. One or more additional domains may also be incorporated into a protein, such as a standard epitope tag used to facilitate detection and/or purification of the protein. A nucleic acid molecule encoding a desired fusion protein can be inserted into any of a variety cloning vectors available in the art for the purpose of replicating the recombinant structural gene for the fusion protein. For expressing a fusion protein, a nucleic acid molecule encoding the fusion protein can be inserted into any of a variety of expression vectors available in the art. An expression vector with the inserted nucleic acid encoding the fusion protein is then introduced into compatible host cells that permit expression of the fusion protein from the expression vector. In the case of an unmodified arrangement, a vector may also contain a copy of functional structural gene encoding the unmodified target protein of interest if the host cell does not possess a functional gene for the target protein of interest.
Expression vectors of the invention include expression vector molecules comprising a nucleic acid segment encoding a protein expression enhancing polypeptide described herein and one or more cloning sites (for example, unique restriction enzyme sites) located 5' or 3' to the protein expression enhancing polypeptide coding sequence into which a nucleic acid molecule encoding another domain of the fusion protein may be inserted: in a modified arrangement, a nucleic acid encoding a target protein of interest may be inserted to form the desired fusion protein (modified target protein);
whereas in an unmodified arrangement, a nucleic acid encoding a target protein binding domain may be inserted to form a fusion protein that is capable of binding to and enhancing expression of an unmodified target protein of interest. An expression vector may also possess multiple cloning sites that permit the insertion of one or more additional nucleic acid segments encoding one or more other desired domains (for example, an epitope tag, Fc region, etc.) to construct and express a desired fusion protein. The final nucleic acid fusion construct encoding a desired fusion is operably linked to a promoter on the expression vector. Engineering cloning sites into a vector molecule and operably linking an inserted nucleic acid segment encoding a desired protein to a promoter and other signals required for expression of the protein in a compatible host cell are within the skill in the art.
While a description herein for assembling a nucleic acid construct encoding a fusion protein of the invention may suggest a particular stepwise order to the linking of various nucleic acid molecules followed by insertion of the fully assembled nucleic acid construct into an expression vector, it is understood and appreciated that the exact order of linking segments of nucleic acid molecules to produce a nucleic acid construct encoding a desired fusion protein is within the discretion, skill, and experience of a practitioner in this art. Moreover, although it is possible to first link all segments together to form a nucleic acid molecule encoding a fusion protein prior to insertion into an expression vector, in some cases, a nucleic acid segment encoding one or more domains may already properly reside within an expression vector so that it is practical to insert one or more nucleic acid segments adjacent to the segment(s) already residing in the expression vector and thereby assemble within the expression vector an operably linked structural gene for a desired fusion protein of the invention.
Expression vectors encoding a fusion protein of the invention may be transfected into any of a variety of host cells that are compatible for expressing the fusion protein from the particular expression vector. Although some steps in the process of constructing a recombinant structural gene encoding a fusion protein of the invention may be conducted in either prokaryotic or eukaryotic cells, the preferred host cell for enhanced expression of fusion proteins according to the invention are eukaryotic cells. Eukaryotic host cells useful in the invention include, but are not limited to, a mammalian host cell, an insect host cell, a plant host cell, a fungal host cell, a eukaryotic algal host cell, a nematode host cell, a protozoan host cell, and a fish host cell.
Mammalian host cells useful for expressing a fusion protein of the invention include, but are not limited to, a Chinese Hamster Ovary (CHO) cell, a COS cell, a Vero cell, an SP2/0 cell, an NS/0 myeloma cell, a human embryonic kidney (HEK293) cell, a baby hamster kidney (BHK) cell, a HeLa cell, a human B cell, a CV-1/EBNA cell, an L cell, a 3T3 cell, an HEPG2 cell, a PerC6 cell, and an MDCK cell. Fungal host cells useful for expressing a J domain fusion protein of the invention include, but are not limited to, Aspergillus, Neurospora, Saccharomyces, Pichia, Hansenula, Schizosaccharomyces, Kluyveromyces, Yarrowia, and Candida. A particularly useful Saccharomyces host cell is a Saccharomyces cerevisiae cell.
Using methods available in the art, nucleic acid molecules encoding a fusion protein of the invention may be introduced into cells of a plant or non-human animal for the purpose of expressing the fusion protein in levels that permit easy purification of the fusion protein or as a gene therapy to provide the plant, human, or non-human animal with the benefit of the function provided by the protein of interest within the expressed fusion protein. Such methods can be used to provide transgenic plants or animals that express the fusion protein encoded by the transferred nucleic acid (transgene) encoding the fusion protein. In the case of plants and non-human animals, techniques are available for incorporating expressible nucleic acid encoding a protein into the germline so that progeny of the transgenic organism also can express the fusion protein. A
variety of vectors and methods are available for introducing nucleic acid into cells of a plant or non-human animal including, but not limited to, syringe injection of naked DNA into cells, ballistic transfer (for example, using a gene gun), liposomes, and virus-derived vector molecules.
A gene therapy for treating a human subject according to the invention may employ a recombinant gene encoding a fusion protein that comprises an expression enhancing polypeptide in either a modified or unmodified arrangement described herein. Such gene therapy is especially useful in diseases in which an improperly folded protein species results in loss or substantial loss of function as to cause a clinically recognized pathological condition. Examples of diseases in which an improperly folded protein species resulting in loss of function has been demonstrated or implicated include, but are not limited to, prion-associated disease (transmissible spongiform encephalopathy), Alzheimer's disease; Parkinson's disease; Huntington's disease; cystic fibrosis (CF), and al-antitrypsin (AAT) deficiency.
In a gene therapy employing a modified arrangement of the invention, a recombinant gene is constructed encoding a fusion protein comprising a protein expression enhancing polypeptide linked to a target protein of interest. The recombinant gene is inserted into a vector, which in turn is integrated into the genome of somatic cells of a human subject. In most cases, it is not necessary for the recombinant vector to be taken up and integrated into the genome of all somatic cells, but only a sub-population of cells that may be relevant to a particular disease. The fusion protein expressed from the integrated recombinant gene in the somatic cells of the human subject treats the disease by restoring a function of the endogenous target protein of interest that is otherwise missing, has been lost, or is so diminished as to cause a clinically recognized disease in a human subject.
In a gene therapy employing an unmodified arrangement of the invention, a recombinant gene is constructed encoding a fusion protein comprising a protein expression enhancing polypeptide linked to a target protein binding domain that has an affinity for and binds a target protein of interest.
The recombinant gene is inserted into a vector, which in turn is integrated into the genome of somatic cells of a human subject. Again, in most cases, it is not necessary for the recombinant vector to be taken up and integrated into that genome of all somatic cells, but only a sub-population of cells that may be relevant to a particular disease. Expression of the fusion protein from the integrated recombinant gene in the cells of the human subject enhances expression of the endogenous target protein of interest so that the protein can provide the cells with the required function provided by the target protein to avoid a clinically recognized disease. If the endogenous gene for the endogenous target protein of interest is not functional or has been deleted, then a recombinant gene encoding the target protein of interest must also be constructed and inserted into a vector for integration into the genome of a human subject for expression along with the fusion protein.
Any of a variety of vectors, agents, and methods may be used to introduce nucleic acid molecules into the somatic cells of a human subject including, but not limited to, modified viruses (e.g., a modified adenovirus, a modified lentivirus), virus-associated virus (e.g., an adenovirus-associated virus), naked DNA (such as naked plasmid DNA), compacted DNA in nanoparticles, and liposomes (e.g., using various cationic lipids).
Fusion Proteins Comprising a Protein Expression Enhancing Polypeptide and a Target Protein of Interest in a Modified Arrangement A fusion protein in a modified arrangement of the invention comprises a protein expression enhancing polypeptide (or PEEP, comprising an isolated J domain, an active J
domain polypeptide fragment, or J domain analog polypeptide as described herein) linked to a target protein of interest.
Preferably, the protein expression enhancing polypeptide is linked to the amino (N) terminus or carboxy (C) terminus of the target protein of interest. The protein expression enhancing polypeptide may also be spaced from the protein of interest by one or more intervening polypeptide sequences such as linkers, enzyme cleavage sites, epitope tags, and the like. Insertion of a protein expression enhancing polypeptide within a target protein of interest is possible, however as a practical matter this requires more complicated recombinant DNA engineering and has a high likelihood of interfering with the proper folding, desired function, or other properties of the target protein of interest, and is therefore generally less preferred. A target protein of interest that may be used to make a fusion protein of a modified arrangement according to the invention may be any protein or polypeptide that has a desirable property, including soluble proteins that normally reside in an intracellular location;
membrane-associated proteins (including transmembrane proteins); secreted proteins; and genetically engineered, non-naturally occurring, proteins. Such engineered, non-naturally occurring proteins may include, but are not limited to, recombinant soluble forms of natural membrane-associated proteins, for example, the extracellular domain of a transmembrane protein (for example, integrins, complement regulatory proteins). Another example of engineered, non-naturally occurring proteins that may be used as a target protein component of a fusion protein in a modified arrangement are recombinant fusion proteins comprising a recombinant soluble receptor molecule in which an extracellular binding domain of a cell surface receptor is fused to an immunoglobulin Fc domain or immunoglobulin scaffold. A non-limiting example of such a non-naturally occurring fusion protein is etanercept in which the extracellular domain of the p75 human TNFa receptor molecule is linked to the hinge and Fc domain of an IgG1 immunoglobulin. Other proteins that may be used as a target protein of interest in a fusion protein of a modified arrangement of the invention include, but are not limited to, antibodies and antigen-binding portions thereof, cytokines, peptide hormones, enzymes (e.g., thrombin, lactase, proteases, transferases, kinases, etc.), and morphogenetic proteins.
Fusion Proteins Comprising a Protein Enhancing Expression Polypeptide and a Target Protein Binding Domain in an Unmodified Arrangement A protein expression enhancing polypeptide (comprising an isolated J domain, active J
domain polypeptide fragment, or J domain analog polypeptide as described herein) may also be used in an unmodified arrangement to enhance expression of a target protein of interest at its intended location. In an unmodified arrangement according to this invention, a fusion protein comprises a protein expression enhancing polypeptide linked to a target protein binding domain that has an affinity for and binds a target protein of interest. Thus, in an unmodified arrangement of the invention, the target protein of interest is not a component of a fusion protein and therefore retains its unaltered primary structure (amino acid sequence). While not intending to be bound by any particular mechanism, the binding of a target protein of interest to a target protein binding domain of the fusion protein appears to bring the target protein of interest into relatively close proximity to the protein expression enhancing polypeptide (also present in the fusion protein) to provide an enhanced level of expression of the target protein at its intended cellular or extracellular location as compared to the level of expression of the target protein in the absence of the fusion protein. This may involve increased recruitment of chaperone proteins or other post-translational cellular mechanisms involved in protein folding, compartmentalization, or secretion, or may involve increase avoidance of cellular degradation pathways. The effect is evidenced by a significant increase in the appearance of expressed protein in the desired intracellular or extracellular location.
Target Protein Binding Domains Useful in an Unmodified Arrangement A fusion protein in an unmodified arrangement of the invention comprises a target protein binding domain that binds a target protein of interest for which an elevation of expression in its proper cellular or extracellular location is desired. A target protein binding domain of a target protein-binding fusion protein of the invention may be any protein or binding domain thereof that is known to bind to a target protein. The more specific the binding affinity of a protein or binding domain thereof is for a target protein, the less likely other proteins may potentially interfere with the enhancement in the level of expression desired for the target protein of interest.
Examples of target protein binding domains include antigen binding sites isolated from natural and genetically engineered antibodies and antigen binding fragments thereof, wherein the antigen binding site of an antibody or antigen binding fragment binds a target protein for which an elevation of expression is desired. In this context, antibodies and antigen binding fragments can easily be raised that bind a target protein of interest using standard methods available in the art. A
variety of genetically engineered antibody formats are known in the art that may be used as a source of a target protein binding domain of a fusion protein in an unmodified arrangement of the invention.
Such formats include, but not limited to, Fab fragments, F(ab')2 fragments, single chain Fv (scFv) antibodies, and single domain antibodies (dAb). See, for example, a review of the variety of functional genetically engineered antibody binding formats available in the art in Marvin et al., Acta Pharmacol. Sin., 26(6): 649-658 (2005); Kufer et al, Trends Biotechnol., 22(5): 238-244 (2004);
Kontermann, Acta Pharmacol. Sin., 26(1): 1-9 (2005), and Chan et al., Nat.
Rev, 10: 301-316 (2010).
Particularly useful in the invention are antibody molecules or fragments in which an antigen binding domain directed to a target protein is provided in a single polypeptide because such polypeptides can be easily linked to a protein expression enhancing polypeptide to form a fusion protein of the invention using standard in vitro DNA methods. For example, a single chain Fv antibody (scFv) comprises both VH and VL domains of an antigen binding site linked in a single polypeptide. Another source of a single chain antigen binding site is a single domain antibody (dAb) in which the entire antigen binding site is present in a single heavy chain variable domain. See, for example, Ward et al., Nature, 341: 544-546 (1989); Muyldermans et al., Protein Eng., 7: 1129-1135 (1994); Vu et al., Mol. Immunol., 34: 1121-1131 (1997); Muyldermans et al., Trends Biochem. Sci., 26: 230-235 (2001); Nguyen et al., Immunogenetics, 54: 39-47 (2002).
For a target protein that possesses an immunoglobulin Fc domain, a target protein binding domain may be an antibody or antigen (Fc domain) binding fragment thereof as discussed above. An alternative to an antibody or antigen binding domain thereof is any of a variety of non-immunoglobulin proteins and polypeptides that are known to specifically bind Fc domains. Proteins that possess Fc binding domains include, but are not limited to, Protein A, Protein G, gE protein of herpes simplex virus type 1 (HSV-1), and the like. A number of synthetic peptides also have been identified that bind Fc domains. See, for example, DeLano et al., Science, 287:1279-1283 (2000);
Yang et al., J. Peptide Res., 66(Suppl. 1): 120-137 (2006). As shown in the Examples below, such Fc-binding proteins and peptides are readily employed as target binding domains for fusion proteins of the invention directed to target proteins of interest comprising an Fc domain.
In the case in which a target protein of interest is a receptor or functional portion thereof that binds a protein ligand, the protein ligand may be used as a target binding domain in a fusion protein of the invention. Functional portions of receptors include, but are not limited to, the extracellular domain of a membrane-associated receptor that includes a functional ligand binding domain.
Typically, such extracellular portions comprising a functional ligand binding domain are referred to as "truncated receptors" because the transmembrane and cytoplasmic domains of the receptor have been removed. According to the invention, the expression of such truncated receptor molecules may be elevated by co-expression with a fusion protein of the invention comprising a protein ligand of the receptor. Accordingly, particularly suited for use as a target binding domain of a fusion protein in a modified arrangement of the invention are ligand proteins that are single polypeptides, such as certain cytokine polypeptides (for example, IL8, IL13, and the like) as shown in the Examples below. Other protein ligands that may be used in a fusion protein to bind a target receptor protein or ligand binding portion thereof, include polypeptide co-receptors, polypeptide co-repressors, and polypeptide co-factors.
In the case in which the target protein is a protein ligand (for example, a cytokine) that is bound by a known receptor molecule, a target protein binding domain of a fusion protein in an unmodified arrangement of the invention may comprise the cognate receptor or extracellular ligand binding portion of the receptor that binds the target protein.
BAG domains have been suggested in the art as fusion partners for enhancement of expression of target proteins. BAG domains of a variety of BAG proteins have been determined.
See, for example, Takayama et al., Nat. Cell Biol., 3: E237-E241 (2001). A BAG
domain has the key defining features of a BAG domain of any member of the BAG protein family.
Accordingly, a BAG
domain comprises a polypeptide domain of a BAG protein that is typically 85-124 amino acids in length, binds the ATPase domain of Hsp70 chaperone proteins, and is characterized by three anti-parallel a-helices (I, II, III, IV), wherein helices III and IV interact with the ATPase domain of Hsp70 chaperone proteins. Recently, it has been reported that when desired recombinant proteins are linked to a BAG domain, the resulting fusion proteins are expressed at levels that are greater than those of the protein alone. See, International Publication No. WO 2012/087835 A2.
From the Examples, below, BAG domains employed in an unmodified arrangement did not provide significant enhancement of the level of expression of target proteins of interest. In contrast, the protein expression enhancing polypeptides described herein significantly enhance levels of expression of target proteins of interest in both modified and unmodified arrangements. As shown in the Examples below, fusion proteins comprising a protein expression enhancing polypeptide (such as an isolated J domain, an active J domain fragment, or a J domain analog polypeptide, e.g., of formula I or particular 10-12 amino acid cognates thereof disclosed herein) linked to a target protein of interest (in a modified arrangement of the invention) were expressed at significantly greater levels than that of control cells (no fusion protein). Other studies showed that fusion proteins comprising a protein expression enhancing polypeptide described herein linked to target protein binding domains (in an unmodified arrangement) were effective in providing significantly greater levels of expression of unmodified target proteins of interest as compared to the levels in the absence of such fusion proteins (control) or fusion proteins comprising a BAG domain linked to a target protein binding domain.
Accordingly, protein expression enhancing polypeptides as described herein provide a new family of polypeptides for use in enhancing expression of target proteins of interest in both modified and unmodified arrangements.
Gene Therapy Approaches for Treating Cystic Fibrosis Cystic fibrosis (CF) is an autosomal recessive disorder caused by mutations in the gene encoding the cystic fibrosis transmembrane conductance regulator (CFTR) protein, a cAMP-regulated chloride channel and channel regulator. The deletion of phenylalanine at position 508 (4508F) in CFTR is the most common mutation that changes the conformation of the CFTR
protein, which is then rapidly degraded by the endoplasmic reticulum (ER) quality systems. A
general consensus is that only partial recovery of the wild-type CFTR protein function is required to provide a beneficial treatment to CF patients. Therefore, a number of gene therapy trials with CFTR
have been attempted, but have not yet been successful owing to inefficient delivery of a gene for CFTR and to immunogenicity of the vehicle (e.g., viral vector). In view of the fact that proper protein folding of wild-type CFTR is known to be difficult, it would be very useful if protein folding of the CFTR
protein could be improved.
Over twenty clinical trials of a gene therapy to treat cystic fibrosis (CF) have been conducted since the identity and isolation of the CFTR gene over twenty years ago. See a review of gene therapy for cystic fibrosis in Davies et al., Proc. Am. Thor. Soc.,7: 408-414 (2010).
Such clinical trials have already established proof of concept to provide replacement cystic fibrosis transmembrane conductance regulator (CFTR) protein, however the sustainability of effective levels of expression of the replacement CFTR protein in the cells of human subjects remains among the most persistent challenges in the development of an effective gene therapy to treat CF. The CFTR wild-type protein is a protein well-known for its instability. Over 90% of CF patients possess at least one copy of a mutated gene for CFTR (CFTRA508F) in which the absence of a phenylalanine at position 508 results in a highly unstable protein that is rapidly degraded in cells. This suggests a fusion gene therapy approach for treating CF that would lead to increased CFTR function or restored CFTR function to those afflicted with CF. Such a gene therapy provides a nucleic acid encoding a fusion protein in either a modified or unmodified arrangement of the invention.
As shown in the Examples below, fusion proteins in which either a wild-type CFTR protein or the CFTR4508F protein is fused to a protein expression enhancing polypeptide (such as J domain) in a modified arrangement were expressed in significantly higher levels than either unfused protein.
This suggests that a J domain fusion gene therapy approach for treating CF
that would lead to increased CFTR function or restored CFTR function to those afflicted with CF.
Accordingly, the modified arrangement of the invention provides new forms of gene therapies that use fusion proteins that are expressed at significantly higher levels and therefore are more effective than past therapies to replace or restore missing or lost protein functions that are associated with various diseases.
For an unmodified arrangement, a fusion protein comprises a protein expression enhancing polypeptide linked to a binding domain that binds the wild-type CFTR protein or the CFTRA508F
protein. A number of proteins are known to contain PDZ domains that bind to the highly conserved, carboxy terminal, PDZ binding region of CFTR. A protein that can be used as a source of a PDZ
domain for use as a target protein binding domain in a fusion protein in an unmodified arrangement of the invention includes, but is not limited to, any of the members of the NHERF
family of PDZ adapter proteins including, but not limited to, of NHERF1 (also known as NHERF, EBP50, or SLC9A3R1), NHERF2 (also known as E3KARP or SLC9A3R2), and PDZK1 (also known as CAP70 or NHERF3).See, for example, Haggie et al., J. Biol. Chem., 279(7): 5494-5500 (2004); Guggino, W.B., Proc. Am. Thorac. Soc., 1: 28-32 (2004); and Singh et al., J. Clin. Investig., 119(3): 540-550 (2009).
Accordingly, a PDZ domain of a PDZ protein may be particularly useful as a target protein binding domain in a fusion protein designed to target either or both CETRA508F and wild-type CFTR proteins in a gene therapy of the invention.
Accordingly, the invention provides new forms of gene therapies that provide fusion proteins that significantly elevate the levels of expression of an endogenous unstable protein (such as the unstable CFTRA508F) and/or the levels of expression of a desired heterologous protein (such as a wild-type CFTR) and therefore are more effective than past therapies to replace or restore missing or lost protein functions that are associated with various diseases.
Additional embodiments and features of the invention will be apparent from the following non-limiting examples.
Examples Example 1. Compositions and Methods for Enhancing Expression of Target Proteins of Interest Using a Modified Arrangement Expression vector plasmids were constructed for expressing a target protein of interest linked to protein expression enhancing polypeptide described herein, which in turn may be linked to an standard epitope tag, which is usually attached at the carboxy (C) terminus or amino (N) terminus of the protein construct for easy identification or isolation using a corresponding anti-tag antibody and standard immunoblot assays.
A DNA linker molecule having a nucleotide sequence containing various restriction enzyme sites was produced by annealing two single-stranded DNA molecules having the sequences shown below (5' to 3'):
AGCTTGGTACCGGATCCGAATTCGATATCGCGGCCGCTCTCGAGTCTAGAGGGCC (SEQ
ID NO:187) and CTCTAGACTCGAGAGCGGCCGCGATATCGAATTCGGATCCGGTACCA (SEQ ID NO:188).
The annealed linker molecule was then inserted into plasmid pcDNA3 (catalogue no. V790-20, Invitrogen) digested with HindIII and ApaI to yield plasmid pcDNA'.
DNA molecules encoding the V5 epitope tag (GKPIPNPLLGLDST (SEQ ID NO:47)) or the Flag epitope tag (DYKDDDDK (SEQ ID NO:111)) were inserted into plasmid pcDNA'.
A double-stranded DNA molecule having the coding sequence for the V5 epitope tag along with an N-terminal methionine, i.e., ATGGGTAAGCCTATCCCTAACCCTCTCCTCGGTCTCGATTCTACG (SEQ ID
NO:189), was inserted into pcDNA' digested with XhoI and XbaI to yield plasmid V5(C)-pcDNA' or with HindIII and KpnI to yield plasmid V5(N)-pcDNA'.
A DNA molecule having the coding sequence for the Flag epitope tag, i.e., GATTACAAGGATGACGATGACAAG (SEQ ID NO:190), was inserted into plasmid pcDNA' digested with XhoI and XbaI to yield plasmid Flag(N)-pcDNA'.
Preparation of DNA molecules DNA molecules encoding protein sequences were obtained by polymerase chain reaction (PCR), gene synthesis, or annealing of complementary DNA molecules using standard protocols. A
DNA molecule encoding the amino acid sequence of an immunoglobulin Fc region was produced by standard oligonucleotide synthesis. A DNA molecule having a DNA sequence GGAGGCGGAAGTGGT GGGAGCGGTGGAAGCGGAGGC (SEQ ID NO:191) encoding the glycine-serine linker sequence GGGSGGSGGSGG (SEQ ID NO:121), was produced by annealing complementary single strands synthesized by standard methods.
Preparation of expression vector plasmids for expressing J domain fusion proteins To express C-terminally VS-tagged IL13Ra2 receptor protein (see, Fig. 1A), a DNA molecule encoding an IL13Ra2 receptor protein was inserted into plasmid V5(C)-pcDNA' digested with HindIII and KpnI.
To express the fusion protein in which a J domain or BAG domain is attached to the N-terminus of IL13Ra2 receptor protein (see, Fig. 3A), a truncated IL13Ra2 receptor protein with its signal sequence deleted was inserted into plasmid V5(C)-pcDNA' digested with NotI and XhoI.
To express a VS-tagged, truncated TNR1 receptor protein (see, Fig. 5A), a DNA
molecule encoding a truncated (extracellular domain only) TNR1 receptor protein was inserted into plasmid V5(C)-pcDNA' digested with HindIII and KpnI.
To express a VS-tagged al anti-trypsin ("al AT") (see, Fig. 4A), a DNA
molecule encoding an al anti-trypsin was inserted into plasmid V5(C)-pcDNA' digested with HindIII and KpnI
To express an N-terminally VS-tagged p53 protein (see, Fig. 7A), a DNA
molecule encoding a p53 protein was inserted into plasmid V5(N)-pcDNA' digested with Nod and XhoI.
To express V-tagged CFTR and VS-tagged mutant CETR4508F (see, Fig. 8A), a DNA
molecule encoding a CFTR protein or a CFTR4508F protein was inserted into plasmid VS(N)-pcDNA' digested with NotI and XhoI.
For expressing fusion proteins comprising a protein of interest fused to a J
domain, DNA
molecules encoding J domains were subcloned into the EcoRI site of plasmid VS(C)-pcDNA' or the EcoRV plasmid VS(N)-pcDNA' to yield plasmid vectors J-VS(C)-pcDNA' or VS(N)-J-pcDNA', respectively. Fusion proteins were produced using Hsp40, SV40, and CSP J
domains.
To express fusion proteins comprising a protein of interest fused to a BAG
domain, DNA
molecules encoding a BAG domain were subcloned into EcoRI and EcoRV sites of plasmid V5(C)-pcDNA' or plasmid VS(N)-pcDNA' to yield plasmid vectors BAG-VS(C)-pcDNA' or VS(N)-BAG-pcDNA', respectively. Fusion proteins were produced using BAG3, BAG4, BAGS, and BAG6 domains as indicated below.
DNA molecules encoding IL13Ra2, TNFR1, a lAT, p53, or CFTR (wild type or 4508F
mutant) were then inserted in frame with the J domain (or, in some instances, a BAG domain) sequence in one or more of the expression vectors to express the resulting fusion protein, which also possessed an N-terminal or C-terminal VS epitope tag for convenient identification of the encoded protein.
Expression and detection of proteins in HEK293 cells Expression vector plasmids encoding various protein constructs were transfected into HEK293 cells with X-tremeGENE HP transfection reagent (catalogue no.
06365752001, Roche). As indicated in the examples below, a separate plasmid expressing the green fluorescent protein (GFP) was co-transfected with each expression vector plasmid encoding a fusion protein of the invention to monitor the transfection efficiency. Cultures of transfectant cells were incubated for two days, and culture medium and/or cell lysates were analyzed for expressed proteins using dot blot or Western immunoblot assays. Samples of culture media were centrifuged to remove debris prior to analysis.
For cell lysates, cells were lysed in lysis buffer (10 mM Tris-HC1, pH8.0, 150 mM NaC1, 10 mM
EDTA, 2% SDS) containing 2 mM PMSF. After brief sonication, the sample was analyzed for express proteins using dot blot or Western immunoblot assays. For Western blot analysis, samples were boiled in SDS-sample buffer and run on polyacrylamide electrophoresis, followed by transfer of separated protein bands to membrane (PVDF membrane).
The expression of GFP as an internal transfection control was detected using an anti-GFP
antibody. Expressed proteins in dot blots and Western blots were detected using a chemiluminescent signal. Briefly, blots were reacted with a primary antibody that binds the particular epitope tag (e.g., VS or Flag) carried by the proteins. After rinsing away unreacted primary antibody, a secondary, enzyme-linked antibody (e.g., horse radish peroxidase linked anti-IgG
antibody) was allowed to react with primary antibody molecules bound to the blots. After rinsing, manufacturer's chemiluminescent reagent was added. Chemiluminescent signals in blots were captured on x-ray film. Where indicated, the images of the chemiluminescent signals were scanned with a densitometer and analyzed using the NIH ImageJ image processing program.
Assays for protein activities Standard assays are available for detecting activities of the proteins of interest used in preparing J domain fusion proteins described herein.
A binding assay for IL13Ra2 binding function is described in "Identification of distinct roles for a dileucine and a tyrosine internalization motif in the interleukin (IL)-13 binding component IL13 receptor alpha 2 chain," J. Biol. Chem., 276(27): 25114-25120 (2001).
A binding assay for TNFR binding function is described in "Recombinant 55-kDa tumor necrosis factor (TNF) receptor: Stoichiometry of binding to TNF alpha and TNF
beta and inhibition of TNF activity," J. Biol. Chem., 266(27): 18324-18329 (1991) An assay for al-antitrypsin (alAT) activity is described in "Alpha 1-antitrypsin and protease complexation is induced by lipopolysaccharide, interleukin-lbeta, and tumor necrosis factor-alpha in monocytes," Am. J. Respir. Grit. Care Med., 157(1): 246-255 (1998).
An assay for p53 activity is described in "Influenza virus infection increases p53 activity: role of p53 activity in cell death and viral replication," J. Virol., 79(14): 8802-8811 (2005).
An assay for CFTR activity is described in "Pharmacology of CFTR chloride channel activity," Physiol. Rev., 79(1 Suppl.): S109-S144 (1999).
Example 2. Enhancement of Expression of Target Proteins in a Modified Arrangement Figure lA shows general diagrams of constructs for a C-terminally V5 epitope-tagged, full-length IL13Ra2 protein ("IL13Ra2WT") and for a C-terminally V5 epitope-tagged fusion protein comprising IL13Ra2 fused to a BAG or to a J domain.
The VS-tagged IL13Ra2WT protein comprises an amino acid sequence for a full-length IL13Ra2 protein linked at the C terminus to a V5 epitope tag, which in turn is linked to twelve C-terminal amino acid residues from the cloning site of the expression vector.
The amino acid sequence for the VS-tagged IL13Ra2WT is shown in the table below.
Table 2. Amino Acid Sequence of a VS-Tagged IL13Ra2WT Protein.
Protein Region Sequence Amino Acid Sequence (N¨ to C¨ Identifier terminal) IL13Ra2WT domain SEQ ID NO:192 MAFVCLAIGCLYTFLISTTFGCTSSSDTEI
(full-length) KVNPPQDFEIVDPGYLGYLYLQWQPPLSLD
HFKECTVEYELKYRNIGSETWKTIITKNLH
YKDGFDLNKGIEAKIHTLLPWQCTNGSEVQ
SSWAETTYWISPQGIPETKVQDMDCVYYNW
QYLLCSWKPGIGVLLDTNYNLFYWYEGLDH
ALQCVDYIKADGQNIGCRFPYLEASDYKDF
YICVNGSSENKPIRSSYFTFQLQNIVKPLP
PVYLTFTRESSCEIKLKWSIPLGPIPARCF
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) 123456789012345678901234567890 DYEIEIREDDTTLVTATVENETYTLKTTNE
TRQLCFVVRSKVNIYCSDDGIWSEWSDKQC
WEGEDLSKKTLLRFWLPFGFILILVIFVTG
LLLRKPNTYPKMIPEFFCDTGTGSEFD IAA
ALEGKPIPNPLLGLDSTSRGPYSIVSPKC
IL13Ra2FL residues 1-380 MAFVCLAIGCLYTFLISTTFGCTSSSDTEI
of SEQ ID KVNPPQDFEIVDPGYLGYLYLQWQPPLSLD
NO: 192 HFKECTVEYELKYRNIGSETWKTIITKNLH
YKDGFDLNKGIEAKIHTLLPWQCTNGSEVQ
SSWAETTYWISPQGIPETKVQDMDCVYYNW
QYLLCSWKPGIGVLLDTNYNLFYWYEGLDH
ALQCVDYIKADGQNIGCRFPYLEASDYKDF
YICVNGSSENKPIRSSYFTFQLQNIVKPLP
PVYLTFTRESSCEIKLKWSIPLGPIPARCF
DYEIEIREDDTTLVTATVENETYTLKTTNE
TRQLCFVVRSKVNIYCSDDGIWSEWSDKQC
WEGEDLSKKTLLRFWLPFGFILILVIFVTG
LLLRKPNTYPKMIPEFFCDT
Linker residues 381- GTGSEFDIAAALE
393 of SEQ ID
NO: 192 V5 epitope residues 394- GKPIPNPLLGLDST
domain 407 of SEQ ID
NO: 192 C-terminal residues 408- SRGPYSIVSPKC
vector residues 419 of SEQ ID
NO: 192 The V5-tagged IL13Ra2WT-BAG3 domain fusion protein comprises an amino (N)-terminal amino acid sequence for a full-length IL13Ra2 protein linked to a BAG domain from the BAG3 protein, which in turn is linked to a V5 epitope tag, which in turn is linked to twelve C-terminal amino acid residues from the cloning site of the expression vector. The amino acid sequence for the IL13Ra2WT-BAG3 domain fusion protein is shown in the table below.
Table 3. Amino Acid Sequence of an IL13Ra2WT-BAG3 Domain Fusion Protein.
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) 123456789012345678901234567890 IL13Ra2WT-BAG3 SEQ ID NO: 193 MAFVCLAIGCLYTFLISTTFGCTSSSDTEI
fusion protein KVNPPQDFEIVDPGYLGYLYLQWQPPLSLD
HFKECTVEYELKYRNIGSETWKTIITKNLH
YKDGFDLNKGIEAKIHTLLPWQCTNGSEVQ
SSWAETTYWISPQGIPETKVQDMDCVYYNW
QYLLCSWKPGIGVLLDTNYNLFYWYEGLDH
ALQCVDYIKADGQNIGCRFPYLEASDYKDF
YICVNGSSENKPIRSSYFTFQLQNIVKPLP
PVYLTFTRESSCEIKLKWSIPLGPIPARCF
DYEIEIREDDTTLVTATVENETYTLKTTNE
TRQLCFVVRSKVNIYCSDDGIWSEWSDKQC
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) 123456789012345678901234567890 WEGEDLSKKTLLRFWLPFGFILILVIFVTG
LLLRKPNTYPKMIPEFFCDTGTGSEFHPGV
LKVEAILEKVQGLEQAVDNFEGKKTDKKYL
MIEEYLTKELLALDSVDPEGRADVRQARRD
GVRKVQTILEKLEQKAIDDIAAALEGKPIP
NPLLGLDSTSRGPYSIVSPKC
IL13Ra2WT domain residues 1-380 MAFVCLAIGCLYTFLISTTFGCTSSSDTEI
(full-length) of SEQ ID KVNPPQDFEIVDPGYLGYLYLQWQPPLSLD
NO: 193 HFKECTVEYELKYRNIGSETWKTIITKNLH
YKDGFDLNKGIEAKIHTLLPWQCTNGSEVQ
SSWAETTYWISPQGIPETKVQDMDCVYYNW
QYLLCSWKPGIGVLLDTNYNLFYWYEGLDH
ALQCVDYIKADGQNIGCRFPYLEASDYKDF
YICVNGSSENKPIRSSYFTFQLQNIVKPLP
PVYLTFTRESSCEIKLKWSIPLGPIPARCF
DYEIEIREDDTTLVTATVENETYTLKTTNE
TRQLCFVVRSKVNIYCSDDGIWSEWSDKQC
WEGEDLSKKTLLRFWLPFGFILILVIFVTG
LLLRKPNTYPKMIPEFFCDT
Linker residues 381- GTGSEF
386 of SEQ ID
NO: 193 BAG domain residues 387- HPGVLKVEAILEKVQGLEQAVDNFEGKKTD
(from BAG3) 468 of SEQ ID KKYLMIEEYLTKELLALDSVDPEGRADVRQ
NO: 193 ARRDGVRKVQTILEKLEQKAID
Linker residues 469- DIAAALE
475 of SEQ ID
NO: 193 V5 epitope residues 476- GKPIPNPLLGLDST
domain 489 of SEQ ID
NO: 193 C-terminal residues 490- SRGPYSIVSPKC
vector residues 501 of SEQ ID
NO: 193 The V5-tagged IL13Ra2WT-BAG4 domain fusion protein comprises an amino (N)-terminal amino acid sequence for a full-length IL13Ra2 protein linked to a BAG domain from the BAG4 protein, which in turn is linked to a V5 epitope tag, which in turn is linked to twelve C-terminal amino acid residues from the cloning site of the expression vector. The amino acid sequence for the IL13Ra2WT-BAG4 domain fusion protein is shown in the table below.
Table 4. Amino Acid Sequence of an IL13Ra2WT-BAG4 Domain Fusion Protein.
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) 123456789012345678901234567890 IL13Ra2WT- SEQ ID NO: 194 MAFVCLAIGCLYTFLISTTFGCTSSSDTEI
BAG4 Domain KVNPPQDFEIVDPGYLGYLYLQWQPPLSLD
Fusion Protein HFKECTVEYELKYRNIGSETWKTIITKNLH
YKDGFDLNKGIEAKIHTLLPWQCTNGSEVQ
Protein Region Sequence Amino Acid Sequence (N¨ to C¨ Identifier terminal) 123456789012345678901234567890 SSWAETTYWISPQGIPETKVQDMDCVYYNW
QYLLCSWKPGIGVLLDTNYNLFYWYEGLDH
ALQCVDYIKADGQNIGCRFPYLEASDYKDF
YICVNGSSENKPIRSSYFTFQLQNIVKPLP
PVYLTFTRESSCEIKLKWSIPLGPIPARCF
DYEIEIREDDTTLVTATVENETYTLKTTNE
TRQLCFVVRSKVNIYCSDDGIWSEWSDKQC
WEGEDLSKKTLLRFWLPFGFILILVIFVTG
LLLRKPNTYPKMIPEFFCDTGTGSEFESTP
PSIKKIIHVLEKVQYLEQEVEEFVGKKTDK
AYWLLEEMLTKELLELDSVETGGQDSVRQA
RKEAVCKIQAILEKLEKKGLDIAAALEGKP
IPNPLLGLDSTSRGPYSIVSPKC
IL13Ra2WT residues 1-380 MAFVCLAIGCLYTFLISTTFGCTSSSDTEI
(full-length) of SEQ ID KVNPPQDFEIVDPGYLGYLYLQWQPPLSLD
NO: 194 HFKECTVEYELKYRNIGSETWKTIITKNLH
YKDGFDLNKGIEAKIHTLLPWQCTNGSEVQ
SSWAETTYWISPQGIPETKVQDMDCVYYNW
QYLLCSWKPGIGVLLDTNYNLFYWYEGLDH
ALQCVDYIKADGQNIGCRFPYLEASDYKDF
YICVNGSSENKPIRSSYFTFQLQNIVKPLP
PVYLTFTRESSCEIKLKWSIPLGPIPARCF
DYEIEIREDDTTLVTATVENETYTLKTTNE
TRQLCFVVRSKVNIYCSDDGIWSEWSDKQC
WEGEDLSKKTLLRFWLPFGFILILVIFVTG
LLLRKPNTYPKMIPEFFCDT
Linker residues 381- GTGSEF
386 of SEQ ID
NO: 194 BAG domain residues 387- ESTPPSIKKIIHVLEKVQYLEQEVEEFVGK
(from BAG4) 470 of SEQ ID KTDKAYWLLEEMLTKELLELDSVETGGQDS
NO: 194 VRQARKEAVCKIQAILEKLEKKGL
Linker residues 471- DIAAALE
477 of SEQ ID
NO: 194 V5 epitope residues 478- GKPIPNPLLGLDST
domain 491 of SEQ ID
NO: 194 C-terminal residues 492- SRGPYSIVSPKC
vector residues 503 of SEQ ID
NO: 194 The V5-tagged IL13Ra2WT-BAG5 domain fusion protein comprises an amino (N)-terminal amino acid sequence for a full-length IL13Ra2 protein linked to a BAG domain from the BAG5 protein, which in turn is linked to a V5 epitope tag, which in turn is linked to twelve C-terminal amino acid residues from the cloning site of the expression vector. The amino acid sequence for the IL13Ra2WT-BAG5 domain fusion protein is shown in the table below.
Table 5. Amino Acid Sequence of an IL13Ra2WT-BAG5 Domain Fusion Protein.
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) 123456789012345678901234567890 IL13Ra2WT- SEQ ID NO: 195 MAFVCLAIGCLYTFLISTTFGCTSSSDTEI
BAG5 domain KVNPPQDFEIVDPGYLGYLYLQWQPPLSLD
fusion protein HFKECTVEYELKYRNIGSETWKTIITKNLH
YKDGFDLNKGIEAKIHTLLPWQCTNGSEVQ
SSWAETTYWISPQGIPETKVQDMDCVYYNW
QYLLCSWKPGIGVLLDTNYNLFYWYEGLDH
ALQCVDYIKADGQNIGCRFPYLEASDYKDF
YICVNGSSENKPIRSSYFTFQLQNIVKPLP
PVYLTFTRESSCEIKLKWSIPLGPIPARCF
DYEIEIREDDTTLVTATVENETYTLKTTNE
TRQLCFVVRSKVNIYCSDDGIWSEWSDKQC
WEGEDLSKKTLLRFWLPFGFILILVIFVTG
LLLRKPNTYPKMIPEFFCDTGTGSEFEHPS
HKAVWNVLGNLSEIQGEVLSFDGNRTDKNY
IRLEELLTKQLLALDAVDPQGEEKCKAARK
QAVRLAQNILSYLDLKSDEDIAAALEGKPI
PNPLLGLDSTSRGPYSIVSPKC
IL13Ra2WT residues 1-380 MAFVCLAIGCLYTFLISTTFGCTSSSDTEI
(full-length) of SEQ ID KVNPPQDFEIVDPGYLGYLYLQWQPPLSLD
NO: 195 HFKECTVEYELKYRNIGSETWKTIITKNLH
YKDGFDLNKGIEAKIHTLLPWQCTNGSEVQ
SSWAETTYWISPQGIPETKVQDMDCVYYNW
QYLLCSWKPGIGVLLDTNYNLFYWYEGLDH
ALQCVDYIKADGQNIGCRFPYLEASDYKDF
YICVNGSSENKPIRSSYFTFQLQNIVKPLP
PVYLTFTRESSCEIKLKWSIPLGPIPARCF
DYEIEIREDDTTLVTATVENETYTLKTTNE
TRQLCFVVRSKVNIYCSDDGIWSEWSDKQC
WEGEDLSKKTLLRFWLPFGFILILVIFVTG
LLLRKPNTYPKMIPEFFCDT
Linker residues 381- GTGSEF
386 of SEQ ID
NO: 195 BAG domain residues 387- EHPSHKAVWNVLGNLSEIQGEVLSFDGNRT
(from BAGS) 469 of SEQ ID DKNYIRLEELLTKQLLALDAVDPQGEEKCK
NO: 195 AARKQAVRLAQNILSYLDLKSDE
Linker residues 470- DIAAALE
476 of SEQ ID
NO: 195 V5 epitope residues 477- GKPIPNPLLGLDST
domain 490 of SEQ ID
NO: 195 C-terminal residues 491- SRGPYSIVSPKC
residues 502 of SEQ ID
NO: 195 The VS-tagged IL13Ra2WT-BAG6 domain fusion protein comprises an amino (N)-terminal amino acid sequence for a full-length IL13Ra2 protein linked to a BAG domain from the BAG6 protein, which in turn is linked to a V5 epitope tag, which in turn is linked to twelve C-terminal amino acid residues from the cloning site of the expression vector. The amino acid sequence for the IL13Ra2WT-BAG6 domain fusion protein is shown in the table below.
Table 6. Amino Acid Sequence of an IL13Ra2WT-BAG6 Domain Fusion Protein.
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) 123456789012345678901234567890 IL13Ra2WT-BAG6 SEQ ID NO: 196 MAFVCLAIGCLYTFLISTTFGCTSSSDTEI
domain fusion KVNPPQDFEIVDPGYLGYLYLQWQPPLSLD
protein HFKECTVEYELKYRNIGSETWKTIITKNLH
YKDGFDLNKGIEAKIHTLLPWQCTNGSEVQ
SSWAETTYWISPQGIPETKVQDMDCVYYNW
QYLLCSWKPGIGVLLDTNYNLFYWYEGLDH
ALQCVDYIKADGQNIGCRFPYLEASDYKDF
YICVNGSSENKPIRSSYFTFQLQNIVKPLP
PVYLTFTRESSCEIKLKWSIPLGPIPARCF
DYEIEIREDDTTLVTATVENETYTLKTTNE
TRQLCFVVRSKVNIYCSDDGIWSEWSDKQC
WEGEDLSKKTLLRFWLPFGFILILVIFVTG
LLLRKPNTYPKMIPEFFCDTGTGSEFMPAK
RRKTMQGEGPQLLLSEAVSRAAKAAGARPL
TSPESLSRDLEAPEVQESYRQQLRSDIQKR
LQEDPNYSPQRFPNAQRAFADDPDIAAALE
GKPIPNPLLGLDSTSRGPYSIVSPKC
IL13Ra2WT residues 1-380 MAFVCLAIGCLYTFLISTTFGCTSSSDTEI
(full-length) of SEQ ID KVNPPQDFEIVDPGYLGYLYLQWQPPLSLD
NO: 196 HFKECTVEYELKYRNIGSETWKTIITKNLH
YKDGFDLNKGIEAKIHTLLPWQCTNGSEVQ
SSWAETTYWISPQGIPETKVQDMDCVYYNW
QYLLCSWKPGIGVLLDTNYNLFYWYEGLDH
ALQCVDYIKADGQNIGCRFPYLEASDYKDF
YICVNGSSENKPIRSSYFTFQLQNIVKPLP
PVYLTFTRESSCEIKLKWSIPLGPIPARCF
DYEIEIREDDTTLVTATVENETYTLKTTNE
TRQLCFVVRSKVNIYCSDDGIWSEWSDKQC
WEGEDLSKKTLLRFWLPFGFILILVIFVTG
LLLRKPNTYPKMIPEFFCDT
Linker residues 381- GTGSEF
386 of SEQ ID
NO: 196 BAG domain residues 387- MPAKRRKTMQGEGPQLLLSEAVSRAAKAAG
(from BAG6) 473 of SEQ ID ARPLTSPESLSRDLEAPEVQESYRQQLRSD
NO: 196 IQKRLQEDPNYSPQRFPNAQRAFADDP
Linker residues 474- DIAAALE
480 of SEQ ID
NO: 196 V5 epitope residues 481- GKPIPNPLLGLDST
domain 494 of SEQ ID
NO: 196 C-terminal residues 495- SRGPYSIVSPKC
vector residues 506 of SEQ ID
NO: 196 The V5-tagged IL13Ra2WT-Hsp40 J domain fusion protein comprises an amino (N)-terminal amino acid sequence for a full-length IL13Ra2 protein linked to a J domain from the Hsp40 protein, which in turn is linked to a V5 epitope tag, which in turn is linked to twelve C-terminal amino acid residues from the cloning site of the expression vector. The amino acid sequence for the IL13Ra2-Hsp40 J domain fusion protein is shown in the table below.
Table 7. Amino Acid Sequence of an IL13Ra2WT-Hsp40 J Domain Fusion Protein.
Protein Region Sequence Amino Acid Sequence (N¨ to C¨ Identifier terminal) IL13Ra2WT-Hsp40 SEQ ID NO: 197 MAFVCLAIGCLYTFLISTTFGCTSSSDTEI
J domain fusion KVNPPQDFEIVDPGYLGYLYLQWQPPLSLD
protein HFKECTVEYELKYRNIGSETWKTIITKNLH
YKDGFDLNKGIEAKIHTLLPWQCTNGSEVQ
SSWAETTYWISPQGIPETKVQDMDCVYYNW
QYLLCSWKPGIGVLLDTNYNLFYWYEGLDH
ALQCVDYIKADGQNIGCRFPYLEASDYKDF
YICVNGSSENKPIRSSYFTFQLQNIVKPLP
PVYLTFTRESSCEIKLKWSIPLGPIPARCF
DYEIEIREDDTTLVTATVENETYTLKTTNE
TRQLCFVVRSKVNIYCSDDGIWSEWSDKQC
WEGEDLSKKTLLRFWLPFGFILILVIFVTG
LLLRKPNTYPKMIPEFFCDTGTGSEFMGKD
YYQTLGLARGASDEEIKRAYRRQALRYHPD
KNKEPGAEEKFKEIAEAYDVLSDPRKREIF
DRYDIAAALEGKPIPNPLLGLDSTSRGPYS
IVSPKC
IL13Ra2WT domain residues 1-380 MAFVCLAIGCLYTFLISTTFGCTSSSDTEI
(full-length) of SEQ ID KVNPPQDFEIVDPGYLGYLYLQWQPPLSLD
NO: 197 HFKECTVEYELKYRNIGSETWKTIITKNLH
YKDGFDLNKGIEAKIHTLLPWQCTNGSEVQ
SSWAETTYWISPQGIPETKVQDMDCVYYNW
QYLLCSWKPGIGVLLDTNYNLFYWYEGLDH
ALQCVDYIKADGQNIGCRFPYLEASDYKDF
YICVNGSSENKPIRSSYFTFQLQNIVKPLP
PVYLTFTRESSCEIKLKWSIPLGPIPARCF
DYEIEIREDDTTLVTATVENETYTLKTTNE
TRQLCFVVRSKVNIYCSDDGIWSEWSDKQC
WEGEDLSKKTLLRFWLPFGFILILVIFVTG
LLLRKPNTYPKMIPEFFCDT
Linker residues 381- GTGSEF
386 of SEQ ID
NO: 197 Hsp40 J domain residues 387- MGKDYYQTLGLARGASDEEIKRAYRRQALR
453 of SEQ ID YHPDKNKEPGAEEKFKEIAEAYDVLSDPRK
NO:197 REIFDRY
Linker residues 454- DIAAALE
460 of SEQ ID
NO: 197 Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) V5 epitope residues 461- GKPIPNPLLGLDST
474 of SEQ ID
NO: 197 C-terminal residues 475- SRGPYSIVSPKC
vector residues 486 of SEQ ID
NO: 197 The V5-tagged IL13Ra2WT-SV40 J domain fusion protein comprises an amino (N)-terminal amino acid sequence for a full-length IL13Ra2 protein linked to a J domain from the SV40 J protein, which in turn is linked to a V5 epitope tag, which in turn is linked to twelve C-terminal amino acid residues from the cloning site of the expression vector. The amino acid sequence for the IL13Ra2-SV40 J domain fusion protein is shown in the table below.
Table 8. Amino Acid Sequence of an IL13Ra2WT-SV40 J Domain Fusion Protein.
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) IL13Ra2WT-5V40 J SEQ ID NO:198 MAFVCLAIGCLYTFLISTTFGCTSSSDTEI
domain fusion KVNPPQDFEIVDPGYLGYLYLQWQPPLSLD
protein HFKECTVEYELKYRNIGSETWKTIITKNLH
YKDGFDLNKGIEAKIHTLLPWQCTNGSEVQ
SSWAETTYWISPQGIPETKVQDMDCVYYNW
QYLLCSWKPGIGVLLDTNYNLFYWYEGLDH
ALQCVDYIKADGQNIGCRFPYLEASDYKDF
YICVNGSSENKPIRSSYFTFQLQNIVKPLP
PVYLTFTRESSCEIKLKWSIPLGPIPARCF
DYEIEIREDDTTLVTATVENETYTLKTTNE
TRQLCFVVRSKVNIYCSDDGIWSEWSDKQC
WEGEDLSKKTLLRFWLPFGFILILVIFVTG
LLLRKPNTYPKMIPEFFCDTGTGSEFMDKV
LNREESLQLMDLLGLERSAWGNIPLMRKAY
LKKCKEFHPDKGGDEEKMKKMNTLYKKMED
GVKYAHQPDFGGFWDADIAAALEGKPIPNP
LLGLDSTSRGPYSIVSPKC
IL13Ra2WT domain residues 1-380 MAFVCLAIGCLYTFLISTTFGCTSSSDTEI
(full-length) of SEQ ID KVNPPQDFEIVDPGYLGYLYLQWQPPLSLD
NO: 198 HFKECTVEYELKYRNIGSETWKTIITKNLH
YKDGFDLNKGIEAKIHTLLPWQCTNGSEVQ
SSWAETTYWISPQGIPETKVQDMDCVYYNW
QYLLCSWKPGIGVLLDTNYNLFYWYEGLDH
ALQCVDYIKADGQNIGCRFPYLEASDYKDF
YICVNGSSENKPIRSSYFTFQLQNIVKPLP
PVYLTFTRESSCEIKLKWSIPLGPIPARCF
DYEIEIREDDTTLVTATVENETYTLKTTNE
TRQLCFVVRSKVNIYCSDDGIWSEWSDKQC
WEGEDLSKKTLLRFWLPFGFILILVIFVTG
LLLRKPNTYPKMIPEFFCDT
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) Linker residues 381- GTGSEF
386 of SEQ ID
NO: 198 5V40 J domain residues 387- MDKVLNREESLQLMDLLGLERSAWGNIPLM
466 of SEQ ID RKAYLKKCKEFHPDKGGDEEKMKKMNTLYK
NO: 198 KMEDGVKYAHQPDFGGFWDA
Linker residues 467- DIAAALE
473 of SEQ ID
NO: 198 V5 epitope residues 474- GKPIPNPLLGLDST
487 of SEQ ID
NO: 198 C-terminal residues 488- SRGPYSIVSPKC
vector residues 499 of SEQ ID
NO: 198 The V5-tagged IL13Ra2WT-CSP J domain fusion protein comprises an amino (N)-terminal amino acid sequence for a full-length IL13Ra2 protein linked to a J domain from the CSP protein, which in turn is linked to a V5 epitope tag, which in turn is linked to twelve C-terminal amino acid residues from the cloning site of the expression vector. The amino acid sequence for the IL13Ra2WT-CSP J domain fusion protein is shown in the table below.
Table 9. Amino Acid Sequence of an IL13Ra2WT-CSP J Domain Fusion Protein.
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) IL13Ra2WT-CSP J SEQ ID NO:199 MAFVCLAIGCLYTFLISTTFGCTSSSDTEI
domain fusion KVNPPQDFEIVDPGYLGYLYLQWQPPLSLD
protein HFKECTVEYELKYRNIGSETWKTIITKNLH
YKDGFDLNKGIEAKIHTLLPWQCTNGSEVQ
SSWAETTYWISPQGIPETKVQDMDCVYYNW
QYLLCSWKPGIGVLLDTNYNLFYWYEGLDH
ALQCVDYIKADGQNIGCRFPYLEASDYKDF
YICVNGSSENKPIRSSYFTFQLQNIVKPLP
PVYLTFTRESSCEIKLKWSIPLGPIPARCF
DYEIEIREDDTTLVTATVENETYTLKTTNE
TRQLCFVVRSKVNIYCSDDGIWSEWSDKQC
WEGEDLSKKTLLRFWLPFGFILILVIFVTG
LLLRKPNTYPKMIPEFFCDTGTGSEFMADQ
RQRSLSTSGESLYHVLGLDKNATSDDIKKS
YRKLALKYHPDKNPDNPEAADKFKEINNAH
AILTDATKRNIYDKYGSLGLYVDIAAALEG
KPIPNPLLGLDSTSRGPYSIVSPKC
IL13Ra2 domain residues 1-380 MAFVCLAIGCLYTFLISTTFGCTSSSDTEI
of SEQ ID KVNPPQDFEIVDPGYLGYLYLQWQPPLSLD
NO: 199 HFKECTVEYELKYRNIGSETWKTIITKNLH
YKDGFDLNKGIEAKIHTLLPWQCTNGSEVQ
Protein Region Sequence Amino Acid Sequence (N¨ to C¨ Identifier terminal) SSWAETTYWISPQGIPETKVQDMDCVYYNW
QYLLCSWKPGIGVLLDTNYNLFYWYEGLDH
ALQCVDYIKADGQNIGCRFPYLEASDYKDF
YICVNGSSENKPIRSSYFTFQLQNIVKPLP
PVYLTFTRESSCEIKLKWSIPLGPIPARCF
DYEIEIREDDTTLVTATVENETYTLKTTNE
TRQLCFVVRSKVNIYCSDDGIWSEWSDKQC
WEGEDLSKKTLLRFWLPFGFILILVIFVTG
LLLRKPNTYPKMIPEFFCDT
Linker residues 381- GTGSEF
386 of SEQ ID
NO: 199 CSP J domain residues 387- MADQRQRSLSTSGESLYHVLGLDKNATSDD
472 of SEQ ID IKKSYRKLALKYHPDKNPDNPEAADKFKEI
NO: 199 NNAHAILTDATKRNIYDKYGSLGLYV
Linker residues 473- DIAAALE
479 of SEQ ID
NO: 199 V5 epitope tag residues 480- GKPIPNPLLGLDST
493 of SEQ ID
NO: 199 C-terminal residues 494- SRGPYSIVSPKC
vector residues 505 of SEQ ID
NO: 199 Using the expression vectors described above, the level of expression IL13Ra2-V5 was compared with that of various IL13Ra2 fusion proteins comprising a BAG domain or J domain in transfected HEK293 cells. The expression level of various fusion proteins in cells are shown in the Western blot in Figure 1B. The first row shows lanes of the gel loaded with equal amounts of cell lysate protein. The second row shows expression of GFP as an internal transfection control. As shown in the first row of Figure 1B, only a faint band was detected for the V5-tagged IL13Ra2, which was used to represent expression of the wild-type (WT) IL13Ra2 protein, indicating poor expression.
Fusion proteins comprising IL13Ra2 and a BAG domain (BAG3, BAG4, BAG5, BAG6) were expressed at slightly higher levels. In contrast, fusion proteins comprising IL13Ra2 and any of the J
domains were all expressed at dramatically higher levels than either the V5 tagged IL13Ra2 or the fusion proteins comprising IL13Ra2 and a BAG domain. The results of a densitometry analysis of the signals in Figure 1B are shown in Figure 1C. The fusion proteins comprising IL13Ra2 and any of the J domains were expressed at a level as much as 25-fold higher than the V5 epitope tagged IL13Ra2 (taken as 100%). See, bar graphs in Figure 1C.
Truncated form of IL13Ra2 expression and secretion IL13Ra2 is a membrane receptor protein that binds to interleukin-13 (IL13) and mediates allergic inflammation. Binding of IL13 to the membrane-associated IL13Ra2 receptor transduces a signal to the cytoplasm that sets off an inflammatory response. Such a response is particularly detrimental in the case of asthma. A portion of the expressed, membrane-associated IL13Ra2 molecules is cleaved on the cell surface, releasing a soluble truncated form of IL13Ra2 (IL13Ra2TF) into the extracellular space. The truncated form of IL13Ra2 retains the ability to bind IL13 but cannot transmit a signal to the cell due to the absence of the transmembrane and cytoplasmic regions found in the full-length, membrane-associates protein. Accordingly, the truncated form of IL13Ra2 has been employed as a decoy receptor to treat asthma by binding to IL13 molecules without transducing a signal to the cell to set off an inflammatory response. For such therapeutic applications, a genetically engineered, truncated form of IL13Ra2 has been expressed in mammalian cells and purified as a secreted protein from culture medium. However, the production of the truncated form of IL13Ra2 is inefficient due to difficulties in expression and secretion of the protein.
The ability of a J domain to enhance expression of a soluble, truncated form of IL13Ra2 (IL13Ra2TF) was studied. In order to confirm if conjugation of a J domain to a truncated form of IL13Ra2 enhances expression of the secreted protein, plasmids that expressed an IL13Ra2TF or a fusion protein comprising IL13Ra2TF and an N-terminal J domain from Erdj3 were constructed. The proteins also possessed the V5 epitope tag for easy identification. See, diagrams of constructs in Figure 2A.
The amino acid sequence for a V5 tagged IL13Ra2TF used in this experiment is shown in the table below.
Table 10. Amino Acid Sequence of a VS-Tagged IL13Ra2TF Fusion Protein.
Protein Region Sequence Amino Acid Sequence (N¨ to C¨ Identifier terminal) IL13Ra2TF SEQ ID NO:200 MAFVCLAIGCLYTFLISTTFGCTSSSDTEI
protein KVNPPQDFEIVDPGYLGYLYLQWQPPLSLD
HFKECTVEYELKYRNIGSETWKTIITKNLH
YKDGFDLNKGIEAKIHTLLPWQCTNGSEVQ
SSWAETTYWISPQGIPETKVQDMDCVYYNW
QYLLCSWKPGIGVLLDTNYNLFYWYEGLDH
ALQCVDYIKADGQNIGCRFPYLEASDYKDF
YICVNGSSENKPIRSSYFTFQLQNIVKPLP
PVYLTFTRESSCEIKLKWSIPLGPIPARCF
DYEIEIREDDTTLVTATVENETYTLKTTNE
TRQLCFVVRSKVNIYCSDDGIWSEWSDKQC
WEGEDLSKKGTGSEFDIAAALEGKPIPNPL
LGLDSTSRGPYSIVSPKC
IL13Ra2TF
residues 1-339 MAFVCLAIGCLYTFLISTTFGCTSSSDTEI
of SEQ ID
KVNPPQDFEIVDPGYLGYLYLQWQPPLSLD
NO: 200 HFKECTVEYELKYRNIGSETWKTIITKNLH
YKDGFDLNKGIEAKIHTLLPWQCTNGSEVQ
SSWAETTYWISPQGIPETKVQDMDCVYYNW
QYLLCSWKPGIGVLLDTNYNLFYWYEGLDH
ALQCVDYIKADGQNIGCRFPYLEASDYKDF
YICVNGSSENKPIRSSYFTFQLQNIVKPLP
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) 123456789012345678901234567890 PVYLTFTRESSCEIKLKWSIPLGPIPARCF
DYEIEIREDDTTLVTATVENETYTLKTTNE
TRQLCFVVRSKVNIYCSDDGIWSEWSDKQC
WEGEDLSKK
Linker residues 340- GTGSEFDIAAALE
352 of SEQ ID
NO: 200 V5 epitope residues 353- GKPIPNPLLGLDST
domain 366 of SEQ ID
NO: 200 Linker residues 367- SRGPYSIVSPKC
378 of SEQ ID
NO: 200 The amino acid sequence for a J domain fusion protein comprising an N-terminal J domain of the Erdj3 J protein, a mature (i.e., no signal sequence) and truncated IL13Ra2 (IL13Ra2TF), and the V5 epitope tag is shown in the table below.
Table 11. Amino Acid Sequence of a V5-Tagged Erdj3 J domain-IL13Ra2TF Protein.
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) 123456789012345678901234567890 Erdj3 J domain- SEQ ID NO:201 MAPQNLSTFCLLLLYLIGAVIAGRDFYKIL
IL13Ra2TF fusion GVPRSASIKDIKKAYRKLALQLHPDRNPDD
protein PQAQEKFQDLGAAYEVLSDSEKRDIAAASD
TEIKVNPPQDFEIVDPGYLGYLYLQWQPPL
SLDHFKECTVEYELKYRNIGSETWKTIITK
NLHYKDGFDLNKGIEAKIHTLLPWQCTNGS
EVQSSWAETTYWISPQGIPETKVQDMDCVY
YNWQYLLCSWKPGIGVLLDTNYNLFYWYEG
LDHALQCVDYIKADGQNIGCRFPYLEASDY
KDFYICVNGSSENKPIRSSYFTFQLQNIVK
PLPPVYLTFTRESSCEIKLKWSIPLGPIPA
RCFDYEIEIREDDTTLVTATVENETYTLKT
TNETRQLCFVVRSKVNIYCSDDGIWSEWSD
KQCWEGEDLSKKLEGKPIPNPLLGLDSTSR
GPYSIVSPKC
Erdj3 J domain residues 1-83 MAPQNLSTFCLLLLYLIGAVIAGRDFYKIL
of SEQ ID GVPRSASIKDIKKAYRKLALQLHPDRNPDD
NO: 201 PQAQEKFQDLGAAYEVLSDSEKR
Linker residues 84-88 DIAAA
of SEQ ID
NO: 201 IL13Ra2TF residues 89-402 SDTEIKVNPPQDFEIVDPGYLGYLYLQWQP
(with mature N- of SEQ ID PLSLDHFKECTVEYELKYRNIGSETWKTII
terminus) NO: 201 TKNLHYKDGFDLNKGIEAKIHTLLPWQCTN
GSEVQSSWAETTYWISPQGIPETKVQDMDC
VYYNWQYLLCSWKPGIGVLLDTNYNLFYWY
EGLDHALQCVDYIKADGQNIGCRFPYLEAS
DYKDFYICVNGSSENKPIRSSYFTFQLQNI
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) 123456789012345678901234567890 VKPLPPVYLTFTRESSCEIKLKWSIPLGPI
PARCFDYEIEIREDDTTLVTATVENETYTL
KTTNETRQLCFVVRSKVNIYCSDDGIWSEW
SDKQCWEGEDLSKK
Linker residues 403- LE
404 of SEQ ID
NO: 201 V5 epitope residues 405- GKPIPNPLLGLDST
domain 418 of SEQ ID
NO: 201 C-terminal residues 419- SRGPYSIVSPKC
vector residues 430 of SEQ ID
NO: 201 The amino acid sequence for a BAG domain fusion protein comprising a signal sequence, a BAG domain of BAG3, a mature (i.e., no signal sequence) and truncated IL13Ra2 (IL13Ra2TF), and the V5 epitope tag is shown in the table below.
Table 12. Amino Acid Sequence of a V5-Tagged BAG domain-IL13Ra2TF Fusion Protein.
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) 123456789012345678901234567890 BAG domain- SEQ ID NO:202 MGVKVLFALICIAVAEAGTGSEFHPGVLKV
IL13Ra2TF fusion EAILEKVQGLEQAVDNFEGKKTDKKYLMIE
protein EYLTKELLALDSVDPEGRADVRQARRDGVR
KVQTILEKLEQKAIDDIAAASDTEIKVNPP
QDFEIVDPGYLGYLYLQWQPPLSLDHFKEC
TVEYELKYRNIGSETWKTIITKNLHYKDGF
DLNKGIEAKIHTLLPWQCTNGSEVQSSWAE
TTYWISPQGIPETKVQDMDCVYYNWQYLLC
SWKPGIGVLLDTNYNLFYWYEGLDHALQCV
DYIKADGQNIGCRFPYLEASDYKDFYICVN
GSSENKPIRSSYFTFQLQNIVKPLPPVYLT
FTRESSCEIKLKWSIPLGPIPARCFDYEIE
IREDDTTLVTATVENETYTLKTTNETRQLC
FVVRSKVNIYCSDDGIWSEWSDKQCWEGED
LSKKLEGKPIPNPLLGLDSTSRGPYSIVSP
KC
Signal Sequence residues 1-17 MGVKVLFALICIAVAEA
of SEQ ID
NO: 202 Linker residues 18-23 GTGSEF
of SEQ ID
NO: 202 BAG domain residues 24-105 HPGVLKVEAILEKVQGLEQAVDNFEGKKTD
(from BAG3) of SEQ ID KKYLMIEEYLTKELLALDSVDPEGRADVRQ
NO: 202 ARRDGVRKVQTILEKLEQKAID
Linker residues 106- DIAAA
110 of SEQ ID
NO: 202 Protein Region Sequence Amino Acid Sequence (N¨ to C¨ Identifier terminal) 123456789012345678901234567890 IL13Ra2TF residues 111- SDTEIKVNPPQDFEIVDPGYLGYLYLQWQP
(with mature N- 424 of SEQ ID PLSLDHFKECTVEYELKYRNIGSETWKTII
terminus) NO: 202 TKNLHYKDGFDLNKGIEAKIHTLLPWQCTN
GSEVQSSWAETTYWISPQGIPETKVQDMDC
VYYNWQYLLCSWKPGIGVLLDTNYNLFYWY
EGLDHALQCVDYIKADGQNIGCRFPYLEAS
DYKDFYICVNGSSENKPIRSSYFTFQLQNI
VKPLPPVYLTFTRESSCEIKLKWSIPLGPI
PARCFDYEIEIREDDTTLVTATVENETYTL
KTTNETRQLCFVVRSKVNIYCSDDGIWSEW
SDKQCWEGEDLSKK
Linker residues 425- LE
426 of SEQ ID
NO: 202 V5 epitope residues 427- GKPIPNPLLGLDST
domain 440 of SEQ ID
NO: 202 C-terminal residues 441- SRGPYSIVSPKC
vector residues 452 of SEQ ID
NO: 202 The expression plasmids were transfected into HEK293 cells. Samples of cell lysates and culture media from two-day cultures of the transfected cells were analyzed by immunoblotting with anti-V5 antibody for expression of IL13Ra2TF or IL13Ra2TF-J domain fusion protein. As shown in Figure 2B, the expression of the IL13Ra2TF protein was barely detected in cell lysates (lane 2), and no detection was observed in the medium. In contrast, the level of expression of the IL13Ra2TF-J
domain fusion protein was dramatically higher both inside the cell (cell lysate samples) and also as secreted into the medium. See, Figure 2B. A similar effect was observed when the J domain was attached to the C-terminus of the truncated form of IL13Ra2 (data not shown).
Another experiment was performed to better quantify the secreted proteins using a dot blot immunoassay. HEK293 cells were transfected with an expression vector plasmid for expressing IL13Ra2TF, a BAG domain fused to IL13Ra2TF (BAG-IL13RaTF), or a J domain fused to IL13Ra2TF (J-IL13RaTF). Transfected cells were cultured for two days, and samples of cell culture media were analyzed for secreted proteins using a dot blot immunoassay. The results are shown in Figure 3A and 3B. Figure 3A shows x-ray film images of chemiluminescent signals for VS-tagged proteins secreted into culture media. As shown in Figure 3A, although the fusion protein comprising a BAG domain linked to IL13Ra2TF (lane 3) may have provided some minor enhancement in the level of secreted protein compared to the unfused IL13Ra2TF (lane 2), a fusion protein comprising a J
domain linked to IL13Ra2TF (lane 3) exhibited a significantly enhanced level of secreted protein relative to either the unfused IL13Ra2TF (lane 2) or the or the BAG domain-IL13Ra2TF fusion protein (lane 3). The results of a densitometry analysis of the signals of the dot blots in Figure 3A
using the NIH ImageJ image processing program are shown in Figure 3B. The bar graphs in Figure 3B clearly show the significantly higher level of expression of secreted J
domain-IL13Ra2TF fusion protein (bar graph 4) compared to either the IL13Ra2TF (bar graph 2) or the BAG domain-IL13Ra2TF fusion protein (bar graph 3). Use of the J domain fusion resulted in an approximate 3.5-fold increase in the amount of IL13Ra2TF being secreted by the transformed cells, compared to the expression level of cells transformed to express the IL13Ra2TF protein alone.
J domain-al Anti-Trypsin Fusion Protein in a Modified Arrangement in Human Cells The ctl anti-trypsin (a1AT) protein is secreted from the liver, and circulates in blood vessels.
The function of a1AT is to protect tissues, particularly lung tissue, from excess proteases. The lung is damaged by proteases in a disease called ctl anti-trypsin deficiency. Subjects affected by ctl anti-trypsin deficiency may develop emphysema, asthma, and/or chronic obstructive pulmonary disease (COPD). Currently a1AT (purified from human serum) is used for the treatment of patients with ctl anti-trypsin deficiency. This treatment is expensive, and subjects that receive the human serum are at risk of contracting pathogens present in the human serum.
The effect of fusing a J domain to an al anti-trypsin (a1AT) was studied as a possible strategy for enhancing the levels of expression and secretion of a desired therapeutically useful protein in transfected cells. As shown in Figure 4A, DNA constructs were prepared encoding a VS-tagged a1AT, a VS-tagged a1AT-BAG domain fusion protein, and a VS-tagged a1AT-J
domain fusion protein.
The amino acid sequence of a VS-tagged a1AT protein is shown in the table below.
Table 13. Amino Acid Sequence of a VS-Tagged a1AT Protein.
Protein Region Sequence Amino Acid Sequence (N¨ to C¨ Identifier terminal) a1AT protein SEQ
ID NO:203 MPSSVSWGILLLAGLCCLVPVSLAEDPQGD
AAQKTDTSHHDQDHPTFNKITPNLAEFAFS
LYRQLAHQSNSTNIFFSPVSIATAFAMLSL
GTKADTHDEILEGLNFNLTEIPEAQIHEGF
QELLRTLNQPDSQLQLTTGNGLFLSEGLKL
VDKFLEDVKKLYHSEAFTVNFGDTEEAKKQ
INDYVEKGTQGKIVDLVKELDRDTVFALVN
YIFFKGKWERPFEVKDTEEEDFHVDQVTTV
KVPMMKRLGMFNIQHCKKLSSWVLLMKYLG
NATAIFFLPDEGKLQHLENELTHDIITKFL
ENEDRRSASLHLPKLSITGTYDLKSVLGQL
GITKVFSNGADLSGVTEEAPLKLSKAVHKA
VLTIDEKGTEAAGAMFLEAIPMSIPPEVKF
NKPFVFLMIEQNTKSPLFMGKVVNPTQKGT
GSEFDIAAALEGKPIPNPLLGLDSTSRGPY
SIVSPKC
a1AT
residues 1-418 MPSSVSWGILLLAGLCCLVPVSLAEDPQGD
of SEQ ID
AAQKTDTSHHDQDHPTFNKITPNLAEFAFS
NO: 203 LYRQLAHQSNSTNIFFSPVSIATAFAMLSL
GTKADTHDEILEGLNFNLTEIPEAQIHEGF
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) QELLRTLNQPDSQLQLTTGNGLFLSEGLKL
VDKFLEDVKKLYHSEAFTVNFGDTEEAKKQ
INDYVEKGTQGKIVDLVKELDRDTVFALVN
YIFFKGKWERPFEVKDTEEEDFHVDQVTTV
KVPMMKRLGMFNIQHCKKLSSWVLLMKYLG
NATAIFFLPDEGKLQHLENELTHDIITKFL
ENEDRRSASLHLPKLSITGTYDLKSVLGQL
GITKVFSNGADLSGVTEEAPLKLSKAVHKA
VLTIDEKGTEAAGAMFLEAIPMSIPPEVKF
NKPFVFLMIEQNTKSPLFMGKVVNPTQK
Linker residues 419- GTGSEFDIAAALE
431 of SEQ ID
NO: 203 V5 epitope residues 432- GKPIPNPLLGLDST
domain 445 of SEQ ID
NO: 203 C-terminal residues 446- SRGPYSIVSPKC
vector residues 457 of SEQ ID
NO: 203 The amino acid sequence of a BAG domain fusion protein comprising a lAT, the BAG
domain of BAG3, and the V5 epitope tag is shown in the table below.
Table 14. Amino Acid Sequence of alAT-BAG Fusion Protein.
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) a1AT-BAG domain SEQ ID
NO:204 MPSSVSWGILLLAGLCCLVPVSLAEDPQGD
fusion protein AAQKTDTSHHDQDHPTFNKITPNLAEFAFS
LYRQLAHQSNSTNIFFSPVSIATAFAMLSL
GTKADTHDEILEGLNFNLTEIPEAQIHEGF
QELLRTLNQPDSQLQLTTGNGLFLSEGLKL
VDKFLEDVKKLYHSEAFTVNFGDTEEAKKQ
INDYVEKGTQGKIVDLVKELDRDTVFALVN
YIFFKGKWERPFEVKDTEEEDFHVDQVTTV
KVPMMKRLGMFNIQHCKKLSSWVLLMKYLG
NATAIFFLPDEGKLQHLENELTHDIITKFL
ENEDRRSASLHLPKLSITGTYDLKSVLGQL
GITKVFSNGADLSGVTEEAPLKLSKAVHKA
VLTIDEKGTEAAGAMFLEAIPMSIPPEVKF
NKPFVFLMIEQNTKSPLFMGKVVNPTQKGT
GSEFHPGVLKVEAILEKVQGLEQAVDNFEG
KKTDKKYLMIEEYLTKELLALDSVDPEGRA
DVRQARRDGVRKVQTILEKLEQKAIDDIAA
ALEGKPIPNPLLGLDSTSRGPYSIVSPKC
a1AT residues of SEQ ID
AAQKTDTSHHDQDHPTFNKITPNLAEFAFS
NO: 204 LYRQLAHQSNSTNIFFSPVSIATAFAMLSL
GTKADTHDEILEGLNFNLTEIPEAQIHEGF
QELLRTLNQPDSQLQLTTGNGLFLSEGLKL
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) 123456789012345678901234567890 VDKFLEDVKKLYHSEAFTVNFGDTEEAKKQ
INDYVEKGTQGKIVDLVKELDRDTVFALVN
YIFFKGKWERPFEVKDTEEEDFHVDQVTTV
KVPMMKRLGMFNIQHCKKLSSWVLLMKYLG
NATAIFFLPDEGKLQHLENELTHDIITKFL
ENEDRRSASLHLPKLSITGTYDLKSVLGQL
GITKVFSNGADLSGVTEEAPLKLSKAVHKA
VLTIDEKGTEAAGAMFLEAIPMSIPPEVKF
NKPFVFLMIEQNTKSPLFMGKVVNPTQK
Linker residues 419- GTGSEF
424 of SEQ ID
NO: 204 BAG domain residues 425- HPGVLKVEAILEKVQGLEQAVDNFEGKKTD
(from BAG3) 506 of SEQ ID KKYLMIEEYLTKELLALDSVDPEGRADVRQ
NO: 204 ARRDGVRKVQTILEKLEQKAID
Linker residues 507- DIAAALE
513 of SEQ ID
NO: 204 V5 epitope residues 514- GKPIPNPLLGLDST
domain 527 of SEQ ID
NO: 204 C-terminal residues 528- SRGPYSIVSPKC
vector residues 539 of SEQ ID
NO: 204 The amino acid sequence of a J domain fusion protein comprising alAT, the Erdj3 J domain, and the V5 epitope tag is shown in the table below.
Table 15. Amino Acid Sequence of alAT-J Domain Protein.
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) 123456789012345678901234567890 a1AT-Erdj3 J SEQ ID NO:205 MPSSVSWGILLLAGLCCLVPVSLAEDPQGD
domain fusion AAQKTDTSHHDQDHPTFNKITPNLAEFAFS
protein LYRQLAHQSNSTNIFFSPVSIATAFAMLSL
GTKADTHDEILEGLNFNLTEIPEAQIHEGF
QELLRTLNQPDSQLQLTTGNGLFLSEGLKL
VDKFLEDVKKLYHSEAFTVNFGDTEEAKKQ
INDYVEKGTQGKIVDLVKELDRDTVFALVN
YIFFKGKWERPFEVKDTEEEDFHVDQVTTV
KVPMMKRLGMFNIQHCKKLSSWVLLMKYLG
NATAIFFLPDEGKLQHLENELTHDIITKFL
ENEDRRSASLHLPKLSITGTYDLKSVLGQL
GITKVFSNGADLSGVTEEAPLKLSKAVHKA
VLTIDEKGTEAAGAMFLEAIPMSIPPEVKF
NKPFVFLMIEQNTKSPLFMGKVVNPTQKGT
GSEFGRDFYKILGVPRSASIKDIKKAYRKL
ALQLHPDRNPDDPQAQEKFQDLGAAYEVLS
DSEKRDIAAALEGKPIPNPLLGLDSTSRGP
YSIVSPKC
Protein Region Sequence Amino Acid Sequence (N¨ to C¨ Identifier terminal) 123456789012345678901234567890 a1AT residues 1-418 MPSSVSWGILLLAGLCCLVPVSLAEDPQGD
of SEQ ID AAQKTDTSHHDQDHPTFNKITPNLAEFAFS
NO: 205 LYRQLAHQSNSTNIFFSPVSIATAFAMLSL
GTKADTHDEILEGLNFNLTEIPEAQIHEGF
QELLRTLNQPDSQLQLTTGNGLFLSEGLKL
VDKFLEDVKKLYHSEAFTVNFGDTEEAKKQ
INDYVEKGTQGKIVDLVKELDRDTVFALVN
YIFFKGKWERPFEVKDTEEEDFHVDQVTTV
KVPMMKRLGMFNIQHCKKLSSWVLLMKYLG
NATAIFFLPDEGKLQHLENELTHDIITKFL
ENEDRRSASLHLPKLSITGTYDLKSVLGQL
GITKVFSNGADLSGVTEEAPLKLSKAVHKA
VLTIDEKGTEAAGAMFLEAIPMSIPPEVKF
NKPFVFLMIEQNTKSPLFMGKVVNPTQK
Linker residues 419- GTGSEF
424 of SEQ ID
NO: 205 Erdj3 J domain residues 425- GRDFYKILGVPRSASIKDIKKAYRKLALQL
485 of SEQ ID HPDRNPDDPQAQEKFQDLGAAYEVLSDSEK
NO:205 Linker residues 486- DIAAALE
492 of SEQ ID
NO: 205 V5 epitope residues 493- GKPIPNPLLGLDST
domain 506 of SEQ ID
NO: 205 C-terminal residues 507- SRGPYSIVSPKC
vector residues 518 of SEQ ID
NO: 205 Expression vector plasmids encoding the above three recombinant a lAT protein constructs were transfected into HEK293 cells. Culture media from two-day cultures of transfected cells were harvested, and the level of the recombinant al AT proteins secreted into the media determined by dot blot immunoassays. Figure 4B shows x-ray film chemiluminescent signals of the dot blot assays.
Although detectable amounts of both unfused alAT (lane 2) and alAT-BAG domain fusion protein (lane 3) were secreted into culture media, an even higher level of expression was obtained for secreted alAT-J domain fusion protein (lane 3). The results of a densitometry analysis of the signals of the dot blots in Figure 4B using the NIH ImageJ image processing program are shown in Figure 4C. The bar graphs in Figure 4C clearly show the significantly higher level of expression of secreted alAT-J
domain fusion protein (bar graph 4) compared to the level of expression of either a lAT (bar graph 2) or the alAT-BAG domain fusion protein (bar graph 3). Use of the J domain fusion resulted in greater than a 1.5-fold increase in the amount of IL13Ra2TF being secreted by the transformed cells, compared to the expression level of cells transformed to express the alAT
protein alone or an a1AT-BAG fusion protein.
Truncated Form of TNFR1 Protein in a Modified Arrangement One format for designing therapeutically active fusion proteins combines a binding domain, which specifically binds a desired target molecule, linked to an immunoglobulin Fc region, which endues the fusion protein with an enhanced in vivo half-life. An example of this class of drugs is etanercept, which binds and inhibits the effect of tumor necrosis factor (TNFa), which is a key protein of the immune system involved in a number of autoimmune diseases. For example, etanercept possesses a truncated form of a tumor necrosis factor a receptor (TNFR1TF) linked to an immunoglobulin Fc domain. The TNFR1TF portion of etanercept provides specificity for the drug target (TNFa), and the Fc domain is believed to add stability and deliverability of the drug in vivo.
Nevertheless, the Fc domain is also known to possess certain effector functions that may not be desired in treatment protocols for some diseases.
The effect of fusing a J domain to a truncated form of a receptor molecule was studied as a possible strategy for enhancing levels of expression and secretion of a desired receptor-based molecule. Such a J domain fusion protein may provide a possible alternative to prior drug designs involving truncated forms of receptor molecules linked to immunoglobulin Fc domains. The expression of a truncated form of a tumor necrosis factor receptor (TNFR1TF) with or without a J
domain was studied using expression vector plasmids TNFR1TF-V5-pcDNA' and domain-V5-pcDNA'. The expression vectors add a V5 epitope tag to both proteins for easy detection with an anti-V5 antibody. See, diagrams of constructs in Figure 5A.
The amino acid sequence of a VS-tagged TNFR1TF is shown in the table below.
Table 16. Amino Acid Sequence of a VS-Tagged TNFR1TF Protein.
Protein Region Sequence Amino Acid Sequence (N¨ to C¨ Identifier terminal) TNFR1TF protein SEQ
ID NO:206 MGLSTVPDLLLPLVLLELLVGIYPSGVIGL
VPHLGDREKRDSVCPQGKYIHPQNNSICCT
KCHKGTYLYNDCPGPGQDTDCRECESGSFT
ASENHLRHCLSCSKCRKEMGQVEISSCTVD
RDTVCGCRKNQYRHYWSENLFQCFNCSLCL
NGTVHLSCQEKQNTVCTCHAGFFLRENECV
SCSNCKKSLECTKLCLPQIENVKGTEDSGT
TGTGSEFDIAAALEGKPIPNPLLGLDSTSR
GPYSIVSPKC
residues 1-211 MGLSTVPDLLLPLVLLELLVGIYPSGVIGL
of SEQ ID
VPHLGDREKRDSVCPQGKYIHPQNNSICCT
NO: 206 KCHKGTYLYNDCPGPGQDTDCRECESGSFT
ASENHLRHCLSCSKCRKEMGQVEISSCTVD
RDTVCGCRKNQYRHYWSENLFQCFNCSLCL
NGTVHLSCQEKQNTVCTCHAGFFLRENECV
SCSNCKKSLECTKLCLPQIENVKGTEDSGT
Linker residues 212- GTGSEFDIAAALE
224 of SEQ ID
NO: 206 V5 epitope residues 225- GKPIPNPLLGLDST
domain 238 of SEQ ID
NO: 206 C-terminal residues 239- SRGPYSIVSPKC
vector residues 250 of SEQ ID
NO: 206 The amino acid sequence of a J domain fusion protein comprising TNFR1TF, the Erdj3 J
domain, and the V5 epitope tag is shown in the table below.
Table 17. Amino Acid Sequence of a V5-Tagged TNFR1TF-Erdj3 J Domain Fusion Protein.
Protein Region Sequence Amino Acid Sequence (N¨ to C¨ Identifier terminal) 123456789012345678901234567890 TNFR1TF-J domain SEQ ID NO:207 MGLSTVPDLLLPLVLLELLVGIYPSGVIGL
fusion protein VPHLGDREKRDSVCPQGKYIHPQNNSICCT
KCHKGTYLYNDCPGPGQDTDCRECESGSFT
ASENHLRHCLSCSKCRKEMGQVEISSCTVD
RDTVCGCRKNQYRHYWSENLFQCFNCSLCL
NGTVHLSCQEKQNTVCTCHAGFFLRENECV
SCSNCKKSLECTKLCLPQIENVKGTEDSGT
TGTGSEFGRDFYKILGVPRSASIKDIKKAY
RKLALQLHPDRNPDDPQAQEKFQDLGAAYE
VLSDSEKRDIAAALEGKPIPNPLLGLDSTS
RGPYSIVSPKC
TNFR1TF residues 1-211 MGLSTVPDLLLPLVLLELLVGIYPSGVIGL
of SEQ ID VPHLGDREKRDSVCPQGKYIHPQNNSICCT
NO:207 KCHKGTYLYNDCPGPGQDTDCRECESGSFT
ASENHLRHCLSCSKCRKEMGQVEISSCTVD
RDTVCGCRKNQYRHYWSENLFQCFNCSLCL
NGTVHLSCQEKQNTVCTCHAGFFLRENECV
SCSNCKKSLECTKLCLPQIENVKGTEDSGT
Linker residues 212- GTGSEF
217 of SEQ ID
NO:207 Erdj3 J domain residues 218- GRDFYKILGVPRSASIKDIKKAYRKLALQL
278 of SEQ ID HPDRNPDDPQAQEKFQDLGAAYEVLSDSEK
NO:207 Linker residues 279- DIAAALE
285 of SEQ ID
NO:207 V5 epitope residues 286- GKPIPNPLLGLDST
domain 299 of SEQ ID
NO: 207 C-terminal residues 300- SRGPYSIVSPKC
vector residues 311 of SEQ ID
NO: 207 The expression plasmids were transfected into HEK293 cells. Samples of cell lysates and culture media from two-day cultures of transfected cells were analyzed by immunoblotting with anti-V5 antibody for expression of TNFR1TF or the TNFR1TF-J domain fusion protein.
As shown in the dot blots in Figure 5B, some TNFR1TF was detected in medium (lane 2), however, the level of the TNFR1TF-J domain fusion protein detected in the medium was significantly greater (lane 3). The results of a densitometry analysis of the signals of the dot blots in Figure 5B using the NIH ImageJ
image processing program are shown in Figure 5C. Clearly, the level of expression of secreted TNFR1TF-J domain fusion protein (bar graph 3) was significantly higher than that of the (unfused) TNFR1TF protein (bar graph 2) , i.e., about a 6-fold increase over the level of TNFR1TF alone.
Secretion of Fc-Fusion Proteins in a Modified Arrangement In view of the above results showing that the level of expression of secreted truncated form of TNFR1 was enhanced by the conjugation of J domain (Figures 5B and 5C), it was of interest to examine whether a J domain would enhance expression of a protein of interest fused to an immunoglobulin Fc domain, such as a TNF1TF-Fc fusion protein. Such Fc-fusion molecules are a type of drug format illustrated by the drug etanercept (commercially available as ENBRELO), which is a TNF1TF-Fc fusion protein approved for treating a number of autoimmune diseases, such as severe rheumatoid arthritis, polyarticular juvenile idiopathic arthritis (JIA), psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis.
For this study, a cDNA encoding each protein of interest (TNFR1TF, IL13Ra2TF, or alAT) was augmented with a segment encoding a V5 epitope tag at the 3' end, which was linked in turn to a segment encoding the constant domains of an immunoglobulin Fc region. For J-domain fusions, a cDNA encoding a J domain was linked in frame between the cDNA encoding each protein of interest and the segment encoding a V5 epitope tag. See, illustration of constructs in Figure 6A. The corresponding expression vector plasmids were transfected into HEK293 cells.
Culture media were assayed for secreted proteins by dot blot assay.
The amino acid sequence of the TNFR1TF-Fc fusion protein is shown in the table below.
Table 18. Amino Acid Sequence of a VS-Tagged TNFR1TF-Fc Fusion Protein.
Protein Region Sequence Amino Acid Sequence (N¨ to C¨ Identifier terminal) TNFR1TF Fc SEQ ID NO:208 MGLSTVPDLLLPLVLLELLVGIYPSGVIGL
fusion protein VPHLGDREKRDSVCPQGKYIHPQNNSICCT
KCHKGTYLYNDCPGPGQDTDCRECESGSFT
ASENHLRHCLSCSKCRKEMGQVEISSCTVD
RDTVCGCRKNQYRHYWSENLFQCFNCSLCL
NGTVHLSCQEKQNTVCTCHAGFFLRENECV
SCSNCKKSLECTKLCLPQIENVKGTEDSGT
TGTGSEFDIAAALEGKPIPNPLLGLDSTSR
PKSCDKTHTCPPCPAPELLGGPSVFLFPPK
PKDTLMISRTPEVTCVVVDVSHEDPEVKFN
WYVDGVEVHNAKTKPREEQYNSTYRVVSVL
TVLHQDWLNGKEYKCKVSNKALPAPIEKTI
SKAKGQPREPQVYTLPPSRDELTKNQVSLT
CLVKGFYPSDIAVEWESNGQPENNYKTTPP
VLDSDGSFFLYSKLTVDKSRWQQGNVFSCS
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) VMHEALHNHYTQKSLSLSPGK
TNFR1TF residues of SEQ ID
VPHLGDREKRDSVCPQGKYIHPQNNSICCT
NO: 208 KCHKGTYLYNDCPGPGQDTDCRECESGSFT
ASENHLRHCLSCSKCRKEMGQVEISSCTVD
RDTVCGCRKNQYRHYWSENLFQCFNCSLCL
NGTVHLSCQEKQNTVCTCHAGFFLRENECV
SCSNCKKSLECTKLCLPQIENVKGTEDSGT
Linker residues 212- GTGSEFDIAAALE
224 of SEQ ID
NO: 208 V5 epitope residues 225- GKPIPNPLLGLDST
domain 238 of SEQ ID
NO: 208 Linker residues 239- SR
240 of SEQ ID
NO: 208 Fc domain residues 241-PKSCDKTHTCPPCPAPELLGGPSVFLFPPK
471 of SEQ ID PKDTLMISRTPEVTCVVVDVSHEDPEVKFN
NO: 208 WYVDGVEVHNAKTKPREEQYNSTYRVVSVL
TVLHQDWLNGKEYKCKVSNKALPAPIEKTI
SKAKGQPREPQVYTLPPSRDELTKNQVSLT
CLVKGFYPSDIAVEWESNGQPENNYKTTPP
VLDSDGSFFLYSKLTVDKSRWQQGNVFSCS
VMHEALHNHYTQKSLSLSPGK
The amino acid sequence of a TNFR1TF-J domain-Fc fusion protein is shown in the table below.
Table 19. Amino Acid Sequence of a V5-Tagged TNFR1TF-Erdj3 J Domain-Fc Protein.
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) TNFR1TF-J domain SEQ ID
NO:209 MGLSTVPDLLLPLVLLELLVGIYPSGVIGL
Fc fusion VPHLGDREKRDSVCPQGKYIHPQNNSICCT
protein KCHKGTYLYNDCPGPGQDTDCRECESGSFT
ASENHLRHCLSCSKCRKEMGQVEISSCTVD
RDTVCGCRKNQYRHYWSENLFQCFNCSLCL
NGTVHLSCQEKQNTVCTCHAGFFLRENECV
SCSNCKKSLECTKLCLPQIENVKGTEDSGT
TGTGSEFGRDFYKILGVPRSASIKDIKKAY
RKLALQLHPDRNPDDPQAQEKFQDLGAAYE
VLSDSEKRDIAAALEGKPIPNPLLGLDSTS
RPKSCDKTHTCPPCPAPELLGGPSVFLFPP
KPKDTLMISRTPEVTCVVVDVSHEDPEVKF
NWYVDGVEVHNAKTKPREEQYNSTYRVVSV
LTVLHQDWLNGKEYKCKVSNKALPAPIEKT
ISKAKGQPREPQVYTLPPSRDELTKNQVSL
TCLVKGFYPSDIAVEWESNGQPENNYKTTP
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) 123456789012345678901234567890 PVLDSDGSFFLYSKLTVDKSRWQQGNVFSC
SVMHEALHNHYTQKSLSLSPGK
TNFR1TF residues 1-211 MGLSTVPDLLLPLVLLELLVGIYPSGVIGL
of SEQ ID VPHLGDREKRDSVCPQGKYIHPQNNSICCT
NO: 209 KCHKGTYLYNDCPGPGQDTDCRECESGSFT
ASENHLRHCLSCSKCRKEMGQVEISSCTVD
RDTVCGCRKNQYRHYWSENLFQCFNCSLCL
NGTVHLSCQEKQNTVCTCHAGFFLRENECV
SCSNCKKSLECTKLCLPQIENVKGTEDSGT
Linker residues 212- GTGSEF
217 of SEQ ID
NO: 209 Erdj3 J domain residues 218- GRDFYKILGVPRSASIKDIKKAYRKLALQL
278 of SEQ ID HPDRNPDDPQAQEKFQDLGAAYEVLSDSEK
NO:209 Linker residues 279- DIAAALE
285 of SEQ ID
NO: 209 V5 epitope residues 286- GKPIPNPLLGLDST
domain 299 of SEQ ID
NO: 209 Linker residues 300- SR
301 of SEQ ID
NO: 209 Fc domain residues 302- PKSCDKTHTCPPCPAPELLGGPSVFLFPPK
532 of SEQ ID PKDTLMISRTPEVTCVVVDVSHEDPEVKFN
NO: 209 WYVDGVEVHNAKTKPREEQYNSTYRVVSVL
TVLHQDWLNGKEYKCKVSNKALPAPIEKTI
SKAKGQPREPQVYTLPPSRDELTKNQVSLT
CLVKGFYPSDIAVEWESNGQPENNYKTTPP
VLDSDGSFFLYSKLTVDKSRWQQGNVFSCS
VMHEALHNHYTQKSLSLSPGK
The amino acid sequence of an IL13Ra2TF-Fc fusion protein is shown in the table below.
Table 20. Amino Acid Sequence of a V5-Tagged IL13Ra2TF-Fc Fusion Protein.
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) 123456789012345678901234567890 IL13Ra2TF-Fc SEQ ID NO:210 MAFVCLAIGCLYTFLISTTFGCTSSSDTEI
fusion protein KVNPPQDFEIVDPGYLGYLYLQWQPPLSLD
HFKECTVEYELKYRNIGSETWKTIITKNLH
YKDGFDLNKGIEAKIHTLLPWQCTNGSEVQ
SSWAETTYWISPQGIPETKVQDMDCVYYNW
QYLLCSWKPGIGVLLDTNYNLFYWYEGLDH
ALQCVDYIKADGQNIGCRFPYLEASDYKDF
YICVNGSSENKPIRSSYFTFQLQNIVKPLP
PVYLTFTRESSCEIKLKWSIPLGPIPARCF
DYEIEIREDDTTLVTATVENETYTLKTTNE
TRQLCFVVRSKVNIYCSDDGIWSEWSDKQC
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) 123456789012345678901234567890 WEGEDLSKKGTGSEFDIAAALEGKPIPNPL
LGLDSTSRPKSCDKTHTCPPCPAPELLGGP
SVFLFPPKPKDTLMISRTPEVTCVVVDVSH
EDPEVKFNWYVDGVEVHNAKTKPREEQYNS
TYRVVSVLTVLHQDWLNGKEYKCKVSNKAL
PAPIEKTISKAKGQPREPQVYTLPPSRDEL
TKNQVSLTCLVKGFYPSDIAVEWESNGQPE
NNYKTTPPVLDSDGSFFLYSKLTVDKSRWQ
QGNVFSCSVMHEALHNHYTQKSLSLSPGK
IL13Ra2TF residues 1-339 MAFVCLAIGCLYTFLISTTFGCTSSSDTEI
of SEQ ID KVNPPQDFEIVDPGYLGYLYLQWQPPLSLD
NO: 210 HFKECTVEYELKYRNIGSETWKTIITKNLH
YKDGFDLNKGIEAKIHTLLPWQCTNGSEVQ
SSWAETTYWISPQGIPETKVQDMDCVYYNW
QYLLCSWKPGIGVLLDTNYNLFYWYEGLDH
ALQCVDYIKADGQNIGCRFPYLEASDYKDF
YICVNGSSENKPIRSSYFTFQLQNIVKPLP
PVYLTFTRESSCEIKLKWSIPLGPIPARCF
DYEIEIREDDTTLVTATVENETYTLKTTNE
TRQLCFVVRSKVNIYCSDDGIWSEWSDKQC
WEGEDLSKK
Linker residues 340- GTGSEFDIAAALE
352 of SEQ ID
NO: 210 V5 epitope residues 353- GKPIPNPLLGLDST
domain 366 of SEQ ID
NO: 210 Linker residues 367- SR
368 of SEQ ID
NO: 210 Fc domain residues 369- PKSCDKTHTCPPCPAPELLGGPSVFLFPPK
599 of SEQ ID PKDTLMISRTPEVTCVVVDVSHEDPEVKFN
NO: 210 WYVDGVEVHNAKTKPREEQYNSTYRVVSVL
TVLHQDWLNGKEYKCKVSNKALPAPIEKTI
SKAKGQPREPQVYTLPPSRDELTKNQVSLT
CLVKGFYPSDIAVEWESNGQPENNYKTTPP
VLDSDGSFFLYSKLTVDKSRWQQGNVFSCS
VMHEALHNHYTQKSLSLSPGK
The amino acid sequence of an IL13Ra2TF-J domain-Fc fusion protein is shown in the table below.
Table 21. Amino Acid Sequence of a V5-Tagged IL13Ra2TF-Erdj3 J Domain-Fc Protein.
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) 123456789012345678901234567890 IL13Ra2TF-J SEQ ID NO:211 MAFVCLAIGCLYTFLISTTFGCTSSSDTEI
domain-Fc fusion KVNPPQDFEIVDPGYLGYLYLQWQPPLSLD
protein HFKECTVEYELKYRNIGSETWKTIITKNLH
YKDGFDLNKGIEAKIHTLLPWQCTNGSEVQ
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) 123456789012345678901234567890 SSWAETTYWISPQGIPETKVQDMDCVYYNW
QYLLCSWKPGIGVLLDTNYNLFYWYEGLDH
ALQCVDYIKADGQNIGCRFPYLEASDYKDF
YICVNGSSENKPIRSSYFTFQLQNIVKPLP
PVYLTFTRESSCEIKLKWSIPLGPIPARCF
DYEIEIREDDTTLVTATVENETYTLKTTNE
TRQLCFVVRSKVNIYCSDDGIWSEWSDKQC
WEGEDLSKKGTGSEFGRDFYKILGVPRSAS
IKDIKKAYRKLALQLHPDRNPDDPQAQEKF
QDLGAAYEVLSDSEKRDIAAALEGKPIPNP
LLGLDSTSRPKSCDKTHTCPPCPAPELLGG
PSVFLFPPKPKDTLMISRTPEVTCVVVDVS
HEDPEVKFNWYVDGVEVHNAKTKPREEQYN
STYRVVSVLTVLHQDWLNGKEYKCKVSNKA
LPAPIEKTISKAKGQPREPQVYTLPPSRDE
LTKNQVSLTCLVKGFYPSDIAVEWESNGQP
ENNYKTTPPVLDSDGSFFLYSKLTVDKSRW
QQGNVFSCSVMHEALHNHYTQKSLSLSPGK
IL13Ra2TF residues 1-339 MAFVCLAIGCLYTFLISTTFGCTSSSDTEI
of SEQ ID KVNPPQDFEIVDPGYLGYLYLQWQPPLSLD
NO: 211 HFKECTVEYELKYRNIGSETWKTIITKNLH
YKDGFDLNKGIEAKIHTLLPWQCTNGSEVQ
SSWAETTYWISPQGIPETKVQDMDCVYYNW
QYLLCSWKPGIGVLLDTNYNLFYWYEGLDH
ALQCVDYIKADGQNIGCRFPYLEASDYKDF
YICVNGSSENKPIRSSYFTFQLQNIVKPLP
PVYLTFTRESSCEIKLKWSIPLGPIPARCF
DYEIEIREDDTTLVTATVENETYTLKTTNE
TRQLCFVVRSKVNIYCSDDGIWSEWSDKQC
WEGEDLSKK
Linker residues 340- GTGSEF
345 of SEQ ID
NO: 211 Erdj3 J domain residues 346- GRDFYKILGVPRSASIKDIKKAYRKLALQL
406 of SEQ ID HPDRNPDDPQAQEKFQDLGAAYEVLSDSEK
NO:211 R
Linker residues 407- DIAAALE
413 of SEQ ID
NO: 211 V5 epitope residues 414- GKPIPNPLLGLDST
domain 427 of SEQ ID
NO: 211 Linker residues 428- SR
429 of SEQ ID
NO: 211 Fc domain residues 430- PKSCDKTHTCPPCPAPELLGGPSVFLFPPK
660 of SEQ ID PKDTLMISRTPEVTCVVVDVSHEDPEVKFN
NO: 211 WYVDGVEVHNAKTKPREEQYNSTYRVVSVL
TVLHQDWLNGKEYKCKVSNKALPAPIEKTI
SKAKGQPREPQVYTLPPSRDELTKNQVSLT
CLVKGFYPSDIAVEWESNGQPENNYKTTPP
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) VLDSDGSFFLYSKLTVDKSRWQQGNVFSCS
VMHEALHNHYTQKSLSLSPGK
The amino acid sequence of an a1AT-Fc fusion protein is shown in the table below.
Table 22. Amino Acid Sequence of V5-Tagged a1AT-Fc Protein.
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) a1AT protein-Fc SEQ ID
NO:212 MPSSVSWGILLLAGLCCLVPVSLAEDPQGD
fusion protein AAQKTDTSHHDQDHPTFNKITPNLAEFAFS
LYRQLAHQSNSTNIFFSPVSIATAFAMLSL
GTKADTHDEILEGLNFNLTEIPEAQIHEGF
QELLRTLNQPDSQLQLTTGNGLFLSEGLKL
VDKFLEDVKKLYHSEAFTVNFGDTEEAKKQ
INDYVEKGTQGKIVDLVKELDRDTVFALVN
YIFFKGKWERPFEVKDTEEEDFHVDQVTTV
KVPMMKRLGMFNIQHCKKLSSWVLLMKYLG
NATAIFFLPDEGKLQHLENELTHDIITKFL
ENEDRRSASLHLPKLSITGTYDLKSVLGQL
GITKVFSNGADLSGVTEEAPLKLSKAVHKA
VLTIDEKGTEAAGAMFLEAIPMSIPPEVKF
NKPFVFLMIEQNTKSPLFMGKVVNPTQKGT
GSEFDIAAALEGKPIPNPLLGLDSTSRPKS
CDKTHTCPPCPAPELLGGPSVFLFPPKPKD
TLMISRTPEVTCVVVDVSHEDPEVKFNWYV
DGVEVHNAKTKPREEQYNSTYRVVSVLTVL
HQDWLNGKEYKCKVSNKALPAPIEKTISKA
KGQPREPQVYTLPPSRDELTKNQVSLTCLV
KGFYPSDIAVEWESNGQPENNYKTTPPVLD
SDGSFFLYSKLTVDKSRWQQGNVFSCSVMH
EALHNHYTQKSLSLSPGK
a1AT residues of SEQ ID
AAQKTDTSHHDQDHPTFNKITPNLAEFAFS
NO: 212 LYRQLAHQSNSTNIFFSPVSIATAFAMLSL
GTKADTHDEILEGLNFNLTEIPEAQIHEGF
QELLRTLNQPDSQLQLTTGNGLFLSEGLKL
VDKFLEDVKKLYHSEAFTVNFGDTEEAKKQ
INDYVEKGTQGKIVDLVKELDRDTVFALVN
YIFFKGKWERPFEVKDTEEEDFHVDQVTTV
KVPMMKRLGMFNIQHCKKLSSWVLLMKYLG
NATAIFFLPDEGKLQHLENELTHDIITKFL
ENEDRRSASLHLPKLSITGTYDLKSVLGQL
GITKVFSNGADLSGVTEEAPLKLSKAVHKA
VLTIDEKGTEAAGAMFLEAIPMSIPPEVKF
NKPFVFLMIEQNTKSPLFMGKVVNPTQK
Linker residues 419- GTGSEFDIAAALE
431 of SEQ ID
NO: 212 V5 epitope residues 432- GKPIPNPLLGLDST
domain 445 of SEQ ID
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) 123456789012345678901234567890 NO: 212 Linker residues 446- SR
447 of SEQ ID
NO: 212 Fc domain residues 448- PKSCDKTHTCPPCPAPELLGGPSVFLFPPK
678 of SEQ ID PKDTLMISRTPEVTCVVVDVSHEDPEVKFN
NO: 212 WYVDGVEVHNAKTKPREEQYNSTYRVVSVL
TVLHQDWLNGKEYKCKVSNKALPAPIEKTI
SKAKGQPREPQVYTLPPSRDELTKNQVSLT
CLVKGFYPSDIAVEWESNGQPENNYKTTPP
VLDSDGSFFLYSKLTVDKSRWQQGNVFSCS
VMHEALHNHYTQKSLSLSPGK
The amino acid sequence of an alAT-J domain-Fc fusion protein is shown in the table below.
Table 23. Amino Acid Sequence of a V5-Tagged al AT-Erdj3 J Domain-Fc Protein.
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) a1AT-J domain-Fc SEQ ID
NO:213 MPSSVSWGILLLAGLCCLVPVSLAEDPQGD
fusion protein AAQKTDTSHHDQDHPTFNKITPNLAEFAFS
LYRQLAHQSNSTNIFFSPVSIATAFAMLSL
GTKADTHDEILEGLNFNLTEIPEAQIHEGF
QELLRTLNQPDSQLQLTTGNGLFLSEGLKL
VDKFLEDVKKLYHSEAFTVNFGDTEEAKKQ
INDYVEKGTQGKIVDLVKELDRDTVFALVN
YIFFKGKWERPFEVKDTEEEDFHVDQVTTV
KVPMMKRLGMFNIQHCKKLSSWVLLMKYLG
NATAIFFLPDEGKLQHLENELTHDIITKFL
ENEDRRSASLHLPKLSITGTYDLKSVLGQL
GITKVFSNGADLSGVTEEAPLKLSKAVHKA
VLTIDEKGTEAAGAMFLEAIPMSIPPEVKF
NKPFVFLMIEQNTKSPLFMGKVVNPTQKGT
GSEFGRDFYKILGVPRSASIKDIKKAYRKL
ALQLHPDRNPDDPQAQEKFQDLGAAYEVLS
DSEKRDIAAALEGKPIPNPLLGLDSTSRPK
SCDKTHTCPPCPAPELLGGPSVFLFPPKPK
DTLMISRTPEVTCVVVDVSHEDPEVKFNWY
VDGVEVHNAKTKPREEQYNSTYRVVSVLTV
LHQDWLNGKEYKCKVSNKALPAPIEKTISK
AKGQPREPQVYTLPPSRDELTKNQVSLTCL
VKGFYPSDIAVEWESNGQPENNYKTTPPVL
DSDGSFFLYSKLTVDKSRWQQGNVFSCSVM
HEALHNHYTQKSLSLSPGK
a1AT residues of SEQ ID
AAQKTDTSHHDQDHPTFNKITPNLAEFAFS
NO: 213 LYRQLAHQSNSTNIFFSPVSIATAFAMLSL
GTKADTHDEILEGLNFNLTEIPEAQIHEGF
QELLRTLNQPDSQLQLTTGNGLFLSEGLKL
VDKFLEDVKKLYHSEAFTVNFGDTEEAKKQ
INDYVEKGTQGKIVDLVKELDRDTVFALVN
Protein Region Sequence Amino Acid Sequence (N¨ to C¨ Identifier terminal) 123456789012345678901234567890 YIFFKGKWERPFEVKDTEEEDFHVDQVTTV
KVPMMKRLGMFNIQHCKKLSSWVLLMKYLG
NATAIFFLPDEGKLQHLENELTHDIITKFL
ENEDRRSASLHLPKLSITGTYDLKSVLGQL
GITKVFSNGADLSGVTEEAPLKLSKAVHKA
VLTIDEKGTEAAGAMFLEAIPMSIPPEVKF
NKPFVFLMIEQNTKSPLFMGKVVNPTQK
Linker residues 419- GTGSEF
424 of SEQ ID
NO: 213 Erdj3 J domain residues 425- GRDFYKILGVPRSASIKDIKKAYRKLALQL
485 of SEQ ID HPDRNPDDPQAQEKFQDLGAAYEVLSDSEK
NO:213 Linker residues 486- DIAAALE
492 of SEQ ID
NO: 213 V5 epitope residues 493- GKPIPNPLLGLDST
domain 506 of SEQ ID
NO: 213 Linker residues 507- SR
508 of SEQ ID
NO: 213 Fc domain residues 509- PKSCDKTHTCPPCPAPELLGGPSVFLFPPK
739 of SEQ ID PKDTLMISRTPEVTCVVVDVSHEDPEVKFN
NO: 213 WYVDGVEVHNAKTKPREEQYNSTYRVVSVL
TVLHQDWLNGKEYKCKVSNKALPAPIEKTI
SKAKGQPREPQVYTLPPSRDELTKNQVSLT
CLVKGFYPSDIAVEWESNGQPENNYKTTPP
VLDSDGSFFLYSKLTVDKSRWQQGNVFSCS
VMHEALHNHYTQKSLSLSPGK
Each of the Fc fusion proteins (TNFRI-V5-Fc, IL13Ra2TF-Fc, alAT-Fc) were expressed in culture media as shown in the dot blots in the middle lane of each panel in Figure 6B. This level of expression of the Fc fusion proteins was greater than that for each of the proteins of interest alone (i.e., without fusion to an Fc domain; data not shown). However, significantly higher levels of expression were obtained in each case when a J domain was linked to the protein of interest segment within the Fc fusion proteins as shown in the dot blots in the right lane of each panel in Figure 6B.
The results of a densitometry analysis of the chemiluminescent signals of the dot blots in Figure 6B
are shown in the corresponding panels of Figure 6C, where the significantly higher level of expression of the J domain fusion proteins is clearly evident.
Enhanced Expression of p53 Protein in a Modified Arrangement in Human Cells Proteins such as IL13Ra2, TNFR, and alAT are synthesized in the endoplasmic reticulum (ER) for delivery to the cell membrane or secretion from the cell. To determine the effect of the presence of a J domain on the expression of cytoplasmic proteins, the expression of a fusion of the p53 protein and J domain was studied. The p53 protein is a transcription factor that plays pivotal roles in genomic stability. More than half of cancer patients have some abnormalities in the pathway involving p53. Therefore, overexpression of p53 in a cancer patient has been attempted as a treatment for cancer.
A cDNA encoding p53 was inserted into expression plasmid V5(N)-pcDNA' to yield plasmid V5(N)-p53-pcDNA' to express a p53 protein containing an N-terminal V5 epitope tag. To express the p53-J domain fusion protein, a cDNA encoding a J domain of the SV40 large T
antigen was then inserted into the V5(N)-p53-pcDNA' vector between the V5 and p53 coding regions. See, diagrams of constructs in Figure 7A.
The amino acid sequence of a VS-tagged p53 protein is shown in the table below.
Table 24. Amino Acid Sequence of a VS-Tagged p53 Protein.
Protein Region Sequence Amino Acid Sequence (N¨ to C¨ Identifier terminal) p53 protein SEQ
ID NO:214 MGKPIPNPLLGLDSTGTGSEFDIAAAMEEP
QSDPSVEPPLSQETFSDLWKLLPENNVLSP
LPSQAMDDLMLSPDDIEQWFTEDPGPDEAP
RMPEAAPPVAPAPAAPTPAAPAPAPSWPLS
SSVPSQKTYQGSYGFRLGFLHSGTAKSVTC
TYSPALNKMFCQLAKTCPVQLWVDSTPPPG
TRVRAMAIYKQSQHMTEVVRRCPHHERCSD
SDGLAPPQHLIRVEGNLRVEYLDDRNTFRH
SVVVPYEPPEVGSDCTTIHYNYMCNSSCMG
GMNRRPILTIITLEDSSGNLLGRNSFEVRV
CACPGRDRRTEEENLRKKGEPHHELPPGST
KRALPNNTSSSPQPKKKPLDGEYFTLQIRG
RERFEMFRELNEALELKDAQAGKEPGGSRA
HSSHLKSKKGQSTSRHKKLMFKTEGPDSDA
AALESRGPYSIVSPKC
V5 epitope residues 1-15 MGKPIPNPLLGLDST
domain of SEQ ID
NO: 214 Linker residues 16-26 GTGSEFDIAAA
of SEQ ID
NO: 214 p53 residues 27-422 MEEPQSDPSVEPPLSQETFSDLWKLLPENN
of SEQ ID
VLSPLPSQAMDDLMLSPDDIEQWFTEDPGP
NO: 214 DEAPRMPEAAPPVAPAPAAPTPAAPAPAPS
WPLSSSVPSQKTYQGSYGFRLGFLHSGTAK
SVTCTYSPALNKMFCQLAKTCPVQLWVDST
PPPGTRVRAMAIYKQSQHMTEVVRRCPHHE
RCSDSDGLAPPQHLIRVEGNLRVEYLDDRN
TFRHSVVVPYEPPEVGSDCTTIHYNYMCNS
SCMGGMNRRPILTIITLEDSSGNLLGRNSF
EVRVCACPGRDRRTEEENLRKKGEPHHELP
PGSTKRALPNNTSSSPQPKKKPLDGEYFTL
QIRGRERFEMFRELNEALELKDAQAGKEPG
GSRAHSSHLKSKKGQSTSRHKKLMFKTEGP
DS DAAA
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) C-terminal residues 423- LESRGPYSIVSPKC
vector residues 436 of SEQ ID
NO: 214 The amino acid sequence of a J domain fusion protein comprising the V5 epitope tag, the SV40 J domain, and the p53 protein is shown in the table below.
Table 25. Amino Acid Sequence of a V5-Tagged 5V40 J Domain-p53 Fusion Protein.
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) p53-5V40 J SEQ ID NO:215 MGKPIPNPLLGLDSTGTGSEFMDKVLNREE
domain fusion SLQLMDLLGLERSAWGNIPLMRKAYLKKCK
protein EFHPDKGGDEEKMKKMNTLYKKMEDGVKYA
HQPDFGGFWDADIAAAMEEPQSDPSVEPPL
SQETFSDLWKLLPENNVLSPLPSQAMDDLM
LSPDDIEQWFTEDPGPDEAPRMPEAAPPVA
PAPAAPTPAAPAPAPSWPLSSSVPSQKTYQ
GSYGFRLGFLHSGTAKSVTCTYSPALNKMF
CQLAKTCPVQLWVDSTPPPGTRVRAMAIYK
QSQHMTEVVRRCPHHERCSDSDGLAPPQHL
IRVEGNLRVEYLDDRNTFRHSVVVPYEPPE
VGSDCTTIHYNYMCNSSCMGGMNRRPILTI
ITLEDSSGNLLGRNSFEVRVCACPGRDRRT
EEENLRKKGEPHHELPPGSTKRALPNNTSS
SPQPKKKPLDGEYFTLQIRGRERFEMFREL
NEALELKDAQAGKEPGGSRAHSSHLKSKKG
QSTSRHKKLMFKTEGPDSDAAALESRGPYS
IVSPKC
V5 epitope residues 1-15 MGKPIPNPLLGLDST
domain of SEQ ID
NO: 215 Linker residues 16-21 GTGSEF
of SEQ ID
NO: 215 5V40 J domain residues of SEQ ID
RKAYLKKCKEFHPDKGGDEEKMKKMNTLYK
NO: 215 KMEDGVKYAHQPDFGGFWDA
Linker residues 102- DIAAA
106 of SEQ ID
NO: 215 p53 residues 107- MEEPQSDPSVEPPLSQETFSDLWKLLPENN
502 of SEQ ID VLSPLPSQAMDDLMLSPDDIEQWFTEDPGP
NO: 215 DEAPRMPEAAPPVAPAPAAPTPAAPAPAPS
WPLSSSVPSQKTYQGSYGFRLGFLHSGTAK
SVTCTYSPALNKMFCQLAKTCPVQLWVDST
PPPGTRVRAMAIYKQSQHMTEVVRRCPHHE
RCSDSDGLAPPQHLIRVEGNLRVEYLDDRN
TFRHSVVVPYEPPEVGSDCTTIHYNYMCNS
SCMGGMNRRPILTIITLEDSSGNLLGRNSF
Protein Region Sequence Amino Acid Sequence (N¨ to C¨ Identifier terminal) 123456789012345678901234567890 EVRVCACPGRDRRTEEENLRKKGEPHHELP
PGSTKRALPNNTSSSPQPKKKPLDGEYFTL
QIRGRERFEMFRELNEALELKDAQAGKEPG
GSRAHSSHLKSKKGQSTSRHKKLMFKTEGP
DSDAAA
Linker residues 503- LESRGPYSIVSPKC
516 of SEQ ID
NO: 215 Plasmids V5(N)-p53-pcDNA' and V5(N)-J-p53-pcDNA' were transfected into MCF
cells, and incubated for two days. Cells were lysed in lysis buffer, and protein was detected by Western immunoblot assay using anti-V5 antibody. As shown in Figure 7B, the level of expression of the p53-J domain fusion protein (lane 3) was significantly greater than that of the p53 protein without a J
domain. Accordingly, the results indicate that fusion with a J domain can enhance not only membrane-associated and secreted proteins, but cytoplasmic proteins as well.
CFTR Expression in a Modified Arrangement in Human Cells Cystic fibrosis (CF) is an autosomal recessive disorder caused by mutations in the gene encoding the cystic fibrosis transmembrane conductance regulator (CFTR) protein, a cAMP-regulated chloride channel and channel regulator. The deletion of phenylalanine at position 508 (4508F) in CFTR is the most common mutation that changes the conformation of the CFTR
protein, which is then rapidly degraded by the ER quality systems. A general consensus is that only partial recovery of the wild-type CFTR protein function is required to provide a beneficial treatment to CF patients.
Therefore, a number of gene therapy trials with CFTR have been attempted, but have not yet been successful owing to inefficient delivery of a gene for CFTR and to immunogenicity of the vehicle (e.g., viral vector). In view of the fact that proper protein folding of wild-type CFTR is known to be difficult, it would be very useful if protein folding of the CFTR protein could be improved.
The cftr gene or its Phe508 deletion mutant (cfti-4508F) was inserted into plasmid V5(N)-pcDNA'. A DNA coding for the BAG domain of the BAG3 protein or a DNA coding for the J
domain from the Hsp40 J protein was inserted in the plasmids between V5 and the cftr coding sequences to yield plasmids to express a wild-type CFTR or mutant CFTR(4508F) protein linked to an N-terminal V5 epitope tag or to express a wild-type or mutant CFTR protein fused at its N-terminus to a BAG or J domain, which in turn was fused to an N-terminal V5 epitope tag. Diagrams of the various constructs used in this experiment are shown in Figure 8A.
The amino acid sequence a VS-tagged wild-type CFTR (CFTR WT) is shown in the table below.
Table 26. Amino Acid Sequence of a V5-Tagged CFTR Protein.
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) V5-tagged CFTR SEQ ID
NO:216 MGKPIPNPLLGLDSTGTGSEFDIAAAMQRS
protein PLEKASVVSKLFFSWTRPILRKGYRQRLEL
SDIYQIPSVDSADNLSEKLEREWDRELASK
KNPKLINALRRCFFWRFMFYGIFLYLGEVT
KAVQPLLLGRIIASYDPDNKEERSIAIYLG
IGLCLLFIVRTLLLHPAIFGLHHIGMQMRI
AMFSLIYKKTLKLSSRVLDKISIGQLVSLL
SNNLNKFDEGLALAHFVWIAPLQVALLMGL
IWELLQASAFCGLGFLIVLALFQAGLGRMM
MKYRDQRAGKISERLVITSEMIENIQSVKA
YCWEEAMEKMIENLRQTELKLTRKAAYVRY
FNSSAFFFSGFFVVFLSVLPYALIKGIILR
KIFTTISFCIVLRMAVTRQFPWAVQTWYDS
LGAINKIQDFLQKQEYKTLEYNLTTTEVVM
ENVTAFWEEGFGELFEKAKQNNNNRKTSNG
DDSLFFSNFSLLGTPVLKDINFKIERGQLL
AVAGSTGAGKTSLLMVIMGELEPSEGKIKH
SGRISFCSQFSWIMPGTIKENIIFGVSYDE
YRYRSVIKACQLEEDISKFAEKDNIVLGEG
GITLSGGQRARISLARAVYKDADLYLLDSP
FGYLDVLTEKEIFESCVCKLMANKTRILVT
SKMEHLKKADKILILHEGSSYFYGTFSELQ
NLQPDFSSKLMGCDSFDQFSAERRNSILTE
TLHRFSLEGDAPVSWTETKKQSFKQTGEFG
EKRKNSILNPINSIRKFSIVQKTPLQMNGI
EEDSDEPLERRLSLVPDSEQGEAILPRISV
ISTGPTLQARRRQSVLNLMTHSVNQGQNIH
RKTTASTRKVSLAPQANLTELDIYSRRLSQ
ETGLEISEEINEEDLKECFFDDMESIPAVT
TWNTYLRYITVHKSLIFVLIWCLVIFLAEV
AASLVVLWLLGNTPLQDKGNSTHSRNNSYA
VIITSTSSYYVFYIYVGVADTLLAMGFFRG
LPLVHTLITVSKILHHKMLHSVLQAPMSTL
NTLKAGGILNRFSKDIAILDDLLPLTIFDF
IQLLLIVIGAIAVVAVLQPYIFVATVPVIV
AFIMLRAYFLQTSQQLKQLESEGRSPIFTH
LVTSLKGLWTLRAFGRQPYFETLFHKALNL
HTANWFLYLSTLRWFQMRIEMIFVIFFIAV
TFISILTTGEGEGRVGIILTLAMNIMSTLQ
WAVNSSIDVDSLMRSVSRVFKFIDMPTEGK
PTKSTKPYKNGQLSKVMIIENSHVKKDDIW
PSGGQMTVKDLTAKYTEGGNAILENISFSI
SPGQRVGLLGRTGSGKSTLLSAFLRLLNTE
GEIQIDGVSWDSITLQQWRKAFGVIPQKVF
IFSGTFRKNLDPYEQWSDQEIWKVADEVGL
RSVIEQFPGKLDFVLVDGGCVLSHGHKQLM
CLARSVLSKAKILLLDEPSAHLDPVTYQII
RRTLKQAFADCTVILCEHRIEAMLECQQFL
VIEENKVRQYDSIQKLLNERSLFRQAISPS
DRVKLFPHRNSSKCKSKPQIAALKEETEEE
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) VQDTRL
V5 epitope residues 1-15 MGKPIPNPLLGLDST
domain of SEQ ID
NO: 216 Linker residues 16-26 GTGSEFDIAAA
of SEQ ID
NO: 216 CFTR residues 27-MQRSPLEKASVVSKLFFSWTRPILRKGYRQ
1506 of SEQ ID RLELSDIYQIPSVDSADNLSEKLEREWDRE
NO: 216 LASKKNPKLINALRRCFFWRFMFYGIFLYL
GEVTKAVQPLLLGRIIASYDPDNKEERSIA
IYLGIGLCLLFIVRTLLLHPAIFGLHHIGM
QMRIAMFSLIYKKTLKLSSRVLDKISIGQL
VSLLSNNLNKFDEGLALAHFVWIAPLQVAL
LMGLIWELLQASAFCGLGFLIVLALFQAGL
GRMMMKYRDQRAGKISERLVITSEMIENIQ
SVKAYCWEEAMEKMIENLRQTELKLTRKAA
YVRYFNSSAFFFSGFFVVFLSVLPYALIKG
IILRKIFTTISFCIVLRMAVTRQFPWAVQT
WYDSLGAINKIQDFLQKQEYKTLEYNLTTT
EVVMENVTAFWEEGFGELFEKAKQNNNNRK
TSNGDDSLFFSNFSLLGTPVLKDINFKIER
GQLLAVAGSTGAGKTSLLMVIMGELEPSEG
KIKHSGRISFCSQFSWIMPGTIKENIIFGV
SYDEYRYRSVIKACQLEEDISKFAEKDNIV
LGEGGITLSGGQRARISLARAVYKDADLYL
LDSPFGYLDVLTEKEIFESCVCKLMANKTR
ILVTSKMEHLKKADKILILHEGSSYFYGTF
SELQNLQPDFSSKLMGCDSFDQFSAERRNS
ILTETLHRFSLEGDAPVSWTETKKQSFKQT
GEFGEKRKNSILNPINSIRKFSIVQKTPLQ
MNGIEEDSDEPLERRLSLVPDSEQGEAILP
RISVISTGPTLQARRRQSVLNLMTHSVNQG
QNIHRKTTASTRKVSLAPQANLTELDIYSR
RLSQETGLEISEEINEEDLKECFFDDMESI
PAVTTWNTYLRYITVHKSLIFVLIWCLVIF
LAEVAASLVVLWLLGNTPLQDKGNSTHSRN
NSYAVIITSTSSYYVFYIYVGVADTLLAMG
FFRGLPLVHTLITVSKILHHKMLHSVLQAP
MSTLNTLKAGGILNRFSKDIAILDDLLPLT
IFDFIQLLLIVIGAIAVVAVLQPYIFVATV
PVIVAFIMLRAYFLQTSQQLKQLESEGRSP
IFTHLVTSLKGLWTLRAFGRQPYFETLFHK
ALNLHTANWFLYLSTLRWFQMRIEMIFVIF
FIAVTFISILTTGEGEGRVGIILTLAMNIM
STLQWAVNSSIDVDSLMRSVSRVFKFIDMP
TEGKPTKSTKPYKNGQLSKVMIIENSHVKK
DDIWPSGGQMTVKDLTAKYTEGGNAILENI
SFSISPGQRVGLLGRTGSGKSTLLSAFLRL
LNTEGEIQIDGVSWDSITLQQWRKAFGVIP
QKVFIFSGTFRKNLDPYEQWSDQEIWKVAD
EVGLRSVIEQFPGKLDFVLVDGGCVLSHGH
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) 123456789012345678901234567890 KQLMCLARSVLSKAKILLLDEPSAHLDPVT
YQIIRRTLKQAFADCTVILCEHRIEAMLEC
QQFLVIEENKVRQYDSIQKLLNERSLFRQA
ISPSDRVKLFPHRNSSKCKSKPQIAALKEE
TEEEVQDTRL
The amino acid sequence of a V5-tagged BAG-CPTR (wild-type) protein is shown in the table below.
Table 27. Amino Acid Sequence of a V5-Tagged BAG Domain-CFTR Protein.
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) V5-tagged BAG SEQ ID
NO:217 MGKPIPNPLLGLDSTGTGSEFHPGVLKVEA
domain-CFTR
ILEKVQGLEQAVDNFEGKKTDKKYLMIEEY
fusion protein LTKELLALDSVDPEGRADVRQARRDGVRKV
QTILEKLEQKAIDDIAAAMQRSPLEKASVV
SKLFFSWTRPILRKGYRQRLELSDIYQIPS
VDSADNLSEKLEREWDRELASKKNPKLINA
LRRCFFWRFMFYGIFLYLGEVTKAVQPLLL
GRIIASYDPDNKEERSIAIYLGIGLCLLFI
VRTLLLHPAIFGLHHIGMQMRIAMFSLIYK
KTLKLSSRVLDKISIGQLVSLLSNNLNKFD
EGLALAHFVWIAPLQVALLMGLIWELLQAS
AFCGLGFLIVLALFQAGLGRMMMKYRDQRA
GKISERLVITSEMIENIQSVKAYCWEEAME
KMIENLRQTELKLTRKAAYVRYFNSSAFFF
SGFFVVFLSVLPYALIKGIILRKIFTTISF
CIVLRMAVTRQFPWAVQTWYDSLGAINKIQ
DFLQKQEYKTLEYNLTTTEVVMENVTAFWE
EGFGELFEKAKQNNNNRKTSNGDDSLFFSN
FSLLGTPVLKDINFKIERGQLLAVAGSTGA
GKTSLLMVIMGELEPSEGKIKHSGRISFCS
QFSWIMPGTIKENIIFGVSYDEYRYRSVIK
ACQLEEDISKFAEKDNIVLGEGGITLSGGQ
RARISLARAVYKDADLYLLDSPFGYLDVLT
EKEIFESCVCKLMANKTRILVTSKMEHLKK
ADKILILHEGSSYFYGTFSELQNLQPDFSS
KLMGCDSFDQFSAERRNSILTETLHRFSLE
GDAPVSWTETKKQSFKQTGEFGEKRKNSIL
NPINSIRKFSIVQKTPLQMNGIEEDSDEPL
ERRLSLVPDSEQGEAILPRISVISTGPTLQ
ARRRQSVLNLMTHSVNQGQNIHRKTTASTR
KVSLAPQANLTELDIYSRRLSQETGLEISE
EINEEDLKECFFDDMESIPAVTTWNTYLRY
ITVHKSLIFVLIWCLVIFLAEVAASLVVLW
LLGNTPLQDKGNSTHSRNNSYAVIITSTSS
YYVFYIYVGVADTLLAMGFFRGLPLVHTLI
TVSKILHHKMLHSVLQAPMSTLNTLKAGGI
LNRFSKDIAILDDLLPLTIFDFIQLLLIVI
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) GAIAVVAVLQPYIFVATVPVIVAFIMLRAY
FLQTSQQLKQLESEGRSPIFTHLVTSLKGL
WTLRAFGRQPYFETLFHKALNLHTANWFLY
LSTLRWFQMRIEMIFVIFFIAVTFISILTT
GEGEGRVGIILTLAMNIMSTLQWAVNSSID
VDSLMRSVSRVFKFIDMPTEGKPTKSTKPY
KNGQLSKVMIIENSHVKKDDIWPSGGQMTV
KDLTAKYTEGGNAILENISFSISPGQRVGL
LGRTGSGKSTLLSAFLRLLNTEGEIQIDGV
SWDSITLQQWRKAFGVIPQKVFIFSGTFRK
NLDPYEQWSDQEIWKVADEVGLRSVIEQFP
GKLDFVLVDGGCVLSHGHKQLMCLARSVLS
KAKILLLDEPSAHLDPVTYQIIRRTLKQAF
ADCTVILCEHRIEAMLECQQFLVIEENKVR
QYDSIQKLLNERSLFRQAISPSDRVKLFPH
RNSSKCKSKPQIAALKEETEEEVQDTRL
V5 epitope residues 1-15 MGKPIPNPLLGLDST
domain of SEQ ID
NO: 217 Linker residues 16-21 GTGSEF
of SEQ ID
NO: 217 BAG domain residues 22-103 HPGVLKVEAILEKVQGLEQAVDNFEGKKTD
(from BAG3) of SEQ ID
KKYLMIEEYLTKELLALDSVDPEGRADVRQ
NO: 217 ARRDGVRKVQTILEKLEQKAID
Linker residues 104- DIAAA
108 of SEQ ID
NO: 217 CFTR residues 109- MQRSPLEKASVVSKLFFSWTRPILRKGYRQ
1588 of SEQ ID RLELSDIYQIPSVDSADNLSEKLEREWDRE
NO: 217 LASKKNPKLINALRRCFFWRFMFYGIFLYL
GEVTKAVQPLLLGRIIASYDPDNKEERSIA
IYLGIGLCLLFIVRTLLLHPAIFGLHHIGM
QMRIAMFSLIYKKTLKLSSRVLDKISIGQL
VSLLSNNLNKFDEGLALAHFVWIAPLQVAL
LMGLIWELLQASAFCGLGFLIVLALFQAGL
GRMMMKYRDQRAGKISERLVITSEMIENIQ
SVKAYCWEEAMEKMIENLRQTELKLTRKAA
YVRYFNSSAFFFSGFFVVFLSVLPYALIKG
IILRKIFTTISFCIVLRMAVTRQFPWAVQT
WYDSLGAINKIQDFLQKQEYKTLEYNLTTT
EVVMENVTAFWEEGFGELFEKAKQNNNNRK
TSNGDDSLFFSNFSLLGTPVLKDINFKIER
GQLLAVAGSTGAGKTSLLMVIMGELEPSEG
KIKHSGRISFCSQFSWIMPGTIKENIIFGV
SYDEYRYRSVIKACQLEEDISKFAEKDNIV
LGEGGITLSGGQRARISLARAVYKDADLYL
LDSPFGYLDVLTEKEIFESCVCKLMANKTR
ILVTSKMEHLKKADKILILHEGSSYFYGTF
SELQNLQPDFSSKLMGCDSFDQFSAERRNS
ILTETLHRFSLEGDAPVSWTETKKQSFKQT
GEFGEKRKNSILNPINSIRKFSIVQKTPLQ
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) 123456789012345678901234567890 MNGIEEDSDEPLERRLSLVPDSEQGEAILP
RISVISTGPTLQARRRQSVLNLMTHSVNQG
QNIHRKTTASTRKVSLAPQANLTELDIYSR
RLSQETGLEISEEINEEDLKECFFDDMESI
PAVTTWNTYLRYITVHKSLIFVLIWCLVIF
LAEVAASLVVLWLLGNTPLQDKGNSTHSRN
NSYAVIITSTSSYYVFYIYVGVADTLLAMG
FFRGLPLVHTLITVSKILHHKMLHSVLQAP
MSTLNTLKAGGILNRFSKDIAILDDLLPLT
IFDFIQLLLIVIGAIAVVAVLQPYIFVATV
PVIVAFIMLRAYFLQTSQQLKQLESEGRSP
IFTHLVTSLKGLWTLRAFGRQPYFETLFHK
ALNLHTANWFLYLSTLRWFQMRIEMIFVIF
FIAVTFISILTTGEGEGRVGIILTLAMNIM
STLQWAVNSSIDVDSLMRSVSRVFKFIDMP
TEGKPTKSTKPYKNGQLSKVMIIENSHVKK
DDIWPSGGQMTVKDLTAKYTEGGNAILENI
SFSISPGQRVGLLGRTGSGKSTLLSAFLRL
LNTEGEIQIDGVSWDSITLQQWRKAFGVIP
QKVFIFSGTFRKNLDPYEQWSDQEIWKVAD
EVGLRSVIEQFPGKLDFVLVDGGCVLSHGH
KQLMCLARSVLSKAKILLLDEPSAHLDPVT
YQIIRRTLKQAFADCTVILCEHRIEAMLEC
QQFLVIEENKVRQYDSIQKLLNERSLFRQA
ISPSDRVKLFPHRNSSKCKSKPQIAALKEE
TEEEVQDTRL
The amino acid sequences a J domain fusion comprising the V5 epitope tag, the domain, and the CPTR wild-type protein is shown in the table below.
Table 28. Amino Acid Sequence of a V5-Tagged 5V40 J Domain-CFTR Protein.
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) V5-tagged SV40 J SEQ ID
NO:218 MGKPIPNPLLGLDSTGTGSEFMDKVLNREE
domain-CFTR
SLQLMDLLGLERSAWGNIPLMRKAYLKKCK
fusion protein EFHPDKGGDEEKMKKMNTLYKKMEDGVKYA
HQPDFGGFWDADIAAAMQRSPLEKASVVSK
LFFSWTRPILRKGYRQRLELSDIYQIPSVD
SADNLSEKLEREWDRELASKKNPKLINALR
RCFFWRFMFYGIFLYLGEVTKAVQPLLLGR
IIASYDPDNKEERSIAIYLGIGLCLLFIVR
TLLLHPAIFGLHHIGMQMRIAMFSLIYKKT
LKLSSRVLDKISIGQLVSLLSNNLNKFDEG
LALAHFVWIAPLQVALLMGLIWELLQASAF
CGLGFLIVLALFQAGLGRMMMKYRDQRAGK
ISERLVITSEMIENIQSVKAYCWEEAMEKM
IENLRQTELKLTRKAAYVRYFNSSAFFFSG
FFVVFLSVLPYALIKGIILRKIFTTISFCI
VLRMAVTRQFPWAVQTWYDSLGAINKIQDF
LQKQEYKTLEYNLTTTEVVMENVTAFWEEG
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) FGELFEKAKQNNNNRKTSNGDDSLFFSNFS
LLGTPVLKDINFKIERGQLLAVAGSTGAGK
TSLLMVIMGELEPSEGKIKHSGRISFCSQF
SWIMPGTIKENIIFGVSYDEYRYRSVIKAC
QLEEDISKFAEKDNIVLGEGGITLSGGQRA
RISLARAVYKDADLYLLDSPFGYLDVLTEK
EIFESCVCKLMANKTRILVTSKMEHLKKAD
KILILHEGSSYFYGTFSELQNLQPDFSSKL
MGCDSFDQFSAERRNSILTETLHRFSLEGD
APVSWTETKKQSFKQTGEFGEKRKNSILNP
INSIRKFSIVQKTPLQMNGIEEDSDEPLER
RLSLVPDSEQGEAILPRISVISTGPTLQAR
RRQSVLNLMTHSVNQGQNIHRKTTASTRKV
SLAPQANLTELDIYSRRLSQETGLEISEEI
NEEDLKECFFDDMESIPAVTTWNTYLRYIT
VHKSLIFVLIWCLVIFLAEVAASLVVLWLL
GNTPLQDKGNSTHSRNNSYAVIITSTSSYY
VFYIYVGVADTLLAMGFFRGLPLVHTLITV
SKILHHKMLHSVLQAPMSTLNTLKAGGILN
RFSKDIAILDDLLPLTIFDFIQLLLIVIGA
IAVVAVLQPYIFVATVPVIVAFIMLRAYFL
QTSQQLKQLESEGRSPIFTHLVTSLKGLWT
LRAFGRQPYFETLFHKALNLHTANWFLYLS
TLRWFQMRIEMIFVIFFIAVTFISILTTGE
GEGRVGIILTLAMNIMSTLQWAVNSSIDVD
SLMRSVSRVFKFIDMPTEGKPTKSTKPYKN
GQLSKVMIIENSHVKKDDIWPSGGQMTVKD
LTAKYTEGGNAILENISFSISPGQRVGLLG
RTGSGKSTLLSAFLRLLNTEGEIQIDGVSW
DSITLQQWRKAFGVIPQKVFIFSGTFRKNL
DPYEQWSDQEIWKVADEVGLRSVIEQFPGK
LDFVLVDGGCVLSHGHKQLMCLARSVLSKA
KILLLDEPSAHLDPVTYQIIRRTLKQAFAD
CTVILCEHRIEAMLECQQFLVIEENKVRQY
DSIQKLLNERSLFRQAISPSDRVKLFPHRN
SSKCKSKPQIAALKEETEEEVQDTRL
V5 epitope residues 1-15 MGKPIPNPLLGLDST
domain of SEQ ID
NO: 218 Linker residues 16-21 GTGSEF
of SEQ ID
NO: 218 5V40 J domain residues of SEQ ID
RKAYLKKCKEFHPDKGGDEEKMKKMNTLYK
NO: 218 KMEDGVKYAHQPDFGGFWDA
Linker residues 102- DIAAA
106 of SEQ ID
NO: 218 CFTR residues 107- MQRSPLEKASVVSKLFFSWTRPILRKGYRQ
1586 of SEQ ID RLELSDIYQIPSVDSADNLSEKLEREWDRE
NO: 218 LASKKNPKLINALRRCFFWRFMFYGIFLYL
GEVTKAVQPLLLGRIIASYDPDNKEERSIA
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) IYLGIGLCLLF IVRTLLLHPAIFGLHHI GM
QMRIAMFSL I YKKTLKLS SRVLDKI S I GQL
VS LL SNNLNKFDEGLALAHFVWIAPLQVAL
LMGL IWELLQASAFCGLGFL IVLALFQAGL
GRMMMKYRDQRAGKI SERLVI T SEMIEN I Q
SVKAYCWEEAMEKMIENLRQTELKLTRKAA
YVRYFNSSAFFFSGFFVVFLSVLPYAL I KG
II LRKIFTT I SFCIVLRMAVTRQFPWAVQT
WYDSLGAINKIQDFLQKQEYKTLEYNLTTT
EVVMENVTAFWEEGFGELFEKAKQNNNNRK
TSNGDDSLFFSNFSLLGTPVLKDINFKIER
GQLLAVAGS TGAGKT SLLMVIMGELEP SEG
KIKHSGRI SFCSQFSWIMPGT IKENI IFGV
SYDEYRYRSVIKACQLEED I SKFAEKDNIV
LGEGGITLSGGQRARISLARAVYKDADLYL
LDSPFGYLDVLTEKEIFESCVCKLMANKTR
ILVT SKMEHLKKADKI L I LHEGS SYFYGTF
SELQNLQPDFSSKLMGCDSFDQFSAERRNS
IL TETLHRF SLEGDAPVSWTETKKQSFKQT
GEFGEKRKNS I LNP INS IRKF S IVQKTPLQ
MNGIEEDSDEPLERRL SLVPDSEQGEAI LP
RI SVI STGPTLQARRRQSVLNLMTHSVNQG
QNIHRKTTASTRKVSLAPQANLTELDIYSR
RL SQETGLE I SEE INEEDLKECFFDDMES I
PAVTTWNTYLRY I TVHKS L I FVL IWCLVIF
LAEVAASLVVLWLLGNTPLQDKGNSTHSRN
NSYAVI ITSTSSYYVFYIYVGVADTLLAMG
FFRGLPLVHTL I TVSKILHHKMLHSVLQAP
MS TLNTLKAGGI LNRF SKD IAI LDDLLPL T
IFDF IQLLL IVIGAIAVVAVLQPYIFVATV
PVIVAF IMLRAYFLQTSQQLKQLESEGRSP
IFTHLVTSLKGLWTLRAFGRQPYFETLFHK
ALNLHTANWFLYLSTLRWFQMRIEMIFVIF
FIAVTFISILTTGEGEGRVGIILTLAMNIM
STLQWAVNSS I DVD S LMRSVSRVFKF I DMP
TEGKPTKSTKPYKNGQLSKVMI IENSHVKK
DDIWPSGGQMTVKDLTAKYTEGGNAILENI
SFS I SPGQRVGLLGRTGSGKSTLLSAFLRL
LNTEGE IQ I DGVSWDS I TLQQWRKAFGVIP
QKVF IF SGTFRKNLDPYEQWSDQE IWKVAD
EVGLRSVIEQFPGKLDFVLVDGGCVLSHGH
KQLMCLARSVLSKAKILLLDEPSAHLDPVT
YQ I IRRTLKQAFADCTVILCEHRIEAMLEC
QQFLVIEENKVRQYDS IQKLLNERSLFRQA
I SP SDRVKLFPHRNS SKCKSKPQ IAALKEE
TEEEVQDTRL
The amino acid sequence of a V5-tagged CFTR(4508F) protein is shown in the table below.
Table 29. Amino Acid Sequence of a V5-Tagged CFTR(4508F) Protein.
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) V5-tagged SEQ ID
NO:219 MGKPIPNPLLGLDSTGTGSEFDIAAAMQRS
CFTR(4508F) PLEKASVVSKLFFSWTRPILRKGYRQRLEL
protein SDIYQIPSVDSADNLSEKLEREWDRELASK
KNPKLINALRRCFFWRFMFYGIFLYLGEVT
KAVQPLLLGRIIASYDPDNKEERSIAIYLG
IGLCLLFIVRTLLLHPAIFGLHHIGMQMRI
AMFSLIYKKTLKLSSRVLDKISIGQLVSLL
SNNLNKFDEGLALAHFVWIAPLQVALLMGL
IWELLQASAFCGLGFLIVLALFQAGLGRMM
MKYRDQRAGKISERLVITSEMIENIQSVKA
YCWEEAMEKMIENLRQTELKLTRKAAYVRY
FNSSAFFFSGFFVVFLSVLPYALIKGIILR
KIFTTISFCIVLRMAVTRQFPWAVQTWYDS
LGAINKIQDFLQKQEYKTLEYNLTTTEVVM
ENVTAFWEEGFGELFEKAKQNNNNRKTSNG
DDSLFFSNFSLLGTPVLKDINFKIERGQLL
AVAGSTGAGKTSLLMVIMGELEPSEGKIKH
SGRISFCSQFSWIMPGTIKENIIGVSYDEY
RYRSVIKACQLEEDISKFAEKDNIVLGEGG
ITLSGGQRARISLARAVYKDADLYLLDSPF
GYLDVLTEKEIFESCVCKLMANKTRILVTS
KMEHLKKADKILILHEGSSYFYGTFSELQN
LQPDFSSKLMGCDSFDQFSAERRNSILTET
LHRFSLEGDAPVSWTETKKQSFKQTGEFGE
KRKNSILNPINSIRKFSIVQKTPLQMNGIE
EDSDEPLERRLSLVPDSEQGEAILPRISVI
STGPTLQARRRQSVLNLMTHSVNQGQNIHR
KTTASTRKVSLAPQANLTELDIYSRRLSQE
TGLEISEEINEEDLKECFFDDMESIPAVTT
WNTYLRYITVHKSLIFVLIWCLVIFLAEVA
ASLVVLWLLGNTPLQDKGNSTHSRNNSYAV
IITSTSSYYVFYIYVGVADTLLAMGFFRGL
PLVHTLITVSKILHHKMLHSVLQAPMSTLN
TLKAGGILNRFSKDIAILDDLLPLTIFDFI
QLLLIVIGAIAVVAVLQPYIFVATVPVIVA
FIMLRAYFLQTSQQLKQLESEGRSPIFTHL
VTSLKGLWTLRAFGRQPYFETLFHKALNLH
TANWFLYLSTLRWFQMRIEMIFVIFFIAVT
FISILTTGEGEGRVGIILTLAMNIMSTLQW
AVNSSIDVDSLMRSVSRVFKFIDMPTEGKP
TKSTKPYKNGQLSKVMIIENSHVKKDDIWP
SGGQMTVKDLTAKYTEGGNAILENISFSIS
PGQRVGLLGRTGSGKSTLLSAFLRLLNTEG
EIQIDGVSWDSITLQQWRKAFGVIPQKVFI
FSGTFRKNLDPYEQWSDQEIWKVADEVGLR
SVIEQFPGKLDFVLVDGGCVLSHGHKQLMC
LARSVLSKAKILLLDEPSAHLDPVTYQIIR
RTLKQAFADCTVILCEHRIEAMLECQQFLV
IEENKVRQYDSIQKLLNERSLFRQAISPSD
RVKLFPHRNSSKCKSKPQIAALKEETEEEV
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) QDTRL
V5 epitope residues 1-15 MGKPIPNPLLGLDST
domain of SEQ ID
NO: 219 Linker residues 16-26 GTGSEFDIAAA
of SEQ ID
NO: 219 CFTR(4508F) residues 27-MQRSPLEKASVVSKLFFSWTRPILRKGYRQ
1505 of SEQ ID RLELSDIYQIPSVDSADNLSEKLEREWDRE
NO: 219 LASKKNPKLINALRRCFFWRFMFYGIFLYL
GEVTKAVQPLLLGRIIASYDPDNKEERSIA
IYLGIGLCLLFIVRTLLLHPAIFGLHHIGM
QMRIAMFSLIYKKTLKLSSRVLDKISIGQL
VSLLSNNLNKFDEGLALAHFVWIAPLQVAL
LMGLIWELLQASAFCGLGFLIVLALFQAGL
GRMMMKYRDQRAGKISERLVITSEMIENIQ
SVKAYCWEEAMEKMIENLRQTELKLTRKAA
YVRYFNSSAFFFSGFFVVFLSVLPYALIKG
IILRKIFTTISFCIVLRMAVTRQFPWAVQT
WYDSLGAINKIQDFLQKQEYKTLEYNLTTT
EVVMENVTAFWEEGFGELFEKAKQNNNNRK
TSNGDDSLFFSNFSLLGTPVLKDINFKIER
GQLLAVAGSTGAGKTSLLMVIMGELEPSEG
KIKHSGRISFCSQFSWIMPGTIKENIIGVS
YDEYRYRSVIKACQLEEDISKFAEKDNIVL
GEGGITLSGGQRARISLARAVYKDADLYLL
DSPFGYLDVLTEKEIFESCVCKLMANKTRI
LVTSKMEHLKKADKILILHEGSSYFYGTFS
ELQNLQPDFSSKLMGCDSFDQFSAERRNSI
LTETLHRFSLEGDAPVSWTETKKQSFKQTG
EFGEKRKNSILNPINSIRKFSIVQKTPLQM
NGIEEDSDEPLERRLSLVPDSEQGEAILPR
ISVISTGPTLQARRRQSVLNLMTHSVNQGQ
NIHRKTTASTRKVSLAPQANLTELDIYSRR
LSQETGLEISEEINEEDLKECFFDDMESIP
AVTTWNTYLRYITVHKSLIFVLIWCLVIFL
AEVAASLVVLWLLGNTPLQDKGNSTHSRNN
SYAVIITSTSSYYVFYIYVGVADTLLAMGF
FRGLPLVHTLITVSKILHHKMLHSVLQAPM
STLNTLKAGGILNRFSKDIAILDDLLPLTI
FDFIQLLLIVIGAIAVVAVLQPYIFVATVP
VIVAFIMLRAYFLQTSQQLKQLESEGRSPI
FTHLVTSLKGLWTLRAFGRQPYFETLFHKA
LNLHTANWFLYLSTLRWFQMRIEMIFVIFF
IAVTFISILTTGEGEGRVGIILTLAMNIMS
TLQWAVNSSIDVDSLMRSVSRVFKFIDMPT
EGKPTKSTKPYKNGQLSKVMIIENSHVKKD
DIWPSGGQMTVKDLTAKYTEGGNAILENIS
FSISPGQRVGLLGRTGSGKSTLLSAFLRLL
NTEGEIQIDGVSWDSITLQQWRKAFGVIPQ
KVFIFSGTFRKNLDPYEQWSDQEIWKVADE
VGLRSVIEQFPGKLDFVLVDGGCVLSHGHK
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) QLMCLARSVLSKAKILLLDEPSAHLDPVTY
QIIRRTLKQAFADCTVILCEHRIEAMLECQ
QFLVIEENKVRQYDSIQKLLNERSLFRQAI
SPSDRVKLFPHRNSSKCKSKPQIAALKEET
EEEVQDTRL
The amino acid sequence of a V5-tagged BAG domain-CPTR(4508F) fusion protein is shown in the table below.
Table 30. Amino Acid Sequence of a V5-Tagged BAG Domain-CFTR(4508F) Fusion Protein.
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) V5-tagged BAG SEQ ID
NO:220 MGKPIPNPLLGLDSTGTGSEFHPGVLKVEA
domain-ILEKVQGLEQAVDNFEGKKTDKKYLMIEEY
CFTR(4508F) LTKELLALDSVDPEGRADVRQARRDGVRKV
fusion protein QTILEKLEQKAIDDIAAAMQRSPLEKASVV
SKLFFSWTRPILRKGYRQRLELSDIYQIPS
VDSADNLSEKLEREWDRELASKKNPKLINA
LRRCFFWRFMFYGIFLYLGEVTKAVQPLLL
GRIIASYDPDNKEERSIAIYLGIGLCLLFI
VRTLLLHPAIFGLHHIGMQMRIAMFSLIYK
KTLKLSSRVLDKISIGQLVSLLSNNLNKFD
EGLALAHFVWIAPLQVALLMGLIWELLQAS
AFCGLGFLIVLALFQAGLGRMMMKYRDQRA
GKISERLVITSEMIENIQSVKAYCWEEAME
KMIENLRQTELKLTRKAAYVRYFNSSAFFF
SGFFVVFLSVLPYALIKGIILRKIFTTISF
CIVLRMAVTRQFPWAVQTWYDSLGAINKIQ
DFLQKQEYKTLEYNLTTTEVVMENVTAFWE
EGFGELFEKAKQNNNNRKTSNGDDSLFFSN
FSLLGTPVLKDINFKIERGQLLAVAGSTGA
GKTSLLMVIMGELEPSEGKIKHSGRISFCS
QFSWIMPGTIKENIIGVSYDEYRYRSVIKA
CQLEEDISKFAEKDNIVLGEGGITLSGGQR
ARISLARAVYKDADLYLLDSPFGYLDVLTE
KEIFESCVCKLMANKTRILVTSKMEHLKKA
DKILILHEGSSYFYGTFSELQNLQPDFSSK
LMGCDSFDQFSAERRNSILTETLHRFSLEG
DAPVSWTETKKQSFKQTGEFGEKRKNSILN
PINSIRKFSIVQKTPLQMNGIEEDSDEPLE
RRLSLVPDSEQGEAILPRISVISTGPTLQA
RRRQSVLNLMTHSVNQGQNIHRKTTASTRK
VSLAPQANLTELDIYSRRLSQETGLEISEE
INEEDLKECFFDDMESIPAVTTWNTYLRYI
TVHKSLIFVLIWCLVIFLAEVAASLVVLWL
LGNTPLQDKGNSTHSRNNSYAVIITSTSSY
YVFYIYVGVADTLLAMGFFRGLPLVHTLIT
VSKILHHKMLHSVLQAPMSTLNTLKAGGIL
NRFSKDIAILDDLLPLTIFDFIQLLLIVIG
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) 123456789012345678901234567890 AIAVVAVLQPYIFVATVPVIVAFIMLRAYF
LQTSQQLKQLESEGRSPIFTHLVTSLKGLW
TLRAFGRQPYFETLFHKALNLHTANWFLYL
STLRWFQMRIEMIFVIFFIAVTFISILTTG
EGEGRVGIILTLAMNIMSTLQWAVNSSIDV
DSLMRSVSRVFKFIDMPTEGKPTKSTKPYK
NGQLSKVMIIENSHVKKDDIWPSGGQMTVK
DLTAKYTEGGNAILENISFSISPGQRVGLL
GRTGSGKSTLLSAFLRLLNTEGEIQIDGVS
WDSITLQQWRKAFGVIPQKVFIFSGTFRKN
LDPYEQWSDQEIWKVADEVGLRSVIEQFPG
KLDFVLVDGGCVLSHGHKQLMCLARSVLSK
AKILLLDEPSAHLDPVTYQIIRRTLKQAFA
DCTVILCEHRIEAMLECQQFLVIEENKVRQ
YDSIQKLLNERSLFRQAISPSDRVKLFPHR
NSSKCKSKPQIAALKEETEEEVQDTRL
V5 epitope residues 1-15 MGKPIPNPLLGLDST
domain of SEQ ID
NO:220 Linker residues 16-21 GTGSEF
of SEQ ID
NO:220 BAG domain residues (from BAG3) of SEQ ID
KKYLMIEEYLTKELLALDSVDPEGRADVRQ
NO: 220 ARRDGVRKVQTILEKLEQKAID
Linker residues 104- DIAAA
108 of SEQ ID
NO:220 CFTR(4508F) residues 109- MQRSPLEKASVVSKLFFSWTRPILRKGYRQ
1587 of SEQ ID RLELSDIYQIPSVDSADNLSEKLEREWDRE
NO: 220 LASKKNPKLINALRRCFFWRFMFYGIFLYL
GEVTKAVQPLLLGRIIASYDPDNKEERSIA
IYLGIGLCLLFIVRTLLLHPAIFGLHHIGM
QMRIAMFSLIYKKTLKLSSRVLDKISIGQL
VSLLSNNLNKFDEGLALAHFVWIAPLQVAL
LMGLIWELLQASAFCGLGFLIVLALFQAGL
GRMMMKYRDQRAGKISERLVITSEMIENIQ
SVKAYCWEEAMEKMIENLRQTELKLTRKAA
YVRYFNSSAFFFSGFFVVFLSVLPYALIKG
IILRKIFTTISFCIVLRMAVTRQFPWAVQT
WYDSLGAINKIQDFLQKQEYKTLEYNLTTT
EVVMENVTAFWEEGFGELFEKAKQNNNNRK
TSNGDDSLFFSNFSLLGTPVLKDINFKIER
GQLLAVAGSTGAGKTSLLMVIMGELEPSEG
KIKHSGRISFCSQFSWIMPGTIKENIIGVS
YDEYRYRSVIKACQLEEDISKFAEKDNIVL
GEGGITLSGGQRARISLARAVYKDADLYLL
DSPFGYLDVLTEKEIFESCVCKLMANKTRI
LVTSKMEHLKKADKILILHEGSSYFYGTFS
ELQNLQPDFSSKLMGCDSFDQFSAERRNSI
LTETLHRFSLEGDAPVSWTETKKQSFKQTG
EFGEKRKNSILNPINSIRKFSIVQKTPLQM
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) NGIEEDSDEPLERRLSLVPDSEQGEAILPR
ISVISTGPTLQARRRQSVLNLMTHSVNQGQ
NIHRKTTASTRKVSLAPQANLTELDIYSRR
LSQETGLEISEEINEEDLKECFFDDMESIP
AVTTWNTYLRYITVHKSLIFVLIWCLVIFL
AEVAASLVVLWLLGNTPLQDKGNSTHSRNN
SYAVIITSTSSYYVFYIYVGVADTLLAMGF
FRGLPLVHTLITVSKILHHKMLHSVLQAPM
STLNTLKAGGILNRFSKDIAILDDLLPLTI
FDFIQLLLIVIGAIAVVAVLQPYIFVATVP
VIVAFIMLRAYFLQTSQQLKQLESEGRSPI
FTHLVTSLKGLWTLRAFGRQPYFETLFHKA
LNLHTANWFLYLSTLRWFQMRIEMIFVIFF
IAVTFISILTTGEGEGRVGIILTLAMNIMS
TLQWAVNSSIDVDSLMRSVSRVFKFIDMPT
EGKPTKSTKPYKNGQLSKVMIIENSHVKKD
DIWPSGGQMTVKDLTAKYTEGGNAILENIS
FSISPGQRVGLLGRTGSGKSTLLSAFLRLL
NTEGEIQIDGVSWDSITLQQWRKAFGVIPQ
KVFIFSGTFRKNLDPYEQWSDQEIWKVADE
VGLRSVIEQFPGKLDFVLVDGGCVLSHGHK
QLMCLARSVLSKAKILLLDEPSAHLDPVTY
QIIRRTLKQAFADCTVILCEHRIEAMLECQ
QFLVIEENKVRQYDSIQKLLNERSLFRQAI
SPSDRVKLFPHRNSSKCKSKPQIAALKEET
EEEVQDTRL
The amino acid of a V5-tagged J domain-CFTR(4508F) fusion protein is shown in the table below.
Table 31. Amino Acid Sequence of a V5-Tagged 5V40 J Domain-CFTR(4508F) Fusion Protein.
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) V5-tagged, SV40 SEQ ID
NO:221 MGKPIPNPLLGLDSTGTGSEFMDKVLNREE
J domain-SLQLMDLLGLERSAWGNIPLMRKAYLKKCK
CFTR(4508F) EFHPDKGGDEEKMKKMNTLYKKMEDGVKYA
fusion protein HQPDFGGFWDADIAAAMQRSPLEKASVVSK
LFFSWTRPILRKGYRQRLELSDIYQIPSVD
SADNLSEKLEREWDRELASKKNPKLINALR
RCFFWRFMFYGIFLYLGEVTKAVQPLLLGR
IIASYDPDNKEERSIAIYLGIGLCLLFIVR
TLLLHPAIFGLHHIGMQMRIAMFSLIYKKT
LKLSSRVLDKISIGQLVSLLSNNLNKFDEG
LALAHFVWIAPLQVALLMGLIWELLQASAF
CGLGFLIVLALFQAGLGRMMMKYRDQRAGK
ISERLVITSEMIENIQSVKAYCWEEAMEKM
IENLRQTELKLTRKAAYVRYFNSSAFFFSG
FFVVFLSVLPYALIKGIILRKIFTTISFCI
VLRMAVTRQFPWAVQTWYDSLGAINKIQDF
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) LQKQEYKTLEYNLTTTEVVMENVTAFWEEG
FGELFEKAKQNNNNRKTSNGDDSLFFSNFS
LLGTPVLKDINFKIERGQLLAVAGSTGAGK
TSLLMVIMGELEPSEGKIKHSGRISFCSQF
SWIMPGTIKENIIGVSYDEYRYRSVIKACQ
LEEDISKFAEKDNIVLGEGGITLSGGQRAR
ISLARAVYKDADLYLLDSPFGYLDVLTEKE
IFESCVCKLMANKTRILVTSKMEHLKKADK
ILILHEGSSYFYGTFSELQNLQPDFSSKLM
GCDSFDQFSAERRNSILTETLHRFSLEGDA
PVSWTETKKQSFKQTGEFGEKRKNSILNPI
NSIRKFSIVQKTPLQMNGIEEDSDEPLERR
LSLVPDSEQGEAILPRISVISTGPTLQARR
RQSVLNLMTHSVNQGQNIHRKTTASTRKVS
LAPQANLTELDIYSRRLSQETGLEISEEIN
EEDLKECFFDDMESIPAVTTWNTYLRYITV
HKSLIFVLIWCLVIFLAEVAASLVVLWLLG
NTPLQDKGNSTHSRNNSYAVIITSTSSYYV
FYIYVGVADTLLAMGFFRGLPLVHTLITVS
KILHHKMLHSVLQAPMSTLNTLKAGGILNR
FSKDIAILDDLLPLTIFDFIQLLLIVIGAI
AVVAVLQPYIFVATVPVIVAFIMLRAYFLQ
TSQQLKQLESEGRSPIFTHLVTSLKGLWTL
RAFGRQPYFETLFHKALNLHTANWFLYLST
LRWFQMRIEMIFVIFFIAVTFISILTTGEG
EGRVGIILTLAMNIMSTLQWAVNSSIDVDS
LMRSVSRVFKFIDMPTEGKPTKSTKPYKNG
QLSKVMIIENSHVKKDDIWPSGGQMTVKDL
TAKYTEGGNAILENISFSISPGQRVGLLGR
TGSGKSTLLSAFLRLLNTEGEIQIDGVSWD
SITLQQWRKAFGVIPQKVFIFSGTFRKNLD
PYEQWSDQEIWKVADEVGLRSVIEQFPGKL
DFVLVDGGCVLSHGHKQLMCLARSVLSKAK
ILLLDEPSAHLDPVTYQIIRRTLKQAFADC
TVILCEHRIEAMLECQQFLVIEENKVRQYD
SIQKLLNERSLFRQAISPSDRVKLFPHRNS
SKCKSKPQIAALKEETEEEVQDTRL
V5 epitope residues 1-15 MGKPIPNPLLGLDST
domain of SEQ ID
NO:221 Linker residues 16-21 GTGSEF
of SEQ ID
NO:221 5V40 J domain residues of SEQ ID
RKAYLKKCKEFHPDKGGDEEKMKKMNTLYK
NO: 221 KMEDGVKYAHQPDFGGFWDA
Linker residues 102- DIAAA
106 of SEQ ID
NO:221 CFTR(4508F) residues 107- MQRSPLEKASVVSKLFFSWTRPILRKGYRQ
1585 of SEQ ID RLELSDIYQIPSVDSADNLSEKLEREWDRE
NO: 221 LASKKNPKLINALRRCFFWRFMFYGIFLYL
Protein Region Sequence Amino Acid Sequence (N¨ to C¨ Identifier terminal) GEVTKAVQPLLLGRI IASYDPDNKEERS IA
IYLGIGLCLLF IVRTLLLHPAIFGLHHI GM
QMRIAMFSL I YKKTLKLS SRVLDKI S I GQL
VS LL SNNLNKFDEGLALAHFVWIAPLQVAL
LMGL IWELLQASAFCGLGFL IVLALFQAGL
GRMMMKYRDQRAGKI SERLVI T SEMIEN I Q
SVKAYCWEEAMEKMIENLRQTELKLTRKAA
YVRYFNSSAFFFSGFFVVFLSVLPYAL I KG
II LRKIFTT I SFCIVLRMAVTRQFPWAVQT
WYDSLGAINKIQDFLQKQEYKTLEYNLTTT
EVVMENVTAFWEEGFGELFEKAKQNNNNRK
TSNGDDSLFFSNFSLLGTPVLKDINFKIER
GQLLAVAGS TGAGKT SLLMVIMGELEP SEG
KIKHSGRI SFCSQFSWIMPGT IKENI I GVS
YDEYRYRSVI KACQLEED I SKFAEKDNIVL
GEGGITLSGGQRARI SLARAVYKDADLYLL
DSPFGYLDVLTEKEIFESCVCKLMANKTRI
LVTSKMEHLKKADKIL ILHEGSSYFYGTFS
ELQNLQPDFSSKLMGCDSFDQFSAERRNS I
LTETLHRFSLEGDAPVSWTETKKQSFKQTG
EFGEKRKNS I LNP INS IRKFS IVQKTPLQM
NGIEEDSDEPLERRLSLVPDSEQGEAILPR
I SVI STGPTLQARRRQSVLNLMTHSVNQGQ
NIHRKTTASTRKVSLAPQANLTELDIYSRR
LSQETGLE I SEE INEEDLKECFFDDMES IP
AVTTWNTYLRY I TVHKSL IFVL IWCLVIFL
AEVAASLVVLWLLGNTPLQDKGNSTHSRNN
SYAVI I TS T S SYYVFY IYVGVADTLLAMGF
FRGLPLVHTL I TVSKI LHHKMLHSVLQAPM
STLNTLKAGGILNRFSKDIAILDDLLPLT I
FDF IQLLL IVIGAIAVVAVLQPYIFVATVP
VIVAF IMLRAYFLQTSQQLKQLESEGRSP I
FTHLVTSLKGLWTLRAFGRQPYFETLFHKA
LNLHTANWFLYLSTLRWFQMRIEMIFVIFF
IAVTF ISILTTGEGEGRVGI I L TLAMNIMS
TLQWAVNSS I DVD S LMRSVSRVFKF I DMPT
EGKPTKSTKPYKNGQLSKVMI IENSHVKKD
DIWPSGGQMTVKDLTAKYTEGGNAILENI S
FS I SPGQRVGLLGRTGSGKSTLLSAFLRLL
NTEGEIQIDGVSWDS I TLQQWRKAFGVIPQ
KVF IF SGTFRKNLDPYEQWSDQE IWKVADE
VGLRSVIEQFPGKLDFVLVDGGCVLSHGHK
QLMCLARSVLSKAKILLLDEPSAHLDPVTY
QI IRRTLKQAFADCTVILCEHRIEAMLECQ
QFLVIEENKVRQYDS I QKLLNERS LFRQAI
SP SDRVKLFPHRNS SKCKSKPQ IAALKEET
EEEVQDTRL
To study the expression of the various CFTR protein constructs, the plasmids were transfected to HEK293 cells. Samples of cell lysates from two-day cultures of transfected cells were analyzed by immunoblotting with anti-V5 antibody. As shown in Figure 8B, neither the wild-type CFIR protein nor the mutant CFTR(4508F) protein expressed well in transfected cells. Fusion of either protein with a BAG3 domain (BAG-CFIR WT, BAG-CFTR 4508F) provided some enhancement of expression. In contrast, fusion with a J domain significantly enhanced the level of expression of both wild-type and mutant proteins (J-CFTR WT, 4508F). See, Figure 8B
Conclusion of Results The results of the above experiments clearly show that fusion with a J domain significantly enhances the level of expression of a protein of interest, including therapeutically useful proteins.
Example 3. Compositions and Methods for Enhancing Expression of Target Proteins of Interest Using an Unmodified Arrangement Expression vector plasmids were constructed for expressing fusion proteins for enhancing expression of specific proteins (target proteins). As described below, fusion proteins were usually linked to a standard epitope tag for easy identification or isolation using a corresponding anti-tag antibody and standard immunoblot (such as dot blot, Western blot) assays.
A DNA linker molecule having a nucleotide sequence containing various restriction enzyme sites for cloning heterologous DNA molecules was produced by annealing two single-stranded DNA
molecules having the sequences shown below (5' to 3'):
AGCTTGGTACCGGATCCGAATTCGATATCGCGGCCGCTCTCGAGTCTAGAGGGCC (SEQ
ID NO:187) and CTCTAGACTCGAGAGCGGCCGCGATATCGAATTCGGATCCGGTACCA (SEQ ID NO:188).
The annealed linker molecule was then inserted into plasmid pcDNA3 (catalogue no. V790-20, Invitrogen) digested with HindIII and ApaI downstream of a CMV promoter to yield the expression vector plasmid pcDNA' for use in mammalian host cells.
DNA molecules encoding the V5 epitope tag (GKPIPNPLLGLDST; SEQ ID NO:110) or the Flag epitope tag (DYKDDDDK; SEQ ID NO:111) were synthesized and inserted into plasmid pcDNA' digested with HindIII and KpnI. A double-stranded DNA molecule having the coding sequence for the V5 epitope tag with an N-terminal methionine, i.e., ATGGGTAAGCCTATCCCTAACCCTCTCCTCGGTCTCGATTCTACG (SEQ ID NO:189), was inserted into pcDNA' digested with XhoI and XbaI to yield plasmid V5-pcDNA'.
A DNA molecule having the coding sequence for the Flag epitope tag, i.e., GATTACAAGGATGACGATGACAAG (SEQ ID NO:190), was inserted into plasmid pcDNA' digested with XhoI and XbaI to yield plasmid Flag-pcDNA'.
To express IL13Ra2 receptor protein, a DNA molecule encoding an IL13Ra2 receptor protein was inserted into plasmid V5-pcDNA' digested with HindIII and KpnI.
To express TNR1 receptor protein, a DNA molecule encoding a TNRI receptor protein was inserted into plasmid V5-pcDNA' digested with HindIII and KpnI.
To express al anti-trypsin ("alAT"), a DNA molecule encoding an al anti-trypsin was inserted into plasmid V5-pcDNA' digested with HindIII and KpnI.
A DNA molecule encoding an Fc region polypeptide of a human IgG1 molecule was synthesized and inserted into V5-pcDNA' digested with XbaI and ApaI.
Unless indicated otherwise, a DNA molecule encoding a particular protein expression enhancing polypeptide was cloned into plasmid Flag-pcDNA' digested with EcoRI
and EcoRV to insert a DNA segment encoding the J domain of an Erdj3 J protein, or digested with KpnI and BamHI
to insert a DNA segment encoding the J domain of an Erdj5 J protein, to yield plasmid (J domain)-Flag-pcDNA', wherein "(J domain)" refers to the particular protein expression enhancing polypeptide specified in the examples below.
Unless indicated otherwise, each DNA molecule encoding a target binding domain for a corresponding target protein in the examples below was inserted into plasmid Flag-pcDNA' digested with NotI and XhoI.
Expression and Detection of Target Proteins in HEK293 cells Expression vector plasmids encoding various protein constructs were transfected into HEK293 cells with X-tremeGENE HP transfection reagent (catalogue no.
06365752001, Roche). As indicated in the examples below, a separate plasmid expressing the green fluorescent protein (GFP) was co-transfected with each expression vector plasmid encoding a fusion protein of the invention to monitor the transfection efficiency. Cultures of transfectant cells were incubated for two days, and cells were lysed in lysis buffer (10 mM Tris-HC1, pH8.0, 150 mM NaC1, 10 mM
EDTA, 2% SDS) containing 2 mM PMSF. After brief sonication, the sample was analyzed for express proteins using dot blot or Western immunoblot assays. For Western blot analysis, samples were boiled in SDS-sample buffer and run on polyacrylamide electrophoresis, followed by transfer of separated protein bands to membrane (PVDF membrane). The expression of GFP as an internal transfection control was detected using an anti-GFP antibody.
Expressed proteins in dot and Western blots were detected using a chemiluminescent signal.
Briefly, blots were reacted with a primary antibody that binds the particular epitope tag (e.g., V5 or Flag) carried by the proteins. After rinsing away unreacted primary antibody, a secondary, enzyme-linked antibody (e.g., horse radish peroxidase linked anti-IgG antibody) was allowed to react with primary antibody molecules bound to the blots. After rinsing, manufacturer's chemiluminescent reagent was added. Chemiluminescent signals in blots were captured on x-ray film. Where indicated, the images of the chemiluminescent signals were scanned with a densitometer and analyzed using the NIH ImageJ image processing program.
Cells expressing humanized anti-IL-8 antibody (CHO DP-12 clone, clone No.
1933; catalog No. CRL-12444) and plasmid p6G425V11N35A.choSD (catalog No. 209552) were purchased from the American Type Culture Collection (Manassas, Virginia).
Example 4. Enhanced Expression of Secreted IL13Ra2TF Protein in an Unmodified Arrangement The IL13 receptor, IL13Ra2 is a membrane protein that binds to interleukin-13 (IL13) and mediates allergic inflammation. The IL13Ra2 receptor protein is known to be an unstable protein in a mammalian cell due to the difficulties of protein folding (Genetic Engineering & Biotechnology News, 28(5) (2008)). Part of the expressed IL13Ra2 proteins is digested on the cell surface and shed into the extracellular space. This truncated form of IL13Ra2 (also referred to as "IL13Ra2TF") still possesses the ability to bind IL13, but cannot transmit a signal to the cell owing to the absence of transmembrane and cytoplasmic regions of the full-length IL13Ra2 protein.
Therefore, the truncated form of IL13Ra2 has been used as a type of decoy receptor to treat asthma by binding IL13 molecules without transducing a signal to the cell to set off an inflammatory response (Zhang, et al., J. Biol.
Chem., 272(14): 9474-80 (1997)). A genetically engineered truncated form of IL13Ra2 has been expressed in bacteria, however the protein aggregated into inclusion bodies, from which the protein was purified (Tang et al., Molec. Immunol. 39: 719-727 (2003)). However, it is known that one limitation to the expression of the IL13Ra2TF protein by transfected cells has been ascribed to inefficient folding of into their proper functional conformations. When proteins cannot fold into their proper conformation they are ushered to the proteasome for degradation and scavenging of amino acids. Accordingly, production of IL13Ra2TF molecules in transfected cells has recognized attendant limitations of expression and secretion of the protein (Lee et al., Cell Technol. for Cell Products, 29-39 (2007)).
This experiment studied the enhancement in the level of and secretion of the IL13Ra2TF protein using an alternative arrangement to the "modified"
arrangement described in Examples 1-3 in which a target protein of interest is modified by fusion to a protein expression enhancing polypeptide of the invention. In an "unmodified"
arrangement, a target protein of interest is "unmodified" in that it is not fused to a protein expression enhancing polypeptide of the invention, but instead is co-expressed with a fusion protein comprising a protein expression enhancing polypeptide linked to a target protein binding domain. Figure 9A shows a schematic diagram of this unmodified arrangement for enhancing expression of a target protein of interest. According to this scheme, a target protein of interest is bound by a target protein binding domain of the fusion protein, which also comprises a protein expression enhancing polypeptide domain. Presumably, binding of the target protein to the fusion protein brings the target protein into close proximity to the protein expression enhancing polypeptide domain, which in turn leads to enhanced expression of the target protein of interest.
Figure 9B shows a diagram of a nucleic acid construct in which a cDNA encoding an IL13Ra2TF protein is augmented at its 3' end with a nucleic acid encoding a V5 epitope tag. Figure 9C shows a diagram of a nucleic acid construct for a fusion protein of the invention. For this experiment, the fusion protein according to the invention comprised a J domain of the Erdj3 J protein as a protein expression enhancing polypeptide linked to an IL13 protein as a target binding domain.
The amino acid sequence of the V5-tagged IL13Ra2TF protein is shown in the table below.
Table 32. Amino Acid Sequence of a V5-Tagged IL13Ra2TF Protein.
Protein Region Sequence Amino Acid Sequence (N¨ to C¨ Identifier terminal) 123456789012345678901234567890 V5-tagged SEQ ID NO:222 MAFVCLAIGCLYTFLISTTFGCTSSSDTEI
IL13Ra2TF KVNPPQDFEIVDPGYLGYLYLQWQPPLSLD
protein HFKECTVEYELKYRNIGSETWKTIITKNLH
YKDGFDLNKGIEAKIHTLLPWQCTNGSEVQ
SSWAETTYWISPQGIPETKVQDMDCVYYNW
QYLLCSWKPGIGVLLDTNYNLFYWYEGLDH
ALQCVDYIKADGQNIGCRFPYLEASDYKDF
YICVNGSSENKPIRSSYFTFQLQNIVKPLP
PVYLTFTRESSCEIKLKWSIPLGPIPARCF
DYEIEIREDDTTLVTATVENETYTLKTTNE
TRQLCFVVRSKVNIYCSDDGIWSEWSDKQC
WEGEDLSKKGTGSEFDIAAALEGKPIPNPL
LGLDSTSRGPYSIVSPKC
IL13Ra2TF residues 1-339 MAFVCLAIGCLYTFLISTTFGCTSSSDTEI
of SEQ ID KVNPPQDFEIVDPGYLGYLYLQWQPPLSLD
NO:222 HFKECTVEYELKYRNIGSETWKTIITKNLH
YKDGFDLNKGIEAKIHTLLPWQCTNGSEVQ
SSWAETTYWISPQGIPETKVQDMDCVYYNW
QYLLCSWKPGIGVLLDTNYNLFYWYEGLDH
ALQCVDYIKADGQNIGCRFPYLEASDYKDF
YICVNGSSENKPIRSSYFTFQLQNIVKPLP
PVYLTFTRESSCEIKLKWSIPLGPIPARCF
DYEIEIREDDTTLVTATVENETYTLKTTNE
TRQLCFVVRSKVNIYCSDDGIWSEWSDKQC
WEGEDLSKK
Linker residues 340- GTGSEFDIAAALE
352 of SEQ ID
NO:222 V5 epitope residues 353- GKPIPNPLLGLDST
domain 366 of SEQ ID
NO : 222 C-terminal residues 367- SRGPYSIVSPKC
vector residues 378 of SEQ ID
NO : 222 The amino acid sequence of the IL13 protein as used in this experiment included a Flag epitope tag, a signal sequence, and 13 additional C-terminal amino acid residues from the expression vector used to express the protein as shown in the table below.
Table 33. Amino Acid Sequence of a Flag-Tagged 1L13 Protein.
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) Flag-tagged SEQ
ID NO:223 MGVKVLFALICIAVAEAGTGSEFDIAAALT
IL13 protein CLGGFASPGPVPPSTALRELIEELVNITQN
QKAPLCNGSMVWSINLTAGMYCAALESLIN
VSGCSAIEKTQRMLSGFCPHKVSAGQFSSL
HVRDTKIEVAQFVKDLLLHLKKLFREGQFN
LEGDYKDDDDKGSRGPYSIVSPKC
Signal Sequence residues 1-17 MGVKVLFALICIAVAEA
of SEQ ID
NO:223 Linker residues 18-28 GTGSEFDIAAA
of SEQ ID
NO:223 residues 29-150 LTCLGGFASPGPVPPSTALRELIEELVNIT
of SEQ ID
QNQKAPLCNGSMVWSINLTAGMYCAALESL
NO:223 INVSGCSAIEKTQRMLSGFCPHKVSAGQFS
SLHVRDTKIEVAQFVKDLLLHLKKLFREGQ
FN
Linker residues 151- LEG
153 of SEQ ID
NO:223 Flag epitope residues 154- DYKDDDDK
domain 161 of SEQ ID
NO:223 C-terminal residues 162- GSRGPYSIVSPKC
vector residues 174 of SEQ ID
NO:223 The amino acid sequence of a J domain-1L13 fusion protein included a Flag epitope tag as shown in the table below.
Table 34. Amino Acid Sequence of a Flag-Tagged Erdj3 J Domain-1L13 Fusion Protein.
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) Flag-tagged SEQ
ID NO:224 MAPQNLSTFCLLLLYLIGAVIAGRDFYKIL
J domain-1L13 GVPRSASIKDIKKAYRKLALQLHPDRNPDD
fusion protein PQAQEKFQDLGAAYEVLSDSEKRDIGGGSG
GSGGSGGAAALTCLGGFASPGPVPPSTALR
ELIEELVNITQNQKAPLCNGSMVWSINLTA
GMYCAALESLINVSGCSAIEKTQRMLSGFC
PHKVSAGQFSSLHVRDTKIEVAQFVKDLLL
HLKKLFREGQFNLEGDYKDDDDKGSRGPYS
IVSPKC
Erdj3 J domain residues 1-83 MAPQNLSTFCLLLLYLIGAVIAGRDFYKIL
of SEQ ID
GVPRSASIKDIKKAYRKLALQLHPDRNPDD
NO: 224 PQAQEKFQDLGAAYEVLSDSEKR
Linker residues 84-100 DIGGGSGGSGGSGGAAA
of SEQ ID
NO:224 Protein Region Sequence Amino Acid Sequence (N¨ to C¨ Identifier terminal) 123456789012345678901234567890 IL13 residues 101- LTCLGGFASPGPVPPSTALRELIEELVNIT
222 of SEQ ID QNQKAPLCNGSMVWSINLTAGMYCAALESL
NO: 224 INVSGCSAIEKTQRMLSGFCPHKVSAGQFS
SLHVRDTKIEVAQFVKDLLLHLKKLFREGQ
FN
Linker residues 223- LEG
225 of SEQ ID
NO:224 Flag epitope residues 226- DYKDDDDK
domain 233 of SEQ ID
NO:224 C-terminal residues 234- GSRGPYSIVSPKC
vector residues 246 of SEQ ID
NO:224 HEK293 cells were co-transfected with expression vectors for expressing the V5-tagged IL13Ra2TF and for expressing the J domain-1L13 fusion protein. Transfected cells were cultured for two days, and cell lysates and samples of cell media were harvested and analyzed by Western blot (immunoblot) assay using an anti-V5 antibody to detect secreted V5-tagged IL13Ra2TF. As shown in Figure 10, cells transfected with an expression vector for expressing the IL13Ra2TF protein alone expressed some protein in the cells (middle panel, lane 2, from the left) but only a very little, if any, IL13Ra2TF protein was detected in culture medium (top panel, lane 2, from the left). Co-expression of the IL13Ra2TF protein and its IL13 protein ligand resulted in some detectable expression of IL13Ra2TF protein in the transfected cells (middle panel, lane 3, from the left) and in culture medium (top panel, lane 3, from the left). This result is consistent with earlier reports that co-expression of IL13Ra2TF with its IL13 ligand improves secretion of the IL13Ra2TF (Lee et al., Cell Technol. for Cell Products, 29-39 (2007)). However, co-expression IL13Ra2TF with a J domain-1L13 fusion protein according to the invention further enhanced the level of expression of IL13Ra2TF within the cells (middle panel, lane 4, from the left) and dramatically enhanced the level of expression of secreted IL13Ra2TF protein (top panel, lane 4, from the left) as compared to expression of IL13Ra2TF alone (top panel, lane 2, from the left) or co-expression of IL13Ra2TF and IL13 ligand (top panel, lane 3, from the left). The results indicate that both stability and secretion of the IL13Ra2TF protein were improved by co-expression with a J domain-1L13 fusion protein of the invention.
Example 5. Enhanced Expression of Secreted IL13Ra2TF-Fc Fusion Protein in an Unmodified Arrangement As noted above, a truncated form of IL13Ra2 (IL13Ra2TF) comprises the extracellular domain of the IL13Ra2 receptor protein, including a functional IL13 ligand binding domain.
However, the production of IL13Ra2TF is also inefficient owing to difficulties in expression and secretion of the protein. One strategy that has been employed to generate more stable forms of therapeutically relevant proteins, and especially receptor proteins, is to prepare a fusion protein in which all or a functional portion of a protein of interest is linked to the constant domains of an immunoglobulin Fc domain. Such an Fc fusion protein format has been used to design a family of potentially useful drugs that provide a desired therapeutically relevant activity and, owing to the Fc domain, also exhibit an increased in vivo serum half-life, which in turn should reduce dosing frequencies. Within such Fc fusion proteins, a "protein of interest" domain (for example, the extracellular, ligand-binding domain of a receptor protein) retains its desired functional property (for example, ligand binding).
This experiment examined the effect on the level of expression of an Fc fusion protein (target protein) when the Fc fusion protein was co-expressed with a fusion protein of the invention in an unmodified arrangement. An IL13Ra2TF-Fc fusion protein was used as a representative example of an Fc fusion protein drug. The IL13Ra2TF-Fc fusion protein also possessed a V5 epitope tag between the IL13Ra2TF ("protein of interest") domain and the Fc domain for easy identification with an anti-V5 epitope antibody. See, an illustration of a DNA construct for the IL13Ra2TF-Fc fusion protein in Figure 11A. For this experiment, examples of fusion proteins according to the invention comprised a J domain of a J protein as a protein expression enhancing polypeptide domain linked to Protein A, which binds immunoglobulin Fc domains, as a target binding domain.
See, Figure 11B.
The amino acid sequence for the VS-tagged IL13Ra2TF-Fc fusion protein used in this experiment is shown in the table below.
Table 35. Amino Acid Sequence of a VS-Tagged IL13Ra2TF-Fc Fusion Protein.
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) V5-tagged SEQ ID NO:225 MAFVCLAIGCLYTFLISTTFGCTSSSDTEI
IL13Ra2TF-Fc KVNPPQDFEIVDPGYLGYLYLQWQPPLSLD
fusion protein HFKECTVEYELKYRNIGSETWKTIITKNLH
YKDGFDLNKGIEAKIHTLLPWQCTNGSEVQ
SSWAETTYWISPQGIPETKVQDMDCVYYNW
QYLLCSWKPGIGVLLDTNYNLFYWYEGLDH
ALQCVDYIKADGQNIGCRFPYLEASDYKDF
YICVNGSSENKPIRSSYFTFQLQNIVKPLP
PVYLTFTRESSCEIKLKWSIPLGPIPARCF
DYEIEIREDDTTLVTATVENETYTLKTTNE
TRQLCFVVRSKVNIYCSDDGIWSEWSDKQC
WEGEDLSKKGTGSEFDIAAALEGKPIPNPL
LGLDSTSRPKSCDKTHTCPPCPAPELLGGP
SVFLFPPKPKDTLMISRTPEVTCVVVDVSH
EDPEVKFNWYVDGVEVHNAKTKPREEQYNS
TYRVVSVLTVLHQDWLNGKEYKCKVSNKAL
PAPIEKTISKAKGQPREPQVYTLPPSRDEL
TKNQVSLTCLVKGFYPSDIAVEWESNGQPE
NNYKTTPPVLDSDGSFFLYSKLTVDKSRWQ
QGNVFSCSVMHEALHNHYTQKSLSLSPGK
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) IL13Ra2TF residues 1-339 MAFVCLAIGCLYTFLISTTFGCTSSSDTEI
of SEQ ID
KVNPPQDFEIVDPGYLGYLYLQWQPPLSLD
NO:225 HFKECTVEYELKYRNIGSETWKTIITKNLH
YKDGFDLNKGIEAKIHTLLPWQCTNGSEVQ
SSWAETTYWISPQGIPETKVQDMDCVYYNW
QYLLCSWKPGIGVLLDTNYNLFYWYEGLDH
ALQCVDYIKADGQNIGCRFPYLEASDYKDF
YICVNGSSENKPIRSSYFTFQLQNIVKPLP
PVYLTFTRESSCEIKLKWSIPLGPIPARCF
DYEIEIREDDTTLVTATVENETYTLKTTNE
TRQLCFVVRSKVNIYCSDDGIWSEWSDKQC
WEGEDLSKK
Linker residues 340- GTGSEFDIAAALE
352 of SEQ ID
NO:225 V5 epitope residues 353- GKPIPNPLLGLDST
domain 366 of SEQ ID
NO:225 Linker residues 367- SR
368 of SEQ ID
NO:225 Fc domain residues 369-PKSCDKTHTCPPCPAPELLGGPSVFLFPPK
599 of SEQ ID PKDTLMISRTPEVTCVVVDVSHEDPEVKFN
NO:225 WYVDGVEVHNAKTKPREEQYNSTYRVVSVL
TVLHQDWLNGKEYKCKVSNKALPAPIEKTI
SKAKGQPREPQVYTLPPSRDELTKNQVSLT
CLVKGFYPSDIAVEWESNGQPENNYKTTPP
VLDSDGSFFLYSKLTVDKSRWQQGNVFSCS
VMHEALHNHYTQKSLSLSPGK
In one aspect of this experiment, the level of expression of an IL13Ra2TF-Fc fusion protein was examined when co-expressed with a Protein A molecule. The Protein A
molecule was tagged with a Flag epitope tag for easy identification with a standard anti-Flag antibody. The amino acid sequence for a Flag-tagged Protein A is shown in the table below.
Table 36. Amino Acid Sequence of a Flag-Tagged Protein A.
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) Flag-tagged SEQ
ID NO:226 MGVKVLFALICIAVAEAGTGSEFDIAAAAD
Protein A
NKFNKEQQNAFYEILNMPNLNEEQRNGFIQ
protein SLKDDPSQSANVLGEAKKLNDSQAPKLEGD
YKDDDDKGSRGPYSIVSPKC
Signal Sequence residues 1-17 MGVKVLFALICIAVAEA
of SEQ ID
NO:226 Linker residues 18-28 GTGSEFDIAAA
of SEQ ID
NO:226 Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) 123456789012345678901234567890 Protein A residues 29-86 ADNKFNKEQQNAFYEILNMPNLNEEQRNGF
of SEQ ID IQSLKDDPSQSANVLGEAKKLNDSQAPK
NO:226 Linker residues 87-89 LEG
of SEQ ID
NO:226 Flag epitope residues 90-97 DYKDDDDK
domain of SEQ ID
NO:226 C-terminal residues 98-110 GSRGPYSIVSPKC
vector residues of SEQ ID
NO:226 An example of a fusion protein for enhancing expression of the IL13Ra2TF-Fc fusion protein possessed the J domain from the Erdj3 protein linked to Protein A. A Flag epitope tag was linked to the C-terminus of the Protein A domain. See illustration of DNA construct in Figure 11B. The amino acid sequence for the J domain-Protein A fusion protein is shown in the table below.
Table 37. Amino Acid Sequence of a Flag-Tagged Erdj3 J domain-Protein A Fusion Protein.
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) 123456789012345678901234567890 Flag-tagged SEQ ID NO:227 MAPQNLSTFCLLLLYLIGAVIAGRDFYKIL
Erdj3 J domain- GVPRSASIKDIKKAYRKLALQLHPDRNPDD
Protein A fusion PQAQEKFQDLGAAYEVLSDSEKRDIGGGSG
protein GSGGSGGAAAADNKFNKEQQNAFYEILNMP
NLNEEQRNGFIQSLKDDPSQSANVLGEAKK
LNDSQAPKLEGDYKDDDDKGSRGPYSIVSP
KC
J domain residues 1-83 MAPQNLSTFCLLLLYLIGAVIAGRDFYKIL
(from Erdj3) of SEQ ID GVPRSASIKDIKKAYRKLALQLHPDRNPDD
NO: 227 PQAQEKFQDLGAAYEVLSDSEKR
Linker residues 84-100 DIGGGSGGSGGSGGAAA
of SEQ ID
NO: 227 Protein A residues 101- ADNKFNKEQQNAFYEILNMPNLNEEQRNGF
158 of SEQ ID IQSLKDDPSQSANVLGEAKKLNDSQAPK
NO: 227 Linker residues 159- LEG
161 of SEQ ID
NO: 227 Flag epitope residues 162- DYKDDDDK
domain 169 of SEQ ID
NO: 227 C-terminal residues 170- GSRGPYSIVSPKC
vector residues 182 of SEQ ID
NO: 227 Another example of a fusion protein for enhancing expression of the IL13Ra2TF-Fc fusion protein possessed the J domain from the Erdj5 protein linked to Protein A. A
Flag epitope tag was linked to the C-terminus of the Protein A domain. See illustration of DNA
construct in Figure 11B.
The amino acid sequence for the Flag-tagged Erdj5 J domain-Protein A fusion protein is shown in the table below.
Table 38. Amino Acid Sequence of a Flag-Tagged Erdj5 J domain-Protein A Fusion Protein.
Protein Region Sequence Amino Acid Sequence (N¨ to C¨ Identifier terminal) Flag-tagged SEQ
ID NO:228 MGVWLNKDDYIRDLKRIILCFLIVYMAILV
Erdj5 J domain-GTDQDFYSLLGVSKTASSREIRQAFKKLAL
Protein A fusion KLHPDKNPNNPNAHGDFLKINRAYEVLKDE
protein DGSEFDIGGGSGGSGGSGGAAAADNKFNKE
QQNAFYEILNMPNLNEEQRNGFIQSLKDDP
SQSANVLGEAKKLNDSQAPKLEGDYKDDDD
KGSRGPYSIVSPKC
J domain residues 1-91 MGVWLNKDDYIRDLKRIILCFLIVYMAILV
(from Erdj5) of SEQ ID
GTDQDFYSLLGVSKTASSREIRQAFKKLAL
NO: 228 KLHPDKNPNNPNAHGDFLKINRAYEVLKDE
Linker residues 92-112 GSEFDIGGGSGGSGGSGGAAA
of SEQ ID
NO:228 Protein A residues 113-ADNKFNKEQQNAFYEILNMPNLNEEQRNGF
170 of SEQ ID IQSLKDDPSQSANVLGEAKKLNDSQAPK
NO:228 Linker residues 171- LEG
173 of SEQ ID
NO:228 Flag epitope residues 174- DYKDDDDK
domain 181 of SEQ ID
NO:228 C-terminal residues 182- GSRGPYSIVSPKC
vector residues 194 of SEQ ID
NO:228 HEK293 cells were transfected with expression vector plasmids to compare levels of expression in culture medium of IL13Ra2TF-Fc fusion protein expressed alone, IL13Ra2TF-Fc fusion protein co-expressed with Protein A ("Protein A Only"), IL13Ra2TF-Fc fusion protein co-expressed with the Erdj3 J domain-Protein A fusion protein ("J-Protein A"), and IL13Ra2TF-Fc fusion protein co-expressed with the Erdj5 J domain-Protein A fusion protein ("J2-Protein A").
Transfected cells were cultured for two days, and samples of cell media were harvested and analyzed by Western blot (immunoblot) assay using an anti-V5 antibody to detect secreted VS-tagged IL13Ra2TF-Fc fusion protein. Figure 12A shows x-ray film images of chemiluminescent signals of the Western blot analysis of culture media. Lane 1 of Figure 12A is culture medium of a "mock"
culture of cells transfected with expression vector lacking a structural gene for expressing any protein PCT/US2013/073442 08.04.2015 (empty vector). When expressed alone (lane 2), some IL13Ra2TF-Fc fusion protein was detected in the medium. As shown in lane 3 of the Figure 12A, co-expression with Protein A
(Protein A Only) provided no significant enhancement in the level of IL13Ra2TF-Fc fusion protein secreted to the medium. However, co-expression with the either J domain-Protein A fusion protein significantly enhanced the level of expression of IL13Ra2TF-Fc fusion protein secreted into the medium (lanes 4 and 5 of Figure 12A). Importantly, the fact that co-expression of IL13Ra2TF-Fc with Protein A alone did not affect the secretion of IL13Ra2TF-Fc (lane 3) indicates that: (1) the J domain of a J domain-Protein A fusion protein is essential for enhancing the level of expression of secreted IL13Ra2TF-Fc and (2) the Protein A domain of the J domain-Protein A fusion protein is essential for providing the target specificity for enhancing the level of expression of the secreted IL13Ra2TF-Fc target protein. .
=
The results of a densitometry analysis of the chemiluminescent signals in the lanes of Figure 12A using the NTH ImageJ image processing program are shown in the respective bar graphs in Figure 12B. The bar graphs in Figure 12B clearly show that co-expression of IL13Ra2TF-Fc with either J domain-Protein A fusion protein (bar graphs 4 and 5) significantly enhanced the level of expression of secreted IL13Ra2TF-Fc as compared to expression of IL13Ra2TF-Fc alone (bar graph 2) or co-expression of IL13Ra2TF-Fc with Protein A alone (bar graph 3).
That the enhanced level of expression of secreted IL13Ra2TF-Fc protein in Figures 12A and 12B was dependent on the specificity of the target binding domain of the J
domain-Protein A fusion protein for the Fc domain is supported by the results shown in Figure 12C. As shown in the Western blot analysis of culture media in Figure 12C, no significant expression of secreted IL13Ra2TF (no Fc domain) was detected in culture media when transfected cells expressed the IL13Ra2TF protein alone (lane 1), co-expressed the IL13Ra2TF protein with the J-Protein A fusion protein (lane 2), or co-expressed the IL13Ra2TF protein with Protein A alone (Protein A Only, lane 3).
The results of a densitometry analysis of the chemiluminescent signals in the lanes of Figure 12C using the NIH
ImageJ image processing program are shown in the respective bar graphs in Figure 12D.
Example 6. Enhanced Expression of an Additional Secreted Fc Fusion Proteins in an Unmodified Arrangement A series of experiments were performed to test and compare the effectiveness of a J domain-Protein A fusion protein of the invention to enhance several different Fc fusion proteins. The results are of a Western blot analysis of culture media from cultures of transfected cells are shown in Figure 13.
Example 6.1. Enhanced Expression of a Secreted IL13Ra2TF-Fc Fusion Protein Consistent with above results in Example 5, co-expression of the IL13Ra2TF-Fc protein with the Erdj3 J domain-Protein A fusion protein in transfected cells significantly enhanced the level of expression of IL13Ra2TF-Fc protein secreted into the culture medium (see, lane 2 of 113 =
=
AMENDED SHEET - IPEA/US
PCT/US2013/073442 08.04.2015 Figure 13A-1) as compared to that observed for transfeeted cells expressing the 11,13Ra2TF-Fc protein alone (lane 1 of Figure 13A-1). The significant enhancement in the level of expression of secreted IL13Ra2TF-Fc protein is also clear from the results of a densitometry analysis of the chemiluminescent signals in Figure 13A-1 using the NIB ImageJ image processing program are shown in the respective bar graphs in Figure 13A-2.
Example 6.2. Enhanced Expression of a Secreted TNFRITF-Fc Fusion Protein Tumor necrosis factor-a (TNF-a) is a major cytokine that binds the TNF-a receptor (TNFR1) and induces an inflammatory response that is involved in a number of autoimmune diseases, such as rheumatoid arthritis, Crohn's disease, and psoriasis. The truncated protein of the TNF-a receptor (TNFR1TF) is used as a decoy receptor to bind to TNF-a and thereby inhibit TNF-a activity.
Etanercept (commercially available as ENBREL , Amgen) is a TNF-a blocker in which a truncated form of TNFR is fused to an Fc domain (TNFRITF-Fc). The TNFRITF domain of the molecule provides the desired TNF-a binding specificity, and the immunoglobulin Fe domain is believed to add in vivo stability to the drug circulating in a patient.
The TNFR1TF-Fc fusion target protein used in this experiment also possessed a V5 epitope tag between the TNFR1 and Pc domains. The amino acid sequence for the TNFR1TF-Fe fusion protein used in this experiment is shown in the table below.
Table 39. Amino Acid Sequence of TNFR1TF-Fc Protein.
Protein Region Sequence Amino Acid Sequence (N¨ to C¨ Identifier terminal) V5-tagged SEQ ID NO:229 MGLSTVPDLLLPLVLLELLVGIYPSGVIGL
TNFR1TF protein VPHLGDREKRDSVCPQGKYIHPQNNSICCT
KCHKGTYLYNDCPGPGQDTDCRECESGSFT
ASENHLRHCLSCSKCRKEMGQVEISSCTVD
RDTVCGCRKNQYRHYWSENLFQCFNCSLCL
NGTVHLSCQEKQNTVCTCHAGFFLRENECV
SCSNCKKSLECTKLCLPQIENVKGTEDSGT
TGTGSEFDIAAALEGKPIPNPLLGLDSTSR
PKSCDKTHTCPPCPAPELLGGPSVFLFPPK
PKDTLMISRTPEVTCVVVDVSHEDPEVKFN
WYVDGVEVHNAKTKPREEQYNSTYRVVSVL
TVLHQDWLNGKEYKCKVSNKALPAPIEKTI
SKAKGQPREPQVYTLPPSRDELTKNQVSLT
CLVKGFYPSDIAVEWESNGQPENNYKTTPP
VLDSDGSFFLYSKLTVDKSRWQQGNVFSCS
VMHEALHNHYTQKSLSLSPGK
TNFRITF
residues 1-211 MGLSTVPDLLLPLVLLELLVGIYPSGVIGL
of SEQ ID
VPHLGDREKRDSVCPQGKYIHPQNNSICCT
NO :229 KCHKGTYLYNDCPGPGQDTDCRECESGSFT
ASENHLRHCLSCSKCRKEMGQVEISSCTVD
RDTVCGCRKNQYRHYWSENLFQCFNCSLCL
NGTVHLSCQEKQNTVCTCHAGFFLRENECV
SCSNCKKSLECTKLCLPQIENVKGTEDSGT
=
AMENDED SHEET - IPEA/US
=
PCT/US13/73442 03-10-2014 PCT/US2013/073442 08.04.2015 Protein Region Sequence Amino Acid Sequence (N¨ to C¨ Identifier terminal) 123456789012345678901234567890 Linker residues 212- GTGSEFDIAAALE
224 of SEQ ID
NO:229 V5 epitope residues 225- GKPIPNPLLGLDST
domain 238 of SEQ ID
NO:229 Linker residues 239- SR
240 of SEQ ID
NO:229 Fc domain residues 241- PKSCDKTHTCPPCPAPELLGGPSVFLFPPK
471 of SEQ ID PKDTLMISRTPEVTCVVVDVSHEDPEVKFN
NO :229 WYVDGVEVHNAKTKPREEQYNSTYRVVSVL
TVLHQDWLNGKEYKCKVSNKALPAPIEKTI
SKAKGQPREPQVYTLPPSRDELTKNQVSLT
CLVKGFYPSDIAVEWESNGQPENNYKTTPP
VLDSDGSFFLYSKLTVDKSRWQQGNVFSCS
VMHEALHNHYTQKSLSLSPGK
Figure 13B-1 shows x-ray film images of chemiluminescent signals of a Western blot analysis of culture media from transfected cells expressing TNFR1TF-Fc fusion protein alone (lane 1) or co-expressing TNFRITF-Fc fusion protein and the Erdj3 J domain-Protein A fusion protein described above (lane 2). The results show a significant enhancement in the level of expression of secreted TNFRITF-Fc fusion protein in transfected cells co-expressing TNFRITF-Fc fusion protein and the Erdj3 J domain-Protein A fusion protein as compared to the level of TNER1TF-Fc fusion protein =
expressed in the absence of the J domain-Protein A fusion protein. The significant enhancement in the level of expression of secreted TNER1TP-Fc fusion protein is also clear from the results of a dcnsitometry analysis of the signals in the lanes in Figure 13B-1 using the NLEI ImageJ image processing program as shown in the respective bar graphs in Figure 13B-2.
Example 6.3. Enhanced Expression of a Secreted alAT-Fc Fusion Protein The al anti-trypsin protein (alAT) is secreted from the liver into the circulatory system. The function of alAT is to protect tissues, particularly lung tissue, from excessive protease activities. The lung tissue of patients with al anti-trypsin deficiency can become severely damaged by proteases.
Such patients may develop emphysema, asthma, and/or chronic obstructive pulmonary disease (COPD). Currently al AT (purified from human serum) is used for the treatment of patients with al anti-trypsin deficiency. This treatment is expensive, and patients that receive the purified al AT may be at risk of contracting pathogens present in the human serum.
The target alAT-Fc fusion protein used in this experiment also possessed a V5 epitope tag between the alAT and Fc domains. The amino acid sequence for the al AT-Fc fusion protein (alAT-Fc) used in this experiment is shown in the table below.
AMENDED SHEET - IPEA/US
Table 40. Amino Acid Sequence of a V5-Tagged a1AT-Fc Fusion Protein.
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) V5-tagged a1AT- SEQ ID
NO:230 MPSSVSWGILLLAGLCCLVPVSLAEDPQGD
Fc fusion AAQKTDTSHHDQDHPTFNKITPNLAEFAFS
protein LYRQLAHQSNSTNIFFSPVSIATAFAMLSL
GTKADTHDEILEGLNFNLTEIPEAQIHEGF
QELLRTLNQPDSQLQLTTGNGLFLSEGLKL
VDKFLEDVKKLYHSEAFTVNFGDTEEAKKQ
INDYVEKGTQGKIVDLVKELDRDTVFALVN
YIFFKGKWERPFEVKDTEEEDFHVDQVTTV
KVPMMKRLGMFNIQHCKKLSSWVLLMKYLG
NATAIFFLPDEGKLQHLENELTHDIITKFL
ENEDRRSASLHLPKLSITGTYDLKSVLGQL
GITKVFSNGADLSGVTEEAPLKLSKAVHKA
VLTIDEKGTEAAGAMFLEAIPMSIPPEVKF
NKPFVFLMIEQNTKSPLFMGKVVNPTQKGT
GSEFDIAAALEGKPIPNPLLGLDSTSRPKS
CDKTHTCPPCPAPELLGGPSVFLFPPKPKD
TLMISRTPEVTCVVVDVSHEDPEVKFNWYV
DGVEVHNAKTKPREEQYNSTYRVVSVLTVL
HQDWLNGKEYKCKVSNKALPAPIEKTISKA
KGQPREPQVYTLPPSRDELTKNQVSLTCLV
KGFYPSDIAVEWESNGQPENNYKTTPPVLD
SDGSFFLYSKLTVDKSRWQQGNVFSCSVMH
EALHNHYTQKSLSLSPGK
a1AT residues of SEQ ID
AAQKTDTSHHDQDHPTFNKITPNLAEFAFS
NO: 230 LYRQLAHQSNSTNIFFSPVSIATAFAMLSL
GTKADTHDEILEGLNFNLTEIPEAQIHEGF
QELLRTLNQPDSQLQLTTGNGLFLSEGLKL
VDKFLEDVKKLYHSEAFTVNFGDTEEAKKQ
INDYVEKGTQGKIVDLVKELDRDTVFALVN
YIFFKGKWERPFEVKDTEEEDFHVDQVTTV
KVPMMKRLGMFNIQHCKKLSSWVLLMKYLG
NATAIFFLPDEGKLQHLENELTHDIITKFL
ENEDRRSASLHLPKLSITGTYDLKSVLGQL
GITKVFSNGADLSGVTEEAPLKLSKAVHKA
VLTIDEKGTEAAGAMFLEAIPMSIPPEVKF
NKPFVFLMIEQNTKSPLFMGKVVNPTQK
Linker residues 419- GTGSEFDIAAALE
431 of SEQ ID
NO: 230 V5 epitope residues 432- GKPIPNPLLGLDST
domain 445 of SEQ ID
NO:230 Linker residues 446- SR
447 of SEQ ID
NO:230 Fc domain residues 448-PKSCDKTHTCPPCPAPELLGGPSVFLFPPK
678 of SEQ ID PKDTLMISRTPEVTCVVVDVSHEDPEVKFN
NO: 230 WYVDGVEVHNAKTKPREEQYNSTYRVVSVL
TVLHQDWLNGKEYKCKVSNKALPAPIEKTI
PCT/US2013/073442 08.04.2015 Protein Region Sequence Amino Acid Sequence (14¨ to C¨ Identifier terminal) 123456789012345678901234567890 SKAKGQPREPQVYTLPPSRDELTKNQVSLT
CLVKGFYPSDIAVEWESNGQPENNYKTTPP
VLDSDGSFFLYSKLTVDKSRWQQGNVFSCS
VMHEALHNHYTQKSLSLSPGK
Figure 13C-1 shows X-ray film images of chemiluminescent signals of a Western blot analysis of culture media from transfected cells expressing alAT-Fc fusion protein alone (lane 1) or =
co-expressing alAT-Fc fusion protein and the Erdj3 J domain-Protein A fusion protein described above (lane 2). The results show a significant enhancement in the level of secreted alAT-Fc fusion protein (lane 2) as compared to the level of alAT-Fc fusion protein expressed in the absence of the J
domain-Protein A fusion protein (lane 1). The significant enhancement in the level of expression of secreted alAT-Fc fusion protein is also clear from the results of a densitometry analysis of the signals in the lanes in Figure 13C-1 using the N11-1 ImageJ image processing program as shown in the respective bar graphs in Figure 13C-2.
Example 7. Enhancement of Expression of Secreted IgG1 Antibody Molecules in an Unmodified Arraneement The above studies showed that expression and secretion of Pc-fusion proteins were significantly enhanced by co-expression of a J domain-Protein A fusion protein. Protein A is a well-known example of a protein that binds to immunoglobulin Pc regions. This study examined whether fusion of other proteins that are known to bind immunoglobulin domains with a J domain of a J
protein can enhance the expression level of a secreted target antibody.
In this study, a humanized IgG1 anti-1L8 antibody was used as a target antibody protein. The expression levels of the secreted anti-1L8 antibody were examined in the presence and absence of various J domain fusion proteins as explained below.
In one aspect of this experiment, the level of expression of the anti-1L8 antibody was examined when co-expressed with a Protein A molecule, which is known to bind the immunoglobulin Fc domain. The Protein A molecule was the same Flag-tagged Protein A described in Example 5, above.
In another aspect of this experiment, the level of expression of the anti-1L8 antibody was examined when co-expressed with a Protein L molecule, which is known to bind antibody light chains. As with the Protein A molecule described above, the Protein L molecule used in this experiment was tagged with a Flag epitope tag for easy identification with a standard anti-Flag antibody. The amino acid sequence for a Flag-tagged Protein L is shown in the table below.
AMENDED SHEET - IPEA/US
Table 41. Amino Acid Sequence of a Flag-Tagged Protein L.
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) 123456789012345678901234567890 Flag-tagged SEQ ID NO:231 MGVKVLFALICIAVAEAGTGSEFDIAAAVT
Protein L IKANLIFADGKTQTAEFKGTFEEATAEAYR
protein YADLLAKENGEYTADLEDGGYTINIKFAKE
TPETPEEPKEELEGDYKDDDDKGSRGPYSI
VSPKC
Signal Sequence residues 1-17 MGVKVLFALICIAVAEA
of SEQ ID
NO:231 Linker residues 18-28 GTGSEFDIAAA
of SEQ ID
NO:231 Protein L residues 29-101 VTIKANLIFADGKTQTAEFKGTFEEATAEA
of SEQ ID YRYADLLAKENGEYTADLEDGGYTINIKFA
NO: 231 KETPETPEEPKEE
Linker residues 102- LEG
104 of SEQ ID
NO:231 Flag epitope residues 105- DYKDDDDK
domain 112 of SEQ ID
NO:231 C-terminal residues 113- GSRGPYSIVSPKC
vector residues 125 of SEQ ID
NO:231 The amino acid sequence of an Erjd3 J domain-Protein L fusion protein included a Flag epitope tag as shown in the table below.
Table 42. Amino Acid Sequence of a Flag-Tagged Erdj3 J domain-Protein L Fusion Protein.
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) 123456789012345678901234567890 Flag-tagged SEQ ID NO:232 MAPQNLSTFCLLLLYLIGAVIAGRDFYKIL
Erdj3 J domain- GVPRSASIKDIKKAYRKLALQLHPDRNPDD
Protein L fusion PQAQEKFQDLGAAYEVLSDSEKRDIGGGSG
protein GSGGSGGAAAVTIKANLIFADGKTQTAEFK
GTFEEATAEAYRYADLLAKENGEYTADLED
GGYTINIKFAKETPETPEEPKEELEGDYKD
DDDKGSRGPYSIVSPKC
J domain residues 1-83 MAPQNLSTFCLLLLYLIGAVIAGRDFYKIL
(from Erdj3) of SEQ ID GVPRSASIKDIKKAYRKLALQLHPDRNPDD
NO:232 PQAQEKFQDLGAAYEVLSDSEKR
Linker residues 84-100 DIGGGSGGSGGSGGAAA
of SEQ ID
NO:232 Protein L residues 101- VTIKANLIFADGKTQTAEFKGTFEEATAEA
173 of SEQ ID YRYADLLAKENGEYTADLEDGGYTINIKFA
NO:232 KETPETPEEPKEE
Linker residues 174- LEG
176 of SEQ ID
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) 123456789012345678901234567890 NO:232 Flag epitope residues 177- DYKDDDDK
domain 184 of SEQ ID
NO:232 C-terminal residues 185- GSRGPYSIVSPKC
vector residues 197 of SEQ ID
NO:232 The amino acid sequence of the IL8 protein used in this experiment included a Flag epitope tag, a signal sequence, and 13 additional C-terminal amino acid residues from the expression vector used to express the protein as shown in the table below.
Table 43. Amino Acid Sequence of a Flag-Tagged IL8 Protein.
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) 123456789012345678901234567890 Flag-tagged IL8 SEQ ID NO:233 MGVKVLFALICIAVAEAGTGSEFDIAAASA
protein KELRCQCIKTYSKPFHPKFIKELRVIESGP
HCANTEIIVKLSDGRELCLDPKENWVQRVV
EKFLKRAENSLEGDYKDDDDKGSRGPYSIV
SPKC
Signal Sequence residues 1-17 MGVKVLFALICIAVAEA
of SEQ ID
NO:233 Linker residues 18-28 GTGSEFDIAAA
of SEQ ID
NO:233 residues 29-100 SAKELRCQCIKTYSKPFHPKFIKELRVIES
of SEQ ID GPHCANTEIIVKLSDGRELCLDPKENWVQR
NO:233 VVEKFLKRAENS
Linker residues 101- LEG
103 of SEQ ID
NO:233 Flag epitope residues 104- DYKDDDDK
domain 111 of SEQ ID
NO:233 C-terminal residues 112- GSRGPYSIVSPKC
vector residues 124 of SEQ ID
NO:233 The amino acid sequence of an Erdj3 J domain-1L8 fusion protein included a Flag epitope tag as shown in the table below.
Table 44. Amino Acid Sequence of a Flag-Tagged Erdj3 J domain-1L8 Fusion Protein.
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) 123456789012345678901234567890 Flag-tagged SEQ ID NO:234 MAPQNLSTFCLLLLYLIGAVIAGRDFYKIL
Erdj3 J domain- GVPRSASIKDIKKAYRKLALQLHPDRNPDD
IL8 fusion PQAQEKFQDLGAAYEVLSDSEKRDIGGGSG
protein GSGGSGGAAASAKELRCQCIKTYSKPFHPK
FIKELRVIESGPHCANTEIIVKLSDGRELC
LDPKENWVQRVVEKFLKRAENSLEGDYKDD
DDKGSRGPYSIVSPKC
J domain residues 1-83 MAPQNLSTFCLLLLYLIGAVIAGRDFYKIL
(from Erdj3) of SEQ ID GVPRSASIKDIKKAYRKLALQLHPDRNPDD
NO: 234 PQAQEKFQDLGAAYEVLSDSEKR
Linker residues 84-100 DI GGGSGGSGGSGG AAA
of SEQ ID
NO:234 IL8 residues 101- SAKELRCQCIKTYSKPFHPKFIKELRVIES
172 of SEQ ID GPHCANTEIIVKLSDGRELCLDPKENWVQR
NO:234 VVEKFLKRAENS
Linker residues 173- LEG
175 of SEQ ID
NO:234 Flag epitope residues 176- DYKDDDDK
domain 183 of SEQ ID
NO:234 C-terminal residues 184- GSRGPYSIVSPKC
vector residues 196 of SEQ ID
NO:234 HEK293 cells were transfected with an expression plasmid for expressing anti-1L8 antibody alone, co-expressing anti-1L8 antibody and Protein A (Protein A Only), co-expressing anti-1L8 antibody and an Erdj3 J domain-Protein A fusion protein of the invention (J-Protein A), co-expressing anti-1L8 antibody and Protein L (Protein L Only), co-expressing anti-1L8 antibody and an Erdj3 J
domain-Protein L fusion protein of the invention (J-Protein L), co-expressing anti-1L8 antibody and its IL8 ligand (IL8), co-expressing an Erdj3 J domain-1L8 ligand fusion protein of the invention (J-1L8), expressing the Erdj3 J-Protein A fusion protein of the invention alone (J-Protein A), expressing the Erdj3 J domain-Protein L fusion protein of the invention alone (J-Protein L), and expressing the Erdj3 J domain-1L8 ligand fusion protein of the invention alone (J-1L8).
Expression of the anti-1L8 antibody in culture media was analyzed by dot blot assay using an anti-human IgG antibody (anti-hIgG antibody, catalog no. AP112P, Millipore).
As shown in the dot blots of culture media in Figure 14A, co-expression in transfected cells of the anti-1L8 antibody with a J domain-Protein A fusion protein (lane 4), with a J domain-Protein L
fusion protein (lane 6), or with a J domain-1L8 fusion protein (lane 8) significantly enhanced the level of expression of anti-1L8 antibody secreted into the culture medium as compared to the level of the antibody expressed in transfected cells expressing the anti-1L8 antibody alone (lane 2), co-expressing with Protein A alone (lane 3, Protein A Only), co-expressing Protein L alone (lane 5, Protein L Only), or co-expressing IL8 ligand alone (lane 7). No signal was detected in culture media of transfected cells expressing the J domain-Protein A fusion protein alone (lane 9, J-Protein A), the J domain-Protein L fusion protein alone (lane 10, J-Protein L), or expressing the J
domain-1L8 fusion protein alone (lane 10, J-1L8), indicating that all three fusion proteins specifically targeted and enhanced the co-expressed anti-1L8 antibody.
The results of a densitometry analysis of the signals in the lanes in Figure 14A using the NIH
ImageJ image processing program are shown in the respective bar graphs in Figure 14B. The results of this series of experiments clearly show that co-expression of the targeted anti-1L8 antibody with a fusion protein of the invention comprising a protein expression enhancing polypeptide (here: Erdj3 J
domain) linked to a target binding domain (here: Protein A, Protein L, or IL8) significantly enhanced the expression of secreted anti-1L8 antibody as compared to co-expression of the antibody with the unfused target binding domain protein alone (Protein G only, Protein L only, or IL8 only).
Example 8. Enhancement of Established Expression in CHO-DP12 Producing Cell Line Using an Unmodified Arrangement This example examined whether a fusion protein of the invention could be used to improve the level of expression of a target protein already being produced in an established commercially relevant production cell line. For this experiment a CHO-DP12 cell line was used that stably expresses a humanized anti-1L8 IgG1 antibody as obtained from the American Type Culture Collection (accession no. CRL-124444, American Type Culture Collection, Manassas, Virginia) along with an expression vector plasmid for expressing the anti-1L8 antibody (accession no. 209552, ATCC, Manassas, Virginia). The fusion protein of the invention was that Erdj3 J domain-Protein A
fusion protein described above. Cells of the CHO-DP12 production cell line were transfected with an expression vector carrying an operably linked structural gene encoding the Erdj3 J domain-Protein A
fusion protein. The transfection efficiency was not as high with the CHO-DP12 cells as compared with HEK293 cells. Nevertheless, as shown in the dot blot assays in Figure 15A, co-expression of the humanized antibody with the J domain-Protein A fusion protein significantly enhanced the level of expression of the antibody secreted into the culture medium (lane 3) as compared to the level of the antibody expressed in the absence of the J domain-Protein A fusion protein (lane 2, none).
The results of a densitometry analysis of the chemiluminescent signals in the dot blots in the lanes in Figure 15A using the NIH ImageJ image processing program are shown in the respective bar graphs in Figure 15B. The results indicate that co-expression of the antibody with the J domain-Protein A fusion protein (bar graph 3) significantly enhanced expression of the secreted antibody, providing an approximately four to five-fold greater enhancement in the level of expression, as compared to that obtained when the antibody was expressed in the absence of the J domain-Protein A
fusion protein (bar graph 2).
The results indicate that a fusion protein of the invention can be employed to significantly enhance the level of production of a protein that is already being stably expressed in an established production cell line.
Example 9. Other Fusion Proteins for Enhancing Expression of Secreted Fc-Containing Molecules in an Unmodified Arrangement Example 9.1. Fusion Proteins Comprising Fc Binding Domains from Additional Protein Species This example provides a series of experiments to test various fusion proteins comprising a J
domain (as a protein expression enhancing polypeptide domain) linked to any of a variety of polypeptides (as the target binding domain) that have been reported to bind the Fc region of antibody molecules. The various J domain fusion proteins were then tested and compared for their ability to enhance levels of expression of the IL13Ra2TF-Fc fusion protein as described in Example 5 above that was secreted into medium of transfected HEK293 cells.
The J-Protein A fusion protein of the invention used in this example is the Erdj3-Protein A
fusion protein described in Example 5 above.
In another fusion protein used in the experiments described herein, the J
domain from the Erdj3 J protein was linked to Protein G, which is known to bind certain immunoglobulin Fc domains.
A Flag epitope tag was linked to the C-terminus of the Protein G domain as shown for the J-Protein A
fusion protein in Example 5 and Figure 11B. The amino acid sequence for a Flag-tagged J domain-Protein G fusion protein of the invention is shown in the table below.
Table 45. Amino Acid Sequence of a Flag-Tagged Erdj3 J domain-Protein G Fusion Protein.
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) 12345678 9012345678 9012345678 90 Flag-tagged SEQ ID N0:235 MAPQNLSTFCLLLLYLIGAVIAGRDFYKIL
Erdj3 J domain- GVPRSASIKDIKKAYRKLALQLHPDRNPDD
Protein G fusion PQAQEKFQDLGAAYEVLSDSEKRDIGGGSG
protein GSGGSGGAAATYKLVINGKTLKGETTTEAV
DAATAEKVFKQYANDNGVDGEWTYDDATKT
FTVTEKPEVIDASELTPAVTLEGDYKDDDD
KGSRGPYSIVSPKC
J domain residues 1-83 MAPQNLSTFCLLLLYLIGAVIAGRDFYKIL
(from Erdj3) of SEQ ID GVPRSASIKDIKKAYRKLALQLHPDRNPDD
NO:235 PQAQEKFQDLGAAYEVLSDSEKR
Linker residues 84-100 DIGGGSGGSGGSGGAAA
of SEQ ID
NO:235 Protein G residues 101- TYKLVINGKTLKGETTTEAVDAATAEKVFK
170 of SEQ ID QYANDNGVDGEWTYDDATKTFTVTEKPEVI
NO:235 DASELTPAVT
Linker residues 171- LEG
173 of SEQ ID
NO:235 Flag epitope residues 174- DYKDDDDK
domain 181 of SEQ ID
NO:235 C-terminal residues 182- GSRGPYSIVSPKC
vector residues 194 of SEQ ID
NO:235 In another fusion protein used in the experiments described herein, the J
domain from the Erdj3 J protein was linked to a human FcR (hFcR) receptor protein, which is a receptor that binds certain immunoglobulin Fc domains. A Flag epitope tag was linked to the C-terminus of the hFcR
domain as shown for the J-Protein A fusion protein in Example 5 and Figure 11B. The amino acid sequence for a Flag-tagged J domain-hFcR fusion protein is shown in the table below.
Table 46. Amino Acid Sequence of a Flag-Tagged Erdj3 J Domain-hFcR Fusion Protein.
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) Flag-tagged SEQ
ID NO:236 MAPQNLSTFCLLLLYLIGAVIAGRDFYKIL
Erdj3 J domain-GVPRSASIKDIKKAYRKLALQLHPDRNPDD
hFcR fusion PQAQEKFQDLGAAYEVLSDSEKRDIGGGSG
protein GSGGSGGAAAAVITLQPPWVSVFQEETVTL
HCEVLHLPGSSSTQWFLNGTATQTSTPSYR
ITSASVNDSGEYRCQRGLSGRSDPIQLEIH
RGWLLLQVSSRVFTEGEPLALRCHAWKDKL
VYNVLYYRNGKAFKFFHWNSNLTILKTNIS
HNGTYHCSGMGKLEGDYKDDDDKGSRGPYS
IVSPKC
J domain residues 1-83 MAPQNLSTFCLLLLYLIGAVIAGRDFYKIL
(from Erdj3) of SEQ ID
GVPRSASIKDIKKAYRKLALQLHPDRNPDD
NO:236 PQAQEKFQDLGAAYEVLSDSEKR
Linker residues 84-100 DIGGGSGGSGGSGGAAA
of SEQ ID
NO:236 hFcR
residues 101- AVITLQPPWVSVFQEETVTLHCEVLHLPGS
252 of SEQ ID
SSTQWFLNGTATQTSTPSYRITSASVNDSG
NO:236 EYRCQRGLSGRSDPIQLEIHRGWLLLQVSS
RVFTEGEPLALRCHAWKDKLVYNVLYYRNG
KAFKFFHWNSNLTILKTNISHNGTYHCSGM
GK
Linker residues 253- LEG
255 of SEQ ID
NO:236 Flag epitope residues 256- DYKDDDDK
domain 263 of SEQ ID
NO:236 C-terminal residues 264- GSRGPYSIVSPKC
vector residues 276 of SEQ ID
NO:236 In another fusion protein used in the experiments described herein, the J
domain from the Erdj3 J protein was linked to the Macaca mulatta rhadinovirus FcR receptor protein (vFcR), which is a receptor that binds certain immunoglobulin Fc domains. A Flag epitope tag was linked to the C-terminus of the vFcR domain as shown for the J-Protein A fusion protein in Example 5 and Figure 11B. The amino acid sequence for a Flag-tagged J domain-vFcR fusion protein is shown in the table below.
Table 47. Amino Acid Sequence of a Flag-Tagged Erdj3 J domain-vFcR Fusion Protein.
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) Flag-tagged SEQ
ID NO:237 MAPQNLSTFCLLLLYLIGAVIAGRDFYKIL
Erdj3 J domain-GVPRSASIKDIKKAYRKLALQLHPDRNPDD
vFcR protein PQAQEKFQDLGAAYEVLSDSEKRDIGGGSG
GSGGSGGAAAAKLTSVPTWCPPHPGDTYLL
TCRGTSTARDQRSTQWFRNNTLMRGSNFYG
RLVSVTPNATISDRYACQTKTTTRSNNIDF
RVSSSRLTLQERCSSYGYTYANNTRVLRCY
SGGNVTLRNVVFHLNGTAVINGTTTNIHTF
VLTEKTGGTYFCSAFLEGDYKDDDDKGSRG
PYSIVSPKC
Erdj3 J domain residues 1-83 MAPQNLSTFCLLLLYLIGAVIAGRDFYKIL
of SEQ ID
GVPRSASIKDIKKAYRKLALQLHPDRNPDD
NO: 237 PQAQEKFQDLGAAYEVLSDSEKR
Linker residues 84-100 DI GGGSGGSGGSGG AAA
of SEQ ID
NO: 237 vFcR residues 101- AKLTSVPTWCPPHPGDTYLLTCRGTSTARD
255 of SEQ ID QRSTQWFRNNTLMRGSNFYGRLVSVTPNAT
NO: 237 ISDRYACQTKTTTRSNNIDFRVSSSRLTLQ
ERCSSYGYTYANNTRVLRCYSGGNVTLRNV
VFHLNGTAVINGTTTNIHTFVLTEKTGGTY
FCSAF
Linker residues 256- LEG
258 of SEQ ID
NO: 237 Flag epitope residues 259- DYKDDDDK
domain 266 of SEQ ID
NO: 237 C-terminal residues 267- GSRGPYSIVSPKC
vector residues 279 of SEQ ID
NO: 237 In another fusion protein used in the experiments described herein, the J
domain from the Erdj3 J protein was linked to a herpes simplex virus type 1 gI protein, which has no significant Fc binding activity. A Flag epitope tag was linked to the C-terminus of the gI
domain as shown for the J-Protein A fusion protein in Example 5 and Figure 11B. The amino acid sequence for a Flag-tagged J
domain-gI fusion protein is shown in the table below.
Table 48. Amino Acid Sequence of a Flag-Tagged Erdj3 J Domain-gI Fusion Protein.
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) Flag-tagged SEQ
ID NO : 238 MAPQNLSTFCLLLLYLIGAVIAGRDFYKIL
Erdj3 J domain-GVPRSASIKDIKKAYRKLALQLHPDRNPDD
gI protein PQAQEKFQDLGAAYEVLSDSEKRDIGGGSG
GSGGSGGAAALVVRGPTVSLVSNSFVDAGA
LGPDGVVEEDLLILGELRFVGDQVPHTTYY
DGVVELWHYPMGHKCPRVVHVVTVTACPRR
PAVAFALCRATDSTHSPAYPTLELNLAQQP
LLRVRRATRDYAGVYVLRVWVGDAPNASLF
VLGMAIAAEGTLAYNGSAHGSCDPKLLPYS
APRLAPASVYQPAPNPASTPSTTIPAPQAS
TTPFPTGDPKPQLEGDYKDDDDKGSRGPYS
IVSPKC
J domain residues 1-83 MAPQNLSTFCLLLLYLIGAVIAGRDFYKIL
(from Erdj3) of SEQ ID
GVPRSASIKDIKKAYRKLALQLHPDRNPDD
NO: 238 PQAQEKFQDLGAAYEVLSDSEKR
Linker residues 84-100 DIGGGSGGSGGSGGAAA
of SEQ ID
NO:238 gI residues 101-LVVRGPTVSLVSNSFVDAGALGPDGVVEED
312 of SEQ ID LLILGELRFVGDQVPHTTYYDGVVELWHYP
NO: 238 MGHKCPRVVHVVTVTACPRRPAVAFALCRA
TDSTHSPAYPTLELNLAQQPLLRVRRATRD
YAGVYVLRVWVGDAPNASLFVLGMAIAAEG
TLAYNGSAHGSCDPKLLPYSAPRLAPASVY
QPAPNPASTPSTTIPAPQASTTPFPTGDPK
PQ
Linker residues 313- LEG
315 of SEQ ID
NO:238 Flag epitope residues 316- DYKDDDDK
domain 323 of SEQ ID
NO:238 C-terminal residues 324- GSRGPYSIVSPKC
vector residues 336 of SEQ ID
NO:238 In another fusion protein used in the experiments described herein, the J
domain from the Erdj3 J protein was linked to a herpes simplex virus type 1 gE protein, which has a relatively weak affinity for the immunoglobulin Fc domain. A Flag epitope tag was linked to the C-terminus of the gE domain as shown for the J-Protein A fusion protein in Example 5 and Figure 11B. The amino acid sequence for a Flag-tagged J domain-gE fusion protein is shown in the table below.
Table 49. Amino Acid Sequence of a Flag-Tagged Erdj3 J domain-gE Fusion Protein.
Protein Region Sequence Amino Acid Sequence (N¨ to C¨ Identifier terminal) Flag-tagged SEQ
ID NO:239 MAPQNLSTFCLLLLYLIGAVIAGRDFYKIL
Erdj3 J domain-GVPRSASIKDIKKAYRKLALQLHPDRNPDD
gE fusion PQAQEKFQDLGAAYEVLSDSEKRDIGGGSG
protein GSGGSGGAAAGTPKTSWRRVSVGEDVSLLP
APGPTGRGPTQKLLWAVEPLDGCGPLHPSW
VSLMPPKQVPETVVDAACMRAPVPLAMAYA
PPAPSATGGLRTDFVWQERAAVVNRSLVIH
GVRETDSGLYTLSVGDIKDPARQVASVVLV
VQPAPVPTPPPTPADYDEDDNDEGEDESLA
GTPASGTPRLPPPPAPPRSWPSAPEVSHVR
GVTVRMETPEAILFSPGETFSTNVSIHAIA
HDDQTYSMDVVWLRFDVPTSCAEMRIYESC
LYHPQLPECLSPADAPCAASTWTSRLAVRS
YAGCSRTNPPPRCSAEAHMEPVPGLAWQAA
SVNLEFRDASPQHSGLYLCVVYVNDHIHAW
GHITISTAAQYRNAVVEQPLPQRGADLAEL
EGDYKDDDDKGSRGPYSIVSPKC
Erdj3 J domain residues 1-83 MAPQNLSTFCLLLLYLIGAVIAGRDFYKIL
of SEQ ID GVPRSASIKDIKKAYRKLALQLHPDRNPDD
NO: 239 PQAQEKFQDLGAAYEVLSDSEKR
Linker residues 84-100 DIGGGSGGSGGSGGAAA
of SEQ ID
NO:239 gE residues 101- GTPKTSWRRVSVGEDVSLLPAPGPTGRGPT
479 of SEQ ID QKLLWAVEPLDGCGPLHPSWVSLMPPKQVP
NO: 239 ETVVDAACMRAPVPLAMAYAPPAPSATGGL
RTDFVWQERAAVVNRSLVIHGVRETDSGLY
TLSVGDIKDPARQVASVVLVVQPAPVPTPP
PTPADYDEDDNDEGEDESLAGTPASGTPRL
PPPPAPPRSWPSAPEVSHVRGVTVRMETPE
AILFSPGETFSTNVSIHAIAHDDQTYSMDV
VWLRFDVPTSCAEMRIYESCLYHPQLPECL
SPADAPCAASTWTSRLAVRSYAGCSRTNPP
PRCSAEAHMEPVPGLAWQAASVNLEFRDAS
PQHSGLYLCVVYVNDHIHAWGHITISTAAQ
YRNAVVEQPLPQRGADLAE
Linker residues 480- LEG
482 of SEQ ID
NO:239 Flag epitope residues 483- DYKDDDDK
domain 490 of SEQ ID
NO:239 C-terminal residues 491- GSRGPYSIVSPKC
vector residues 503 of SEQ ID
NO:239 HEK293 cells were transfected with expression vector plasmids to compare levels of expression in culture medium of the IL13Ra2TF-Fc fusion protein expressed alone, co-expressed with a J domain-Protein A fusion protein (as described above in Example 5), co-expressed with Protein A
("Protein A Only", as described in Example 5), co-expressed with a J domain-Protein G fusion protein (J-Protein G), co-expressed with a J domain fusion protein in which a J domain is linked to a human FcR receptor protein ("J-hFcR"), co-expressed with a J domain fusion protein in which a J domain is linked to a viral FcR receptor protein ("J-vFcR"), co-expressed with a J
domain fusion protein in which a J domain is linked to a herpes simplex virus type 1 gI protein ("J-gI"), co-expressed with a J
domain fusion protein in which a J domain is linked to a herpes simplex virus type 1 gE protein ("J-gE"), and co-expressed with both J-gI and J-gE fusion proteins ("J-gI + J-gE"). Transfected cells were cultured for two days, and samples of cell media were harvested and analyzed by Western blot (immunoblot) assay using an anti-V5 antibody to detect secreted VS-tagged IL13Ra2TF.
Figure 16A shows X-ray film images of chemiluminescent signals of a Western blot analysis of culture media from cultures of transfected cells. Lane 1 of Figure 16A is medium from a culture of cells transfected with an expression vector to express the IL13Ra2TF-Fc fusion protein alone. When expressed alone, some IL13Ra2TF-Fc fusion protein was detected in the medium (lane 1 of Figure 16A). Some IL13Ra2TF-Fc protein was also detected when expressed with Protein A only (lane 3 of Figure 16A), as previously noted above with respect to the results described in Example 5 and Figure 12A. Also as previously described in Example 5 and Figure 12A above, co-expression of IL13Ra2TF-Fc fusion protein with a J domain-Protein A fusion protein significantly enhanced the level of expression of IL13Ra2TF-Fc fusion protein secreted into culture medium (lane 2 of Figure 16A) as compared to the level of expression of IL13Ra2TF alone (lane 1 of Figure 16A) or co-expression of IL13Ra2TF-Fc with Protein A alone (lane 3 of Figure 16A). Co-expression of the IL13Ra2TF-Fc protein with a J domain-Protein G fusion protein also significantly enhanced the level of expression of secreted IL13Ra2TF-Fc protein (lane 4 of Figure 16A) as compared to the level of expression of IL13Ra2TF alone (lane 1 of Figure 16A) or co-expression of IL13Ra2TF-Fc with Protein A alone (lane 3 of Figure 16A).
Viral proteins gI and gE from herpes simplex virus type 1 are known to form a heterodimer, wherein the gE protein weakly binds antibody molecules. In addition, whereas the gE protein alone weakly binds to antibody molecules, gI alone does not bind antibody molecules.
Consistent with these prior findings, co-expression of the IL13Ra2TF-Fc fusion protein with a J domain-gI fusion protein (lane 7 of Figure 16A) resulted in a relatively low level of expression of secreted IL13Ra2TF-Fc that was similar to that observed in cells expressing the IL13Ra2TF-Fc alone (lane 1 of Figure 16A). In contrast, co-expression of the IL13Ra2TF-Fc fusion protein with a J
domain-gE fusion protein significantly enhanced the level of expression of secreted IL13Ra2TF-Fc (lane 8 of Figure 16A). A similar enhancement in the level of secreted IL13Ra2TF-Fc was observed when IL13Ra2TF-Fc was co-expressed with both J-gI and J-gE fusion proteins (lane 9 of Figure 16A), indicating that the J-gI fusion protein does not significantly enhance the level of expression of secreted IL13Ra2TF-Fc, consistent with the previous finding that the gI
protein does not bind Fc domains.
The human Fc binding receptor (hFcR) and the Macaca mulatta rhadinovirus Fc binding receptor (vFcR) are well characterized receptors for binding Fc regions of antibody molecules. J
domain fusions comprising these FcR molecules were prepared and tested for the ability to enhance expression of the IL13Ra2TF-Fc fusion protein. As shown in Figure 16A, co-expression of the IL13Ra2TF-Fc protein with either a J domain-hFcR fusion protein or a J domain-vFcR fusion protein not only failed to enhance expression of secreted IL13Ra2TF-Fc (lanes 5 and 6 of Figure 16A), but actually appeared to suppress even a low level of expression of secreted protein observed in cells expressing the IL13Ra2TF-Fc protein alone (lane 1 of Figure 16A). One possible explanation for such apparent suppression of even baseline secretion may be that the J domain-FcR fusion proteins employed in these experiments becomes caught in the endoplasmic reticulum (ER). Further work is required to find functional constructs containing FcR regions to target and enhance expression of proteins that possess an Fc region.
The results of a densitometry analysis of the chemiluminescent signals in the Western blot in Figure 16A using the NIH ImageJ image processing program are shown in the respective bar graphs in Figure 16B.
Example 9.2. Fusion Proteins Comprising Fc Targeting Peptides for Use in Enhancing Expression of Target Proteins in an Unmodified Arrangement A variety of peptides are known that bind the Fc domain of immunoglobulin molecules. This experiment tested various fusion proteins comprising a J domain (as a protein expression enhancing polypeptide) linked to each of several representative Fc-binding peptides (as a target binding domain) for use in enhancing the level of expression of proteins that possess an Fc domain. The six peptides used to construct fusion proteins are shown in the table below.
Table 50. Amino Acid Sequences of Representative Peptides that Bind Fc Domains.
Peptide Designation Amino Acid Sequence Reference FcBP1 DCAWHLGELVWCT DeLano et al., Science, 287: 1279-1283 (2000) (SEQ ID NO:240) FcBP2 HWRGWV Yang et al., J. Peptide Res., 66(Suppl.
1): 120-(SEQ ID NO:241) 137 (2006) FcBP3 HVHYYW Yang et al., J. Peptide Res., 66(Suppl.
1): 120-(SEQ ID NO:242) 137 (2006) FcBP4 YYWLHH Yang et al., J. Peptide Res., 66(Suppl.
1): 120-(SEQ ID NO:243) 137 (2006) FcBP5 HVHYY Yang et al., J. Peptide Res., 66(Suppl.
1): 120-(SEQ ID NO:244) 137 (2006) FcBP6 YYWL Yang et al., J. Peptide Res., 66(Suppl.
1): 120-(SEQ ID NO:245) 137 (2006) Expression vector plasmids were prepared for expressing J domain fusion proteins comprising a J domain (from the Erdj3 protein) linked to each of the six peptides. The IL13Ra2TF-Fc fusion protein was used as a representative target protein comprising an Fc domain.
The amino acid sequence for a J domain fusion protein comprising a J domain of the Erdj3 J
protein linked to the FcBP1 peptide used in this experiment included a Flag epitope tag and 13 additional C-terminal amino acid residues from the expression vector used to express the protein as shown in the table below.
Table 51. Amino Acid Sequence of a Flag-Tagged Erdj3 J Domain-FcBP1 Fusion Protein.
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) 123456789012345678901234567890 Flag-tagged SEQ ID NO:246 MAPQNLSTFCLLLLYLIGAVIAGRDFYKIL
Erdj3 J domain- GVPRSASIKDIKKAYRKLALQLHPDRNPDD
FcBP1 fusion PQAQEKFQDLGAAYEVLSDSEKRDIGGGSG
protein GSGGSGGAAADCAWHLGELVWCTLEGDYKD
DDDKGSRGPYSIVSPKC
J domain residues 1-83 MAPQNLSTFCLLLLYLIGAVIAGRDFYKIL
(from Erdj3) of SEQ ID GVPRSASIKDIKKAYRKLALQLHPDRNPDD
NO: 246 PQAQEKFQDLGAAYEVLSDSEKR
Linker residues 84-100 DIGGGSGGSGGSGGAAA
of SEQ ID
NO: 246 FcBP1 residues 101- DCAWHLGELVWCT
113 of SEQ ID
NO: 246 Linker residues 114- LEG
116 of SEQ ID
NO: 246 Flag epitope residues 117- DYKDDDDK
domain 124 of SEQ ID
NO: 246 C-terminal residues 125- GSRGPYSIVSPKC
vector residues 137 of SEQ ID
NO: 246 The amino acid sequence for a J domain fusion protein comprising a J domain of the Erdj3 J
protein linked to the FcBP2 peptide used in this experiment included a Flag epitope tag and 13 additional C-terminal amino acid residues from the expression vector used to express the protein as shown in the table below.
Table 52. Amino Acid Sequence of a Flag-Tagged Erdj3 J Domain-FcBP2 Fusion Protein.
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) 123456789012345678901234567890 Flag-tagged SEQ ID NO:247 MAPQNLSTFCLLLLYLIGAVIAGRDFYKIL
Erdj3 J domain- GVPRSASIKDIKKAYRKLALQLHPDRNPDD
FcBP2 fusion PQAQEKFQDLGAAYEVLSDSEKRDIGGGSG
protein GSGGSGGAAAHWRGWVLEGDYKDDDDKGSR
GPYSIVSPKC
J domain residues 1-83 MAPQNLSTFCLLLLYLIGAVIAGRDFYKIL
(from Erdj3) of SEQ ID GVPRSASIKDIKKAYRKLALQLHPDRNPDD
NO: 247 PQAQEKFQDLGAAYEVLSDSEKR
Linker residues 84-100 DIGGGSGGSGGSGGAAA
of SEQ ID
NO: 247 FcBP2 residues 101- HWRGWV
106 of SEQ ID
NO: 247 Linker residues 107- LEG
109 of SEQ ID
NO: 247 Flag epitope residues 110- DYKDDDDK
domain 117 of SEQ ID
NO: 247 C-terminal residues 118- GSRGPYSIVSPKC
vector residues 130 of SEQ ID
NO: 247 The amino acid sequence for a J domain fusion protein comprising a J domain of the Erdj3 J
protein linked to the FcBP3 peptide used in this experiment included a Flag epitope tag and 13 additional C-terminal amino acid residues from the expression vector used to express the protein as shown in the table below.
Table 53. Amino Acid Sequence of a Flag-Tagged Erdj3 J Domain-FcBP3 Fusion Protein.
Protein Region Sequence Amino Acid Sequence (N¨ to C¨ Identifier terminal) 123456789012345678901234567890 Flag-tagged SEQ ID NO:248 MAPQNLSTFCLLLLYLIGAVIAGRDFYKIL
Erdj3 J domain- GVPRSASIKDIKKAYRKLALQLHPDRNPDD
FcBP3 fusion PQAQEKFQDLGAAYEVLSDSEKRDIGGGSG
protein GSGGSGGAAAHVHYYWLEGDYKDDDDKGSR
GPYSIVSPKC
J domain residues 1-83 MAPQNLSTFCLLLLYLIGAVIAGRDFYKIL
(from Erdj3) of SEQ ID GVPRSASIKDIKKAYRKLALQLHPDRNPDD
NO: 248 PQAQEKFQDLGAAYEVLSDSEKR
Linker residues 84-100 DI GGGSGGSGGSGG AAA
of SEQ ID
NO: 248 FcBP3 residues 101- HVHYYW
106 of SEQ ID
NO: 248 Linker residues 107- LEG
109 of SEQ ID
NO: 248 Flag epitope residues 110- DYKDDDDK
domain 117 of SEQ ID
NO: 248 C-terminal residues 118- GSRGPYSIVSPKC
vector residues 130 of SEQ ID
NO: 248 The amino acid sequence for a J domain fusion protein comprising a J domain of the Erdj3 J
protein linked to the FcBP4 peptide used in this experiment included a Flag epitope tag and 13 additional C-terminal amino acid residues from the expression vector used to express the protein as shown in the table below.
Table 54. Amino Acid Sequence of a Flag-Tagged Erdj3 J domain-FcBP4 Fusion Protein.
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) 123456789012345678901234567890 Flag-tagged SEQ ID NO:249 MAPQNLSTFCLLLLYLIGAVIAGRDFYKIL
Erdj3 J domain- GVPRSASIKDIKKAYRKLALQLHPDRNPDD
FcBP4 fusion PQAQEKFQDLGAAYEVLSDSEKRDIGGGSG
protein GSGGSGGAAAYYWLHHLEGDYKDDDDKGSR
GPYSIVSPKC
J domain residues 1-83 MAPQNLSTFCLLLLYLIGAVIAGRDFYKIL
(from Erdj3) of SEQ ID GVPRSASIKDIKKAYRKLALQLHPDRNPDD
NO: 249 PQAQEKFQDLGAAYEVLSDSEKR
Linker residues 84-100 DIGGGSGGSGGSGGAAA
of SEQ ID
NO: 249 FcBP4 residues 101- YYWLHH
106 of SEQ ID
NO: 249 Linker residues 107- LEG
109 of SEQ ID
NO: 249 Flag epitope residues 110- DYKDDDDK
domain 117 of SEQ ID
NO: 249 C-terminal residues 118- GSRGPYSIVSPKC
vector residues 130 of SEQ ID
NO: 249 The amino acid sequence for a J domain fusion protein comprising a J domain of the Erdj3 J
protein linked to the FcBP5 peptide used in this experiment included a Flag epitope tag and 13 additional C-terminal amino acid residues from the expression vector used to express the protein as shown in the table below.
Table 55. Amino Acid Sequence of a Flag-Tagged Erdj3 J domain-FcBP5 Fusion Protein.
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) 123456789012345678901234567890 Flag-tagged SEQ ID NO:250 MAPQNLSTFCLLLLYLIGAVIAGRDFYKIL
Erdj3 J domain- GVPRSASIKDIKKAYRKLALQLHPDRNPDD
FcBP5 fusion PQAQEKFQDLGAAYEVLSDSEKRDIGGGSG
protein GSGGSGGAAAHVHYYLEGDYKDDDDKGSRG
PYSIVSPKC
J domain residues 1-83 MAPQNLSTFCLLLLYLIGAVIAGRDFYKIL
(from Erdj3) of SEQ ID GVPRSASIKDIKKAYRKLALQLHPDRNPDD
NO:250 PQAQEKFQDLGAAYEVLSDSEKR
Linker residues 84-100 DI GGGSGGSGGSGG AAA
of SEQ ID
NO:250 FcBP5 residues 101- HVHYY
105 of SEQ ID
NO:250 Linker residues 106- LEG
108 of SEQ ID
NO : 250 Flag epitope residues 109- DYKDDDDK
domain 116 of SEQ ID
NO:250 C-terminal residues 117- GSRGPYSIVSPKC
vector residues 129 of SEQ ID
NO:250 The amino acid sequence for a J domain fusion protein comprising a J domain of the Erdj3 J
protein linked to the FcBP6 peptide used in this experiment included a Flag epitope tag and 13 additional C-terminal amino acid residues from the expression vector used to express the protein as shown in the table below.
Table 56. Amino Acid Sequence of a Flag-Tagged Erdj3 J domain-FcBP6 Fusion Protein.
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) 123456789012345678901234567890 Flag-tagged SEQ ID NO:251 MAPQNLSTFCLLLLYLIGAVIAGRDFYKIL
Erdj3 J domain- GVPRSASIKDIKKAYRKLALQLHPDRNPDD
FcBP6 fusion PQAQEKFQDLGAAYEVLSDSEKRDIGGGSG
protein GSGGSGGAAAYYWLLEGDYKDDDDKGSRGP
YSIVSPKC
J domain residues 1-83 MAPQNLSTFCLLLLYLIGAVIAGRDFYKIL
(from Erdj3) of SEQ ID GVPRSASIKDIKKAYRKLALQLHPDRNPDD
NO:251 PQAQEKFQDLGAAYEVLSDSEKR
Linker residues 84-100 DIGGGSGGSGGSGGAAA
of SEQ ID
NO:251 FcBP6 residues 101- YYWL
104 of SEQ ID
NO:251 Linker residues 105- LEG
107 of SEQ ID
NO:251 Flag epitope residues 108- DYKDDDDK
domain 115 of SEQ ID
NO:251 C-terminal residues 116- GSRGPYSIVSPKC
vector residues 128 of SEQ ID
NO:251 Transfected cells were cultured for two days, and samples of cell media were harvested and analyzed by Western blot assay using an anti-V5 antibody to detect secreted VS-tagged IL13Ra2TF-Fc fusion protein. Figure 17A shows X-ray film images of chemiluminescent signals of the Western blot analysis of culture media. As shown in Figure 17A, co-expression of the IL13Ra2TF-Fc fusion protein with each of the six J domain-peptide fusion proteins in HEK293 transfectants significantly enhanced the level of expression of secreted IL13Ra2TF-Fc fusion protein (lanes 4-9) as compared to the level of expression of IL13Ra2TF-Fc fusion protein alone (lanes 1 and 3).
The experiment also included for comparison the effect of co-expression of IL13Ra2TF-Fc fusion protein with a J domain-Protein A fusion protein (lane 2) or with a J domain-Protein G fusion protein (lane 10) on the expression of secreted IL13Ra2TF-Fc fusion protein. As shown in Figure 17A, co-expression of IL13Ra2TF-Fc fusion protein with either J domain-Protein A fusion protein (lane 2) or the J domain-Protein G fusion protein (lane 10) significantly enhanced the level of expression of secreted the IL13Ra2TF-Fc fusion protein.
The results of a densitometry analysis of the chemiluminescent signals in the Western blot in Figure 17A using the NIH ImageJ image processing program are shown in the respective bar graphs in Figure 17B.
Conclusion of Results of Experiments The results of the experiments described above indicate that co-expression of a target protein of interest and a fusion protein comprising a protein expression enhancing polypeptide domain linked to a target protein binding domain that binds the target protein significantly enhances the level of expression of the target protein in its proper cellular or extracellular location as compared to the level of expression of the target protein in the absence of the fusion protein.
Example 10. Minimal Sequence Requirements for Protein Expression Enhancing Polypeptides Further analysis was undertaken to determine the minimal amino acid sequence that is effective for enhancing the level of expression of a target protein of interest when employed in an unmodified or a modified arrangement.
Sequence homology analysis using BLAST was conducted on the existing library of J domain sequences to determine whether J domains shared a similar minimal "core"
sequence that could enhance the level of protein expression. The analysis indicated that the J
domain of the Erdj3 protein was typical of J domains of other J proteins. Since the J domain of Erdj3 was already known to be effective at enhancing protein expression in both the modified and unmodified arrangements (see, examples above), it was chosen for further deletion and substitution mutation analysis to determine whether a minimal polypeptide sequence could be identified that retained protein expression enhancing activity.
In this study, various deletion and substitution mutations of the J domain of Erdj3 were assessed for enhancing expression of an engineered IL13Ra2TF-V5-Fc protein as the target protein of interest. This engineered protein possesses a V5 epitope tag between the IL13Ra2TF polypeptide and the Fc domain, permitting easy detection with an anti-V5 antibody. Fusion proteins were constructed comprising either the full length J domain of Erdj3 or the various mutated polypeptides linked to Protein A, which binds the Fc domain of the engineered IL13Ra2-Fc target protein (thus acting as a target protein binding domain). Thus, for each of the mutated polypeptides, the general formula of the corresponding fusion proteins used in the study was:
signal sequence¨linker 1¨(J domain, fragment or J domain analog polypeptide sequence¨linker 2¨
Protein A¨linker 3¨Flag epitope tag.
The amino acid sequences of the domains of these fusion proteins, excluding the inserted J
domain, J domain fragment, or J domain analog sequences, is shown in the table below.
Table 57. Amino Acid Structure of Test Flag-Tagged Protein A Fusions.
Protein Region Sequence Amino Acid Sequence Identifier 123456789012345678901234567890 signal sequence SEQ ID MGVKVLFALICIAVAEA
NO:251 linker 1 SEQ ID GTGSGEF
NO:252 J domain, (various polypeptide fragment or sequences) analog sequence linker 2 SEQ ID DIGGGSGGSGGSGGAAA
NO: 122 Protein A SEQ ID ADNKFNKEQQNAFYEILNMPNLNEEQRNGF
NO:254 IQSLKDDPSQSANVLGEAKKLNDSQAPK
linker 3 SEQ ID LEG
NO:255 Flag epitope tag SEQ ID DYKDDDDK
NO: 111 The protein expression enhancing activity of each fusion protein was determined by dot blot assay using detectable anti-VS antibody. The IL13Ra2-V5-Fc target protein was expressed with or without the fusion proteins containing each mutated polypeptide sequence, and the cell culture medium was harvested and briefly spun to remove debris. The sample was blotted onto nitrocellulose membrane, and the dried membrane was processed for immunoblot assay. The deletion and substitution polypeptides tested for protein expression enhancement activity are shown in the table below along with the protein expression enhancing activity determined by immunoblotting.
Table 58. Amino Acid Sequences of Polypeptides Tested for Protein Expression Enhancing Activity.
Polypeptide Sequence Polypeptide Amino Acid Sequence Activity*
No. Identifier 3 SEQ ID NO:256 GRE)FYK I I, GVPRSAS KDKKAYP.H.L.ALQL, HA
I-IP DRY? DDPQAQEKFODL, GAAYEVI, S D SEK
3-1 SEQ ID NO:257 L. GVPR.SA S KD IKKAYRKL ALQL DRNP HA
D P QE KIT Q D GAAYEVI, S D S EKR
3-2 SEQ ID NO:258 S AS IKD IKKAYRKLALQL, I-IP D RNP D DP QAQ HA
EKFQDLGAAYEVLSDSEKR
3-3 SEQ ID NO:259 GRDFY:K I LGVPRSAS I KD I KKAYRKLALQL HA
HPORNPDDPQAQ.EKFULG
3-4 SEQ ID NO:260 if LGVPRSAS IKDIKKAYRKLALQI,I-IPDP,NP HA
D DP QAQE KFQDLG
3-5 SEQIDNO:261 SAfIKDIKKAYRKLADDLHFDRNPDDPQAQ HA
Polypeptide Sequence Polypeptide Amino Acid Sequence Activity*
No. Identifier EK.FQDLG
3-6 SEQ ID NO:262 KAY RKLAL Q L HP MN'? D DP c),AOKE QDLG NA
3-7 SEQ ID NO:263 KAYRKLALQL HP DRNP DDPQAQEKFQDL NA
AYEVL SDSEKR
3-8 SEQ ID NO:264 LQLH2DRN2DDPOAQEKFULLG NA
3-9 SEQ ID NO:265 LQLHPDRNPDDPQAQKFQDLGAYEVLS D NA
SEKR
3-10 SEQ ID NO:266 I KD IKKAI RELALOL HP DRN D DP QAOEKF HA
ODLG
3-11 SEQ ID NO:267 S S TKD ALQI ,FIPDRNPDDP9AQ HA
3-12 SEQ ID NO:268 SAS IKDTKKAYRKLADDT,HP HA
3-13 SEQ ID NO:269 IKE) I KIK.7-\ YRKI2\.LQE:LIP DRNP D DP QAQE
HA
3-14 SEQ ID NO:270 IKDIKAYPLZLQLHPDRN HA
3-15 SEQ ID NO:271 D K KAYRK.LALQL I-IP DRNP D DP ()A QE HA
3-16 SEQ ID NO:272 IRD IKKAYRKLALQ L HP D HA
3-17 SEQ ID NO:273 IKE) KKAY RKLALOL HA
3-18 SEQ ID NO:274 D KKAY RKLALOL HA.
3-19 SEQ ID NO:275 D KKAYRKLALQ HA
3-20 SEQ ID NO:276 D =AI RKLAL HA.
3-21 SEQ ID NO:277 D KKI-\ YRKLA HA
3-22 SEQ ID NO:278 s .i.K.KAYRKL NA.
3-23 SEQ ID NO:279 1:-.) KKAYRK NA
3-24 SEQ ID NO:280 D K KAY R NA
3-25 SEQ ID NO:281 IKKRKL2LL HA
3-26 SEQ ID NO:282 KICA.YRKLALOL NA
3-27 SEQ ID NO:283 I KKAYRKLALQ HA
3-28 SEQ ID NO:284 I KKAYRKLAL HA
3-29 SEQ ID NO:48 I KKAYRKLA HA.
3-30 SEQ ID NO:285 I KKAYRKL A
3-31 SEQ ID NO:286 KKAYRKLALQ NA.
3-32 SEQ ID NO:287 k-H'T.AYP, A NA
3-33 SEQ ID NO:288 KKT;IRKLA NA
3-34 SEQ ID NO:289 K AY RK LAT, Q NA
3-35 SEQ ID NO:290 I KKAYRK NA
3-36 SEQ ID NO:291 IRKAYR NA
3-37 SEQ ID NO:292 I KAYRK LALO NA
3-38 SEQ ID NO:293 I KKYRKLALQ A
3-39 SEQ ID NO:294 I KKARKLAL NA
3-40 SEQ ID NO:49 I KKAYKLALQ HA
3-41 SEQ ID NO:50 .1.,T.K7Y. RLALQ HA
3-42 SEQ ID NO:51 IKKA.YRKALQ HA
3-43 SEQ ID NO:52 K.K:a 77R KT :T,c) HA
3-44 SEQ ID NO:295 I KAYRKI2s1. NA
3-45 SEQ ID NO:53 iKKYPLZ A
3-46 SEQ ID NO:54 IKKAYKLA A
3-47 SEQ ID NO:55 IRKAYRLA A
3-48 SEQ ID NO:56 I KKAYRKA A
3-49 SEQ ID NO:57 LKKAYRKLA HA.
Polypeptide Sequence Polypeptide Amino Acid Sequence Activity*
No. Identifier 3-50 SEQ ID NO:58 -\,risT.K7A.YRKI:7\ HA
3-51 SEQ ID NO:59 MKKAYRK LA HA
3-52 SEQ ID NO:60 AKKAYRKLA HA
3-53 SEQ ID NO:296 SKKAYRKLA NA
3-54 SEQ ID NO:297 FKKAYRKLA NA
3-55 SEQ ID NO:298 I AQAYRKLA NA
3-56 SEQ ID NO:299 I LAAYRKLA NA
3-57 SEQ ID NO:61 I AK AY RK I: .7J% A
3-58 SEQ ID NO:62 I K7\ AYRK LA A
3-59 SEQ ID NO:63 I KKR77. RKE:7\ HA
3-60 SEQ ID NO:64 I KK SYRK LA A
3-61 SEQ ID NO:65 I IsT.KQYRKI:7\ A
3-62 SEQ ID NO:66 I KKEYRKLA A
3-63 SEQ ID NO:67 I KKFY. RKLA A
3-64 SEQ ID NO:68 I KKCYRKLA A
3-65 SEQ ID NO:69 I KKAF RKLA HA.
3-66 SEQ ID NO:300 I KKAHRKLA NA
3-67 SEQ ID NO:301 if KI--Aiii RI--H,A. NA.
3-68 SEQ ID NO:70 ii.T.T.K.:Al;^m.KE:.%% HA
3-69 SEQ ID NO:302 I KKAARK LA NA
3-70 SEQ ID NO:303 I IsT.KAS RKI:7\ NA
3-71 SEQ ID NO:304 1KKAYHQLA NA
3-72 SEQ ID NO:305 I KKAY 1 Q LA NA
3-73 SEQ ID NO:306 I KE<AYFS LA NA
3-74 SEQ ID NO:307 I KKAY RKO S NA
3-75 SEQ ID NO:308 I KKAYRKQ C NA
3-76 SEQ ID NO:309 I KIU,YRK D iii NA.
3-77 SEQ ID NO:71 T .IT.K.7-_\-,7. RKQ .7J% HA
3-78 SEQ ID NO:72 I K KAYRK MA HA
3-79 SEQ ID NO:73 I KK23,:y7R.K I 7\ A
3-80 SEQ ID NO:74 I KKAYRKAA A
3-81 SEQ ID NO:75 I KKAYRKVA A
3-82 SEQ ID NO:76 I KKAYRKRA A
3-83 SEQ ID NO:77 I KKAY RKLM HA.
3-84 SEQ ID NO:78 I KKAYRKIL I tiA
3-85 SEQ ID NO:79 1 KKAYRKL v HA.
3-86 SEQ ID NO:80 I .1.T.K.A77. RKLC A
3-87 SEQ ID NO:81 if KKAyRka, s HA
3-88 SEQ ID NO:82 I KK23,:y7R.K I: Y A.
3-89 SEQ ID NO:83 I RKAYRK IL S I: T IL A
3-90 SEQ ID NO:84 I KKQY R. 1_, I: S I, KY A
3-91 SEQ ID NO:85 I KKAF iiKLAMKY HA
3-92 SEQ ID NO:86 'I ROAFKKLALKL A
3-93 SEQ ID NO:87 I I KAYRKLAL QW A
3-94 SEQ ID NO:88 I ARAY ROLARR Y HA.
3-95 SEQ ID NO:89 I KRAYRRQAL RI HA
3-96 SEQ ID NO:90 I KI--: 3 YRI,J,AL }--- y HA
3-97 SEQ ID NO:91 I .1.T.K13, v F RT = 7J%T1KY HA
3-98 SEQ ID NO:310 M7R KAY I: K K C NA
Polypeptide Sequence Polypeptide Amino Acid Sequence Activity*
No. Identifier 3-99 SEQ ID NO:311 I LAEFKVRAL NA
* "HA" = high activity, i.e., protein expression enhancement activity is significantly enhanced, e.g., similar to that provided by the full-length J domain of the Erdj3 protein, as compared to negative control (no fusion protein used); "A" = improved protein expression enhancement activity in comparison to negative control (no fusion protein used); level of protein production typically less than provided by the full-length J domain of Erdj3; "NA" = no activity compared to negative control.
As indicated in the above table, each mutated polypeptide was assessed for expression enhancing activity when co-expressed with the IL13Ra2-V5-Fc target protein.
The levels of expression were classified as high activity ("HA"), activity ("A"), or no activity ("NA"). Examples of these levels of expression are shown in the immunoblot in Figure 18. The level of expression of the IL13Ra2-V5-Fc target protein in the absence of a fusion protein was taken as "no activity". See, lane 2 (from the left) in Figure 18). Co-expression of a fusion protein comprising the complete J domain of Erdj3, designated polypeptide 3 in Table 58 above, linked to Protein A
dramatically enhanced the level of expression of the secreted IL13Ra2-V5-Fc target protein. See, lane 3, from the left, in Figure 18. This level of expression enhancement is designated "High Activity". As shown in lane 4 of Figure 18, co-expression of a fusion protein comprising an internal deletion mutated polypeptide, designated 3-45, linked to Protein A clearly provided a significantly enhanced level of expression of the secreted IL13Ra2-V5-Fc target protein as compared to the control (no fusion protein, lane 2 of Figure 18), but the expression level was somewhat less than the high activity shown in lane 3 of Figure 18. This level of expression enhancement is designated "Activity." In contrast, as shown in lane 5 of Figure 18, co-expression of a fusion protein comprising a substitution mutation within the minimal polypeptide sequence, designated 3-72, linked to Protein A provided no more than the level of expression detected for the control in lane 2 of Figure 18. This was designated "No Activity".
The results of this analysis indicated that an internal polypeptide fragment of the J domain of Erdj3, designated 3-29, has the minimal polypeptide sequence (IKKAYRKLA; SEQ
ID NO:48) that provides a high activity for enhancing protein expression. The polypeptide 3-29 sequence is located within a helix II of the J domain, but does not include any residues of the adjacent (C-proximal) loop domain.
Various mutations of the J domain fragment 3-29 sequence were made and assessed for protein expression enhancing activity. The mutated sequences are shown in the table above, see polypeptide nos. 3-44 to 3-88.
The J domains of other J proteins were also assessed for internal polypeptide sequences located in positions similar to that of the 3-29 polypeptide within the J
domain of Erdj3. Such sequences are designated 3-89 to 3-99 in the table above. Most of these polypeptides provided complete or partial activity in the assay for enhanced expression of the secreted IL13Ra2-V5-Fc 08.04.2015 =
target protein. However, two of the polypeptides, designated 3-98 and 3-99, possessed amino acid sequences that diverged considerably from that of polypeptide 3-29, and these polypeptides also lacked protein expression enhancing activity.
Example 11. Structural Formula Defining a New Family of Protein Expression Enhancing Polvueotides Below is an overview of the analysis of the polypeptide sequence mutation data that led not only to the discovery of the minimal sequence of a polypeptide fragment of the J domain of Erdj3 that provides protein expression enhancing activity (polypeptide 3-29, SEQ ID
NO:48), but also to a structural formula that defines a new family of protein expression enhancing polypeptides as shown below.
Figure 19 shows an alignment of the amino acid sequence for the J domain of Erdj3 with a series of deletion mutated polypeptides along with their protein expression enhancing activity determined using the unmodified arrangement in which each polypeptide was used to construct a Hag-tagged Protein A fusion protein as described above. The level of expression of secreted IL13Ra2-V5-Fc target protein in the media of cultures of cells co-expressing each Flag-tagged Protein A fusion and the IL13Ra2-V5-Fc target protein was determined by immunoblot using an anti-V5 antibody as described above.
Deletion mutated polypcptides designated 3-6, 3-7, 3-8, and 3-9 in Figure 19 all lacked =
protein expression enhancing activity (no activity), indicating that ahelix II
amino acid sequences are essential for activity. Deletion mutated polypeptides designated 3-15 and 3-17 in Figure 19 retained high activity, indicating that the sequence DIKICAYRKLALQL (SEQ ID NO:274) was sufficient for providing high protein expression enhancing activity. This polypeptide was then subjected to further mutation analysis as shown in the table below.
Table 59. Amino Acid Sequence and Protein Expression Enhancing Activity of Mutated Polypeptides.
PP No. an sequence SEQ ID NO: Act 3-21 10 DI KKAYRKLA 277 HA ) The last amino acid is essential 3-25 12 I KKAYRKLALQL 281 HA }The first amino acid is essential 3-29 9 IKKAYRKLA 48 HA 4- Identified Minimum Sequence = 3-30 8 IKKAYRKL 285 A
AMENDED SHEET -IPEA/US
PCT/US2013/073442 08.04.2015 3-33 8 .KKAYRKLA 288 NA
As noted above, the difference in activity between that of the polypeptide designated 3-21 (high activity, HA) and that of the polypeptide designated 3-22 (no activity, NA) indicated that the C-terminal leucine (L) residue is essential for protein expression enhancing activity. Similarly, the difference in activity between that of polypeptide 3-25 and that of polypeptide 3-26 indicated that the N-terminal isoleucine (I) is essential for activity. As noted previously, polypeptide 3-29 defines the minimal polypeptide sequence of the J domain of Erdj3 for providing complete protein expression enhancing activity.
In addition to the results described above, additional analyses as outlined below led to the identification of an essential amino acid consensus sequence for a protein expression enhancing polypeptide of the invention.
To identify the essential amino acid sequence for providing protein expression enhancing activity, each amino acid of the 3-29 sequence was deleted and the polypeptide tested for protein expression enhancing activity using the IL13Ra2-V5-Fc target protein in the unmodified arrangement described above.
Starting with the minimum sequence of the polypeptide fragment of the J domain of Erdj3, the polypeptide 3-29 sequence (I KKAYRKLA; SEQ ID NO:48) was subjected to the following mutation analysis at each of the nine amino acid positions:
(a) 3-29: I KKAYRKLA (SEQ ID NO:48), regarding position 1, see summary analysis (1) below, (b) 3-44: IK_AYRKLA (SEQ ID NO:295), no activity, regarding position 3, see summary analysis (2) below, (c) 3-45: IKK YRKLA (SEQ ID NO:53), some activity, regarding position 4, see summary analysis (3) below, (d) 3-39: IKKA_RKLA (SEQ ID NO:294), no activity, regarding position 5, see summary analysis (4), below, (e) 3-46: IKKAY_KLA (SEQ ID NO:54), some activity, regarding position 6, see summary analysis (5) below, (I) 3-47: IKKAYR_LA (SEQ ID NO:55), some activity, regarding position 7, see summary analysis (5) below, =
(g) 3-48: IKKAYRK_A (SEQ ID NO:56), some activity, regarding position 8, see summary analysis (6) below, AMENDED SHEET -IPEA/US
(h) 3-29: I KKAYRKLA (SEQ ID NO:48), high activity, regarding position 9, see summary analysis (6) below.
Summary Analyses (1) I KKAYRKLA (SEQ ID NO:48) First amino acid is essential for the activity.
The result for the comparison of the first amino acid among J members (47 J
proteins) indicated the following incidences of amino acids at position 1:
1(34), L (6), V (4), M (1), A (1), R (1) All of these amino acids have a nonpolar side chain group, except Arg (R).
The following constructions derived from other J members were made and tested:
3-49: LKKAYRKLA (SEQ ID NO:57), high activity 3-50: VKKAYRKLA (SEQ ID NO:58), high activity 3-51: MKKAYRKLA (SEQ ID NO:59), high activity 3-52: AKKAYRKLA ( SEQ ID NO:60), high activity 3-53: SKKAYRKLA (SEQ ID NO:296), no activity 3-54: FKKAYRKLA (SEQ ID NO:297), no activity.
Therefore, it the first position is preferably an amino acid with a nonpolar amino acid side group that is I, L, V, A, and M.
(2) IK AYRKLA (SEQ ID NO:295); no activity This implies two possibilities:
a) two amino acids are required at this position 3-55: IAQAYRKLA (SEQ ID NO:298), no activity 3-56: ILAAYRKLA (SEQ ID NO:299), no activity indicating some specific amino acid is required, b) two lysines are required or only one is enough.
Through the comparison of these two positions among J members (47 J proteins), these two positions are well conserved as indicated by the following incidences:
KK (26), KR (5), RK (3), AR (3), KA (2), KQ (2), KL (1), IK (1), NK (1), RQ
(1), RD (1), LA (1) All of these harbor at least one amino acid with a basic amino acid side chain with one exception.
Therefore, the following substitution mutations were made and tested:
3-57: IAKAYRKLA (SEQ ID NO:61), some activity 3-58: IKAAYRKLA (SEQ ID NO:62), some activity.
Therefore, it is concluded that at least one amino acid at positions 2 and 3 is a basic amino acid K or R.
(3) IKK YRKLA (SEQ ID NO:53), some activity This result indicates that it is better to have some amino acid in this position but not absolutely necessary.
Through a comparison of this position among J members (47 J proteins), this position is also well conserved as indicated by the following incidences:
A (36), K (2), R (2), S (2), Q (2), T (1), I (1), E (1) The following polypeptides were constructed and tested:
Basic amino acid 3-59 IKKRYRKLA (SEQ ID NO:63); high activity Polar uncharged amino acid 3-60 IKKSYRKLA (SEQ ID NO:64); some activity Polar uncharged amino acid 3-61 IKKQYRKLA (SEQ ID NO:65); some activity Acidic amino acid 3-62 IKKEYRKLA (SEQ ID NO:66); some activity Aromatic amino acid 3-63 IKKFYRKLA (SEQ ID NO:67); some activity Polar uncharged amino acid 3-64 IKKCYRKLA (SEQ ID NO:68); some activity.
From the above substitution mutations, it is concluded that any of the 20 naturally occurring amino acids may occupy position 4 since deletion at this position still retains activity.
(4) IKKA_RKLA (SEQ ID NO:312); no activity This result implies that some amino acid in position 5 is essential.
Through the comparison of this position among J members (47 J proteins), the amino acid distribution is given below.
Y (34), F (10), H (2), 1(1) Therefore the following polypeptides were made and tested:
Aromatic amino acid 3-65 IKKAFRKLA (SEQ ID NO:69), high activity Positive charged amino acid 3-66 IKKAHRKLA (SEQ ID NO:300), no activity Nonpolar amino acid 3-67 IKKAIRKLA (SEQ ID NO:301), no activity Aromatic amino acid 3-68 IKKAWRKLA (SEQ ID NO:70), high activity Nonpolar amino acid 3-69 IKKAARKLA (SEQ ID NO:302), no activity Nonpolar amino acid 3-70 IKKASRKLA (SEQ ID NO:303), no activity.
Therefore, the amino acid at position 5 is an aromatic amino acid that is Y, F, or W.
(5) IKKAY KLA (SEQ ID NO:313), some activity IKKAYR LA (SEQ ID NO:314) some activity Through the comparison of this position among J members (47 J proteins), the case that at least one amino acid is a basic amino acid is 43 out of 47 (both 23, and either one 20).
The following mutated polypeptides have two amino acids replaced at positions 6 and 7:
3-71 IKKAYHQLA (SEQ ID NO:304), no activity 3-72 IKKAYYQLA (SEQ ID NO:305), no activity 3-73 IKKAYF S LA (SEQ ID NO:306), no activity.
Therefore, at least one of the amino acids at positions 6 and 7 is a basic amino acid K or R.
(6) IKKAYRK A (SEQ ID NO:56), some activity I KKAYRKL (SEQ ID NO:315), some activity Through the comparison of these positions among J members (47 J proteins), the case that two positions are occupied with L and A is 25 out of 47, in which all of them are L-A. The case that at least one amino acid at these positions is L or A is 14, and 8 cases indicates neither L nor A.
The following mutated polypeptides were made with two amino acids replaced and tested for activity:
3-74 IKKAYRKQS (SEQ ID NO:307), no activity 3-75 IKKAYRKQC (SEQ ID NO:308), no activity 3-76 IKKAYRKD I (SEQ ID NO:309), no activity.
The following mutated polypeptides have position 8 replaced as indicated:
Polar amino acid 3-77 IKKAYRKQA (SEQ ID NO:71), high activity Nonpolar amino acid 3-78 IKKAYRKMA (SEQ ID NO:72), high activity Nonpolar amino acid 3-79 IKKAYRK IA (SEQ ID NO:73), some activity Nonpolar amino acid 3-80 IKKAYRKAA (SEQ ID NO:74), some activity Nonpolar amino acid 3-81 IKKAYRKVA (SEQ ID NO:75), some activity Basic amino acid 3-82 IKKAYRKRA (SEQ ID NO:76), some activity.
The following mutated polypeptides have position 9 replaced as indicated:
Nonpolar amino acid 3-83 IKKAYRKLM (SEQ ID NO:77), high activity Nonpolar amino acid 3-84 IKKAYRKL I (SEQ ID NO:78), high activity Nonpolar amino acid 3-85 IKKAYRKLV (SEQ ID NO:79), high activity Polar uncharged amino acid 3-86 IKKAYRKLC (SEQ ID NO:80), some activity Polar uncharged amino acid 3-87 IKKAYRKL S (SEQ ID NO:81), high activity Aromatic amino acid 3-88 IKKAYRKLY (SEQ ID NO:82), some activity.
Results of other mutated polypeptides:
Replacement L and A 3-42 IKKAYRKALQ (SEQ ID NO:51), high activity Double L 3-43 IKKAYRKLLQ (SEQ ID NO:52), high activity.
Therefore, at least one of the amino acids at X8 and X9 is L or A.
Through these studies, it is concluded that an isolated protein expression enhancing J domain analog polypeptide comprises the formula:
X1-X2-X3-X4-X5-X6-X7-X8-X9 (SEQ ID NO:47), wherein:
X1 is isoleucine (I), leucine (L), valine (V), alanine (A), or methionine (M);
X2 and X3 are each independently any amino acid with the proviso that one or both are lysine (K) or arginine (R);
X4 is any amino acid or X4 may be absent when X1 through X3 are present and X5 through X9 are present;
X5 is tyrosine (Y), tryptophan (W), or phenylalanine (F);
X6 and X7 are each independently any amino acid with the proviso that one or both are lysine (K) or arginine (R); or either one of X6 and X7 may be absent when the other is K or R and when X1 through X5 are present and X8 and X9 are present;
and X8 and X9 are any amino acid with the proviso that one or both are leucine (L) or alanine (A); or one of X8 and X9 may be absent when the other is L or A and when X1 through X7 are present.
The above formula is applicable to the sequence of the following polypeptide fragments from other J proteins, and all of these polypeptides have activity:
Erdjl 3-89 IRKAYRKLSLTL (SEQ ID NO:83), some activity Erdj2 3-90 IKKQYRLLSLKY (SEQ ID NO:84), some activity Erdj4 3-91 IKKAFHKLAMKY (SEQ ID NO :85), high activity Erdj5 3-92 IRQAFKKLALKL (SEQ ID NO:86), some activity Erdj6 3-93 IIKAYRKLALQW (SEQ ID NO:87), some activity Erdj7 3-94 IARAYRQLARRY (SEQ ID NO: 88), high activity Hsp40 3-95 IKRAYRRQALRY (SEQ ID NO: 89), high activity CSP 3-96 IKKSYRKLALKY (SEQ ID NO:90), high activity DnaJ 3-97 IKKAYKRLAMKY (SEQ ID NO:91), high activity The sequences below from other J proteins do not match the above formula and these polypeptides do not have protein expression enhancing activity:
From 5V40 J protein 3-98 MRKAYLKKC (SEQ ID NO:310), no activity From Dnaj homolog subfamily C member 12 3-99 ILAEFKVRAL (SEQ ID
NO:311), no activity.
The analyses and results summarized above indicate that the above formula defines a new family of polypeptides that provide protein expression enhancing activity.
Example 12. Minimal Polypeptide of J Domain Enhances Target Protein Expression in a Modified Arrangement As explained above, the results of the mutation analysis of the J domain of Erdj3 indicated that an internal polypeptide sequence, designated 3-29, is the minimal sequence with the J domain for a polypeptide (IKKAYRKLA; SEQ ID NO:48) to provides high activity for enhancing protein expression using the above assay in an unmodified arrangement. The protein expression enhancing activity of the 3-29 polypeptide was also examined in a modified arrangement.
In this experiment, a first fusion protein comprised IL13Ra2TF as the target protein of interest linked to the BSC1 polypeptide (SEQ ID NO:48), which in turn was linked to an V5 epitope tag. This fusion protein was designated IL13Ra2TF-BSC1 shown in the table below.
Table 60. Amino Acid Sequence of a V5-Tagged IL13Ra2TF-BSC1 Fusion Protein.
Protein Region Sequence Amino Acid Sequence (N¨ to C¨ Identifier terminal) 123456789012345678901234567890 IL13Ra2TF-BSC1 SEQ ID NO:316 MAFVCLAIGCLYTFLISTTFGCTSSSDTEI
protein KVNPPQDFEIVDPGYLGYLYLQWQPPLSLD
HFKECTVEYELKYRNIGSETWKTIITKNLH
YKDGFDLNKGIEAKIHTLLPWQCTNGSEVQ
SSWAETTYWISPQGIPETKVQDMDCVYYNW
QYLLCSWKPGIGVLLDTNYNLFYWYEGLDH
ALQCVDYIKADGQNIGCRFPYLEASDYKDF
YICVNGSSENKPIRSSYFTFQLQNIVKPLP
PVYLTFTRESSCEIKLKWSIPLGPIPARCF
DYEIEIREDDTTLVTATVENETYTLKTTNE
TRQLCFVVRSKVNIYCSDDGIWSEWSDKQC
WEGEDLSKKGTGSEFIKKAYRKLADIGGGS
GGSGGSGGAAALEGKPIPNPLLGLDST
IL13Ra2TF residues 1-339 MAFVCLAIGCLYTFLISTTFGCTSSSDTEI
of SEQ ID KVNPPQDFEIVDPGYLGYLYLQWQPPLSLD
NO: 316 HFKECTVEYELKYRNIGSETWKTIITKNLH
YKDGFDLNKGIEAKIHTLLPWQCTNGSEVQ
SSWAETTYWISPQGIPETKVQDMDCVYYNW
QYLLCSWKPGIGVLLDTNYNLFYWYEGLDH
ALQCVDYIKADGQNIGCRFPYLEASDYKDF
YICVNGSSENKPIRSSYFTFQLQNIVKPLP
PVYLTFTRESSCEIKLKWSIPLGPIPARCF
DYEIEIREDDTTLVTATVENETYTLKTTNE
TRQLCFVVRSKVNIYCSDDGIWSEWSDKQC
WEGEDLSKK
Linker residues 340- GTGSEF
345 of SEQ ID
NO: 316 BSC1 residues 346- IKKAYRKLA
354 of SEQ ID
NO: 316 Linker residues 355- DIGGGSGGSGGSGGAAALE
373 of SEQ ID
NO: 316 V5 epitope residues 374- GKPIPNPLLGLDST
domain 387 of SEQ ID
NO: 316 A second fusion protein comprised IL13Ra2TF as the target protein of interest linked to a mutated version of the BSC1 polypeptide, designated "IL13Ra2TF-BSC1MT" in which the second and third positions of the BSC1 polypeptide were mutated from K-K to A-Q as shown in the table below. The BSC1MT polypeptide is designated 3-55.
Table 61. Amino Acid Sequence of a V5-Tagged IL13Ra2TF-BSC1MT Fusion Protein.
Protein Region Sequence Amino Acid Sequence (N¨ to C¨ Identifier terminal) 123456789012345678901234567890 IL13Ra2TF-BSC1MT SEQ ID NO:317 MAFVCLAIGCLYTFLISTTFGCTSSSDTEI
protein KVNPPQDFEIVDPGYLGYLYLQWQPPLSLD
HFKECTVEYELKYRNIGSETWKTIITKNLH
YKDGFDLNKGIEAKIHTLLPWQCTNGSEVQ
SSWAETTYWISPQGIPETKVQDMDCVYYNW
QYLLCSWKPGIGVLLDTNYNLFYWYEGLDH
ALQCVDYIKADGQNIGCRFPYLEASDYKDF
YICVNGSSENKPIRSSYFTFQLQNIVKPLP
PVYLTFTRESSCEIKLKWSIPLGPIPARCF
DYEIEIREDDTTLVTATVENETYTLKTTNE
TRQLCFVVRSKVNIYCSDDGIWSEWSDKQC
WEGEDLSKKGTGSEFIAQAYRKLADIGGGS
GGSGGSGGAAALEGKPIPNPLLGLDST
IL13Ra2TF residues 1-339 MAFVCLAIGCLYTFLISTTFGCTSSSDTEI
of SEQ ID KVNPPQDFEIVDPGYLGYLYLQWQPPLSLD
NO: 317 HFKECTVEYELKYRNIGSETWKTIITKNLH
YKDGFDLNKGIEAKIHTLLPWQCTNGSEVQ
SSWAETTYWISPQGIPETKVQDMDCVYYNW
QYLLCSWKPGIGVLLDTNYNLFYWYEGLDH
ALQCVDYIKADGQNIGCRFPYLEASDYKDF
YICVNGSSENKPIRSSYFTFQLQNIVKPLP
PVYLTFTRESSCEIKLKWSIPLGPIPARCF
DYEIEIREDDTTLVTATVENETYTLKTTNE
TRQLCFVVRSKVNIYCSDDGIWSEWSDKQC
WEGEDLSKK
Linker residues 340- GTGSEF
345 of SEQ ID
NO: 317 BSC1MT residues 346- IAQAYRKLA
354 of SEQ ID
NO: 317 Linker residues 355- DIGGGSGGSGGSGGAAALE
373 of SEQ ID
NO: 317 V5 epitope residues 374- GKPIPNPLLGLDST
domain 387 of SEQ ID
NO: 317 Schematic diagrams of IL13Ra2TF (target protein alone), IL13Ra2TF-BSC1, and IL13Ra2TF-BSC1MT proteins are shown in Fig. 20A. Cells were transfected with vector comprising a recombinant gene encoding IL13Ra2TF (control), IL13Ra2TF-BSC1, or IL13Ra2TF-BSC1MT and grown in separate cultures as described above. Culture media from each culture was assayed for the presence of the proteins by immunoblot using an anti-V5 antibody as described above.
As shown in Figure 20B, relatively little IL13Ra2TF protein was detected in culture medium of the control cell culture. See, lane 2 of Fig. 20B. In contrast, a significantly higher level of the IL13Ra2TF-BSC1 fusion protein was detected in culture medium of cells transfected with a vector comprising a gene encoding the IL13Ra2TF-BSC1 fusion protein. See, lane 3 of Fig. 20B. The amount of IL13Ra2TF-BSC1 fusion protein detected in the culture medium was also significantly higher than the level of protein detected in culture medium of cells transfected with a vector encoding the IL13Ra2TF-BSC1MT fusion protein. This latter protein was expressed at approximately the same low level as detected for the IL13Ra2TF protein in control cells. See, lane 4 of Fig. 20B. The results show the BSC1 polypeptide (IKKAYRKLA; SEQ ID NO:48) is effective as a protein expression enhancing polypeptide in a modified arrangement of the invention and that alteration of the internal K-K dipeptide can destroy such activity.
Example 13. BSC1-Protein A Fusion Protein Enhances Expression of IL13Ra2TF-V5-Fc Target Protein in an Unmodified Arrangement The BSC1 polypeptide (IKKAYRKLA, SEQ ID NO:48), the minimal polypeptide fragment of the J domain of Erdj3 described above, was used to construct a BSC1-Protein A fusion protein shown in the table below to determine whether the BSC1-Protein A fusion protein could be used in an unmodified arrangement for enhancing expression of an IL13Ra2TF-V5-Fc target protein described above.
Table 62. Amino acid Sequence of a Flag-Tagged BSC1-Protein A Fusion Protein Protein Domain Sequence Amino Acid Sequence Identifier 123456789012345678901234567890 Flag-tagged BSC1- SEQ ID NO:318 MGVKVLFALICIAVAEAGTGSGEFIKKAYR
Protein A Fusion KLADIGGGSGGSGGSGGAAAADNKFNKEQQ
NAFYEILNMPNLNEEQRNGFIQSLKDDPSQ
SANVLGEAKKLNDSQAPKLEGDYKDDDDK
signal sequence residues 1-17 MGVKVLFALICIAVAEA
of SEQ ID
NO: 318 linker 1 residues 18-24 GTGSGEF
of SEQ ID
NO: 318 BSC1 polypeptide residues 25-33 IKKAYRKLA
of SEQ ID
NO: 318 linker 2 residues 34-50 DIGGGSGGSGGSGGAAA
of SEQ ID
NO: 318 Protein A residues 51-108 ADNKFNKEQQNAFYEILNMPNLNEEQRNGF
of SEQ ID IQSLKDDPSQSANVLGEAKKLNDSQAPK
NO: 318 linker 3 residues 109- LEG
111 of SEQ ID
NO: 318 Flag epitope tag residues 112- DYKDDDDK
119 of SEQ ID
NO: 318 The IL13Ra2TF-V5-Fc target protein was expressed with or without BSC1-Protein A fusion protein in HEK293 cells. Cultures were grown for two days, and the media were harvested and centrifuged to remove the debris. Expression of the IL13Ra2TF-V5-Fc target protein was significantly enhanced in the medium of cells co-expressing the target protein and the BSC1-Protein A fusion compared to level of expression of the target protein in the absence of the BSC1-Protein A
fusion protein (data not shown).
To determine whether the IL13Ra2TF-V5-Fc target protein expressed in culture medium retained IL13 binding activity, the following binding assay was performed.
Recombinant human IL13 was added to samples of the media from cultures of cells that did not express either of the proteins (control), that expressed only the IL13Ra2TF-V5-Fc target protein, and that co-expressed the IL13Ra2TF-V5-Fc target protein and the BSC1-Protein A fusion protein. The samples were incubated with the IL13 for 2 hours. The samples were used in an IL13 detection assay (RayBio0 Human IL13 ELISA Kit; ELH-1L13-001). In this assay, the detection of human IL13 decreases when human IL13 is trapped by IL13Ra2TF-V5-Fc target protein. As shown in Figure 21B, the medium from a culture of cells expressing neither protein clearly did not bind IL13 as indicated by the high level absorbance (lane 1 of Fig. 21). Medium from a culture of cells expressing only the IL13Ra2TF-V5-Fc target protein bound some IL13 (lane 2), but a significantly greater amount of IL13 was bound the medium from a culture of cells co-expressing the IL13Ra2TF-V5-Fc target protein and the BSC1-Protein A fusion protein (lane 3). The results clearly show that more human IL13 was bound in medium containing the enhanced level of expression of the IL13Ra2TF-V5-Fc target protein.
Accordingly, the IL13Ra2TF-V5-Fc target protein expressed in culture medium at an enhanced level retained its IL13 binding activity.
Example 14. BSC1-Protein G Fusion Protein Enhances Expression of a Factor VII-V5-Fc Target Protein in an Unmodified Arrangement Factor VII (FVII) is the serine esterase of the extrinsic coagulation pathway and widely used to treat a variety of bleeding complications. See, Hedner, Semin. Hematol., 43(suppl 1): S105-S107 (2006). A complex of FVII and tissue factor (TF) in the presence of phospholipids and calcium activates Factor X to Factor Xa.
A BSC1 polypeptide was used to construct a BSC1-Protein G fusion protein to determine whether the fusion protein was effective in enhancing an FVII-V5-Fc target protein in an unmodified arrangement.
The amino acid sequence of the VS-tagged FVII-Fc target protein is shown in the table below.
Table 63. Amino Acid Sequence of a VS-Tagged FVII-Fc Target Protein.
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) 123456789012345678901234567890 V5-tagged FVII- SEQ ID NO:319 MVSQALRLLCLLLGLQGCLAAGGVAKASGG
Fc target ETRDMPWKPGPHRVFVTQEEAHGVLHRRRR
protein ANAFLEELRPGSLERECKEEQCSFEEAREI
FKDAERTKLFWISYSDGDQCASSPCQNGGS
CKDQLQSYICFCLPAFEGRNCETHKDDQLI
CVNENGGCEQYCSDHTGTKRSCRCHEGYSL
LADGVSCTPTVEYPCGKIPILEKRNASKPQ
GRIVGGKVCPKGECPWQVLLLVNGAQLCGG
TLINTIWVVSAAHCFDKIKNWRNLIAVLGE
HDLSEHDGDEQSRRVAQVIIPSTYVPGTTN
HDIALLRLHQPVVLTDHVVPLCLPERTFSE
RTLAFVRFSLVSGWGQLLDRGATALELMVL
NVPRLMTQDCLQQSRKVGDSPNITEYMFCA
GYSDGSKDSCKGDSGGPHATHYRGTWYLTG
IVSWGQGCATVGHFGVYTRVSQYIEWLQKL
MRSEPRPGVLLRAPFPLEGKPIPNPLLGLD
STSRPKSCDKTHTCPPCPAPELLGGPSVFL
FPPKPKDTLMISRTPEVTCVVVDVSHEDPE
VKFNWYVDGVEVHNAKTKPREEQYNSTYRV
VSVLTVLHQDWLNGKEYKCKVSNKALPAPI
EKTISKAKGQPREPQVYTLPPSRDELTKNQ
VSLTCLVKGFYPSDIAVEWESNGQPENNYK
TTPPVLDSDGSFFLYSKLTVDKSRWQQGNV
FSCSVMHEALHNHYTQKSLSLSPGK
FVII residues of SEQ ID ETRDMPWKPGPHRVFVTQEEAHGVLHRRRR
NO: 319 ANAFLEELRPGSLERECKEEQCSFEEAREI
FKDAERTKLFWISYSDGDQCASSPCQNGGS
CKDQLQSYICFCLPAFEGRNCETHKDDQLI
CVNENGGCEQYCSDHTGTKRSCRCHEGYSL
LADGVSCTPTVEYPCGKIPILEKRNASKPQ
GRIVGGKVCPKGECPWQVLLLVNGAQLCGG
TLINTIWVVSAAHCFDKIKNWRNLIAVLGE
HDLSEHDGDEQSRRVAQVIIPSTYVPGTTN
HDIALLRLHQPVVLTDHVVPLCLPERTFSE
RTLAFVRFSLVSGWGQLLDRGATALELMVL
NVPRLMTQDCLQQSRKVGDSPNITEYMFCA
GYSDGSKDSCKGDSGGPHATHYRGTWYLTG
IVSWGQGCATVGHFGVYTRVSQYIEWLQKL
MRSEPRPGVLLRAPFP
Linker 1 residues 467- LE
468 of SEQ ID
NO: 319 V5 epitope residues 469- GKPIPNPLLGLDST
domain 482 of SEQ ID
NO: 319 Linker 2 residues 483- SR
484 of SEQ ID
NO: 319 Fc domain residues 485- PKSCDKTHTCPPCPAPELLGGPSVFLFPPK
715 of SEQ ID PKDTLMISRTPEVTCVVVDVSHEDPEVKFN
NO: 319 WYVDGVEVHNAKTKPREEQYNSTYRVVSVL
Protein Region Sequence Amino Acid Sequence (N¨ to C¨ Identifier terminal) 123456789012345678901234567890 TVLHQDWLNGKEYKCKVSNKALPAP IEKT I
SKAKGQPREPQVYTLPPSRDELTKNQVSLT
CLVKGFYP SD IAVEWESNGQPENNYKTTPP
VLDSDGSFFLYSKLTVDKSRWQQGNVFSCS
VMHEALHNHYTQKSLSLSPGK
The amino acid sequence of the Flag-tagged BSC1-Protein G fusion protein is shown in the table below.
Table 64. Amino Acid Sequence of a Flag-Tagged BSC1-Protein G Fusion Protein Protein Domain Sequence Amino Acid Sequence Identifier 123456789012345678901234567890 Flag-tagged BSC1- SEQ ID NO:320 MGVKVLFAL I C IAVAEAGTGSGEF I KKAYR
Protein G Fusion KLADIGGGSGGSGGSGGAAAATYKLVINGK
TLKGETTTEAVDAATAEKVFKQYANDNGVD
GEWTYDDATKTFTVTEKPEVIDASELTPAV
TLEGDYKDDDDK
signal sequence residues 1-17 MGVKVLFALICIAVAEA
of SEQ ID
NO:320 linker 1 residues 18-24 GTGSGEF
of SEQ ID
NO:320 BSC1 polypeptide residues 25-33 IKKAYRKLA
of SEQ ID
NO:320 linker 2 residues 34-50 DIGGGSGGSGGSGGAAA
of SEQ ID
NO:320 Protein G residues 51-121 TYKLVINGKTLKGETTTEAVDAATAEKVFK
of SEQ ID QYANDNGVDGEWTYDDATKTFTVTEKPEVI
NO:320 DASELTPAVT
linker 3 residues 122- LEG
124 of SEQ ID
NO:320 Flag epitope tag residues 126- DYKDDDDK
132 of SEQ ID
NO: 320 The level of expression of the FVII-Fc target protein was determined by immunoblot assay using anti-Flag antibody in both culture media and lysates of cells expressing neither protein, of cells expressing only the FVII-Fc target protein, and of cells co-expressing the FVII-Fc target protein and the BSC1-Protein G fusion proteins. The results are shown in Figure 22A. As shown in the top panel of Figure 22A, the level of expression of the FVII-Fc target protein secreted into the culture medium was significantly greater in a culture of cells co-expressing the FVII-Fc target protein and the BSC1-Protein G fusion protein (lane 2) than in a culture of cells expressing the FVII-Fc target protein alone (lane 3). The middle panel of Figure 22A is an immunoblot of cell lysates using an anti-Flag antibody. The immunoblot shows that the BSC1-Protein G fusion protein was expressed in cells expressing both the FVII-Fc target protein and the BSC1-Protein G fusion protein. As shown in the bottom panel of Figure 22A, no significant amount of the BSC1-Protein G fusion protein was secreted into the medium with the FVII-Fc target protein (see, lane 3).
Figure 22B shows bar graphs of a densitometry analysis of the signal of the for FVII-Fc target protein expression in culture media shown in the top immunoblot in Figure 22A.
Bar graphs 1, 2, and 3 of Figure 22B correspond to the signals of lanes 1, 2, and 3 in the top immunoblot in Figure 22A.
The results show that the co-expression of the BSC1-Protein G fusion protein and the FVII-Fc target protein significantly enhanced the level of expression of the target protein secreted into culture medium as compared to the level in that absence of the BSC1-Protein G fusion protein.
Example 15. BSC1-Protein A Fusion Protein Enhances Expression of a Factor IX-V5-Fc Target Protein in an Unmodified Arrangement Factor IX has been widely used for the treatment of hemophilia B, and its Fc fusion protein (FIX-Fc) is currently in a clinical trial (phase III) with positive result (prolonged effect).
In this experiment, the effect of the BSC1-Protein A fusion protein described above on the level of expression of an FIX-Fc target protein in an unmodified arrangement was determined.
The amino acid sequence of the VS-tagged FIX-Fc target protein is shown in the table below.
Table 65. Amino Acid Sequence of a VS-Tagged FIX-Fc Target Protein.
Protein Region Sequence Amino Acid Sequence (N¨ to C¨ Identifier terminal) V5-tagged FIX-Fc SEQ
ID NO:321 MQRVNMIMAESPGLITICLLGYLLSAECTV
fusion molecule FLDHENANKILNRPKRYNSGKLEEFVQGNL
ERECMEEKCSFEEAREVFENTERTTEFWKQ
YVDGDQCESNPCLNGGSCKDDINSYECWCP
FGFEGKNCELDVTCNIKNGRCEQFCKNSAD
NKVVCSCTEGYRLAENQKSCEPAVPFPCGR
VSVSQTSKLTRAETVFPDVDYVNSTEAETI
LDNITQSTQSFNDFTRVVGGEDAKPGQFPW
QVVLNGKVDAFCGGSIVNEKWIVTAAHCVE
TGVKITVVAGEHNIEETEHTEQKRNVIRII
PHHNYNAAINKYNHDIALLELDEPLVLNSY
VTPICIADKEYTNIFLKFGSGYVSGWGRVF
HKGRSALVLQYLRVPLVDRATCLRSTKFTI
YNNMFCAGFHEGGRDSCQGDSGGPHVTEVE
GTSFLTGIISWGEECAMKGKYGIYTKVSRY
VNWIKEKTKLTLEGKPIPNPLLGLDSTSRP
KSCDKTHTCPPCPAPELLGGPSVFLFPPKP
KDTLMISRTPEVTCVVVDVSHEDPEVKFNW
YVDGVEVHNAKTKPREEQYNSTYRVVSVLT
VLHQDWLNGKEYKCKVSNKALPAPIEKTIS
KAKGQPREPQVYTLPPSRDELTKNQVSLTC
LVKGFYPSDIAVEWESNGQPENNYKTTPPV
LDSDGSFFLYSKLTVDKSRWQQGNVFSCSV
Protein Region Sequence Amino Acid Sequence (N¨ to C¨ Identifier terminal) MHEALHNHYTQKSLSLSPGK
FIX
residues 1-461 MQRVNMIMAESPGLITICLLGYLLSAECTV
of SEQ ID
FLDHENANKILNRPKRYNSGKLEEFVQGNL
NO: 321 ERECMEEKCSFEEAREVFENTERTTEFWKQ
YVDGDQCESNPCLNGGSCKDDINSYECWCP
FGFEGKNCELDVTCNIKNGRCEQFCKNSAD
NKVVCSCTEGYRLAENQKSCEPAVPFPCGR
VSVSQTSKLTRAETVFPDVDYVNSTEAETI
LDNITQSTQSFNDFTRVVGGEDAKPGQFPW
QVVLNGKVDAFCGGSIVNEKWIVTAAHCVE
TGVKITVVAGEHNIEETEHTEQKRNVIRII
PHHNYNAAINKYNHDIALLELDEPLVLNSY
VTPICIADKEYTNIFLKFGSGYVSGWGRVF
HKGRSALVLQYLRVPLVDRATCLRSTKFTI
YNNMFCAGFHEGGRDSCQGDSGGPHVTEVE
GTSFLTGIISWGEECAMKGKYGIYTKVSRY
VNWIKEKTKLT
Linker 1 residues 462- LE
463 of SEQ ID
NO:321 V5 epitope residues 464- GKPIPNPLLGLDST
domain 477 of SEQ ID
NO:321 Linker 2 residues 478- SR
479 of SEQ ID
NO:321 Fc domain residues 480- PKSCDKTHTCPPCPAPELLGGPSVFLFPPK
710 of SEQ ID PKDTLMISRTPEVTCVVVDVSHEDPEVKFN
NO: 321 WYVDGVEVHNAKTKPREEQYNSTYRVVSVL
TVLHQDWLNGKEYKCKVSNKALPAPIEKTI
SKAKGQPREPQVYTLPPSRDELTKNQVSLT
CLVKGFYPSDIAVEWESNGQPENNYKTTPP
VLDSDGSFFLYSKLTVDKSRWQQGNVFSCS
VMHEALHNHYTQKSLSLSPGK
Figure 23A shows the expression of the FIX-Fc target protein secreted into the media of cultures of transfected cells expressing the FIX-Fc target protein alone (lane 2) and of transfected cells co-expressing the FIX-Fc fusion protein and the BSC1-Protein A fusion protein (lane 3). Lane 1 of Figure 23A shows medium from a culture of non-expressing cells as a control.
As shown in lane 2 of Figure 23A, some FIX-Fc target protein is secreted by cells expressing the FIX-Fc target protein alone. However, as clearly shown in lane 3 of Figure 23A, the level of expression of the target protein secreted into medium is significantly enhanced in cells expressing the FIX-Fc target protein and the BSC1-Protein A fusion protein. Figure 23B shows bar graphs of a densitometry analysis of the signals in the immunoblot of Figure 23A. Bar graphs 1, 2, and 3 of Figure 23B correspond to the signals of lanes 1, 2, and 3 in Figure 23A.
The results clearly show that the co-expression of the BSC1-Protein A fusion protein and the FIX-Fc target protein significantly enhanced the level of expression of the target protein secreted into culture medium as compared to the level in that absence of the BSC1-Protein A
fusion protein.
Example 16. BSC1-Protein G Fusion Protein Enhances Expression of a Factor VIII-V5-Fc Target Protein in an Unmodified Arrangement The biological importance of Factor FVIII is demonstrated in hemophilia A, a congenital bleeding disorder occurring primarily in males that results from an X-chromosome-linked deficiency of FVIII. Standard treatment involves replacing the missing FVIII to stop the bleeding. A FVIII-Fc fusion protein was developed to provide a prolonged half-life of FVIII
activity in hemophilia A
patients (Powell et al., Blood, 119(13): 3031-3037 (2012)). The fusion protein was approved by the United States Food and Drug Administration in 2013 (ELOCTATETm; Biogen Idec).
This experiment examined the effect of the BSC1-Protein G fusion protein described above on the level of expression of a VS-tagged FVIII-Fc target protein in an unmodified arrangement. The amino acid sequence of the VS-tagged FVIII-Fc target protein is shown in the table below.
Table 66. Amino Acid Sequence of a VS-Tagged FVIII-Fc Target Protein.
Protein Region Sequence Amino Acid Sequence (N¨ to C¨ Identifier terminal) V5-tagged FVIII- SEQ
ID NO:322 MQIELSTCFFLCLLRFCFSATRRYYLGAVE
Fc fusion LSWDYMQSDLGELPVDARFPPRVPKSFPFN
molecule TSVVYKKTLFVEFTDHLFNIAKPRPPWMGL
LGPTIQAEVYDTVVITLKNMASHPVSLHAV
GVSYWKASEGAEYDDQTSQREKEDDKVFPG
GSHTYVWQVLKENGPMASDPLCLTYSYLSH
VDLVKDLNSGLIGALLVCREGSLAKEKTQT
LHKFILLFAVFDEGKSWHSETKNSLMQDRD
AASARAWPKMHTVNGYVNRSLPGLIGCHRK
SVYWHVIGMGTTPEVHSIFLEGHTFLVRNH
RQASLEISPITFLTAQTLLMDLGQFLLFCH
ISSHQHDGMEAYVKVDSCPEEPQLRMKNNE
EAEDYDDDLTDSEMDVVRFDDDNSPSFIQI
RSVAKKHPKTWVHYIAAEEEDWDYAPLVLA
PDDRSYKSQYLNNGPQRIGRKYKKVRFMAY
TDETFKTREAIQHESGILGPLLYGEVGDTL
LIIFKNQASRPYNIYPHGITDVRPLYSRRL
PKGVKHLKDFPILPGEIFKYKWTVTVEDGP
TKSDPRCLTRYYSSFVNMERDLASGLIGPL
LICYKESVDQRGNQIMSDKRNVILFSVFDE
NRSWYLTENIQRFLPNPAGVQLEDPEFQAS
NIMHSINGYVFDSLQLSVCLHEVAYWYILS
IGAQTDFLSVFFSGYTFKHKMVYEDTLTLF
PFSGETVFMSMENPGLWILGCHNSDFRNRG
MTALLKVSSCDKNTGDYYEDSYEDISAYLL
SKNNAIEPRSFSQNSRHPSTRQKQFNATTI
PENDIEKTDPWFAHRTPMPKIQNVSSSDLL
MLLRQSPTPHGLSLSDLQEAKYETFSDDPS
PGAIDSNNSLSEMTHFRPQLHHSGDMVFTP
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) ESGLQLRLNEKLGTTAATELKKLDFKVSST
SNNL I S T IP SDNLAAGTDNT S SLGPPSMPV
HYD S QL DTT LF GKKS SPL TES GGPL SL SEE
NND SKL LE SGLMNS QE SSWGKNVS S TES GR
LFKGKRAHGPALLTKDNALFKVS I SLLKTN
KT SNNSATNRKTHI DGPSLL IENSPSVWQN
I LE S DTEFKKVTPL I HDRMLMDKNATALRL
NHMSNKTTSSKNMEMVQQKKEGP I PPDAQN
PDMSFFKMLFLPESARWIQRTHGKNSLNSG
QGPSPKQLVSLGPEKSVEGQNFLSEKNKVV
VGKGEFTKDVGLKEMVFPSSRNLFLTNLDN
LHENNTHNQEKKIQEEIEKKETL I QENVVL
PQIHTVTGTKNFMKNLFLLSTRQNVEGSYD
GAYAPVLQDFRSLNDSTNRTKKHTAHFSKK
GEEENLEGLGNQTKQIVEKYACTTRISPNT
SQQNFVTQRSKRALKQFRLP LEE TE LEKR I
IVDDT S TQWSKNMKHL TP S TL TQ I DYNEKE
KGAITQSPLSDCLTRSHS IPQANRSPLP IA
KVS SETS IRP I YL TRVLFQDNS SHLPAASY
RKKDSGVQESSHFLQGAKKNNLSLAILTLE
MTGDQREVGSLGTSATNSVTYKKVENTVLP
KPDLPKTSGKVELLPKVHIYQKDLFPTETS
NGSPGHLDLVEGSLLQGTEGAIKWNEANRP
GKVPFLRVATESSAKTPSKLLDPLAWDNHY
GTQ IPKEEWKSQEKSPEKTAFKKKDT I L SL
NACE SNHAIAAINEGQNKPE I EVTWAKQGR
TERLC SQNPPVLKRHQRE I TRTTLQSDQEE
IDYDDT I SVEMKKEDFDI YDEDENQSPRSF
QKKTRHYF IAAVERLWDYGMSSSPHVLRNR
AQSGSVPQFKKVVFQEFTDGSFTQPLYRGE
LNEHLGLLGPYIRAEVEDNIMVTFRNQASR
PYSFYSSL I SYEEDQRQGAEPRKNFVKPNE
TKTYFWKVQHHMAPTKDEFDCKAWAYF S DV
DLEKDVHSGL I GPLLVCHTNTLNPAHGRQV
TVQEFALFFT IFDETKSWYFTENMERNCRA
PCNIQMEDPTFKENYRFHAINGYIMDTLPG
LVMAQDQRIRWYLLSMGSNENIHS IHFSGH
VFTVRKKEEYKMALYNLYPGVFETVEMLPS
KAGIWRVECL I GEHLHAGMS TLFLVYSNKC
QTPLGMAS GH I RDFQ I TAS GQYGQWAPKLA
RLHYSGSINAWSTKEPFSWIKVDLLAPMI I
HGIKTQGARQKFSSLYI SQF I IMYSLDGKK
WQTYRGNSTGTLMVFFGNVDSSGIKHNIFN
PP I IARYIRLHPTHYS IRS TLRMELMGCDL
NSCSMPLGMESKAI SDAQ I TAS SYFTNMFA
TWSPSKARLHLQGRSNAWRPQVNNPKEWLQ
VDFQKTMKVTGVTTQGVKSLLTSMYVKEFL
I S S SQDGHQWTLFFQNGKVKVFQGNQDSFT
PVVNSLDPPLLTRYLRIHPQSWVHQIALRM
EVLGCEAQDLYLEGKPIPNPLLGLDSTSRP
KS CDKTHT CPP CPAPE LL GGP SVF LFPPKP
KDTLMI SRTPEVTCVVVDVSHEDPEVKFNW
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) 123456789012345678901234567890 YVDGVEVHNAKTKPREEQYNSTYRVVSVLT
VLHQDWLNGKEYKCKVSNKALPAPIEKTIS
KAKGQPREPQVYTLPPSRDELTKNQVSLTC
LVKGFYPSDIAVEWESNGQPENNYKTTPPV
LDSDGSFFLYSKLTVDKSRWQQGNVFSCSV
MHEALHNHYTQKSLSLSPGK
FVIII residues of SEQ ID
LSWDYMQSDLGELPVDARFPPRVPKSFPFN
NO: 322 TSVVYKKTLFVEFTDHLFNIAKPRPPWMGL
LGPTIQAEVYDTVVITLKNMASHPVSLHAV
GVSYWKASEGAEYDDQTSQREKEDDKVFPG
GSHTYVWQVLKENGPMASDPLCLTYSYLSH
VDLVKDLNSGLIGALLVCREGSLAKEKTQT
LHKFILLFAVFDEGKSWHSETKNSLMQDRD
AASARAWPKMHTVNGYVNRSLPGLIGCHRK
SVYWHVIGMGTTPEVHSIFLEGHTFLVRNH
RQASLEISPITFLTAQTLLMDLGQFLLFCH
ISSHQHDGMEAYVKVDSCPEEPQLRMKNNE
EAEDYDDDLTDSEMDVVRFDDDNSPSFIQI
RSVAKKHPKTWVHYIAAEEEDWDYAPLVLA
PDDRSYKSQYLNNGPQRIGRKYKKVRFMAY
TDETFKTREAIQHESGILGPLLYGEVGDTL
LIIFKNQASRPYNIYPHGITDVRPLYSRRL
PKGVKHLKDFPILPGEIFKYKWTVTVEDGP
TKSDPRCLTRYYSSFVNMERDLASGLIGPL
LICYKESVDQRGNQIMSDKRNVILFSVFDE
NRSWYLTENIQRFLPNPAGVQLEDPEFQAS
NIMHSINGYVFDSLQLSVCLHEVAYWYILS
IGAQTDFLSVFFSGYTFKHKMVYEDTLTLF
PFSGETVFMSMENPGLWILGCHNSDFRNRG
MTALLKVSSCDKNTGDYYEDSYEDISAYLL
SKNNAIEPRSFSQNSRHPSTRQKQFNATTI
PENDIEKTDPWFAHRTPMPKIQNVSSSDLL
MLLRQSPTPHGLSLSDLQEAKYETFSDDPS
PGAIDSNNSLSEMTHFRPQLHHSGDMVFTP
ESGLQLRLNEKLGTTAATELKKLDFKVSST
SNNLISTIPSDNLAAGTDNTSSLGPPSMPV
HYDSQLDTTLFGKKSSPLTESGGPLSLSEE
NNDSKLLESGLMNSQESSWGKNVSSTESGR
LFKGKRAHGPALLTKDNALFKVSISLLKTN
KTSNNSATNRKTHIDGPSLLIENSPSVWQN
ILESDTEFKKVTPLIHDRMLMDKNATALRL
NHMSNKTTSSKNMEMVQQKKEGPIPPDAQN
PDMSFFKMLFLPESARWIQRTHGKNSLNSG
QGPSPKQLVSLGPEKSVEGQNFLSEKNKVV
VGKGEFTKDVGLKEMVFPSSRNLFLTNLDN
LHENNTHNQEKKIQEEIEKKETLIQENVVL
PQIHTVTGTKNFMKNLFLLSTRQNVEGSYD
GAYAPVLQDFRSLNDSTNRTKKHTAHFSKK
GEEENLEGLGNQTKQIVEKYACTTRISPNT
SQQNFVTQRSKRALKQFRLPLEETELEKRI
IVDDTSTQWSKNMKHLTPSTLTQIDYNEKE
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) KGAITQSPLSDCLTRSHSIPQANRSPLPIA
KVSSFPSIRPIYLTRVLFQDNSSHLPAASY
RKKDSGVQESSHFLQGAKKNNLSLAILTLE
MTGDQREVGSLGTSATNSVTYKKVENTVLP
KPDLPKTSGKVELLPKVHIYQKDLFPTETS
NGSPGHLDLVEGSLLQGTEGAIKWNEANRP
GKVPFLRVATESSAKTPSKLLDPLAWDNHY
GTQIPKEEWKSQEKSPEKTAFKKKDTILSL
NACESNHAIAAINEGQNKPEIEVTWAKQGR
TERLCSQNPPVLKRHQREITRTTLQSDQEE
IDYDDTISVEMKKEDFDIYDEDENQSPRSF
QKKTRHYFIAAVERLWDYGMSSSPHVLRNR
AQSGSVPQFKKVVFQEFTDGSFTQPLYRGE
LNEHLGLLGPYIRAEVEDNIMVTFRNQASR
PYSFYSSLISYEEDQRQGAEPRKNFVKPNE
TKTYFWKVQHHMAPTKDEFDCKAWAYFSDV
DLEKDVHSGLIGPLLVCHTNTLNPAHGRQV
TVQEFALFFTIFDETKSWYFTENMERNCRA
PCNIQMEDPTFKENYRFHAINGYIMDTLPG
LVMAQDQRIRWYLLSMGSNENIHSIHFSGH
VFTVRKKEEYKMALYNLYPGVFETVEMLPS
KAGIWRVECLIGEHLHAGMSTLFLVYSNKC
QTPLGMASGHIRDFQITASGQYGQWAPKLA
RLHYSGSINAWSTKEPFSWIKVDLLAPMII
HGIKTQGARQKFSSLYISQFIIMYSLDGKK
WQTYRGNSTGTLMVFFGNVDSSGIKHNIFN
PPIIARYIRLHPTHYSIRSTLRMELMGCDL
NSCSMPLGMESKAISDAQITASSYFTNMFA
TWSPSKARLHLQGRSNAWRPQVNNPKEWLQ
VDFQKTMKVTGVTTQGVKSLLTSMYVKEFL
ISSSQDGHQWTLFFQNGKVKVFQGNQDSFT
PVVNSLDPPLLTRYLRIHPQSWVHQIALRM
EVLGCEAQDLY
Linker residues 2352- LE
2353 of SEQ ID
NO:322 V5 epitope residues 2354- GKPIPNPLLGLDST
domain 2367 of SEQ ID
NO:322 Linker residues 2368- SR
2369 of SEQ ID
NO:322 Fc domain residues 2370- PKSCDKTHTCPPCPAPELLGGPSVFLFPPK
2600 of SEQ ID PKDTLMISRTPEVTCVVVDVSHEDPEVKFN
NO:322 WYVDGVEVHNAKTKPREEQYNSTYRVVSVL
TVLHQDWLNGKEYKCKVSNKALPAPIEKTI
SKAKGQPREPQVYTLPPSRDELTKNQVSLT
CLVKGFYPSDIAVEWESNGQPENNYKTTPP
VLDSDGSFFLYSKLTVDKSRWQQGNVFSCS
VMHEALHNHYTQKSLSLSPGK
In this experiment, the level of expression of the FVIII-Fc target protein in the presence and absence of the BSC1-Protein G fusion protein. Media from cultures of cells (HEK293) expressing neither protein, of cells expressing only the FVIII-Fc target protein, and of cells co-expressing the BSC1-Protein G fusion protein and the FVIII-Fc target protein was assayed for FVIII using a commercially available, enzyme-linked immunosorbent assay (ELISA) (VisulizeTM
FVIII Antigen Kit, Affinity Biologics Inc.). The results are shown as bar graphs of Absorbance at 450 nm in Figure 24. Culture medium from cells transfected with an empty vector and expressing neither protein was used for a negative control (first bar graph from left in Figure 24), and human serum was used as a positive control (last bar graph on right of Figure 24). The results show that co-expression of the BSC1-Protein G fusion protein with the FVIII-Fc target protein significantly enhanced the level of expression of the FVIII-Fc target protein secreted into the culture medium (third bar graph from left in Figure 24) as compared to the level of expression of the target protein in the absence of the BSC1-Protein G fusion protein (second bar graph from left in Figure 24).
Example 17. BSC1-Protein A Fusion Protein Enhances Expression of an Anti-IL-8 Antibody Target Protein in an Unmodified Arrangement This experiment examined whether a BSC1-Protein A fusion protein as described above could be used in an unmodified arrangement to improve the level of expression of an anti-IL-8 antibody target protein expressed in transfected HEK293 cells.
Expression of anti-IL-8 antibody in culture media was determined by immunodot blot using an anti-IgG antibody. As shown in the immunodot blots in Figure 25A, co-expression of the anti-1L8 antibody target protein with the BSC1-Protein A fusion protein significantly enhanced the level of expression of the antibody secreted into the culture medium (bottom row 3 of Figure 25A) as compared to the level of the antibody expressed in cells expressing the antibody alone (middle row 2 of Figure 25A). The top row of Figure 25A shows no antibody was secreted into medium from a mock culture of control cells that expressed neither protein.
The results of a densitometry analysis of the chemiluminescent signals in the dot blots in the rows in Figure 25A using the NIH ImageJ image processing program are shown in the respective bar graphs in Figure 25B. The bars of Figure 25B are numbered to correspond to the row numbers of Figure 25A. The results of this series of experiments clearly show that co-expression of the anti-1L8 antibody target protein with a fusion protein of the invention comprising the BSC1 polypeptide linked to a Protein A (target protein binding domain) significantly enhanced the expression of secreted anti-1L8 antibody.
Figure 25C shows the results of an ELISA assay. A 96-well plate was coated with recombinant purified human IL8, and incubated with the anti-IL-8 antibody (target protein) secreted into the media of cultures of transfected cells expressing the anti-1L8 antibody alone (lane 2) and of cells co-expressing anti-1L8 antibody target protein and the BSC1-Protein A
fusion protein (lane 3, PCT/US13/73442 03-10-2014 PCT/US2013/073442 08.04.2015 BSC1-Protein A). Mock cultures contained cells transfected with expression vector lacking a structural gene for expressing any protein (no anti-1L8 antibody, first lane).
The results clearly show that the secreted anti-1L8 antibody that was expressed at enhanced levels when co-expressed with BSC I-Protein A fusion protein retained its binding activity for human 11,8.
Example 18. BSC1-Protein A Fusion Protein Enhances Expression of a Therapeutic Anti-VEGF Antibody (Bevacizumab) Target Protein in an Unmodified Arrangement This experiment examined whether a BSC1-Protein A fusion protein as described above could be used in an unmodified arrangement to improve the level of expression of a therapeutic antibody.
Bevacizumab (Avastin , Genentech/Roche) is a humanized monoclonal antibody that inhibits angiogenesis by inhibiting vascular endothelial growth factor A (VEGF-A). Sales of bevacizumab in 2010 were close to $7 billion and exceeded all other antibody drugs. The addition of bevacizumab to standard treatment can prolong the lives of breast and lung cancer patients by several months at a current cost of approximately $100,000 a year in the United States.
The amino acid sequences for the light and heavy chains of bevacizumab are shown in the table below.
Table 67. Amino Acid Sequences Light and Heavy Chains of Bevacizumab.
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) Light chain SEQ ID NO:323 MGWSCIILFLVATATGVHSDIQMTQSPSSL
SASVGDRVTITCSASQDISNYLNWYQQKPG
KAPKVLIYFTSSLHSGVPSRFSGSGSGTDF
TLTISSLQPEDFATYYCQQYSTVPWTFGQG =
TKVEIKRTVAAPSVFIFPPSDEQLKSGTAS
VVCLLNNFYPREAKVQWKVDNALQSGNSQE
SVTEQDSKDSTYSLSSTLTLSKADYEKHKV
YACEVTHQGLSSPVTKSFNRGEC
Heavy chain SEQ ID NO:327 MGWSLIILFLVATATGVHSEVQLVESGGGL
VQPGGSLRLSCAASGYTFTNYGMNWVRQAP
GKGLEWVGWINTYTGEPTYAADFKRRFTFS
LDTSKSTAYLQMNSLRAEDTAVYYCAKYPH
YYGSSHWYFDVWGQGTLVTVSSASTKGPSV
FPLAPSSKSTSGGTAALGCLVKDYFPEPVT
VSWNSGALTSGVHTFPAVLQSSGLYSLSSV
VTVPSSSLGTQTYICNVNHKPSNTKVDKKV
EPKSCDKTHTCPPCPAPELLGGPSVFLFPP
KPKDTLMISRTPEVTCVVVDVSHEDPEVKF
NWYVDGVEVHNAKTKPREEQYNSTYRVVSV
LTVLHQDWLNGKEYKCKVSNKALPAPIEKT
ISKAKGQPREPQVYTLPPSRDELTKNQVSL
TCLVKGFYPSDIAVEWESNGQPENNYKTTP
PVLDSDGSFFLYSKLTVDKSRWQQGNVFSC
SVMHEALHNHYTQKSLSLSPGK
AMENDED SHEET - IPEA/US
The anti-VEGF antibody bevacizumab (target protein) was expressed in human cells in the presence and absence of the BSC1-Protein A fusion protein. A mock culture contained cells that expressed neither protein. Samples of the media from cell cultures were assayed for antibody by immunodot blot assay using an anti-human IgG antibody.
Figure 26A shows a dot blot assay for expression of the bevacizumab (anti-VEGF
antibody) secreted into the media of cultures of transfected cells expressing bevacizumab alone (middle row) and co-expressing bevacizumab and the BSC1-Protein A fusion protein (bottom row). The top row of Figure 26A shows that no antibody was secreted into medium from a mock culture of control cells that lacked a structural gene for either protein. The results show that co-expression in transfected cells of the bevacizumab target protein and the BSC1-Protein A fusion protein significantly enhanced the level of expression of bevacizumab secreted into the culture medium as compared to the level of the antibody secreted into medium of a culture of cells expressing bevacizumab alone.
Figure 26B shows the results of a densitometry analysis of the chemiluminescent signals in each of the rows of the dot blot in Figure 26A using the NIH ImageJ image processing program. The bar graphs of Figure 26B are numbered to correspond to the row numbers of Figure 26A. The results of this series of experiments clearly show that co-expression of the anti-VEGF
antibody target protein with a BSC1-Protein A fusion protein significantly enhanced the level of expression of the anti-VEGF
antibody secreted into the culture medium.
Figure 26C shows the results of an ELISA to detect VEGF binding activity in culture media.
A 96-well plate was coated with recombinant purified human VEGF-A and incubated with the bevacizumab (anti-VEGF antibody target protein) secreted into the media of cultures of transfected cells that expressed the anti-VEGF antibody alone (bar graph 2) or of transfected cells that co-expressed the anti-VEGF antibody and the BSC1-Protein A fusion protein (bar graph 3). Bar graph 1 of Figure 26C shows that no significant VEGF binding activity was present in medium from a mock culture of cells transfected with expression vector lacking a structural gene for expressing either protein. The results clearly show that the secreted anti-VEGF antibody that was expressed at enhanced levels when co-expressed with the BSC1-Protein A fusion protein retained its binding activity for human VEGF-A.
Example 19. BSC1-Protein A Fusion Protein Enhances Expression of a Therapeutic Anti-TNFa Antibody (Adalimumab) Target Protein in an Unmodified Arrangement This experiment examined whether a BSC1-Protein A fusion protein as described above could be used in an unmodified arrangement to improve the level of expression of a therapeutic anti-TNFa antibody (adalimumab; Humira0, AbbVie).
Table 68. Amino Acid Sequences of Light and Heavy Chains of Adalimumab.
PCT/US2013/073442 08.04.2015 Protein Region Sequence Amino Acid Sequence (N¨ to C¨ Identifier terminal) Light chain SEQ ID NO:324 MGWSCIILFLVATATGVHSDIQMTQSPSSL
SASVGDRVTITCkSSQGIRNYLHWYQQKPG
KAPKLLIYAASTLQSGVPSRFSGSGSGTDF
TLTISSLQPEDVATYYCQRYNRAPYTFGQG
TKVEIKRTVAAPSVFIFPPSDEQLKSGTAS
VVCLLNNFYPREAKVQWKVDNALQSGNSQE
SVTEQDSKDSTYSLSSTLTLSKADYEKHKV
YACEVTHQGLSSPVTKSFNRGEC
Heavy chain SEQ ID NO:328 MGWSLIILFLVATATGVHSEVQLVESGGGL
VQPGRSLRLSCAASGFTFDDYAMHWVRQAP
= GKGLEWVSAITWNSGHIDYADSVEGRFTIS
RDNAKNSLYLQMNSLRAEDTAVYYCAKVSY
= LSTASSLDVWGQGTLVTVSSASTKGPSVFP
LAPSSKSTSGGTAALGCLVKDYFPEPVTVS
WNSGALTSGVHTFPAVLQSSGLYSLSSVVT
VPSSSLGTQTYICNVNHKPSNTKVDKKVEP
KSCDKTHTCPPCPAPELLGGPSVFLFPPKP
KDTLMISRTPEVTCVVVDVSHEDPEVKFNW
YVDGVEVHNAKTKPREEQYNSTYRVVSVLT
VLHQDWLNGKEYKCKVSNKALPAPIEKTIS
KAKGQPREPQVYTLPPSRDELTKNQVSLTC
LVKGFYPSDIAVEWESNGQPENNYKTTPPV
LDSDGSFFLYSKLTVDKSRWQQGNVFSCSV
MHEALHNHYTQKSLSLSPGK
Figure 27A shows a dot blot assay for expression of the anti-TNFa antibody (target protein) secreted into the media of cultures of transfected cells expressing the anti-TNFa antibody alone (middle row) and of transfected cells co-expressing the anti-TNFa antibody and the BSC1-Protein A
fusion protein (bottom row of Figure 27A). No anti -TNFa antibody was detected in medium of mock cultures containing cells transfected with expression vector lacking a structural gene for expressing either protein (top row of Figure 27A). Expression of the anti-INFa antibody in culture media was analyzed in the dot blot assay using an anti-human IgG antibody. It can be seen that co-expression in transfected cells of the anti-TNFa antibody and the BSC1-Protein A fusion protein (bottom row) significantly enhanced the level of expression of anti-TNFa antibody secreted into the culture medium as compared to the level of the antibody expressed in transfected cells expressing the anti-TNFa antibody alone (middle row).
Figure 27B shows the results of a densitometry analysis of the chemiluminescent signals in dot blots in each of the rows in Figure 27A using the NTH ImageJ image processing program. The bar graphs of Figure 27B are numbered to correspond to the row numbers of Figure 27A. The results of this series of experiments clearly show that co-expression of the anti-TNFa antibody target protein with a fusion protein comprising a BSC1 polypeptide linked to a target binding domain (Protein A) significantly enhanced the level of expression of secreted anti-TNFa antibody.
AMENDED SHEET - IPEA/US
Figure 27C shows the results of an ELISA for TNFa binding activity by the expressed anti-TNFa antibody. A 96-well plate was coated with recombinant purified human TNFa and incubated with the anti-TNFa antibody (target protein) secreted into the media of cultures of transfected cells expressing the anti-TNFa antibody alone (bar graph 2) or co-expressing anti-TNFa antibody and the BSC1-Protein A fusion protein (bar graph 3). No TNFa binding activity was detected in medium from mock cultures containing cells transfected with an expression vector lacking a structural gene for expressing either protein (bar graph 1). The results of this series of experiments clearly show that the secreted anti-TNFa antibody that was expressed at enhanced levels when co-expressed with the BSC1-Protein A fusion protein retained its binding activity for human TNFa.
Example 20. BSC1-Protein A Fusion Protein Enhances Established Expression of an Anti-1L8 Antibody in CHO-D12 Cell Line in an Unmodified Arrangement Similar in design to Example 8, above, this experiment examined whether a BSC1-Protein A fusion protein could enhance the level of expression of an anti-1L8 antibody already being produced in an established commercially relevant production CHO-DP12 cell line (American Type Culture Collection Accession No. CRL-124444, American Type Culture Collection, Manassas, Virginia).
Figure 28A shows results of an immune dot blot assay for expression of the anti-1L8 antibody (target protein) secreted into the media of cultures of cells of a CHO-DP12 cell line expressing the anti-1L8 antibody alone (middle row 2) and of cells co-expressing the anti-1L8 antibody and the BSC1-Protein A fusion protein (bottom row 3). It can be seen that co-expression of the antibody with the BSC1-Protein A fusion molecule significantly enhanced the level of expression of the antibody secreted into the culture medium (bottom row 3) as compared to the level of the antibody expressed in the absence of the BSC1-Protein A fusion molecule (row 2). No antibody was detected in medium alone (top row of Figure 28A).
Figure 28B shows the results of a densitometry analysis of the chemiluminescent signals in the dot blots in the rows of Figure 28A using the NIH ImageJ image processing program. The bar graphs in Figure 28B are numbered to correspond to the rows in Figure 28A. The results indicate that co-expression of the antibody with the BSC1-Protein A fusion molecule (bar graph 3) significantly enhanced expression of the secreted antibody, providing an approximately four to five-fold greater enhancement in the level of expression as compared to that obtained when the antibody was expressed in the absence of the BSC1-Protein A fusion protein (bar graph 2).
Figure 28C shows the results of an ELISA for IL8 binding. A 96-well plate was coated with recombinant purified human IL8 and incubated with the anti-1L8 antibody (target protein) secreted into the media of cultures stably expressing the anti-1L8 antibody alone (bar graph 2) or co-expressing the anti-1L8 antibody and the BSC1-Protein A fusion protein (bar graph 3).
Cell culture medium was used as a negative control (bar graph 1, no anti-1L8 antibody). The results of this series of experiments clearly show that the secreted anti-1L8 antibody that was expressed at enhanced levels when co-expressed with the BSC1-Protein A fusion protein retained its binding activity for IL8.
The results indicate that a BSC1-Protein A fusion protein can be employed in an unmodified arrangement to significantly enhance the level of production of a target protein that is already stably expressed in an established production cell line.
Example 21. Enhancement of Expression of Secreted Alpha-1 Antitrvpsin Z
Protein This experiment indicates that enhancement of protein expression according to the invention has the potential to treat a disease resulting from an improper conformation of a critical protein.
Alphal antitrypsin (AAT) deficiency is an autosomal genetic disorder that affects both genders. AAT is a 52-1(Da serine protease inhibitor produced mainly in the liver. Over 90 genetic variants have been identified in the protease inhibitor 1 (PI) gene on chromosome 14 that are associated with AAT deficiency. The most common basis of AAT deficiency is the Z mutation, a single base pair substitution that changes a Glu to Lys at codon 342 (G1u342Lys). The mutant AAT
protein with the Z mutation (AATZ protein) retains approximately 80% of the serine protease activity of the wild type AAT protein. The AATZ protein also cannot fold to establish a normal conformation and consequently accumulates in aggregates within the endoplasmic reticulum (ER). Accumulation of aggregated AATZ in liver cells leads to liver toxicity and liver cirrhosis.
For this experiment, the target proteins were an engineered AAT-Fc fusion protein and an engineered VS-tagged al ATZ-Fc fusion protein. The amino acid sequence of the AAT-Fc fusion protein is the same as described in Example 4.3 above. The amino acid sequence for the AATZ-Fc fusion protein is shown in the table below.
Table 69. Amino Acid Sequence of a VS-Tagged al AATZ-Fc Target Protein.
Protein Region Sequence Amino Acid Sequence (N¨ to C¨ Identifier terminal) V5-tagged SEQ
ID NO:325 MPSSVSWGILLLAGLCCLVPVSLAEDPQGD
alAATZ-Fc fusion AAQKTDTSHHDQDHPTFNKITPNLAEFAFS
molecule LYRQLAHQSNSTNIFFSPVSIATAFAMLSL
GTKADTHDEILEGLNFNLTEIPEAQIHEGF
QELLRTLNQPDSQLQLTTGNGLFLSEGLKL
VDKFLEDVKKLYHSEAFTVNFGDTEEAKKQ
INDYVEKGTQGKIVDLVKELDRDTVFALVN
YIFFKGKWERPFEVKDTEEEDFHVDQVTTV
KVPMMKRLGMFNIQHCKKLSSWVLLMKYLG
NATAIFFLPDEGKLQHLENELTHDIITKFL
ENEDRRSASLHLPKLSITGTYDLKSVLGQL
GITKVFSNGADLSGVTEEAPLKLSKAVHKA
VLTIDKKGTEAAGAMFLEAIPMSIPPEVKF
NKPFVFLMIEQNTKSPLFMGKVVNPTQKGT
GSEFDIAAALEGKPIPNPLLGLDSTSRPKS
CDKTHTCPPCPAPELLGGPSVFLFPPKPKD
TLMISRTPEVTCVVVDVSHEDPEVKFNWYV
DGVEVHNAKTKPREEQYNSTYRVVSVLTVL
Protein Region Sequence Amino Acid Sequence (N¨ to C¨ Identifier terminal) 123456789012345678901234567890 HQDWLNGKEYKCKVSNKALPAPIEKTISKA
KGQPREPQVYTLPPSRDELTKNQVSLTCLV
KGFYPSDIAVEWESNGQPENNYKTTPPVLD
SDGSFFLYSKLTVDKSRWQQGNVFSCSVMH
EALHNHYTQKSLSLSPGK
a1AATZ
residues 1-418 MPSSVSWGILLLAGLCCLVPVSLAEDPQGD
of SEQ ID
AAQKTDTSHHDQDHPTFNKITPNLAEFAFS
NO:325 LYRQLAHQSNSTNIFFSPVSIATAFAMLSL
GTKADTHDEILEGLNFNLTEIPEAQIHEGF
QELLRTLNQPDSQLQLTTGNGLFLSEGLKL
VDKFLEDVKKLYHSEAFTVNFGDTEEAKKQ
INDYVEKGTQGKIVDLVKELDRDTVFALVN
YIFFKGKWERPFEVKDTEEEDFHVDQVTTV
KVPMMKRLGMFNIQHCKKLSSWVLLMKYLG
NATAIFFLPDEGKLQHLENELTHDIITKFL
ENEDRRSASLHLPKLSITGTYDLKSVLGQL
GITKVFSNGADLSGVTEEAPLKLSKAVHKA
VLTIDKKGTEAAGAMFLEAIPMSIPPEVKF
NKPFVFLMIEQNTKSPLFMGKVVNPTQK
Linker 1 residues 419- GTGSEFDIAAALE
431 of SEQ ID
NO:325 V5 epitope residues 432- GKPIPNPLLGLDST
domain 445 of SEQ ID
NO:325 Linker 2 residues 446- SR
447 of SEQ ID
NO:325 Fc domain residues 448- PKSCDKTHTCPPCPAPELLGGPSVFLFPPK
678 of SEQ ID PKDTLMISRTPEVTCVVVDVSHEDPEVKFN
NO:325 WYVDGVEVHNAKTKPREEQYNSTYRVVSVL
TVLHQDWLNGKEYKCKVSNKALPAPIEKTI
SKAKGQPREPQVYTLPPSRDELTKNQVSLT
CLVKGFYPSDIAVEWESNGQPENNYKTTPP
VLDSDGSFFLYSKLTVDKSRWQQGNVFSCS
VMHEALHNHYTQKSLSLSPGK
Figure 29A shows images of chemiluminescent signals of a Western blot assay using anti-V5 antibody to detect expression of the V5-tagged AAT- and AATZ-Fc fusion proteins. Lane 1 in the top panel of Figure 29A shows non-expressing cell culture medium as a control.
Lane 2 of the top panel shows culture medium of cells expressing AAT-Fc alone. As expected for the wild type AAT
protein, the AAT-Fc fusion was secreted into the culture medium. Lane 3 of the top panel of Figure 29A shows that little if any of AATZ-Fc protein was secreted into the medium of a culture of transfected cells expressing the AATZ-Fc fusion protein alone. As expected for the AATZ protein, which is known to be retained in the endoplasmic reticulum, AATZ-Fc fusion protein was detected in cell lysates of the cells expressing AATZ-Fc protein alone. See, lane 3 of the middle panel (cell lysates). Surprisingly, as shown in lane 4 of the top panel of Figure 29A, co-expression of the AATZ-Fc protein and the BSC1-Protein A fusion protein resulted in a dramatic increase in the level of expression of AATZ-Fc protein secreted into the cultures medium. Moreover, little if any of AATZ-Fc fusion protein was detected in cell lysate (lane 4, middle panel of Figure 29A). The same membrane was blotted with anti-tubulin antibody for a loading control.
The results clearly show that co-expression of the BSC1-Protein A fusion protein significantly elevated the level of expression of the AATZ-Fc target protein secreted into the culture medium as compared to the level of expression of the target protein in the absence of the BSC1-Protein A fusion protein. Moreover, little if any of the AATZ-Fc proteins was detected in cell lysates, indicating that the AATZ-Fc protein was not retained in the endoplasmic reticulum.
Accordingly, these data suggest for the first time that a gene therapy that would provide a fusion protein comprising an AATZ-binding domain and a protein expression enhancing polypeptide of this invention would be effective in treating an individual for AAT deficiency due to the Z mutation by enhancing expression of secreted AATZ protein from cells of the individual, eliminating or reducing liver toxicity due to retention of AATZ in the endoplasmic reticulum, and restoring required levels of extracellular AAT serine protease activity to individual.
All patents, applications, and publications cited in the above text are incorporated herein by reference.
Other variations and embodiments of the invention described herein will now be apparent to those of skill in the art without departing from the disclosure of the invention or the claims below.
Figures llA and 11B show schematic diagrams of nucleic acid constructs encoding proteins for insertion into expression vector plasmids used to transfect host cells for the experiments described iri Example 5 below. Figure 11A depicts a DNA construct encoding an Fe fusion protein (target protein) comprising a cDNA encoding a protein of interest augmented at its 3' end with a segment encoding a VS epitope tag, which in turn was linked to a segment encoding the constant domains of an immunoglobulin Fc domain. For Example 5 below, the Fc fusion protein target comprised a truncated form of the IL13Ra2 receptor protein (IL13Ra2TF), which was linked to a VS epitope tag, which in turn was linked to an Fc domain to yield the desired IL13Ra2TF-Fc fusion protein. Figure 11B depicts a DNA construct encoding a fusion protein of the invention in which a protein expression enhancing polypeptide (PEEP) domain (such as a J domain of a J protein) is linked to a target protein binding domain (such as Protein A, which is known to bind Fc domains). The construct was further augmented at the 3' end with a coding segment for a Flag epitope tag for easy identification and isolation with a standard anti-Flag antibody.
Figures 12A ¨ 12D show results of an experiment described in Example 5 that demonstrate significant enhancement in the expression of an 1L13Ra2TF-Fc fusion protein (target protein) in an unmodified arrangement in which the target protein is co-expressed with a J
domain-Protein A fusion protein but not when the target protein is co-expressed with Protein A alone.
Figure 12A shows x-ray film images of chemiluminescent signals of a Western blot analysis of media from cultures of transfected cells expressing the IL13Ra2TF-Fc fusion protein (target protein) when expressed alone (lane 2, none), when co-expressed with Protein A
alone (lane 3, Protein A Only), when co-expressed with an Erdj3 J domain-Protein A fusion protein (lane 4, J-Protein A), and when co-expressed with an Erdj5 J domain-Protein A fusion protein (lane 5, J2-Protein A), as described in Example 5. Mock cultures contained cells transfected with expression vector lacking a structural gene for expressing any protein (lane 1 from the left). It can be seen that co-expression of the IL13Ra2TF-Fc fusion target protein and either J domain-Protein A fusion protein (lanes 4 and 5 from the left) resulted in a significantly greater level of expression of the IL13Ra2TF-Fc fusion target protein secreted into culture medium as compared to the level of expression in transfectant cells expressing the 1L13Ra2TF-Fc fusion target protein alone (lane 2 from the left) or co-expressing the IL13Ra2TF-Fc fusion target protein with unfused Protein A
(lane 3 from the left).
AMENDED SHEET - IPEA/US
PCT/US2013/073442 08.04.2015 = Figure 12B shows results of a densitometry analysis of the chemiluminescent signals in Figure 12A using the NTH ImageJ image processing program. Bar graphs 1-5 of Figure 12B
correspond to signals in lanes 1-5 in Figure 12A. The bar graphs in Figure 12B
clearly show that co-expression of the IL13Ra2TF-Fc target protein with either J domain-Protein A
fusion protein (bar graphs 4 and 5) significantly enhanced the level of expression of secreted IL13Ra2TF-Fc as compared to expression of IL13Ra2TF-Fc alone (bar graph 2) or co-expression of IL13Ra2TF-Fc with (unfused) Protein A alone (bar graph 3).
Figure 12C shows x-ray film images of chemiluminescent signals of a Western blot analysis of media from cultures of transfected cells expressing the IL13Ro2TF (no Pc domain) protein alone (lane 1, none), when co-expressed with an Erdj3 J domain-Protein A fusion protein (lane 2, J-Protein A), and when co-expressed with Protein A alone (lane 3, Protein A Only), as described in Example 5.
The results show that little if any expression of secreted IL13Ra2TF protein was observed, as expected if the enhanced level of the secreted IL13Ra2TF-Fc fusion target protein in Figures 12A and 12B was dependent on the specificity of the target protein binding domain of the J domain-Protein A
fusion protein for the Fc domain of 1L13Ra2TF-Fc target protein. Figure 12D
provides the results of a densitometry analysis of the chemiluminescent signals in Figure 12C using the NIH ImageJ image processing program: Figures 12C and 12D thus show a control experimental result in that the IL13Ra2TF protein was not recognized by the J domain-Protein A fusion (the Fe ligand for the target binding domain (Protein A) being absent), and thus the enhancement in the level of expression that could be provided by the J domain (a protein expression enhancing polypeptide domain) was not . targeted to the IL13Ra2TF, as the results indicate.
Figures 13A-1 ¨ 13C-2 provide results of a series of experiments that demonstrate significant = enhancement of the level of expression of three different Fe fusion target proteins when co-expressed with a corresponding fusion protein of the invention as described in Example 6 below. Figure 13A-1 shows x-ray film images of chemiluminescent signals of a Western blot assay for expression of an IL13Ra2TE-Fc fusion protein (target protein) secreted into the media of cultures of transfected cells expressing the 1L13Ra2TF-Fc fusion protein alone (lane 1 from the left) and of transfected cells co-expressing the IL13Ra2TF-Fc fusion protein and the J domain-Protein A fusion protein (lane 2 from -the left) as described in Example 6.1 below and similar to the experiment described in Example 5.
30, Figure 13A-2 provides the results of a densitometry analysis of the chemiluminescent signals in Figure 13A-1 using the N1H ImageJ image processing program. Bar graphs 1 and 2 (from left to right) in Figure 13A-2 correspond to the signals in lanes 1 and 2 (from left to right) in Figure 13A-1.
The results show that co-expression of the J domain-Protein A fusion protein of the invention significantly elevated (8-fold) the level of expression of the IL13Ra2TF-Fc target protein secreted into the culture AMENDED SHEET - IPEA/US
PCT/US2013/073442 08.04.2015 medium as compared to the level of expression of the target protein in the absence of the J domain-Protein A fusion protein. Results are consistent with those described in Example 5 and Figure 12.
Figure 13B-1 shows x-ray film images of chemiluminescent signals of a Western blot assay for expression of a TNFR1TF-Fc fusion protein (target protein) secreted into the media of cultures of transfected cells expressing the TNFRITF-Fc fusion target protein alone (lane I from the left) and of transfected cells co-expressing the TNFRITF-Fc fusion protein and the J domain-Protein A fusion (lane 2 from the left) .as described in Example 6.2 below. Figure 13B-2 provides the results of a densitometry analysis of the chemiluminescent signals in Figure 13B-1 using the NIN ImageJ image processing program. Bar graphs 1 and 2 (from left to right) in Figure 13B-2 correspond to the signals in lanes 1 and 2 (from left to right) in Figure 13B-1. The results show that co-expression of J domain-Protein A fusion protein significantly elevated (6-fold) the level of expression of the TNFR1TF-Fc target protein secreted into the culture medium as compared to the level of expression of the target protein in the absence of the J domain-Protein A fusion protein.
Figure 13C-1 shows x-ray film images of chemiluminescent signals of a Western blot assay for expression of an at anti-trypsin (alAT)-Fc fusion protein (target protein) secreted into the media of cultures of transfected cells expressing the alAT-Fc fusion target protein alone (lane 1 from the left) and of transfected cells co-expressing the alAT-Fc fusion target protein and the J domain-Protein A fusion protein. (lane 2 from the left) as described in Example,6.3. Figure 13C-2 provides the results of a densitometry analysis of the chemiluminescent signals in Figure 13C-1 using the NIH ImageJ
image processing program. Bar graphs 1 and 2 (from left to right) in Figure 13C-2 correspond to the signals in lanes 1 and 2 (from left to right) in Figure 13C-1. The results show that co-expression of J
domain-Protein A fusion protein significantly elevated (3-fold) the level of expression of the al AT-Fe fusion target protein secreted into the culture medium as compared to the level of expression of the target protein in the absence of the J domain-Protein A fusion protein.
Figures 14A and 14B provide results from a series of experiments that test the enhancement in the level of expression of a secreted humanized anti-1L8 IgG1 antibody in an unmodified arrangement described in Example 7 below. Figure 14A shows x-ray film images of chemiluminescent signals of a dot blot assay for expression of the anti-1L8 antibody (target protein) secreted into the media of cultures of transfected cells expressing the anti-IL8 antibody alone (lane 2), co-expressing anti-1L8 antibody and Protein A (lane 3, Protein A Only), co-expressing anti-[L8 antibody and an Erdj3 J domain-Protein A fusion protein of the invention (lane 4, J-Protein A), co-expressing anti-1L8 antibody and Protein L (lane 5, Protein L Only), co-expressing anti-1L8 antibody and an Erdj3 J domain-Protein L fusion protein of the invention (lane 6, J-Protein L), co-expressing anti-1L8 antibody and its IL8 ligand (lane 7, IL8), co-expressing an Erdj3 J
domain-1L8 ligand fusion protein = AMENDED SHEET - IPEA/US
PCT/US2013/073442 08.04.2015 "
of the invention (lane 8, J-1L8), expressing the Erdj3 J-Protein A fusion protein alone (lane 9, J-Protein A), expressing the Erdj3 J domain-Protein L fusion protein alone (lane 10, J-Protein L), and expressing the Erdj3 J domain-1L8 ligand fusion protein (lane 11, J-1L8). Mock cultures contained cells transfected with expression vector lacking a structural gene for expressing any protein (no anti-IL8 antibody, lane 1). Expression of the anti -1L8 antibody in culture media was analyzed in the dot blot assay using an anti-human IgG antibody ("anti-huIgG Ab") (catalog no.
AP112P, Millipore). It can be seen that co-expression in transfected cells of the anti-1L8 antibody with a J domain-Protein A
fusion protein (lane 4), with a J domain-Protein L fusion protein (lane 6), or with a J domain-1L8 fusion protein (lane 8) significantly enhanced the level of expression of anti-1L8 antibody secreted into the culture medium as compared to the level of the antibody expressed in transfected cells expressing the anti-1L8 antibody alone (lane 2), co-expressing with Protein A
alone (lane 3, Protein A
Only), co-expressing Protein L alone (lane 5, Protein L Only), or co-expressing IL8 ligand protein alone (lane 7). No signal was.detected in culture media of transfected cells expressing the J domain-Protein A fusion protein alone (lane 9, 1-Protein A), of transfected cells expressing the J domain-Protein L fusion protein alone (lane 10, J-Protein L), or of transfected cells expressing the J domain-1L8 fusion protein alone (lane 10, J-1L8), indicating that all three fusion proteins specifically targeted and enhanced expression of the co-expressed anti-1L8 antibody target protein.
Figure 14B shows the results of a densitometry analysis of the chethiluminescent signals in each of the lanes in Figure 14A using the NIH ImageJ image processing program.
The bar graphs of Figure 14B are numbered to correspond to the lane numbers of Figure 14A. The results of this series of experiments clearly show that co-expression of the targeted anti-1L8 antibody with a fusion protein of the invention comprising a protein expression enhancing polypeptide (here, an Erdj3 J domain) linked to a target protein binding domain (here, Protein A, Protein L, or 1L8) significantly enhanced the expression of secreted anti-1L8 antibody as compared to co-expression of the antibody with the unfused target protein binding domain protein alone (Protein G only, Protein L
only, or IL8 only).
Figures 15A and 15B provide results that demonstrate that a fusion protein according to the invention can be used to enhance the level of expression of a target protein that is already stably produced in an established commercially relevant cell line as described in Example 8 below. Figure 15A shows x-ray film images of chemiluminescent signals of a dot blot assay for expression of the anti-1L8 antibody (target protein) secreted into the media of cultures of cells of a CHO-DP12 cell line (accession no. CRL-124444, American Type Culture Collection, Manassas, Virginia) expressing the anti-IL8 antibody alone (lane 2) and in transfected cells co-expressing anti-1L8 antibody and an Erdj3 J domain-Protein A fusion protein (lane 3, J-Protein A). Expression of the anti-IL8 antibody in culture media was analyzed in the dot blot assay using an anti-human IgG
antibody ("anti-huIgG
Ab"). It can be seen that co-expression of the antibody with the J domain-Protein A fusion protein AMENDED SHEET - IPEA/US
PCT/US2013/073442 08.04.2015 significantly enhanced the level of expression of the antibody secreted into the culture medium (lane 3) as =
=
PCT/US2013/073442 08.04.2015 compared to the level of the antibody expressed in the absence of the J domain-Protein A fusion protein (lane 2, none). Lane 1 is control (Medium Only). Figure 15B shows the results of a densitometry analysis of the chemiluminescent signals in the dot blots in the lanes in Figure I5A
using the NIII IrnageJ image processing program is shown in the respective bar graphs in Figure 15B.
The results indicate that co-expression of the antibody with the J domain-Protein A fusion protein (bar graph 3) significantly enhanced expression of the secreted antibody, providing an approximately four-to five-fold greater enhancement in the level of expression, as compared to that obtained when the antibody was expressed in the absence of the J domain-Protein A fusion protein (bar graph 2). The results indicate that a fusion protein of the invention can be employed to significantly enhance the level of production of a target protein that is already stably expressed in an established production cell line.
Figures 16A and 16B provide results from a series of experiments that tested various fusion proteins comprising a J domain (as a protein expression enhancing polypeptide domain) of a J protein linked to any of a variety of proteins, as described in Example 9.1 below. The various J domain fusion proteins and other proteins were then tested and compared for their ability to enhance levels of expression of the IL13Ra2TF-Fc fusion protein (target protein) secreted into media of cultures of transfected HEK293 cells. Figure 16A shows x-ray film images of chemiluminescent signals of a Western blot analysis of samples of media from cultures of transfected cells expressing the IL13Ra2TF-Fc fusion protein (target protein) alone (lane 1), co-expressing IL13Ra2TF-Fc with a J
domain-Protein A fusion protein (lane 2), co-expressing IL13Ra2TF-Fc with Protein A alone (lane 3, Protein A Only), co-expressing IL13Ra2TF-Fc with a J domain-Protein G fusion protein (lane 4), co-expressing IL13Ra2TF-Fc with a J domain-hFcR fusion protein (lane 5, J-hFcR), co-expressing 1L13Ra2TF-Fc with a J domain-vFcR fusion protein (lane 6, J-vFeR), co-expressing IL13Ra2TF-Fc with a J domain-gI fusion protein (lane 7, J-g[), co-expressing IL13Ra2TF-Fc with a J domain-gE
fusion protein (lane 8, J-gE), and co-expressing IL13Ra2TF-Fc with both J
domain-gI fusion protein and J domain-gE fusion protein (lane 9, J-gI + J-gE). The results of a densitometry analysis of the chemiluminescent signals in the Western blot in Figure 16A using the N1HImageJ
image processing program are shown in the respective bar graphs in Figure 16B. See, Example 9.1 for details.
Figures 17A-1 and 17B provide results from a series of experiments that tested various fusion proteins comprising a J domain (as a protein expression enhancing polypeptide domain) of a J protein linked to each of six Fe-binding peptides (FcBP1 through FcBP6) for use in enhancing the level of expression of proteins that possess an Fc domain as described in Example 9.2 below. The amino acid sequences of the Pc binding peptides are given in Figure 17A-2 (SEQ ID NOS:240-245, respectively).
Figure 17A-1 shows x-ray film images of chemiluminescent signals of a Western blot assay of samples of media of cultures of transfected cells expressing the IL13Ra2TF-Fc fusion protein (target AMENDED SHEET - IPEA/US
=
PCT/US2013/073442 08.04.2015 protein) alone (lanes 1 and 3), co-expressing IL13Ra2TF-Fc with a J domain-Protein A fusion protein (lane 2, J-Protein A), co-=
AMENDED SHEET -IPEA/US
PCT/US2013/073442 08.04.2015 expressing IL13Ra2TF-Fc with a J domain-FcBP1 fusion protein (lane 4, J-FcBP1), co-expressing ILI3Ra2TF-Fc with a J domain-FcBP2 fusion protein (lane 5, J-FcBP2), co-expressing IL13Ra2TF-Fc with a J domain-FcBP3 fusion protein (lane 6, J-FcBP3), co-expressing IL13Ra2TF-Fc with a J
=domain-FcBP4 fusion protein (lane 7, J-FcBP4), co-expressing IL13Ra2TF-Fc with a J domain-FcBP5 fusion protein (lane 8, J-FcBP5), co-expressing IL13Ra2TF-Fc with a J
domain-FcBP6 fusion protein (lane 9, J-FcBP6), and co-expressing IL13Ra2TF-Fc with a J domain-Protein G fusion protein (lane 10, J-Protein G),. As shown in Figure 17A-1, co-expression of the IL13Ra2TF-Fc fusion protein with each of the six J domain-peptide fusion proteins in HEK293 transfectants significantly enhanced the level of expression of secreted IL13Ra2TF-Fc fusion protein (lanes 4-9) as compared to the level of expression of 1L13Ra2TF-Fc fusion protein alone (lanes 1 and 3).
The experiment also included for comparison the effect of co-expression of IL13Ra2TF-Fclusion protein with a J domain-Protein A fusion protein (lane 2) or with a J domain-Protein G fusion protein (lane 10) on the expression of secreted IL13Ra2TF-Fc fusion protein. As shown in Figure 17A-1, co-expression of IL13Ra2TF-Fc fusion protein with either J domain-Protein A fusion protein (lane 2) or the J domain-Protein G fusion protein (lane 10) significantly enhanced the level of expression of secreted the IL13Ra2TF-Fc fusion protein as also observed in Examples 5 (Figures 12A and 12B), 6.1 (Figures 13A-1 and 13A-2), and 9.1 (Figures 16A and 16B). The results of a densitometry analysis of the chemiluminescent signals in the Western blot in Figure 17A-1 using the NIH
ImageJ image processing program are shown in the respective bar graphs in Figure 17B.
Figure 18 shows x-ray film images of chemiluminescent signals of a dot blot assay showing examples of relative levels of target protein expression enhancing activity of three polyp" eptides used in an unmodified arrangement described in Example 10. The levels of expression indicated in the dot blot, i.e., High Activity (HA), Activity (A), and No Activity (NA), were determined for polypeptides designated "3 (J domain)", "3-45", and "3-72" (see Table 58, infra.). Each polypeptide was linked to Protein A to form a fusion protein that was co-expressed with a V5-tagged IL13Ra2-Fc target protein in transfected cells. The level of expression of the VS-tagged IL13Ra2-Fe target protein in culture media was determined in the dot blot using an anti-V5 antibody. The dot blot shows expression of the V5-tagged IL13Ra2-Fc target protein in the media of cultures of transfected cells expressing the target protein alone (lane 2 from left), of transfected cells co-expressing the target protein and the polypeptide 3-Protein A fusion protein (lane 3 from left), of transfected cells co-expressing the target protein and the polypeptide 3-45-Protein A fusion protein (lane 4 from left), and of transfected cells co-expressing the target protein and the polypeptide 3-72-Protein A fusion protein (lane 5 from left).
The high activity (HA) of a polypeptide for enhancing expression of a target protein in an unmodified arrangement is represented by the level of expression shown in lane 3 (from the left) of the dot blot.
Improved activity compared to negative control (A) of a polypeptide for enhancing expression of a AMENDED SHEET - IPEA/US
PCT/US2013/073442 08.04.2015 target protein is represented by the level of expression shown in lane 4 (from the left) of the dot blot.
No activity (NA) of a polypeptide for enhancing expression of a target protein is shown in lane 5 =
=
=
AMENDED SHEET - IPEA/US
PCT/US2013/073442 08.04.2015 (from the left) of the dot blot. Lane 1 (from the left) of the dot blot shows no target protein was expressed in the medium of a mock culture of cells that did not express the target protein or any polypeptide-Fc fusion protein.
Figure 19 shows an alignment of the amino acid sequence of the J domain of Erdj3 with the amino acid sequences of a series of polypeptides that were generated as N- and C-terminal deletion mutations of the full-length J domain as described in Example 11. The alpha helices and loop domains of the J domain are indicated by brackets. Also shown are a designation number, length (amino acid residues), protein expression enhancing activity (HA, NA), and sequence identification number for each of the polypeptides. (See, Figure 18 and Example 10 for a description of high activity (HA), improved activity (A), and no activity (NA) for enhancing target protein expression.) As shown in the alignment, the J domain is designated polypeptide 3, is 61 amino acids in length, and has high activity (HA) for enhancing expression of a target protein in an unmodified arrangement.
Figures 20A and 20B show results of a series of experiments described in Example 12 that compares the target protein expression enhancing activity of two polypeptides used in a modified arrangement. Figure 20A shows diagrams of nucleic acid constructs for insertion into an expression vector used to transfect cells. The IL13Ra2TF construct encodes a fusion polypeptide comprising a truncated form of 11,13Ra2 that contains the extracellular IL13 binding domain fused to a C-terminal V5 epitope tag. The IL13Ra2TF-BSC1 construct encodes a fusion polypeptide comprising the truncated form of IL13Ra2 fused to the BSC1 sequence (polypeptide 3-29, IKKAYRKLA, SEQ ID
NO:48), which is fused to a C-tenninal V5 epitope tag. The IL13Ra2TF-BSC1MT
construct encodes the truncated from of IL13Ra2 fused to the BSC1MT sequence (polypeptide 3-55, IAQAYRKLA, SEQ ID NO:298), which is fused to a C-terminal V5 epitopc tag. The amino acid sequence of polypeptide 3-55 differs from that of polypeptide 3-29 at two positions as shown at the bottom of Figure 20A. Cells transfected with a vector containing the IL13Ra2TF construct were taken as the _25 control (no fusion with a BSC I or BSC1MT polypeptide).
Figure 20B shows X-ray film images of chemiluminescent signals of a dot blot analysis of the media of cultures of transfected cells expressing the IL13Ra2TF, IL13Ra2TF-BSC1, and IL13Ra2TF-BSC I MT proteins using an anti-V5 antibody. Lane 2 (from the left) of Fig. 208 shows that only a very low level of IL13Ra2TF fusion protein was detected in medium of a culture of control cells. Lane 3 (from the left) in Fig. 20B shows that a significant level of the IL13Ra2TF-BSCI fusion protein was expressed in the medium of a culture of cells transfected with a vector containing the IL13Ra2TF-BSC I construct. Lane 4 (from the left) in Fig. 208 shows that only a very low level of the IL13Ra2TF-BSC1MT fusion protein was expressed in the medium of culture of cells transfected with a vector containing the IL13Ra2TF-BSCIMT construct. The results indicate that polypeptide 3-29 has "high activity" for enhancing expression of a target protein in a modified AMENDED SHEET - IPEA/US
PCT/US2013/073442 08.04.2015 arrangement, whereas polypeptide 3-55 is considered to have "no activity" for enhancing expression of a target protein in a modified arrangement.
Figure 21 is a bar graph showing IL13 binding activity of 11,13Ra2TF-Fc target protein co expressed in an unmodified arrangement with a BSC1-Protein A in HEK293 cells as described in Example 13. The BSC1-Protein A protein if a fusion protein comprising the polypeptide 3-29 (IKKAYRKLA, SEQ ID NO:48) linked to Protein A as shown in Example 13. The assay used for determining IL13 binding activity is a sandwich ELISA in which detection of human IL13 decreases when the IL13 is trapped by the IL13Ra2TF-Fc protein. The first bar graph (from the left) in Fig. 21 shows no IL13 binding activity was present in medium from a culture of control cells that did not =
express either IL13Ra2TF-Fc or the BSC1-Protein A fusion protein. Bar 2 (middle) in Fig. 21 shows that some low level of IL13 binding activity was detected in medium from a culture of cells expressing only the IL13Ra2TF-Fc protein. In contrast, as shown in Bar 3 (far right) in Fig. 21, a significant level of human IL13 binding activity was present in the medium of a culture of cells co-expressing IL13Ra2TF-Fc and the BSC1-Protein A fusion protein. The results shown that the = 15 IL13Ra2TF-Fc target protein expressed at enhanced levels in culture medium in an unmodified arrangement retains its IL13 binding activity.
Figures 22A and 22B show results of an experiment that demonstrates significant enhancement in the level of expression of a Factor VII (FVII)-Fc fusion protein (target protein) secreted into culture medium when co-expressed in an unmodified arrangement with a BSC1-Protein G fusion protein comprising polypeptide 3-29 (IKKAYRKLA, SEQ 1D NO:48) linked to Protein G as described in Example 14. Figure 22A shows X-ray film images of chemiluminescent signals of a Western blot assay for expression of an FV1I-Fc fusion protein (top panel) secreted into the media of cultures of transfected cells expressing the FV1.1-Fc fusion protein alone (lane 2) and of transfected cells co-expressing the FVII-Fc fusion protein and the BSC1-Protein G fusion protein (lane 3). Lane I shows non-expressing cell culture medium as a control. Anti-Flag antibody was used to detect BSC1-Protein G in cell lysate (middle panel) and secreted BSC1-Protein G
(bottom panel), respectively. Figure 22B provides the results of a densitometry analysis of the chemiluminescent signals in the top panel of Figure 22A using the NIH ImageJ image processing program. Bar graphs 1, 2, and 3 in Figure 228 correspond to the signals in lanes 1, 2, and 3 in the top panel of Figure 22A.
The results show that co-expression of the FVH-Fc target protein and the BSC1-Protein G fusion protein significantly elevated the level of expression of the FV1.1-Fc target protein secreted into the culture medium as compared to the level of expression of the target protein expressed in the absence of the BSC1-Protein G fusion protein. In addition, the BSC1-Protein G fusion protein was not secreted but remained in the cells. Compare expression of BSC1-Protein G
fusion protein cell lysates (middle panel of Fig. 22A) with that in medium (bottom panel of Fig. 22A).
AMENDED SHEET -IPEA/US
PCT/US2013/073442 08.04.2015 Figures 23A and 23B show results of an experiment to demonstrate improvement in the level of expression of a Factor IX (FIX)-Fc fusion protein (FIX-Pc) target protein in the presence of a =
BSC 1-Protein A fusion protein comprising polypeptide 3-29 (HUCAYRKLA, SEQ ID
NO:48) linked to Protein A as described in Example 15. Figure 23A shows X-ray film images of chemiluminescent signals of a Western blot assay for expression of an FIX-Fe fusion protein secreted into the media of cultures of transfected cells expressing the FIX-Fc fusion protein alone (row 2) and of transfected cells co-expressing the FIX-Pc fusion protein and the BSC1-Protein A fusion protein (row 3). Row 1 shows non-expressing cell culture medium as a control. Figure 23B provides the results of a densitometry analysis of the chemiluminescent signals in the top panel of Figure 23A using the NI11 Imagel image processing program. Bar graphs 1, 2, and 3 in Figure 23B
correspond to the signals in rows 1, 2, and 3 in Figure 23A. The results show that co-expression of the FIX-Fe target protein and the BSC1-Protein A fusion protein significantly elevated the level of expression of the FIX-Fe target = protein secreted into the culture medium as compared to the level of expression of the target protein in the absence of the BSC1-Protein A fusion Protein.
Figure 24 provides results of a series of experiments that demonstrate significant enhancement of the level of expression of a Factor VIII (FV111)-Fc fusion protein (FVBI-Fc) when co-expressed in an unmodified arrangement with a BSC1-Protein G fusion protein comprising polypeptide 3-29 (LICKAYRKLA, SEQ ID NO:48) linked to Protein G as described in Example 16.
Media was harvested from cultures of transfected HEK293 cells co-expressing the FVIH-Fc fusion protein (target protein) with BSC I-Protein G fusion protein or cells expressing the FVIII-Fc fusion protein alone. The media was assayed for WM activity by ELISA (VisuLizemi FVHI
Antigen Kit, Affinity Biologicals Inc.). Cell culture medium in which empty vector was transfected was used for a negative control (first bar from the left). Second bar from the left shows no FV1.11 was detected in medium from cells expressing the FVIII-Fc target protein alone. Third bar from the left shows that = 25 significant level of FVIII-Fc target protein was secreted into the medium of cells co-expressing the = FVHI-Fe target protein and the BSC 1-Protein G fusion protein. Human serum was used as a positive control (last bar from left). The results show that co-expression of the FV111-Fc target protein and the BSCI -Protein G fusion protein significantly elevated the level of expression of the FVIII-Fc target , protein secreted into the culture medium as compared to the level of expression of the target protein in the absence of the BSC1-Protein G fusion protein.
Figures 25A ¨ 25C show results of an experiment demonstrating improved levels of expression of an anti-1L8 antibody (target protein) secreted into the culture medium when co-expressed in an unmodified arrangement with a BSC1-Protein A comprising the 3-29 polypeptide (IKKAYRICLA, SEQ ID NO:48) linked to Protein A as described in Example 17.
Figure 25A shows X-ray film images of chemiluminescent signals of a dot blot assay for expression of the anti-1L8 AMENDED SHEET - IPEA/US
PCT/US2013/073442 08.04.2015 antibody (target protein) secreted into the media of cultures of transfected cells expressing the anti-1L8 antibody alone AMENDED SHEET - IPEA/US
PCT/US2013/073442 08.04.2015 (row 2) and of cells co-expressing the anti-1L8 antibody and a BSC1-Protein A
fusion protein (row 3, BSC1-Protein A). Expression of the anti-1L8 antibody in culture media was analyzed in the dot blot assay using an anti-human IgG antibody. Mock cultures contained cells transfected with expression vector lacking a structural gene for expressing any protein (no anti-1L8 antibody, row 1). It can be seen that co-expression in transfected cells of the anti-1L8 antibody with a BSC1-Protein A fusion protein (row 3) significantly enhanced the level of expression of anti-1L8 antibody secreted into the culture medium as compared to the level of the antibody expressed in transfected cells expressing the anti-1L8 antibody alone (row 2).
Figure 25B shows the results of a densitometry analysis of the chemiluminescent signals in each of the rows in Figure 25A using the N1H hnageJ image processing program.
The bars of Figure 25B are numbered to correspond to the row numbers of Figure 25A. The results of this series of experiments clearly show that co-expression of the targeted anti-1L8 antibody with a BSC1-Protein A
fusion protein significantly enhanced the expression of secreted anti-1L8 antibody compared to the level of expression of the antibody in the absence of the BSC1-Protein A
fusion protein.
Figure 25C shows a bar graph of the results of an ELISA to detect IL8 binding activity by the expressed anti-1L8 antibody (target protein). A 96-well plate was coated with recombinant purified human IL8, and incubated with the anti-1L8 antibody (target protein) secreted into the media of cultures of transfected cells expressing the anti-1L8 antibody alone (bar graph 2) or co-expressing the anti-1L8 antibody with the BSC1-Protein A fusion protein (bar graph 3, BSC I -Protein A). Mock cultures contained cells transfected with expression vector lacking a structural gene for expressing any protein (no anti-1L8 antibody, bar graph 1). The results of this series of experiments clearly show that the anti-1L8 antibody expressed at enhanced levels and secreted into the culture medium retains its binding activity for human 1L8, indicating proper conformation of the antibody.
Figures 26A ¨ 26C show results of a series of experiments demonstrating significant enhancement in the level of expression of the anti-VEGF antibody, bevacizumab, when co-expressed with a BSC1-Protein A fusion comprising the 3-29 polypeptide (IKKAYRICLA, SEQ
ID NO:48) linked to Protein A as described in Example 18. Figure 26A shows X-ray film images of chemiluminescent signals of a dot blot assay for expression of the anti-VEGF
antibody secreted into the media of cultures of transfected cells expressing the anti-VEGF antibody alone (row 2) or co-expressing the anti-VEGF antibody and a BSC 1-Protein A fusion protein (row 3). Mock cultures contained cells transfected with expression vector lacking a structural gene for expressing any protein (no anti-VEGF antibody, row 1). Expression of the anti-VEGF antibody in culture media was analyzed in the dot blot assay using an anti-human IgG antibody. It can be seen that co-expression in transfected cells of the anti-VEGF antibody with the BSC1-Protein A fusion protein (row 3) significantly enhanced the level of expression of anti-VEGF antibody secreted into the culture PCT/US2013/073442 08.04.2015 medium as compared to the level of the antibody expressed in transfeeted cells expressing the anti-VEGF antibody alone (row 2).
AMENDED SHEET - IPEA/US
PCT/US13/73442 03-10-2014PCT/US2013/073442 08.04.2015 =
Figure 26B shows the results of a densitometry analysis of the chemiluminescent signals in each of the rows in Figure 26A using the NIH ImageJ image processing program.
The bar graphs in Figure 26B are numbered to correspond to the row numbers in Figure 26A. The results clearly show that co-expression of the anti-VEGF antibody with a BSC1-Protein A fusion protein significantly enhanced the expression of secreted anti-VEGF antibody compared to the level of the antibody expressed alone.
Figure 26C shows the results of an ELISA to detect VEGF binding by the anti-VEGF
antibody expressed in the media of cultures of transfected cells. A 96-well plate was coated with recombinant purified human VEGF-A, and incubated with the anti-VEGF antibody (target protein) secreted into the media of cultures of transfected cells expressing the anti-VEGF antibody alone (bar graph 2) or co-expressing anti-VEGF antibody and the BSC1-Protein A fusion protein of the invention (bar graph 3). Mock cultures contained cells transfected with expression vector lacking a structural gene for expressing any protein (no anti-VEGF antibody, bar graph 1). The results of this series of experiments clearly show that the anti-VEGF antibody expressed at enhanced levels and secreted into the culture medium retains its binding activity for human VEGF-A, indicating proper conformation of the secreted antibody.
Figures 27A ¨ 27C show results from a series of experiments demonstrating significant enhancement in the level of expression the therapeutic anti-TNFa antibody, adalimumab (Humira , AbbVie), when co-expressed with a BSC1-Protein A fusion comprising the 3-29 polypeptide (IKKAYRKLA, SEQ ID NO:48) linked to Protein A as described in Example 19.
Figure 27A shows X-ray film images of chemiluminescent signals of a dot blot assay for expression of the anti-TNFa antibody secreted into the media of cultures of transfected cells expressing the anti-TNFa antibody alone (row 2) or co-expressing the anti-TNFa antibody and the BSC1-Protein A
fusion (row 3).
Mock cultures contained cells transfected with expression vector lacking a structural gene for expressing any protein (row 1, no anti-TNFa antibody). Expression of the anti-TNFa antibody in culture media was analyzed in the dot blot assay using an anti-human IgG
antibody. It can be seen that co-expression in transfected cells of the anti-TNFa antibody with a BSCI-Protein A fusion protein (bottom row) significantly enhanced the level of expression of anti-TNFa antibody secreted into the culture medium as compared to the level of the antibody expressed in transfected cells expressing the anti-TNFa antibody alone (middle).
Figure 27B shows the results of a densitometry analysis of the chemiluminescent signals in each of the rows in Figure 27A using the NIH ImageJ image processing program.
The bar graphs of Figure 27B are numbered to correspond to the row numbers of Figure 27A. The results of this series of experiments clearly show that co-expression of the anti-TNFa antibody (target protein) with the BSC1-Protein A fusion protein significantly enhanced the expression of secreted anti-TNFa antibody.
AMENDED SHEET - IPEA/US
PCT/US2013/073442 08.04.2015 Figure 27C shows the results of an ELBA to detect TNFa binding activity by the anti- TNFa antibody expressed in the media of cultures of transfected cells. A 96-well plate was coated with =
AMENDED SHEET - IPEA/US
PCT/US2013/073442 08.04.2015 recombinant purified human TNFa and incubated with the anti-TNFa antibody (target protein) secreted into the media of cultures of transfected cells expressing the anti-TNFa antibody alone (bar graph 2) or cells co-expressing the anti-TNFa antibody and the BSC1-Protein A
fusion protein (bar graph 3). Mock cultures contained cells transfected with expression vector lacking a structural gene =
for expressing any protein (bar graph 1). The results of this series of experiments clearly show that the anti-TNFa antibody expressed at enhanced levels and secreted into the culture medium retains its binding activity for human TNFa, indicating proper conformation of the secreted antibody.
Figures 28A ¨ 28C provide results that demonstrate that the level of expression of a protein that is already stably produced in an established commercially relevant cell line can be enhanced when co-expressed with as BSC1-Protein A fusion comprising the 3-29 polypeptide (11KKAYRKLA, SEQ ID NO:48) linked to Protein A as described in Example 20. Figure 28A shows X-ray film images of chemiluminescent signals of a dot blot assay for expression of the anti-1L8 antibody (target protein) secreted into the media of cultures of cells of a CHO-DP12 cell line (accession no. CRL-124444, American Type Culture Collection, Manassas, Virginia) expressing the anti-1L8 antibody alone (row 2) and of transfected cells co-expressing the anti-1L8 antibody and the BSC1-Protein A
fusion protein (row 3). It can be seen that co-expression of the antibody with the BSC1-Protein A
fusion protein significantly enhanced the level of expression of the antibody secreted into the culture medium (row 3) as compared to the level of the antibody expressed in the absence of the BSC1-Protein A fusion protein (row 2). Row 1 is control (Medium Only). Figure 28B
shows the results of a densitometry analysis of the chemiluminescent signals in the dot blots in the rows in Figure 28A using the NIB ImageJ image processing program are shown in the respective bar graphs in Figure 28B. The results indicate that co-expression of the antibody with the BSC1-Protein A
fusion molecule (bar graph 3) significantly enhanced expression of the secreted antibody, providing an approximately four to five-fold greater enhancement in the level of expression, as compared to that obtained when the antibody was expressed in the absence of the BSC1-Protein A fusion molecule (bar graph 2).
Figure 28C shows the results of an ELISA to detect IL8 binding activity by the anti-1L8 antibody expressed in the media of cultures of transfected cells. A 96-well plate was coated with recombinant purified human IL8 and incubated with the anti-1L8 antibody (target protein) secreted into the media of cultures stably expressing the anti-1L8 antibody (bar graph 2) or co-expressing the antibody and the BSC1-Protein A fusion protein (bar graph 3). Culture medium was used as a negative control (bar graph 1, no IL8 binding activity). The results of this series of experiments clearly show that the anti-1L8 antibody secreted at enhanced levels into the culture medium retains its binding activity for human IL8, indicating proper conformation of the secreted antibody.
Figure 29 provides results of an experiment described in Example 21 that indicate that protein expression enhancing polypeptides of the invention may be used to treat a disease caused by a mutant protein that does not fold into its proper conformation. Figure 29 shows X-ray film images of AMENDED SHEET - IPEA/US
=
chemiluminescent signals of a Western blot assay for expression of fusion proteins comprising wild type alphal-antitrypsin (AAT) or the mutant alphal-antitrypsin containing the Z mutation (AATZ, wherein Glu is replaced by Lys at codon 342) linked to the Fc domain from human IgG with or without co-expression of a BSC1-Protein A comprising the 3-29 polypeptide (IKKAYRKLA, SEQ ID
NO:48) linked to Protein A. The top panel of Figure 29 shows expression of Fc fusion proteins in the media of cultures of transfected cells expressing the AAT-Fc fusion protein alone (lane 2, from the left), of transfected cells expressing the AATZ-Fc fusion protein alone (lane 3, from the left), and of transfected cells co-expressing the AATZ-Fc fusion protein and the BSC1-Protein A fusion protein (lane 4, from the left). Lane 1 shows non-expressing cell culture medium as a control. Clearly, no AATZ-Fc fusion protein was secreted into media of cultures of cells expressing AATZ-Fc fusion protein alone (lane 3, from the left). As shown in the middle panel (Cell Lysate) of Figure 29, for cells expressing the AATZ-Fc fusion protein alone, the AATZ-Fc fusion protein remained in the cells (lane 3, from the left), presumably lodged in the endoplasmic reticulum as is known for the unfused AATZ protein. In contrast, co-expression of the AATZ-Fc fusion protein and the BSC1-Protein A
fusion protein significantly enhanced the level of AATZ-Fc fusion protein secreted into the culture medium as shown in lane 4 (from the left) in the top panel (medium) of Figure 29. Moreover, as shown in lane 4 (from the left) in the middle panel (Cell Lysate) of Figure 29, virtually no AATZ-Fc fusion protein was retained in the cells. The same membrane was blotted with anti-Tubulin antibody for a loading control (lower panel) in Figure 29. The results show that co-expression of the BSC1-Protein A fusion protein significantly elevated the level the AATZ-Fc target protein secreted into the culture medium as compared to the level of expression of the target protein in the absence of the BSC1-Protein A fusion protein with virtually no AATZ-Fc retained in the cells.
Detailed Description of the Invention The invention provides a new family of polypeptides for enhancing the level of expression of a target protein of interest. The invention is based on the discovery that a target protein of interest can be expressed at a significantly higher level and in the proper cellular or extracellular location when co-expressed in either of two arrangements in a host cell with a protein expression enhancing polypeptide comprising:
an isolated J domain of a J protein, a protein expression enhancing polypeptide fragment of a J domain, or a protein expression enhancing J domain analog polypeptide comprising the formula:
X1-X2-X3-X4-X5-X6-X7-X8-X9 (SEQ ID NO:47), wherein:
X1 is isoleucine (I), leucine (L), valine (V), alanine (A), or methionine (M);
X2 and X3 are each independently any amino acid with the proviso that at least one is lysine (K) or arginine (R);
X4 is any amino acid; or X4 may be absent when X1 through X3 are present and through X9 are present;
X5 is tyrosine (Y), tryptophan (W), or phenylalanine (F);
X6 and X7 are each independently any amino acid with the proviso at least one is lysine (K) or arginine (R); or one of X6 and X7 may be absent when the other is K or R and when X1 through X5 are present and X8 and X9 are present; and X8 and X9 are any amino acid with the proviso that at least one is leucine (L) or alanine (A); or one of X8 and X9 may be absent when the other is L or A and when X1 through X7 are present.
A protein expression enhancing polypeptide of the invention may be employed in either of two arrangements for enhancing expression of a target protein of interest by a host cell. In a "modified" arrangement, a fusion protein comprises a protein expression enhancing polypeptide linked (fused) to a target protein of interest. The fusion protein is thus a "modified" target protein that acts as a functional surrogate for the target protein of interest and is expressed at an enhanced level by a host cell compared to the level of expression of the unmodified target protein alone. In an "unmodified" arrangement, a fusion protein comprises a protein expression enhancing polypeptide of the invention linked to a target protein binding domain that has an affinity for and binds the regular "unmodified" target protein of interest, wherein co-expression of the fusion protein and the target protein of interest in a host cell enhances the expression of the unmodified target protein as compared to the level of expression in the absence of the target protein-binding fusion protein according to the invention. In accordance with the invention, the enhanced level of protein expression in the modified and unmodified arrangements includes expression of the respective modified or unmodified target protein of interest in the proper location (cellular or extracellular) of the target protein of interest.
Accordingly, the invention provides a technical solution when there is a failure to express desired quantities of an endogenous or heterologous (recombinant) protein of interest in cells. The present invention also provides compositions and methods for treating individuals for a disease or disorder in which there is a failure to express sufficient levels of a functional protein in vivo, where inadequate expression of the protein or a functional version thereof leads to a pathological state.
Examples of diseases in which an improperly folded protein species has been demonstrated or implicated include, but are not limited to, prion-associated disease (transmissible spongiform encephalopathy), Alzheimer's disease; Parkinson's disease; Huntington's disease; and cystic fibrosis (CF).
In order to more clearly describe the invention the following comments and definitions of terms apply.
Unless otherwise defined herein, scientific and technical terms used in connection with the present invention shall have the meanings that are commonly understood by those of ordinary skill in the art. The meaning and scope of the terms should be clear; however, in the event of any latent ambiguity, definitions provided herein take precedent over any dictionary or extrinsic definition.
Further, unless otherwise required by context, singular terms shall include pluralities and plural terms shall include the singular. In this application, the use of the term "or"
means "and/or," unless stated otherwise. Furthermore, the use of the term "including", as well as other forms, such as "includes"
and "included", is not limiting.
Generally, nomenclatures used in connection with and techniques of protein and nucleic acid chemistry (including methods of recombinant nucleic acid and polymerase chain reaction (PCR)), cell and tissue culture, molecular biology, genetics, microbiology, biochemistry, proteomics, pharmacology, and pharmaceutical science described herein are those well-known and commonly used in the art. The methods and techniques of the present invention are generally performed according to conventional methods in the art and as described in various general and more specific references available in the art. Assays and purification techniques are performed according to protocols available in the art, including in manuals of laboratory techniques and manufacturer's specifications, as commonly accomplished in the art or as described herein.
Unless indicated otherwise, when the terms "about" and "approximately" are used in combination with an amount, number, or value, then that combination describes the recited amount, number, or value alone as well as the amount, number, or value plus or minus 10% of that amount, number, or value. By way of example, the phrases "about 40%" and "approximately 40%" disclose both "40%" and "from 36% to 44%, inclusive".
The term "target protein of interest", "target protein", or "protein of interest" refers to any protein for which there is a need or desire to enhance the level of expression in its intended cellular (including intracellular and membrane-associated) or extracellular (secreted) location.
The term "isolated" as in an "isolated molecule" (e.g., "isolated protein" or "isolated nucleic acid") is a molecule that by virtue of its origin or source of derivation: is not associated with naturally associated components that accompany it in its native state; is substantially free of other kinds of molecules from the same species; is expressed by a cell from a different species; or does not occur in nature. Thus, a protein or nucleic acid molecule that is chemically synthesized or synthesized in a cellular system different from the cell from which it naturally originates will be "isolated" from its naturally associated components. A protein or nucleic acid molecule may also be rendered substantially free of naturally associated components by isolation, using respectively protein or nucleic acid purification techniques well known in the art.
The term "vector", as used herein, is intended to refer to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. One type of vector is a "plasmid", which refers to a circular double stranded nucleic acid (typically, DNA) loop into which additional nucleic acid segments may be inserted. Another type of vector is a viral vector, wherein additional DNA segments may be inserted into the viral genome. Certain vectors are capable of autonomous replication in a host cell into which they are introduced (e.g., bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). Other vectors (e.g., non-episomal mammalian vectors) can be integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome. Moreover, certain vectors are capable of directing the expression of genes to which they are operatively linked. Such vectors are referred to herein as "recombinant expression vectors" (or simply, "expression vectors").
In general, expression vectors of utility in recombinant DNA techniques are often in the form of plasmids. In the present specification, "plasmid" and "vector" may be used interchangeably as the plasmid is the most commonly used form of vector. However, the invention is intended to include other forms of expression vectors, such as viral vectors (e.g., replication defective retroviruses, lentivirus-derived vectors, and adenovirus-derived viruses), which serve equivalent or comparable functions.
The term "operably linked" refers to a juxtaposition of described components wherein the components are in a relationship permitting them to function in their intended manner. A control sequence "operably linked" to a coding sequence is ligated in such a way that expression of the coding sequence is achieved under conditions compatible with the control sequences.
"Operably linked"
sequences may include both expression control sequences that are contiguous with the gene of interest and expression control sequences that act in trans or at a distance to control the gene of interest. The term "expression control sequence" refers to polynucleotide sequences that are necessary to effect the expression and processing of coding sequences to which they are ligated.
Expression control sequences include appropriate transcription initiation, termination, promoter and enhancer sequences;
efficient RNA processing signals such as splicing and polyadenylation signals;
sequences that stabilize cytoplasmic mRNA; sequences that enhance translation efficiency (such as, a Kozak consensus sequence); sequences that enhance protein stability; and when desired, sequences that enhance protein secretion. The nature of such control sequences differs depending upon the host organism; in prokaryotes, such control sequences generally include promoter, ribosomal binding site, and transcription termination sequence; in eukaryotes, generally, such control sequences include promoters and transcription termination sequence. The term "control sequences"
is intended to include components whose presence is essential for expression and processing, and can also include additional components whose presence is advantageous, for example, leader sequences and fusion partner sequences. Unless stated otherwise, a description or statement herein of inserting a nucleic acid molecule encoding a fusion protein of the invention into an expression vector means that the inserted nucleic acid has also been operably linked within the vector to a functional promoter and other transcriptional and translational control elements required for expression of the encoded fusion protein when the expression vector containing the inserted nucleic acid molecule is introduced into compatible host cells or compatible cells of an organism.
As used herein, the term "recombinant" when used as an adjective describes non-naturally altered or manipulated nucleic acids, host cells transfected with exogenous nucleic acids, or polypeptides expressed non-naturally, through manipulation of isolated nucleic acid (typically DNA) and transfection of host cells or through manipulation of endogenous nucleic acid to alternative expression by introduction of non-endogenous nucleic acid. "Recombinant" is a term that specifically encompasses DNA molecules that have been constructed in vitro using genetic engineering techniques, and use of the term "recombinant" as an adjective to describe a molecule, construct, vector, cell, protein, polypeptide, peptide, or polynucleotide specifically excludes naturally occurring ("endogenous") such molecules, constructs, vectors, cells, proteins, polypeptides, peptides, and polynucleotides in their respective, unisolated, native locations (for example, intracellular, tissue, or organ locations).
The term "recombinant host cell" (or simply, in context, "host cell"), as used herein, is intended to refer to a cell into which exogenous nucleic acid has been introduced. It should be understood that such terms are intended to refer not only to the particular subject cell but to the progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term "host cell" as used herein. Host cells useful in various aspects of the invention may be prokaryotic and eukaryotic cells.
Preferred prokaryotic host cells include various bacterial cells, including Escherichia coli. While some manipulations, constructions, expressions, or replications of nucleic acids or encoded polypeptides related to the invention may be conducted using prokaryotic or eukaryotic host cells, the preferred host cells for enhanced expression of a target protein of interest, whether in the modified or unmodified arrangements described herein, are eukaryotic host cells. Preferred eukaryotic host cells include, without limitation, a mammalian host cell, an insect host cell, a plant host cell, a fungal host cell, a eukaryotic algal host cell, a nematode host cell, a protozoan host cell, and a fish host cell. Preferably, a mammalian host cell is a Chinese Hamster Ovary (CHO) cell, a COS cell, a Vero cell, an SP2/0 cell, an NS/0 myeloma cell, a human embryonic kidney (HEK293) cell, a baby hamster kidney (BHK) cell, a HeLa cell, a human B cell, a CV-1/EBNA cell, an L cell, a 3T3 cell, an HEPG2 cell, a PerC6 cell, or an MDCK cell. Preferred fungal host cells include Aspergillus, Neurospora, Saccharomyces, Pichia, Hansenula, Schizosaccharomyces, Kluyveromyces, Yarrowia, and Candida. A
particularly preferred Saccharomyces host cell is a Saccharomyces cerevisiae cell. A particularly preferred insect host cell is an Sf9 cell.
The terms "heterologous" and "exogenous" are synonymous and are used broadly as adjectives to describe any molecule (e.g., protein, polypeptide, nucleic acid) that is not native to a host cell containing or expressing the molecule. Accordingly, "heterologous" and "exogenous" encompass the term "recombinant" as defined above.
"Transgenic organism", as known in the art and as used herein, refers to an organism having cells that contain a transgene, wherein the transgene introduced into the organism (or an ancestor of the organism) expresses a polypeptide not naturally expressed in the organism or not naturally expressed at the normal or proper level to provide the intended function of the polypeptide to the organism. A "transgene" is a nucleic acid construct, which is stably and operably integrated into the genome of a cell from which a transgenic organism develops, directing the expression of an encoded gene product in one or more cell types or tissues of the transgenic organism.
The terms "disease" and "disorder" are used interchangeably to indicate a pathological state identified according to acceptable medical standards and practices in the art.
As used herein, the term "effective amount" refers to the amount of a therapy that is sufficient to reduce or ameliorate the severity and/or duration of a disease or one or more symptoms thereof; to prevent the advancement of a detrimental or pathological state; to cause regression of a pathological state; to prevent recurrence, development, onset, or progression of one or more symptoms associated with a pathological state; to detect a disorder; or to enhance or improve the prophylactic or therapeutic effect(s) of a therapy (e.g. , the administration of another prophylactic or therapeutic agent).
A "biological sample," as used herein, includes, but is not limited to, any quantity of a substance from a living organism or formerly living organism. Such organisms include, but are not limited to, humans, non-human primates, mice, rats, monkeys, dogs, rabbits, ruminants, and other animals. Such substances of a biological sample may include, but are not limited to, blood, serum, plasma, urine, saliva, sputum, mucus, synovial fluid, milk, semen, cells, organs (for example, heart, spleen, lung, kidney, breast, brain, eye, tongue, stomach, pancreas, intestines, gall bladder, reproductive organs, appendix), tissues (for example, bone, cartilage, muscle, skin), bone marrow, and lymph nodes.
A composition or method described herein as "comprising" (or which "comprises") one or more named elements or steps is open-ended, meaning that the named elements or steps are essential, but other elements or steps may be added within the scope of the composition or method. To avoid prolixity, it is also understood that any composition or method described as "comprising" (or which "comprises") one or more named elements or steps also describes the corresponding, more limited, composition or method "consisting essentially of" (or which "consists essentially of") the same named elements or steps, meaning that the composition or method includes the named essential elements or steps and may also include additional elements or steps that do not materially affect the basic and novel characteristic(s) of the composition or method. It is also understood that any composition or method described herein as "comprising" or "consisting essentially of" one or more named elements or steps also describes the corresponding, more limited, and close-ended composition or method "consisting of' (or which "consists of") the named elements or steps to the exclusion of any other unnamed element or step.
The term "J domain analog" as used herein refers to a target protein expression enhancing polypeptide (or PEEP) that comprises the sequence of amino acids of formula I
(SEQ ID NO:47).
Such polypeptides, where incorporated into a target protein sequence to make a modified target protein or when used to construct a protein expression enhancing polypeptide-target protein binding domain fusion protein, are useful for effecting an increase in expression of a target protein of interest.
The terms "J domain active fragment" or "active fragment of a J domain" refer to a fragment of a J domain of a J protein which retains the ability to increase the level of expression of a target protein when used in the two types of fusion proteins (PEEP/target protein fusion or PEEP/target protein binding domain fusion) described herein. The Examples below indicate that J domain active fragments will commonly retain the region of a J domain at the C-terminal extremity of a helix II.
Larger portions of a J domain may be active as well, but excision of all or part of the C-terminal nine amino acids of a helix II invariably leads to loss of protein expression enhancement activity.
In any composition or method disclosed herein, known or disclosed equivalents of any named essential element or step may be substituted for that element or step.
Unless specifically indicated, a composition or method is not limited by any particular order of the listed elements or steps, unless a particular method step requires the prior performance of another step.
It is also understood that an element or step "selected from the group consisting of" or "any of' (or equivalent phrase) refers to one or more of the elements or steps in the list that follows, including combinations of any two or more of the listed elements or steps.
J Domains Useful in the Invention The J domains of a variety of J proteins have been determined. See, for example, Kampinga et al., Nat. Rev., 11: 579-592 (2010); Hennessy et al., Protein Science, 14:1697-1709 (2005). A J
domain useful in preparing a fusion protein of the invention (whether in the modified or unmodified arrangement) has the key defining features of a J domain of any member of the J protein family.
Accordingly, an isolated J domain useful in the invention comprises a polypeptide domain from a J
protein, which is characterized by four a-helices (I, II, III, IV) and usually having the highly conserved tripeptide sequence of histidine, proline, and aspartic acid (referred to as the "HPD motif") between helices II and III. Typically, the J domain of a J protein is between fifty and seventy amino acids in length, and the site of interaction (binding) of a J domain with an Hsp7O-ATP chaperone protein is believed to be a region extending from within helix II and including the HPD motif.
Representative J domains include, but are not limited, a J domain of an ERdj protein (for example, a J
domain of ERdj3 or ERdj5), a J domain of a large T antigen of 5V40, and a J
domain of a mammalian cysteine string protein (CSP-a). The amino acid sequences for these and other J domains that may be used in fusion proteins of the invention are provided in Table 1.
Table 1. Amino acid sequences of representative isolated J domains.
J Protein Source of J Domain SEQ ID J Domain Amino Acid Sequence NO:
human Hsp40 1 KID YYQ 7A.P. GAS D.E.E K RAYR H
(NP_006136; Heat Shock Protein PDKNKEPGAEEKFKEIAEAYDVLSDPRK
40) human ErdJ1 2 LNFY0FLTIQUAS SAD I RKAYRKL SLILH
(NM_022365; DnaJC1, HTJ1, PDKNKDENAETQFKI,V7kIYEVI,KDDEP.
MTJ1, DnaJ homolog subfamily C
member 1 protein, DNAJL1) human ErdJ2 3 YNPYFVLNLDPGATVA.EIKQYPLLSLKYH
(NM_001017975; HFM1, PDKGGDEVMFMRIAR:AYAAL I' DEES
5EC63 domain containing 1 protein, MER3, hHFM1) human ErdJ3 4 RDL.YKiLGVPRSASIKDIKKAYRKLALQLH
(NM_016306; DNAJB11, DnaJ PDP.1%.=PDD1-:,QAQEKFQDLGAAYEVISDSEK
(Hsp40) homolog, subfamily B, member 11, ERj3p, HEDJ, ERj3, ABBP2, ER-associated DNAJ
protein 3) human ErdJ4 5 .1.T.SYYDTT,GyPK :A3ERQIKK7F.LIKLANK:zi.-I
(NM_012328; DNAJB9, PDKNKSPDAEAKE'RE IAEAYETLSDANR
microvascular differentiation gene 1 protein, MDG1, endothelial Mdgl) human ErdJ5 6 QD.FYS (3`,TSJ:: TAS S RE Pc.).AFKK L.7E:K
(NM_018981; DNAJC10, ER- PDKNPNNPNAHGDFLKINPAYEVI,KDEDI, resident protein ERdj5, JPD1, J-domain-containing protein disulfide isomerase-like protein, DnaJ (Hsp40) homolog, subfamily C, member 10, hMTHr protein) human ErdJ6 7 RDYYKiLGV-KRNAKKQEIIKAYRKLALQWH
(NM_006260; DNAJC3, PONE' Q.NE E E KKKAE KKE' ID I Als,A.KENIL
SDP
DnaJ (Hsp40) EM
homolog, subfamily C, member 3 protein, protein-kinase, interferon-inducible double stranded RNA
dependent inhibitor protein, P58IPK protein, PRKRI, 58 kDa cellular inhibitor protein, p58 inhibitor of protein kinase) human CSP 8 E.SLY:HVLGLDKNi-VISDDIKKSYRKLALK"YE
(NP_079495; cysteine string PliK1:4P1)1\111).EAADRTKEINNAHAI LTDATK
protein alpha, CSPalpha protein, DNAJC5 protein, cysteine string protein, DnaJ (Hsp40) homolog, subfamily C, member 5 protein, CSP protein) J Protein Source of J Domain SEQ ID J Domain Amino Acid Sequence NO:
SV40 large T antigen 9 DDLMDLI,GLERSAWGNIPI,PIRKAYLKKCIsTE
(YP_003708382; large tumor FHPDKGGDEEKTAKKNINTLYKKMEDGVK
antigen T-ag [Simian virus 40]) DnaJ 10 QDYYEILGVSKTAEEREIKKAYKRLAMKIE
PDRNQGDKEAEAKFKE KEAYEVLT DS QK
human dnaJ homolog subfamily C, 11 NPFEVLQIDPEVTDEEIKKRFRQLSILVHP
member 8 DKNQDDADRAQKAFEAVDKAYKLLLDQEQK
KRAL DVI Q
human dnaJ homolog subfamily C, 12 F2J%i .Y7 T3,,C31_,Iii--:.GASNEETKKTYP.K.LALEHt-i member 5B PL)KNPDDPAATEKFREINNAHAILTDISK
human dnaJ homolog subfamily C, 13 LNPFHVY_,GVL;ATASENELKKAYRQLAVMVE
member 14 PliBINHHPRAEEAFKVERAAWD I V SNAEK
human dnaJ homolog subfamily C, 14 RDCYEVLGAISRSAGKAEIARAYROLARRYE
member 25 precursor P DRY RPQP G DEGP GRTPQ SAE EAF INATA
T LKDEE T
human dnaJ homolog subfamily B, 15 71\SYYFILDvPRSASADDIKNAYRRRALQwH
member 2, isoform a DKNPDNKEFAEKKFKEVAEAYEVL S D I-1K
human dnaJ homolog subfamily B, 16 ASYYETLIWPRSASADDIKKAYRRKALQWH
member 2, isoform b PDKNDNKEFAEKKFKEVAEAYEVLSDKHK
Chain A, 17 TTYYDVI,GVKPNATaTEELKKAYRKLALKYI-i nmr structure of Bc008182 protein, PL)KNPNEGEKFKQI SQAYEVLSDAKK
a human Dnaj-like domain Chain A, 18 7A.SYYE L DVPIR SAS AD I) I KKAYRRKAL (2Toq H
solution structure of J Domain of DKNPDNKEFAEKKFKEVAEAYEVL S D K
Hsjla Chain A, 19 KD SWD1',1L GYKE) GASRDEVisaAYRKLAVL LH
solution structure of a Dnaj-like PDKOVAPGSEDAFKAVVNARTALLKNIK
domain from human ras-associated protein Rapl Chain A, 20 VDIYEVLDVE'RQAS SEAI KFAYRKLALKWH
solution structure of Dnaj domain PDKNPENKEEAERRFNQVAEAYEVLSDARK
of human protein Hcg3, a hypothetical protein Tmp_locus_21 Chain A, 21 GDYYQT.LGVPRNASQKE I KJ.'AYYQLAKKYH
solution structure of J domain from PDTNKDDPKAREKFSQLAEAYEVLSDEVK
Dnaj homolog, human Tidl protein Chain A, 22 C-;SYYD L GVK. SA. E RQ K
solution structure of J domain from PDKNKSPDAEAKFRE 1AF:22:YETI, ST)13,NR.
human Dnaj subfamily B, member Chain A, 23 GDYYEILGVSRGASDEDLKKIYRLAJKFH:
solution structure of J domain fromD KN HAP GAT EAF"..f2k I G TA YAW., SNPE
human Dnaj subfamily B, member J Protein Source of J Domain SEQ ID J Domain Amino Acid Sequence NO:
Chain A, 24 KDYYQTLGLARGASDFFIKRAYRRQA.LRH
human Hsp40 (HDJ-1), nmr PDKNKEPGAEEKFKE I AEAYDVL S DPRK
Chain A, solution structure of Dnaj 25 T2LYDLLGVPSTATQAQIKAAYYRQCF Y H
domain from human Williams- I-1'DR.NSGSAEAAERFTRI SOAYVVL GS AT I, Beuren syndrome chromosome region 18 protein Chain A, solution structure of J 26 ANYYEVI, GVOASASP ED I KNAYRKLALP.WH
domain of Dnaj homolog PDKNPDNKEEAEKKFKLVSEAfEVLSDSKK
subfamily B, member 8 Chain A, solution structure of J 27 EDYYTI,T,GCDET
.SSVEQII,A.EFKVR.ALECH
domain of Dnaj homolog DKHPENPKAVE TFQKLQKAKE I L TNEE S
subfamily C, member 12 Chain A, Dnaj domain of human 28 S LKEVTSVVEQAWKLPESERKKI I RRLYL
Kiaa0730 protein KWHPDKNPENHD IANEVFKHLQNE I NR
human dnaJ homolog, subfamily 29 v 1) YEVL GVQRHASE)E D KKA Y RK AL KWH
B, PDKNPENREEAERKFRQVAEAYEVLSDARR
member 6, isoform a human dnaJ homolog, subfamily 30 -,,,T)YYEVL GVQRHA.3 P ED KKAYRKLALKWH
B, P DKNP EN KEEAF. RKF KQVAEAYEVL S DAKK
member 6, isoform b human dnaJ homolog, subfamily 31 IsT.S YY F) 1- ,C-;-\IPKSASERQ I KKTIF
FIKLAT.4KY1.5:
B, PDKNKSPDAEAKFREIAEAYETLSDANR
member 9 precursor human DnaJ (Hsp40) homolog, 32 LNPFEVLQI DPIEVT DEE I KKPEI-ZOL S I LVE-i subfamily C, PDKNQDDADRAQKAFEAVDKAYKLLLDQEC, member 8, isoform CRA_c human DnaJ (Hsp40) homolog, 33 DDAYEVLNLPQGQGP FIDE SK I RKAYFRLAQ
subfamily C, .1.<:Yf1P1) KNFEGRDMF E MTN YEFLCTKS
member 13, isoform CRA_b human DnaJ (Hsp40) homolog, 34 RALiLGVSPT7NKGKIRD7J-TRRI.MLLNH
subfamily C, P DKGK
member 19, isoform CRA_e human DnaJ (Hsp40) homolog, 35 ESLYi-1\71C-;LDKNATSDD IKKSYRKLA.LKH
subfamily C, PDKNDNPEPADKFKEI.NNAHAi L T DA T K
member 5, isoform CRA_b human DnaJ (Hsp40) homolog, 36 i GV.H.P GA.3 TEEVKR.%%17F SK SKELLI
subfamily C, P DRDP GNP SLHSRFVELSEAYRVLSREQS
member 4, isoform CRA _f human zinc finger, CSL-type 37 .1.<:DwY S GADP SAN :I SDI,KQKYQKI, I
I,M7y71.-I
containing 3, isoform CRA_c PDKQSTDVPAGTVEECVQKF E I DQAWK L
E E
J Protein Source of J Domain SEQ ID J Domain Amino Acid Sequence NO:
human DnaJ (Hsp40) homolog, 38 MD I, YALLGIEE KAAD KEVEIKAI I-Z K AL
SC H
subfamily C, P DKNP DNPRAAE LE HQL S Q.7k EVI:77 DAAA
member 17, isoform CRA_a human DnaJ (Hsp40) homolog, 39 KS YY D IiGVPKSASERIKKAFBKLAMKYH
subfamily B, P D KNK S P DA.EAKF RE I 7-1E GA SVPAA
SSE
member 9, isoform CRA_a human DnaJ (Hsp40) homolog, 40 T :CY C-;7s.S SKSKEJH
SKE
subfamily C, PDRDGNPSLI-iSFVELSEAYRVLSREQS
member 4, isoform CRA_g human DnaJ (Hsp40) homolog, 41 3TI{YELLGVH.PGAST.EVKRFSKSKELH
subfamily C, PDRDGNPSLI-iSFVELSEAYRVLSREQS
member 4, isoform CRA_a human DnaJ (Hsp40) homolog, 42 ED :(YS Li_,NVRREA.3 S EE I, KAAYRRI,CML7y71.-I
subfamily C, PDKHRDPELKSQ2-1,ERISNLVHQAYEVL SDP
member 11, QT
isoform CRA_c human zinc finger, CSL-type 43 .T.ungYS GADP SAN S D I,K.QK 'N.M., T.
I,M7y71.-I
containing 3, isoform CRA_b PDKQS TDVPAGTVEECVQKIF E DQAcIK L
Gis,EET
human J-type co-chaperone 44 RDT{FSLMDCNR3FRVDTARLQHRT{QQLQRL
HSC20, isoform CRA_c VI-IPDFFSQRSQTEKDFSEKFISTLAMDKYKT
lii3LP I, S
human hCG1994888, isoform 45 RDCY FAIL GV S R S AG A.E I A RAY P.
c.). LAR R Y H
CRA_d I-1'DRYRPOP GDE GP GP. TPQSAEEAFT., LVATA
E T KDE: E T
human DnaJ (Hsp40) homolog, 46 ' 'I H
subfamily A, P DKNPNE GEKVKML YISS
member 1, isoform CRA_a J Domain Fragments and Analogs with Protein Expression Enhancing Activity Further study of J domains using sequence analysis, including amino and carboxy terminal deletion analysis, revealed that only a relatively small portion of a J domain is required to provide protein expression enhancement activity. Surprisingly, the analysis determined that protein expression enhancement activity according to the invention can be provided by a polypeptide fragment isolated from within a J domain and that consists of as little as 9 or 10 amino acids. See, Examples 10 and 11, infra. As with isolated J domains, such J domain polypeptide fragments may be used in the methods and compositions described herein to enhance expression of a target protein of interest in its intended cellular (intracellular, membrane-associated) or extracellular (secreted) location. The individual J domain polypeptide fragments are not all identical in amino acid sequence, but may share some sequence homology and structural features in addition to providing a protein expression enhancement activity in either a modified or an unmodified arrangement described herein.
Further deletion and substitution mutation analysis of the above-mentioned J
domain polypeptide fragments provided the basis for defining a structural formula for a new family of J
domain analog polypeptides that possess target protein expression enhancement activity. The members of this family of analog polypeptides comprise 8 to 9 amino acids and include some J
domain polypeptide fragments as well as polypeptides that have not been previously identified in the current library of J domains. See, Example 11.
The smaller size of J domain polypeptide fragments and of J domain analog polypeptides compared to complete (full-length) J domains reduces the size of fusion proteins that can be constructed and expressed in the modified and unmodified arrangements of the invention for enhancing expression of a target protein of interest. Thus, the size of recombinant nucleic acid molecules encoding such fusion proteins can be correspondingly smaller than nucleic acid molecules that encode fusion proteins comprising a complete J domain. The relatively small size of J domain polypeptide fragments and J domain analog polypeptides of the invention may be particularly beneficial in reducing the immunogenicity of fusion proteins of the modified arrangement in which a protein expression enhancing polypeptide is linked (fused) to a target protein of interest to form a modified (fusion) target protein that is expressed in or administered to a subject in place of the (unlinked) target protein of interest. The less immunogenic the fusion protein is, the more likely the fusion protein can persist in the subject in order to provide the subject with the beneficial property or effect of the fusion protein without being rapidly eliminated or inhibited by an immune response directed to the fusion protein.
Fusion Proteins Comprising a Protein Expression Enhancing Polypeptide According to the invention, a protein expression enhancing polypeptide described herein is used as a component of a fusion protein that enhances expression of a target protein of interest for which there is a need to improve expression in a host cell. The protein expression enhancing polypeptide is used to enhance expression of a target protein of interest in either of two arrangements that describe the primary structure (amino acid sequence) of the expressed target protein of interest.
In the "modified" arrangement for enhancing protein expression, a protein expression enhancing polypeptide is linked to a target protein of interest to form a fusion protein, i.e., a "modified" target protein of interest, which is expressed at an enhanced level compared to that of the unmodified target protein that is poorly expressed in the absence of a protein expression enhancing polypeptide. Thus, the fusion protein in the modified arrangement is a modified form of the target protein of interest that is expressed and employed as a surrogate in place of the poorly expressed, unmodified target protein.
In the "unmodified" arrangement for enhancing protein expression, the primary structure of the target protein of interest remains unaltered ("unmodified") in that it is not fused to a protein expression enhancing polypeptide. A protein expression enhancing polypeptide of the invention is linked to a target protein binding domain that has an affinity for and binds to a target protein of interest. Co-expression of the fusion protein and the unmodified target protein of interest in a host cell results in an enhanced level of expression of the target protein of interest as compared to the level of expression in the absence of the target protein-binding fusion protein.
As the primary structure (amino acid sequence) of a target protein of interest remains unaltered (not linked in a fusion protein) in the unmodified arrangement, it is likely that for many applications, the unmodified arrangement for enhancing protein expression will be preferred over the modified arrangement. However, as explained below, it is also possible to engineer the fusion protein of a modified arrangement so that the protein expression enhancing polypeptide component of the fusion protein is easily cleaved to liberate the target protein component comprising the original amino acid sequence of the target protein with no or only a few additional remnant amino acids from the fusion protein. Such a fusion protein may be more suitable than the unmodified target protein for certain applications.
While it is possible to synthesize a fusion protein in either arrangement using direct synthesis (for example, solid-phase peptide synthesis, solution-phase synthesis, etc.), it is likely that in most cases a fusion protein described herein will be more economically produced using standard recombinant nucleic acid techniques, including polymerase chain reaction (PCR) techniques, in concert with cell culture methods or transgenic methods.
Standard techniques may be used for recombinant DNA, oligonucleotide synthesis, transfection of cells (for example, without limitation, electroporation, liposome-mediated transfection, transformation methods), and cell and tissue culture methods to express a fusion protein of the invention. Enzymatic reactions and purification techniques may be performed as commonly accomplished in the art, as described in a manufacturer's specifications, or as described herein. The foregoing techniques and procedures may be generally performed according to conventional methods well known in the art and as described in various general and more specific references that are cited and discussed throughout the present specification. See e.g., Sambrook et al., eds., Molecular Cloning: A Laboratory Manual, Second Edition (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1989) and Ausubel et al. (eds.), Current Protocols in Molecular Biology (John Wiley & Sons, New York, 2012), which are incorporated herein by reference.
As noted above, the terms "modified" and "unmodified" refer to whether or not a target protein of interest is linked to a protein expression enhancing polypeptide.
It is understood that in some embodiments of both the modified and unmodified arrangements, it may be beneficial to link one or more additional domains may to a fusion protein or target protein of interest. For example, any of the well-known epitope tag peptides (epitope tags) may be incorporated into a protein to facilitate detection and/or purification of the expressed protein. Such epitope tags include, but are not limited to, a V5 epitope tag (GKPIPNPLLGLDST (SEQ ID NO:110)), a Flag epitope tag (DYKDDDDK
(SEQ ID NO:111)), a hexa-histidine epitope tag (HHHHHH (SEQ ID NO:112)), a hemagglutinin epitope tag (YPYDVPDYA (SEQ ID NO:113)), a c-myc epitope tag (EQKLISEEDL (SEQ
ID
NO:114)), a VSV-G epitope tag (YTDIEMNRLGK (SEQ ID NO:115)), and a HSV epitope tag (QPELAPEDPED (SEQ ID NO:116)). As explained below, it is also possible to link a protein with such an epitope tag using a linker that can be cleaved by a proteolytic enzyme and thereby removed (or substantially removed) from the protein.
Linkers Any domain may be linked to another domain within a fusion protein of the invention by methods known in the art. For example, in the modified arrangement of the invention, a fusion protein comprises a protein expression enhancing polypeptide linked to a target protein of interest.
The expressed fusion protein is therefore a modified target protein that can be used as a surrogate for the unfused and poorly expressed target protein of interest. The protein expression enhancing polypeptide may be linked directly to the target protein of interest or linked indirectly via a linker molecule. In the unmodified arrangement of the invention, a fusion protein comprises a protein expression enhancing polypeptide linked to a target protein binding domain that has an affinity for and binds to a target protein of interest. Co-expression of the fusion protein with the target protein of interest enhances the level of expression of the unmodified (unfused) target protein of interest compared to the level of expression in the absence of the fusion protein. The protein expression enhancing polypeptide may be linked directly to the target protein binding domain or linked indirectly via a linker molecule. Other domains may also be linked to a fusion protein or unfused protein in either the modified and unmodified arrangements to provide one or more additional features. For example, an epitope tag may be linked to a fusion protein or unfused protein to facilitate detection or purification of the tagged protein.
At the amino acid level, a linker may be one or more amino acids, including 1 to 10 amino acids, 1 to 20 amino acids, and even 1 to 50 amino acids. Typically, with respect to linking a protein expression enhancing polypeptide to a target protein of interest (in the modified arrangement) or to a target protein binding domain (in the unmodified arrangement), it is not necessary to use a linker that is more than 20 amino acids because linking a protein expression enhancing polypeptide directly to a target protein of interest or to a target protein binding domain does not appear to significantly diminish the necessary biochemical and functional properties of the protein of interest or the target protein binding domain (data not shown).
Selecting one or more linkers to produce a fusion protein according to the invention is within the knowledge and skill of the art. See, for example, Arai et al., Protein Eng., 14(8): 529-532 (2001);
Crasto et al., Protein Eng., 13(5): 309-314 (2000); George et al., Protein Eng., 15(11): 871-879 (2003); Robinson et al., Proc. Natl. Acad. Sci. USA, 95: 5929-5934 (1998).
General considerations for using a particular linker to link a protein expression enhancing polypeptide to a target protein of interest or to a target protein binding domain may include those in making other fusion proteins in which one functional domain is linked to another functional domain, for example, as may be considered in linking immunoglobulin variable and/or constant domains in a wide variety of formats for producing engineered functional binding proteins. Clearly, a linker should not interfere with the folding of a target protein of interest or a target protein binding domain that is linked to a protein expression enhancing polypeptide. A linker, if present in a fusion protein, is selected to optimize the contribution of the protein expression enhancing polypeptide to increase levels of expression or yield of the fusion protein in the modified arrangement or the (unfused) target protein of interest in the in the unmodified arrangement, and it may be omitted if direct attachment of a protein expression enhancement polypeptide to the target protein of interest or target protein binding domain achieves a desired enhanced level of expression. Linker molecules present in a fusion protein of the invention may comprise one or more amino acids encoded by a nucleotide sequence present on a segment of nucleic acid in or around a cloning site of an expression vector into which is inserted in frame a nucleic acid segment encoding a protein domain (e.g., protein expression enhancing polypeptide, protein of interest, target protein binding domain) or an entire fusion protein.
Linker molecules, especially those that are four amino acids and longer, preferably possess a flexibility that permits the protein of interest to fold into its proper conformation. A variety of relatively flexible linkers are known in the field for linking functional domains. A linker may also be used to link one or more additional domains, such as an epitope tag, to the protein expression enhancing polypeptide or protein of interest of a fusion protein of the invention. Linkers that may be used in preparing a fusion protein according to the invention, include, by are not limited to, DIAAA
(SEQ ID NO:117); DIAAALE (SEQ ID NO:118); GTGSEF (SEQ ID NO:119); AS; TVA;
ASTK
(SEQ ID NO:120); GGGSGGSGGSGG (SEQ ID NO:121); DIGGGSGGSGGSGGAAA (SEQ ID
NO:122); AKTTPKLEEGEFSEAR (SEQ ID NO:123); AKTTPKLEEGEFSEARV (SEQ ID
NO:124); AKTTPKLGG (SEQ ID NO:125); SAKTTPKLGG (SEQ ID NO:126); SAKTTP (SEQ ID
NO:127); RADAAP (SEQ ID NO:128); RADAAPTVS (SEQ ID NO:129); RADAAAAGGPGS
(SEQ ID NO:130); RADAAAA(G45)4 (SEQ ID NO:131); SAKTTPKLEEGEFSEARV (SEQ ID
NO:132); ADAAP (SEQ ID NO:133); ADAAPTVSIFPP (SEQ ID NO:134); TVAAP (SEQ ID
NO:135); TVAAPSVFIFPP (SEQ ID NO:136); QPKAAP (SEQ ID NO:137); QPKAAPSVTLFPP
(SEQ ID NO:138); AKTTPP (SEQ ID NO:139); AKTTPPSVTPLAP (SEQ ID NO:140); AKTTAP
(SEQ ID NO:141); AKTTAPSVYPLAP (SEQ ID NO:142); ASTKGP (SEQ ID NO:143);
ASTKGPSVFPLAP (SEQ ID NO:144), GGGGSGGGGSGGGGS (SEQ ID NO:145);
GENKVEYAPALMALS (SEQ ID NO:146); GPAKELTPLKEAKVS (SEQ ID NO:147);
GHEAAAVMQVQYPAS (SEQ ID NO:148); GGGGGGGP (SEQ ID NO:149); GGGGGGGGP
(SEQ ID NO:150); PAPNLLGGP (SEQ ID NO:151); PNLLGGP (SEQ ID NO:152); GGGGGGP
(SEQ ID NO:153); PAPELLGGP (SEQ ID NO:154); PTISPAPNLLGGP (SEQ ID NO:155);
TVAADDDDKSVFIVPP (SEQ ID NO:156); TVDDDDKAAP (SEQ ID NO:157); LVPRGSAAP
(SEQ ID NO:158); ASTKGPSV (SEQ ID NO:159); ASTKGPSVFP (SEQ ID NO:160); TVAAPSV
(SEQ ID NO:161); TVAAPSVFI (SEQ ID NO:162); and the like.
In some embodiments, a fusion protein may contain one or more linkers that can be cleaved by one or more proteases. Such linkers possess an amino acid sequence that is recognized by a protease for cleavage of the protein at or near the recognition sequence.
Incorporating one or more cleavable linker molecules into a fusion protein provides the option of removing one or more domains from the expressed fusion protein. By way of non-limiting examples, in some applications or preparations, it may be desirable to remove the polypeptide expression enhancing polypeptide linked to the protein of interest (for example, to reduce potential immunogenicity) and/or to remove an epitope tag that had been incorporated into a fusion protein to facilitate detection or purification of the expressed fusion protein. In another example, if the fusion protein is secreted, a polypeptide expression enhancing polypeptide (or other domain) linked by a cleavable linker to the protein of interest may be removed by adding the appropriate protease directly to the medium of cultures expressing the fusion protein. Alternatively, the protein expression enhancing polypeptide (or other domain) linked by the cleavable linker may be removed after performing one or more steps to purify the fusion protein from the culture medium.
It may be useful in some situations to remove a domain or epitope tag linked to a protein.
This can be accomplished, for example, by expressing the protein comprising the additional domain or tag in cells in which the expression of a protease that can cleave a linker of the protein is regulated, such as incorporating into the cell a recombinant gene for the appropriate protease under the control of a promoter that can be regulated by a signal (e.g., temperature shift) or agent (ion change) that can be applied to a culture after the cells have expressed the fusion protein. A
variety of promoters are available in the art for regulating gene expression in prokaryotic or eukaryotic cells. In addition, some cells express one or more proteases that can cleave a linker molecule containing a corresponding cleavage site. It is within the skill of a practitioner in the art to determine whether use of a protease that may be expressed by a host cell may be useful to cleave a linker in a fusion protein expressed by the same host cell. Alternatively, it is possible to add an appropriate protease to a sample, such as culture medium or cell lysate, containing a protein linked to an additional domain or tag via a protease-cleavable linker.
A variety of linker molecules containing proteolytic cleavage sites are known and available in the art for linking one protein or protein domain to another. Such linkers include, but are not limited to, one of more of the following examples, where the asterisk (*) indicates the proteolytic cleavage site: DYKDDDDK* (SEQ ID NO:163); ASDDDDK*GGP (SEQ ID NO:164); ALVPR*GSGP (SEQ
ID NO:165 ); ASTDDDDK*SVFPLAP (SEQ ID NO:166 ); TVALVPR*GSVFIFPP (SEQ ID
NO:167 ); ASTLVPR*GSVFPLAP (SEQ ID NO: 168); TVAADDDK*SVFIVPP (SEQ ID NO:169);
ASTDDDK*SVFPLAP (SEQ ID NO:170); LEVLFQ*GP (SEQ ID NO:171);
TVAALEVLFQ*GPAP (SEQ ID NO:172); ASTLEVLFQ*GPLAP (SEQ ID NO:173);
PAPLEVLFQ*GP (SEQ ID NO:174); TAENLYFQ*GAP (SEQ ID NO:175); AENLYFQ*GA (SEQ
ID NO:176); PGPFGR*SAGGP (SEQ ID NO:177); PGPFGR*SAGG (SEQ ID NO:178);
PQRGR*SAG (SEQ ID NO:179); PHYGR*SGG (SEQ ID NO:180); GPFGR*SAGP (SEQ ID
NO:181); GDDDDK*GGP (SEQ ID NO:182); AGDDDDK*GGP (SEQ ID NO:183);
GGDDDDK*GGP (SEQ ID NO:184); ENLYFQ*G (SEQ ID NO:185); ENLYFQ*S (SEQ ID
NO:186); and the like.
A variety of proteolytic enzymes are known in the art that may be used to cleave a cleavable linker employed in a protein of the invention. Clearly, a protease that is selected to cleave a cleavable linker in a fusion protein comprising a target protein of interest should not also cleave the target protein of interest or any other domain that is desired to be retained after cleavage of the linker.
Proteolytic enzymes that may be used to cleave a fusion protein at a site in a linker within the fusion protein include, but are not limited to, enterokinase, factor Xa, thrombin, PreScission, tobacco etch virus (TEV) protease, tissue plasminogen activator (tPA), a zinc-dependent endopeptidase, a matrix metalloproteinase (MMP), a serralysin, an astacin, an adamalysin, a disintegrin, an ADAM, a caspase, a cathespsin, a calpain, and the like.
Nucleic Acids Encoding Fusion Proteins Using standard methods available in the art, a nucleic acid (typically DNA) molecule is constructed that encodes a fusion protein employed in a modified or unmodified arrangement for enhancing expression of a target protein of interest. One or more additional domains may also be incorporated into a protein, such as a standard epitope tag used to facilitate detection and/or purification of the protein. A nucleic acid molecule encoding a desired fusion protein can be inserted into any of a variety cloning vectors available in the art for the purpose of replicating the recombinant structural gene for the fusion protein. For expressing a fusion protein, a nucleic acid molecule encoding the fusion protein can be inserted into any of a variety of expression vectors available in the art. An expression vector with the inserted nucleic acid encoding the fusion protein is then introduced into compatible host cells that permit expression of the fusion protein from the expression vector. In the case of an unmodified arrangement, a vector may also contain a copy of functional structural gene encoding the unmodified target protein of interest if the host cell does not possess a functional gene for the target protein of interest.
Expression vectors of the invention include expression vector molecules comprising a nucleic acid segment encoding a protein expression enhancing polypeptide described herein and one or more cloning sites (for example, unique restriction enzyme sites) located 5' or 3' to the protein expression enhancing polypeptide coding sequence into which a nucleic acid molecule encoding another domain of the fusion protein may be inserted: in a modified arrangement, a nucleic acid encoding a target protein of interest may be inserted to form the desired fusion protein (modified target protein);
whereas in an unmodified arrangement, a nucleic acid encoding a target protein binding domain may be inserted to form a fusion protein that is capable of binding to and enhancing expression of an unmodified target protein of interest. An expression vector may also possess multiple cloning sites that permit the insertion of one or more additional nucleic acid segments encoding one or more other desired domains (for example, an epitope tag, Fc region, etc.) to construct and express a desired fusion protein. The final nucleic acid fusion construct encoding a desired fusion is operably linked to a promoter on the expression vector. Engineering cloning sites into a vector molecule and operably linking an inserted nucleic acid segment encoding a desired protein to a promoter and other signals required for expression of the protein in a compatible host cell are within the skill in the art.
While a description herein for assembling a nucleic acid construct encoding a fusion protein of the invention may suggest a particular stepwise order to the linking of various nucleic acid molecules followed by insertion of the fully assembled nucleic acid construct into an expression vector, it is understood and appreciated that the exact order of linking segments of nucleic acid molecules to produce a nucleic acid construct encoding a desired fusion protein is within the discretion, skill, and experience of a practitioner in this art. Moreover, although it is possible to first link all segments together to form a nucleic acid molecule encoding a fusion protein prior to insertion into an expression vector, in some cases, a nucleic acid segment encoding one or more domains may already properly reside within an expression vector so that it is practical to insert one or more nucleic acid segments adjacent to the segment(s) already residing in the expression vector and thereby assemble within the expression vector an operably linked structural gene for a desired fusion protein of the invention.
Expression vectors encoding a fusion protein of the invention may be transfected into any of a variety of host cells that are compatible for expressing the fusion protein from the particular expression vector. Although some steps in the process of constructing a recombinant structural gene encoding a fusion protein of the invention may be conducted in either prokaryotic or eukaryotic cells, the preferred host cell for enhanced expression of fusion proteins according to the invention are eukaryotic cells. Eukaryotic host cells useful in the invention include, but are not limited to, a mammalian host cell, an insect host cell, a plant host cell, a fungal host cell, a eukaryotic algal host cell, a nematode host cell, a protozoan host cell, and a fish host cell.
Mammalian host cells useful for expressing a fusion protein of the invention include, but are not limited to, a Chinese Hamster Ovary (CHO) cell, a COS cell, a Vero cell, an SP2/0 cell, an NS/0 myeloma cell, a human embryonic kidney (HEK293) cell, a baby hamster kidney (BHK) cell, a HeLa cell, a human B cell, a CV-1/EBNA cell, an L cell, a 3T3 cell, an HEPG2 cell, a PerC6 cell, and an MDCK cell. Fungal host cells useful for expressing a J domain fusion protein of the invention include, but are not limited to, Aspergillus, Neurospora, Saccharomyces, Pichia, Hansenula, Schizosaccharomyces, Kluyveromyces, Yarrowia, and Candida. A particularly useful Saccharomyces host cell is a Saccharomyces cerevisiae cell.
Using methods available in the art, nucleic acid molecules encoding a fusion protein of the invention may be introduced into cells of a plant or non-human animal for the purpose of expressing the fusion protein in levels that permit easy purification of the fusion protein or as a gene therapy to provide the plant, human, or non-human animal with the benefit of the function provided by the protein of interest within the expressed fusion protein. Such methods can be used to provide transgenic plants or animals that express the fusion protein encoded by the transferred nucleic acid (transgene) encoding the fusion protein. In the case of plants and non-human animals, techniques are available for incorporating expressible nucleic acid encoding a protein into the germline so that progeny of the transgenic organism also can express the fusion protein. A
variety of vectors and methods are available for introducing nucleic acid into cells of a plant or non-human animal including, but not limited to, syringe injection of naked DNA into cells, ballistic transfer (for example, using a gene gun), liposomes, and virus-derived vector molecules.
A gene therapy for treating a human subject according to the invention may employ a recombinant gene encoding a fusion protein that comprises an expression enhancing polypeptide in either a modified or unmodified arrangement described herein. Such gene therapy is especially useful in diseases in which an improperly folded protein species results in loss or substantial loss of function as to cause a clinically recognized pathological condition. Examples of diseases in which an improperly folded protein species resulting in loss of function has been demonstrated or implicated include, but are not limited to, prion-associated disease (transmissible spongiform encephalopathy), Alzheimer's disease; Parkinson's disease; Huntington's disease; cystic fibrosis (CF), and al-antitrypsin (AAT) deficiency.
In a gene therapy employing a modified arrangement of the invention, a recombinant gene is constructed encoding a fusion protein comprising a protein expression enhancing polypeptide linked to a target protein of interest. The recombinant gene is inserted into a vector, which in turn is integrated into the genome of somatic cells of a human subject. In most cases, it is not necessary for the recombinant vector to be taken up and integrated into the genome of all somatic cells, but only a sub-population of cells that may be relevant to a particular disease. The fusion protein expressed from the integrated recombinant gene in the somatic cells of the human subject treats the disease by restoring a function of the endogenous target protein of interest that is otherwise missing, has been lost, or is so diminished as to cause a clinically recognized disease in a human subject.
In a gene therapy employing an unmodified arrangement of the invention, a recombinant gene is constructed encoding a fusion protein comprising a protein expression enhancing polypeptide linked to a target protein binding domain that has an affinity for and binds a target protein of interest.
The recombinant gene is inserted into a vector, which in turn is integrated into the genome of somatic cells of a human subject. Again, in most cases, it is not necessary for the recombinant vector to be taken up and integrated into that genome of all somatic cells, but only a sub-population of cells that may be relevant to a particular disease. Expression of the fusion protein from the integrated recombinant gene in the cells of the human subject enhances expression of the endogenous target protein of interest so that the protein can provide the cells with the required function provided by the target protein to avoid a clinically recognized disease. If the endogenous gene for the endogenous target protein of interest is not functional or has been deleted, then a recombinant gene encoding the target protein of interest must also be constructed and inserted into a vector for integration into the genome of a human subject for expression along with the fusion protein.
Any of a variety of vectors, agents, and methods may be used to introduce nucleic acid molecules into the somatic cells of a human subject including, but not limited to, modified viruses (e.g., a modified adenovirus, a modified lentivirus), virus-associated virus (e.g., an adenovirus-associated virus), naked DNA (such as naked plasmid DNA), compacted DNA in nanoparticles, and liposomes (e.g., using various cationic lipids).
Fusion Proteins Comprising a Protein Expression Enhancing Polypeptide and a Target Protein of Interest in a Modified Arrangement A fusion protein in a modified arrangement of the invention comprises a protein expression enhancing polypeptide (or PEEP, comprising an isolated J domain, an active J
domain polypeptide fragment, or J domain analog polypeptide as described herein) linked to a target protein of interest.
Preferably, the protein expression enhancing polypeptide is linked to the amino (N) terminus or carboxy (C) terminus of the target protein of interest. The protein expression enhancing polypeptide may also be spaced from the protein of interest by one or more intervening polypeptide sequences such as linkers, enzyme cleavage sites, epitope tags, and the like. Insertion of a protein expression enhancing polypeptide within a target protein of interest is possible, however as a practical matter this requires more complicated recombinant DNA engineering and has a high likelihood of interfering with the proper folding, desired function, or other properties of the target protein of interest, and is therefore generally less preferred. A target protein of interest that may be used to make a fusion protein of a modified arrangement according to the invention may be any protein or polypeptide that has a desirable property, including soluble proteins that normally reside in an intracellular location;
membrane-associated proteins (including transmembrane proteins); secreted proteins; and genetically engineered, non-naturally occurring, proteins. Such engineered, non-naturally occurring proteins may include, but are not limited to, recombinant soluble forms of natural membrane-associated proteins, for example, the extracellular domain of a transmembrane protein (for example, integrins, complement regulatory proteins). Another example of engineered, non-naturally occurring proteins that may be used as a target protein component of a fusion protein in a modified arrangement are recombinant fusion proteins comprising a recombinant soluble receptor molecule in which an extracellular binding domain of a cell surface receptor is fused to an immunoglobulin Fc domain or immunoglobulin scaffold. A non-limiting example of such a non-naturally occurring fusion protein is etanercept in which the extracellular domain of the p75 human TNFa receptor molecule is linked to the hinge and Fc domain of an IgG1 immunoglobulin. Other proteins that may be used as a target protein of interest in a fusion protein of a modified arrangement of the invention include, but are not limited to, antibodies and antigen-binding portions thereof, cytokines, peptide hormones, enzymes (e.g., thrombin, lactase, proteases, transferases, kinases, etc.), and morphogenetic proteins.
Fusion Proteins Comprising a Protein Enhancing Expression Polypeptide and a Target Protein Binding Domain in an Unmodified Arrangement A protein expression enhancing polypeptide (comprising an isolated J domain, active J
domain polypeptide fragment, or J domain analog polypeptide as described herein) may also be used in an unmodified arrangement to enhance expression of a target protein of interest at its intended location. In an unmodified arrangement according to this invention, a fusion protein comprises a protein expression enhancing polypeptide linked to a target protein binding domain that has an affinity for and binds a target protein of interest. Thus, in an unmodified arrangement of the invention, the target protein of interest is not a component of a fusion protein and therefore retains its unaltered primary structure (amino acid sequence). While not intending to be bound by any particular mechanism, the binding of a target protein of interest to a target protein binding domain of the fusion protein appears to bring the target protein of interest into relatively close proximity to the protein expression enhancing polypeptide (also present in the fusion protein) to provide an enhanced level of expression of the target protein at its intended cellular or extracellular location as compared to the level of expression of the target protein in the absence of the fusion protein. This may involve increased recruitment of chaperone proteins or other post-translational cellular mechanisms involved in protein folding, compartmentalization, or secretion, or may involve increase avoidance of cellular degradation pathways. The effect is evidenced by a significant increase in the appearance of expressed protein in the desired intracellular or extracellular location.
Target Protein Binding Domains Useful in an Unmodified Arrangement A fusion protein in an unmodified arrangement of the invention comprises a target protein binding domain that binds a target protein of interest for which an elevation of expression in its proper cellular or extracellular location is desired. A target protein binding domain of a target protein-binding fusion protein of the invention may be any protein or binding domain thereof that is known to bind to a target protein. The more specific the binding affinity of a protein or binding domain thereof is for a target protein, the less likely other proteins may potentially interfere with the enhancement in the level of expression desired for the target protein of interest.
Examples of target protein binding domains include antigen binding sites isolated from natural and genetically engineered antibodies and antigen binding fragments thereof, wherein the antigen binding site of an antibody or antigen binding fragment binds a target protein for which an elevation of expression is desired. In this context, antibodies and antigen binding fragments can easily be raised that bind a target protein of interest using standard methods available in the art. A
variety of genetically engineered antibody formats are known in the art that may be used as a source of a target protein binding domain of a fusion protein in an unmodified arrangement of the invention.
Such formats include, but not limited to, Fab fragments, F(ab')2 fragments, single chain Fv (scFv) antibodies, and single domain antibodies (dAb). See, for example, a review of the variety of functional genetically engineered antibody binding formats available in the art in Marvin et al., Acta Pharmacol. Sin., 26(6): 649-658 (2005); Kufer et al, Trends Biotechnol., 22(5): 238-244 (2004);
Kontermann, Acta Pharmacol. Sin., 26(1): 1-9 (2005), and Chan et al., Nat.
Rev, 10: 301-316 (2010).
Particularly useful in the invention are antibody molecules or fragments in which an antigen binding domain directed to a target protein is provided in a single polypeptide because such polypeptides can be easily linked to a protein expression enhancing polypeptide to form a fusion protein of the invention using standard in vitro DNA methods. For example, a single chain Fv antibody (scFv) comprises both VH and VL domains of an antigen binding site linked in a single polypeptide. Another source of a single chain antigen binding site is a single domain antibody (dAb) in which the entire antigen binding site is present in a single heavy chain variable domain. See, for example, Ward et al., Nature, 341: 544-546 (1989); Muyldermans et al., Protein Eng., 7: 1129-1135 (1994); Vu et al., Mol. Immunol., 34: 1121-1131 (1997); Muyldermans et al., Trends Biochem. Sci., 26: 230-235 (2001); Nguyen et al., Immunogenetics, 54: 39-47 (2002).
For a target protein that possesses an immunoglobulin Fc domain, a target protein binding domain may be an antibody or antigen (Fc domain) binding fragment thereof as discussed above. An alternative to an antibody or antigen binding domain thereof is any of a variety of non-immunoglobulin proteins and polypeptides that are known to specifically bind Fc domains. Proteins that possess Fc binding domains include, but are not limited to, Protein A, Protein G, gE protein of herpes simplex virus type 1 (HSV-1), and the like. A number of synthetic peptides also have been identified that bind Fc domains. See, for example, DeLano et al., Science, 287:1279-1283 (2000);
Yang et al., J. Peptide Res., 66(Suppl. 1): 120-137 (2006). As shown in the Examples below, such Fc-binding proteins and peptides are readily employed as target binding domains for fusion proteins of the invention directed to target proteins of interest comprising an Fc domain.
In the case in which a target protein of interest is a receptor or functional portion thereof that binds a protein ligand, the protein ligand may be used as a target binding domain in a fusion protein of the invention. Functional portions of receptors include, but are not limited to, the extracellular domain of a membrane-associated receptor that includes a functional ligand binding domain.
Typically, such extracellular portions comprising a functional ligand binding domain are referred to as "truncated receptors" because the transmembrane and cytoplasmic domains of the receptor have been removed. According to the invention, the expression of such truncated receptor molecules may be elevated by co-expression with a fusion protein of the invention comprising a protein ligand of the receptor. Accordingly, particularly suited for use as a target binding domain of a fusion protein in a modified arrangement of the invention are ligand proteins that are single polypeptides, such as certain cytokine polypeptides (for example, IL8, IL13, and the like) as shown in the Examples below. Other protein ligands that may be used in a fusion protein to bind a target receptor protein or ligand binding portion thereof, include polypeptide co-receptors, polypeptide co-repressors, and polypeptide co-factors.
In the case in which the target protein is a protein ligand (for example, a cytokine) that is bound by a known receptor molecule, a target protein binding domain of a fusion protein in an unmodified arrangement of the invention may comprise the cognate receptor or extracellular ligand binding portion of the receptor that binds the target protein.
BAG domains have been suggested in the art as fusion partners for enhancement of expression of target proteins. BAG domains of a variety of BAG proteins have been determined.
See, for example, Takayama et al., Nat. Cell Biol., 3: E237-E241 (2001). A BAG
domain has the key defining features of a BAG domain of any member of the BAG protein family.
Accordingly, a BAG
domain comprises a polypeptide domain of a BAG protein that is typically 85-124 amino acids in length, binds the ATPase domain of Hsp70 chaperone proteins, and is characterized by three anti-parallel a-helices (I, II, III, IV), wherein helices III and IV interact with the ATPase domain of Hsp70 chaperone proteins. Recently, it has been reported that when desired recombinant proteins are linked to a BAG domain, the resulting fusion proteins are expressed at levels that are greater than those of the protein alone. See, International Publication No. WO 2012/087835 A2.
From the Examples, below, BAG domains employed in an unmodified arrangement did not provide significant enhancement of the level of expression of target proteins of interest. In contrast, the protein expression enhancing polypeptides described herein significantly enhance levels of expression of target proteins of interest in both modified and unmodified arrangements. As shown in the Examples below, fusion proteins comprising a protein expression enhancing polypeptide (such as an isolated J domain, an active J domain fragment, or a J domain analog polypeptide, e.g., of formula I or particular 10-12 amino acid cognates thereof disclosed herein) linked to a target protein of interest (in a modified arrangement of the invention) were expressed at significantly greater levels than that of control cells (no fusion protein). Other studies showed that fusion proteins comprising a protein expression enhancing polypeptide described herein linked to target protein binding domains (in an unmodified arrangement) were effective in providing significantly greater levels of expression of unmodified target proteins of interest as compared to the levels in the absence of such fusion proteins (control) or fusion proteins comprising a BAG domain linked to a target protein binding domain.
Accordingly, protein expression enhancing polypeptides as described herein provide a new family of polypeptides for use in enhancing expression of target proteins of interest in both modified and unmodified arrangements.
Gene Therapy Approaches for Treating Cystic Fibrosis Cystic fibrosis (CF) is an autosomal recessive disorder caused by mutations in the gene encoding the cystic fibrosis transmembrane conductance regulator (CFTR) protein, a cAMP-regulated chloride channel and channel regulator. The deletion of phenylalanine at position 508 (4508F) in CFTR is the most common mutation that changes the conformation of the CFTR
protein, which is then rapidly degraded by the endoplasmic reticulum (ER) quality systems. A
general consensus is that only partial recovery of the wild-type CFTR protein function is required to provide a beneficial treatment to CF patients. Therefore, a number of gene therapy trials with CFTR
have been attempted, but have not yet been successful owing to inefficient delivery of a gene for CFTR and to immunogenicity of the vehicle (e.g., viral vector). In view of the fact that proper protein folding of wild-type CFTR is known to be difficult, it would be very useful if protein folding of the CFTR
protein could be improved.
Over twenty clinical trials of a gene therapy to treat cystic fibrosis (CF) have been conducted since the identity and isolation of the CFTR gene over twenty years ago. See a review of gene therapy for cystic fibrosis in Davies et al., Proc. Am. Thor. Soc.,7: 408-414 (2010).
Such clinical trials have already established proof of concept to provide replacement cystic fibrosis transmembrane conductance regulator (CFTR) protein, however the sustainability of effective levels of expression of the replacement CFTR protein in the cells of human subjects remains among the most persistent challenges in the development of an effective gene therapy to treat CF. The CFTR wild-type protein is a protein well-known for its instability. Over 90% of CF patients possess at least one copy of a mutated gene for CFTR (CFTRA508F) in which the absence of a phenylalanine at position 508 results in a highly unstable protein that is rapidly degraded in cells. This suggests a fusion gene therapy approach for treating CF that would lead to increased CFTR function or restored CFTR function to those afflicted with CF. Such a gene therapy provides a nucleic acid encoding a fusion protein in either a modified or unmodified arrangement of the invention.
As shown in the Examples below, fusion proteins in which either a wild-type CFTR protein or the CFTR4508F protein is fused to a protein expression enhancing polypeptide (such as J domain) in a modified arrangement were expressed in significantly higher levels than either unfused protein.
This suggests that a J domain fusion gene therapy approach for treating CF
that would lead to increased CFTR function or restored CFTR function to those afflicted with CF.
Accordingly, the modified arrangement of the invention provides new forms of gene therapies that use fusion proteins that are expressed at significantly higher levels and therefore are more effective than past therapies to replace or restore missing or lost protein functions that are associated with various diseases.
For an unmodified arrangement, a fusion protein comprises a protein expression enhancing polypeptide linked to a binding domain that binds the wild-type CFTR protein or the CFTRA508F
protein. A number of proteins are known to contain PDZ domains that bind to the highly conserved, carboxy terminal, PDZ binding region of CFTR. A protein that can be used as a source of a PDZ
domain for use as a target protein binding domain in a fusion protein in an unmodified arrangement of the invention includes, but is not limited to, any of the members of the NHERF
family of PDZ adapter proteins including, but not limited to, of NHERF1 (also known as NHERF, EBP50, or SLC9A3R1), NHERF2 (also known as E3KARP or SLC9A3R2), and PDZK1 (also known as CAP70 or NHERF3).See, for example, Haggie et al., J. Biol. Chem., 279(7): 5494-5500 (2004); Guggino, W.B., Proc. Am. Thorac. Soc., 1: 28-32 (2004); and Singh et al., J. Clin. Investig., 119(3): 540-550 (2009).
Accordingly, a PDZ domain of a PDZ protein may be particularly useful as a target protein binding domain in a fusion protein designed to target either or both CETRA508F and wild-type CFTR proteins in a gene therapy of the invention.
Accordingly, the invention provides new forms of gene therapies that provide fusion proteins that significantly elevate the levels of expression of an endogenous unstable protein (such as the unstable CFTRA508F) and/or the levels of expression of a desired heterologous protein (such as a wild-type CFTR) and therefore are more effective than past therapies to replace or restore missing or lost protein functions that are associated with various diseases.
Additional embodiments and features of the invention will be apparent from the following non-limiting examples.
Examples Example 1. Compositions and Methods for Enhancing Expression of Target Proteins of Interest Using a Modified Arrangement Expression vector plasmids were constructed for expressing a target protein of interest linked to protein expression enhancing polypeptide described herein, which in turn may be linked to an standard epitope tag, which is usually attached at the carboxy (C) terminus or amino (N) terminus of the protein construct for easy identification or isolation using a corresponding anti-tag antibody and standard immunoblot assays.
A DNA linker molecule having a nucleotide sequence containing various restriction enzyme sites was produced by annealing two single-stranded DNA molecules having the sequences shown below (5' to 3'):
AGCTTGGTACCGGATCCGAATTCGATATCGCGGCCGCTCTCGAGTCTAGAGGGCC (SEQ
ID NO:187) and CTCTAGACTCGAGAGCGGCCGCGATATCGAATTCGGATCCGGTACCA (SEQ ID NO:188).
The annealed linker molecule was then inserted into plasmid pcDNA3 (catalogue no. V790-20, Invitrogen) digested with HindIII and ApaI to yield plasmid pcDNA'.
DNA molecules encoding the V5 epitope tag (GKPIPNPLLGLDST (SEQ ID NO:47)) or the Flag epitope tag (DYKDDDDK (SEQ ID NO:111)) were inserted into plasmid pcDNA'.
A double-stranded DNA molecule having the coding sequence for the V5 epitope tag along with an N-terminal methionine, i.e., ATGGGTAAGCCTATCCCTAACCCTCTCCTCGGTCTCGATTCTACG (SEQ ID
NO:189), was inserted into pcDNA' digested with XhoI and XbaI to yield plasmid V5(C)-pcDNA' or with HindIII and KpnI to yield plasmid V5(N)-pcDNA'.
A DNA molecule having the coding sequence for the Flag epitope tag, i.e., GATTACAAGGATGACGATGACAAG (SEQ ID NO:190), was inserted into plasmid pcDNA' digested with XhoI and XbaI to yield plasmid Flag(N)-pcDNA'.
Preparation of DNA molecules DNA molecules encoding protein sequences were obtained by polymerase chain reaction (PCR), gene synthesis, or annealing of complementary DNA molecules using standard protocols. A
DNA molecule encoding the amino acid sequence of an immunoglobulin Fc region was produced by standard oligonucleotide synthesis. A DNA molecule having a DNA sequence GGAGGCGGAAGTGGT GGGAGCGGTGGAAGCGGAGGC (SEQ ID NO:191) encoding the glycine-serine linker sequence GGGSGGSGGSGG (SEQ ID NO:121), was produced by annealing complementary single strands synthesized by standard methods.
Preparation of expression vector plasmids for expressing J domain fusion proteins To express C-terminally VS-tagged IL13Ra2 receptor protein (see, Fig. 1A), a DNA molecule encoding an IL13Ra2 receptor protein was inserted into plasmid V5(C)-pcDNA' digested with HindIII and KpnI.
To express the fusion protein in which a J domain or BAG domain is attached to the N-terminus of IL13Ra2 receptor protein (see, Fig. 3A), a truncated IL13Ra2 receptor protein with its signal sequence deleted was inserted into plasmid V5(C)-pcDNA' digested with NotI and XhoI.
To express a VS-tagged, truncated TNR1 receptor protein (see, Fig. 5A), a DNA
molecule encoding a truncated (extracellular domain only) TNR1 receptor protein was inserted into plasmid V5(C)-pcDNA' digested with HindIII and KpnI.
To express a VS-tagged al anti-trypsin ("al AT") (see, Fig. 4A), a DNA
molecule encoding an al anti-trypsin was inserted into plasmid V5(C)-pcDNA' digested with HindIII and KpnI
To express an N-terminally VS-tagged p53 protein (see, Fig. 7A), a DNA
molecule encoding a p53 protein was inserted into plasmid V5(N)-pcDNA' digested with Nod and XhoI.
To express V-tagged CFTR and VS-tagged mutant CETR4508F (see, Fig. 8A), a DNA
molecule encoding a CFTR protein or a CFTR4508F protein was inserted into plasmid VS(N)-pcDNA' digested with NotI and XhoI.
For expressing fusion proteins comprising a protein of interest fused to a J
domain, DNA
molecules encoding J domains were subcloned into the EcoRI site of plasmid VS(C)-pcDNA' or the EcoRV plasmid VS(N)-pcDNA' to yield plasmid vectors J-VS(C)-pcDNA' or VS(N)-J-pcDNA', respectively. Fusion proteins were produced using Hsp40, SV40, and CSP J
domains.
To express fusion proteins comprising a protein of interest fused to a BAG
domain, DNA
molecules encoding a BAG domain were subcloned into EcoRI and EcoRV sites of plasmid V5(C)-pcDNA' or plasmid VS(N)-pcDNA' to yield plasmid vectors BAG-VS(C)-pcDNA' or VS(N)-BAG-pcDNA', respectively. Fusion proteins were produced using BAG3, BAG4, BAGS, and BAG6 domains as indicated below.
DNA molecules encoding IL13Ra2, TNFR1, a lAT, p53, or CFTR (wild type or 4508F
mutant) were then inserted in frame with the J domain (or, in some instances, a BAG domain) sequence in one or more of the expression vectors to express the resulting fusion protein, which also possessed an N-terminal or C-terminal VS epitope tag for convenient identification of the encoded protein.
Expression and detection of proteins in HEK293 cells Expression vector plasmids encoding various protein constructs were transfected into HEK293 cells with X-tremeGENE HP transfection reagent (catalogue no.
06365752001, Roche). As indicated in the examples below, a separate plasmid expressing the green fluorescent protein (GFP) was co-transfected with each expression vector plasmid encoding a fusion protein of the invention to monitor the transfection efficiency. Cultures of transfectant cells were incubated for two days, and culture medium and/or cell lysates were analyzed for expressed proteins using dot blot or Western immunoblot assays. Samples of culture media were centrifuged to remove debris prior to analysis.
For cell lysates, cells were lysed in lysis buffer (10 mM Tris-HC1, pH8.0, 150 mM NaC1, 10 mM
EDTA, 2% SDS) containing 2 mM PMSF. After brief sonication, the sample was analyzed for express proteins using dot blot or Western immunoblot assays. For Western blot analysis, samples were boiled in SDS-sample buffer and run on polyacrylamide electrophoresis, followed by transfer of separated protein bands to membrane (PVDF membrane).
The expression of GFP as an internal transfection control was detected using an anti-GFP
antibody. Expressed proteins in dot blots and Western blots were detected using a chemiluminescent signal. Briefly, blots were reacted with a primary antibody that binds the particular epitope tag (e.g., VS or Flag) carried by the proteins. After rinsing away unreacted primary antibody, a secondary, enzyme-linked antibody (e.g., horse radish peroxidase linked anti-IgG
antibody) was allowed to react with primary antibody molecules bound to the blots. After rinsing, manufacturer's chemiluminescent reagent was added. Chemiluminescent signals in blots were captured on x-ray film. Where indicated, the images of the chemiluminescent signals were scanned with a densitometer and analyzed using the NIH ImageJ image processing program.
Assays for protein activities Standard assays are available for detecting activities of the proteins of interest used in preparing J domain fusion proteins described herein.
A binding assay for IL13Ra2 binding function is described in "Identification of distinct roles for a dileucine and a tyrosine internalization motif in the interleukin (IL)-13 binding component IL13 receptor alpha 2 chain," J. Biol. Chem., 276(27): 25114-25120 (2001).
A binding assay for TNFR binding function is described in "Recombinant 55-kDa tumor necrosis factor (TNF) receptor: Stoichiometry of binding to TNF alpha and TNF
beta and inhibition of TNF activity," J. Biol. Chem., 266(27): 18324-18329 (1991) An assay for al-antitrypsin (alAT) activity is described in "Alpha 1-antitrypsin and protease complexation is induced by lipopolysaccharide, interleukin-lbeta, and tumor necrosis factor-alpha in monocytes," Am. J. Respir. Grit. Care Med., 157(1): 246-255 (1998).
An assay for p53 activity is described in "Influenza virus infection increases p53 activity: role of p53 activity in cell death and viral replication," J. Virol., 79(14): 8802-8811 (2005).
An assay for CFTR activity is described in "Pharmacology of CFTR chloride channel activity," Physiol. Rev., 79(1 Suppl.): S109-S144 (1999).
Example 2. Enhancement of Expression of Target Proteins in a Modified Arrangement Figure lA shows general diagrams of constructs for a C-terminally V5 epitope-tagged, full-length IL13Ra2 protein ("IL13Ra2WT") and for a C-terminally V5 epitope-tagged fusion protein comprising IL13Ra2 fused to a BAG or to a J domain.
The VS-tagged IL13Ra2WT protein comprises an amino acid sequence for a full-length IL13Ra2 protein linked at the C terminus to a V5 epitope tag, which in turn is linked to twelve C-terminal amino acid residues from the cloning site of the expression vector.
The amino acid sequence for the VS-tagged IL13Ra2WT is shown in the table below.
Table 2. Amino Acid Sequence of a VS-Tagged IL13Ra2WT Protein.
Protein Region Sequence Amino Acid Sequence (N¨ to C¨ Identifier terminal) IL13Ra2WT domain SEQ ID NO:192 MAFVCLAIGCLYTFLISTTFGCTSSSDTEI
(full-length) KVNPPQDFEIVDPGYLGYLYLQWQPPLSLD
HFKECTVEYELKYRNIGSETWKTIITKNLH
YKDGFDLNKGIEAKIHTLLPWQCTNGSEVQ
SSWAETTYWISPQGIPETKVQDMDCVYYNW
QYLLCSWKPGIGVLLDTNYNLFYWYEGLDH
ALQCVDYIKADGQNIGCRFPYLEASDYKDF
YICVNGSSENKPIRSSYFTFQLQNIVKPLP
PVYLTFTRESSCEIKLKWSIPLGPIPARCF
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) 123456789012345678901234567890 DYEIEIREDDTTLVTATVENETYTLKTTNE
TRQLCFVVRSKVNIYCSDDGIWSEWSDKQC
WEGEDLSKKTLLRFWLPFGFILILVIFVTG
LLLRKPNTYPKMIPEFFCDTGTGSEFD IAA
ALEGKPIPNPLLGLDSTSRGPYSIVSPKC
IL13Ra2FL residues 1-380 MAFVCLAIGCLYTFLISTTFGCTSSSDTEI
of SEQ ID KVNPPQDFEIVDPGYLGYLYLQWQPPLSLD
NO: 192 HFKECTVEYELKYRNIGSETWKTIITKNLH
YKDGFDLNKGIEAKIHTLLPWQCTNGSEVQ
SSWAETTYWISPQGIPETKVQDMDCVYYNW
QYLLCSWKPGIGVLLDTNYNLFYWYEGLDH
ALQCVDYIKADGQNIGCRFPYLEASDYKDF
YICVNGSSENKPIRSSYFTFQLQNIVKPLP
PVYLTFTRESSCEIKLKWSIPLGPIPARCF
DYEIEIREDDTTLVTATVENETYTLKTTNE
TRQLCFVVRSKVNIYCSDDGIWSEWSDKQC
WEGEDLSKKTLLRFWLPFGFILILVIFVTG
LLLRKPNTYPKMIPEFFCDT
Linker residues 381- GTGSEFDIAAALE
393 of SEQ ID
NO: 192 V5 epitope residues 394- GKPIPNPLLGLDST
domain 407 of SEQ ID
NO: 192 C-terminal residues 408- SRGPYSIVSPKC
vector residues 419 of SEQ ID
NO: 192 The V5-tagged IL13Ra2WT-BAG3 domain fusion protein comprises an amino (N)-terminal amino acid sequence for a full-length IL13Ra2 protein linked to a BAG domain from the BAG3 protein, which in turn is linked to a V5 epitope tag, which in turn is linked to twelve C-terminal amino acid residues from the cloning site of the expression vector. The amino acid sequence for the IL13Ra2WT-BAG3 domain fusion protein is shown in the table below.
Table 3. Amino Acid Sequence of an IL13Ra2WT-BAG3 Domain Fusion Protein.
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) 123456789012345678901234567890 IL13Ra2WT-BAG3 SEQ ID NO: 193 MAFVCLAIGCLYTFLISTTFGCTSSSDTEI
fusion protein KVNPPQDFEIVDPGYLGYLYLQWQPPLSLD
HFKECTVEYELKYRNIGSETWKTIITKNLH
YKDGFDLNKGIEAKIHTLLPWQCTNGSEVQ
SSWAETTYWISPQGIPETKVQDMDCVYYNW
QYLLCSWKPGIGVLLDTNYNLFYWYEGLDH
ALQCVDYIKADGQNIGCRFPYLEASDYKDF
YICVNGSSENKPIRSSYFTFQLQNIVKPLP
PVYLTFTRESSCEIKLKWSIPLGPIPARCF
DYEIEIREDDTTLVTATVENETYTLKTTNE
TRQLCFVVRSKVNIYCSDDGIWSEWSDKQC
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) 123456789012345678901234567890 WEGEDLSKKTLLRFWLPFGFILILVIFVTG
LLLRKPNTYPKMIPEFFCDTGTGSEFHPGV
LKVEAILEKVQGLEQAVDNFEGKKTDKKYL
MIEEYLTKELLALDSVDPEGRADVRQARRD
GVRKVQTILEKLEQKAIDDIAAALEGKPIP
NPLLGLDSTSRGPYSIVSPKC
IL13Ra2WT domain residues 1-380 MAFVCLAIGCLYTFLISTTFGCTSSSDTEI
(full-length) of SEQ ID KVNPPQDFEIVDPGYLGYLYLQWQPPLSLD
NO: 193 HFKECTVEYELKYRNIGSETWKTIITKNLH
YKDGFDLNKGIEAKIHTLLPWQCTNGSEVQ
SSWAETTYWISPQGIPETKVQDMDCVYYNW
QYLLCSWKPGIGVLLDTNYNLFYWYEGLDH
ALQCVDYIKADGQNIGCRFPYLEASDYKDF
YICVNGSSENKPIRSSYFTFQLQNIVKPLP
PVYLTFTRESSCEIKLKWSIPLGPIPARCF
DYEIEIREDDTTLVTATVENETYTLKTTNE
TRQLCFVVRSKVNIYCSDDGIWSEWSDKQC
WEGEDLSKKTLLRFWLPFGFILILVIFVTG
LLLRKPNTYPKMIPEFFCDT
Linker residues 381- GTGSEF
386 of SEQ ID
NO: 193 BAG domain residues 387- HPGVLKVEAILEKVQGLEQAVDNFEGKKTD
(from BAG3) 468 of SEQ ID KKYLMIEEYLTKELLALDSVDPEGRADVRQ
NO: 193 ARRDGVRKVQTILEKLEQKAID
Linker residues 469- DIAAALE
475 of SEQ ID
NO: 193 V5 epitope residues 476- GKPIPNPLLGLDST
domain 489 of SEQ ID
NO: 193 C-terminal residues 490- SRGPYSIVSPKC
vector residues 501 of SEQ ID
NO: 193 The V5-tagged IL13Ra2WT-BAG4 domain fusion protein comprises an amino (N)-terminal amino acid sequence for a full-length IL13Ra2 protein linked to a BAG domain from the BAG4 protein, which in turn is linked to a V5 epitope tag, which in turn is linked to twelve C-terminal amino acid residues from the cloning site of the expression vector. The amino acid sequence for the IL13Ra2WT-BAG4 domain fusion protein is shown in the table below.
Table 4. Amino Acid Sequence of an IL13Ra2WT-BAG4 Domain Fusion Protein.
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) 123456789012345678901234567890 IL13Ra2WT- SEQ ID NO: 194 MAFVCLAIGCLYTFLISTTFGCTSSSDTEI
BAG4 Domain KVNPPQDFEIVDPGYLGYLYLQWQPPLSLD
Fusion Protein HFKECTVEYELKYRNIGSETWKTIITKNLH
YKDGFDLNKGIEAKIHTLLPWQCTNGSEVQ
Protein Region Sequence Amino Acid Sequence (N¨ to C¨ Identifier terminal) 123456789012345678901234567890 SSWAETTYWISPQGIPETKVQDMDCVYYNW
QYLLCSWKPGIGVLLDTNYNLFYWYEGLDH
ALQCVDYIKADGQNIGCRFPYLEASDYKDF
YICVNGSSENKPIRSSYFTFQLQNIVKPLP
PVYLTFTRESSCEIKLKWSIPLGPIPARCF
DYEIEIREDDTTLVTATVENETYTLKTTNE
TRQLCFVVRSKVNIYCSDDGIWSEWSDKQC
WEGEDLSKKTLLRFWLPFGFILILVIFVTG
LLLRKPNTYPKMIPEFFCDTGTGSEFESTP
PSIKKIIHVLEKVQYLEQEVEEFVGKKTDK
AYWLLEEMLTKELLELDSVETGGQDSVRQA
RKEAVCKIQAILEKLEKKGLDIAAALEGKP
IPNPLLGLDSTSRGPYSIVSPKC
IL13Ra2WT residues 1-380 MAFVCLAIGCLYTFLISTTFGCTSSSDTEI
(full-length) of SEQ ID KVNPPQDFEIVDPGYLGYLYLQWQPPLSLD
NO: 194 HFKECTVEYELKYRNIGSETWKTIITKNLH
YKDGFDLNKGIEAKIHTLLPWQCTNGSEVQ
SSWAETTYWISPQGIPETKVQDMDCVYYNW
QYLLCSWKPGIGVLLDTNYNLFYWYEGLDH
ALQCVDYIKADGQNIGCRFPYLEASDYKDF
YICVNGSSENKPIRSSYFTFQLQNIVKPLP
PVYLTFTRESSCEIKLKWSIPLGPIPARCF
DYEIEIREDDTTLVTATVENETYTLKTTNE
TRQLCFVVRSKVNIYCSDDGIWSEWSDKQC
WEGEDLSKKTLLRFWLPFGFILILVIFVTG
LLLRKPNTYPKMIPEFFCDT
Linker residues 381- GTGSEF
386 of SEQ ID
NO: 194 BAG domain residues 387- ESTPPSIKKIIHVLEKVQYLEQEVEEFVGK
(from BAG4) 470 of SEQ ID KTDKAYWLLEEMLTKELLELDSVETGGQDS
NO: 194 VRQARKEAVCKIQAILEKLEKKGL
Linker residues 471- DIAAALE
477 of SEQ ID
NO: 194 V5 epitope residues 478- GKPIPNPLLGLDST
domain 491 of SEQ ID
NO: 194 C-terminal residues 492- SRGPYSIVSPKC
vector residues 503 of SEQ ID
NO: 194 The V5-tagged IL13Ra2WT-BAG5 domain fusion protein comprises an amino (N)-terminal amino acid sequence for a full-length IL13Ra2 protein linked to a BAG domain from the BAG5 protein, which in turn is linked to a V5 epitope tag, which in turn is linked to twelve C-terminal amino acid residues from the cloning site of the expression vector. The amino acid sequence for the IL13Ra2WT-BAG5 domain fusion protein is shown in the table below.
Table 5. Amino Acid Sequence of an IL13Ra2WT-BAG5 Domain Fusion Protein.
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) 123456789012345678901234567890 IL13Ra2WT- SEQ ID NO: 195 MAFVCLAIGCLYTFLISTTFGCTSSSDTEI
BAG5 domain KVNPPQDFEIVDPGYLGYLYLQWQPPLSLD
fusion protein HFKECTVEYELKYRNIGSETWKTIITKNLH
YKDGFDLNKGIEAKIHTLLPWQCTNGSEVQ
SSWAETTYWISPQGIPETKVQDMDCVYYNW
QYLLCSWKPGIGVLLDTNYNLFYWYEGLDH
ALQCVDYIKADGQNIGCRFPYLEASDYKDF
YICVNGSSENKPIRSSYFTFQLQNIVKPLP
PVYLTFTRESSCEIKLKWSIPLGPIPARCF
DYEIEIREDDTTLVTATVENETYTLKTTNE
TRQLCFVVRSKVNIYCSDDGIWSEWSDKQC
WEGEDLSKKTLLRFWLPFGFILILVIFVTG
LLLRKPNTYPKMIPEFFCDTGTGSEFEHPS
HKAVWNVLGNLSEIQGEVLSFDGNRTDKNY
IRLEELLTKQLLALDAVDPQGEEKCKAARK
QAVRLAQNILSYLDLKSDEDIAAALEGKPI
PNPLLGLDSTSRGPYSIVSPKC
IL13Ra2WT residues 1-380 MAFVCLAIGCLYTFLISTTFGCTSSSDTEI
(full-length) of SEQ ID KVNPPQDFEIVDPGYLGYLYLQWQPPLSLD
NO: 195 HFKECTVEYELKYRNIGSETWKTIITKNLH
YKDGFDLNKGIEAKIHTLLPWQCTNGSEVQ
SSWAETTYWISPQGIPETKVQDMDCVYYNW
QYLLCSWKPGIGVLLDTNYNLFYWYEGLDH
ALQCVDYIKADGQNIGCRFPYLEASDYKDF
YICVNGSSENKPIRSSYFTFQLQNIVKPLP
PVYLTFTRESSCEIKLKWSIPLGPIPARCF
DYEIEIREDDTTLVTATVENETYTLKTTNE
TRQLCFVVRSKVNIYCSDDGIWSEWSDKQC
WEGEDLSKKTLLRFWLPFGFILILVIFVTG
LLLRKPNTYPKMIPEFFCDT
Linker residues 381- GTGSEF
386 of SEQ ID
NO: 195 BAG domain residues 387- EHPSHKAVWNVLGNLSEIQGEVLSFDGNRT
(from BAGS) 469 of SEQ ID DKNYIRLEELLTKQLLALDAVDPQGEEKCK
NO: 195 AARKQAVRLAQNILSYLDLKSDE
Linker residues 470- DIAAALE
476 of SEQ ID
NO: 195 V5 epitope residues 477- GKPIPNPLLGLDST
domain 490 of SEQ ID
NO: 195 C-terminal residues 491- SRGPYSIVSPKC
residues 502 of SEQ ID
NO: 195 The VS-tagged IL13Ra2WT-BAG6 domain fusion protein comprises an amino (N)-terminal amino acid sequence for a full-length IL13Ra2 protein linked to a BAG domain from the BAG6 protein, which in turn is linked to a V5 epitope tag, which in turn is linked to twelve C-terminal amino acid residues from the cloning site of the expression vector. The amino acid sequence for the IL13Ra2WT-BAG6 domain fusion protein is shown in the table below.
Table 6. Amino Acid Sequence of an IL13Ra2WT-BAG6 Domain Fusion Protein.
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) 123456789012345678901234567890 IL13Ra2WT-BAG6 SEQ ID NO: 196 MAFVCLAIGCLYTFLISTTFGCTSSSDTEI
domain fusion KVNPPQDFEIVDPGYLGYLYLQWQPPLSLD
protein HFKECTVEYELKYRNIGSETWKTIITKNLH
YKDGFDLNKGIEAKIHTLLPWQCTNGSEVQ
SSWAETTYWISPQGIPETKVQDMDCVYYNW
QYLLCSWKPGIGVLLDTNYNLFYWYEGLDH
ALQCVDYIKADGQNIGCRFPYLEASDYKDF
YICVNGSSENKPIRSSYFTFQLQNIVKPLP
PVYLTFTRESSCEIKLKWSIPLGPIPARCF
DYEIEIREDDTTLVTATVENETYTLKTTNE
TRQLCFVVRSKVNIYCSDDGIWSEWSDKQC
WEGEDLSKKTLLRFWLPFGFILILVIFVTG
LLLRKPNTYPKMIPEFFCDTGTGSEFMPAK
RRKTMQGEGPQLLLSEAVSRAAKAAGARPL
TSPESLSRDLEAPEVQESYRQQLRSDIQKR
LQEDPNYSPQRFPNAQRAFADDPDIAAALE
GKPIPNPLLGLDSTSRGPYSIVSPKC
IL13Ra2WT residues 1-380 MAFVCLAIGCLYTFLISTTFGCTSSSDTEI
(full-length) of SEQ ID KVNPPQDFEIVDPGYLGYLYLQWQPPLSLD
NO: 196 HFKECTVEYELKYRNIGSETWKTIITKNLH
YKDGFDLNKGIEAKIHTLLPWQCTNGSEVQ
SSWAETTYWISPQGIPETKVQDMDCVYYNW
QYLLCSWKPGIGVLLDTNYNLFYWYEGLDH
ALQCVDYIKADGQNIGCRFPYLEASDYKDF
YICVNGSSENKPIRSSYFTFQLQNIVKPLP
PVYLTFTRESSCEIKLKWSIPLGPIPARCF
DYEIEIREDDTTLVTATVENETYTLKTTNE
TRQLCFVVRSKVNIYCSDDGIWSEWSDKQC
WEGEDLSKKTLLRFWLPFGFILILVIFVTG
LLLRKPNTYPKMIPEFFCDT
Linker residues 381- GTGSEF
386 of SEQ ID
NO: 196 BAG domain residues 387- MPAKRRKTMQGEGPQLLLSEAVSRAAKAAG
(from BAG6) 473 of SEQ ID ARPLTSPESLSRDLEAPEVQESYRQQLRSD
NO: 196 IQKRLQEDPNYSPQRFPNAQRAFADDP
Linker residues 474- DIAAALE
480 of SEQ ID
NO: 196 V5 epitope residues 481- GKPIPNPLLGLDST
domain 494 of SEQ ID
NO: 196 C-terminal residues 495- SRGPYSIVSPKC
vector residues 506 of SEQ ID
NO: 196 The V5-tagged IL13Ra2WT-Hsp40 J domain fusion protein comprises an amino (N)-terminal amino acid sequence for a full-length IL13Ra2 protein linked to a J domain from the Hsp40 protein, which in turn is linked to a V5 epitope tag, which in turn is linked to twelve C-terminal amino acid residues from the cloning site of the expression vector. The amino acid sequence for the IL13Ra2-Hsp40 J domain fusion protein is shown in the table below.
Table 7. Amino Acid Sequence of an IL13Ra2WT-Hsp40 J Domain Fusion Protein.
Protein Region Sequence Amino Acid Sequence (N¨ to C¨ Identifier terminal) IL13Ra2WT-Hsp40 SEQ ID NO: 197 MAFVCLAIGCLYTFLISTTFGCTSSSDTEI
J domain fusion KVNPPQDFEIVDPGYLGYLYLQWQPPLSLD
protein HFKECTVEYELKYRNIGSETWKTIITKNLH
YKDGFDLNKGIEAKIHTLLPWQCTNGSEVQ
SSWAETTYWISPQGIPETKVQDMDCVYYNW
QYLLCSWKPGIGVLLDTNYNLFYWYEGLDH
ALQCVDYIKADGQNIGCRFPYLEASDYKDF
YICVNGSSENKPIRSSYFTFQLQNIVKPLP
PVYLTFTRESSCEIKLKWSIPLGPIPARCF
DYEIEIREDDTTLVTATVENETYTLKTTNE
TRQLCFVVRSKVNIYCSDDGIWSEWSDKQC
WEGEDLSKKTLLRFWLPFGFILILVIFVTG
LLLRKPNTYPKMIPEFFCDTGTGSEFMGKD
YYQTLGLARGASDEEIKRAYRRQALRYHPD
KNKEPGAEEKFKEIAEAYDVLSDPRKREIF
DRYDIAAALEGKPIPNPLLGLDSTSRGPYS
IVSPKC
IL13Ra2WT domain residues 1-380 MAFVCLAIGCLYTFLISTTFGCTSSSDTEI
(full-length) of SEQ ID KVNPPQDFEIVDPGYLGYLYLQWQPPLSLD
NO: 197 HFKECTVEYELKYRNIGSETWKTIITKNLH
YKDGFDLNKGIEAKIHTLLPWQCTNGSEVQ
SSWAETTYWISPQGIPETKVQDMDCVYYNW
QYLLCSWKPGIGVLLDTNYNLFYWYEGLDH
ALQCVDYIKADGQNIGCRFPYLEASDYKDF
YICVNGSSENKPIRSSYFTFQLQNIVKPLP
PVYLTFTRESSCEIKLKWSIPLGPIPARCF
DYEIEIREDDTTLVTATVENETYTLKTTNE
TRQLCFVVRSKVNIYCSDDGIWSEWSDKQC
WEGEDLSKKTLLRFWLPFGFILILVIFVTG
LLLRKPNTYPKMIPEFFCDT
Linker residues 381- GTGSEF
386 of SEQ ID
NO: 197 Hsp40 J domain residues 387- MGKDYYQTLGLARGASDEEIKRAYRRQALR
453 of SEQ ID YHPDKNKEPGAEEKFKEIAEAYDVLSDPRK
NO:197 REIFDRY
Linker residues 454- DIAAALE
460 of SEQ ID
NO: 197 Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) V5 epitope residues 461- GKPIPNPLLGLDST
474 of SEQ ID
NO: 197 C-terminal residues 475- SRGPYSIVSPKC
vector residues 486 of SEQ ID
NO: 197 The V5-tagged IL13Ra2WT-SV40 J domain fusion protein comprises an amino (N)-terminal amino acid sequence for a full-length IL13Ra2 protein linked to a J domain from the SV40 J protein, which in turn is linked to a V5 epitope tag, which in turn is linked to twelve C-terminal amino acid residues from the cloning site of the expression vector. The amino acid sequence for the IL13Ra2-SV40 J domain fusion protein is shown in the table below.
Table 8. Amino Acid Sequence of an IL13Ra2WT-SV40 J Domain Fusion Protein.
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) IL13Ra2WT-5V40 J SEQ ID NO:198 MAFVCLAIGCLYTFLISTTFGCTSSSDTEI
domain fusion KVNPPQDFEIVDPGYLGYLYLQWQPPLSLD
protein HFKECTVEYELKYRNIGSETWKTIITKNLH
YKDGFDLNKGIEAKIHTLLPWQCTNGSEVQ
SSWAETTYWISPQGIPETKVQDMDCVYYNW
QYLLCSWKPGIGVLLDTNYNLFYWYEGLDH
ALQCVDYIKADGQNIGCRFPYLEASDYKDF
YICVNGSSENKPIRSSYFTFQLQNIVKPLP
PVYLTFTRESSCEIKLKWSIPLGPIPARCF
DYEIEIREDDTTLVTATVENETYTLKTTNE
TRQLCFVVRSKVNIYCSDDGIWSEWSDKQC
WEGEDLSKKTLLRFWLPFGFILILVIFVTG
LLLRKPNTYPKMIPEFFCDTGTGSEFMDKV
LNREESLQLMDLLGLERSAWGNIPLMRKAY
LKKCKEFHPDKGGDEEKMKKMNTLYKKMED
GVKYAHQPDFGGFWDADIAAALEGKPIPNP
LLGLDSTSRGPYSIVSPKC
IL13Ra2WT domain residues 1-380 MAFVCLAIGCLYTFLISTTFGCTSSSDTEI
(full-length) of SEQ ID KVNPPQDFEIVDPGYLGYLYLQWQPPLSLD
NO: 198 HFKECTVEYELKYRNIGSETWKTIITKNLH
YKDGFDLNKGIEAKIHTLLPWQCTNGSEVQ
SSWAETTYWISPQGIPETKVQDMDCVYYNW
QYLLCSWKPGIGVLLDTNYNLFYWYEGLDH
ALQCVDYIKADGQNIGCRFPYLEASDYKDF
YICVNGSSENKPIRSSYFTFQLQNIVKPLP
PVYLTFTRESSCEIKLKWSIPLGPIPARCF
DYEIEIREDDTTLVTATVENETYTLKTTNE
TRQLCFVVRSKVNIYCSDDGIWSEWSDKQC
WEGEDLSKKTLLRFWLPFGFILILVIFVTG
LLLRKPNTYPKMIPEFFCDT
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) Linker residues 381- GTGSEF
386 of SEQ ID
NO: 198 5V40 J domain residues 387- MDKVLNREESLQLMDLLGLERSAWGNIPLM
466 of SEQ ID RKAYLKKCKEFHPDKGGDEEKMKKMNTLYK
NO: 198 KMEDGVKYAHQPDFGGFWDA
Linker residues 467- DIAAALE
473 of SEQ ID
NO: 198 V5 epitope residues 474- GKPIPNPLLGLDST
487 of SEQ ID
NO: 198 C-terminal residues 488- SRGPYSIVSPKC
vector residues 499 of SEQ ID
NO: 198 The V5-tagged IL13Ra2WT-CSP J domain fusion protein comprises an amino (N)-terminal amino acid sequence for a full-length IL13Ra2 protein linked to a J domain from the CSP protein, which in turn is linked to a V5 epitope tag, which in turn is linked to twelve C-terminal amino acid residues from the cloning site of the expression vector. The amino acid sequence for the IL13Ra2WT-CSP J domain fusion protein is shown in the table below.
Table 9. Amino Acid Sequence of an IL13Ra2WT-CSP J Domain Fusion Protein.
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) IL13Ra2WT-CSP J SEQ ID NO:199 MAFVCLAIGCLYTFLISTTFGCTSSSDTEI
domain fusion KVNPPQDFEIVDPGYLGYLYLQWQPPLSLD
protein HFKECTVEYELKYRNIGSETWKTIITKNLH
YKDGFDLNKGIEAKIHTLLPWQCTNGSEVQ
SSWAETTYWISPQGIPETKVQDMDCVYYNW
QYLLCSWKPGIGVLLDTNYNLFYWYEGLDH
ALQCVDYIKADGQNIGCRFPYLEASDYKDF
YICVNGSSENKPIRSSYFTFQLQNIVKPLP
PVYLTFTRESSCEIKLKWSIPLGPIPARCF
DYEIEIREDDTTLVTATVENETYTLKTTNE
TRQLCFVVRSKVNIYCSDDGIWSEWSDKQC
WEGEDLSKKTLLRFWLPFGFILILVIFVTG
LLLRKPNTYPKMIPEFFCDTGTGSEFMADQ
RQRSLSTSGESLYHVLGLDKNATSDDIKKS
YRKLALKYHPDKNPDNPEAADKFKEINNAH
AILTDATKRNIYDKYGSLGLYVDIAAALEG
KPIPNPLLGLDSTSRGPYSIVSPKC
IL13Ra2 domain residues 1-380 MAFVCLAIGCLYTFLISTTFGCTSSSDTEI
of SEQ ID KVNPPQDFEIVDPGYLGYLYLQWQPPLSLD
NO: 199 HFKECTVEYELKYRNIGSETWKTIITKNLH
YKDGFDLNKGIEAKIHTLLPWQCTNGSEVQ
Protein Region Sequence Amino Acid Sequence (N¨ to C¨ Identifier terminal) SSWAETTYWISPQGIPETKVQDMDCVYYNW
QYLLCSWKPGIGVLLDTNYNLFYWYEGLDH
ALQCVDYIKADGQNIGCRFPYLEASDYKDF
YICVNGSSENKPIRSSYFTFQLQNIVKPLP
PVYLTFTRESSCEIKLKWSIPLGPIPARCF
DYEIEIREDDTTLVTATVENETYTLKTTNE
TRQLCFVVRSKVNIYCSDDGIWSEWSDKQC
WEGEDLSKKTLLRFWLPFGFILILVIFVTG
LLLRKPNTYPKMIPEFFCDT
Linker residues 381- GTGSEF
386 of SEQ ID
NO: 199 CSP J domain residues 387- MADQRQRSLSTSGESLYHVLGLDKNATSDD
472 of SEQ ID IKKSYRKLALKYHPDKNPDNPEAADKFKEI
NO: 199 NNAHAILTDATKRNIYDKYGSLGLYV
Linker residues 473- DIAAALE
479 of SEQ ID
NO: 199 V5 epitope tag residues 480- GKPIPNPLLGLDST
493 of SEQ ID
NO: 199 C-terminal residues 494- SRGPYSIVSPKC
vector residues 505 of SEQ ID
NO: 199 Using the expression vectors described above, the level of expression IL13Ra2-V5 was compared with that of various IL13Ra2 fusion proteins comprising a BAG domain or J domain in transfected HEK293 cells. The expression level of various fusion proteins in cells are shown in the Western blot in Figure 1B. The first row shows lanes of the gel loaded with equal amounts of cell lysate protein. The second row shows expression of GFP as an internal transfection control. As shown in the first row of Figure 1B, only a faint band was detected for the V5-tagged IL13Ra2, which was used to represent expression of the wild-type (WT) IL13Ra2 protein, indicating poor expression.
Fusion proteins comprising IL13Ra2 and a BAG domain (BAG3, BAG4, BAG5, BAG6) were expressed at slightly higher levels. In contrast, fusion proteins comprising IL13Ra2 and any of the J
domains were all expressed at dramatically higher levels than either the V5 tagged IL13Ra2 or the fusion proteins comprising IL13Ra2 and a BAG domain. The results of a densitometry analysis of the signals in Figure 1B are shown in Figure 1C. The fusion proteins comprising IL13Ra2 and any of the J domains were expressed at a level as much as 25-fold higher than the V5 epitope tagged IL13Ra2 (taken as 100%). See, bar graphs in Figure 1C.
Truncated form of IL13Ra2 expression and secretion IL13Ra2 is a membrane receptor protein that binds to interleukin-13 (IL13) and mediates allergic inflammation. Binding of IL13 to the membrane-associated IL13Ra2 receptor transduces a signal to the cytoplasm that sets off an inflammatory response. Such a response is particularly detrimental in the case of asthma. A portion of the expressed, membrane-associated IL13Ra2 molecules is cleaved on the cell surface, releasing a soluble truncated form of IL13Ra2 (IL13Ra2TF) into the extracellular space. The truncated form of IL13Ra2 retains the ability to bind IL13 but cannot transmit a signal to the cell due to the absence of the transmembrane and cytoplasmic regions found in the full-length, membrane-associates protein. Accordingly, the truncated form of IL13Ra2 has been employed as a decoy receptor to treat asthma by binding to IL13 molecules without transducing a signal to the cell to set off an inflammatory response. For such therapeutic applications, a genetically engineered, truncated form of IL13Ra2 has been expressed in mammalian cells and purified as a secreted protein from culture medium. However, the production of the truncated form of IL13Ra2 is inefficient due to difficulties in expression and secretion of the protein.
The ability of a J domain to enhance expression of a soluble, truncated form of IL13Ra2 (IL13Ra2TF) was studied. In order to confirm if conjugation of a J domain to a truncated form of IL13Ra2 enhances expression of the secreted protein, plasmids that expressed an IL13Ra2TF or a fusion protein comprising IL13Ra2TF and an N-terminal J domain from Erdj3 were constructed. The proteins also possessed the V5 epitope tag for easy identification. See, diagrams of constructs in Figure 2A.
The amino acid sequence for a V5 tagged IL13Ra2TF used in this experiment is shown in the table below.
Table 10. Amino Acid Sequence of a VS-Tagged IL13Ra2TF Fusion Protein.
Protein Region Sequence Amino Acid Sequence (N¨ to C¨ Identifier terminal) IL13Ra2TF SEQ ID NO:200 MAFVCLAIGCLYTFLISTTFGCTSSSDTEI
protein KVNPPQDFEIVDPGYLGYLYLQWQPPLSLD
HFKECTVEYELKYRNIGSETWKTIITKNLH
YKDGFDLNKGIEAKIHTLLPWQCTNGSEVQ
SSWAETTYWISPQGIPETKVQDMDCVYYNW
QYLLCSWKPGIGVLLDTNYNLFYWYEGLDH
ALQCVDYIKADGQNIGCRFPYLEASDYKDF
YICVNGSSENKPIRSSYFTFQLQNIVKPLP
PVYLTFTRESSCEIKLKWSIPLGPIPARCF
DYEIEIREDDTTLVTATVENETYTLKTTNE
TRQLCFVVRSKVNIYCSDDGIWSEWSDKQC
WEGEDLSKKGTGSEFDIAAALEGKPIPNPL
LGLDSTSRGPYSIVSPKC
IL13Ra2TF
residues 1-339 MAFVCLAIGCLYTFLISTTFGCTSSSDTEI
of SEQ ID
KVNPPQDFEIVDPGYLGYLYLQWQPPLSLD
NO: 200 HFKECTVEYELKYRNIGSETWKTIITKNLH
YKDGFDLNKGIEAKIHTLLPWQCTNGSEVQ
SSWAETTYWISPQGIPETKVQDMDCVYYNW
QYLLCSWKPGIGVLLDTNYNLFYWYEGLDH
ALQCVDYIKADGQNIGCRFPYLEASDYKDF
YICVNGSSENKPIRSSYFTFQLQNIVKPLP
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) 123456789012345678901234567890 PVYLTFTRESSCEIKLKWSIPLGPIPARCF
DYEIEIREDDTTLVTATVENETYTLKTTNE
TRQLCFVVRSKVNIYCSDDGIWSEWSDKQC
WEGEDLSKK
Linker residues 340- GTGSEFDIAAALE
352 of SEQ ID
NO: 200 V5 epitope residues 353- GKPIPNPLLGLDST
domain 366 of SEQ ID
NO: 200 Linker residues 367- SRGPYSIVSPKC
378 of SEQ ID
NO: 200 The amino acid sequence for a J domain fusion protein comprising an N-terminal J domain of the Erdj3 J protein, a mature (i.e., no signal sequence) and truncated IL13Ra2 (IL13Ra2TF), and the V5 epitope tag is shown in the table below.
Table 11. Amino Acid Sequence of a V5-Tagged Erdj3 J domain-IL13Ra2TF Protein.
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) 123456789012345678901234567890 Erdj3 J domain- SEQ ID NO:201 MAPQNLSTFCLLLLYLIGAVIAGRDFYKIL
IL13Ra2TF fusion GVPRSASIKDIKKAYRKLALQLHPDRNPDD
protein PQAQEKFQDLGAAYEVLSDSEKRDIAAASD
TEIKVNPPQDFEIVDPGYLGYLYLQWQPPL
SLDHFKECTVEYELKYRNIGSETWKTIITK
NLHYKDGFDLNKGIEAKIHTLLPWQCTNGS
EVQSSWAETTYWISPQGIPETKVQDMDCVY
YNWQYLLCSWKPGIGVLLDTNYNLFYWYEG
LDHALQCVDYIKADGQNIGCRFPYLEASDY
KDFYICVNGSSENKPIRSSYFTFQLQNIVK
PLPPVYLTFTRESSCEIKLKWSIPLGPIPA
RCFDYEIEIREDDTTLVTATVENETYTLKT
TNETRQLCFVVRSKVNIYCSDDGIWSEWSD
KQCWEGEDLSKKLEGKPIPNPLLGLDSTSR
GPYSIVSPKC
Erdj3 J domain residues 1-83 MAPQNLSTFCLLLLYLIGAVIAGRDFYKIL
of SEQ ID GVPRSASIKDIKKAYRKLALQLHPDRNPDD
NO: 201 PQAQEKFQDLGAAYEVLSDSEKR
Linker residues 84-88 DIAAA
of SEQ ID
NO: 201 IL13Ra2TF residues 89-402 SDTEIKVNPPQDFEIVDPGYLGYLYLQWQP
(with mature N- of SEQ ID PLSLDHFKECTVEYELKYRNIGSETWKTII
terminus) NO: 201 TKNLHYKDGFDLNKGIEAKIHTLLPWQCTN
GSEVQSSWAETTYWISPQGIPETKVQDMDC
VYYNWQYLLCSWKPGIGVLLDTNYNLFYWY
EGLDHALQCVDYIKADGQNIGCRFPYLEAS
DYKDFYICVNGSSENKPIRSSYFTFQLQNI
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) 123456789012345678901234567890 VKPLPPVYLTFTRESSCEIKLKWSIPLGPI
PARCFDYEIEIREDDTTLVTATVENETYTL
KTTNETRQLCFVVRSKVNIYCSDDGIWSEW
SDKQCWEGEDLSKK
Linker residues 403- LE
404 of SEQ ID
NO: 201 V5 epitope residues 405- GKPIPNPLLGLDST
domain 418 of SEQ ID
NO: 201 C-terminal residues 419- SRGPYSIVSPKC
vector residues 430 of SEQ ID
NO: 201 The amino acid sequence for a BAG domain fusion protein comprising a signal sequence, a BAG domain of BAG3, a mature (i.e., no signal sequence) and truncated IL13Ra2 (IL13Ra2TF), and the V5 epitope tag is shown in the table below.
Table 12. Amino Acid Sequence of a V5-Tagged BAG domain-IL13Ra2TF Fusion Protein.
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) 123456789012345678901234567890 BAG domain- SEQ ID NO:202 MGVKVLFALICIAVAEAGTGSEFHPGVLKV
IL13Ra2TF fusion EAILEKVQGLEQAVDNFEGKKTDKKYLMIE
protein EYLTKELLALDSVDPEGRADVRQARRDGVR
KVQTILEKLEQKAIDDIAAASDTEIKVNPP
QDFEIVDPGYLGYLYLQWQPPLSLDHFKEC
TVEYELKYRNIGSETWKTIITKNLHYKDGF
DLNKGIEAKIHTLLPWQCTNGSEVQSSWAE
TTYWISPQGIPETKVQDMDCVYYNWQYLLC
SWKPGIGVLLDTNYNLFYWYEGLDHALQCV
DYIKADGQNIGCRFPYLEASDYKDFYICVN
GSSENKPIRSSYFTFQLQNIVKPLPPVYLT
FTRESSCEIKLKWSIPLGPIPARCFDYEIE
IREDDTTLVTATVENETYTLKTTNETRQLC
FVVRSKVNIYCSDDGIWSEWSDKQCWEGED
LSKKLEGKPIPNPLLGLDSTSRGPYSIVSP
KC
Signal Sequence residues 1-17 MGVKVLFALICIAVAEA
of SEQ ID
NO: 202 Linker residues 18-23 GTGSEF
of SEQ ID
NO: 202 BAG domain residues 24-105 HPGVLKVEAILEKVQGLEQAVDNFEGKKTD
(from BAG3) of SEQ ID KKYLMIEEYLTKELLALDSVDPEGRADVRQ
NO: 202 ARRDGVRKVQTILEKLEQKAID
Linker residues 106- DIAAA
110 of SEQ ID
NO: 202 Protein Region Sequence Amino Acid Sequence (N¨ to C¨ Identifier terminal) 123456789012345678901234567890 IL13Ra2TF residues 111- SDTEIKVNPPQDFEIVDPGYLGYLYLQWQP
(with mature N- 424 of SEQ ID PLSLDHFKECTVEYELKYRNIGSETWKTII
terminus) NO: 202 TKNLHYKDGFDLNKGIEAKIHTLLPWQCTN
GSEVQSSWAETTYWISPQGIPETKVQDMDC
VYYNWQYLLCSWKPGIGVLLDTNYNLFYWY
EGLDHALQCVDYIKADGQNIGCRFPYLEAS
DYKDFYICVNGSSENKPIRSSYFTFQLQNI
VKPLPPVYLTFTRESSCEIKLKWSIPLGPI
PARCFDYEIEIREDDTTLVTATVENETYTL
KTTNETRQLCFVVRSKVNIYCSDDGIWSEW
SDKQCWEGEDLSKK
Linker residues 425- LE
426 of SEQ ID
NO: 202 V5 epitope residues 427- GKPIPNPLLGLDST
domain 440 of SEQ ID
NO: 202 C-terminal residues 441- SRGPYSIVSPKC
vector residues 452 of SEQ ID
NO: 202 The expression plasmids were transfected into HEK293 cells. Samples of cell lysates and culture media from two-day cultures of the transfected cells were analyzed by immunoblotting with anti-V5 antibody for expression of IL13Ra2TF or IL13Ra2TF-J domain fusion protein. As shown in Figure 2B, the expression of the IL13Ra2TF protein was barely detected in cell lysates (lane 2), and no detection was observed in the medium. In contrast, the level of expression of the IL13Ra2TF-J
domain fusion protein was dramatically higher both inside the cell (cell lysate samples) and also as secreted into the medium. See, Figure 2B. A similar effect was observed when the J domain was attached to the C-terminus of the truncated form of IL13Ra2 (data not shown).
Another experiment was performed to better quantify the secreted proteins using a dot blot immunoassay. HEK293 cells were transfected with an expression vector plasmid for expressing IL13Ra2TF, a BAG domain fused to IL13Ra2TF (BAG-IL13RaTF), or a J domain fused to IL13Ra2TF (J-IL13RaTF). Transfected cells were cultured for two days, and samples of cell culture media were analyzed for secreted proteins using a dot blot immunoassay. The results are shown in Figure 3A and 3B. Figure 3A shows x-ray film images of chemiluminescent signals for VS-tagged proteins secreted into culture media. As shown in Figure 3A, although the fusion protein comprising a BAG domain linked to IL13Ra2TF (lane 3) may have provided some minor enhancement in the level of secreted protein compared to the unfused IL13Ra2TF (lane 2), a fusion protein comprising a J
domain linked to IL13Ra2TF (lane 3) exhibited a significantly enhanced level of secreted protein relative to either the unfused IL13Ra2TF (lane 2) or the or the BAG domain-IL13Ra2TF fusion protein (lane 3). The results of a densitometry analysis of the signals of the dot blots in Figure 3A
using the NIH ImageJ image processing program are shown in Figure 3B. The bar graphs in Figure 3B clearly show the significantly higher level of expression of secreted J
domain-IL13Ra2TF fusion protein (bar graph 4) compared to either the IL13Ra2TF (bar graph 2) or the BAG domain-IL13Ra2TF fusion protein (bar graph 3). Use of the J domain fusion resulted in an approximate 3.5-fold increase in the amount of IL13Ra2TF being secreted by the transformed cells, compared to the expression level of cells transformed to express the IL13Ra2TF protein alone.
J domain-al Anti-Trypsin Fusion Protein in a Modified Arrangement in Human Cells The ctl anti-trypsin (a1AT) protein is secreted from the liver, and circulates in blood vessels.
The function of a1AT is to protect tissues, particularly lung tissue, from excess proteases. The lung is damaged by proteases in a disease called ctl anti-trypsin deficiency. Subjects affected by ctl anti-trypsin deficiency may develop emphysema, asthma, and/or chronic obstructive pulmonary disease (COPD). Currently a1AT (purified from human serum) is used for the treatment of patients with ctl anti-trypsin deficiency. This treatment is expensive, and subjects that receive the human serum are at risk of contracting pathogens present in the human serum.
The effect of fusing a J domain to an al anti-trypsin (a1AT) was studied as a possible strategy for enhancing the levels of expression and secretion of a desired therapeutically useful protein in transfected cells. As shown in Figure 4A, DNA constructs were prepared encoding a VS-tagged a1AT, a VS-tagged a1AT-BAG domain fusion protein, and a VS-tagged a1AT-J
domain fusion protein.
The amino acid sequence of a VS-tagged a1AT protein is shown in the table below.
Table 13. Amino Acid Sequence of a VS-Tagged a1AT Protein.
Protein Region Sequence Amino Acid Sequence (N¨ to C¨ Identifier terminal) a1AT protein SEQ
ID NO:203 MPSSVSWGILLLAGLCCLVPVSLAEDPQGD
AAQKTDTSHHDQDHPTFNKITPNLAEFAFS
LYRQLAHQSNSTNIFFSPVSIATAFAMLSL
GTKADTHDEILEGLNFNLTEIPEAQIHEGF
QELLRTLNQPDSQLQLTTGNGLFLSEGLKL
VDKFLEDVKKLYHSEAFTVNFGDTEEAKKQ
INDYVEKGTQGKIVDLVKELDRDTVFALVN
YIFFKGKWERPFEVKDTEEEDFHVDQVTTV
KVPMMKRLGMFNIQHCKKLSSWVLLMKYLG
NATAIFFLPDEGKLQHLENELTHDIITKFL
ENEDRRSASLHLPKLSITGTYDLKSVLGQL
GITKVFSNGADLSGVTEEAPLKLSKAVHKA
VLTIDEKGTEAAGAMFLEAIPMSIPPEVKF
NKPFVFLMIEQNTKSPLFMGKVVNPTQKGT
GSEFDIAAALEGKPIPNPLLGLDSTSRGPY
SIVSPKC
a1AT
residues 1-418 MPSSVSWGILLLAGLCCLVPVSLAEDPQGD
of SEQ ID
AAQKTDTSHHDQDHPTFNKITPNLAEFAFS
NO: 203 LYRQLAHQSNSTNIFFSPVSIATAFAMLSL
GTKADTHDEILEGLNFNLTEIPEAQIHEGF
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) QELLRTLNQPDSQLQLTTGNGLFLSEGLKL
VDKFLEDVKKLYHSEAFTVNFGDTEEAKKQ
INDYVEKGTQGKIVDLVKELDRDTVFALVN
YIFFKGKWERPFEVKDTEEEDFHVDQVTTV
KVPMMKRLGMFNIQHCKKLSSWVLLMKYLG
NATAIFFLPDEGKLQHLENELTHDIITKFL
ENEDRRSASLHLPKLSITGTYDLKSVLGQL
GITKVFSNGADLSGVTEEAPLKLSKAVHKA
VLTIDEKGTEAAGAMFLEAIPMSIPPEVKF
NKPFVFLMIEQNTKSPLFMGKVVNPTQK
Linker residues 419- GTGSEFDIAAALE
431 of SEQ ID
NO: 203 V5 epitope residues 432- GKPIPNPLLGLDST
domain 445 of SEQ ID
NO: 203 C-terminal residues 446- SRGPYSIVSPKC
vector residues 457 of SEQ ID
NO: 203 The amino acid sequence of a BAG domain fusion protein comprising a lAT, the BAG
domain of BAG3, and the V5 epitope tag is shown in the table below.
Table 14. Amino Acid Sequence of alAT-BAG Fusion Protein.
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) a1AT-BAG domain SEQ ID
NO:204 MPSSVSWGILLLAGLCCLVPVSLAEDPQGD
fusion protein AAQKTDTSHHDQDHPTFNKITPNLAEFAFS
LYRQLAHQSNSTNIFFSPVSIATAFAMLSL
GTKADTHDEILEGLNFNLTEIPEAQIHEGF
QELLRTLNQPDSQLQLTTGNGLFLSEGLKL
VDKFLEDVKKLYHSEAFTVNFGDTEEAKKQ
INDYVEKGTQGKIVDLVKELDRDTVFALVN
YIFFKGKWERPFEVKDTEEEDFHVDQVTTV
KVPMMKRLGMFNIQHCKKLSSWVLLMKYLG
NATAIFFLPDEGKLQHLENELTHDIITKFL
ENEDRRSASLHLPKLSITGTYDLKSVLGQL
GITKVFSNGADLSGVTEEAPLKLSKAVHKA
VLTIDEKGTEAAGAMFLEAIPMSIPPEVKF
NKPFVFLMIEQNTKSPLFMGKVVNPTQKGT
GSEFHPGVLKVEAILEKVQGLEQAVDNFEG
KKTDKKYLMIEEYLTKELLALDSVDPEGRA
DVRQARRDGVRKVQTILEKLEQKAIDDIAA
ALEGKPIPNPLLGLDSTSRGPYSIVSPKC
a1AT residues of SEQ ID
AAQKTDTSHHDQDHPTFNKITPNLAEFAFS
NO: 204 LYRQLAHQSNSTNIFFSPVSIATAFAMLSL
GTKADTHDEILEGLNFNLTEIPEAQIHEGF
QELLRTLNQPDSQLQLTTGNGLFLSEGLKL
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) 123456789012345678901234567890 VDKFLEDVKKLYHSEAFTVNFGDTEEAKKQ
INDYVEKGTQGKIVDLVKELDRDTVFALVN
YIFFKGKWERPFEVKDTEEEDFHVDQVTTV
KVPMMKRLGMFNIQHCKKLSSWVLLMKYLG
NATAIFFLPDEGKLQHLENELTHDIITKFL
ENEDRRSASLHLPKLSITGTYDLKSVLGQL
GITKVFSNGADLSGVTEEAPLKLSKAVHKA
VLTIDEKGTEAAGAMFLEAIPMSIPPEVKF
NKPFVFLMIEQNTKSPLFMGKVVNPTQK
Linker residues 419- GTGSEF
424 of SEQ ID
NO: 204 BAG domain residues 425- HPGVLKVEAILEKVQGLEQAVDNFEGKKTD
(from BAG3) 506 of SEQ ID KKYLMIEEYLTKELLALDSVDPEGRADVRQ
NO: 204 ARRDGVRKVQTILEKLEQKAID
Linker residues 507- DIAAALE
513 of SEQ ID
NO: 204 V5 epitope residues 514- GKPIPNPLLGLDST
domain 527 of SEQ ID
NO: 204 C-terminal residues 528- SRGPYSIVSPKC
vector residues 539 of SEQ ID
NO: 204 The amino acid sequence of a J domain fusion protein comprising alAT, the Erdj3 J domain, and the V5 epitope tag is shown in the table below.
Table 15. Amino Acid Sequence of alAT-J Domain Protein.
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) 123456789012345678901234567890 a1AT-Erdj3 J SEQ ID NO:205 MPSSVSWGILLLAGLCCLVPVSLAEDPQGD
domain fusion AAQKTDTSHHDQDHPTFNKITPNLAEFAFS
protein LYRQLAHQSNSTNIFFSPVSIATAFAMLSL
GTKADTHDEILEGLNFNLTEIPEAQIHEGF
QELLRTLNQPDSQLQLTTGNGLFLSEGLKL
VDKFLEDVKKLYHSEAFTVNFGDTEEAKKQ
INDYVEKGTQGKIVDLVKELDRDTVFALVN
YIFFKGKWERPFEVKDTEEEDFHVDQVTTV
KVPMMKRLGMFNIQHCKKLSSWVLLMKYLG
NATAIFFLPDEGKLQHLENELTHDIITKFL
ENEDRRSASLHLPKLSITGTYDLKSVLGQL
GITKVFSNGADLSGVTEEAPLKLSKAVHKA
VLTIDEKGTEAAGAMFLEAIPMSIPPEVKF
NKPFVFLMIEQNTKSPLFMGKVVNPTQKGT
GSEFGRDFYKILGVPRSASIKDIKKAYRKL
ALQLHPDRNPDDPQAQEKFQDLGAAYEVLS
DSEKRDIAAALEGKPIPNPLLGLDSTSRGP
YSIVSPKC
Protein Region Sequence Amino Acid Sequence (N¨ to C¨ Identifier terminal) 123456789012345678901234567890 a1AT residues 1-418 MPSSVSWGILLLAGLCCLVPVSLAEDPQGD
of SEQ ID AAQKTDTSHHDQDHPTFNKITPNLAEFAFS
NO: 205 LYRQLAHQSNSTNIFFSPVSIATAFAMLSL
GTKADTHDEILEGLNFNLTEIPEAQIHEGF
QELLRTLNQPDSQLQLTTGNGLFLSEGLKL
VDKFLEDVKKLYHSEAFTVNFGDTEEAKKQ
INDYVEKGTQGKIVDLVKELDRDTVFALVN
YIFFKGKWERPFEVKDTEEEDFHVDQVTTV
KVPMMKRLGMFNIQHCKKLSSWVLLMKYLG
NATAIFFLPDEGKLQHLENELTHDIITKFL
ENEDRRSASLHLPKLSITGTYDLKSVLGQL
GITKVFSNGADLSGVTEEAPLKLSKAVHKA
VLTIDEKGTEAAGAMFLEAIPMSIPPEVKF
NKPFVFLMIEQNTKSPLFMGKVVNPTQK
Linker residues 419- GTGSEF
424 of SEQ ID
NO: 205 Erdj3 J domain residues 425- GRDFYKILGVPRSASIKDIKKAYRKLALQL
485 of SEQ ID HPDRNPDDPQAQEKFQDLGAAYEVLSDSEK
NO:205 Linker residues 486- DIAAALE
492 of SEQ ID
NO: 205 V5 epitope residues 493- GKPIPNPLLGLDST
domain 506 of SEQ ID
NO: 205 C-terminal residues 507- SRGPYSIVSPKC
vector residues 518 of SEQ ID
NO: 205 Expression vector plasmids encoding the above three recombinant a lAT protein constructs were transfected into HEK293 cells. Culture media from two-day cultures of transfected cells were harvested, and the level of the recombinant al AT proteins secreted into the media determined by dot blot immunoassays. Figure 4B shows x-ray film chemiluminescent signals of the dot blot assays.
Although detectable amounts of both unfused alAT (lane 2) and alAT-BAG domain fusion protein (lane 3) were secreted into culture media, an even higher level of expression was obtained for secreted alAT-J domain fusion protein (lane 3). The results of a densitometry analysis of the signals of the dot blots in Figure 4B using the NIH ImageJ image processing program are shown in Figure 4C. The bar graphs in Figure 4C clearly show the significantly higher level of expression of secreted alAT-J
domain fusion protein (bar graph 4) compared to the level of expression of either a lAT (bar graph 2) or the alAT-BAG domain fusion protein (bar graph 3). Use of the J domain fusion resulted in greater than a 1.5-fold increase in the amount of IL13Ra2TF being secreted by the transformed cells, compared to the expression level of cells transformed to express the alAT
protein alone or an a1AT-BAG fusion protein.
Truncated Form of TNFR1 Protein in a Modified Arrangement One format for designing therapeutically active fusion proteins combines a binding domain, which specifically binds a desired target molecule, linked to an immunoglobulin Fc region, which endues the fusion protein with an enhanced in vivo half-life. An example of this class of drugs is etanercept, which binds and inhibits the effect of tumor necrosis factor (TNFa), which is a key protein of the immune system involved in a number of autoimmune diseases. For example, etanercept possesses a truncated form of a tumor necrosis factor a receptor (TNFR1TF) linked to an immunoglobulin Fc domain. The TNFR1TF portion of etanercept provides specificity for the drug target (TNFa), and the Fc domain is believed to add stability and deliverability of the drug in vivo.
Nevertheless, the Fc domain is also known to possess certain effector functions that may not be desired in treatment protocols for some diseases.
The effect of fusing a J domain to a truncated form of a receptor molecule was studied as a possible strategy for enhancing levels of expression and secretion of a desired receptor-based molecule. Such a J domain fusion protein may provide a possible alternative to prior drug designs involving truncated forms of receptor molecules linked to immunoglobulin Fc domains. The expression of a truncated form of a tumor necrosis factor receptor (TNFR1TF) with or without a J
domain was studied using expression vector plasmids TNFR1TF-V5-pcDNA' and domain-V5-pcDNA'. The expression vectors add a V5 epitope tag to both proteins for easy detection with an anti-V5 antibody. See, diagrams of constructs in Figure 5A.
The amino acid sequence of a VS-tagged TNFR1TF is shown in the table below.
Table 16. Amino Acid Sequence of a VS-Tagged TNFR1TF Protein.
Protein Region Sequence Amino Acid Sequence (N¨ to C¨ Identifier terminal) TNFR1TF protein SEQ
ID NO:206 MGLSTVPDLLLPLVLLELLVGIYPSGVIGL
VPHLGDREKRDSVCPQGKYIHPQNNSICCT
KCHKGTYLYNDCPGPGQDTDCRECESGSFT
ASENHLRHCLSCSKCRKEMGQVEISSCTVD
RDTVCGCRKNQYRHYWSENLFQCFNCSLCL
NGTVHLSCQEKQNTVCTCHAGFFLRENECV
SCSNCKKSLECTKLCLPQIENVKGTEDSGT
TGTGSEFDIAAALEGKPIPNPLLGLDSTSR
GPYSIVSPKC
residues 1-211 MGLSTVPDLLLPLVLLELLVGIYPSGVIGL
of SEQ ID
VPHLGDREKRDSVCPQGKYIHPQNNSICCT
NO: 206 KCHKGTYLYNDCPGPGQDTDCRECESGSFT
ASENHLRHCLSCSKCRKEMGQVEISSCTVD
RDTVCGCRKNQYRHYWSENLFQCFNCSLCL
NGTVHLSCQEKQNTVCTCHAGFFLRENECV
SCSNCKKSLECTKLCLPQIENVKGTEDSGT
Linker residues 212- GTGSEFDIAAALE
224 of SEQ ID
NO: 206 V5 epitope residues 225- GKPIPNPLLGLDST
domain 238 of SEQ ID
NO: 206 C-terminal residues 239- SRGPYSIVSPKC
vector residues 250 of SEQ ID
NO: 206 The amino acid sequence of a J domain fusion protein comprising TNFR1TF, the Erdj3 J
domain, and the V5 epitope tag is shown in the table below.
Table 17. Amino Acid Sequence of a V5-Tagged TNFR1TF-Erdj3 J Domain Fusion Protein.
Protein Region Sequence Amino Acid Sequence (N¨ to C¨ Identifier terminal) 123456789012345678901234567890 TNFR1TF-J domain SEQ ID NO:207 MGLSTVPDLLLPLVLLELLVGIYPSGVIGL
fusion protein VPHLGDREKRDSVCPQGKYIHPQNNSICCT
KCHKGTYLYNDCPGPGQDTDCRECESGSFT
ASENHLRHCLSCSKCRKEMGQVEISSCTVD
RDTVCGCRKNQYRHYWSENLFQCFNCSLCL
NGTVHLSCQEKQNTVCTCHAGFFLRENECV
SCSNCKKSLECTKLCLPQIENVKGTEDSGT
TGTGSEFGRDFYKILGVPRSASIKDIKKAY
RKLALQLHPDRNPDDPQAQEKFQDLGAAYE
VLSDSEKRDIAAALEGKPIPNPLLGLDSTS
RGPYSIVSPKC
TNFR1TF residues 1-211 MGLSTVPDLLLPLVLLELLVGIYPSGVIGL
of SEQ ID VPHLGDREKRDSVCPQGKYIHPQNNSICCT
NO:207 KCHKGTYLYNDCPGPGQDTDCRECESGSFT
ASENHLRHCLSCSKCRKEMGQVEISSCTVD
RDTVCGCRKNQYRHYWSENLFQCFNCSLCL
NGTVHLSCQEKQNTVCTCHAGFFLRENECV
SCSNCKKSLECTKLCLPQIENVKGTEDSGT
Linker residues 212- GTGSEF
217 of SEQ ID
NO:207 Erdj3 J domain residues 218- GRDFYKILGVPRSASIKDIKKAYRKLALQL
278 of SEQ ID HPDRNPDDPQAQEKFQDLGAAYEVLSDSEK
NO:207 Linker residues 279- DIAAALE
285 of SEQ ID
NO:207 V5 epitope residues 286- GKPIPNPLLGLDST
domain 299 of SEQ ID
NO: 207 C-terminal residues 300- SRGPYSIVSPKC
vector residues 311 of SEQ ID
NO: 207 The expression plasmids were transfected into HEK293 cells. Samples of cell lysates and culture media from two-day cultures of transfected cells were analyzed by immunoblotting with anti-V5 antibody for expression of TNFR1TF or the TNFR1TF-J domain fusion protein.
As shown in the dot blots in Figure 5B, some TNFR1TF was detected in medium (lane 2), however, the level of the TNFR1TF-J domain fusion protein detected in the medium was significantly greater (lane 3). The results of a densitometry analysis of the signals of the dot blots in Figure 5B using the NIH ImageJ
image processing program are shown in Figure 5C. Clearly, the level of expression of secreted TNFR1TF-J domain fusion protein (bar graph 3) was significantly higher than that of the (unfused) TNFR1TF protein (bar graph 2) , i.e., about a 6-fold increase over the level of TNFR1TF alone.
Secretion of Fc-Fusion Proteins in a Modified Arrangement In view of the above results showing that the level of expression of secreted truncated form of TNFR1 was enhanced by the conjugation of J domain (Figures 5B and 5C), it was of interest to examine whether a J domain would enhance expression of a protein of interest fused to an immunoglobulin Fc domain, such as a TNF1TF-Fc fusion protein. Such Fc-fusion molecules are a type of drug format illustrated by the drug etanercept (commercially available as ENBRELO), which is a TNF1TF-Fc fusion protein approved for treating a number of autoimmune diseases, such as severe rheumatoid arthritis, polyarticular juvenile idiopathic arthritis (JIA), psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis.
For this study, a cDNA encoding each protein of interest (TNFR1TF, IL13Ra2TF, or alAT) was augmented with a segment encoding a V5 epitope tag at the 3' end, which was linked in turn to a segment encoding the constant domains of an immunoglobulin Fc region. For J-domain fusions, a cDNA encoding a J domain was linked in frame between the cDNA encoding each protein of interest and the segment encoding a V5 epitope tag. See, illustration of constructs in Figure 6A. The corresponding expression vector plasmids were transfected into HEK293 cells.
Culture media were assayed for secreted proteins by dot blot assay.
The amino acid sequence of the TNFR1TF-Fc fusion protein is shown in the table below.
Table 18. Amino Acid Sequence of a VS-Tagged TNFR1TF-Fc Fusion Protein.
Protein Region Sequence Amino Acid Sequence (N¨ to C¨ Identifier terminal) TNFR1TF Fc SEQ ID NO:208 MGLSTVPDLLLPLVLLELLVGIYPSGVIGL
fusion protein VPHLGDREKRDSVCPQGKYIHPQNNSICCT
KCHKGTYLYNDCPGPGQDTDCRECESGSFT
ASENHLRHCLSCSKCRKEMGQVEISSCTVD
RDTVCGCRKNQYRHYWSENLFQCFNCSLCL
NGTVHLSCQEKQNTVCTCHAGFFLRENECV
SCSNCKKSLECTKLCLPQIENVKGTEDSGT
TGTGSEFDIAAALEGKPIPNPLLGLDSTSR
PKSCDKTHTCPPCPAPELLGGPSVFLFPPK
PKDTLMISRTPEVTCVVVDVSHEDPEVKFN
WYVDGVEVHNAKTKPREEQYNSTYRVVSVL
TVLHQDWLNGKEYKCKVSNKALPAPIEKTI
SKAKGQPREPQVYTLPPSRDELTKNQVSLT
CLVKGFYPSDIAVEWESNGQPENNYKTTPP
VLDSDGSFFLYSKLTVDKSRWQQGNVFSCS
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) VMHEALHNHYTQKSLSLSPGK
TNFR1TF residues of SEQ ID
VPHLGDREKRDSVCPQGKYIHPQNNSICCT
NO: 208 KCHKGTYLYNDCPGPGQDTDCRECESGSFT
ASENHLRHCLSCSKCRKEMGQVEISSCTVD
RDTVCGCRKNQYRHYWSENLFQCFNCSLCL
NGTVHLSCQEKQNTVCTCHAGFFLRENECV
SCSNCKKSLECTKLCLPQIENVKGTEDSGT
Linker residues 212- GTGSEFDIAAALE
224 of SEQ ID
NO: 208 V5 epitope residues 225- GKPIPNPLLGLDST
domain 238 of SEQ ID
NO: 208 Linker residues 239- SR
240 of SEQ ID
NO: 208 Fc domain residues 241-PKSCDKTHTCPPCPAPELLGGPSVFLFPPK
471 of SEQ ID PKDTLMISRTPEVTCVVVDVSHEDPEVKFN
NO: 208 WYVDGVEVHNAKTKPREEQYNSTYRVVSVL
TVLHQDWLNGKEYKCKVSNKALPAPIEKTI
SKAKGQPREPQVYTLPPSRDELTKNQVSLT
CLVKGFYPSDIAVEWESNGQPENNYKTTPP
VLDSDGSFFLYSKLTVDKSRWQQGNVFSCS
VMHEALHNHYTQKSLSLSPGK
The amino acid sequence of a TNFR1TF-J domain-Fc fusion protein is shown in the table below.
Table 19. Amino Acid Sequence of a V5-Tagged TNFR1TF-Erdj3 J Domain-Fc Protein.
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) TNFR1TF-J domain SEQ ID
NO:209 MGLSTVPDLLLPLVLLELLVGIYPSGVIGL
Fc fusion VPHLGDREKRDSVCPQGKYIHPQNNSICCT
protein KCHKGTYLYNDCPGPGQDTDCRECESGSFT
ASENHLRHCLSCSKCRKEMGQVEISSCTVD
RDTVCGCRKNQYRHYWSENLFQCFNCSLCL
NGTVHLSCQEKQNTVCTCHAGFFLRENECV
SCSNCKKSLECTKLCLPQIENVKGTEDSGT
TGTGSEFGRDFYKILGVPRSASIKDIKKAY
RKLALQLHPDRNPDDPQAQEKFQDLGAAYE
VLSDSEKRDIAAALEGKPIPNPLLGLDSTS
RPKSCDKTHTCPPCPAPELLGGPSVFLFPP
KPKDTLMISRTPEVTCVVVDVSHEDPEVKF
NWYVDGVEVHNAKTKPREEQYNSTYRVVSV
LTVLHQDWLNGKEYKCKVSNKALPAPIEKT
ISKAKGQPREPQVYTLPPSRDELTKNQVSL
TCLVKGFYPSDIAVEWESNGQPENNYKTTP
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) 123456789012345678901234567890 PVLDSDGSFFLYSKLTVDKSRWQQGNVFSC
SVMHEALHNHYTQKSLSLSPGK
TNFR1TF residues 1-211 MGLSTVPDLLLPLVLLELLVGIYPSGVIGL
of SEQ ID VPHLGDREKRDSVCPQGKYIHPQNNSICCT
NO: 209 KCHKGTYLYNDCPGPGQDTDCRECESGSFT
ASENHLRHCLSCSKCRKEMGQVEISSCTVD
RDTVCGCRKNQYRHYWSENLFQCFNCSLCL
NGTVHLSCQEKQNTVCTCHAGFFLRENECV
SCSNCKKSLECTKLCLPQIENVKGTEDSGT
Linker residues 212- GTGSEF
217 of SEQ ID
NO: 209 Erdj3 J domain residues 218- GRDFYKILGVPRSASIKDIKKAYRKLALQL
278 of SEQ ID HPDRNPDDPQAQEKFQDLGAAYEVLSDSEK
NO:209 Linker residues 279- DIAAALE
285 of SEQ ID
NO: 209 V5 epitope residues 286- GKPIPNPLLGLDST
domain 299 of SEQ ID
NO: 209 Linker residues 300- SR
301 of SEQ ID
NO: 209 Fc domain residues 302- PKSCDKTHTCPPCPAPELLGGPSVFLFPPK
532 of SEQ ID PKDTLMISRTPEVTCVVVDVSHEDPEVKFN
NO: 209 WYVDGVEVHNAKTKPREEQYNSTYRVVSVL
TVLHQDWLNGKEYKCKVSNKALPAPIEKTI
SKAKGQPREPQVYTLPPSRDELTKNQVSLT
CLVKGFYPSDIAVEWESNGQPENNYKTTPP
VLDSDGSFFLYSKLTVDKSRWQQGNVFSCS
VMHEALHNHYTQKSLSLSPGK
The amino acid sequence of an IL13Ra2TF-Fc fusion protein is shown in the table below.
Table 20. Amino Acid Sequence of a V5-Tagged IL13Ra2TF-Fc Fusion Protein.
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) 123456789012345678901234567890 IL13Ra2TF-Fc SEQ ID NO:210 MAFVCLAIGCLYTFLISTTFGCTSSSDTEI
fusion protein KVNPPQDFEIVDPGYLGYLYLQWQPPLSLD
HFKECTVEYELKYRNIGSETWKTIITKNLH
YKDGFDLNKGIEAKIHTLLPWQCTNGSEVQ
SSWAETTYWISPQGIPETKVQDMDCVYYNW
QYLLCSWKPGIGVLLDTNYNLFYWYEGLDH
ALQCVDYIKADGQNIGCRFPYLEASDYKDF
YICVNGSSENKPIRSSYFTFQLQNIVKPLP
PVYLTFTRESSCEIKLKWSIPLGPIPARCF
DYEIEIREDDTTLVTATVENETYTLKTTNE
TRQLCFVVRSKVNIYCSDDGIWSEWSDKQC
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) 123456789012345678901234567890 WEGEDLSKKGTGSEFDIAAALEGKPIPNPL
LGLDSTSRPKSCDKTHTCPPCPAPELLGGP
SVFLFPPKPKDTLMISRTPEVTCVVVDVSH
EDPEVKFNWYVDGVEVHNAKTKPREEQYNS
TYRVVSVLTVLHQDWLNGKEYKCKVSNKAL
PAPIEKTISKAKGQPREPQVYTLPPSRDEL
TKNQVSLTCLVKGFYPSDIAVEWESNGQPE
NNYKTTPPVLDSDGSFFLYSKLTVDKSRWQ
QGNVFSCSVMHEALHNHYTQKSLSLSPGK
IL13Ra2TF residues 1-339 MAFVCLAIGCLYTFLISTTFGCTSSSDTEI
of SEQ ID KVNPPQDFEIVDPGYLGYLYLQWQPPLSLD
NO: 210 HFKECTVEYELKYRNIGSETWKTIITKNLH
YKDGFDLNKGIEAKIHTLLPWQCTNGSEVQ
SSWAETTYWISPQGIPETKVQDMDCVYYNW
QYLLCSWKPGIGVLLDTNYNLFYWYEGLDH
ALQCVDYIKADGQNIGCRFPYLEASDYKDF
YICVNGSSENKPIRSSYFTFQLQNIVKPLP
PVYLTFTRESSCEIKLKWSIPLGPIPARCF
DYEIEIREDDTTLVTATVENETYTLKTTNE
TRQLCFVVRSKVNIYCSDDGIWSEWSDKQC
WEGEDLSKK
Linker residues 340- GTGSEFDIAAALE
352 of SEQ ID
NO: 210 V5 epitope residues 353- GKPIPNPLLGLDST
domain 366 of SEQ ID
NO: 210 Linker residues 367- SR
368 of SEQ ID
NO: 210 Fc domain residues 369- PKSCDKTHTCPPCPAPELLGGPSVFLFPPK
599 of SEQ ID PKDTLMISRTPEVTCVVVDVSHEDPEVKFN
NO: 210 WYVDGVEVHNAKTKPREEQYNSTYRVVSVL
TVLHQDWLNGKEYKCKVSNKALPAPIEKTI
SKAKGQPREPQVYTLPPSRDELTKNQVSLT
CLVKGFYPSDIAVEWESNGQPENNYKTTPP
VLDSDGSFFLYSKLTVDKSRWQQGNVFSCS
VMHEALHNHYTQKSLSLSPGK
The amino acid sequence of an IL13Ra2TF-J domain-Fc fusion protein is shown in the table below.
Table 21. Amino Acid Sequence of a V5-Tagged IL13Ra2TF-Erdj3 J Domain-Fc Protein.
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) 123456789012345678901234567890 IL13Ra2TF-J SEQ ID NO:211 MAFVCLAIGCLYTFLISTTFGCTSSSDTEI
domain-Fc fusion KVNPPQDFEIVDPGYLGYLYLQWQPPLSLD
protein HFKECTVEYELKYRNIGSETWKTIITKNLH
YKDGFDLNKGIEAKIHTLLPWQCTNGSEVQ
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) 123456789012345678901234567890 SSWAETTYWISPQGIPETKVQDMDCVYYNW
QYLLCSWKPGIGVLLDTNYNLFYWYEGLDH
ALQCVDYIKADGQNIGCRFPYLEASDYKDF
YICVNGSSENKPIRSSYFTFQLQNIVKPLP
PVYLTFTRESSCEIKLKWSIPLGPIPARCF
DYEIEIREDDTTLVTATVENETYTLKTTNE
TRQLCFVVRSKVNIYCSDDGIWSEWSDKQC
WEGEDLSKKGTGSEFGRDFYKILGVPRSAS
IKDIKKAYRKLALQLHPDRNPDDPQAQEKF
QDLGAAYEVLSDSEKRDIAAALEGKPIPNP
LLGLDSTSRPKSCDKTHTCPPCPAPELLGG
PSVFLFPPKPKDTLMISRTPEVTCVVVDVS
HEDPEVKFNWYVDGVEVHNAKTKPREEQYN
STYRVVSVLTVLHQDWLNGKEYKCKVSNKA
LPAPIEKTISKAKGQPREPQVYTLPPSRDE
LTKNQVSLTCLVKGFYPSDIAVEWESNGQP
ENNYKTTPPVLDSDGSFFLYSKLTVDKSRW
QQGNVFSCSVMHEALHNHYTQKSLSLSPGK
IL13Ra2TF residues 1-339 MAFVCLAIGCLYTFLISTTFGCTSSSDTEI
of SEQ ID KVNPPQDFEIVDPGYLGYLYLQWQPPLSLD
NO: 211 HFKECTVEYELKYRNIGSETWKTIITKNLH
YKDGFDLNKGIEAKIHTLLPWQCTNGSEVQ
SSWAETTYWISPQGIPETKVQDMDCVYYNW
QYLLCSWKPGIGVLLDTNYNLFYWYEGLDH
ALQCVDYIKADGQNIGCRFPYLEASDYKDF
YICVNGSSENKPIRSSYFTFQLQNIVKPLP
PVYLTFTRESSCEIKLKWSIPLGPIPARCF
DYEIEIREDDTTLVTATVENETYTLKTTNE
TRQLCFVVRSKVNIYCSDDGIWSEWSDKQC
WEGEDLSKK
Linker residues 340- GTGSEF
345 of SEQ ID
NO: 211 Erdj3 J domain residues 346- GRDFYKILGVPRSASIKDIKKAYRKLALQL
406 of SEQ ID HPDRNPDDPQAQEKFQDLGAAYEVLSDSEK
NO:211 R
Linker residues 407- DIAAALE
413 of SEQ ID
NO: 211 V5 epitope residues 414- GKPIPNPLLGLDST
domain 427 of SEQ ID
NO: 211 Linker residues 428- SR
429 of SEQ ID
NO: 211 Fc domain residues 430- PKSCDKTHTCPPCPAPELLGGPSVFLFPPK
660 of SEQ ID PKDTLMISRTPEVTCVVVDVSHEDPEVKFN
NO: 211 WYVDGVEVHNAKTKPREEQYNSTYRVVSVL
TVLHQDWLNGKEYKCKVSNKALPAPIEKTI
SKAKGQPREPQVYTLPPSRDELTKNQVSLT
CLVKGFYPSDIAVEWESNGQPENNYKTTPP
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) VLDSDGSFFLYSKLTVDKSRWQQGNVFSCS
VMHEALHNHYTQKSLSLSPGK
The amino acid sequence of an a1AT-Fc fusion protein is shown in the table below.
Table 22. Amino Acid Sequence of V5-Tagged a1AT-Fc Protein.
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) a1AT protein-Fc SEQ ID
NO:212 MPSSVSWGILLLAGLCCLVPVSLAEDPQGD
fusion protein AAQKTDTSHHDQDHPTFNKITPNLAEFAFS
LYRQLAHQSNSTNIFFSPVSIATAFAMLSL
GTKADTHDEILEGLNFNLTEIPEAQIHEGF
QELLRTLNQPDSQLQLTTGNGLFLSEGLKL
VDKFLEDVKKLYHSEAFTVNFGDTEEAKKQ
INDYVEKGTQGKIVDLVKELDRDTVFALVN
YIFFKGKWERPFEVKDTEEEDFHVDQVTTV
KVPMMKRLGMFNIQHCKKLSSWVLLMKYLG
NATAIFFLPDEGKLQHLENELTHDIITKFL
ENEDRRSASLHLPKLSITGTYDLKSVLGQL
GITKVFSNGADLSGVTEEAPLKLSKAVHKA
VLTIDEKGTEAAGAMFLEAIPMSIPPEVKF
NKPFVFLMIEQNTKSPLFMGKVVNPTQKGT
GSEFDIAAALEGKPIPNPLLGLDSTSRPKS
CDKTHTCPPCPAPELLGGPSVFLFPPKPKD
TLMISRTPEVTCVVVDVSHEDPEVKFNWYV
DGVEVHNAKTKPREEQYNSTYRVVSVLTVL
HQDWLNGKEYKCKVSNKALPAPIEKTISKA
KGQPREPQVYTLPPSRDELTKNQVSLTCLV
KGFYPSDIAVEWESNGQPENNYKTTPPVLD
SDGSFFLYSKLTVDKSRWQQGNVFSCSVMH
EALHNHYTQKSLSLSPGK
a1AT residues of SEQ ID
AAQKTDTSHHDQDHPTFNKITPNLAEFAFS
NO: 212 LYRQLAHQSNSTNIFFSPVSIATAFAMLSL
GTKADTHDEILEGLNFNLTEIPEAQIHEGF
QELLRTLNQPDSQLQLTTGNGLFLSEGLKL
VDKFLEDVKKLYHSEAFTVNFGDTEEAKKQ
INDYVEKGTQGKIVDLVKELDRDTVFALVN
YIFFKGKWERPFEVKDTEEEDFHVDQVTTV
KVPMMKRLGMFNIQHCKKLSSWVLLMKYLG
NATAIFFLPDEGKLQHLENELTHDIITKFL
ENEDRRSASLHLPKLSITGTYDLKSVLGQL
GITKVFSNGADLSGVTEEAPLKLSKAVHKA
VLTIDEKGTEAAGAMFLEAIPMSIPPEVKF
NKPFVFLMIEQNTKSPLFMGKVVNPTQK
Linker residues 419- GTGSEFDIAAALE
431 of SEQ ID
NO: 212 V5 epitope residues 432- GKPIPNPLLGLDST
domain 445 of SEQ ID
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) 123456789012345678901234567890 NO: 212 Linker residues 446- SR
447 of SEQ ID
NO: 212 Fc domain residues 448- PKSCDKTHTCPPCPAPELLGGPSVFLFPPK
678 of SEQ ID PKDTLMISRTPEVTCVVVDVSHEDPEVKFN
NO: 212 WYVDGVEVHNAKTKPREEQYNSTYRVVSVL
TVLHQDWLNGKEYKCKVSNKALPAPIEKTI
SKAKGQPREPQVYTLPPSRDELTKNQVSLT
CLVKGFYPSDIAVEWESNGQPENNYKTTPP
VLDSDGSFFLYSKLTVDKSRWQQGNVFSCS
VMHEALHNHYTQKSLSLSPGK
The amino acid sequence of an alAT-J domain-Fc fusion protein is shown in the table below.
Table 23. Amino Acid Sequence of a V5-Tagged al AT-Erdj3 J Domain-Fc Protein.
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) a1AT-J domain-Fc SEQ ID
NO:213 MPSSVSWGILLLAGLCCLVPVSLAEDPQGD
fusion protein AAQKTDTSHHDQDHPTFNKITPNLAEFAFS
LYRQLAHQSNSTNIFFSPVSIATAFAMLSL
GTKADTHDEILEGLNFNLTEIPEAQIHEGF
QELLRTLNQPDSQLQLTTGNGLFLSEGLKL
VDKFLEDVKKLYHSEAFTVNFGDTEEAKKQ
INDYVEKGTQGKIVDLVKELDRDTVFALVN
YIFFKGKWERPFEVKDTEEEDFHVDQVTTV
KVPMMKRLGMFNIQHCKKLSSWVLLMKYLG
NATAIFFLPDEGKLQHLENELTHDIITKFL
ENEDRRSASLHLPKLSITGTYDLKSVLGQL
GITKVFSNGADLSGVTEEAPLKLSKAVHKA
VLTIDEKGTEAAGAMFLEAIPMSIPPEVKF
NKPFVFLMIEQNTKSPLFMGKVVNPTQKGT
GSEFGRDFYKILGVPRSASIKDIKKAYRKL
ALQLHPDRNPDDPQAQEKFQDLGAAYEVLS
DSEKRDIAAALEGKPIPNPLLGLDSTSRPK
SCDKTHTCPPCPAPELLGGPSVFLFPPKPK
DTLMISRTPEVTCVVVDVSHEDPEVKFNWY
VDGVEVHNAKTKPREEQYNSTYRVVSVLTV
LHQDWLNGKEYKCKVSNKALPAPIEKTISK
AKGQPREPQVYTLPPSRDELTKNQVSLTCL
VKGFYPSDIAVEWESNGQPENNYKTTPPVL
DSDGSFFLYSKLTVDKSRWQQGNVFSCSVM
HEALHNHYTQKSLSLSPGK
a1AT residues of SEQ ID
AAQKTDTSHHDQDHPTFNKITPNLAEFAFS
NO: 213 LYRQLAHQSNSTNIFFSPVSIATAFAMLSL
GTKADTHDEILEGLNFNLTEIPEAQIHEGF
QELLRTLNQPDSQLQLTTGNGLFLSEGLKL
VDKFLEDVKKLYHSEAFTVNFGDTEEAKKQ
INDYVEKGTQGKIVDLVKELDRDTVFALVN
Protein Region Sequence Amino Acid Sequence (N¨ to C¨ Identifier terminal) 123456789012345678901234567890 YIFFKGKWERPFEVKDTEEEDFHVDQVTTV
KVPMMKRLGMFNIQHCKKLSSWVLLMKYLG
NATAIFFLPDEGKLQHLENELTHDIITKFL
ENEDRRSASLHLPKLSITGTYDLKSVLGQL
GITKVFSNGADLSGVTEEAPLKLSKAVHKA
VLTIDEKGTEAAGAMFLEAIPMSIPPEVKF
NKPFVFLMIEQNTKSPLFMGKVVNPTQK
Linker residues 419- GTGSEF
424 of SEQ ID
NO: 213 Erdj3 J domain residues 425- GRDFYKILGVPRSASIKDIKKAYRKLALQL
485 of SEQ ID HPDRNPDDPQAQEKFQDLGAAYEVLSDSEK
NO:213 Linker residues 486- DIAAALE
492 of SEQ ID
NO: 213 V5 epitope residues 493- GKPIPNPLLGLDST
domain 506 of SEQ ID
NO: 213 Linker residues 507- SR
508 of SEQ ID
NO: 213 Fc domain residues 509- PKSCDKTHTCPPCPAPELLGGPSVFLFPPK
739 of SEQ ID PKDTLMISRTPEVTCVVVDVSHEDPEVKFN
NO: 213 WYVDGVEVHNAKTKPREEQYNSTYRVVSVL
TVLHQDWLNGKEYKCKVSNKALPAPIEKTI
SKAKGQPREPQVYTLPPSRDELTKNQVSLT
CLVKGFYPSDIAVEWESNGQPENNYKTTPP
VLDSDGSFFLYSKLTVDKSRWQQGNVFSCS
VMHEALHNHYTQKSLSLSPGK
Each of the Fc fusion proteins (TNFRI-V5-Fc, IL13Ra2TF-Fc, alAT-Fc) were expressed in culture media as shown in the dot blots in the middle lane of each panel in Figure 6B. This level of expression of the Fc fusion proteins was greater than that for each of the proteins of interest alone (i.e., without fusion to an Fc domain; data not shown). However, significantly higher levels of expression were obtained in each case when a J domain was linked to the protein of interest segment within the Fc fusion proteins as shown in the dot blots in the right lane of each panel in Figure 6B.
The results of a densitometry analysis of the chemiluminescent signals of the dot blots in Figure 6B
are shown in the corresponding panels of Figure 6C, where the significantly higher level of expression of the J domain fusion proteins is clearly evident.
Enhanced Expression of p53 Protein in a Modified Arrangement in Human Cells Proteins such as IL13Ra2, TNFR, and alAT are synthesized in the endoplasmic reticulum (ER) for delivery to the cell membrane or secretion from the cell. To determine the effect of the presence of a J domain on the expression of cytoplasmic proteins, the expression of a fusion of the p53 protein and J domain was studied. The p53 protein is a transcription factor that plays pivotal roles in genomic stability. More than half of cancer patients have some abnormalities in the pathway involving p53. Therefore, overexpression of p53 in a cancer patient has been attempted as a treatment for cancer.
A cDNA encoding p53 was inserted into expression plasmid V5(N)-pcDNA' to yield plasmid V5(N)-p53-pcDNA' to express a p53 protein containing an N-terminal V5 epitope tag. To express the p53-J domain fusion protein, a cDNA encoding a J domain of the SV40 large T
antigen was then inserted into the V5(N)-p53-pcDNA' vector between the V5 and p53 coding regions. See, diagrams of constructs in Figure 7A.
The amino acid sequence of a VS-tagged p53 protein is shown in the table below.
Table 24. Amino Acid Sequence of a VS-Tagged p53 Protein.
Protein Region Sequence Amino Acid Sequence (N¨ to C¨ Identifier terminal) p53 protein SEQ
ID NO:214 MGKPIPNPLLGLDSTGTGSEFDIAAAMEEP
QSDPSVEPPLSQETFSDLWKLLPENNVLSP
LPSQAMDDLMLSPDDIEQWFTEDPGPDEAP
RMPEAAPPVAPAPAAPTPAAPAPAPSWPLS
SSVPSQKTYQGSYGFRLGFLHSGTAKSVTC
TYSPALNKMFCQLAKTCPVQLWVDSTPPPG
TRVRAMAIYKQSQHMTEVVRRCPHHERCSD
SDGLAPPQHLIRVEGNLRVEYLDDRNTFRH
SVVVPYEPPEVGSDCTTIHYNYMCNSSCMG
GMNRRPILTIITLEDSSGNLLGRNSFEVRV
CACPGRDRRTEEENLRKKGEPHHELPPGST
KRALPNNTSSSPQPKKKPLDGEYFTLQIRG
RERFEMFRELNEALELKDAQAGKEPGGSRA
HSSHLKSKKGQSTSRHKKLMFKTEGPDSDA
AALESRGPYSIVSPKC
V5 epitope residues 1-15 MGKPIPNPLLGLDST
domain of SEQ ID
NO: 214 Linker residues 16-26 GTGSEFDIAAA
of SEQ ID
NO: 214 p53 residues 27-422 MEEPQSDPSVEPPLSQETFSDLWKLLPENN
of SEQ ID
VLSPLPSQAMDDLMLSPDDIEQWFTEDPGP
NO: 214 DEAPRMPEAAPPVAPAPAAPTPAAPAPAPS
WPLSSSVPSQKTYQGSYGFRLGFLHSGTAK
SVTCTYSPALNKMFCQLAKTCPVQLWVDST
PPPGTRVRAMAIYKQSQHMTEVVRRCPHHE
RCSDSDGLAPPQHLIRVEGNLRVEYLDDRN
TFRHSVVVPYEPPEVGSDCTTIHYNYMCNS
SCMGGMNRRPILTIITLEDSSGNLLGRNSF
EVRVCACPGRDRRTEEENLRKKGEPHHELP
PGSTKRALPNNTSSSPQPKKKPLDGEYFTL
QIRGRERFEMFRELNEALELKDAQAGKEPG
GSRAHSSHLKSKKGQSTSRHKKLMFKTEGP
DS DAAA
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) C-terminal residues 423- LESRGPYSIVSPKC
vector residues 436 of SEQ ID
NO: 214 The amino acid sequence of a J domain fusion protein comprising the V5 epitope tag, the SV40 J domain, and the p53 protein is shown in the table below.
Table 25. Amino Acid Sequence of a V5-Tagged 5V40 J Domain-p53 Fusion Protein.
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) p53-5V40 J SEQ ID NO:215 MGKPIPNPLLGLDSTGTGSEFMDKVLNREE
domain fusion SLQLMDLLGLERSAWGNIPLMRKAYLKKCK
protein EFHPDKGGDEEKMKKMNTLYKKMEDGVKYA
HQPDFGGFWDADIAAAMEEPQSDPSVEPPL
SQETFSDLWKLLPENNVLSPLPSQAMDDLM
LSPDDIEQWFTEDPGPDEAPRMPEAAPPVA
PAPAAPTPAAPAPAPSWPLSSSVPSQKTYQ
GSYGFRLGFLHSGTAKSVTCTYSPALNKMF
CQLAKTCPVQLWVDSTPPPGTRVRAMAIYK
QSQHMTEVVRRCPHHERCSDSDGLAPPQHL
IRVEGNLRVEYLDDRNTFRHSVVVPYEPPE
VGSDCTTIHYNYMCNSSCMGGMNRRPILTI
ITLEDSSGNLLGRNSFEVRVCACPGRDRRT
EEENLRKKGEPHHELPPGSTKRALPNNTSS
SPQPKKKPLDGEYFTLQIRGRERFEMFREL
NEALELKDAQAGKEPGGSRAHSSHLKSKKG
QSTSRHKKLMFKTEGPDSDAAALESRGPYS
IVSPKC
V5 epitope residues 1-15 MGKPIPNPLLGLDST
domain of SEQ ID
NO: 215 Linker residues 16-21 GTGSEF
of SEQ ID
NO: 215 5V40 J domain residues of SEQ ID
RKAYLKKCKEFHPDKGGDEEKMKKMNTLYK
NO: 215 KMEDGVKYAHQPDFGGFWDA
Linker residues 102- DIAAA
106 of SEQ ID
NO: 215 p53 residues 107- MEEPQSDPSVEPPLSQETFSDLWKLLPENN
502 of SEQ ID VLSPLPSQAMDDLMLSPDDIEQWFTEDPGP
NO: 215 DEAPRMPEAAPPVAPAPAAPTPAAPAPAPS
WPLSSSVPSQKTYQGSYGFRLGFLHSGTAK
SVTCTYSPALNKMFCQLAKTCPVQLWVDST
PPPGTRVRAMAIYKQSQHMTEVVRRCPHHE
RCSDSDGLAPPQHLIRVEGNLRVEYLDDRN
TFRHSVVVPYEPPEVGSDCTTIHYNYMCNS
SCMGGMNRRPILTIITLEDSSGNLLGRNSF
Protein Region Sequence Amino Acid Sequence (N¨ to C¨ Identifier terminal) 123456789012345678901234567890 EVRVCACPGRDRRTEEENLRKKGEPHHELP
PGSTKRALPNNTSSSPQPKKKPLDGEYFTL
QIRGRERFEMFRELNEALELKDAQAGKEPG
GSRAHSSHLKSKKGQSTSRHKKLMFKTEGP
DSDAAA
Linker residues 503- LESRGPYSIVSPKC
516 of SEQ ID
NO: 215 Plasmids V5(N)-p53-pcDNA' and V5(N)-J-p53-pcDNA' were transfected into MCF
cells, and incubated for two days. Cells were lysed in lysis buffer, and protein was detected by Western immunoblot assay using anti-V5 antibody. As shown in Figure 7B, the level of expression of the p53-J domain fusion protein (lane 3) was significantly greater than that of the p53 protein without a J
domain. Accordingly, the results indicate that fusion with a J domain can enhance not only membrane-associated and secreted proteins, but cytoplasmic proteins as well.
CFTR Expression in a Modified Arrangement in Human Cells Cystic fibrosis (CF) is an autosomal recessive disorder caused by mutations in the gene encoding the cystic fibrosis transmembrane conductance regulator (CFTR) protein, a cAMP-regulated chloride channel and channel regulator. The deletion of phenylalanine at position 508 (4508F) in CFTR is the most common mutation that changes the conformation of the CFTR
protein, which is then rapidly degraded by the ER quality systems. A general consensus is that only partial recovery of the wild-type CFTR protein function is required to provide a beneficial treatment to CF patients.
Therefore, a number of gene therapy trials with CFTR have been attempted, but have not yet been successful owing to inefficient delivery of a gene for CFTR and to immunogenicity of the vehicle (e.g., viral vector). In view of the fact that proper protein folding of wild-type CFTR is known to be difficult, it would be very useful if protein folding of the CFTR protein could be improved.
The cftr gene or its Phe508 deletion mutant (cfti-4508F) was inserted into plasmid V5(N)-pcDNA'. A DNA coding for the BAG domain of the BAG3 protein or a DNA coding for the J
domain from the Hsp40 J protein was inserted in the plasmids between V5 and the cftr coding sequences to yield plasmids to express a wild-type CFTR or mutant CFTR(4508F) protein linked to an N-terminal V5 epitope tag or to express a wild-type or mutant CFTR protein fused at its N-terminus to a BAG or J domain, which in turn was fused to an N-terminal V5 epitope tag. Diagrams of the various constructs used in this experiment are shown in Figure 8A.
The amino acid sequence a VS-tagged wild-type CFTR (CFTR WT) is shown in the table below.
Table 26. Amino Acid Sequence of a V5-Tagged CFTR Protein.
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) V5-tagged CFTR SEQ ID
NO:216 MGKPIPNPLLGLDSTGTGSEFDIAAAMQRS
protein PLEKASVVSKLFFSWTRPILRKGYRQRLEL
SDIYQIPSVDSADNLSEKLEREWDRELASK
KNPKLINALRRCFFWRFMFYGIFLYLGEVT
KAVQPLLLGRIIASYDPDNKEERSIAIYLG
IGLCLLFIVRTLLLHPAIFGLHHIGMQMRI
AMFSLIYKKTLKLSSRVLDKISIGQLVSLL
SNNLNKFDEGLALAHFVWIAPLQVALLMGL
IWELLQASAFCGLGFLIVLALFQAGLGRMM
MKYRDQRAGKISERLVITSEMIENIQSVKA
YCWEEAMEKMIENLRQTELKLTRKAAYVRY
FNSSAFFFSGFFVVFLSVLPYALIKGIILR
KIFTTISFCIVLRMAVTRQFPWAVQTWYDS
LGAINKIQDFLQKQEYKTLEYNLTTTEVVM
ENVTAFWEEGFGELFEKAKQNNNNRKTSNG
DDSLFFSNFSLLGTPVLKDINFKIERGQLL
AVAGSTGAGKTSLLMVIMGELEPSEGKIKH
SGRISFCSQFSWIMPGTIKENIIFGVSYDE
YRYRSVIKACQLEEDISKFAEKDNIVLGEG
GITLSGGQRARISLARAVYKDADLYLLDSP
FGYLDVLTEKEIFESCVCKLMANKTRILVT
SKMEHLKKADKILILHEGSSYFYGTFSELQ
NLQPDFSSKLMGCDSFDQFSAERRNSILTE
TLHRFSLEGDAPVSWTETKKQSFKQTGEFG
EKRKNSILNPINSIRKFSIVQKTPLQMNGI
EEDSDEPLERRLSLVPDSEQGEAILPRISV
ISTGPTLQARRRQSVLNLMTHSVNQGQNIH
RKTTASTRKVSLAPQANLTELDIYSRRLSQ
ETGLEISEEINEEDLKECFFDDMESIPAVT
TWNTYLRYITVHKSLIFVLIWCLVIFLAEV
AASLVVLWLLGNTPLQDKGNSTHSRNNSYA
VIITSTSSYYVFYIYVGVADTLLAMGFFRG
LPLVHTLITVSKILHHKMLHSVLQAPMSTL
NTLKAGGILNRFSKDIAILDDLLPLTIFDF
IQLLLIVIGAIAVVAVLQPYIFVATVPVIV
AFIMLRAYFLQTSQQLKQLESEGRSPIFTH
LVTSLKGLWTLRAFGRQPYFETLFHKALNL
HTANWFLYLSTLRWFQMRIEMIFVIFFIAV
TFISILTTGEGEGRVGIILTLAMNIMSTLQ
WAVNSSIDVDSLMRSVSRVFKFIDMPTEGK
PTKSTKPYKNGQLSKVMIIENSHVKKDDIW
PSGGQMTVKDLTAKYTEGGNAILENISFSI
SPGQRVGLLGRTGSGKSTLLSAFLRLLNTE
GEIQIDGVSWDSITLQQWRKAFGVIPQKVF
IFSGTFRKNLDPYEQWSDQEIWKVADEVGL
RSVIEQFPGKLDFVLVDGGCVLSHGHKQLM
CLARSVLSKAKILLLDEPSAHLDPVTYQII
RRTLKQAFADCTVILCEHRIEAMLECQQFL
VIEENKVRQYDSIQKLLNERSLFRQAISPS
DRVKLFPHRNSSKCKSKPQIAALKEETEEE
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) VQDTRL
V5 epitope residues 1-15 MGKPIPNPLLGLDST
domain of SEQ ID
NO: 216 Linker residues 16-26 GTGSEFDIAAA
of SEQ ID
NO: 216 CFTR residues 27-MQRSPLEKASVVSKLFFSWTRPILRKGYRQ
1506 of SEQ ID RLELSDIYQIPSVDSADNLSEKLEREWDRE
NO: 216 LASKKNPKLINALRRCFFWRFMFYGIFLYL
GEVTKAVQPLLLGRIIASYDPDNKEERSIA
IYLGIGLCLLFIVRTLLLHPAIFGLHHIGM
QMRIAMFSLIYKKTLKLSSRVLDKISIGQL
VSLLSNNLNKFDEGLALAHFVWIAPLQVAL
LMGLIWELLQASAFCGLGFLIVLALFQAGL
GRMMMKYRDQRAGKISERLVITSEMIENIQ
SVKAYCWEEAMEKMIENLRQTELKLTRKAA
YVRYFNSSAFFFSGFFVVFLSVLPYALIKG
IILRKIFTTISFCIVLRMAVTRQFPWAVQT
WYDSLGAINKIQDFLQKQEYKTLEYNLTTT
EVVMENVTAFWEEGFGELFEKAKQNNNNRK
TSNGDDSLFFSNFSLLGTPVLKDINFKIER
GQLLAVAGSTGAGKTSLLMVIMGELEPSEG
KIKHSGRISFCSQFSWIMPGTIKENIIFGV
SYDEYRYRSVIKACQLEEDISKFAEKDNIV
LGEGGITLSGGQRARISLARAVYKDADLYL
LDSPFGYLDVLTEKEIFESCVCKLMANKTR
ILVTSKMEHLKKADKILILHEGSSYFYGTF
SELQNLQPDFSSKLMGCDSFDQFSAERRNS
ILTETLHRFSLEGDAPVSWTETKKQSFKQT
GEFGEKRKNSILNPINSIRKFSIVQKTPLQ
MNGIEEDSDEPLERRLSLVPDSEQGEAILP
RISVISTGPTLQARRRQSVLNLMTHSVNQG
QNIHRKTTASTRKVSLAPQANLTELDIYSR
RLSQETGLEISEEINEEDLKECFFDDMESI
PAVTTWNTYLRYITVHKSLIFVLIWCLVIF
LAEVAASLVVLWLLGNTPLQDKGNSTHSRN
NSYAVIITSTSSYYVFYIYVGVADTLLAMG
FFRGLPLVHTLITVSKILHHKMLHSVLQAP
MSTLNTLKAGGILNRFSKDIAILDDLLPLT
IFDFIQLLLIVIGAIAVVAVLQPYIFVATV
PVIVAFIMLRAYFLQTSQQLKQLESEGRSP
IFTHLVTSLKGLWTLRAFGRQPYFETLFHK
ALNLHTANWFLYLSTLRWFQMRIEMIFVIF
FIAVTFISILTTGEGEGRVGIILTLAMNIM
STLQWAVNSSIDVDSLMRSVSRVFKFIDMP
TEGKPTKSTKPYKNGQLSKVMIIENSHVKK
DDIWPSGGQMTVKDLTAKYTEGGNAILENI
SFSISPGQRVGLLGRTGSGKSTLLSAFLRL
LNTEGEIQIDGVSWDSITLQQWRKAFGVIP
QKVFIFSGTFRKNLDPYEQWSDQEIWKVAD
EVGLRSVIEQFPGKLDFVLVDGGCVLSHGH
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) 123456789012345678901234567890 KQLMCLARSVLSKAKILLLDEPSAHLDPVT
YQIIRRTLKQAFADCTVILCEHRIEAMLEC
QQFLVIEENKVRQYDSIQKLLNERSLFRQA
ISPSDRVKLFPHRNSSKCKSKPQIAALKEE
TEEEVQDTRL
The amino acid sequence of a V5-tagged BAG-CPTR (wild-type) protein is shown in the table below.
Table 27. Amino Acid Sequence of a V5-Tagged BAG Domain-CFTR Protein.
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) V5-tagged BAG SEQ ID
NO:217 MGKPIPNPLLGLDSTGTGSEFHPGVLKVEA
domain-CFTR
ILEKVQGLEQAVDNFEGKKTDKKYLMIEEY
fusion protein LTKELLALDSVDPEGRADVRQARRDGVRKV
QTILEKLEQKAIDDIAAAMQRSPLEKASVV
SKLFFSWTRPILRKGYRQRLELSDIYQIPS
VDSADNLSEKLEREWDRELASKKNPKLINA
LRRCFFWRFMFYGIFLYLGEVTKAVQPLLL
GRIIASYDPDNKEERSIAIYLGIGLCLLFI
VRTLLLHPAIFGLHHIGMQMRIAMFSLIYK
KTLKLSSRVLDKISIGQLVSLLSNNLNKFD
EGLALAHFVWIAPLQVALLMGLIWELLQAS
AFCGLGFLIVLALFQAGLGRMMMKYRDQRA
GKISERLVITSEMIENIQSVKAYCWEEAME
KMIENLRQTELKLTRKAAYVRYFNSSAFFF
SGFFVVFLSVLPYALIKGIILRKIFTTISF
CIVLRMAVTRQFPWAVQTWYDSLGAINKIQ
DFLQKQEYKTLEYNLTTTEVVMENVTAFWE
EGFGELFEKAKQNNNNRKTSNGDDSLFFSN
FSLLGTPVLKDINFKIERGQLLAVAGSTGA
GKTSLLMVIMGELEPSEGKIKHSGRISFCS
QFSWIMPGTIKENIIFGVSYDEYRYRSVIK
ACQLEEDISKFAEKDNIVLGEGGITLSGGQ
RARISLARAVYKDADLYLLDSPFGYLDVLT
EKEIFESCVCKLMANKTRILVTSKMEHLKK
ADKILILHEGSSYFYGTFSELQNLQPDFSS
KLMGCDSFDQFSAERRNSILTETLHRFSLE
GDAPVSWTETKKQSFKQTGEFGEKRKNSIL
NPINSIRKFSIVQKTPLQMNGIEEDSDEPL
ERRLSLVPDSEQGEAILPRISVISTGPTLQ
ARRRQSVLNLMTHSVNQGQNIHRKTTASTR
KVSLAPQANLTELDIYSRRLSQETGLEISE
EINEEDLKECFFDDMESIPAVTTWNTYLRY
ITVHKSLIFVLIWCLVIFLAEVAASLVVLW
LLGNTPLQDKGNSTHSRNNSYAVIITSTSS
YYVFYIYVGVADTLLAMGFFRGLPLVHTLI
TVSKILHHKMLHSVLQAPMSTLNTLKAGGI
LNRFSKDIAILDDLLPLTIFDFIQLLLIVI
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) GAIAVVAVLQPYIFVATVPVIVAFIMLRAY
FLQTSQQLKQLESEGRSPIFTHLVTSLKGL
WTLRAFGRQPYFETLFHKALNLHTANWFLY
LSTLRWFQMRIEMIFVIFFIAVTFISILTT
GEGEGRVGIILTLAMNIMSTLQWAVNSSID
VDSLMRSVSRVFKFIDMPTEGKPTKSTKPY
KNGQLSKVMIIENSHVKKDDIWPSGGQMTV
KDLTAKYTEGGNAILENISFSISPGQRVGL
LGRTGSGKSTLLSAFLRLLNTEGEIQIDGV
SWDSITLQQWRKAFGVIPQKVFIFSGTFRK
NLDPYEQWSDQEIWKVADEVGLRSVIEQFP
GKLDFVLVDGGCVLSHGHKQLMCLARSVLS
KAKILLLDEPSAHLDPVTYQIIRRTLKQAF
ADCTVILCEHRIEAMLECQQFLVIEENKVR
QYDSIQKLLNERSLFRQAISPSDRVKLFPH
RNSSKCKSKPQIAALKEETEEEVQDTRL
V5 epitope residues 1-15 MGKPIPNPLLGLDST
domain of SEQ ID
NO: 217 Linker residues 16-21 GTGSEF
of SEQ ID
NO: 217 BAG domain residues 22-103 HPGVLKVEAILEKVQGLEQAVDNFEGKKTD
(from BAG3) of SEQ ID
KKYLMIEEYLTKELLALDSVDPEGRADVRQ
NO: 217 ARRDGVRKVQTILEKLEQKAID
Linker residues 104- DIAAA
108 of SEQ ID
NO: 217 CFTR residues 109- MQRSPLEKASVVSKLFFSWTRPILRKGYRQ
1588 of SEQ ID RLELSDIYQIPSVDSADNLSEKLEREWDRE
NO: 217 LASKKNPKLINALRRCFFWRFMFYGIFLYL
GEVTKAVQPLLLGRIIASYDPDNKEERSIA
IYLGIGLCLLFIVRTLLLHPAIFGLHHIGM
QMRIAMFSLIYKKTLKLSSRVLDKISIGQL
VSLLSNNLNKFDEGLALAHFVWIAPLQVAL
LMGLIWELLQASAFCGLGFLIVLALFQAGL
GRMMMKYRDQRAGKISERLVITSEMIENIQ
SVKAYCWEEAMEKMIENLRQTELKLTRKAA
YVRYFNSSAFFFSGFFVVFLSVLPYALIKG
IILRKIFTTISFCIVLRMAVTRQFPWAVQT
WYDSLGAINKIQDFLQKQEYKTLEYNLTTT
EVVMENVTAFWEEGFGELFEKAKQNNNNRK
TSNGDDSLFFSNFSLLGTPVLKDINFKIER
GQLLAVAGSTGAGKTSLLMVIMGELEPSEG
KIKHSGRISFCSQFSWIMPGTIKENIIFGV
SYDEYRYRSVIKACQLEEDISKFAEKDNIV
LGEGGITLSGGQRARISLARAVYKDADLYL
LDSPFGYLDVLTEKEIFESCVCKLMANKTR
ILVTSKMEHLKKADKILILHEGSSYFYGTF
SELQNLQPDFSSKLMGCDSFDQFSAERRNS
ILTETLHRFSLEGDAPVSWTETKKQSFKQT
GEFGEKRKNSILNPINSIRKFSIVQKTPLQ
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) 123456789012345678901234567890 MNGIEEDSDEPLERRLSLVPDSEQGEAILP
RISVISTGPTLQARRRQSVLNLMTHSVNQG
QNIHRKTTASTRKVSLAPQANLTELDIYSR
RLSQETGLEISEEINEEDLKECFFDDMESI
PAVTTWNTYLRYITVHKSLIFVLIWCLVIF
LAEVAASLVVLWLLGNTPLQDKGNSTHSRN
NSYAVIITSTSSYYVFYIYVGVADTLLAMG
FFRGLPLVHTLITVSKILHHKMLHSVLQAP
MSTLNTLKAGGILNRFSKDIAILDDLLPLT
IFDFIQLLLIVIGAIAVVAVLQPYIFVATV
PVIVAFIMLRAYFLQTSQQLKQLESEGRSP
IFTHLVTSLKGLWTLRAFGRQPYFETLFHK
ALNLHTANWFLYLSTLRWFQMRIEMIFVIF
FIAVTFISILTTGEGEGRVGIILTLAMNIM
STLQWAVNSSIDVDSLMRSVSRVFKFIDMP
TEGKPTKSTKPYKNGQLSKVMIIENSHVKK
DDIWPSGGQMTVKDLTAKYTEGGNAILENI
SFSISPGQRVGLLGRTGSGKSTLLSAFLRL
LNTEGEIQIDGVSWDSITLQQWRKAFGVIP
QKVFIFSGTFRKNLDPYEQWSDQEIWKVAD
EVGLRSVIEQFPGKLDFVLVDGGCVLSHGH
KQLMCLARSVLSKAKILLLDEPSAHLDPVT
YQIIRRTLKQAFADCTVILCEHRIEAMLEC
QQFLVIEENKVRQYDSIQKLLNERSLFRQA
ISPSDRVKLFPHRNSSKCKSKPQIAALKEE
TEEEVQDTRL
The amino acid sequences a J domain fusion comprising the V5 epitope tag, the domain, and the CPTR wild-type protein is shown in the table below.
Table 28. Amino Acid Sequence of a V5-Tagged 5V40 J Domain-CFTR Protein.
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) V5-tagged SV40 J SEQ ID
NO:218 MGKPIPNPLLGLDSTGTGSEFMDKVLNREE
domain-CFTR
SLQLMDLLGLERSAWGNIPLMRKAYLKKCK
fusion protein EFHPDKGGDEEKMKKMNTLYKKMEDGVKYA
HQPDFGGFWDADIAAAMQRSPLEKASVVSK
LFFSWTRPILRKGYRQRLELSDIYQIPSVD
SADNLSEKLEREWDRELASKKNPKLINALR
RCFFWRFMFYGIFLYLGEVTKAVQPLLLGR
IIASYDPDNKEERSIAIYLGIGLCLLFIVR
TLLLHPAIFGLHHIGMQMRIAMFSLIYKKT
LKLSSRVLDKISIGQLVSLLSNNLNKFDEG
LALAHFVWIAPLQVALLMGLIWELLQASAF
CGLGFLIVLALFQAGLGRMMMKYRDQRAGK
ISERLVITSEMIENIQSVKAYCWEEAMEKM
IENLRQTELKLTRKAAYVRYFNSSAFFFSG
FFVVFLSVLPYALIKGIILRKIFTTISFCI
VLRMAVTRQFPWAVQTWYDSLGAINKIQDF
LQKQEYKTLEYNLTTTEVVMENVTAFWEEG
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) FGELFEKAKQNNNNRKTSNGDDSLFFSNFS
LLGTPVLKDINFKIERGQLLAVAGSTGAGK
TSLLMVIMGELEPSEGKIKHSGRISFCSQF
SWIMPGTIKENIIFGVSYDEYRYRSVIKAC
QLEEDISKFAEKDNIVLGEGGITLSGGQRA
RISLARAVYKDADLYLLDSPFGYLDVLTEK
EIFESCVCKLMANKTRILVTSKMEHLKKAD
KILILHEGSSYFYGTFSELQNLQPDFSSKL
MGCDSFDQFSAERRNSILTETLHRFSLEGD
APVSWTETKKQSFKQTGEFGEKRKNSILNP
INSIRKFSIVQKTPLQMNGIEEDSDEPLER
RLSLVPDSEQGEAILPRISVISTGPTLQAR
RRQSVLNLMTHSVNQGQNIHRKTTASTRKV
SLAPQANLTELDIYSRRLSQETGLEISEEI
NEEDLKECFFDDMESIPAVTTWNTYLRYIT
VHKSLIFVLIWCLVIFLAEVAASLVVLWLL
GNTPLQDKGNSTHSRNNSYAVIITSTSSYY
VFYIYVGVADTLLAMGFFRGLPLVHTLITV
SKILHHKMLHSVLQAPMSTLNTLKAGGILN
RFSKDIAILDDLLPLTIFDFIQLLLIVIGA
IAVVAVLQPYIFVATVPVIVAFIMLRAYFL
QTSQQLKQLESEGRSPIFTHLVTSLKGLWT
LRAFGRQPYFETLFHKALNLHTANWFLYLS
TLRWFQMRIEMIFVIFFIAVTFISILTTGE
GEGRVGIILTLAMNIMSTLQWAVNSSIDVD
SLMRSVSRVFKFIDMPTEGKPTKSTKPYKN
GQLSKVMIIENSHVKKDDIWPSGGQMTVKD
LTAKYTEGGNAILENISFSISPGQRVGLLG
RTGSGKSTLLSAFLRLLNTEGEIQIDGVSW
DSITLQQWRKAFGVIPQKVFIFSGTFRKNL
DPYEQWSDQEIWKVADEVGLRSVIEQFPGK
LDFVLVDGGCVLSHGHKQLMCLARSVLSKA
KILLLDEPSAHLDPVTYQIIRRTLKQAFAD
CTVILCEHRIEAMLECQQFLVIEENKVRQY
DSIQKLLNERSLFRQAISPSDRVKLFPHRN
SSKCKSKPQIAALKEETEEEVQDTRL
V5 epitope residues 1-15 MGKPIPNPLLGLDST
domain of SEQ ID
NO: 218 Linker residues 16-21 GTGSEF
of SEQ ID
NO: 218 5V40 J domain residues of SEQ ID
RKAYLKKCKEFHPDKGGDEEKMKKMNTLYK
NO: 218 KMEDGVKYAHQPDFGGFWDA
Linker residues 102- DIAAA
106 of SEQ ID
NO: 218 CFTR residues 107- MQRSPLEKASVVSKLFFSWTRPILRKGYRQ
1586 of SEQ ID RLELSDIYQIPSVDSADNLSEKLEREWDRE
NO: 218 LASKKNPKLINALRRCFFWRFMFYGIFLYL
GEVTKAVQPLLLGRIIASYDPDNKEERSIA
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) IYLGIGLCLLF IVRTLLLHPAIFGLHHI GM
QMRIAMFSL I YKKTLKLS SRVLDKI S I GQL
VS LL SNNLNKFDEGLALAHFVWIAPLQVAL
LMGL IWELLQASAFCGLGFL IVLALFQAGL
GRMMMKYRDQRAGKI SERLVI T SEMIEN I Q
SVKAYCWEEAMEKMIENLRQTELKLTRKAA
YVRYFNSSAFFFSGFFVVFLSVLPYAL I KG
II LRKIFTT I SFCIVLRMAVTRQFPWAVQT
WYDSLGAINKIQDFLQKQEYKTLEYNLTTT
EVVMENVTAFWEEGFGELFEKAKQNNNNRK
TSNGDDSLFFSNFSLLGTPVLKDINFKIER
GQLLAVAGS TGAGKT SLLMVIMGELEP SEG
KIKHSGRI SFCSQFSWIMPGT IKENI IFGV
SYDEYRYRSVIKACQLEED I SKFAEKDNIV
LGEGGITLSGGQRARISLARAVYKDADLYL
LDSPFGYLDVLTEKEIFESCVCKLMANKTR
ILVT SKMEHLKKADKI L I LHEGS SYFYGTF
SELQNLQPDFSSKLMGCDSFDQFSAERRNS
IL TETLHRF SLEGDAPVSWTETKKQSFKQT
GEFGEKRKNS I LNP INS IRKF S IVQKTPLQ
MNGIEEDSDEPLERRL SLVPDSEQGEAI LP
RI SVI STGPTLQARRRQSVLNLMTHSVNQG
QNIHRKTTASTRKVSLAPQANLTELDIYSR
RL SQETGLE I SEE INEEDLKECFFDDMES I
PAVTTWNTYLRY I TVHKS L I FVL IWCLVIF
LAEVAASLVVLWLLGNTPLQDKGNSTHSRN
NSYAVI ITSTSSYYVFYIYVGVADTLLAMG
FFRGLPLVHTL I TVSKILHHKMLHSVLQAP
MS TLNTLKAGGI LNRF SKD IAI LDDLLPL T
IFDF IQLLL IVIGAIAVVAVLQPYIFVATV
PVIVAF IMLRAYFLQTSQQLKQLESEGRSP
IFTHLVTSLKGLWTLRAFGRQPYFETLFHK
ALNLHTANWFLYLSTLRWFQMRIEMIFVIF
FIAVTFISILTTGEGEGRVGIILTLAMNIM
STLQWAVNSS I DVD S LMRSVSRVFKF I DMP
TEGKPTKSTKPYKNGQLSKVMI IENSHVKK
DDIWPSGGQMTVKDLTAKYTEGGNAILENI
SFS I SPGQRVGLLGRTGSGKSTLLSAFLRL
LNTEGE IQ I DGVSWDS I TLQQWRKAFGVIP
QKVF IF SGTFRKNLDPYEQWSDQE IWKVAD
EVGLRSVIEQFPGKLDFVLVDGGCVLSHGH
KQLMCLARSVLSKAKILLLDEPSAHLDPVT
YQ I IRRTLKQAFADCTVILCEHRIEAMLEC
QQFLVIEENKVRQYDS IQKLLNERSLFRQA
I SP SDRVKLFPHRNS SKCKSKPQ IAALKEE
TEEEVQDTRL
The amino acid sequence of a V5-tagged CFTR(4508F) protein is shown in the table below.
Table 29. Amino Acid Sequence of a V5-Tagged CFTR(4508F) Protein.
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) V5-tagged SEQ ID
NO:219 MGKPIPNPLLGLDSTGTGSEFDIAAAMQRS
CFTR(4508F) PLEKASVVSKLFFSWTRPILRKGYRQRLEL
protein SDIYQIPSVDSADNLSEKLEREWDRELASK
KNPKLINALRRCFFWRFMFYGIFLYLGEVT
KAVQPLLLGRIIASYDPDNKEERSIAIYLG
IGLCLLFIVRTLLLHPAIFGLHHIGMQMRI
AMFSLIYKKTLKLSSRVLDKISIGQLVSLL
SNNLNKFDEGLALAHFVWIAPLQVALLMGL
IWELLQASAFCGLGFLIVLALFQAGLGRMM
MKYRDQRAGKISERLVITSEMIENIQSVKA
YCWEEAMEKMIENLRQTELKLTRKAAYVRY
FNSSAFFFSGFFVVFLSVLPYALIKGIILR
KIFTTISFCIVLRMAVTRQFPWAVQTWYDS
LGAINKIQDFLQKQEYKTLEYNLTTTEVVM
ENVTAFWEEGFGELFEKAKQNNNNRKTSNG
DDSLFFSNFSLLGTPVLKDINFKIERGQLL
AVAGSTGAGKTSLLMVIMGELEPSEGKIKH
SGRISFCSQFSWIMPGTIKENIIGVSYDEY
RYRSVIKACQLEEDISKFAEKDNIVLGEGG
ITLSGGQRARISLARAVYKDADLYLLDSPF
GYLDVLTEKEIFESCVCKLMANKTRILVTS
KMEHLKKADKILILHEGSSYFYGTFSELQN
LQPDFSSKLMGCDSFDQFSAERRNSILTET
LHRFSLEGDAPVSWTETKKQSFKQTGEFGE
KRKNSILNPINSIRKFSIVQKTPLQMNGIE
EDSDEPLERRLSLVPDSEQGEAILPRISVI
STGPTLQARRRQSVLNLMTHSVNQGQNIHR
KTTASTRKVSLAPQANLTELDIYSRRLSQE
TGLEISEEINEEDLKECFFDDMESIPAVTT
WNTYLRYITVHKSLIFVLIWCLVIFLAEVA
ASLVVLWLLGNTPLQDKGNSTHSRNNSYAV
IITSTSSYYVFYIYVGVADTLLAMGFFRGL
PLVHTLITVSKILHHKMLHSVLQAPMSTLN
TLKAGGILNRFSKDIAILDDLLPLTIFDFI
QLLLIVIGAIAVVAVLQPYIFVATVPVIVA
FIMLRAYFLQTSQQLKQLESEGRSPIFTHL
VTSLKGLWTLRAFGRQPYFETLFHKALNLH
TANWFLYLSTLRWFQMRIEMIFVIFFIAVT
FISILTTGEGEGRVGIILTLAMNIMSTLQW
AVNSSIDVDSLMRSVSRVFKFIDMPTEGKP
TKSTKPYKNGQLSKVMIIENSHVKKDDIWP
SGGQMTVKDLTAKYTEGGNAILENISFSIS
PGQRVGLLGRTGSGKSTLLSAFLRLLNTEG
EIQIDGVSWDSITLQQWRKAFGVIPQKVFI
FSGTFRKNLDPYEQWSDQEIWKVADEVGLR
SVIEQFPGKLDFVLVDGGCVLSHGHKQLMC
LARSVLSKAKILLLDEPSAHLDPVTYQIIR
RTLKQAFADCTVILCEHRIEAMLECQQFLV
IEENKVRQYDSIQKLLNERSLFRQAISPSD
RVKLFPHRNSSKCKSKPQIAALKEETEEEV
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) QDTRL
V5 epitope residues 1-15 MGKPIPNPLLGLDST
domain of SEQ ID
NO: 219 Linker residues 16-26 GTGSEFDIAAA
of SEQ ID
NO: 219 CFTR(4508F) residues 27-MQRSPLEKASVVSKLFFSWTRPILRKGYRQ
1505 of SEQ ID RLELSDIYQIPSVDSADNLSEKLEREWDRE
NO: 219 LASKKNPKLINALRRCFFWRFMFYGIFLYL
GEVTKAVQPLLLGRIIASYDPDNKEERSIA
IYLGIGLCLLFIVRTLLLHPAIFGLHHIGM
QMRIAMFSLIYKKTLKLSSRVLDKISIGQL
VSLLSNNLNKFDEGLALAHFVWIAPLQVAL
LMGLIWELLQASAFCGLGFLIVLALFQAGL
GRMMMKYRDQRAGKISERLVITSEMIENIQ
SVKAYCWEEAMEKMIENLRQTELKLTRKAA
YVRYFNSSAFFFSGFFVVFLSVLPYALIKG
IILRKIFTTISFCIVLRMAVTRQFPWAVQT
WYDSLGAINKIQDFLQKQEYKTLEYNLTTT
EVVMENVTAFWEEGFGELFEKAKQNNNNRK
TSNGDDSLFFSNFSLLGTPVLKDINFKIER
GQLLAVAGSTGAGKTSLLMVIMGELEPSEG
KIKHSGRISFCSQFSWIMPGTIKENIIGVS
YDEYRYRSVIKACQLEEDISKFAEKDNIVL
GEGGITLSGGQRARISLARAVYKDADLYLL
DSPFGYLDVLTEKEIFESCVCKLMANKTRI
LVTSKMEHLKKADKILILHEGSSYFYGTFS
ELQNLQPDFSSKLMGCDSFDQFSAERRNSI
LTETLHRFSLEGDAPVSWTETKKQSFKQTG
EFGEKRKNSILNPINSIRKFSIVQKTPLQM
NGIEEDSDEPLERRLSLVPDSEQGEAILPR
ISVISTGPTLQARRRQSVLNLMTHSVNQGQ
NIHRKTTASTRKVSLAPQANLTELDIYSRR
LSQETGLEISEEINEEDLKECFFDDMESIP
AVTTWNTYLRYITVHKSLIFVLIWCLVIFL
AEVAASLVVLWLLGNTPLQDKGNSTHSRNN
SYAVIITSTSSYYVFYIYVGVADTLLAMGF
FRGLPLVHTLITVSKILHHKMLHSVLQAPM
STLNTLKAGGILNRFSKDIAILDDLLPLTI
FDFIQLLLIVIGAIAVVAVLQPYIFVATVP
VIVAFIMLRAYFLQTSQQLKQLESEGRSPI
FTHLVTSLKGLWTLRAFGRQPYFETLFHKA
LNLHTANWFLYLSTLRWFQMRIEMIFVIFF
IAVTFISILTTGEGEGRVGIILTLAMNIMS
TLQWAVNSSIDVDSLMRSVSRVFKFIDMPT
EGKPTKSTKPYKNGQLSKVMIIENSHVKKD
DIWPSGGQMTVKDLTAKYTEGGNAILENIS
FSISPGQRVGLLGRTGSGKSTLLSAFLRLL
NTEGEIQIDGVSWDSITLQQWRKAFGVIPQ
KVFIFSGTFRKNLDPYEQWSDQEIWKVADE
VGLRSVIEQFPGKLDFVLVDGGCVLSHGHK
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) QLMCLARSVLSKAKILLLDEPSAHLDPVTY
QIIRRTLKQAFADCTVILCEHRIEAMLECQ
QFLVIEENKVRQYDSIQKLLNERSLFRQAI
SPSDRVKLFPHRNSSKCKSKPQIAALKEET
EEEVQDTRL
The amino acid sequence of a V5-tagged BAG domain-CPTR(4508F) fusion protein is shown in the table below.
Table 30. Amino Acid Sequence of a V5-Tagged BAG Domain-CFTR(4508F) Fusion Protein.
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) V5-tagged BAG SEQ ID
NO:220 MGKPIPNPLLGLDSTGTGSEFHPGVLKVEA
domain-ILEKVQGLEQAVDNFEGKKTDKKYLMIEEY
CFTR(4508F) LTKELLALDSVDPEGRADVRQARRDGVRKV
fusion protein QTILEKLEQKAIDDIAAAMQRSPLEKASVV
SKLFFSWTRPILRKGYRQRLELSDIYQIPS
VDSADNLSEKLEREWDRELASKKNPKLINA
LRRCFFWRFMFYGIFLYLGEVTKAVQPLLL
GRIIASYDPDNKEERSIAIYLGIGLCLLFI
VRTLLLHPAIFGLHHIGMQMRIAMFSLIYK
KTLKLSSRVLDKISIGQLVSLLSNNLNKFD
EGLALAHFVWIAPLQVALLMGLIWELLQAS
AFCGLGFLIVLALFQAGLGRMMMKYRDQRA
GKISERLVITSEMIENIQSVKAYCWEEAME
KMIENLRQTELKLTRKAAYVRYFNSSAFFF
SGFFVVFLSVLPYALIKGIILRKIFTTISF
CIVLRMAVTRQFPWAVQTWYDSLGAINKIQ
DFLQKQEYKTLEYNLTTTEVVMENVTAFWE
EGFGELFEKAKQNNNNRKTSNGDDSLFFSN
FSLLGTPVLKDINFKIERGQLLAVAGSTGA
GKTSLLMVIMGELEPSEGKIKHSGRISFCS
QFSWIMPGTIKENIIGVSYDEYRYRSVIKA
CQLEEDISKFAEKDNIVLGEGGITLSGGQR
ARISLARAVYKDADLYLLDSPFGYLDVLTE
KEIFESCVCKLMANKTRILVTSKMEHLKKA
DKILILHEGSSYFYGTFSELQNLQPDFSSK
LMGCDSFDQFSAERRNSILTETLHRFSLEG
DAPVSWTETKKQSFKQTGEFGEKRKNSILN
PINSIRKFSIVQKTPLQMNGIEEDSDEPLE
RRLSLVPDSEQGEAILPRISVISTGPTLQA
RRRQSVLNLMTHSVNQGQNIHRKTTASTRK
VSLAPQANLTELDIYSRRLSQETGLEISEE
INEEDLKECFFDDMESIPAVTTWNTYLRYI
TVHKSLIFVLIWCLVIFLAEVAASLVVLWL
LGNTPLQDKGNSTHSRNNSYAVIITSTSSY
YVFYIYVGVADTLLAMGFFRGLPLVHTLIT
VSKILHHKMLHSVLQAPMSTLNTLKAGGIL
NRFSKDIAILDDLLPLTIFDFIQLLLIVIG
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) 123456789012345678901234567890 AIAVVAVLQPYIFVATVPVIVAFIMLRAYF
LQTSQQLKQLESEGRSPIFTHLVTSLKGLW
TLRAFGRQPYFETLFHKALNLHTANWFLYL
STLRWFQMRIEMIFVIFFIAVTFISILTTG
EGEGRVGIILTLAMNIMSTLQWAVNSSIDV
DSLMRSVSRVFKFIDMPTEGKPTKSTKPYK
NGQLSKVMIIENSHVKKDDIWPSGGQMTVK
DLTAKYTEGGNAILENISFSISPGQRVGLL
GRTGSGKSTLLSAFLRLLNTEGEIQIDGVS
WDSITLQQWRKAFGVIPQKVFIFSGTFRKN
LDPYEQWSDQEIWKVADEVGLRSVIEQFPG
KLDFVLVDGGCVLSHGHKQLMCLARSVLSK
AKILLLDEPSAHLDPVTYQIIRRTLKQAFA
DCTVILCEHRIEAMLECQQFLVIEENKVRQ
YDSIQKLLNERSLFRQAISPSDRVKLFPHR
NSSKCKSKPQIAALKEETEEEVQDTRL
V5 epitope residues 1-15 MGKPIPNPLLGLDST
domain of SEQ ID
NO:220 Linker residues 16-21 GTGSEF
of SEQ ID
NO:220 BAG domain residues (from BAG3) of SEQ ID
KKYLMIEEYLTKELLALDSVDPEGRADVRQ
NO: 220 ARRDGVRKVQTILEKLEQKAID
Linker residues 104- DIAAA
108 of SEQ ID
NO:220 CFTR(4508F) residues 109- MQRSPLEKASVVSKLFFSWTRPILRKGYRQ
1587 of SEQ ID RLELSDIYQIPSVDSADNLSEKLEREWDRE
NO: 220 LASKKNPKLINALRRCFFWRFMFYGIFLYL
GEVTKAVQPLLLGRIIASYDPDNKEERSIA
IYLGIGLCLLFIVRTLLLHPAIFGLHHIGM
QMRIAMFSLIYKKTLKLSSRVLDKISIGQL
VSLLSNNLNKFDEGLALAHFVWIAPLQVAL
LMGLIWELLQASAFCGLGFLIVLALFQAGL
GRMMMKYRDQRAGKISERLVITSEMIENIQ
SVKAYCWEEAMEKMIENLRQTELKLTRKAA
YVRYFNSSAFFFSGFFVVFLSVLPYALIKG
IILRKIFTTISFCIVLRMAVTRQFPWAVQT
WYDSLGAINKIQDFLQKQEYKTLEYNLTTT
EVVMENVTAFWEEGFGELFEKAKQNNNNRK
TSNGDDSLFFSNFSLLGTPVLKDINFKIER
GQLLAVAGSTGAGKTSLLMVIMGELEPSEG
KIKHSGRISFCSQFSWIMPGTIKENIIGVS
YDEYRYRSVIKACQLEEDISKFAEKDNIVL
GEGGITLSGGQRARISLARAVYKDADLYLL
DSPFGYLDVLTEKEIFESCVCKLMANKTRI
LVTSKMEHLKKADKILILHEGSSYFYGTFS
ELQNLQPDFSSKLMGCDSFDQFSAERRNSI
LTETLHRFSLEGDAPVSWTETKKQSFKQTG
EFGEKRKNSILNPINSIRKFSIVQKTPLQM
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) NGIEEDSDEPLERRLSLVPDSEQGEAILPR
ISVISTGPTLQARRRQSVLNLMTHSVNQGQ
NIHRKTTASTRKVSLAPQANLTELDIYSRR
LSQETGLEISEEINEEDLKECFFDDMESIP
AVTTWNTYLRYITVHKSLIFVLIWCLVIFL
AEVAASLVVLWLLGNTPLQDKGNSTHSRNN
SYAVIITSTSSYYVFYIYVGVADTLLAMGF
FRGLPLVHTLITVSKILHHKMLHSVLQAPM
STLNTLKAGGILNRFSKDIAILDDLLPLTI
FDFIQLLLIVIGAIAVVAVLQPYIFVATVP
VIVAFIMLRAYFLQTSQQLKQLESEGRSPI
FTHLVTSLKGLWTLRAFGRQPYFETLFHKA
LNLHTANWFLYLSTLRWFQMRIEMIFVIFF
IAVTFISILTTGEGEGRVGIILTLAMNIMS
TLQWAVNSSIDVDSLMRSVSRVFKFIDMPT
EGKPTKSTKPYKNGQLSKVMIIENSHVKKD
DIWPSGGQMTVKDLTAKYTEGGNAILENIS
FSISPGQRVGLLGRTGSGKSTLLSAFLRLL
NTEGEIQIDGVSWDSITLQQWRKAFGVIPQ
KVFIFSGTFRKNLDPYEQWSDQEIWKVADE
VGLRSVIEQFPGKLDFVLVDGGCVLSHGHK
QLMCLARSVLSKAKILLLDEPSAHLDPVTY
QIIRRTLKQAFADCTVILCEHRIEAMLECQ
QFLVIEENKVRQYDSIQKLLNERSLFRQAI
SPSDRVKLFPHRNSSKCKSKPQIAALKEET
EEEVQDTRL
The amino acid of a V5-tagged J domain-CFTR(4508F) fusion protein is shown in the table below.
Table 31. Amino Acid Sequence of a V5-Tagged 5V40 J Domain-CFTR(4508F) Fusion Protein.
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) V5-tagged, SV40 SEQ ID
NO:221 MGKPIPNPLLGLDSTGTGSEFMDKVLNREE
J domain-SLQLMDLLGLERSAWGNIPLMRKAYLKKCK
CFTR(4508F) EFHPDKGGDEEKMKKMNTLYKKMEDGVKYA
fusion protein HQPDFGGFWDADIAAAMQRSPLEKASVVSK
LFFSWTRPILRKGYRQRLELSDIYQIPSVD
SADNLSEKLEREWDRELASKKNPKLINALR
RCFFWRFMFYGIFLYLGEVTKAVQPLLLGR
IIASYDPDNKEERSIAIYLGIGLCLLFIVR
TLLLHPAIFGLHHIGMQMRIAMFSLIYKKT
LKLSSRVLDKISIGQLVSLLSNNLNKFDEG
LALAHFVWIAPLQVALLMGLIWELLQASAF
CGLGFLIVLALFQAGLGRMMMKYRDQRAGK
ISERLVITSEMIENIQSVKAYCWEEAMEKM
IENLRQTELKLTRKAAYVRYFNSSAFFFSG
FFVVFLSVLPYALIKGIILRKIFTTISFCI
VLRMAVTRQFPWAVQTWYDSLGAINKIQDF
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) LQKQEYKTLEYNLTTTEVVMENVTAFWEEG
FGELFEKAKQNNNNRKTSNGDDSLFFSNFS
LLGTPVLKDINFKIERGQLLAVAGSTGAGK
TSLLMVIMGELEPSEGKIKHSGRISFCSQF
SWIMPGTIKENIIGVSYDEYRYRSVIKACQ
LEEDISKFAEKDNIVLGEGGITLSGGQRAR
ISLARAVYKDADLYLLDSPFGYLDVLTEKE
IFESCVCKLMANKTRILVTSKMEHLKKADK
ILILHEGSSYFYGTFSELQNLQPDFSSKLM
GCDSFDQFSAERRNSILTETLHRFSLEGDA
PVSWTETKKQSFKQTGEFGEKRKNSILNPI
NSIRKFSIVQKTPLQMNGIEEDSDEPLERR
LSLVPDSEQGEAILPRISVISTGPTLQARR
RQSVLNLMTHSVNQGQNIHRKTTASTRKVS
LAPQANLTELDIYSRRLSQETGLEISEEIN
EEDLKECFFDDMESIPAVTTWNTYLRYITV
HKSLIFVLIWCLVIFLAEVAASLVVLWLLG
NTPLQDKGNSTHSRNNSYAVIITSTSSYYV
FYIYVGVADTLLAMGFFRGLPLVHTLITVS
KILHHKMLHSVLQAPMSTLNTLKAGGILNR
FSKDIAILDDLLPLTIFDFIQLLLIVIGAI
AVVAVLQPYIFVATVPVIVAFIMLRAYFLQ
TSQQLKQLESEGRSPIFTHLVTSLKGLWTL
RAFGRQPYFETLFHKALNLHTANWFLYLST
LRWFQMRIEMIFVIFFIAVTFISILTTGEG
EGRVGIILTLAMNIMSTLQWAVNSSIDVDS
LMRSVSRVFKFIDMPTEGKPTKSTKPYKNG
QLSKVMIIENSHVKKDDIWPSGGQMTVKDL
TAKYTEGGNAILENISFSISPGQRVGLLGR
TGSGKSTLLSAFLRLLNTEGEIQIDGVSWD
SITLQQWRKAFGVIPQKVFIFSGTFRKNLD
PYEQWSDQEIWKVADEVGLRSVIEQFPGKL
DFVLVDGGCVLSHGHKQLMCLARSVLSKAK
ILLLDEPSAHLDPVTYQIIRRTLKQAFADC
TVILCEHRIEAMLECQQFLVIEENKVRQYD
SIQKLLNERSLFRQAISPSDRVKLFPHRNS
SKCKSKPQIAALKEETEEEVQDTRL
V5 epitope residues 1-15 MGKPIPNPLLGLDST
domain of SEQ ID
NO:221 Linker residues 16-21 GTGSEF
of SEQ ID
NO:221 5V40 J domain residues of SEQ ID
RKAYLKKCKEFHPDKGGDEEKMKKMNTLYK
NO: 221 KMEDGVKYAHQPDFGGFWDA
Linker residues 102- DIAAA
106 of SEQ ID
NO:221 CFTR(4508F) residues 107- MQRSPLEKASVVSKLFFSWTRPILRKGYRQ
1585 of SEQ ID RLELSDIYQIPSVDSADNLSEKLEREWDRE
NO: 221 LASKKNPKLINALRRCFFWRFMFYGIFLYL
Protein Region Sequence Amino Acid Sequence (N¨ to C¨ Identifier terminal) GEVTKAVQPLLLGRI IASYDPDNKEERS IA
IYLGIGLCLLF IVRTLLLHPAIFGLHHI GM
QMRIAMFSL I YKKTLKLS SRVLDKI S I GQL
VS LL SNNLNKFDEGLALAHFVWIAPLQVAL
LMGL IWELLQASAFCGLGFL IVLALFQAGL
GRMMMKYRDQRAGKI SERLVI T SEMIEN I Q
SVKAYCWEEAMEKMIENLRQTELKLTRKAA
YVRYFNSSAFFFSGFFVVFLSVLPYAL I KG
II LRKIFTT I SFCIVLRMAVTRQFPWAVQT
WYDSLGAINKIQDFLQKQEYKTLEYNLTTT
EVVMENVTAFWEEGFGELFEKAKQNNNNRK
TSNGDDSLFFSNFSLLGTPVLKDINFKIER
GQLLAVAGS TGAGKT SLLMVIMGELEP SEG
KIKHSGRI SFCSQFSWIMPGT IKENI I GVS
YDEYRYRSVI KACQLEED I SKFAEKDNIVL
GEGGITLSGGQRARI SLARAVYKDADLYLL
DSPFGYLDVLTEKEIFESCVCKLMANKTRI
LVTSKMEHLKKADKIL ILHEGSSYFYGTFS
ELQNLQPDFSSKLMGCDSFDQFSAERRNS I
LTETLHRFSLEGDAPVSWTETKKQSFKQTG
EFGEKRKNS I LNP INS IRKFS IVQKTPLQM
NGIEEDSDEPLERRLSLVPDSEQGEAILPR
I SVI STGPTLQARRRQSVLNLMTHSVNQGQ
NIHRKTTASTRKVSLAPQANLTELDIYSRR
LSQETGLE I SEE INEEDLKECFFDDMES IP
AVTTWNTYLRY I TVHKSL IFVL IWCLVIFL
AEVAASLVVLWLLGNTPLQDKGNSTHSRNN
SYAVI I TS T S SYYVFY IYVGVADTLLAMGF
FRGLPLVHTL I TVSKI LHHKMLHSVLQAPM
STLNTLKAGGILNRFSKDIAILDDLLPLT I
FDF IQLLL IVIGAIAVVAVLQPYIFVATVP
VIVAF IMLRAYFLQTSQQLKQLESEGRSP I
FTHLVTSLKGLWTLRAFGRQPYFETLFHKA
LNLHTANWFLYLSTLRWFQMRIEMIFVIFF
IAVTF ISILTTGEGEGRVGI I L TLAMNIMS
TLQWAVNSS I DVD S LMRSVSRVFKF I DMPT
EGKPTKSTKPYKNGQLSKVMI IENSHVKKD
DIWPSGGQMTVKDLTAKYTEGGNAILENI S
FS I SPGQRVGLLGRTGSGKSTLLSAFLRLL
NTEGEIQIDGVSWDS I TLQQWRKAFGVIPQ
KVF IF SGTFRKNLDPYEQWSDQE IWKVADE
VGLRSVIEQFPGKLDFVLVDGGCVLSHGHK
QLMCLARSVLSKAKILLLDEPSAHLDPVTY
QI IRRTLKQAFADCTVILCEHRIEAMLECQ
QFLVIEENKVRQYDS I QKLLNERS LFRQAI
SP SDRVKLFPHRNS SKCKSKPQ IAALKEET
EEEVQDTRL
To study the expression of the various CFTR protein constructs, the plasmids were transfected to HEK293 cells. Samples of cell lysates from two-day cultures of transfected cells were analyzed by immunoblotting with anti-V5 antibody. As shown in Figure 8B, neither the wild-type CFIR protein nor the mutant CFTR(4508F) protein expressed well in transfected cells. Fusion of either protein with a BAG3 domain (BAG-CFIR WT, BAG-CFTR 4508F) provided some enhancement of expression. In contrast, fusion with a J domain significantly enhanced the level of expression of both wild-type and mutant proteins (J-CFTR WT, 4508F). See, Figure 8B
Conclusion of Results The results of the above experiments clearly show that fusion with a J domain significantly enhances the level of expression of a protein of interest, including therapeutically useful proteins.
Example 3. Compositions and Methods for Enhancing Expression of Target Proteins of Interest Using an Unmodified Arrangement Expression vector plasmids were constructed for expressing fusion proteins for enhancing expression of specific proteins (target proteins). As described below, fusion proteins were usually linked to a standard epitope tag for easy identification or isolation using a corresponding anti-tag antibody and standard immunoblot (such as dot blot, Western blot) assays.
A DNA linker molecule having a nucleotide sequence containing various restriction enzyme sites for cloning heterologous DNA molecules was produced by annealing two single-stranded DNA
molecules having the sequences shown below (5' to 3'):
AGCTTGGTACCGGATCCGAATTCGATATCGCGGCCGCTCTCGAGTCTAGAGGGCC (SEQ
ID NO:187) and CTCTAGACTCGAGAGCGGCCGCGATATCGAATTCGGATCCGGTACCA (SEQ ID NO:188).
The annealed linker molecule was then inserted into plasmid pcDNA3 (catalogue no. V790-20, Invitrogen) digested with HindIII and ApaI downstream of a CMV promoter to yield the expression vector plasmid pcDNA' for use in mammalian host cells.
DNA molecules encoding the V5 epitope tag (GKPIPNPLLGLDST; SEQ ID NO:110) or the Flag epitope tag (DYKDDDDK; SEQ ID NO:111) were synthesized and inserted into plasmid pcDNA' digested with HindIII and KpnI. A double-stranded DNA molecule having the coding sequence for the V5 epitope tag with an N-terminal methionine, i.e., ATGGGTAAGCCTATCCCTAACCCTCTCCTCGGTCTCGATTCTACG (SEQ ID NO:189), was inserted into pcDNA' digested with XhoI and XbaI to yield plasmid V5-pcDNA'.
A DNA molecule having the coding sequence for the Flag epitope tag, i.e., GATTACAAGGATGACGATGACAAG (SEQ ID NO:190), was inserted into plasmid pcDNA' digested with XhoI and XbaI to yield plasmid Flag-pcDNA'.
To express IL13Ra2 receptor protein, a DNA molecule encoding an IL13Ra2 receptor protein was inserted into plasmid V5-pcDNA' digested with HindIII and KpnI.
To express TNR1 receptor protein, a DNA molecule encoding a TNRI receptor protein was inserted into plasmid V5-pcDNA' digested with HindIII and KpnI.
To express al anti-trypsin ("alAT"), a DNA molecule encoding an al anti-trypsin was inserted into plasmid V5-pcDNA' digested with HindIII and KpnI.
A DNA molecule encoding an Fc region polypeptide of a human IgG1 molecule was synthesized and inserted into V5-pcDNA' digested with XbaI and ApaI.
Unless indicated otherwise, a DNA molecule encoding a particular protein expression enhancing polypeptide was cloned into plasmid Flag-pcDNA' digested with EcoRI
and EcoRV to insert a DNA segment encoding the J domain of an Erdj3 J protein, or digested with KpnI and BamHI
to insert a DNA segment encoding the J domain of an Erdj5 J protein, to yield plasmid (J domain)-Flag-pcDNA', wherein "(J domain)" refers to the particular protein expression enhancing polypeptide specified in the examples below.
Unless indicated otherwise, each DNA molecule encoding a target binding domain for a corresponding target protein in the examples below was inserted into plasmid Flag-pcDNA' digested with NotI and XhoI.
Expression and Detection of Target Proteins in HEK293 cells Expression vector plasmids encoding various protein constructs were transfected into HEK293 cells with X-tremeGENE HP transfection reagent (catalogue no.
06365752001, Roche). As indicated in the examples below, a separate plasmid expressing the green fluorescent protein (GFP) was co-transfected with each expression vector plasmid encoding a fusion protein of the invention to monitor the transfection efficiency. Cultures of transfectant cells were incubated for two days, and cells were lysed in lysis buffer (10 mM Tris-HC1, pH8.0, 150 mM NaC1, 10 mM
EDTA, 2% SDS) containing 2 mM PMSF. After brief sonication, the sample was analyzed for express proteins using dot blot or Western immunoblot assays. For Western blot analysis, samples were boiled in SDS-sample buffer and run on polyacrylamide electrophoresis, followed by transfer of separated protein bands to membrane (PVDF membrane). The expression of GFP as an internal transfection control was detected using an anti-GFP antibody.
Expressed proteins in dot and Western blots were detected using a chemiluminescent signal.
Briefly, blots were reacted with a primary antibody that binds the particular epitope tag (e.g., V5 or Flag) carried by the proteins. After rinsing away unreacted primary antibody, a secondary, enzyme-linked antibody (e.g., horse radish peroxidase linked anti-IgG antibody) was allowed to react with primary antibody molecules bound to the blots. After rinsing, manufacturer's chemiluminescent reagent was added. Chemiluminescent signals in blots were captured on x-ray film. Where indicated, the images of the chemiluminescent signals were scanned with a densitometer and analyzed using the NIH ImageJ image processing program.
Cells expressing humanized anti-IL-8 antibody (CHO DP-12 clone, clone No.
1933; catalog No. CRL-12444) and plasmid p6G425V11N35A.choSD (catalog No. 209552) were purchased from the American Type Culture Collection (Manassas, Virginia).
Example 4. Enhanced Expression of Secreted IL13Ra2TF Protein in an Unmodified Arrangement The IL13 receptor, IL13Ra2 is a membrane protein that binds to interleukin-13 (IL13) and mediates allergic inflammation. The IL13Ra2 receptor protein is known to be an unstable protein in a mammalian cell due to the difficulties of protein folding (Genetic Engineering & Biotechnology News, 28(5) (2008)). Part of the expressed IL13Ra2 proteins is digested on the cell surface and shed into the extracellular space. This truncated form of IL13Ra2 (also referred to as "IL13Ra2TF") still possesses the ability to bind IL13, but cannot transmit a signal to the cell owing to the absence of transmembrane and cytoplasmic regions of the full-length IL13Ra2 protein.
Therefore, the truncated form of IL13Ra2 has been used as a type of decoy receptor to treat asthma by binding IL13 molecules without transducing a signal to the cell to set off an inflammatory response (Zhang, et al., J. Biol.
Chem., 272(14): 9474-80 (1997)). A genetically engineered truncated form of IL13Ra2 has been expressed in bacteria, however the protein aggregated into inclusion bodies, from which the protein was purified (Tang et al., Molec. Immunol. 39: 719-727 (2003)). However, it is known that one limitation to the expression of the IL13Ra2TF protein by transfected cells has been ascribed to inefficient folding of into their proper functional conformations. When proteins cannot fold into their proper conformation they are ushered to the proteasome for degradation and scavenging of amino acids. Accordingly, production of IL13Ra2TF molecules in transfected cells has recognized attendant limitations of expression and secretion of the protein (Lee et al., Cell Technol. for Cell Products, 29-39 (2007)).
This experiment studied the enhancement in the level of and secretion of the IL13Ra2TF protein using an alternative arrangement to the "modified"
arrangement described in Examples 1-3 in which a target protein of interest is modified by fusion to a protein expression enhancing polypeptide of the invention. In an "unmodified"
arrangement, a target protein of interest is "unmodified" in that it is not fused to a protein expression enhancing polypeptide of the invention, but instead is co-expressed with a fusion protein comprising a protein expression enhancing polypeptide linked to a target protein binding domain. Figure 9A shows a schematic diagram of this unmodified arrangement for enhancing expression of a target protein of interest. According to this scheme, a target protein of interest is bound by a target protein binding domain of the fusion protein, which also comprises a protein expression enhancing polypeptide domain. Presumably, binding of the target protein to the fusion protein brings the target protein into close proximity to the protein expression enhancing polypeptide domain, which in turn leads to enhanced expression of the target protein of interest.
Figure 9B shows a diagram of a nucleic acid construct in which a cDNA encoding an IL13Ra2TF protein is augmented at its 3' end with a nucleic acid encoding a V5 epitope tag. Figure 9C shows a diagram of a nucleic acid construct for a fusion protein of the invention. For this experiment, the fusion protein according to the invention comprised a J domain of the Erdj3 J protein as a protein expression enhancing polypeptide linked to an IL13 protein as a target binding domain.
The amino acid sequence of the V5-tagged IL13Ra2TF protein is shown in the table below.
Table 32. Amino Acid Sequence of a V5-Tagged IL13Ra2TF Protein.
Protein Region Sequence Amino Acid Sequence (N¨ to C¨ Identifier terminal) 123456789012345678901234567890 V5-tagged SEQ ID NO:222 MAFVCLAIGCLYTFLISTTFGCTSSSDTEI
IL13Ra2TF KVNPPQDFEIVDPGYLGYLYLQWQPPLSLD
protein HFKECTVEYELKYRNIGSETWKTIITKNLH
YKDGFDLNKGIEAKIHTLLPWQCTNGSEVQ
SSWAETTYWISPQGIPETKVQDMDCVYYNW
QYLLCSWKPGIGVLLDTNYNLFYWYEGLDH
ALQCVDYIKADGQNIGCRFPYLEASDYKDF
YICVNGSSENKPIRSSYFTFQLQNIVKPLP
PVYLTFTRESSCEIKLKWSIPLGPIPARCF
DYEIEIREDDTTLVTATVENETYTLKTTNE
TRQLCFVVRSKVNIYCSDDGIWSEWSDKQC
WEGEDLSKKGTGSEFDIAAALEGKPIPNPL
LGLDSTSRGPYSIVSPKC
IL13Ra2TF residues 1-339 MAFVCLAIGCLYTFLISTTFGCTSSSDTEI
of SEQ ID KVNPPQDFEIVDPGYLGYLYLQWQPPLSLD
NO:222 HFKECTVEYELKYRNIGSETWKTIITKNLH
YKDGFDLNKGIEAKIHTLLPWQCTNGSEVQ
SSWAETTYWISPQGIPETKVQDMDCVYYNW
QYLLCSWKPGIGVLLDTNYNLFYWYEGLDH
ALQCVDYIKADGQNIGCRFPYLEASDYKDF
YICVNGSSENKPIRSSYFTFQLQNIVKPLP
PVYLTFTRESSCEIKLKWSIPLGPIPARCF
DYEIEIREDDTTLVTATVENETYTLKTTNE
TRQLCFVVRSKVNIYCSDDGIWSEWSDKQC
WEGEDLSKK
Linker residues 340- GTGSEFDIAAALE
352 of SEQ ID
NO:222 V5 epitope residues 353- GKPIPNPLLGLDST
domain 366 of SEQ ID
NO : 222 C-terminal residues 367- SRGPYSIVSPKC
vector residues 378 of SEQ ID
NO : 222 The amino acid sequence of the IL13 protein as used in this experiment included a Flag epitope tag, a signal sequence, and 13 additional C-terminal amino acid residues from the expression vector used to express the protein as shown in the table below.
Table 33. Amino Acid Sequence of a Flag-Tagged 1L13 Protein.
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) Flag-tagged SEQ
ID NO:223 MGVKVLFALICIAVAEAGTGSEFDIAAALT
IL13 protein CLGGFASPGPVPPSTALRELIEELVNITQN
QKAPLCNGSMVWSINLTAGMYCAALESLIN
VSGCSAIEKTQRMLSGFCPHKVSAGQFSSL
HVRDTKIEVAQFVKDLLLHLKKLFREGQFN
LEGDYKDDDDKGSRGPYSIVSPKC
Signal Sequence residues 1-17 MGVKVLFALICIAVAEA
of SEQ ID
NO:223 Linker residues 18-28 GTGSEFDIAAA
of SEQ ID
NO:223 residues 29-150 LTCLGGFASPGPVPPSTALRELIEELVNIT
of SEQ ID
QNQKAPLCNGSMVWSINLTAGMYCAALESL
NO:223 INVSGCSAIEKTQRMLSGFCPHKVSAGQFS
SLHVRDTKIEVAQFVKDLLLHLKKLFREGQ
FN
Linker residues 151- LEG
153 of SEQ ID
NO:223 Flag epitope residues 154- DYKDDDDK
domain 161 of SEQ ID
NO:223 C-terminal residues 162- GSRGPYSIVSPKC
vector residues 174 of SEQ ID
NO:223 The amino acid sequence of a J domain-1L13 fusion protein included a Flag epitope tag as shown in the table below.
Table 34. Amino Acid Sequence of a Flag-Tagged Erdj3 J Domain-1L13 Fusion Protein.
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) Flag-tagged SEQ
ID NO:224 MAPQNLSTFCLLLLYLIGAVIAGRDFYKIL
J domain-1L13 GVPRSASIKDIKKAYRKLALQLHPDRNPDD
fusion protein PQAQEKFQDLGAAYEVLSDSEKRDIGGGSG
GSGGSGGAAALTCLGGFASPGPVPPSTALR
ELIEELVNITQNQKAPLCNGSMVWSINLTA
GMYCAALESLINVSGCSAIEKTQRMLSGFC
PHKVSAGQFSSLHVRDTKIEVAQFVKDLLL
HLKKLFREGQFNLEGDYKDDDDKGSRGPYS
IVSPKC
Erdj3 J domain residues 1-83 MAPQNLSTFCLLLLYLIGAVIAGRDFYKIL
of SEQ ID
GVPRSASIKDIKKAYRKLALQLHPDRNPDD
NO: 224 PQAQEKFQDLGAAYEVLSDSEKR
Linker residues 84-100 DIGGGSGGSGGSGGAAA
of SEQ ID
NO:224 Protein Region Sequence Amino Acid Sequence (N¨ to C¨ Identifier terminal) 123456789012345678901234567890 IL13 residues 101- LTCLGGFASPGPVPPSTALRELIEELVNIT
222 of SEQ ID QNQKAPLCNGSMVWSINLTAGMYCAALESL
NO: 224 INVSGCSAIEKTQRMLSGFCPHKVSAGQFS
SLHVRDTKIEVAQFVKDLLLHLKKLFREGQ
FN
Linker residues 223- LEG
225 of SEQ ID
NO:224 Flag epitope residues 226- DYKDDDDK
domain 233 of SEQ ID
NO:224 C-terminal residues 234- GSRGPYSIVSPKC
vector residues 246 of SEQ ID
NO:224 HEK293 cells were co-transfected with expression vectors for expressing the V5-tagged IL13Ra2TF and for expressing the J domain-1L13 fusion protein. Transfected cells were cultured for two days, and cell lysates and samples of cell media were harvested and analyzed by Western blot (immunoblot) assay using an anti-V5 antibody to detect secreted V5-tagged IL13Ra2TF. As shown in Figure 10, cells transfected with an expression vector for expressing the IL13Ra2TF protein alone expressed some protein in the cells (middle panel, lane 2, from the left) but only a very little, if any, IL13Ra2TF protein was detected in culture medium (top panel, lane 2, from the left). Co-expression of the IL13Ra2TF protein and its IL13 protein ligand resulted in some detectable expression of IL13Ra2TF protein in the transfected cells (middle panel, lane 3, from the left) and in culture medium (top panel, lane 3, from the left). This result is consistent with earlier reports that co-expression of IL13Ra2TF with its IL13 ligand improves secretion of the IL13Ra2TF (Lee et al., Cell Technol. for Cell Products, 29-39 (2007)). However, co-expression IL13Ra2TF with a J domain-1L13 fusion protein according to the invention further enhanced the level of expression of IL13Ra2TF within the cells (middle panel, lane 4, from the left) and dramatically enhanced the level of expression of secreted IL13Ra2TF protein (top panel, lane 4, from the left) as compared to expression of IL13Ra2TF alone (top panel, lane 2, from the left) or co-expression of IL13Ra2TF and IL13 ligand (top panel, lane 3, from the left). The results indicate that both stability and secretion of the IL13Ra2TF protein were improved by co-expression with a J domain-1L13 fusion protein of the invention.
Example 5. Enhanced Expression of Secreted IL13Ra2TF-Fc Fusion Protein in an Unmodified Arrangement As noted above, a truncated form of IL13Ra2 (IL13Ra2TF) comprises the extracellular domain of the IL13Ra2 receptor protein, including a functional IL13 ligand binding domain.
However, the production of IL13Ra2TF is also inefficient owing to difficulties in expression and secretion of the protein. One strategy that has been employed to generate more stable forms of therapeutically relevant proteins, and especially receptor proteins, is to prepare a fusion protein in which all or a functional portion of a protein of interest is linked to the constant domains of an immunoglobulin Fc domain. Such an Fc fusion protein format has been used to design a family of potentially useful drugs that provide a desired therapeutically relevant activity and, owing to the Fc domain, also exhibit an increased in vivo serum half-life, which in turn should reduce dosing frequencies. Within such Fc fusion proteins, a "protein of interest" domain (for example, the extracellular, ligand-binding domain of a receptor protein) retains its desired functional property (for example, ligand binding).
This experiment examined the effect on the level of expression of an Fc fusion protein (target protein) when the Fc fusion protein was co-expressed with a fusion protein of the invention in an unmodified arrangement. An IL13Ra2TF-Fc fusion protein was used as a representative example of an Fc fusion protein drug. The IL13Ra2TF-Fc fusion protein also possessed a V5 epitope tag between the IL13Ra2TF ("protein of interest") domain and the Fc domain for easy identification with an anti-V5 epitope antibody. See, an illustration of a DNA construct for the IL13Ra2TF-Fc fusion protein in Figure 11A. For this experiment, examples of fusion proteins according to the invention comprised a J domain of a J protein as a protein expression enhancing polypeptide domain linked to Protein A, which binds immunoglobulin Fc domains, as a target binding domain.
See, Figure 11B.
The amino acid sequence for the VS-tagged IL13Ra2TF-Fc fusion protein used in this experiment is shown in the table below.
Table 35. Amino Acid Sequence of a VS-Tagged IL13Ra2TF-Fc Fusion Protein.
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) V5-tagged SEQ ID NO:225 MAFVCLAIGCLYTFLISTTFGCTSSSDTEI
IL13Ra2TF-Fc KVNPPQDFEIVDPGYLGYLYLQWQPPLSLD
fusion protein HFKECTVEYELKYRNIGSETWKTIITKNLH
YKDGFDLNKGIEAKIHTLLPWQCTNGSEVQ
SSWAETTYWISPQGIPETKVQDMDCVYYNW
QYLLCSWKPGIGVLLDTNYNLFYWYEGLDH
ALQCVDYIKADGQNIGCRFPYLEASDYKDF
YICVNGSSENKPIRSSYFTFQLQNIVKPLP
PVYLTFTRESSCEIKLKWSIPLGPIPARCF
DYEIEIREDDTTLVTATVENETYTLKTTNE
TRQLCFVVRSKVNIYCSDDGIWSEWSDKQC
WEGEDLSKKGTGSEFDIAAALEGKPIPNPL
LGLDSTSRPKSCDKTHTCPPCPAPELLGGP
SVFLFPPKPKDTLMISRTPEVTCVVVDVSH
EDPEVKFNWYVDGVEVHNAKTKPREEQYNS
TYRVVSVLTVLHQDWLNGKEYKCKVSNKAL
PAPIEKTISKAKGQPREPQVYTLPPSRDEL
TKNQVSLTCLVKGFYPSDIAVEWESNGQPE
NNYKTTPPVLDSDGSFFLYSKLTVDKSRWQ
QGNVFSCSVMHEALHNHYTQKSLSLSPGK
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) IL13Ra2TF residues 1-339 MAFVCLAIGCLYTFLISTTFGCTSSSDTEI
of SEQ ID
KVNPPQDFEIVDPGYLGYLYLQWQPPLSLD
NO:225 HFKECTVEYELKYRNIGSETWKTIITKNLH
YKDGFDLNKGIEAKIHTLLPWQCTNGSEVQ
SSWAETTYWISPQGIPETKVQDMDCVYYNW
QYLLCSWKPGIGVLLDTNYNLFYWYEGLDH
ALQCVDYIKADGQNIGCRFPYLEASDYKDF
YICVNGSSENKPIRSSYFTFQLQNIVKPLP
PVYLTFTRESSCEIKLKWSIPLGPIPARCF
DYEIEIREDDTTLVTATVENETYTLKTTNE
TRQLCFVVRSKVNIYCSDDGIWSEWSDKQC
WEGEDLSKK
Linker residues 340- GTGSEFDIAAALE
352 of SEQ ID
NO:225 V5 epitope residues 353- GKPIPNPLLGLDST
domain 366 of SEQ ID
NO:225 Linker residues 367- SR
368 of SEQ ID
NO:225 Fc domain residues 369-PKSCDKTHTCPPCPAPELLGGPSVFLFPPK
599 of SEQ ID PKDTLMISRTPEVTCVVVDVSHEDPEVKFN
NO:225 WYVDGVEVHNAKTKPREEQYNSTYRVVSVL
TVLHQDWLNGKEYKCKVSNKALPAPIEKTI
SKAKGQPREPQVYTLPPSRDELTKNQVSLT
CLVKGFYPSDIAVEWESNGQPENNYKTTPP
VLDSDGSFFLYSKLTVDKSRWQQGNVFSCS
VMHEALHNHYTQKSLSLSPGK
In one aspect of this experiment, the level of expression of an IL13Ra2TF-Fc fusion protein was examined when co-expressed with a Protein A molecule. The Protein A
molecule was tagged with a Flag epitope tag for easy identification with a standard anti-Flag antibody. The amino acid sequence for a Flag-tagged Protein A is shown in the table below.
Table 36. Amino Acid Sequence of a Flag-Tagged Protein A.
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) Flag-tagged SEQ
ID NO:226 MGVKVLFALICIAVAEAGTGSEFDIAAAAD
Protein A
NKFNKEQQNAFYEILNMPNLNEEQRNGFIQ
protein SLKDDPSQSANVLGEAKKLNDSQAPKLEGD
YKDDDDKGSRGPYSIVSPKC
Signal Sequence residues 1-17 MGVKVLFALICIAVAEA
of SEQ ID
NO:226 Linker residues 18-28 GTGSEFDIAAA
of SEQ ID
NO:226 Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) 123456789012345678901234567890 Protein A residues 29-86 ADNKFNKEQQNAFYEILNMPNLNEEQRNGF
of SEQ ID IQSLKDDPSQSANVLGEAKKLNDSQAPK
NO:226 Linker residues 87-89 LEG
of SEQ ID
NO:226 Flag epitope residues 90-97 DYKDDDDK
domain of SEQ ID
NO:226 C-terminal residues 98-110 GSRGPYSIVSPKC
vector residues of SEQ ID
NO:226 An example of a fusion protein for enhancing expression of the IL13Ra2TF-Fc fusion protein possessed the J domain from the Erdj3 protein linked to Protein A. A Flag epitope tag was linked to the C-terminus of the Protein A domain. See illustration of DNA construct in Figure 11B. The amino acid sequence for the J domain-Protein A fusion protein is shown in the table below.
Table 37. Amino Acid Sequence of a Flag-Tagged Erdj3 J domain-Protein A Fusion Protein.
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) 123456789012345678901234567890 Flag-tagged SEQ ID NO:227 MAPQNLSTFCLLLLYLIGAVIAGRDFYKIL
Erdj3 J domain- GVPRSASIKDIKKAYRKLALQLHPDRNPDD
Protein A fusion PQAQEKFQDLGAAYEVLSDSEKRDIGGGSG
protein GSGGSGGAAAADNKFNKEQQNAFYEILNMP
NLNEEQRNGFIQSLKDDPSQSANVLGEAKK
LNDSQAPKLEGDYKDDDDKGSRGPYSIVSP
KC
J domain residues 1-83 MAPQNLSTFCLLLLYLIGAVIAGRDFYKIL
(from Erdj3) of SEQ ID GVPRSASIKDIKKAYRKLALQLHPDRNPDD
NO: 227 PQAQEKFQDLGAAYEVLSDSEKR
Linker residues 84-100 DIGGGSGGSGGSGGAAA
of SEQ ID
NO: 227 Protein A residues 101- ADNKFNKEQQNAFYEILNMPNLNEEQRNGF
158 of SEQ ID IQSLKDDPSQSANVLGEAKKLNDSQAPK
NO: 227 Linker residues 159- LEG
161 of SEQ ID
NO: 227 Flag epitope residues 162- DYKDDDDK
domain 169 of SEQ ID
NO: 227 C-terminal residues 170- GSRGPYSIVSPKC
vector residues 182 of SEQ ID
NO: 227 Another example of a fusion protein for enhancing expression of the IL13Ra2TF-Fc fusion protein possessed the J domain from the Erdj5 protein linked to Protein A. A
Flag epitope tag was linked to the C-terminus of the Protein A domain. See illustration of DNA
construct in Figure 11B.
The amino acid sequence for the Flag-tagged Erdj5 J domain-Protein A fusion protein is shown in the table below.
Table 38. Amino Acid Sequence of a Flag-Tagged Erdj5 J domain-Protein A Fusion Protein.
Protein Region Sequence Amino Acid Sequence (N¨ to C¨ Identifier terminal) Flag-tagged SEQ
ID NO:228 MGVWLNKDDYIRDLKRIILCFLIVYMAILV
Erdj5 J domain-GTDQDFYSLLGVSKTASSREIRQAFKKLAL
Protein A fusion KLHPDKNPNNPNAHGDFLKINRAYEVLKDE
protein DGSEFDIGGGSGGSGGSGGAAAADNKFNKE
QQNAFYEILNMPNLNEEQRNGFIQSLKDDP
SQSANVLGEAKKLNDSQAPKLEGDYKDDDD
KGSRGPYSIVSPKC
J domain residues 1-91 MGVWLNKDDYIRDLKRIILCFLIVYMAILV
(from Erdj5) of SEQ ID
GTDQDFYSLLGVSKTASSREIRQAFKKLAL
NO: 228 KLHPDKNPNNPNAHGDFLKINRAYEVLKDE
Linker residues 92-112 GSEFDIGGGSGGSGGSGGAAA
of SEQ ID
NO:228 Protein A residues 113-ADNKFNKEQQNAFYEILNMPNLNEEQRNGF
170 of SEQ ID IQSLKDDPSQSANVLGEAKKLNDSQAPK
NO:228 Linker residues 171- LEG
173 of SEQ ID
NO:228 Flag epitope residues 174- DYKDDDDK
domain 181 of SEQ ID
NO:228 C-terminal residues 182- GSRGPYSIVSPKC
vector residues 194 of SEQ ID
NO:228 HEK293 cells were transfected with expression vector plasmids to compare levels of expression in culture medium of IL13Ra2TF-Fc fusion protein expressed alone, IL13Ra2TF-Fc fusion protein co-expressed with Protein A ("Protein A Only"), IL13Ra2TF-Fc fusion protein co-expressed with the Erdj3 J domain-Protein A fusion protein ("J-Protein A"), and IL13Ra2TF-Fc fusion protein co-expressed with the Erdj5 J domain-Protein A fusion protein ("J2-Protein A").
Transfected cells were cultured for two days, and samples of cell media were harvested and analyzed by Western blot (immunoblot) assay using an anti-V5 antibody to detect secreted VS-tagged IL13Ra2TF-Fc fusion protein. Figure 12A shows x-ray film images of chemiluminescent signals of the Western blot analysis of culture media. Lane 1 of Figure 12A is culture medium of a "mock"
culture of cells transfected with expression vector lacking a structural gene for expressing any protein PCT/US2013/073442 08.04.2015 (empty vector). When expressed alone (lane 2), some IL13Ra2TF-Fc fusion protein was detected in the medium. As shown in lane 3 of the Figure 12A, co-expression with Protein A
(Protein A Only) provided no significant enhancement in the level of IL13Ra2TF-Fc fusion protein secreted to the medium. However, co-expression with the either J domain-Protein A fusion protein significantly enhanced the level of expression of IL13Ra2TF-Fc fusion protein secreted into the medium (lanes 4 and 5 of Figure 12A). Importantly, the fact that co-expression of IL13Ra2TF-Fc with Protein A alone did not affect the secretion of IL13Ra2TF-Fc (lane 3) indicates that: (1) the J domain of a J domain-Protein A fusion protein is essential for enhancing the level of expression of secreted IL13Ra2TF-Fc and (2) the Protein A domain of the J domain-Protein A fusion protein is essential for providing the target specificity for enhancing the level of expression of the secreted IL13Ra2TF-Fc target protein. .
=
The results of a densitometry analysis of the chemiluminescent signals in the lanes of Figure 12A using the NTH ImageJ image processing program are shown in the respective bar graphs in Figure 12B. The bar graphs in Figure 12B clearly show that co-expression of IL13Ra2TF-Fc with either J domain-Protein A fusion protein (bar graphs 4 and 5) significantly enhanced the level of expression of secreted IL13Ra2TF-Fc as compared to expression of IL13Ra2TF-Fc alone (bar graph 2) or co-expression of IL13Ra2TF-Fc with Protein A alone (bar graph 3).
That the enhanced level of expression of secreted IL13Ra2TF-Fc protein in Figures 12A and 12B was dependent on the specificity of the target binding domain of the J
domain-Protein A fusion protein for the Fc domain is supported by the results shown in Figure 12C. As shown in the Western blot analysis of culture media in Figure 12C, no significant expression of secreted IL13Ra2TF (no Fc domain) was detected in culture media when transfected cells expressed the IL13Ra2TF protein alone (lane 1), co-expressed the IL13Ra2TF protein with the J-Protein A fusion protein (lane 2), or co-expressed the IL13Ra2TF protein with Protein A alone (Protein A Only, lane 3).
The results of a densitometry analysis of the chemiluminescent signals in the lanes of Figure 12C using the NIH
ImageJ image processing program are shown in the respective bar graphs in Figure 12D.
Example 6. Enhanced Expression of an Additional Secreted Fc Fusion Proteins in an Unmodified Arrangement A series of experiments were performed to test and compare the effectiveness of a J domain-Protein A fusion protein of the invention to enhance several different Fc fusion proteins. The results are of a Western blot analysis of culture media from cultures of transfected cells are shown in Figure 13.
Example 6.1. Enhanced Expression of a Secreted IL13Ra2TF-Fc Fusion Protein Consistent with above results in Example 5, co-expression of the IL13Ra2TF-Fc protein with the Erdj3 J domain-Protein A fusion protein in transfected cells significantly enhanced the level of expression of IL13Ra2TF-Fc protein secreted into the culture medium (see, lane 2 of 113 =
=
AMENDED SHEET - IPEA/US
PCT/US2013/073442 08.04.2015 Figure 13A-1) as compared to that observed for transfeeted cells expressing the 11,13Ra2TF-Fc protein alone (lane 1 of Figure 13A-1). The significant enhancement in the level of expression of secreted IL13Ra2TF-Fc protein is also clear from the results of a densitometry analysis of the chemiluminescent signals in Figure 13A-1 using the NIB ImageJ image processing program are shown in the respective bar graphs in Figure 13A-2.
Example 6.2. Enhanced Expression of a Secreted TNFRITF-Fc Fusion Protein Tumor necrosis factor-a (TNF-a) is a major cytokine that binds the TNF-a receptor (TNFR1) and induces an inflammatory response that is involved in a number of autoimmune diseases, such as rheumatoid arthritis, Crohn's disease, and psoriasis. The truncated protein of the TNF-a receptor (TNFR1TF) is used as a decoy receptor to bind to TNF-a and thereby inhibit TNF-a activity.
Etanercept (commercially available as ENBREL , Amgen) is a TNF-a blocker in which a truncated form of TNFR is fused to an Fc domain (TNFRITF-Fc). The TNFRITF domain of the molecule provides the desired TNF-a binding specificity, and the immunoglobulin Fe domain is believed to add in vivo stability to the drug circulating in a patient.
The TNFR1TF-Fc fusion target protein used in this experiment also possessed a V5 epitope tag between the TNFR1 and Pc domains. The amino acid sequence for the TNFR1TF-Fe fusion protein used in this experiment is shown in the table below.
Table 39. Amino Acid Sequence of TNFR1TF-Fc Protein.
Protein Region Sequence Amino Acid Sequence (N¨ to C¨ Identifier terminal) V5-tagged SEQ ID NO:229 MGLSTVPDLLLPLVLLELLVGIYPSGVIGL
TNFR1TF protein VPHLGDREKRDSVCPQGKYIHPQNNSICCT
KCHKGTYLYNDCPGPGQDTDCRECESGSFT
ASENHLRHCLSCSKCRKEMGQVEISSCTVD
RDTVCGCRKNQYRHYWSENLFQCFNCSLCL
NGTVHLSCQEKQNTVCTCHAGFFLRENECV
SCSNCKKSLECTKLCLPQIENVKGTEDSGT
TGTGSEFDIAAALEGKPIPNPLLGLDSTSR
PKSCDKTHTCPPCPAPELLGGPSVFLFPPK
PKDTLMISRTPEVTCVVVDVSHEDPEVKFN
WYVDGVEVHNAKTKPREEQYNSTYRVVSVL
TVLHQDWLNGKEYKCKVSNKALPAPIEKTI
SKAKGQPREPQVYTLPPSRDELTKNQVSLT
CLVKGFYPSDIAVEWESNGQPENNYKTTPP
VLDSDGSFFLYSKLTVDKSRWQQGNVFSCS
VMHEALHNHYTQKSLSLSPGK
TNFRITF
residues 1-211 MGLSTVPDLLLPLVLLELLVGIYPSGVIGL
of SEQ ID
VPHLGDREKRDSVCPQGKYIHPQNNSICCT
NO :229 KCHKGTYLYNDCPGPGQDTDCRECESGSFT
ASENHLRHCLSCSKCRKEMGQVEISSCTVD
RDTVCGCRKNQYRHYWSENLFQCFNCSLCL
NGTVHLSCQEKQNTVCTCHAGFFLRENECV
SCSNCKKSLECTKLCLPQIENVKGTEDSGT
=
AMENDED SHEET - IPEA/US
=
PCT/US13/73442 03-10-2014 PCT/US2013/073442 08.04.2015 Protein Region Sequence Amino Acid Sequence (N¨ to C¨ Identifier terminal) 123456789012345678901234567890 Linker residues 212- GTGSEFDIAAALE
224 of SEQ ID
NO:229 V5 epitope residues 225- GKPIPNPLLGLDST
domain 238 of SEQ ID
NO:229 Linker residues 239- SR
240 of SEQ ID
NO:229 Fc domain residues 241- PKSCDKTHTCPPCPAPELLGGPSVFLFPPK
471 of SEQ ID PKDTLMISRTPEVTCVVVDVSHEDPEVKFN
NO :229 WYVDGVEVHNAKTKPREEQYNSTYRVVSVL
TVLHQDWLNGKEYKCKVSNKALPAPIEKTI
SKAKGQPREPQVYTLPPSRDELTKNQVSLT
CLVKGFYPSDIAVEWESNGQPENNYKTTPP
VLDSDGSFFLYSKLTVDKSRWQQGNVFSCS
VMHEALHNHYTQKSLSLSPGK
Figure 13B-1 shows x-ray film images of chemiluminescent signals of a Western blot analysis of culture media from transfected cells expressing TNFR1TF-Fc fusion protein alone (lane 1) or co-expressing TNFRITF-Fc fusion protein and the Erdj3 J domain-Protein A fusion protein described above (lane 2). The results show a significant enhancement in the level of expression of secreted TNFRITF-Fc fusion protein in transfected cells co-expressing TNFRITF-Fc fusion protein and the Erdj3 J domain-Protein A fusion protein as compared to the level of TNER1TF-Fc fusion protein =
expressed in the absence of the J domain-Protein A fusion protein. The significant enhancement in the level of expression of secreted TNER1TP-Fc fusion protein is also clear from the results of a dcnsitometry analysis of the signals in the lanes in Figure 13B-1 using the NLEI ImageJ image processing program as shown in the respective bar graphs in Figure 13B-2.
Example 6.3. Enhanced Expression of a Secreted alAT-Fc Fusion Protein The al anti-trypsin protein (alAT) is secreted from the liver into the circulatory system. The function of alAT is to protect tissues, particularly lung tissue, from excessive protease activities. The lung tissue of patients with al anti-trypsin deficiency can become severely damaged by proteases.
Such patients may develop emphysema, asthma, and/or chronic obstructive pulmonary disease (COPD). Currently al AT (purified from human serum) is used for the treatment of patients with al anti-trypsin deficiency. This treatment is expensive, and patients that receive the purified al AT may be at risk of contracting pathogens present in the human serum.
The target alAT-Fc fusion protein used in this experiment also possessed a V5 epitope tag between the alAT and Fc domains. The amino acid sequence for the al AT-Fc fusion protein (alAT-Fc) used in this experiment is shown in the table below.
AMENDED SHEET - IPEA/US
Table 40. Amino Acid Sequence of a V5-Tagged a1AT-Fc Fusion Protein.
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) V5-tagged a1AT- SEQ ID
NO:230 MPSSVSWGILLLAGLCCLVPVSLAEDPQGD
Fc fusion AAQKTDTSHHDQDHPTFNKITPNLAEFAFS
protein LYRQLAHQSNSTNIFFSPVSIATAFAMLSL
GTKADTHDEILEGLNFNLTEIPEAQIHEGF
QELLRTLNQPDSQLQLTTGNGLFLSEGLKL
VDKFLEDVKKLYHSEAFTVNFGDTEEAKKQ
INDYVEKGTQGKIVDLVKELDRDTVFALVN
YIFFKGKWERPFEVKDTEEEDFHVDQVTTV
KVPMMKRLGMFNIQHCKKLSSWVLLMKYLG
NATAIFFLPDEGKLQHLENELTHDIITKFL
ENEDRRSASLHLPKLSITGTYDLKSVLGQL
GITKVFSNGADLSGVTEEAPLKLSKAVHKA
VLTIDEKGTEAAGAMFLEAIPMSIPPEVKF
NKPFVFLMIEQNTKSPLFMGKVVNPTQKGT
GSEFDIAAALEGKPIPNPLLGLDSTSRPKS
CDKTHTCPPCPAPELLGGPSVFLFPPKPKD
TLMISRTPEVTCVVVDVSHEDPEVKFNWYV
DGVEVHNAKTKPREEQYNSTYRVVSVLTVL
HQDWLNGKEYKCKVSNKALPAPIEKTISKA
KGQPREPQVYTLPPSRDELTKNQVSLTCLV
KGFYPSDIAVEWESNGQPENNYKTTPPVLD
SDGSFFLYSKLTVDKSRWQQGNVFSCSVMH
EALHNHYTQKSLSLSPGK
a1AT residues of SEQ ID
AAQKTDTSHHDQDHPTFNKITPNLAEFAFS
NO: 230 LYRQLAHQSNSTNIFFSPVSIATAFAMLSL
GTKADTHDEILEGLNFNLTEIPEAQIHEGF
QELLRTLNQPDSQLQLTTGNGLFLSEGLKL
VDKFLEDVKKLYHSEAFTVNFGDTEEAKKQ
INDYVEKGTQGKIVDLVKELDRDTVFALVN
YIFFKGKWERPFEVKDTEEEDFHVDQVTTV
KVPMMKRLGMFNIQHCKKLSSWVLLMKYLG
NATAIFFLPDEGKLQHLENELTHDIITKFL
ENEDRRSASLHLPKLSITGTYDLKSVLGQL
GITKVFSNGADLSGVTEEAPLKLSKAVHKA
VLTIDEKGTEAAGAMFLEAIPMSIPPEVKF
NKPFVFLMIEQNTKSPLFMGKVVNPTQK
Linker residues 419- GTGSEFDIAAALE
431 of SEQ ID
NO: 230 V5 epitope residues 432- GKPIPNPLLGLDST
domain 445 of SEQ ID
NO:230 Linker residues 446- SR
447 of SEQ ID
NO:230 Fc domain residues 448-PKSCDKTHTCPPCPAPELLGGPSVFLFPPK
678 of SEQ ID PKDTLMISRTPEVTCVVVDVSHEDPEVKFN
NO: 230 WYVDGVEVHNAKTKPREEQYNSTYRVVSVL
TVLHQDWLNGKEYKCKVSNKALPAPIEKTI
PCT/US2013/073442 08.04.2015 Protein Region Sequence Amino Acid Sequence (14¨ to C¨ Identifier terminal) 123456789012345678901234567890 SKAKGQPREPQVYTLPPSRDELTKNQVSLT
CLVKGFYPSDIAVEWESNGQPENNYKTTPP
VLDSDGSFFLYSKLTVDKSRWQQGNVFSCS
VMHEALHNHYTQKSLSLSPGK
Figure 13C-1 shows X-ray film images of chemiluminescent signals of a Western blot analysis of culture media from transfected cells expressing alAT-Fc fusion protein alone (lane 1) or =
co-expressing alAT-Fc fusion protein and the Erdj3 J domain-Protein A fusion protein described above (lane 2). The results show a significant enhancement in the level of secreted alAT-Fc fusion protein (lane 2) as compared to the level of alAT-Fc fusion protein expressed in the absence of the J
domain-Protein A fusion protein (lane 1). The significant enhancement in the level of expression of secreted alAT-Fc fusion protein is also clear from the results of a densitometry analysis of the signals in the lanes in Figure 13C-1 using the N11-1 ImageJ image processing program as shown in the respective bar graphs in Figure 13C-2.
Example 7. Enhancement of Expression of Secreted IgG1 Antibody Molecules in an Unmodified Arraneement The above studies showed that expression and secretion of Pc-fusion proteins were significantly enhanced by co-expression of a J domain-Protein A fusion protein. Protein A is a well-known example of a protein that binds to immunoglobulin Pc regions. This study examined whether fusion of other proteins that are known to bind immunoglobulin domains with a J domain of a J
protein can enhance the expression level of a secreted target antibody.
In this study, a humanized IgG1 anti-1L8 antibody was used as a target antibody protein. The expression levels of the secreted anti-1L8 antibody were examined in the presence and absence of various J domain fusion proteins as explained below.
In one aspect of this experiment, the level of expression of the anti-1L8 antibody was examined when co-expressed with a Protein A molecule, which is known to bind the immunoglobulin Fc domain. The Protein A molecule was the same Flag-tagged Protein A described in Example 5, above.
In another aspect of this experiment, the level of expression of the anti-1L8 antibody was examined when co-expressed with a Protein L molecule, which is known to bind antibody light chains. As with the Protein A molecule described above, the Protein L molecule used in this experiment was tagged with a Flag epitope tag for easy identification with a standard anti-Flag antibody. The amino acid sequence for a Flag-tagged Protein L is shown in the table below.
AMENDED SHEET - IPEA/US
Table 41. Amino Acid Sequence of a Flag-Tagged Protein L.
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) 123456789012345678901234567890 Flag-tagged SEQ ID NO:231 MGVKVLFALICIAVAEAGTGSEFDIAAAVT
Protein L IKANLIFADGKTQTAEFKGTFEEATAEAYR
protein YADLLAKENGEYTADLEDGGYTINIKFAKE
TPETPEEPKEELEGDYKDDDDKGSRGPYSI
VSPKC
Signal Sequence residues 1-17 MGVKVLFALICIAVAEA
of SEQ ID
NO:231 Linker residues 18-28 GTGSEFDIAAA
of SEQ ID
NO:231 Protein L residues 29-101 VTIKANLIFADGKTQTAEFKGTFEEATAEA
of SEQ ID YRYADLLAKENGEYTADLEDGGYTINIKFA
NO: 231 KETPETPEEPKEE
Linker residues 102- LEG
104 of SEQ ID
NO:231 Flag epitope residues 105- DYKDDDDK
domain 112 of SEQ ID
NO:231 C-terminal residues 113- GSRGPYSIVSPKC
vector residues 125 of SEQ ID
NO:231 The amino acid sequence of an Erjd3 J domain-Protein L fusion protein included a Flag epitope tag as shown in the table below.
Table 42. Amino Acid Sequence of a Flag-Tagged Erdj3 J domain-Protein L Fusion Protein.
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) 123456789012345678901234567890 Flag-tagged SEQ ID NO:232 MAPQNLSTFCLLLLYLIGAVIAGRDFYKIL
Erdj3 J domain- GVPRSASIKDIKKAYRKLALQLHPDRNPDD
Protein L fusion PQAQEKFQDLGAAYEVLSDSEKRDIGGGSG
protein GSGGSGGAAAVTIKANLIFADGKTQTAEFK
GTFEEATAEAYRYADLLAKENGEYTADLED
GGYTINIKFAKETPETPEEPKEELEGDYKD
DDDKGSRGPYSIVSPKC
J domain residues 1-83 MAPQNLSTFCLLLLYLIGAVIAGRDFYKIL
(from Erdj3) of SEQ ID GVPRSASIKDIKKAYRKLALQLHPDRNPDD
NO:232 PQAQEKFQDLGAAYEVLSDSEKR
Linker residues 84-100 DIGGGSGGSGGSGGAAA
of SEQ ID
NO:232 Protein L residues 101- VTIKANLIFADGKTQTAEFKGTFEEATAEA
173 of SEQ ID YRYADLLAKENGEYTADLEDGGYTINIKFA
NO:232 KETPETPEEPKEE
Linker residues 174- LEG
176 of SEQ ID
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) 123456789012345678901234567890 NO:232 Flag epitope residues 177- DYKDDDDK
domain 184 of SEQ ID
NO:232 C-terminal residues 185- GSRGPYSIVSPKC
vector residues 197 of SEQ ID
NO:232 The amino acid sequence of the IL8 protein used in this experiment included a Flag epitope tag, a signal sequence, and 13 additional C-terminal amino acid residues from the expression vector used to express the protein as shown in the table below.
Table 43. Amino Acid Sequence of a Flag-Tagged IL8 Protein.
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) 123456789012345678901234567890 Flag-tagged IL8 SEQ ID NO:233 MGVKVLFALICIAVAEAGTGSEFDIAAASA
protein KELRCQCIKTYSKPFHPKFIKELRVIESGP
HCANTEIIVKLSDGRELCLDPKENWVQRVV
EKFLKRAENSLEGDYKDDDDKGSRGPYSIV
SPKC
Signal Sequence residues 1-17 MGVKVLFALICIAVAEA
of SEQ ID
NO:233 Linker residues 18-28 GTGSEFDIAAA
of SEQ ID
NO:233 residues 29-100 SAKELRCQCIKTYSKPFHPKFIKELRVIES
of SEQ ID GPHCANTEIIVKLSDGRELCLDPKENWVQR
NO:233 VVEKFLKRAENS
Linker residues 101- LEG
103 of SEQ ID
NO:233 Flag epitope residues 104- DYKDDDDK
domain 111 of SEQ ID
NO:233 C-terminal residues 112- GSRGPYSIVSPKC
vector residues 124 of SEQ ID
NO:233 The amino acid sequence of an Erdj3 J domain-1L8 fusion protein included a Flag epitope tag as shown in the table below.
Table 44. Amino Acid Sequence of a Flag-Tagged Erdj3 J domain-1L8 Fusion Protein.
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) 123456789012345678901234567890 Flag-tagged SEQ ID NO:234 MAPQNLSTFCLLLLYLIGAVIAGRDFYKIL
Erdj3 J domain- GVPRSASIKDIKKAYRKLALQLHPDRNPDD
IL8 fusion PQAQEKFQDLGAAYEVLSDSEKRDIGGGSG
protein GSGGSGGAAASAKELRCQCIKTYSKPFHPK
FIKELRVIESGPHCANTEIIVKLSDGRELC
LDPKENWVQRVVEKFLKRAENSLEGDYKDD
DDKGSRGPYSIVSPKC
J domain residues 1-83 MAPQNLSTFCLLLLYLIGAVIAGRDFYKIL
(from Erdj3) of SEQ ID GVPRSASIKDIKKAYRKLALQLHPDRNPDD
NO: 234 PQAQEKFQDLGAAYEVLSDSEKR
Linker residues 84-100 DI GGGSGGSGGSGG AAA
of SEQ ID
NO:234 IL8 residues 101- SAKELRCQCIKTYSKPFHPKFIKELRVIES
172 of SEQ ID GPHCANTEIIVKLSDGRELCLDPKENWVQR
NO:234 VVEKFLKRAENS
Linker residues 173- LEG
175 of SEQ ID
NO:234 Flag epitope residues 176- DYKDDDDK
domain 183 of SEQ ID
NO:234 C-terminal residues 184- GSRGPYSIVSPKC
vector residues 196 of SEQ ID
NO:234 HEK293 cells were transfected with an expression plasmid for expressing anti-1L8 antibody alone, co-expressing anti-1L8 antibody and Protein A (Protein A Only), co-expressing anti-1L8 antibody and an Erdj3 J domain-Protein A fusion protein of the invention (J-Protein A), co-expressing anti-1L8 antibody and Protein L (Protein L Only), co-expressing anti-1L8 antibody and an Erdj3 J
domain-Protein L fusion protein of the invention (J-Protein L), co-expressing anti-1L8 antibody and its IL8 ligand (IL8), co-expressing an Erdj3 J domain-1L8 ligand fusion protein of the invention (J-1L8), expressing the Erdj3 J-Protein A fusion protein of the invention alone (J-Protein A), expressing the Erdj3 J domain-Protein L fusion protein of the invention alone (J-Protein L), and expressing the Erdj3 J domain-1L8 ligand fusion protein of the invention alone (J-1L8).
Expression of the anti-1L8 antibody in culture media was analyzed by dot blot assay using an anti-human IgG antibody (anti-hIgG antibody, catalog no. AP112P, Millipore).
As shown in the dot blots of culture media in Figure 14A, co-expression in transfected cells of the anti-1L8 antibody with a J domain-Protein A fusion protein (lane 4), with a J domain-Protein L
fusion protein (lane 6), or with a J domain-1L8 fusion protein (lane 8) significantly enhanced the level of expression of anti-1L8 antibody secreted into the culture medium as compared to the level of the antibody expressed in transfected cells expressing the anti-1L8 antibody alone (lane 2), co-expressing with Protein A alone (lane 3, Protein A Only), co-expressing Protein L alone (lane 5, Protein L Only), or co-expressing IL8 ligand alone (lane 7). No signal was detected in culture media of transfected cells expressing the J domain-Protein A fusion protein alone (lane 9, J-Protein A), the J domain-Protein L fusion protein alone (lane 10, J-Protein L), or expressing the J
domain-1L8 fusion protein alone (lane 10, J-1L8), indicating that all three fusion proteins specifically targeted and enhanced the co-expressed anti-1L8 antibody.
The results of a densitometry analysis of the signals in the lanes in Figure 14A using the NIH
ImageJ image processing program are shown in the respective bar graphs in Figure 14B. The results of this series of experiments clearly show that co-expression of the targeted anti-1L8 antibody with a fusion protein of the invention comprising a protein expression enhancing polypeptide (here: Erdj3 J
domain) linked to a target binding domain (here: Protein A, Protein L, or IL8) significantly enhanced the expression of secreted anti-1L8 antibody as compared to co-expression of the antibody with the unfused target binding domain protein alone (Protein G only, Protein L only, or IL8 only).
Example 8. Enhancement of Established Expression in CHO-DP12 Producing Cell Line Using an Unmodified Arrangement This example examined whether a fusion protein of the invention could be used to improve the level of expression of a target protein already being produced in an established commercially relevant production cell line. For this experiment a CHO-DP12 cell line was used that stably expresses a humanized anti-1L8 IgG1 antibody as obtained from the American Type Culture Collection (accession no. CRL-124444, American Type Culture Collection, Manassas, Virginia) along with an expression vector plasmid for expressing the anti-1L8 antibody (accession no. 209552, ATCC, Manassas, Virginia). The fusion protein of the invention was that Erdj3 J domain-Protein A
fusion protein described above. Cells of the CHO-DP12 production cell line were transfected with an expression vector carrying an operably linked structural gene encoding the Erdj3 J domain-Protein A
fusion protein. The transfection efficiency was not as high with the CHO-DP12 cells as compared with HEK293 cells. Nevertheless, as shown in the dot blot assays in Figure 15A, co-expression of the humanized antibody with the J domain-Protein A fusion protein significantly enhanced the level of expression of the antibody secreted into the culture medium (lane 3) as compared to the level of the antibody expressed in the absence of the J domain-Protein A fusion protein (lane 2, none).
The results of a densitometry analysis of the chemiluminescent signals in the dot blots in the lanes in Figure 15A using the NIH ImageJ image processing program are shown in the respective bar graphs in Figure 15B. The results indicate that co-expression of the antibody with the J domain-Protein A fusion protein (bar graph 3) significantly enhanced expression of the secreted antibody, providing an approximately four to five-fold greater enhancement in the level of expression, as compared to that obtained when the antibody was expressed in the absence of the J domain-Protein A
fusion protein (bar graph 2).
The results indicate that a fusion protein of the invention can be employed to significantly enhance the level of production of a protein that is already being stably expressed in an established production cell line.
Example 9. Other Fusion Proteins for Enhancing Expression of Secreted Fc-Containing Molecules in an Unmodified Arrangement Example 9.1. Fusion Proteins Comprising Fc Binding Domains from Additional Protein Species This example provides a series of experiments to test various fusion proteins comprising a J
domain (as a protein expression enhancing polypeptide domain) linked to any of a variety of polypeptides (as the target binding domain) that have been reported to bind the Fc region of antibody molecules. The various J domain fusion proteins were then tested and compared for their ability to enhance levels of expression of the IL13Ra2TF-Fc fusion protein as described in Example 5 above that was secreted into medium of transfected HEK293 cells.
The J-Protein A fusion protein of the invention used in this example is the Erdj3-Protein A
fusion protein described in Example 5 above.
In another fusion protein used in the experiments described herein, the J
domain from the Erdj3 J protein was linked to Protein G, which is known to bind certain immunoglobulin Fc domains.
A Flag epitope tag was linked to the C-terminus of the Protein G domain as shown for the J-Protein A
fusion protein in Example 5 and Figure 11B. The amino acid sequence for a Flag-tagged J domain-Protein G fusion protein of the invention is shown in the table below.
Table 45. Amino Acid Sequence of a Flag-Tagged Erdj3 J domain-Protein G Fusion Protein.
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) 12345678 9012345678 9012345678 90 Flag-tagged SEQ ID N0:235 MAPQNLSTFCLLLLYLIGAVIAGRDFYKIL
Erdj3 J domain- GVPRSASIKDIKKAYRKLALQLHPDRNPDD
Protein G fusion PQAQEKFQDLGAAYEVLSDSEKRDIGGGSG
protein GSGGSGGAAATYKLVINGKTLKGETTTEAV
DAATAEKVFKQYANDNGVDGEWTYDDATKT
FTVTEKPEVIDASELTPAVTLEGDYKDDDD
KGSRGPYSIVSPKC
J domain residues 1-83 MAPQNLSTFCLLLLYLIGAVIAGRDFYKIL
(from Erdj3) of SEQ ID GVPRSASIKDIKKAYRKLALQLHPDRNPDD
NO:235 PQAQEKFQDLGAAYEVLSDSEKR
Linker residues 84-100 DIGGGSGGSGGSGGAAA
of SEQ ID
NO:235 Protein G residues 101- TYKLVINGKTLKGETTTEAVDAATAEKVFK
170 of SEQ ID QYANDNGVDGEWTYDDATKTFTVTEKPEVI
NO:235 DASELTPAVT
Linker residues 171- LEG
173 of SEQ ID
NO:235 Flag epitope residues 174- DYKDDDDK
domain 181 of SEQ ID
NO:235 C-terminal residues 182- GSRGPYSIVSPKC
vector residues 194 of SEQ ID
NO:235 In another fusion protein used in the experiments described herein, the J
domain from the Erdj3 J protein was linked to a human FcR (hFcR) receptor protein, which is a receptor that binds certain immunoglobulin Fc domains. A Flag epitope tag was linked to the C-terminus of the hFcR
domain as shown for the J-Protein A fusion protein in Example 5 and Figure 11B. The amino acid sequence for a Flag-tagged J domain-hFcR fusion protein is shown in the table below.
Table 46. Amino Acid Sequence of a Flag-Tagged Erdj3 J Domain-hFcR Fusion Protein.
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) Flag-tagged SEQ
ID NO:236 MAPQNLSTFCLLLLYLIGAVIAGRDFYKIL
Erdj3 J domain-GVPRSASIKDIKKAYRKLALQLHPDRNPDD
hFcR fusion PQAQEKFQDLGAAYEVLSDSEKRDIGGGSG
protein GSGGSGGAAAAVITLQPPWVSVFQEETVTL
HCEVLHLPGSSSTQWFLNGTATQTSTPSYR
ITSASVNDSGEYRCQRGLSGRSDPIQLEIH
RGWLLLQVSSRVFTEGEPLALRCHAWKDKL
VYNVLYYRNGKAFKFFHWNSNLTILKTNIS
HNGTYHCSGMGKLEGDYKDDDDKGSRGPYS
IVSPKC
J domain residues 1-83 MAPQNLSTFCLLLLYLIGAVIAGRDFYKIL
(from Erdj3) of SEQ ID
GVPRSASIKDIKKAYRKLALQLHPDRNPDD
NO:236 PQAQEKFQDLGAAYEVLSDSEKR
Linker residues 84-100 DIGGGSGGSGGSGGAAA
of SEQ ID
NO:236 hFcR
residues 101- AVITLQPPWVSVFQEETVTLHCEVLHLPGS
252 of SEQ ID
SSTQWFLNGTATQTSTPSYRITSASVNDSG
NO:236 EYRCQRGLSGRSDPIQLEIHRGWLLLQVSS
RVFTEGEPLALRCHAWKDKLVYNVLYYRNG
KAFKFFHWNSNLTILKTNISHNGTYHCSGM
GK
Linker residues 253- LEG
255 of SEQ ID
NO:236 Flag epitope residues 256- DYKDDDDK
domain 263 of SEQ ID
NO:236 C-terminal residues 264- GSRGPYSIVSPKC
vector residues 276 of SEQ ID
NO:236 In another fusion protein used in the experiments described herein, the J
domain from the Erdj3 J protein was linked to the Macaca mulatta rhadinovirus FcR receptor protein (vFcR), which is a receptor that binds certain immunoglobulin Fc domains. A Flag epitope tag was linked to the C-terminus of the vFcR domain as shown for the J-Protein A fusion protein in Example 5 and Figure 11B. The amino acid sequence for a Flag-tagged J domain-vFcR fusion protein is shown in the table below.
Table 47. Amino Acid Sequence of a Flag-Tagged Erdj3 J domain-vFcR Fusion Protein.
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) Flag-tagged SEQ
ID NO:237 MAPQNLSTFCLLLLYLIGAVIAGRDFYKIL
Erdj3 J domain-GVPRSASIKDIKKAYRKLALQLHPDRNPDD
vFcR protein PQAQEKFQDLGAAYEVLSDSEKRDIGGGSG
GSGGSGGAAAAKLTSVPTWCPPHPGDTYLL
TCRGTSTARDQRSTQWFRNNTLMRGSNFYG
RLVSVTPNATISDRYACQTKTTTRSNNIDF
RVSSSRLTLQERCSSYGYTYANNTRVLRCY
SGGNVTLRNVVFHLNGTAVINGTTTNIHTF
VLTEKTGGTYFCSAFLEGDYKDDDDKGSRG
PYSIVSPKC
Erdj3 J domain residues 1-83 MAPQNLSTFCLLLLYLIGAVIAGRDFYKIL
of SEQ ID
GVPRSASIKDIKKAYRKLALQLHPDRNPDD
NO: 237 PQAQEKFQDLGAAYEVLSDSEKR
Linker residues 84-100 DI GGGSGGSGGSGG AAA
of SEQ ID
NO: 237 vFcR residues 101- AKLTSVPTWCPPHPGDTYLLTCRGTSTARD
255 of SEQ ID QRSTQWFRNNTLMRGSNFYGRLVSVTPNAT
NO: 237 ISDRYACQTKTTTRSNNIDFRVSSSRLTLQ
ERCSSYGYTYANNTRVLRCYSGGNVTLRNV
VFHLNGTAVINGTTTNIHTFVLTEKTGGTY
FCSAF
Linker residues 256- LEG
258 of SEQ ID
NO: 237 Flag epitope residues 259- DYKDDDDK
domain 266 of SEQ ID
NO: 237 C-terminal residues 267- GSRGPYSIVSPKC
vector residues 279 of SEQ ID
NO: 237 In another fusion protein used in the experiments described herein, the J
domain from the Erdj3 J protein was linked to a herpes simplex virus type 1 gI protein, which has no significant Fc binding activity. A Flag epitope tag was linked to the C-terminus of the gI
domain as shown for the J-Protein A fusion protein in Example 5 and Figure 11B. The amino acid sequence for a Flag-tagged J
domain-gI fusion protein is shown in the table below.
Table 48. Amino Acid Sequence of a Flag-Tagged Erdj3 J Domain-gI Fusion Protein.
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) Flag-tagged SEQ
ID NO : 238 MAPQNLSTFCLLLLYLIGAVIAGRDFYKIL
Erdj3 J domain-GVPRSASIKDIKKAYRKLALQLHPDRNPDD
gI protein PQAQEKFQDLGAAYEVLSDSEKRDIGGGSG
GSGGSGGAAALVVRGPTVSLVSNSFVDAGA
LGPDGVVEEDLLILGELRFVGDQVPHTTYY
DGVVELWHYPMGHKCPRVVHVVTVTACPRR
PAVAFALCRATDSTHSPAYPTLELNLAQQP
LLRVRRATRDYAGVYVLRVWVGDAPNASLF
VLGMAIAAEGTLAYNGSAHGSCDPKLLPYS
APRLAPASVYQPAPNPASTPSTTIPAPQAS
TTPFPTGDPKPQLEGDYKDDDDKGSRGPYS
IVSPKC
J domain residues 1-83 MAPQNLSTFCLLLLYLIGAVIAGRDFYKIL
(from Erdj3) of SEQ ID
GVPRSASIKDIKKAYRKLALQLHPDRNPDD
NO: 238 PQAQEKFQDLGAAYEVLSDSEKR
Linker residues 84-100 DIGGGSGGSGGSGGAAA
of SEQ ID
NO:238 gI residues 101-LVVRGPTVSLVSNSFVDAGALGPDGVVEED
312 of SEQ ID LLILGELRFVGDQVPHTTYYDGVVELWHYP
NO: 238 MGHKCPRVVHVVTVTACPRRPAVAFALCRA
TDSTHSPAYPTLELNLAQQPLLRVRRATRD
YAGVYVLRVWVGDAPNASLFVLGMAIAAEG
TLAYNGSAHGSCDPKLLPYSAPRLAPASVY
QPAPNPASTPSTTIPAPQASTTPFPTGDPK
PQ
Linker residues 313- LEG
315 of SEQ ID
NO:238 Flag epitope residues 316- DYKDDDDK
domain 323 of SEQ ID
NO:238 C-terminal residues 324- GSRGPYSIVSPKC
vector residues 336 of SEQ ID
NO:238 In another fusion protein used in the experiments described herein, the J
domain from the Erdj3 J protein was linked to a herpes simplex virus type 1 gE protein, which has a relatively weak affinity for the immunoglobulin Fc domain. A Flag epitope tag was linked to the C-terminus of the gE domain as shown for the J-Protein A fusion protein in Example 5 and Figure 11B. The amino acid sequence for a Flag-tagged J domain-gE fusion protein is shown in the table below.
Table 49. Amino Acid Sequence of a Flag-Tagged Erdj3 J domain-gE Fusion Protein.
Protein Region Sequence Amino Acid Sequence (N¨ to C¨ Identifier terminal) Flag-tagged SEQ
ID NO:239 MAPQNLSTFCLLLLYLIGAVIAGRDFYKIL
Erdj3 J domain-GVPRSASIKDIKKAYRKLALQLHPDRNPDD
gE fusion PQAQEKFQDLGAAYEVLSDSEKRDIGGGSG
protein GSGGSGGAAAGTPKTSWRRVSVGEDVSLLP
APGPTGRGPTQKLLWAVEPLDGCGPLHPSW
VSLMPPKQVPETVVDAACMRAPVPLAMAYA
PPAPSATGGLRTDFVWQERAAVVNRSLVIH
GVRETDSGLYTLSVGDIKDPARQVASVVLV
VQPAPVPTPPPTPADYDEDDNDEGEDESLA
GTPASGTPRLPPPPAPPRSWPSAPEVSHVR
GVTVRMETPEAILFSPGETFSTNVSIHAIA
HDDQTYSMDVVWLRFDVPTSCAEMRIYESC
LYHPQLPECLSPADAPCAASTWTSRLAVRS
YAGCSRTNPPPRCSAEAHMEPVPGLAWQAA
SVNLEFRDASPQHSGLYLCVVYVNDHIHAW
GHITISTAAQYRNAVVEQPLPQRGADLAEL
EGDYKDDDDKGSRGPYSIVSPKC
Erdj3 J domain residues 1-83 MAPQNLSTFCLLLLYLIGAVIAGRDFYKIL
of SEQ ID GVPRSASIKDIKKAYRKLALQLHPDRNPDD
NO: 239 PQAQEKFQDLGAAYEVLSDSEKR
Linker residues 84-100 DIGGGSGGSGGSGGAAA
of SEQ ID
NO:239 gE residues 101- GTPKTSWRRVSVGEDVSLLPAPGPTGRGPT
479 of SEQ ID QKLLWAVEPLDGCGPLHPSWVSLMPPKQVP
NO: 239 ETVVDAACMRAPVPLAMAYAPPAPSATGGL
RTDFVWQERAAVVNRSLVIHGVRETDSGLY
TLSVGDIKDPARQVASVVLVVQPAPVPTPP
PTPADYDEDDNDEGEDESLAGTPASGTPRL
PPPPAPPRSWPSAPEVSHVRGVTVRMETPE
AILFSPGETFSTNVSIHAIAHDDQTYSMDV
VWLRFDVPTSCAEMRIYESCLYHPQLPECL
SPADAPCAASTWTSRLAVRSYAGCSRTNPP
PRCSAEAHMEPVPGLAWQAASVNLEFRDAS
PQHSGLYLCVVYVNDHIHAWGHITISTAAQ
YRNAVVEQPLPQRGADLAE
Linker residues 480- LEG
482 of SEQ ID
NO:239 Flag epitope residues 483- DYKDDDDK
domain 490 of SEQ ID
NO:239 C-terminal residues 491- GSRGPYSIVSPKC
vector residues 503 of SEQ ID
NO:239 HEK293 cells were transfected with expression vector plasmids to compare levels of expression in culture medium of the IL13Ra2TF-Fc fusion protein expressed alone, co-expressed with a J domain-Protein A fusion protein (as described above in Example 5), co-expressed with Protein A
("Protein A Only", as described in Example 5), co-expressed with a J domain-Protein G fusion protein (J-Protein G), co-expressed with a J domain fusion protein in which a J domain is linked to a human FcR receptor protein ("J-hFcR"), co-expressed with a J domain fusion protein in which a J domain is linked to a viral FcR receptor protein ("J-vFcR"), co-expressed with a J
domain fusion protein in which a J domain is linked to a herpes simplex virus type 1 gI protein ("J-gI"), co-expressed with a J
domain fusion protein in which a J domain is linked to a herpes simplex virus type 1 gE protein ("J-gE"), and co-expressed with both J-gI and J-gE fusion proteins ("J-gI + J-gE"). Transfected cells were cultured for two days, and samples of cell media were harvested and analyzed by Western blot (immunoblot) assay using an anti-V5 antibody to detect secreted VS-tagged IL13Ra2TF.
Figure 16A shows X-ray film images of chemiluminescent signals of a Western blot analysis of culture media from cultures of transfected cells. Lane 1 of Figure 16A is medium from a culture of cells transfected with an expression vector to express the IL13Ra2TF-Fc fusion protein alone. When expressed alone, some IL13Ra2TF-Fc fusion protein was detected in the medium (lane 1 of Figure 16A). Some IL13Ra2TF-Fc protein was also detected when expressed with Protein A only (lane 3 of Figure 16A), as previously noted above with respect to the results described in Example 5 and Figure 12A. Also as previously described in Example 5 and Figure 12A above, co-expression of IL13Ra2TF-Fc fusion protein with a J domain-Protein A fusion protein significantly enhanced the level of expression of IL13Ra2TF-Fc fusion protein secreted into culture medium (lane 2 of Figure 16A) as compared to the level of expression of IL13Ra2TF alone (lane 1 of Figure 16A) or co-expression of IL13Ra2TF-Fc with Protein A alone (lane 3 of Figure 16A). Co-expression of the IL13Ra2TF-Fc protein with a J domain-Protein G fusion protein also significantly enhanced the level of expression of secreted IL13Ra2TF-Fc protein (lane 4 of Figure 16A) as compared to the level of expression of IL13Ra2TF alone (lane 1 of Figure 16A) or co-expression of IL13Ra2TF-Fc with Protein A alone (lane 3 of Figure 16A).
Viral proteins gI and gE from herpes simplex virus type 1 are known to form a heterodimer, wherein the gE protein weakly binds antibody molecules. In addition, whereas the gE protein alone weakly binds to antibody molecules, gI alone does not bind antibody molecules.
Consistent with these prior findings, co-expression of the IL13Ra2TF-Fc fusion protein with a J domain-gI fusion protein (lane 7 of Figure 16A) resulted in a relatively low level of expression of secreted IL13Ra2TF-Fc that was similar to that observed in cells expressing the IL13Ra2TF-Fc alone (lane 1 of Figure 16A). In contrast, co-expression of the IL13Ra2TF-Fc fusion protein with a J
domain-gE fusion protein significantly enhanced the level of expression of secreted IL13Ra2TF-Fc (lane 8 of Figure 16A). A similar enhancement in the level of secreted IL13Ra2TF-Fc was observed when IL13Ra2TF-Fc was co-expressed with both J-gI and J-gE fusion proteins (lane 9 of Figure 16A), indicating that the J-gI fusion protein does not significantly enhance the level of expression of secreted IL13Ra2TF-Fc, consistent with the previous finding that the gI
protein does not bind Fc domains.
The human Fc binding receptor (hFcR) and the Macaca mulatta rhadinovirus Fc binding receptor (vFcR) are well characterized receptors for binding Fc regions of antibody molecules. J
domain fusions comprising these FcR molecules were prepared and tested for the ability to enhance expression of the IL13Ra2TF-Fc fusion protein. As shown in Figure 16A, co-expression of the IL13Ra2TF-Fc protein with either a J domain-hFcR fusion protein or a J domain-vFcR fusion protein not only failed to enhance expression of secreted IL13Ra2TF-Fc (lanes 5 and 6 of Figure 16A), but actually appeared to suppress even a low level of expression of secreted protein observed in cells expressing the IL13Ra2TF-Fc protein alone (lane 1 of Figure 16A). One possible explanation for such apparent suppression of even baseline secretion may be that the J domain-FcR fusion proteins employed in these experiments becomes caught in the endoplasmic reticulum (ER). Further work is required to find functional constructs containing FcR regions to target and enhance expression of proteins that possess an Fc region.
The results of a densitometry analysis of the chemiluminescent signals in the Western blot in Figure 16A using the NIH ImageJ image processing program are shown in the respective bar graphs in Figure 16B.
Example 9.2. Fusion Proteins Comprising Fc Targeting Peptides for Use in Enhancing Expression of Target Proteins in an Unmodified Arrangement A variety of peptides are known that bind the Fc domain of immunoglobulin molecules. This experiment tested various fusion proteins comprising a J domain (as a protein expression enhancing polypeptide) linked to each of several representative Fc-binding peptides (as a target binding domain) for use in enhancing the level of expression of proteins that possess an Fc domain. The six peptides used to construct fusion proteins are shown in the table below.
Table 50. Amino Acid Sequences of Representative Peptides that Bind Fc Domains.
Peptide Designation Amino Acid Sequence Reference FcBP1 DCAWHLGELVWCT DeLano et al., Science, 287: 1279-1283 (2000) (SEQ ID NO:240) FcBP2 HWRGWV Yang et al., J. Peptide Res., 66(Suppl.
1): 120-(SEQ ID NO:241) 137 (2006) FcBP3 HVHYYW Yang et al., J. Peptide Res., 66(Suppl.
1): 120-(SEQ ID NO:242) 137 (2006) FcBP4 YYWLHH Yang et al., J. Peptide Res., 66(Suppl.
1): 120-(SEQ ID NO:243) 137 (2006) FcBP5 HVHYY Yang et al., J. Peptide Res., 66(Suppl.
1): 120-(SEQ ID NO:244) 137 (2006) FcBP6 YYWL Yang et al., J. Peptide Res., 66(Suppl.
1): 120-(SEQ ID NO:245) 137 (2006) Expression vector plasmids were prepared for expressing J domain fusion proteins comprising a J domain (from the Erdj3 protein) linked to each of the six peptides. The IL13Ra2TF-Fc fusion protein was used as a representative target protein comprising an Fc domain.
The amino acid sequence for a J domain fusion protein comprising a J domain of the Erdj3 J
protein linked to the FcBP1 peptide used in this experiment included a Flag epitope tag and 13 additional C-terminal amino acid residues from the expression vector used to express the protein as shown in the table below.
Table 51. Amino Acid Sequence of a Flag-Tagged Erdj3 J Domain-FcBP1 Fusion Protein.
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) 123456789012345678901234567890 Flag-tagged SEQ ID NO:246 MAPQNLSTFCLLLLYLIGAVIAGRDFYKIL
Erdj3 J domain- GVPRSASIKDIKKAYRKLALQLHPDRNPDD
FcBP1 fusion PQAQEKFQDLGAAYEVLSDSEKRDIGGGSG
protein GSGGSGGAAADCAWHLGELVWCTLEGDYKD
DDDKGSRGPYSIVSPKC
J domain residues 1-83 MAPQNLSTFCLLLLYLIGAVIAGRDFYKIL
(from Erdj3) of SEQ ID GVPRSASIKDIKKAYRKLALQLHPDRNPDD
NO: 246 PQAQEKFQDLGAAYEVLSDSEKR
Linker residues 84-100 DIGGGSGGSGGSGGAAA
of SEQ ID
NO: 246 FcBP1 residues 101- DCAWHLGELVWCT
113 of SEQ ID
NO: 246 Linker residues 114- LEG
116 of SEQ ID
NO: 246 Flag epitope residues 117- DYKDDDDK
domain 124 of SEQ ID
NO: 246 C-terminal residues 125- GSRGPYSIVSPKC
vector residues 137 of SEQ ID
NO: 246 The amino acid sequence for a J domain fusion protein comprising a J domain of the Erdj3 J
protein linked to the FcBP2 peptide used in this experiment included a Flag epitope tag and 13 additional C-terminal amino acid residues from the expression vector used to express the protein as shown in the table below.
Table 52. Amino Acid Sequence of a Flag-Tagged Erdj3 J Domain-FcBP2 Fusion Protein.
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) 123456789012345678901234567890 Flag-tagged SEQ ID NO:247 MAPQNLSTFCLLLLYLIGAVIAGRDFYKIL
Erdj3 J domain- GVPRSASIKDIKKAYRKLALQLHPDRNPDD
FcBP2 fusion PQAQEKFQDLGAAYEVLSDSEKRDIGGGSG
protein GSGGSGGAAAHWRGWVLEGDYKDDDDKGSR
GPYSIVSPKC
J domain residues 1-83 MAPQNLSTFCLLLLYLIGAVIAGRDFYKIL
(from Erdj3) of SEQ ID GVPRSASIKDIKKAYRKLALQLHPDRNPDD
NO: 247 PQAQEKFQDLGAAYEVLSDSEKR
Linker residues 84-100 DIGGGSGGSGGSGGAAA
of SEQ ID
NO: 247 FcBP2 residues 101- HWRGWV
106 of SEQ ID
NO: 247 Linker residues 107- LEG
109 of SEQ ID
NO: 247 Flag epitope residues 110- DYKDDDDK
domain 117 of SEQ ID
NO: 247 C-terminal residues 118- GSRGPYSIVSPKC
vector residues 130 of SEQ ID
NO: 247 The amino acid sequence for a J domain fusion protein comprising a J domain of the Erdj3 J
protein linked to the FcBP3 peptide used in this experiment included a Flag epitope tag and 13 additional C-terminal amino acid residues from the expression vector used to express the protein as shown in the table below.
Table 53. Amino Acid Sequence of a Flag-Tagged Erdj3 J Domain-FcBP3 Fusion Protein.
Protein Region Sequence Amino Acid Sequence (N¨ to C¨ Identifier terminal) 123456789012345678901234567890 Flag-tagged SEQ ID NO:248 MAPQNLSTFCLLLLYLIGAVIAGRDFYKIL
Erdj3 J domain- GVPRSASIKDIKKAYRKLALQLHPDRNPDD
FcBP3 fusion PQAQEKFQDLGAAYEVLSDSEKRDIGGGSG
protein GSGGSGGAAAHVHYYWLEGDYKDDDDKGSR
GPYSIVSPKC
J domain residues 1-83 MAPQNLSTFCLLLLYLIGAVIAGRDFYKIL
(from Erdj3) of SEQ ID GVPRSASIKDIKKAYRKLALQLHPDRNPDD
NO: 248 PQAQEKFQDLGAAYEVLSDSEKR
Linker residues 84-100 DI GGGSGGSGGSGG AAA
of SEQ ID
NO: 248 FcBP3 residues 101- HVHYYW
106 of SEQ ID
NO: 248 Linker residues 107- LEG
109 of SEQ ID
NO: 248 Flag epitope residues 110- DYKDDDDK
domain 117 of SEQ ID
NO: 248 C-terminal residues 118- GSRGPYSIVSPKC
vector residues 130 of SEQ ID
NO: 248 The amino acid sequence for a J domain fusion protein comprising a J domain of the Erdj3 J
protein linked to the FcBP4 peptide used in this experiment included a Flag epitope tag and 13 additional C-terminal amino acid residues from the expression vector used to express the protein as shown in the table below.
Table 54. Amino Acid Sequence of a Flag-Tagged Erdj3 J domain-FcBP4 Fusion Protein.
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) 123456789012345678901234567890 Flag-tagged SEQ ID NO:249 MAPQNLSTFCLLLLYLIGAVIAGRDFYKIL
Erdj3 J domain- GVPRSASIKDIKKAYRKLALQLHPDRNPDD
FcBP4 fusion PQAQEKFQDLGAAYEVLSDSEKRDIGGGSG
protein GSGGSGGAAAYYWLHHLEGDYKDDDDKGSR
GPYSIVSPKC
J domain residues 1-83 MAPQNLSTFCLLLLYLIGAVIAGRDFYKIL
(from Erdj3) of SEQ ID GVPRSASIKDIKKAYRKLALQLHPDRNPDD
NO: 249 PQAQEKFQDLGAAYEVLSDSEKR
Linker residues 84-100 DIGGGSGGSGGSGGAAA
of SEQ ID
NO: 249 FcBP4 residues 101- YYWLHH
106 of SEQ ID
NO: 249 Linker residues 107- LEG
109 of SEQ ID
NO: 249 Flag epitope residues 110- DYKDDDDK
domain 117 of SEQ ID
NO: 249 C-terminal residues 118- GSRGPYSIVSPKC
vector residues 130 of SEQ ID
NO: 249 The amino acid sequence for a J domain fusion protein comprising a J domain of the Erdj3 J
protein linked to the FcBP5 peptide used in this experiment included a Flag epitope tag and 13 additional C-terminal amino acid residues from the expression vector used to express the protein as shown in the table below.
Table 55. Amino Acid Sequence of a Flag-Tagged Erdj3 J domain-FcBP5 Fusion Protein.
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) 123456789012345678901234567890 Flag-tagged SEQ ID NO:250 MAPQNLSTFCLLLLYLIGAVIAGRDFYKIL
Erdj3 J domain- GVPRSASIKDIKKAYRKLALQLHPDRNPDD
FcBP5 fusion PQAQEKFQDLGAAYEVLSDSEKRDIGGGSG
protein GSGGSGGAAAHVHYYLEGDYKDDDDKGSRG
PYSIVSPKC
J domain residues 1-83 MAPQNLSTFCLLLLYLIGAVIAGRDFYKIL
(from Erdj3) of SEQ ID GVPRSASIKDIKKAYRKLALQLHPDRNPDD
NO:250 PQAQEKFQDLGAAYEVLSDSEKR
Linker residues 84-100 DI GGGSGGSGGSGG AAA
of SEQ ID
NO:250 FcBP5 residues 101- HVHYY
105 of SEQ ID
NO:250 Linker residues 106- LEG
108 of SEQ ID
NO : 250 Flag epitope residues 109- DYKDDDDK
domain 116 of SEQ ID
NO:250 C-terminal residues 117- GSRGPYSIVSPKC
vector residues 129 of SEQ ID
NO:250 The amino acid sequence for a J domain fusion protein comprising a J domain of the Erdj3 J
protein linked to the FcBP6 peptide used in this experiment included a Flag epitope tag and 13 additional C-terminal amino acid residues from the expression vector used to express the protein as shown in the table below.
Table 56. Amino Acid Sequence of a Flag-Tagged Erdj3 J domain-FcBP6 Fusion Protein.
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) 123456789012345678901234567890 Flag-tagged SEQ ID NO:251 MAPQNLSTFCLLLLYLIGAVIAGRDFYKIL
Erdj3 J domain- GVPRSASIKDIKKAYRKLALQLHPDRNPDD
FcBP6 fusion PQAQEKFQDLGAAYEVLSDSEKRDIGGGSG
protein GSGGSGGAAAYYWLLEGDYKDDDDKGSRGP
YSIVSPKC
J domain residues 1-83 MAPQNLSTFCLLLLYLIGAVIAGRDFYKIL
(from Erdj3) of SEQ ID GVPRSASIKDIKKAYRKLALQLHPDRNPDD
NO:251 PQAQEKFQDLGAAYEVLSDSEKR
Linker residues 84-100 DIGGGSGGSGGSGGAAA
of SEQ ID
NO:251 FcBP6 residues 101- YYWL
104 of SEQ ID
NO:251 Linker residues 105- LEG
107 of SEQ ID
NO:251 Flag epitope residues 108- DYKDDDDK
domain 115 of SEQ ID
NO:251 C-terminal residues 116- GSRGPYSIVSPKC
vector residues 128 of SEQ ID
NO:251 Transfected cells were cultured for two days, and samples of cell media were harvested and analyzed by Western blot assay using an anti-V5 antibody to detect secreted VS-tagged IL13Ra2TF-Fc fusion protein. Figure 17A shows X-ray film images of chemiluminescent signals of the Western blot analysis of culture media. As shown in Figure 17A, co-expression of the IL13Ra2TF-Fc fusion protein with each of the six J domain-peptide fusion proteins in HEK293 transfectants significantly enhanced the level of expression of secreted IL13Ra2TF-Fc fusion protein (lanes 4-9) as compared to the level of expression of IL13Ra2TF-Fc fusion protein alone (lanes 1 and 3).
The experiment also included for comparison the effect of co-expression of IL13Ra2TF-Fc fusion protein with a J domain-Protein A fusion protein (lane 2) or with a J domain-Protein G fusion protein (lane 10) on the expression of secreted IL13Ra2TF-Fc fusion protein. As shown in Figure 17A, co-expression of IL13Ra2TF-Fc fusion protein with either J domain-Protein A fusion protein (lane 2) or the J domain-Protein G fusion protein (lane 10) significantly enhanced the level of expression of secreted the IL13Ra2TF-Fc fusion protein.
The results of a densitometry analysis of the chemiluminescent signals in the Western blot in Figure 17A using the NIH ImageJ image processing program are shown in the respective bar graphs in Figure 17B.
Conclusion of Results of Experiments The results of the experiments described above indicate that co-expression of a target protein of interest and a fusion protein comprising a protein expression enhancing polypeptide domain linked to a target protein binding domain that binds the target protein significantly enhances the level of expression of the target protein in its proper cellular or extracellular location as compared to the level of expression of the target protein in the absence of the fusion protein.
Example 10. Minimal Sequence Requirements for Protein Expression Enhancing Polypeptides Further analysis was undertaken to determine the minimal amino acid sequence that is effective for enhancing the level of expression of a target protein of interest when employed in an unmodified or a modified arrangement.
Sequence homology analysis using BLAST was conducted on the existing library of J domain sequences to determine whether J domains shared a similar minimal "core"
sequence that could enhance the level of protein expression. The analysis indicated that the J
domain of the Erdj3 protein was typical of J domains of other J proteins. Since the J domain of Erdj3 was already known to be effective at enhancing protein expression in both the modified and unmodified arrangements (see, examples above), it was chosen for further deletion and substitution mutation analysis to determine whether a minimal polypeptide sequence could be identified that retained protein expression enhancing activity.
In this study, various deletion and substitution mutations of the J domain of Erdj3 were assessed for enhancing expression of an engineered IL13Ra2TF-V5-Fc protein as the target protein of interest. This engineered protein possesses a V5 epitope tag between the IL13Ra2TF polypeptide and the Fc domain, permitting easy detection with an anti-V5 antibody. Fusion proteins were constructed comprising either the full length J domain of Erdj3 or the various mutated polypeptides linked to Protein A, which binds the Fc domain of the engineered IL13Ra2-Fc target protein (thus acting as a target protein binding domain). Thus, for each of the mutated polypeptides, the general formula of the corresponding fusion proteins used in the study was:
signal sequence¨linker 1¨(J domain, fragment or J domain analog polypeptide sequence¨linker 2¨
Protein A¨linker 3¨Flag epitope tag.
The amino acid sequences of the domains of these fusion proteins, excluding the inserted J
domain, J domain fragment, or J domain analog sequences, is shown in the table below.
Table 57. Amino Acid Structure of Test Flag-Tagged Protein A Fusions.
Protein Region Sequence Amino Acid Sequence Identifier 123456789012345678901234567890 signal sequence SEQ ID MGVKVLFALICIAVAEA
NO:251 linker 1 SEQ ID GTGSGEF
NO:252 J domain, (various polypeptide fragment or sequences) analog sequence linker 2 SEQ ID DIGGGSGGSGGSGGAAA
NO: 122 Protein A SEQ ID ADNKFNKEQQNAFYEILNMPNLNEEQRNGF
NO:254 IQSLKDDPSQSANVLGEAKKLNDSQAPK
linker 3 SEQ ID LEG
NO:255 Flag epitope tag SEQ ID DYKDDDDK
NO: 111 The protein expression enhancing activity of each fusion protein was determined by dot blot assay using detectable anti-VS antibody. The IL13Ra2-V5-Fc target protein was expressed with or without the fusion proteins containing each mutated polypeptide sequence, and the cell culture medium was harvested and briefly spun to remove debris. The sample was blotted onto nitrocellulose membrane, and the dried membrane was processed for immunoblot assay. The deletion and substitution polypeptides tested for protein expression enhancement activity are shown in the table below along with the protein expression enhancing activity determined by immunoblotting.
Table 58. Amino Acid Sequences of Polypeptides Tested for Protein Expression Enhancing Activity.
Polypeptide Sequence Polypeptide Amino Acid Sequence Activity*
No. Identifier 3 SEQ ID NO:256 GRE)FYK I I, GVPRSAS KDKKAYP.H.L.ALQL, HA
I-IP DRY? DDPQAQEKFODL, GAAYEVI, S D SEK
3-1 SEQ ID NO:257 L. GVPR.SA S KD IKKAYRKL ALQL DRNP HA
D P QE KIT Q D GAAYEVI, S D S EKR
3-2 SEQ ID NO:258 S AS IKD IKKAYRKLALQL, I-IP D RNP D DP QAQ HA
EKFQDLGAAYEVLSDSEKR
3-3 SEQ ID NO:259 GRDFY:K I LGVPRSAS I KD I KKAYRKLALQL HA
HPORNPDDPQAQ.EKFULG
3-4 SEQ ID NO:260 if LGVPRSAS IKDIKKAYRKLALQI,I-IPDP,NP HA
D DP QAQE KFQDLG
3-5 SEQIDNO:261 SAfIKDIKKAYRKLADDLHFDRNPDDPQAQ HA
Polypeptide Sequence Polypeptide Amino Acid Sequence Activity*
No. Identifier EK.FQDLG
3-6 SEQ ID NO:262 KAY RKLAL Q L HP MN'? D DP c),AOKE QDLG NA
3-7 SEQ ID NO:263 KAYRKLALQL HP DRNP DDPQAQEKFQDL NA
AYEVL SDSEKR
3-8 SEQ ID NO:264 LQLH2DRN2DDPOAQEKFULLG NA
3-9 SEQ ID NO:265 LQLHPDRNPDDPQAQKFQDLGAYEVLS D NA
SEKR
3-10 SEQ ID NO:266 I KD IKKAI RELALOL HP DRN D DP QAOEKF HA
ODLG
3-11 SEQ ID NO:267 S S TKD ALQI ,FIPDRNPDDP9AQ HA
3-12 SEQ ID NO:268 SAS IKDTKKAYRKLADDT,HP HA
3-13 SEQ ID NO:269 IKE) I KIK.7-\ YRKI2\.LQE:LIP DRNP D DP QAQE
HA
3-14 SEQ ID NO:270 IKDIKAYPLZLQLHPDRN HA
3-15 SEQ ID NO:271 D K KAYRK.LALQL I-IP DRNP D DP ()A QE HA
3-16 SEQ ID NO:272 IRD IKKAYRKLALQ L HP D HA
3-17 SEQ ID NO:273 IKE) KKAY RKLALOL HA
3-18 SEQ ID NO:274 D KKAY RKLALOL HA.
3-19 SEQ ID NO:275 D KKAYRKLALQ HA
3-20 SEQ ID NO:276 D =AI RKLAL HA.
3-21 SEQ ID NO:277 D KKI-\ YRKLA HA
3-22 SEQ ID NO:278 s .i.K.KAYRKL NA.
3-23 SEQ ID NO:279 1:-.) KKAYRK NA
3-24 SEQ ID NO:280 D K KAY R NA
3-25 SEQ ID NO:281 IKKRKL2LL HA
3-26 SEQ ID NO:282 KICA.YRKLALOL NA
3-27 SEQ ID NO:283 I KKAYRKLALQ HA
3-28 SEQ ID NO:284 I KKAYRKLAL HA
3-29 SEQ ID NO:48 I KKAYRKLA HA.
3-30 SEQ ID NO:285 I KKAYRKL A
3-31 SEQ ID NO:286 KKAYRKLALQ NA.
3-32 SEQ ID NO:287 k-H'T.AYP, A NA
3-33 SEQ ID NO:288 KKT;IRKLA NA
3-34 SEQ ID NO:289 K AY RK LAT, Q NA
3-35 SEQ ID NO:290 I KKAYRK NA
3-36 SEQ ID NO:291 IRKAYR NA
3-37 SEQ ID NO:292 I KAYRK LALO NA
3-38 SEQ ID NO:293 I KKYRKLALQ A
3-39 SEQ ID NO:294 I KKARKLAL NA
3-40 SEQ ID NO:49 I KKAYKLALQ HA
3-41 SEQ ID NO:50 .1.,T.K7Y. RLALQ HA
3-42 SEQ ID NO:51 IKKA.YRKALQ HA
3-43 SEQ ID NO:52 K.K:a 77R KT :T,c) HA
3-44 SEQ ID NO:295 I KAYRKI2s1. NA
3-45 SEQ ID NO:53 iKKYPLZ A
3-46 SEQ ID NO:54 IKKAYKLA A
3-47 SEQ ID NO:55 IRKAYRLA A
3-48 SEQ ID NO:56 I KKAYRKA A
3-49 SEQ ID NO:57 LKKAYRKLA HA.
Polypeptide Sequence Polypeptide Amino Acid Sequence Activity*
No. Identifier 3-50 SEQ ID NO:58 -\,risT.K7A.YRKI:7\ HA
3-51 SEQ ID NO:59 MKKAYRK LA HA
3-52 SEQ ID NO:60 AKKAYRKLA HA
3-53 SEQ ID NO:296 SKKAYRKLA NA
3-54 SEQ ID NO:297 FKKAYRKLA NA
3-55 SEQ ID NO:298 I AQAYRKLA NA
3-56 SEQ ID NO:299 I LAAYRKLA NA
3-57 SEQ ID NO:61 I AK AY RK I: .7J% A
3-58 SEQ ID NO:62 I K7\ AYRK LA A
3-59 SEQ ID NO:63 I KKR77. RKE:7\ HA
3-60 SEQ ID NO:64 I KK SYRK LA A
3-61 SEQ ID NO:65 I IsT.KQYRKI:7\ A
3-62 SEQ ID NO:66 I KKEYRKLA A
3-63 SEQ ID NO:67 I KKFY. RKLA A
3-64 SEQ ID NO:68 I KKCYRKLA A
3-65 SEQ ID NO:69 I KKAF RKLA HA.
3-66 SEQ ID NO:300 I KKAHRKLA NA
3-67 SEQ ID NO:301 if KI--Aiii RI--H,A. NA.
3-68 SEQ ID NO:70 ii.T.T.K.:Al;^m.KE:.%% HA
3-69 SEQ ID NO:302 I KKAARK LA NA
3-70 SEQ ID NO:303 I IsT.KAS RKI:7\ NA
3-71 SEQ ID NO:304 1KKAYHQLA NA
3-72 SEQ ID NO:305 I KKAY 1 Q LA NA
3-73 SEQ ID NO:306 I KE<AYFS LA NA
3-74 SEQ ID NO:307 I KKAY RKO S NA
3-75 SEQ ID NO:308 I KKAYRKQ C NA
3-76 SEQ ID NO:309 I KIU,YRK D iii NA.
3-77 SEQ ID NO:71 T .IT.K.7-_\-,7. RKQ .7J% HA
3-78 SEQ ID NO:72 I K KAYRK MA HA
3-79 SEQ ID NO:73 I KK23,:y7R.K I 7\ A
3-80 SEQ ID NO:74 I KKAYRKAA A
3-81 SEQ ID NO:75 I KKAYRKVA A
3-82 SEQ ID NO:76 I KKAYRKRA A
3-83 SEQ ID NO:77 I KKAY RKLM HA.
3-84 SEQ ID NO:78 I KKAYRKIL I tiA
3-85 SEQ ID NO:79 1 KKAYRKL v HA.
3-86 SEQ ID NO:80 I .1.T.K.A77. RKLC A
3-87 SEQ ID NO:81 if KKAyRka, s HA
3-88 SEQ ID NO:82 I KK23,:y7R.K I: Y A.
3-89 SEQ ID NO:83 I RKAYRK IL S I: T IL A
3-90 SEQ ID NO:84 I KKQY R. 1_, I: S I, KY A
3-91 SEQ ID NO:85 I KKAF iiKLAMKY HA
3-92 SEQ ID NO:86 'I ROAFKKLALKL A
3-93 SEQ ID NO:87 I I KAYRKLAL QW A
3-94 SEQ ID NO:88 I ARAY ROLARR Y HA.
3-95 SEQ ID NO:89 I KRAYRRQAL RI HA
3-96 SEQ ID NO:90 I KI--: 3 YRI,J,AL }--- y HA
3-97 SEQ ID NO:91 I .1.T.K13, v F RT = 7J%T1KY HA
3-98 SEQ ID NO:310 M7R KAY I: K K C NA
Polypeptide Sequence Polypeptide Amino Acid Sequence Activity*
No. Identifier 3-99 SEQ ID NO:311 I LAEFKVRAL NA
* "HA" = high activity, i.e., protein expression enhancement activity is significantly enhanced, e.g., similar to that provided by the full-length J domain of the Erdj3 protein, as compared to negative control (no fusion protein used); "A" = improved protein expression enhancement activity in comparison to negative control (no fusion protein used); level of protein production typically less than provided by the full-length J domain of Erdj3; "NA" = no activity compared to negative control.
As indicated in the above table, each mutated polypeptide was assessed for expression enhancing activity when co-expressed with the IL13Ra2-V5-Fc target protein.
The levels of expression were classified as high activity ("HA"), activity ("A"), or no activity ("NA"). Examples of these levels of expression are shown in the immunoblot in Figure 18. The level of expression of the IL13Ra2-V5-Fc target protein in the absence of a fusion protein was taken as "no activity". See, lane 2 (from the left) in Figure 18). Co-expression of a fusion protein comprising the complete J domain of Erdj3, designated polypeptide 3 in Table 58 above, linked to Protein A
dramatically enhanced the level of expression of the secreted IL13Ra2-V5-Fc target protein. See, lane 3, from the left, in Figure 18. This level of expression enhancement is designated "High Activity". As shown in lane 4 of Figure 18, co-expression of a fusion protein comprising an internal deletion mutated polypeptide, designated 3-45, linked to Protein A clearly provided a significantly enhanced level of expression of the secreted IL13Ra2-V5-Fc target protein as compared to the control (no fusion protein, lane 2 of Figure 18), but the expression level was somewhat less than the high activity shown in lane 3 of Figure 18. This level of expression enhancement is designated "Activity." In contrast, as shown in lane 5 of Figure 18, co-expression of a fusion protein comprising a substitution mutation within the minimal polypeptide sequence, designated 3-72, linked to Protein A provided no more than the level of expression detected for the control in lane 2 of Figure 18. This was designated "No Activity".
The results of this analysis indicated that an internal polypeptide fragment of the J domain of Erdj3, designated 3-29, has the minimal polypeptide sequence (IKKAYRKLA; SEQ
ID NO:48) that provides a high activity for enhancing protein expression. The polypeptide 3-29 sequence is located within a helix II of the J domain, but does not include any residues of the adjacent (C-proximal) loop domain.
Various mutations of the J domain fragment 3-29 sequence were made and assessed for protein expression enhancing activity. The mutated sequences are shown in the table above, see polypeptide nos. 3-44 to 3-88.
The J domains of other J proteins were also assessed for internal polypeptide sequences located in positions similar to that of the 3-29 polypeptide within the J
domain of Erdj3. Such sequences are designated 3-89 to 3-99 in the table above. Most of these polypeptides provided complete or partial activity in the assay for enhanced expression of the secreted IL13Ra2-V5-Fc 08.04.2015 =
target protein. However, two of the polypeptides, designated 3-98 and 3-99, possessed amino acid sequences that diverged considerably from that of polypeptide 3-29, and these polypeptides also lacked protein expression enhancing activity.
Example 11. Structural Formula Defining a New Family of Protein Expression Enhancing Polvueotides Below is an overview of the analysis of the polypeptide sequence mutation data that led not only to the discovery of the minimal sequence of a polypeptide fragment of the J domain of Erdj3 that provides protein expression enhancing activity (polypeptide 3-29, SEQ ID
NO:48), but also to a structural formula that defines a new family of protein expression enhancing polypeptides as shown below.
Figure 19 shows an alignment of the amino acid sequence for the J domain of Erdj3 with a series of deletion mutated polypeptides along with their protein expression enhancing activity determined using the unmodified arrangement in which each polypeptide was used to construct a Hag-tagged Protein A fusion protein as described above. The level of expression of secreted IL13Ra2-V5-Fc target protein in the media of cultures of cells co-expressing each Flag-tagged Protein A fusion and the IL13Ra2-V5-Fc target protein was determined by immunoblot using an anti-V5 antibody as described above.
Deletion mutated polypcptides designated 3-6, 3-7, 3-8, and 3-9 in Figure 19 all lacked =
protein expression enhancing activity (no activity), indicating that ahelix II
amino acid sequences are essential for activity. Deletion mutated polypeptides designated 3-15 and 3-17 in Figure 19 retained high activity, indicating that the sequence DIKICAYRKLALQL (SEQ ID NO:274) was sufficient for providing high protein expression enhancing activity. This polypeptide was then subjected to further mutation analysis as shown in the table below.
Table 59. Amino Acid Sequence and Protein Expression Enhancing Activity of Mutated Polypeptides.
PP No. an sequence SEQ ID NO: Act 3-21 10 DI KKAYRKLA 277 HA ) The last amino acid is essential 3-25 12 I KKAYRKLALQL 281 HA }The first amino acid is essential 3-29 9 IKKAYRKLA 48 HA 4- Identified Minimum Sequence = 3-30 8 IKKAYRKL 285 A
AMENDED SHEET -IPEA/US
PCT/US2013/073442 08.04.2015 3-33 8 .KKAYRKLA 288 NA
As noted above, the difference in activity between that of the polypeptide designated 3-21 (high activity, HA) and that of the polypeptide designated 3-22 (no activity, NA) indicated that the C-terminal leucine (L) residue is essential for protein expression enhancing activity. Similarly, the difference in activity between that of polypeptide 3-25 and that of polypeptide 3-26 indicated that the N-terminal isoleucine (I) is essential for activity. As noted previously, polypeptide 3-29 defines the minimal polypeptide sequence of the J domain of Erdj3 for providing complete protein expression enhancing activity.
In addition to the results described above, additional analyses as outlined below led to the identification of an essential amino acid consensus sequence for a protein expression enhancing polypeptide of the invention.
To identify the essential amino acid sequence for providing protein expression enhancing activity, each amino acid of the 3-29 sequence was deleted and the polypeptide tested for protein expression enhancing activity using the IL13Ra2-V5-Fc target protein in the unmodified arrangement described above.
Starting with the minimum sequence of the polypeptide fragment of the J domain of Erdj3, the polypeptide 3-29 sequence (I KKAYRKLA; SEQ ID NO:48) was subjected to the following mutation analysis at each of the nine amino acid positions:
(a) 3-29: I KKAYRKLA (SEQ ID NO:48), regarding position 1, see summary analysis (1) below, (b) 3-44: IK_AYRKLA (SEQ ID NO:295), no activity, regarding position 3, see summary analysis (2) below, (c) 3-45: IKK YRKLA (SEQ ID NO:53), some activity, regarding position 4, see summary analysis (3) below, (d) 3-39: IKKA_RKLA (SEQ ID NO:294), no activity, regarding position 5, see summary analysis (4), below, (e) 3-46: IKKAY_KLA (SEQ ID NO:54), some activity, regarding position 6, see summary analysis (5) below, (I) 3-47: IKKAYR_LA (SEQ ID NO:55), some activity, regarding position 7, see summary analysis (5) below, =
(g) 3-48: IKKAYRK_A (SEQ ID NO:56), some activity, regarding position 8, see summary analysis (6) below, AMENDED SHEET -IPEA/US
(h) 3-29: I KKAYRKLA (SEQ ID NO:48), high activity, regarding position 9, see summary analysis (6) below.
Summary Analyses (1) I KKAYRKLA (SEQ ID NO:48) First amino acid is essential for the activity.
The result for the comparison of the first amino acid among J members (47 J
proteins) indicated the following incidences of amino acids at position 1:
1(34), L (6), V (4), M (1), A (1), R (1) All of these amino acids have a nonpolar side chain group, except Arg (R).
The following constructions derived from other J members were made and tested:
3-49: LKKAYRKLA (SEQ ID NO:57), high activity 3-50: VKKAYRKLA (SEQ ID NO:58), high activity 3-51: MKKAYRKLA (SEQ ID NO:59), high activity 3-52: AKKAYRKLA ( SEQ ID NO:60), high activity 3-53: SKKAYRKLA (SEQ ID NO:296), no activity 3-54: FKKAYRKLA (SEQ ID NO:297), no activity.
Therefore, it the first position is preferably an amino acid with a nonpolar amino acid side group that is I, L, V, A, and M.
(2) IK AYRKLA (SEQ ID NO:295); no activity This implies two possibilities:
a) two amino acids are required at this position 3-55: IAQAYRKLA (SEQ ID NO:298), no activity 3-56: ILAAYRKLA (SEQ ID NO:299), no activity indicating some specific amino acid is required, b) two lysines are required or only one is enough.
Through the comparison of these two positions among J members (47 J proteins), these two positions are well conserved as indicated by the following incidences:
KK (26), KR (5), RK (3), AR (3), KA (2), KQ (2), KL (1), IK (1), NK (1), RQ
(1), RD (1), LA (1) All of these harbor at least one amino acid with a basic amino acid side chain with one exception.
Therefore, the following substitution mutations were made and tested:
3-57: IAKAYRKLA (SEQ ID NO:61), some activity 3-58: IKAAYRKLA (SEQ ID NO:62), some activity.
Therefore, it is concluded that at least one amino acid at positions 2 and 3 is a basic amino acid K or R.
(3) IKK YRKLA (SEQ ID NO:53), some activity This result indicates that it is better to have some amino acid in this position but not absolutely necessary.
Through a comparison of this position among J members (47 J proteins), this position is also well conserved as indicated by the following incidences:
A (36), K (2), R (2), S (2), Q (2), T (1), I (1), E (1) The following polypeptides were constructed and tested:
Basic amino acid 3-59 IKKRYRKLA (SEQ ID NO:63); high activity Polar uncharged amino acid 3-60 IKKSYRKLA (SEQ ID NO:64); some activity Polar uncharged amino acid 3-61 IKKQYRKLA (SEQ ID NO:65); some activity Acidic amino acid 3-62 IKKEYRKLA (SEQ ID NO:66); some activity Aromatic amino acid 3-63 IKKFYRKLA (SEQ ID NO:67); some activity Polar uncharged amino acid 3-64 IKKCYRKLA (SEQ ID NO:68); some activity.
From the above substitution mutations, it is concluded that any of the 20 naturally occurring amino acids may occupy position 4 since deletion at this position still retains activity.
(4) IKKA_RKLA (SEQ ID NO:312); no activity This result implies that some amino acid in position 5 is essential.
Through the comparison of this position among J members (47 J proteins), the amino acid distribution is given below.
Y (34), F (10), H (2), 1(1) Therefore the following polypeptides were made and tested:
Aromatic amino acid 3-65 IKKAFRKLA (SEQ ID NO:69), high activity Positive charged amino acid 3-66 IKKAHRKLA (SEQ ID NO:300), no activity Nonpolar amino acid 3-67 IKKAIRKLA (SEQ ID NO:301), no activity Aromatic amino acid 3-68 IKKAWRKLA (SEQ ID NO:70), high activity Nonpolar amino acid 3-69 IKKAARKLA (SEQ ID NO:302), no activity Nonpolar amino acid 3-70 IKKASRKLA (SEQ ID NO:303), no activity.
Therefore, the amino acid at position 5 is an aromatic amino acid that is Y, F, or W.
(5) IKKAY KLA (SEQ ID NO:313), some activity IKKAYR LA (SEQ ID NO:314) some activity Through the comparison of this position among J members (47 J proteins), the case that at least one amino acid is a basic amino acid is 43 out of 47 (both 23, and either one 20).
The following mutated polypeptides have two amino acids replaced at positions 6 and 7:
3-71 IKKAYHQLA (SEQ ID NO:304), no activity 3-72 IKKAYYQLA (SEQ ID NO:305), no activity 3-73 IKKAYF S LA (SEQ ID NO:306), no activity.
Therefore, at least one of the amino acids at positions 6 and 7 is a basic amino acid K or R.
(6) IKKAYRK A (SEQ ID NO:56), some activity I KKAYRKL (SEQ ID NO:315), some activity Through the comparison of these positions among J members (47 J proteins), the case that two positions are occupied with L and A is 25 out of 47, in which all of them are L-A. The case that at least one amino acid at these positions is L or A is 14, and 8 cases indicates neither L nor A.
The following mutated polypeptides were made with two amino acids replaced and tested for activity:
3-74 IKKAYRKQS (SEQ ID NO:307), no activity 3-75 IKKAYRKQC (SEQ ID NO:308), no activity 3-76 IKKAYRKD I (SEQ ID NO:309), no activity.
The following mutated polypeptides have position 8 replaced as indicated:
Polar amino acid 3-77 IKKAYRKQA (SEQ ID NO:71), high activity Nonpolar amino acid 3-78 IKKAYRKMA (SEQ ID NO:72), high activity Nonpolar amino acid 3-79 IKKAYRK IA (SEQ ID NO:73), some activity Nonpolar amino acid 3-80 IKKAYRKAA (SEQ ID NO:74), some activity Nonpolar amino acid 3-81 IKKAYRKVA (SEQ ID NO:75), some activity Basic amino acid 3-82 IKKAYRKRA (SEQ ID NO:76), some activity.
The following mutated polypeptides have position 9 replaced as indicated:
Nonpolar amino acid 3-83 IKKAYRKLM (SEQ ID NO:77), high activity Nonpolar amino acid 3-84 IKKAYRKL I (SEQ ID NO:78), high activity Nonpolar amino acid 3-85 IKKAYRKLV (SEQ ID NO:79), high activity Polar uncharged amino acid 3-86 IKKAYRKLC (SEQ ID NO:80), some activity Polar uncharged amino acid 3-87 IKKAYRKL S (SEQ ID NO:81), high activity Aromatic amino acid 3-88 IKKAYRKLY (SEQ ID NO:82), some activity.
Results of other mutated polypeptides:
Replacement L and A 3-42 IKKAYRKALQ (SEQ ID NO:51), high activity Double L 3-43 IKKAYRKLLQ (SEQ ID NO:52), high activity.
Therefore, at least one of the amino acids at X8 and X9 is L or A.
Through these studies, it is concluded that an isolated protein expression enhancing J domain analog polypeptide comprises the formula:
X1-X2-X3-X4-X5-X6-X7-X8-X9 (SEQ ID NO:47), wherein:
X1 is isoleucine (I), leucine (L), valine (V), alanine (A), or methionine (M);
X2 and X3 are each independently any amino acid with the proviso that one or both are lysine (K) or arginine (R);
X4 is any amino acid or X4 may be absent when X1 through X3 are present and X5 through X9 are present;
X5 is tyrosine (Y), tryptophan (W), or phenylalanine (F);
X6 and X7 are each independently any amino acid with the proviso that one or both are lysine (K) or arginine (R); or either one of X6 and X7 may be absent when the other is K or R and when X1 through X5 are present and X8 and X9 are present;
and X8 and X9 are any amino acid with the proviso that one or both are leucine (L) or alanine (A); or one of X8 and X9 may be absent when the other is L or A and when X1 through X7 are present.
The above formula is applicable to the sequence of the following polypeptide fragments from other J proteins, and all of these polypeptides have activity:
Erdjl 3-89 IRKAYRKLSLTL (SEQ ID NO:83), some activity Erdj2 3-90 IKKQYRLLSLKY (SEQ ID NO:84), some activity Erdj4 3-91 IKKAFHKLAMKY (SEQ ID NO :85), high activity Erdj5 3-92 IRQAFKKLALKL (SEQ ID NO:86), some activity Erdj6 3-93 IIKAYRKLALQW (SEQ ID NO:87), some activity Erdj7 3-94 IARAYRQLARRY (SEQ ID NO: 88), high activity Hsp40 3-95 IKRAYRRQALRY (SEQ ID NO: 89), high activity CSP 3-96 IKKSYRKLALKY (SEQ ID NO:90), high activity DnaJ 3-97 IKKAYKRLAMKY (SEQ ID NO:91), high activity The sequences below from other J proteins do not match the above formula and these polypeptides do not have protein expression enhancing activity:
From 5V40 J protein 3-98 MRKAYLKKC (SEQ ID NO:310), no activity From Dnaj homolog subfamily C member 12 3-99 ILAEFKVRAL (SEQ ID
NO:311), no activity.
The analyses and results summarized above indicate that the above formula defines a new family of polypeptides that provide protein expression enhancing activity.
Example 12. Minimal Polypeptide of J Domain Enhances Target Protein Expression in a Modified Arrangement As explained above, the results of the mutation analysis of the J domain of Erdj3 indicated that an internal polypeptide sequence, designated 3-29, is the minimal sequence with the J domain for a polypeptide (IKKAYRKLA; SEQ ID NO:48) to provides high activity for enhancing protein expression using the above assay in an unmodified arrangement. The protein expression enhancing activity of the 3-29 polypeptide was also examined in a modified arrangement.
In this experiment, a first fusion protein comprised IL13Ra2TF as the target protein of interest linked to the BSC1 polypeptide (SEQ ID NO:48), which in turn was linked to an V5 epitope tag. This fusion protein was designated IL13Ra2TF-BSC1 shown in the table below.
Table 60. Amino Acid Sequence of a V5-Tagged IL13Ra2TF-BSC1 Fusion Protein.
Protein Region Sequence Amino Acid Sequence (N¨ to C¨ Identifier terminal) 123456789012345678901234567890 IL13Ra2TF-BSC1 SEQ ID NO:316 MAFVCLAIGCLYTFLISTTFGCTSSSDTEI
protein KVNPPQDFEIVDPGYLGYLYLQWQPPLSLD
HFKECTVEYELKYRNIGSETWKTIITKNLH
YKDGFDLNKGIEAKIHTLLPWQCTNGSEVQ
SSWAETTYWISPQGIPETKVQDMDCVYYNW
QYLLCSWKPGIGVLLDTNYNLFYWYEGLDH
ALQCVDYIKADGQNIGCRFPYLEASDYKDF
YICVNGSSENKPIRSSYFTFQLQNIVKPLP
PVYLTFTRESSCEIKLKWSIPLGPIPARCF
DYEIEIREDDTTLVTATVENETYTLKTTNE
TRQLCFVVRSKVNIYCSDDGIWSEWSDKQC
WEGEDLSKKGTGSEFIKKAYRKLADIGGGS
GGSGGSGGAAALEGKPIPNPLLGLDST
IL13Ra2TF residues 1-339 MAFVCLAIGCLYTFLISTTFGCTSSSDTEI
of SEQ ID KVNPPQDFEIVDPGYLGYLYLQWQPPLSLD
NO: 316 HFKECTVEYELKYRNIGSETWKTIITKNLH
YKDGFDLNKGIEAKIHTLLPWQCTNGSEVQ
SSWAETTYWISPQGIPETKVQDMDCVYYNW
QYLLCSWKPGIGVLLDTNYNLFYWYEGLDH
ALQCVDYIKADGQNIGCRFPYLEASDYKDF
YICVNGSSENKPIRSSYFTFQLQNIVKPLP
PVYLTFTRESSCEIKLKWSIPLGPIPARCF
DYEIEIREDDTTLVTATVENETYTLKTTNE
TRQLCFVVRSKVNIYCSDDGIWSEWSDKQC
WEGEDLSKK
Linker residues 340- GTGSEF
345 of SEQ ID
NO: 316 BSC1 residues 346- IKKAYRKLA
354 of SEQ ID
NO: 316 Linker residues 355- DIGGGSGGSGGSGGAAALE
373 of SEQ ID
NO: 316 V5 epitope residues 374- GKPIPNPLLGLDST
domain 387 of SEQ ID
NO: 316 A second fusion protein comprised IL13Ra2TF as the target protein of interest linked to a mutated version of the BSC1 polypeptide, designated "IL13Ra2TF-BSC1MT" in which the second and third positions of the BSC1 polypeptide were mutated from K-K to A-Q as shown in the table below. The BSC1MT polypeptide is designated 3-55.
Table 61. Amino Acid Sequence of a V5-Tagged IL13Ra2TF-BSC1MT Fusion Protein.
Protein Region Sequence Amino Acid Sequence (N¨ to C¨ Identifier terminal) 123456789012345678901234567890 IL13Ra2TF-BSC1MT SEQ ID NO:317 MAFVCLAIGCLYTFLISTTFGCTSSSDTEI
protein KVNPPQDFEIVDPGYLGYLYLQWQPPLSLD
HFKECTVEYELKYRNIGSETWKTIITKNLH
YKDGFDLNKGIEAKIHTLLPWQCTNGSEVQ
SSWAETTYWISPQGIPETKVQDMDCVYYNW
QYLLCSWKPGIGVLLDTNYNLFYWYEGLDH
ALQCVDYIKADGQNIGCRFPYLEASDYKDF
YICVNGSSENKPIRSSYFTFQLQNIVKPLP
PVYLTFTRESSCEIKLKWSIPLGPIPARCF
DYEIEIREDDTTLVTATVENETYTLKTTNE
TRQLCFVVRSKVNIYCSDDGIWSEWSDKQC
WEGEDLSKKGTGSEFIAQAYRKLADIGGGS
GGSGGSGGAAALEGKPIPNPLLGLDST
IL13Ra2TF residues 1-339 MAFVCLAIGCLYTFLISTTFGCTSSSDTEI
of SEQ ID KVNPPQDFEIVDPGYLGYLYLQWQPPLSLD
NO: 317 HFKECTVEYELKYRNIGSETWKTIITKNLH
YKDGFDLNKGIEAKIHTLLPWQCTNGSEVQ
SSWAETTYWISPQGIPETKVQDMDCVYYNW
QYLLCSWKPGIGVLLDTNYNLFYWYEGLDH
ALQCVDYIKADGQNIGCRFPYLEASDYKDF
YICVNGSSENKPIRSSYFTFQLQNIVKPLP
PVYLTFTRESSCEIKLKWSIPLGPIPARCF
DYEIEIREDDTTLVTATVENETYTLKTTNE
TRQLCFVVRSKVNIYCSDDGIWSEWSDKQC
WEGEDLSKK
Linker residues 340- GTGSEF
345 of SEQ ID
NO: 317 BSC1MT residues 346- IAQAYRKLA
354 of SEQ ID
NO: 317 Linker residues 355- DIGGGSGGSGGSGGAAALE
373 of SEQ ID
NO: 317 V5 epitope residues 374- GKPIPNPLLGLDST
domain 387 of SEQ ID
NO: 317 Schematic diagrams of IL13Ra2TF (target protein alone), IL13Ra2TF-BSC1, and IL13Ra2TF-BSC1MT proteins are shown in Fig. 20A. Cells were transfected with vector comprising a recombinant gene encoding IL13Ra2TF (control), IL13Ra2TF-BSC1, or IL13Ra2TF-BSC1MT and grown in separate cultures as described above. Culture media from each culture was assayed for the presence of the proteins by immunoblot using an anti-V5 antibody as described above.
As shown in Figure 20B, relatively little IL13Ra2TF protein was detected in culture medium of the control cell culture. See, lane 2 of Fig. 20B. In contrast, a significantly higher level of the IL13Ra2TF-BSC1 fusion protein was detected in culture medium of cells transfected with a vector comprising a gene encoding the IL13Ra2TF-BSC1 fusion protein. See, lane 3 of Fig. 20B. The amount of IL13Ra2TF-BSC1 fusion protein detected in the culture medium was also significantly higher than the level of protein detected in culture medium of cells transfected with a vector encoding the IL13Ra2TF-BSC1MT fusion protein. This latter protein was expressed at approximately the same low level as detected for the IL13Ra2TF protein in control cells. See, lane 4 of Fig. 20B. The results show the BSC1 polypeptide (IKKAYRKLA; SEQ ID NO:48) is effective as a protein expression enhancing polypeptide in a modified arrangement of the invention and that alteration of the internal K-K dipeptide can destroy such activity.
Example 13. BSC1-Protein A Fusion Protein Enhances Expression of IL13Ra2TF-V5-Fc Target Protein in an Unmodified Arrangement The BSC1 polypeptide (IKKAYRKLA, SEQ ID NO:48), the minimal polypeptide fragment of the J domain of Erdj3 described above, was used to construct a BSC1-Protein A fusion protein shown in the table below to determine whether the BSC1-Protein A fusion protein could be used in an unmodified arrangement for enhancing expression of an IL13Ra2TF-V5-Fc target protein described above.
Table 62. Amino acid Sequence of a Flag-Tagged BSC1-Protein A Fusion Protein Protein Domain Sequence Amino Acid Sequence Identifier 123456789012345678901234567890 Flag-tagged BSC1- SEQ ID NO:318 MGVKVLFALICIAVAEAGTGSGEFIKKAYR
Protein A Fusion KLADIGGGSGGSGGSGGAAAADNKFNKEQQ
NAFYEILNMPNLNEEQRNGFIQSLKDDPSQ
SANVLGEAKKLNDSQAPKLEGDYKDDDDK
signal sequence residues 1-17 MGVKVLFALICIAVAEA
of SEQ ID
NO: 318 linker 1 residues 18-24 GTGSGEF
of SEQ ID
NO: 318 BSC1 polypeptide residues 25-33 IKKAYRKLA
of SEQ ID
NO: 318 linker 2 residues 34-50 DIGGGSGGSGGSGGAAA
of SEQ ID
NO: 318 Protein A residues 51-108 ADNKFNKEQQNAFYEILNMPNLNEEQRNGF
of SEQ ID IQSLKDDPSQSANVLGEAKKLNDSQAPK
NO: 318 linker 3 residues 109- LEG
111 of SEQ ID
NO: 318 Flag epitope tag residues 112- DYKDDDDK
119 of SEQ ID
NO: 318 The IL13Ra2TF-V5-Fc target protein was expressed with or without BSC1-Protein A fusion protein in HEK293 cells. Cultures were grown for two days, and the media were harvested and centrifuged to remove the debris. Expression of the IL13Ra2TF-V5-Fc target protein was significantly enhanced in the medium of cells co-expressing the target protein and the BSC1-Protein A fusion compared to level of expression of the target protein in the absence of the BSC1-Protein A
fusion protein (data not shown).
To determine whether the IL13Ra2TF-V5-Fc target protein expressed in culture medium retained IL13 binding activity, the following binding assay was performed.
Recombinant human IL13 was added to samples of the media from cultures of cells that did not express either of the proteins (control), that expressed only the IL13Ra2TF-V5-Fc target protein, and that co-expressed the IL13Ra2TF-V5-Fc target protein and the BSC1-Protein A fusion protein. The samples were incubated with the IL13 for 2 hours. The samples were used in an IL13 detection assay (RayBio0 Human IL13 ELISA Kit; ELH-1L13-001). In this assay, the detection of human IL13 decreases when human IL13 is trapped by IL13Ra2TF-V5-Fc target protein. As shown in Figure 21B, the medium from a culture of cells expressing neither protein clearly did not bind IL13 as indicated by the high level absorbance (lane 1 of Fig. 21). Medium from a culture of cells expressing only the IL13Ra2TF-V5-Fc target protein bound some IL13 (lane 2), but a significantly greater amount of IL13 was bound the medium from a culture of cells co-expressing the IL13Ra2TF-V5-Fc target protein and the BSC1-Protein A fusion protein (lane 3). The results clearly show that more human IL13 was bound in medium containing the enhanced level of expression of the IL13Ra2TF-V5-Fc target protein.
Accordingly, the IL13Ra2TF-V5-Fc target protein expressed in culture medium at an enhanced level retained its IL13 binding activity.
Example 14. BSC1-Protein G Fusion Protein Enhances Expression of a Factor VII-V5-Fc Target Protein in an Unmodified Arrangement Factor VII (FVII) is the serine esterase of the extrinsic coagulation pathway and widely used to treat a variety of bleeding complications. See, Hedner, Semin. Hematol., 43(suppl 1): S105-S107 (2006). A complex of FVII and tissue factor (TF) in the presence of phospholipids and calcium activates Factor X to Factor Xa.
A BSC1 polypeptide was used to construct a BSC1-Protein G fusion protein to determine whether the fusion protein was effective in enhancing an FVII-V5-Fc target protein in an unmodified arrangement.
The amino acid sequence of the VS-tagged FVII-Fc target protein is shown in the table below.
Table 63. Amino Acid Sequence of a VS-Tagged FVII-Fc Target Protein.
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) 123456789012345678901234567890 V5-tagged FVII- SEQ ID NO:319 MVSQALRLLCLLLGLQGCLAAGGVAKASGG
Fc target ETRDMPWKPGPHRVFVTQEEAHGVLHRRRR
protein ANAFLEELRPGSLERECKEEQCSFEEAREI
FKDAERTKLFWISYSDGDQCASSPCQNGGS
CKDQLQSYICFCLPAFEGRNCETHKDDQLI
CVNENGGCEQYCSDHTGTKRSCRCHEGYSL
LADGVSCTPTVEYPCGKIPILEKRNASKPQ
GRIVGGKVCPKGECPWQVLLLVNGAQLCGG
TLINTIWVVSAAHCFDKIKNWRNLIAVLGE
HDLSEHDGDEQSRRVAQVIIPSTYVPGTTN
HDIALLRLHQPVVLTDHVVPLCLPERTFSE
RTLAFVRFSLVSGWGQLLDRGATALELMVL
NVPRLMTQDCLQQSRKVGDSPNITEYMFCA
GYSDGSKDSCKGDSGGPHATHYRGTWYLTG
IVSWGQGCATVGHFGVYTRVSQYIEWLQKL
MRSEPRPGVLLRAPFPLEGKPIPNPLLGLD
STSRPKSCDKTHTCPPCPAPELLGGPSVFL
FPPKPKDTLMISRTPEVTCVVVDVSHEDPE
VKFNWYVDGVEVHNAKTKPREEQYNSTYRV
VSVLTVLHQDWLNGKEYKCKVSNKALPAPI
EKTISKAKGQPREPQVYTLPPSRDELTKNQ
VSLTCLVKGFYPSDIAVEWESNGQPENNYK
TTPPVLDSDGSFFLYSKLTVDKSRWQQGNV
FSCSVMHEALHNHYTQKSLSLSPGK
FVII residues of SEQ ID ETRDMPWKPGPHRVFVTQEEAHGVLHRRRR
NO: 319 ANAFLEELRPGSLERECKEEQCSFEEAREI
FKDAERTKLFWISYSDGDQCASSPCQNGGS
CKDQLQSYICFCLPAFEGRNCETHKDDQLI
CVNENGGCEQYCSDHTGTKRSCRCHEGYSL
LADGVSCTPTVEYPCGKIPILEKRNASKPQ
GRIVGGKVCPKGECPWQVLLLVNGAQLCGG
TLINTIWVVSAAHCFDKIKNWRNLIAVLGE
HDLSEHDGDEQSRRVAQVIIPSTYVPGTTN
HDIALLRLHQPVVLTDHVVPLCLPERTFSE
RTLAFVRFSLVSGWGQLLDRGATALELMVL
NVPRLMTQDCLQQSRKVGDSPNITEYMFCA
GYSDGSKDSCKGDSGGPHATHYRGTWYLTG
IVSWGQGCATVGHFGVYTRVSQYIEWLQKL
MRSEPRPGVLLRAPFP
Linker 1 residues 467- LE
468 of SEQ ID
NO: 319 V5 epitope residues 469- GKPIPNPLLGLDST
domain 482 of SEQ ID
NO: 319 Linker 2 residues 483- SR
484 of SEQ ID
NO: 319 Fc domain residues 485- PKSCDKTHTCPPCPAPELLGGPSVFLFPPK
715 of SEQ ID PKDTLMISRTPEVTCVVVDVSHEDPEVKFN
NO: 319 WYVDGVEVHNAKTKPREEQYNSTYRVVSVL
Protein Region Sequence Amino Acid Sequence (N¨ to C¨ Identifier terminal) 123456789012345678901234567890 TVLHQDWLNGKEYKCKVSNKALPAP IEKT I
SKAKGQPREPQVYTLPPSRDELTKNQVSLT
CLVKGFYP SD IAVEWESNGQPENNYKTTPP
VLDSDGSFFLYSKLTVDKSRWQQGNVFSCS
VMHEALHNHYTQKSLSLSPGK
The amino acid sequence of the Flag-tagged BSC1-Protein G fusion protein is shown in the table below.
Table 64. Amino Acid Sequence of a Flag-Tagged BSC1-Protein G Fusion Protein Protein Domain Sequence Amino Acid Sequence Identifier 123456789012345678901234567890 Flag-tagged BSC1- SEQ ID NO:320 MGVKVLFAL I C IAVAEAGTGSGEF I KKAYR
Protein G Fusion KLADIGGGSGGSGGSGGAAAATYKLVINGK
TLKGETTTEAVDAATAEKVFKQYANDNGVD
GEWTYDDATKTFTVTEKPEVIDASELTPAV
TLEGDYKDDDDK
signal sequence residues 1-17 MGVKVLFALICIAVAEA
of SEQ ID
NO:320 linker 1 residues 18-24 GTGSGEF
of SEQ ID
NO:320 BSC1 polypeptide residues 25-33 IKKAYRKLA
of SEQ ID
NO:320 linker 2 residues 34-50 DIGGGSGGSGGSGGAAA
of SEQ ID
NO:320 Protein G residues 51-121 TYKLVINGKTLKGETTTEAVDAATAEKVFK
of SEQ ID QYANDNGVDGEWTYDDATKTFTVTEKPEVI
NO:320 DASELTPAVT
linker 3 residues 122- LEG
124 of SEQ ID
NO:320 Flag epitope tag residues 126- DYKDDDDK
132 of SEQ ID
NO: 320 The level of expression of the FVII-Fc target protein was determined by immunoblot assay using anti-Flag antibody in both culture media and lysates of cells expressing neither protein, of cells expressing only the FVII-Fc target protein, and of cells co-expressing the FVII-Fc target protein and the BSC1-Protein G fusion proteins. The results are shown in Figure 22A. As shown in the top panel of Figure 22A, the level of expression of the FVII-Fc target protein secreted into the culture medium was significantly greater in a culture of cells co-expressing the FVII-Fc target protein and the BSC1-Protein G fusion protein (lane 2) than in a culture of cells expressing the FVII-Fc target protein alone (lane 3). The middle panel of Figure 22A is an immunoblot of cell lysates using an anti-Flag antibody. The immunoblot shows that the BSC1-Protein G fusion protein was expressed in cells expressing both the FVII-Fc target protein and the BSC1-Protein G fusion protein. As shown in the bottom panel of Figure 22A, no significant amount of the BSC1-Protein G fusion protein was secreted into the medium with the FVII-Fc target protein (see, lane 3).
Figure 22B shows bar graphs of a densitometry analysis of the signal of the for FVII-Fc target protein expression in culture media shown in the top immunoblot in Figure 22A.
Bar graphs 1, 2, and 3 of Figure 22B correspond to the signals of lanes 1, 2, and 3 in the top immunoblot in Figure 22A.
The results show that the co-expression of the BSC1-Protein G fusion protein and the FVII-Fc target protein significantly enhanced the level of expression of the target protein secreted into culture medium as compared to the level in that absence of the BSC1-Protein G fusion protein.
Example 15. BSC1-Protein A Fusion Protein Enhances Expression of a Factor IX-V5-Fc Target Protein in an Unmodified Arrangement Factor IX has been widely used for the treatment of hemophilia B, and its Fc fusion protein (FIX-Fc) is currently in a clinical trial (phase III) with positive result (prolonged effect).
In this experiment, the effect of the BSC1-Protein A fusion protein described above on the level of expression of an FIX-Fc target protein in an unmodified arrangement was determined.
The amino acid sequence of the VS-tagged FIX-Fc target protein is shown in the table below.
Table 65. Amino Acid Sequence of a VS-Tagged FIX-Fc Target Protein.
Protein Region Sequence Amino Acid Sequence (N¨ to C¨ Identifier terminal) V5-tagged FIX-Fc SEQ
ID NO:321 MQRVNMIMAESPGLITICLLGYLLSAECTV
fusion molecule FLDHENANKILNRPKRYNSGKLEEFVQGNL
ERECMEEKCSFEEAREVFENTERTTEFWKQ
YVDGDQCESNPCLNGGSCKDDINSYECWCP
FGFEGKNCELDVTCNIKNGRCEQFCKNSAD
NKVVCSCTEGYRLAENQKSCEPAVPFPCGR
VSVSQTSKLTRAETVFPDVDYVNSTEAETI
LDNITQSTQSFNDFTRVVGGEDAKPGQFPW
QVVLNGKVDAFCGGSIVNEKWIVTAAHCVE
TGVKITVVAGEHNIEETEHTEQKRNVIRII
PHHNYNAAINKYNHDIALLELDEPLVLNSY
VTPICIADKEYTNIFLKFGSGYVSGWGRVF
HKGRSALVLQYLRVPLVDRATCLRSTKFTI
YNNMFCAGFHEGGRDSCQGDSGGPHVTEVE
GTSFLTGIISWGEECAMKGKYGIYTKVSRY
VNWIKEKTKLTLEGKPIPNPLLGLDSTSRP
KSCDKTHTCPPCPAPELLGGPSVFLFPPKP
KDTLMISRTPEVTCVVVDVSHEDPEVKFNW
YVDGVEVHNAKTKPREEQYNSTYRVVSVLT
VLHQDWLNGKEYKCKVSNKALPAPIEKTIS
KAKGQPREPQVYTLPPSRDELTKNQVSLTC
LVKGFYPSDIAVEWESNGQPENNYKTTPPV
LDSDGSFFLYSKLTVDKSRWQQGNVFSCSV
Protein Region Sequence Amino Acid Sequence (N¨ to C¨ Identifier terminal) MHEALHNHYTQKSLSLSPGK
FIX
residues 1-461 MQRVNMIMAESPGLITICLLGYLLSAECTV
of SEQ ID
FLDHENANKILNRPKRYNSGKLEEFVQGNL
NO: 321 ERECMEEKCSFEEAREVFENTERTTEFWKQ
YVDGDQCESNPCLNGGSCKDDINSYECWCP
FGFEGKNCELDVTCNIKNGRCEQFCKNSAD
NKVVCSCTEGYRLAENQKSCEPAVPFPCGR
VSVSQTSKLTRAETVFPDVDYVNSTEAETI
LDNITQSTQSFNDFTRVVGGEDAKPGQFPW
QVVLNGKVDAFCGGSIVNEKWIVTAAHCVE
TGVKITVVAGEHNIEETEHTEQKRNVIRII
PHHNYNAAINKYNHDIALLELDEPLVLNSY
VTPICIADKEYTNIFLKFGSGYVSGWGRVF
HKGRSALVLQYLRVPLVDRATCLRSTKFTI
YNNMFCAGFHEGGRDSCQGDSGGPHVTEVE
GTSFLTGIISWGEECAMKGKYGIYTKVSRY
VNWIKEKTKLT
Linker 1 residues 462- LE
463 of SEQ ID
NO:321 V5 epitope residues 464- GKPIPNPLLGLDST
domain 477 of SEQ ID
NO:321 Linker 2 residues 478- SR
479 of SEQ ID
NO:321 Fc domain residues 480- PKSCDKTHTCPPCPAPELLGGPSVFLFPPK
710 of SEQ ID PKDTLMISRTPEVTCVVVDVSHEDPEVKFN
NO: 321 WYVDGVEVHNAKTKPREEQYNSTYRVVSVL
TVLHQDWLNGKEYKCKVSNKALPAPIEKTI
SKAKGQPREPQVYTLPPSRDELTKNQVSLT
CLVKGFYPSDIAVEWESNGQPENNYKTTPP
VLDSDGSFFLYSKLTVDKSRWQQGNVFSCS
VMHEALHNHYTQKSLSLSPGK
Figure 23A shows the expression of the FIX-Fc target protein secreted into the media of cultures of transfected cells expressing the FIX-Fc target protein alone (lane 2) and of transfected cells co-expressing the FIX-Fc fusion protein and the BSC1-Protein A fusion protein (lane 3). Lane 1 of Figure 23A shows medium from a culture of non-expressing cells as a control.
As shown in lane 2 of Figure 23A, some FIX-Fc target protein is secreted by cells expressing the FIX-Fc target protein alone. However, as clearly shown in lane 3 of Figure 23A, the level of expression of the target protein secreted into medium is significantly enhanced in cells expressing the FIX-Fc target protein and the BSC1-Protein A fusion protein. Figure 23B shows bar graphs of a densitometry analysis of the signals in the immunoblot of Figure 23A. Bar graphs 1, 2, and 3 of Figure 23B correspond to the signals of lanes 1, 2, and 3 in Figure 23A.
The results clearly show that the co-expression of the BSC1-Protein A fusion protein and the FIX-Fc target protein significantly enhanced the level of expression of the target protein secreted into culture medium as compared to the level in that absence of the BSC1-Protein A
fusion protein.
Example 16. BSC1-Protein G Fusion Protein Enhances Expression of a Factor VIII-V5-Fc Target Protein in an Unmodified Arrangement The biological importance of Factor FVIII is demonstrated in hemophilia A, a congenital bleeding disorder occurring primarily in males that results from an X-chromosome-linked deficiency of FVIII. Standard treatment involves replacing the missing FVIII to stop the bleeding. A FVIII-Fc fusion protein was developed to provide a prolonged half-life of FVIII
activity in hemophilia A
patients (Powell et al., Blood, 119(13): 3031-3037 (2012)). The fusion protein was approved by the United States Food and Drug Administration in 2013 (ELOCTATETm; Biogen Idec).
This experiment examined the effect of the BSC1-Protein G fusion protein described above on the level of expression of a VS-tagged FVIII-Fc target protein in an unmodified arrangement. The amino acid sequence of the VS-tagged FVIII-Fc target protein is shown in the table below.
Table 66. Amino Acid Sequence of a VS-Tagged FVIII-Fc Target Protein.
Protein Region Sequence Amino Acid Sequence (N¨ to C¨ Identifier terminal) V5-tagged FVIII- SEQ
ID NO:322 MQIELSTCFFLCLLRFCFSATRRYYLGAVE
Fc fusion LSWDYMQSDLGELPVDARFPPRVPKSFPFN
molecule TSVVYKKTLFVEFTDHLFNIAKPRPPWMGL
LGPTIQAEVYDTVVITLKNMASHPVSLHAV
GVSYWKASEGAEYDDQTSQREKEDDKVFPG
GSHTYVWQVLKENGPMASDPLCLTYSYLSH
VDLVKDLNSGLIGALLVCREGSLAKEKTQT
LHKFILLFAVFDEGKSWHSETKNSLMQDRD
AASARAWPKMHTVNGYVNRSLPGLIGCHRK
SVYWHVIGMGTTPEVHSIFLEGHTFLVRNH
RQASLEISPITFLTAQTLLMDLGQFLLFCH
ISSHQHDGMEAYVKVDSCPEEPQLRMKNNE
EAEDYDDDLTDSEMDVVRFDDDNSPSFIQI
RSVAKKHPKTWVHYIAAEEEDWDYAPLVLA
PDDRSYKSQYLNNGPQRIGRKYKKVRFMAY
TDETFKTREAIQHESGILGPLLYGEVGDTL
LIIFKNQASRPYNIYPHGITDVRPLYSRRL
PKGVKHLKDFPILPGEIFKYKWTVTVEDGP
TKSDPRCLTRYYSSFVNMERDLASGLIGPL
LICYKESVDQRGNQIMSDKRNVILFSVFDE
NRSWYLTENIQRFLPNPAGVQLEDPEFQAS
NIMHSINGYVFDSLQLSVCLHEVAYWYILS
IGAQTDFLSVFFSGYTFKHKMVYEDTLTLF
PFSGETVFMSMENPGLWILGCHNSDFRNRG
MTALLKVSSCDKNTGDYYEDSYEDISAYLL
SKNNAIEPRSFSQNSRHPSTRQKQFNATTI
PENDIEKTDPWFAHRTPMPKIQNVSSSDLL
MLLRQSPTPHGLSLSDLQEAKYETFSDDPS
PGAIDSNNSLSEMTHFRPQLHHSGDMVFTP
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) ESGLQLRLNEKLGTTAATELKKLDFKVSST
SNNL I S T IP SDNLAAGTDNT S SLGPPSMPV
HYD S QL DTT LF GKKS SPL TES GGPL SL SEE
NND SKL LE SGLMNS QE SSWGKNVS S TES GR
LFKGKRAHGPALLTKDNALFKVS I SLLKTN
KT SNNSATNRKTHI DGPSLL IENSPSVWQN
I LE S DTEFKKVTPL I HDRMLMDKNATALRL
NHMSNKTTSSKNMEMVQQKKEGP I PPDAQN
PDMSFFKMLFLPESARWIQRTHGKNSLNSG
QGPSPKQLVSLGPEKSVEGQNFLSEKNKVV
VGKGEFTKDVGLKEMVFPSSRNLFLTNLDN
LHENNTHNQEKKIQEEIEKKETL I QENVVL
PQIHTVTGTKNFMKNLFLLSTRQNVEGSYD
GAYAPVLQDFRSLNDSTNRTKKHTAHFSKK
GEEENLEGLGNQTKQIVEKYACTTRISPNT
SQQNFVTQRSKRALKQFRLP LEE TE LEKR I
IVDDT S TQWSKNMKHL TP S TL TQ I DYNEKE
KGAITQSPLSDCLTRSHS IPQANRSPLP IA
KVS SETS IRP I YL TRVLFQDNS SHLPAASY
RKKDSGVQESSHFLQGAKKNNLSLAILTLE
MTGDQREVGSLGTSATNSVTYKKVENTVLP
KPDLPKTSGKVELLPKVHIYQKDLFPTETS
NGSPGHLDLVEGSLLQGTEGAIKWNEANRP
GKVPFLRVATESSAKTPSKLLDPLAWDNHY
GTQ IPKEEWKSQEKSPEKTAFKKKDT I L SL
NACE SNHAIAAINEGQNKPE I EVTWAKQGR
TERLC SQNPPVLKRHQRE I TRTTLQSDQEE
IDYDDT I SVEMKKEDFDI YDEDENQSPRSF
QKKTRHYF IAAVERLWDYGMSSSPHVLRNR
AQSGSVPQFKKVVFQEFTDGSFTQPLYRGE
LNEHLGLLGPYIRAEVEDNIMVTFRNQASR
PYSFYSSL I SYEEDQRQGAEPRKNFVKPNE
TKTYFWKVQHHMAPTKDEFDCKAWAYF S DV
DLEKDVHSGL I GPLLVCHTNTLNPAHGRQV
TVQEFALFFT IFDETKSWYFTENMERNCRA
PCNIQMEDPTFKENYRFHAINGYIMDTLPG
LVMAQDQRIRWYLLSMGSNENIHS IHFSGH
VFTVRKKEEYKMALYNLYPGVFETVEMLPS
KAGIWRVECL I GEHLHAGMS TLFLVYSNKC
QTPLGMAS GH I RDFQ I TAS GQYGQWAPKLA
RLHYSGSINAWSTKEPFSWIKVDLLAPMI I
HGIKTQGARQKFSSLYI SQF I IMYSLDGKK
WQTYRGNSTGTLMVFFGNVDSSGIKHNIFN
PP I IARYIRLHPTHYS IRS TLRMELMGCDL
NSCSMPLGMESKAI SDAQ I TAS SYFTNMFA
TWSPSKARLHLQGRSNAWRPQVNNPKEWLQ
VDFQKTMKVTGVTTQGVKSLLTSMYVKEFL
I S S SQDGHQWTLFFQNGKVKVFQGNQDSFT
PVVNSLDPPLLTRYLRIHPQSWVHQIALRM
EVLGCEAQDLYLEGKPIPNPLLGLDSTSRP
KS CDKTHT CPP CPAPE LL GGP SVF LFPPKP
KDTLMI SRTPEVTCVVVDVSHEDPEVKFNW
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) 123456789012345678901234567890 YVDGVEVHNAKTKPREEQYNSTYRVVSVLT
VLHQDWLNGKEYKCKVSNKALPAPIEKTIS
KAKGQPREPQVYTLPPSRDELTKNQVSLTC
LVKGFYPSDIAVEWESNGQPENNYKTTPPV
LDSDGSFFLYSKLTVDKSRWQQGNVFSCSV
MHEALHNHYTQKSLSLSPGK
FVIII residues of SEQ ID
LSWDYMQSDLGELPVDARFPPRVPKSFPFN
NO: 322 TSVVYKKTLFVEFTDHLFNIAKPRPPWMGL
LGPTIQAEVYDTVVITLKNMASHPVSLHAV
GVSYWKASEGAEYDDQTSQREKEDDKVFPG
GSHTYVWQVLKENGPMASDPLCLTYSYLSH
VDLVKDLNSGLIGALLVCREGSLAKEKTQT
LHKFILLFAVFDEGKSWHSETKNSLMQDRD
AASARAWPKMHTVNGYVNRSLPGLIGCHRK
SVYWHVIGMGTTPEVHSIFLEGHTFLVRNH
RQASLEISPITFLTAQTLLMDLGQFLLFCH
ISSHQHDGMEAYVKVDSCPEEPQLRMKNNE
EAEDYDDDLTDSEMDVVRFDDDNSPSFIQI
RSVAKKHPKTWVHYIAAEEEDWDYAPLVLA
PDDRSYKSQYLNNGPQRIGRKYKKVRFMAY
TDETFKTREAIQHESGILGPLLYGEVGDTL
LIIFKNQASRPYNIYPHGITDVRPLYSRRL
PKGVKHLKDFPILPGEIFKYKWTVTVEDGP
TKSDPRCLTRYYSSFVNMERDLASGLIGPL
LICYKESVDQRGNQIMSDKRNVILFSVFDE
NRSWYLTENIQRFLPNPAGVQLEDPEFQAS
NIMHSINGYVFDSLQLSVCLHEVAYWYILS
IGAQTDFLSVFFSGYTFKHKMVYEDTLTLF
PFSGETVFMSMENPGLWILGCHNSDFRNRG
MTALLKVSSCDKNTGDYYEDSYEDISAYLL
SKNNAIEPRSFSQNSRHPSTRQKQFNATTI
PENDIEKTDPWFAHRTPMPKIQNVSSSDLL
MLLRQSPTPHGLSLSDLQEAKYETFSDDPS
PGAIDSNNSLSEMTHFRPQLHHSGDMVFTP
ESGLQLRLNEKLGTTAATELKKLDFKVSST
SNNLISTIPSDNLAAGTDNTSSLGPPSMPV
HYDSQLDTTLFGKKSSPLTESGGPLSLSEE
NNDSKLLESGLMNSQESSWGKNVSSTESGR
LFKGKRAHGPALLTKDNALFKVSISLLKTN
KTSNNSATNRKTHIDGPSLLIENSPSVWQN
ILESDTEFKKVTPLIHDRMLMDKNATALRL
NHMSNKTTSSKNMEMVQQKKEGPIPPDAQN
PDMSFFKMLFLPESARWIQRTHGKNSLNSG
QGPSPKQLVSLGPEKSVEGQNFLSEKNKVV
VGKGEFTKDVGLKEMVFPSSRNLFLTNLDN
LHENNTHNQEKKIQEEIEKKETLIQENVVL
PQIHTVTGTKNFMKNLFLLSTRQNVEGSYD
GAYAPVLQDFRSLNDSTNRTKKHTAHFSKK
GEEENLEGLGNQTKQIVEKYACTTRISPNT
SQQNFVTQRSKRALKQFRLPLEETELEKRI
IVDDTSTQWSKNMKHLTPSTLTQIDYNEKE
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) KGAITQSPLSDCLTRSHSIPQANRSPLPIA
KVSSFPSIRPIYLTRVLFQDNSSHLPAASY
RKKDSGVQESSHFLQGAKKNNLSLAILTLE
MTGDQREVGSLGTSATNSVTYKKVENTVLP
KPDLPKTSGKVELLPKVHIYQKDLFPTETS
NGSPGHLDLVEGSLLQGTEGAIKWNEANRP
GKVPFLRVATESSAKTPSKLLDPLAWDNHY
GTQIPKEEWKSQEKSPEKTAFKKKDTILSL
NACESNHAIAAINEGQNKPEIEVTWAKQGR
TERLCSQNPPVLKRHQREITRTTLQSDQEE
IDYDDTISVEMKKEDFDIYDEDENQSPRSF
QKKTRHYFIAAVERLWDYGMSSSPHVLRNR
AQSGSVPQFKKVVFQEFTDGSFTQPLYRGE
LNEHLGLLGPYIRAEVEDNIMVTFRNQASR
PYSFYSSLISYEEDQRQGAEPRKNFVKPNE
TKTYFWKVQHHMAPTKDEFDCKAWAYFSDV
DLEKDVHSGLIGPLLVCHTNTLNPAHGRQV
TVQEFALFFTIFDETKSWYFTENMERNCRA
PCNIQMEDPTFKENYRFHAINGYIMDTLPG
LVMAQDQRIRWYLLSMGSNENIHSIHFSGH
VFTVRKKEEYKMALYNLYPGVFETVEMLPS
KAGIWRVECLIGEHLHAGMSTLFLVYSNKC
QTPLGMASGHIRDFQITASGQYGQWAPKLA
RLHYSGSINAWSTKEPFSWIKVDLLAPMII
HGIKTQGARQKFSSLYISQFIIMYSLDGKK
WQTYRGNSTGTLMVFFGNVDSSGIKHNIFN
PPIIARYIRLHPTHYSIRSTLRMELMGCDL
NSCSMPLGMESKAISDAQITASSYFTNMFA
TWSPSKARLHLQGRSNAWRPQVNNPKEWLQ
VDFQKTMKVTGVTTQGVKSLLTSMYVKEFL
ISSSQDGHQWTLFFQNGKVKVFQGNQDSFT
PVVNSLDPPLLTRYLRIHPQSWVHQIALRM
EVLGCEAQDLY
Linker residues 2352- LE
2353 of SEQ ID
NO:322 V5 epitope residues 2354- GKPIPNPLLGLDST
domain 2367 of SEQ ID
NO:322 Linker residues 2368- SR
2369 of SEQ ID
NO:322 Fc domain residues 2370- PKSCDKTHTCPPCPAPELLGGPSVFLFPPK
2600 of SEQ ID PKDTLMISRTPEVTCVVVDVSHEDPEVKFN
NO:322 WYVDGVEVHNAKTKPREEQYNSTYRVVSVL
TVLHQDWLNGKEYKCKVSNKALPAPIEKTI
SKAKGQPREPQVYTLPPSRDELTKNQVSLT
CLVKGFYPSDIAVEWESNGQPENNYKTTPP
VLDSDGSFFLYSKLTVDKSRWQQGNVFSCS
VMHEALHNHYTQKSLSLSPGK
In this experiment, the level of expression of the FVIII-Fc target protein in the presence and absence of the BSC1-Protein G fusion protein. Media from cultures of cells (HEK293) expressing neither protein, of cells expressing only the FVIII-Fc target protein, and of cells co-expressing the BSC1-Protein G fusion protein and the FVIII-Fc target protein was assayed for FVIII using a commercially available, enzyme-linked immunosorbent assay (ELISA) (VisulizeTM
FVIII Antigen Kit, Affinity Biologics Inc.). The results are shown as bar graphs of Absorbance at 450 nm in Figure 24. Culture medium from cells transfected with an empty vector and expressing neither protein was used for a negative control (first bar graph from left in Figure 24), and human serum was used as a positive control (last bar graph on right of Figure 24). The results show that co-expression of the BSC1-Protein G fusion protein with the FVIII-Fc target protein significantly enhanced the level of expression of the FVIII-Fc target protein secreted into the culture medium (third bar graph from left in Figure 24) as compared to the level of expression of the target protein in the absence of the BSC1-Protein G fusion protein (second bar graph from left in Figure 24).
Example 17. BSC1-Protein A Fusion Protein Enhances Expression of an Anti-IL-8 Antibody Target Protein in an Unmodified Arrangement This experiment examined whether a BSC1-Protein A fusion protein as described above could be used in an unmodified arrangement to improve the level of expression of an anti-IL-8 antibody target protein expressed in transfected HEK293 cells.
Expression of anti-IL-8 antibody in culture media was determined by immunodot blot using an anti-IgG antibody. As shown in the immunodot blots in Figure 25A, co-expression of the anti-1L8 antibody target protein with the BSC1-Protein A fusion protein significantly enhanced the level of expression of the antibody secreted into the culture medium (bottom row 3 of Figure 25A) as compared to the level of the antibody expressed in cells expressing the antibody alone (middle row 2 of Figure 25A). The top row of Figure 25A shows no antibody was secreted into medium from a mock culture of control cells that expressed neither protein.
The results of a densitometry analysis of the chemiluminescent signals in the dot blots in the rows in Figure 25A using the NIH ImageJ image processing program are shown in the respective bar graphs in Figure 25B. The bars of Figure 25B are numbered to correspond to the row numbers of Figure 25A. The results of this series of experiments clearly show that co-expression of the anti-1L8 antibody target protein with a fusion protein of the invention comprising the BSC1 polypeptide linked to a Protein A (target protein binding domain) significantly enhanced the expression of secreted anti-1L8 antibody.
Figure 25C shows the results of an ELISA assay. A 96-well plate was coated with recombinant purified human IL8, and incubated with the anti-IL-8 antibody (target protein) secreted into the media of cultures of transfected cells expressing the anti-1L8 antibody alone (lane 2) and of cells co-expressing anti-1L8 antibody target protein and the BSC1-Protein A
fusion protein (lane 3, PCT/US13/73442 03-10-2014 PCT/US2013/073442 08.04.2015 BSC1-Protein A). Mock cultures contained cells transfected with expression vector lacking a structural gene for expressing any protein (no anti-1L8 antibody, first lane).
The results clearly show that the secreted anti-1L8 antibody that was expressed at enhanced levels when co-expressed with BSC I-Protein A fusion protein retained its binding activity for human 11,8.
Example 18. BSC1-Protein A Fusion Protein Enhances Expression of a Therapeutic Anti-VEGF Antibody (Bevacizumab) Target Protein in an Unmodified Arrangement This experiment examined whether a BSC1-Protein A fusion protein as described above could be used in an unmodified arrangement to improve the level of expression of a therapeutic antibody.
Bevacizumab (Avastin , Genentech/Roche) is a humanized monoclonal antibody that inhibits angiogenesis by inhibiting vascular endothelial growth factor A (VEGF-A). Sales of bevacizumab in 2010 were close to $7 billion and exceeded all other antibody drugs. The addition of bevacizumab to standard treatment can prolong the lives of breast and lung cancer patients by several months at a current cost of approximately $100,000 a year in the United States.
The amino acid sequences for the light and heavy chains of bevacizumab are shown in the table below.
Table 67. Amino Acid Sequences Light and Heavy Chains of Bevacizumab.
Protein Region Sequence Amino Acid Sequence (N- to C- Identifier terminal) Light chain SEQ ID NO:323 MGWSCIILFLVATATGVHSDIQMTQSPSSL
SASVGDRVTITCSASQDISNYLNWYQQKPG
KAPKVLIYFTSSLHSGVPSRFSGSGSGTDF
TLTISSLQPEDFATYYCQQYSTVPWTFGQG =
TKVEIKRTVAAPSVFIFPPSDEQLKSGTAS
VVCLLNNFYPREAKVQWKVDNALQSGNSQE
SVTEQDSKDSTYSLSSTLTLSKADYEKHKV
YACEVTHQGLSSPVTKSFNRGEC
Heavy chain SEQ ID NO:327 MGWSLIILFLVATATGVHSEVQLVESGGGL
VQPGGSLRLSCAASGYTFTNYGMNWVRQAP
GKGLEWVGWINTYTGEPTYAADFKRRFTFS
LDTSKSTAYLQMNSLRAEDTAVYYCAKYPH
YYGSSHWYFDVWGQGTLVTVSSASTKGPSV
FPLAPSSKSTSGGTAALGCLVKDYFPEPVT
VSWNSGALTSGVHTFPAVLQSSGLYSLSSV
VTVPSSSLGTQTYICNVNHKPSNTKVDKKV
EPKSCDKTHTCPPCPAPELLGGPSVFLFPP
KPKDTLMISRTPEVTCVVVDVSHEDPEVKF
NWYVDGVEVHNAKTKPREEQYNSTYRVVSV
LTVLHQDWLNGKEYKCKVSNKALPAPIEKT
ISKAKGQPREPQVYTLPPSRDELTKNQVSL
TCLVKGFYPSDIAVEWESNGQPENNYKTTP
PVLDSDGSFFLYSKLTVDKSRWQQGNVFSC
SVMHEALHNHYTQKSLSLSPGK
AMENDED SHEET - IPEA/US
The anti-VEGF antibody bevacizumab (target protein) was expressed in human cells in the presence and absence of the BSC1-Protein A fusion protein. A mock culture contained cells that expressed neither protein. Samples of the media from cell cultures were assayed for antibody by immunodot blot assay using an anti-human IgG antibody.
Figure 26A shows a dot blot assay for expression of the bevacizumab (anti-VEGF
antibody) secreted into the media of cultures of transfected cells expressing bevacizumab alone (middle row) and co-expressing bevacizumab and the BSC1-Protein A fusion protein (bottom row). The top row of Figure 26A shows that no antibody was secreted into medium from a mock culture of control cells that lacked a structural gene for either protein. The results show that co-expression in transfected cells of the bevacizumab target protein and the BSC1-Protein A fusion protein significantly enhanced the level of expression of bevacizumab secreted into the culture medium as compared to the level of the antibody secreted into medium of a culture of cells expressing bevacizumab alone.
Figure 26B shows the results of a densitometry analysis of the chemiluminescent signals in each of the rows of the dot blot in Figure 26A using the NIH ImageJ image processing program. The bar graphs of Figure 26B are numbered to correspond to the row numbers of Figure 26A. The results of this series of experiments clearly show that co-expression of the anti-VEGF
antibody target protein with a BSC1-Protein A fusion protein significantly enhanced the level of expression of the anti-VEGF
antibody secreted into the culture medium.
Figure 26C shows the results of an ELISA to detect VEGF binding activity in culture media.
A 96-well plate was coated with recombinant purified human VEGF-A and incubated with the bevacizumab (anti-VEGF antibody target protein) secreted into the media of cultures of transfected cells that expressed the anti-VEGF antibody alone (bar graph 2) or of transfected cells that co-expressed the anti-VEGF antibody and the BSC1-Protein A fusion protein (bar graph 3). Bar graph 1 of Figure 26C shows that no significant VEGF binding activity was present in medium from a mock culture of cells transfected with expression vector lacking a structural gene for expressing either protein. The results clearly show that the secreted anti-VEGF antibody that was expressed at enhanced levels when co-expressed with the BSC1-Protein A fusion protein retained its binding activity for human VEGF-A.
Example 19. BSC1-Protein A Fusion Protein Enhances Expression of a Therapeutic Anti-TNFa Antibody (Adalimumab) Target Protein in an Unmodified Arrangement This experiment examined whether a BSC1-Protein A fusion protein as described above could be used in an unmodified arrangement to improve the level of expression of a therapeutic anti-TNFa antibody (adalimumab; Humira0, AbbVie).
Table 68. Amino Acid Sequences of Light and Heavy Chains of Adalimumab.
PCT/US2013/073442 08.04.2015 Protein Region Sequence Amino Acid Sequence (N¨ to C¨ Identifier terminal) Light chain SEQ ID NO:324 MGWSCIILFLVATATGVHSDIQMTQSPSSL
SASVGDRVTITCkSSQGIRNYLHWYQQKPG
KAPKLLIYAASTLQSGVPSRFSGSGSGTDF
TLTISSLQPEDVATYYCQRYNRAPYTFGQG
TKVEIKRTVAAPSVFIFPPSDEQLKSGTAS
VVCLLNNFYPREAKVQWKVDNALQSGNSQE
SVTEQDSKDSTYSLSSTLTLSKADYEKHKV
YACEVTHQGLSSPVTKSFNRGEC
Heavy chain SEQ ID NO:328 MGWSLIILFLVATATGVHSEVQLVESGGGL
VQPGRSLRLSCAASGFTFDDYAMHWVRQAP
= GKGLEWVSAITWNSGHIDYADSVEGRFTIS
RDNAKNSLYLQMNSLRAEDTAVYYCAKVSY
= LSTASSLDVWGQGTLVTVSSASTKGPSVFP
LAPSSKSTSGGTAALGCLVKDYFPEPVTVS
WNSGALTSGVHTFPAVLQSSGLYSLSSVVT
VPSSSLGTQTYICNVNHKPSNTKVDKKVEP
KSCDKTHTCPPCPAPELLGGPSVFLFPPKP
KDTLMISRTPEVTCVVVDVSHEDPEVKFNW
YVDGVEVHNAKTKPREEQYNSTYRVVSVLT
VLHQDWLNGKEYKCKVSNKALPAPIEKTIS
KAKGQPREPQVYTLPPSRDELTKNQVSLTC
LVKGFYPSDIAVEWESNGQPENNYKTTPPV
LDSDGSFFLYSKLTVDKSRWQQGNVFSCSV
MHEALHNHYTQKSLSLSPGK
Figure 27A shows a dot blot assay for expression of the anti-TNFa antibody (target protein) secreted into the media of cultures of transfected cells expressing the anti-TNFa antibody alone (middle row) and of transfected cells co-expressing the anti-TNFa antibody and the BSC1-Protein A
fusion protein (bottom row of Figure 27A). No anti -TNFa antibody was detected in medium of mock cultures containing cells transfected with expression vector lacking a structural gene for expressing either protein (top row of Figure 27A). Expression of the anti-INFa antibody in culture media was analyzed in the dot blot assay using an anti-human IgG antibody. It can be seen that co-expression in transfected cells of the anti-TNFa antibody and the BSC1-Protein A fusion protein (bottom row) significantly enhanced the level of expression of anti-TNFa antibody secreted into the culture medium as compared to the level of the antibody expressed in transfected cells expressing the anti-TNFa antibody alone (middle row).
Figure 27B shows the results of a densitometry analysis of the chemiluminescent signals in dot blots in each of the rows in Figure 27A using the NTH ImageJ image processing program. The bar graphs of Figure 27B are numbered to correspond to the row numbers of Figure 27A. The results of this series of experiments clearly show that co-expression of the anti-TNFa antibody target protein with a fusion protein comprising a BSC1 polypeptide linked to a target binding domain (Protein A) significantly enhanced the level of expression of secreted anti-TNFa antibody.
AMENDED SHEET - IPEA/US
Figure 27C shows the results of an ELISA for TNFa binding activity by the expressed anti-TNFa antibody. A 96-well plate was coated with recombinant purified human TNFa and incubated with the anti-TNFa antibody (target protein) secreted into the media of cultures of transfected cells expressing the anti-TNFa antibody alone (bar graph 2) or co-expressing anti-TNFa antibody and the BSC1-Protein A fusion protein (bar graph 3). No TNFa binding activity was detected in medium from mock cultures containing cells transfected with an expression vector lacking a structural gene for expressing either protein (bar graph 1). The results of this series of experiments clearly show that the secreted anti-TNFa antibody that was expressed at enhanced levels when co-expressed with the BSC1-Protein A fusion protein retained its binding activity for human TNFa.
Example 20. BSC1-Protein A Fusion Protein Enhances Established Expression of an Anti-1L8 Antibody in CHO-D12 Cell Line in an Unmodified Arrangement Similar in design to Example 8, above, this experiment examined whether a BSC1-Protein A fusion protein could enhance the level of expression of an anti-1L8 antibody already being produced in an established commercially relevant production CHO-DP12 cell line (American Type Culture Collection Accession No. CRL-124444, American Type Culture Collection, Manassas, Virginia).
Figure 28A shows results of an immune dot blot assay for expression of the anti-1L8 antibody (target protein) secreted into the media of cultures of cells of a CHO-DP12 cell line expressing the anti-1L8 antibody alone (middle row 2) and of cells co-expressing the anti-1L8 antibody and the BSC1-Protein A fusion protein (bottom row 3). It can be seen that co-expression of the antibody with the BSC1-Protein A fusion molecule significantly enhanced the level of expression of the antibody secreted into the culture medium (bottom row 3) as compared to the level of the antibody expressed in the absence of the BSC1-Protein A fusion molecule (row 2). No antibody was detected in medium alone (top row of Figure 28A).
Figure 28B shows the results of a densitometry analysis of the chemiluminescent signals in the dot blots in the rows of Figure 28A using the NIH ImageJ image processing program. The bar graphs in Figure 28B are numbered to correspond to the rows in Figure 28A. The results indicate that co-expression of the antibody with the BSC1-Protein A fusion molecule (bar graph 3) significantly enhanced expression of the secreted antibody, providing an approximately four to five-fold greater enhancement in the level of expression as compared to that obtained when the antibody was expressed in the absence of the BSC1-Protein A fusion protein (bar graph 2).
Figure 28C shows the results of an ELISA for IL8 binding. A 96-well plate was coated with recombinant purified human IL8 and incubated with the anti-1L8 antibody (target protein) secreted into the media of cultures stably expressing the anti-1L8 antibody alone (bar graph 2) or co-expressing the anti-1L8 antibody and the BSC1-Protein A fusion protein (bar graph 3).
Cell culture medium was used as a negative control (bar graph 1, no anti-1L8 antibody). The results of this series of experiments clearly show that the secreted anti-1L8 antibody that was expressed at enhanced levels when co-expressed with the BSC1-Protein A fusion protein retained its binding activity for IL8.
The results indicate that a BSC1-Protein A fusion protein can be employed in an unmodified arrangement to significantly enhance the level of production of a target protein that is already stably expressed in an established production cell line.
Example 21. Enhancement of Expression of Secreted Alpha-1 Antitrvpsin Z
Protein This experiment indicates that enhancement of protein expression according to the invention has the potential to treat a disease resulting from an improper conformation of a critical protein.
Alphal antitrypsin (AAT) deficiency is an autosomal genetic disorder that affects both genders. AAT is a 52-1(Da serine protease inhibitor produced mainly in the liver. Over 90 genetic variants have been identified in the protease inhibitor 1 (PI) gene on chromosome 14 that are associated with AAT deficiency. The most common basis of AAT deficiency is the Z mutation, a single base pair substitution that changes a Glu to Lys at codon 342 (G1u342Lys). The mutant AAT
protein with the Z mutation (AATZ protein) retains approximately 80% of the serine protease activity of the wild type AAT protein. The AATZ protein also cannot fold to establish a normal conformation and consequently accumulates in aggregates within the endoplasmic reticulum (ER). Accumulation of aggregated AATZ in liver cells leads to liver toxicity and liver cirrhosis.
For this experiment, the target proteins were an engineered AAT-Fc fusion protein and an engineered VS-tagged al ATZ-Fc fusion protein. The amino acid sequence of the AAT-Fc fusion protein is the same as described in Example 4.3 above. The amino acid sequence for the AATZ-Fc fusion protein is shown in the table below.
Table 69. Amino Acid Sequence of a VS-Tagged al AATZ-Fc Target Protein.
Protein Region Sequence Amino Acid Sequence (N¨ to C¨ Identifier terminal) V5-tagged SEQ
ID NO:325 MPSSVSWGILLLAGLCCLVPVSLAEDPQGD
alAATZ-Fc fusion AAQKTDTSHHDQDHPTFNKITPNLAEFAFS
molecule LYRQLAHQSNSTNIFFSPVSIATAFAMLSL
GTKADTHDEILEGLNFNLTEIPEAQIHEGF
QELLRTLNQPDSQLQLTTGNGLFLSEGLKL
VDKFLEDVKKLYHSEAFTVNFGDTEEAKKQ
INDYVEKGTQGKIVDLVKELDRDTVFALVN
YIFFKGKWERPFEVKDTEEEDFHVDQVTTV
KVPMMKRLGMFNIQHCKKLSSWVLLMKYLG
NATAIFFLPDEGKLQHLENELTHDIITKFL
ENEDRRSASLHLPKLSITGTYDLKSVLGQL
GITKVFSNGADLSGVTEEAPLKLSKAVHKA
VLTIDKKGTEAAGAMFLEAIPMSIPPEVKF
NKPFVFLMIEQNTKSPLFMGKVVNPTQKGT
GSEFDIAAALEGKPIPNPLLGLDSTSRPKS
CDKTHTCPPCPAPELLGGPSVFLFPPKPKD
TLMISRTPEVTCVVVDVSHEDPEVKFNWYV
DGVEVHNAKTKPREEQYNSTYRVVSVLTVL
Protein Region Sequence Amino Acid Sequence (N¨ to C¨ Identifier terminal) 123456789012345678901234567890 HQDWLNGKEYKCKVSNKALPAPIEKTISKA
KGQPREPQVYTLPPSRDELTKNQVSLTCLV
KGFYPSDIAVEWESNGQPENNYKTTPPVLD
SDGSFFLYSKLTVDKSRWQQGNVFSCSVMH
EALHNHYTQKSLSLSPGK
a1AATZ
residues 1-418 MPSSVSWGILLLAGLCCLVPVSLAEDPQGD
of SEQ ID
AAQKTDTSHHDQDHPTFNKITPNLAEFAFS
NO:325 LYRQLAHQSNSTNIFFSPVSIATAFAMLSL
GTKADTHDEILEGLNFNLTEIPEAQIHEGF
QELLRTLNQPDSQLQLTTGNGLFLSEGLKL
VDKFLEDVKKLYHSEAFTVNFGDTEEAKKQ
INDYVEKGTQGKIVDLVKELDRDTVFALVN
YIFFKGKWERPFEVKDTEEEDFHVDQVTTV
KVPMMKRLGMFNIQHCKKLSSWVLLMKYLG
NATAIFFLPDEGKLQHLENELTHDIITKFL
ENEDRRSASLHLPKLSITGTYDLKSVLGQL
GITKVFSNGADLSGVTEEAPLKLSKAVHKA
VLTIDKKGTEAAGAMFLEAIPMSIPPEVKF
NKPFVFLMIEQNTKSPLFMGKVVNPTQK
Linker 1 residues 419- GTGSEFDIAAALE
431 of SEQ ID
NO:325 V5 epitope residues 432- GKPIPNPLLGLDST
domain 445 of SEQ ID
NO:325 Linker 2 residues 446- SR
447 of SEQ ID
NO:325 Fc domain residues 448- PKSCDKTHTCPPCPAPELLGGPSVFLFPPK
678 of SEQ ID PKDTLMISRTPEVTCVVVDVSHEDPEVKFN
NO:325 WYVDGVEVHNAKTKPREEQYNSTYRVVSVL
TVLHQDWLNGKEYKCKVSNKALPAPIEKTI
SKAKGQPREPQVYTLPPSRDELTKNQVSLT
CLVKGFYPSDIAVEWESNGQPENNYKTTPP
VLDSDGSFFLYSKLTVDKSRWQQGNVFSCS
VMHEALHNHYTQKSLSLSPGK
Figure 29A shows images of chemiluminescent signals of a Western blot assay using anti-V5 antibody to detect expression of the V5-tagged AAT- and AATZ-Fc fusion proteins. Lane 1 in the top panel of Figure 29A shows non-expressing cell culture medium as a control.
Lane 2 of the top panel shows culture medium of cells expressing AAT-Fc alone. As expected for the wild type AAT
protein, the AAT-Fc fusion was secreted into the culture medium. Lane 3 of the top panel of Figure 29A shows that little if any of AATZ-Fc protein was secreted into the medium of a culture of transfected cells expressing the AATZ-Fc fusion protein alone. As expected for the AATZ protein, which is known to be retained in the endoplasmic reticulum, AATZ-Fc fusion protein was detected in cell lysates of the cells expressing AATZ-Fc protein alone. See, lane 3 of the middle panel (cell lysates). Surprisingly, as shown in lane 4 of the top panel of Figure 29A, co-expression of the AATZ-Fc protein and the BSC1-Protein A fusion protein resulted in a dramatic increase in the level of expression of AATZ-Fc protein secreted into the cultures medium. Moreover, little if any of AATZ-Fc fusion protein was detected in cell lysate (lane 4, middle panel of Figure 29A). The same membrane was blotted with anti-tubulin antibody for a loading control.
The results clearly show that co-expression of the BSC1-Protein A fusion protein significantly elevated the level of expression of the AATZ-Fc target protein secreted into the culture medium as compared to the level of expression of the target protein in the absence of the BSC1-Protein A fusion protein. Moreover, little if any of the AATZ-Fc proteins was detected in cell lysates, indicating that the AATZ-Fc protein was not retained in the endoplasmic reticulum.
Accordingly, these data suggest for the first time that a gene therapy that would provide a fusion protein comprising an AATZ-binding domain and a protein expression enhancing polypeptide of this invention would be effective in treating an individual for AAT deficiency due to the Z mutation by enhancing expression of secreted AATZ protein from cells of the individual, eliminating or reducing liver toxicity due to retention of AATZ in the endoplasmic reticulum, and restoring required levels of extracellular AAT serine protease activity to individual.
All patents, applications, and publications cited in the above text are incorporated herein by reference.
Other variations and embodiments of the invention described herein will now be apparent to those of skill in the art without departing from the disclosure of the invention or the claims below.
Claims (61)
1. A protein expression enhancing polypeptide selected from the group consisting of:
(a) an active fragment of a J domain;
(b) a J domain analog polypeptide comprising the amino acid sequence of formula I:
X1-X2-X3-X4-X5-X6-X7-X8-X9 (SEQ ID NO:47), wherein:
X1 is isoleucine (I), leucine (L), valine (V), alanine (A), or methionine (M);
X2 and X3 are each independently any amino acid with the proviso that one or both are K or R;
X4 is any amino acid or X4 may be absent when X1 through X3 are present and X5 through X9 are present;
X5 is tyrosine (Y), tryptophan (W), or phenylalanine (F);
X6 and X7 are each independently any amino acid with the proviso that one or both are lysine (K) or arginine (R); or either one of X6 and X7 may be absent when the other is K or R and when X1 through X5 are present and X8 and X9 are present; and X8 and X9 are any amino acid with the proviso that one or both are leucine (L) or alanine (A); or one of X8 and X9 may be absent when the other is L or A and when X1 through X7 are present; and (c) a decapeptide selected from the group consisting of:
IKKAYKLALQ (SEQ ID NO:49), IKKAYRLALQ (SEQ ID NO:50), IKKAYRKALQ (SEQ ID NO:51), and IKKAYRKLLQ (SEQ ID NO:52);
said protein expression enhancing polypeptide being capable of enhancing expression of a target protein of interest when co-expressed with said target protein as either (i) a fusion partner of said target protein or (ii) a fusion partner with a target protein binding domain.
(a) an active fragment of a J domain;
(b) a J domain analog polypeptide comprising the amino acid sequence of formula I:
X1-X2-X3-X4-X5-X6-X7-X8-X9 (SEQ ID NO:47), wherein:
X1 is isoleucine (I), leucine (L), valine (V), alanine (A), or methionine (M);
X2 and X3 are each independently any amino acid with the proviso that one or both are K or R;
X4 is any amino acid or X4 may be absent when X1 through X3 are present and X5 through X9 are present;
X5 is tyrosine (Y), tryptophan (W), or phenylalanine (F);
X6 and X7 are each independently any amino acid with the proviso that one or both are lysine (K) or arginine (R); or either one of X6 and X7 may be absent when the other is K or R and when X1 through X5 are present and X8 and X9 are present; and X8 and X9 are any amino acid with the proviso that one or both are leucine (L) or alanine (A); or one of X8 and X9 may be absent when the other is L or A and when X1 through X7 are present; and (c) a decapeptide selected from the group consisting of:
IKKAYKLALQ (SEQ ID NO:49), IKKAYRLALQ (SEQ ID NO:50), IKKAYRKALQ (SEQ ID NO:51), and IKKAYRKLLQ (SEQ ID NO:52);
said protein expression enhancing polypeptide being capable of enhancing expression of a target protein of interest when co-expressed with said target protein as either (i) a fusion partner of said target protein or (ii) a fusion partner with a target protein binding domain.
2. The polypeptide according to Claim 1, wherein the protein expression enhancing polypeptide is an isolated J domain of a J protein.
3. The polypeptide according to Claim 2, wherein the isolated J domain is an isolated J domain of an ERdj protein, a large T antigen of SV40, or a mammalian cysteine string protein alpha (CSP-.alpha.).
4. The polypeptide according to Claim 3, wherein the isolated J domain is an isolated J domain of an Erdj protein selected from Erdj1, Erdj2, Erdj3, Erdj4, Erdj5, Erdj6 and Erdj7.
5. The polypeptide according to Claim 4, wherein the isolated J domain is an isolated J domain of Erdj3.
6. The polypeptide according to Claim 1, wherein the protein expression enhancing polypeptide is an active fragment of a J domain.
7. The polypeptide according to Claim 6, wherein the protein expression enhancing polypeptide is an active fragment of a J domain selected from the group consisting of:
I-K-K-A-Y-R-K-L-A (SEQ ID NO:48), I-R-K-A-Y-R-K-L-S-L-T-L (SEQ ID NO:83), I-K-K-Q-Y-R-L-L-S-L-K-Y (SEQ ID NO:84), I-K-K-A-F-H-K-L-A-M-K-Y (SEQ ID NO:85), I-R-Q-A-F-K-K-L-A-L-K-L (SEQ ID NO:86), I-I-K-A-Y-R-K-L-A-L-Q-W (SEQ ID NO:87), I-A-R-A-Y-R-Q-L-A-R-R-Y (SEQ ID NO:88), I-K-R-A-Y-R-R-Q-A-L-R-Y (SEQ ID NO:89), I-K-K-S-Y-R-K-L-A-L-K-Y (SEQ I) NO:90), and I-K-K-A-Y-K-R-L-A-M-K-Y (SEQ ID NO:91).
I-K-K-A-Y-R-K-L-A (SEQ ID NO:48), I-R-K-A-Y-R-K-L-S-L-T-L (SEQ ID NO:83), I-K-K-Q-Y-R-L-L-S-L-K-Y (SEQ ID NO:84), I-K-K-A-F-H-K-L-A-M-K-Y (SEQ ID NO:85), I-R-Q-A-F-K-K-L-A-L-K-L (SEQ ID NO:86), I-I-K-A-Y-R-K-L-A-L-Q-W (SEQ ID NO:87), I-A-R-A-Y-R-Q-L-A-R-R-Y (SEQ ID NO:88), I-K-R-A-Y-R-R-Q-A-L-R-Y (SEQ ID NO:89), I-K-K-S-Y-R-K-L-A-L-K-Y (SEQ I) NO:90), and I-K-K-A-Y-K-R-L-A-M-K-Y (SEQ ID NO:91).
8. The polypeptide according to Claim 1, wherein the protein expression enhancing polypeptide is a J domain analog polypeptide, wherein said J domain analog polypeptide comprises the amino acid sequence of formula I.
9. The polypeptide according to Claim 8, wherein said J domain analog polypeptide comprises the amino acid sequence (SEQ ID NO:326) wherein:
X1 is I, L, V, A, or M;
the dipeptide X2-X3 is selected from the group consisting of: KR, KK, RK, RR, AK, AR, KA, IK, NK, KQ, RQ, and RD;
X4 is A, S, T, R, Q, E, F, C, or I;
X5 is Y or F;
the dipeptide X6-X7 is selected from the group consisting of: KR, KK, RK, RR, RQ, FR, RL, KL, HK, LK, QK, and KV; and the dipeptide X8-X9 is selected from the group consisting of: LA, LL, AL, AA, LC, LV, QA, KA, LS, LI, LY, and RA.
X1 is I, L, V, A, or M;
the dipeptide X2-X3 is selected from the group consisting of: KR, KK, RK, RR, AK, AR, KA, IK, NK, KQ, RQ, and RD;
X4 is A, S, T, R, Q, E, F, C, or I;
X5 is Y or F;
the dipeptide X6-X7 is selected from the group consisting of: KR, KK, RK, RR, RQ, FR, RL, KL, HK, LK, QK, and KV; and the dipeptide X8-X9 is selected from the group consisting of: LA, LL, AL, AA, LC, LV, QA, KA, LS, LI, LY, and RA.
10. The polypeptide according to Claim 1, wherein said protein expression enhancing polypeptide comprises one of the following amino acid sequences:
11. An isolated nucleic acid molecule comprising a nucleic acid sequence encoding a protein expression enhancing polypeptide according to any one of Claims 1-10.
12. A nucleic acid vector molecule comprising the isolated nucleic acid molecule according to Claim 11
13. A host cell comprising the nucleic acid vector molecule according to Claim 12.
14. A fusion protein comprising:
a protein expression enhancing polypeptide linked to a target protein of interest, wherein said protein expression enhancing polypeptide is selected from the group consisting of:
(a) an isolated J domain of a J protein;
(b) an active fragment of a J domain;
(c) a J domain analog polypeptide comprising the amino acid sequence of formula I:
(I) X1 -X2-X3-X4-X5-X6-X7-X8-X9 (SEQ ID NO:47), wherein:
X1 is isoleucine (I), leucme (L), vahne (V), alanme (A), or methionine (M), X2 and X3 are each independently any amino acid with the proviso that one or both are K or R;
X4 is any aimno acid or X4 may be absent when X1 through X3 are present and X5 through X9 are present;
X5 is tyrosine (Y), tryptophan (W), or phenylalanme (F);
X6 and X7 are each independently any amino acid with the proviso that one or both are lysme (K) or argmme (R); or either one of X6 and X7 may be absent when the other is K or R and when X1 through X5 are present and X8 and X9 are present; and X8 and X9 are any amino acid with the proviso that one or both are leucine (L) or alanme (A); or one of X8 and X9 may be absent when the other is L or A and when X1 through X7 are present, and (d) a decapepude selected from the group consisting of IKKAYKLALQ (SEQ ID NO:49), IKKAYRLALQ (SEQ ID NO:50), IKKAYRKALQ (SEQ ID NO:51), and IKKAYRKLLQ (SEQ ID NO:52);
wherein said fusion protein is expressed at an enhanced level compared to the level of expression of said target protein alone.
a protein expression enhancing polypeptide linked to a target protein of interest, wherein said protein expression enhancing polypeptide is selected from the group consisting of:
(a) an isolated J domain of a J protein;
(b) an active fragment of a J domain;
(c) a J domain analog polypeptide comprising the amino acid sequence of formula I:
(I) X1 -X2-X3-X4-X5-X6-X7-X8-X9 (SEQ ID NO:47), wherein:
X1 is isoleucine (I), leucme (L), vahne (V), alanme (A), or methionine (M), X2 and X3 are each independently any amino acid with the proviso that one or both are K or R;
X4 is any aimno acid or X4 may be absent when X1 through X3 are present and X5 through X9 are present;
X5 is tyrosine (Y), tryptophan (W), or phenylalanme (F);
X6 and X7 are each independently any amino acid with the proviso that one or both are lysme (K) or argmme (R); or either one of X6 and X7 may be absent when the other is K or R and when X1 through X5 are present and X8 and X9 are present; and X8 and X9 are any amino acid with the proviso that one or both are leucine (L) or alanme (A); or one of X8 and X9 may be absent when the other is L or A and when X1 through X7 are present, and (d) a decapepude selected from the group consisting of IKKAYKLALQ (SEQ ID NO:49), IKKAYRLALQ (SEQ ID NO:50), IKKAYRKALQ (SEQ ID NO:51), and IKKAYRKLLQ (SEQ ID NO:52);
wherein said fusion protein is expressed at an enhanced level compared to the level of expression of said target protein alone.
15. The fusion protein according to Claim 14, wherein the protein expression enhancing polypeptide is an isolated J domain.
16. The fusion protein according to Claim 15, wherein the isolated J domain is an isolated J
domain of an ERdj protein, a large T antigen of SV40, or a mammalian cysteine string protein alpha (CSP-.alpha.).
domain of an ERdj protein, a large T antigen of SV40, or a mammalian cysteine string protein alpha (CSP-.alpha.).
17. The fusion protein according to Claim 16, wherein the isolated J domain is an isolated J
domain of an Erdj protein selected from Erdj1, Erdj2, Erdj3, Erdj4, Erdj5, Erdj6 and Erdj7.
domain of an Erdj protein selected from Erdj1, Erdj2, Erdj3, Erdj4, Erdj5, Erdj6 and Erdj7.
18. The fusion protein according to Claim 17, wherein the isolated J domain is an isolated J
domain of Erdj3.
domain of Erdj3.
19. The fusion protein according to Claim 14, wherein the protein expression enhancing polypeptide is an active fragment of a J domain.
20. The fusion protein according to Claim 19, wherein the protein expression enhancing polypeptide is an active fragment of a J domain selected from the group consisting of:
I-K-K-A-Y-R-K-L-A (SEQ ID NO:48), I-R-K-A-Y-R-K-L-S-L-T-L (SEQ ID NO:83), I-K-K-Q-Y-R-L-L-S-L-K-Y (SEQ ID NO:84), I-K-K-A-F-H-K-L-A-M-K-Y (SEQ ID NO:85), I-R-Q-A-F-K-K-L-A-L-K-L (SEQ ID NO:86), I-I-K-A-Y-R-K-L-A-L-Q-W (SEQ ID NO:87), I-A-R-A-Y-R-Q-L-A-R-R-Y (SEQ ID NO:88), I-K-R-A-Y-R-R-Q-A-L-R-Y (SEQID NO:89), I-K-K-S-Y-R-K-L-A-L-K-Y (SEQ ID NO:90), and I-K-K-A-Y-K-R-L-A-M-K-Y (SEQ ID NO:91).
I-K-K-A-Y-R-K-L-A (SEQ ID NO:48), I-R-K-A-Y-R-K-L-S-L-T-L (SEQ ID NO:83), I-K-K-Q-Y-R-L-L-S-L-K-Y (SEQ ID NO:84), I-K-K-A-F-H-K-L-A-M-K-Y (SEQ ID NO:85), I-R-Q-A-F-K-K-L-A-L-K-L (SEQ ID NO:86), I-I-K-A-Y-R-K-L-A-L-Q-W (SEQ ID NO:87), I-A-R-A-Y-R-Q-L-A-R-R-Y (SEQ ID NO:88), I-K-R-A-Y-R-R-Q-A-L-R-Y (SEQID NO:89), I-K-K-S-Y-R-K-L-A-L-K-Y (SEQ ID NO:90), and I-K-K-A-Y-K-R-L-A-M-K-Y (SEQ ID NO:91).
21. The fusion protein according to Claim 14, wherein the protein expression enhancing polypeptide is a J domain analog polypeptide, wherein said J domain analog polypeptide comprises the amino acid sequence of formula I.
22. The fusion protein according to Claim 21, wherein said J domain analog polypeptide comprises the amino acid sequence (SEQ ID NO:326) wherein:
X1 is I, L, V, A, or M;
the dipeptide X2-X3 is selected from the group consisting of: KR, KK, RK, RR, AK, AR, KA, IK, NK, KQ, RQ, and RD;
X4 is A, S, T, R, Q, E, F, C, or I;
X5 is Y or F;
the dipeptide X6-X7 is selected from the group consisting of: KR, KK, RK, RR, RQ, FR, RL, KL, HK, LK, QK, and KV; and the dipeptide X8-X9 is selected from the group consisting of: LA, LL, AL, AA, LC, LV, QA, KA, LS, LI, LY, and RA.
X1 is I, L, V, A, or M;
the dipeptide X2-X3 is selected from the group consisting of: KR, KK, RK, RR, AK, AR, KA, IK, NK, KQ, RQ, and RD;
X4 is A, S, T, R, Q, E, F, C, or I;
X5 is Y or F;
the dipeptide X6-X7 is selected from the group consisting of: KR, KK, RK, RR, RQ, FR, RL, KL, HK, LK, QK, and KV; and the dipeptide X8-X9 is selected from the group consisting of: LA, LL, AL, AA, LC, LV, QA, KA, LS, LI, LY, and RA.
23. The fusion protein according to Claim 14, wherein said protein expression enhancing polypeptide comprises one of the following amino acid sequences:
24. An isolated nucleic acid molecule comprising a nucleic acid sequence encoding a fusion protein according to any one of Claims 14-23.
25. A nucleic acid vector molecule comprising the isolated nucleic acid molecule according to Claim 24.
26. A host cell comprising the nucleic acid vector molecule according to Claim 25.
27. A method of expressing a fusion protein comprising a protein expression enhancing polypeptide linked to a target protein of interest comprising culturing a host cell according to Claim 26 under conditions sufficient to produce the fusion protein.
28. A method of expressing a fusion protein comprising a protein expression enhancing polypeptide linked to a target protein of interest comprising transfecting a host cell with an expression vector comprising a structural gene encoding a fusion protein according to Claim 14 and culturing said transfected host cell under conditions causing the expression of said fusion protein.
29 A method of expressing a fusion protein comprising a protein expression enhancing polypeptide linked to a target protein of interest comprising the steps of:
1) constructing a recombinant gene sequence encoding a fusion protein according to Claim 14;
2) inserting the recombinant gene sequence into an expression vector to form a recombinant expression vector wherein said recombinant gene sequence is operably linked to a transcriptional promoter sequence;
3) transfecting said recombinant expression vector into host cells that are compatible with said promoter sequence; and 4) culturing said transfected host cells under conditions that permit expression of said fusion protein.
1) constructing a recombinant gene sequence encoding a fusion protein according to Claim 14;
2) inserting the recombinant gene sequence into an expression vector to form a recombinant expression vector wherein said recombinant gene sequence is operably linked to a transcriptional promoter sequence;
3) transfecting said recombinant expression vector into host cells that are compatible with said promoter sequence; and 4) culturing said transfected host cells under conditions that permit expression of said fusion protein.
30. A method of restoring a protein function in cells of a mammalian subject that are deficient in the secretion of a native secreted protein that provides said protein function comprising inserting into cells of the subject an exogenous nucleic acid molecule encoding a fusion protein according to Claim 14 comprising a protein expression enhancing polypeptide linked to the secreted protein, wherein expression of the fusion protein provides the function of the native secreted protein whose secretion is deficient m cells of the subject m the absence of the exogenous nucleic acid.
31 The method according to Claim 30, wherein the subject has a disease associated with the deficient secretion of a native secreted protein in the subject.
32. The method according to Claim 31, wherein said disease is selected from the group consisting of a prion-associated disease, Alzheimer's disease, Parkinson's disease, Huntington's disease, cystic fibrosis (CF), and al-antitrypsin deficiency.
33. The method according to Claim 32, wherein the subject is a human subject deficient in the secretion of cystic fibrosis transmembrane conductance regulator protein and the disease is cystic fibrosis.
34. A fusion protein comprising.
a protein expression enhancing polypeptide linked to a target protein binding domain, wherein said protein expression enhancing polypeptide is selected from the group consisting of:
(a) an isolated J domain of a J protein;
(b) an active fragment of a J domain;
(c) a J domain analog polypeptide comprising the amino acid sequence of formula I:
X1-X2-X3-X4-X5-X6-X7-X8-X9 (SEQ ID NO:47), wherein:
X1 is isoleucine (I), leucine (L), valine (V), alanine (A), or methionine (M);
X2 and X3 are each independently any amino acid with the proviso that one or both are K or R;
X4 is any amino acid or X4 may be absent when X1 through X3 are present and X5 through X9 are present;
X5 is tyrosine (Y), tryptophan (W), or phenylalanine (F);
X6 and X7 are each independently any amino acid with the proviso that one or both are lysine (K) or arginine (R); or either one of X6 and X7 may be absent when the other is K or R and when X1 through X5 are present and X8 and X9 are present; and X8 and X9 are any amino acid with the proviso that one or both are leucine (L) or alanine (A); or one of X8 and X9 may be absent when the other is L or A and when X1 through X7 are present; and (d) a decapeptide selected from the group consisting of:
EKKAYKLALQ (SEQ ID NO:49), IKKAYRLALQ (SEQ ID NO:50), IKKAYRKALQ (SEQ ID NO:51), and IKKAYRKLLQ (SEQ ID NO:52);
wherein co-expression of said fusion protein with a target protein of interest that is bound by said target protein binding domain of said fusion protein results in an enhanced level of expression of said target protein of interest compared to the level of expression in the absence of said fusion protein.
a protein expression enhancing polypeptide linked to a target protein binding domain, wherein said protein expression enhancing polypeptide is selected from the group consisting of:
(a) an isolated J domain of a J protein;
(b) an active fragment of a J domain;
(c) a J domain analog polypeptide comprising the amino acid sequence of formula I:
X1-X2-X3-X4-X5-X6-X7-X8-X9 (SEQ ID NO:47), wherein:
X1 is isoleucine (I), leucine (L), valine (V), alanine (A), or methionine (M);
X2 and X3 are each independently any amino acid with the proviso that one or both are K or R;
X4 is any amino acid or X4 may be absent when X1 through X3 are present and X5 through X9 are present;
X5 is tyrosine (Y), tryptophan (W), or phenylalanine (F);
X6 and X7 are each independently any amino acid with the proviso that one or both are lysine (K) or arginine (R); or either one of X6 and X7 may be absent when the other is K or R and when X1 through X5 are present and X8 and X9 are present; and X8 and X9 are any amino acid with the proviso that one or both are leucine (L) or alanine (A); or one of X8 and X9 may be absent when the other is L or A and when X1 through X7 are present; and (d) a decapeptide selected from the group consisting of:
EKKAYKLALQ (SEQ ID NO:49), IKKAYRLALQ (SEQ ID NO:50), IKKAYRKALQ (SEQ ID NO:51), and IKKAYRKLLQ (SEQ ID NO:52);
wherein co-expression of said fusion protein with a target protein of interest that is bound by said target protein binding domain of said fusion protein results in an enhanced level of expression of said target protein of interest compared to the level of expression in the absence of said fusion protein.
35. The fusion protein according to Claim 34, wherein the protein expression enhancing polypeptide is an isolated J protein.
36. The fusion protein according to Claim 35, wherein the isolated J domain is an isolated J
domain of an ERdj protein, a large T antigen of SV40, or a mammalian cysteine string protein alpha (CSP-.alpha.).
domain of an ERdj protein, a large T antigen of SV40, or a mammalian cysteine string protein alpha (CSP-.alpha.).
37. The fusion protein according to Claim 35, wherein the isolated J domain is an isolated J
domain of an Erdj protein selected from Erdj1, Erdj2, Erdj3, Erdj4, Erdj5, Erdj6 and Erdj7.
domain of an Erdj protein selected from Erdj1, Erdj2, Erdj3, Erdj4, Erdj5, Erdj6 and Erdj7.
38. The fusion protein according to Claim 37, wherein the isolated J domain is an isolated J
domain of Erdj3.
domain of Erdj3.
39. The fusion protein according to Claim 34, wherein the protein expression enhancing polypeptide is an active fragment of a J domain.
40. The fusion protein according to Claim 39, wherein the protein expression enhancing polypeptide is an active fragment of a J domain selected from the group consisting of:
I-K-K-A-Y-R-K-L-A (SEQ ID NO:48), I-R-K-A-Y-R-K-L-S-L-T-L (SEQ ID NO:83), I-K-K-Q-Y-R-L-L-S-L-K-Y (SEQ ID NO:84), I-K-K-A-F-H-K-L-A-M-K-Y (SEQ ID NO:85), I-R-Q-A-F-K-K-L-A-L-K-L (SEQ ID NO:86), I-I-K-A-Y-R-K-L-A-L-Q-W (SEQ ID NO:87), I-A-R-A-Y-R-Q-L-A-R-R-Y (SEQ ID NO:88), I-K-R-A-Y-R-R-Q-A-L-R-Y (SEQ ID NO:89), (SEQ ID NO:90), and (SEQ ID NO:91).
I-K-K-A-Y-R-K-L-A (SEQ ID NO:48), I-R-K-A-Y-R-K-L-S-L-T-L (SEQ ID NO:83), I-K-K-Q-Y-R-L-L-S-L-K-Y (SEQ ID NO:84), I-K-K-A-F-H-K-L-A-M-K-Y (SEQ ID NO:85), I-R-Q-A-F-K-K-L-A-L-K-L (SEQ ID NO:86), I-I-K-A-Y-R-K-L-A-L-Q-W (SEQ ID NO:87), I-A-R-A-Y-R-Q-L-A-R-R-Y (SEQ ID NO:88), I-K-R-A-Y-R-R-Q-A-L-R-Y (SEQ ID NO:89), (SEQ ID NO:90), and (SEQ ID NO:91).
41. The fusion protein according to Claim 34, wherein the protein expression enhancing polypeptide is a J domain analog polypeptide, wherein said J domain analog polypeptide comprises the amino acid sequence of formula I.
42. The fusion protein according to Claim 41, wherein said J domain analog polypeptide comprises the amino acid sequence (SEQ ID NO:326) wherein:
X1 is I, L, V, A, or M;
the dipeptide X2-X3 is selected from the group consisting of: KR, KK, RK, RR, AK, AR, KA, LK, NK, KQ, RQ, and RD;
X4 is A, S, T, R, Q, E, F, C, or I;
X5 is Y or F;
the dipeptide X6-X7 is selected from the group consisting of: KR, KK, RK, RR, RQ, FR, RL, KL, HK, LK, QK, and KV; and the dipeptide X8-X9 is selected from the group consisting of: LA, LL, AL, AA, LC, LV, QA, KA, LS, LI, LY, and RA.
X1 is I, L, V, A, or M;
the dipeptide X2-X3 is selected from the group consisting of: KR, KK, RK, RR, AK, AR, KA, LK, NK, KQ, RQ, and RD;
X4 is A, S, T, R, Q, E, F, C, or I;
X5 is Y or F;
the dipeptide X6-X7 is selected from the group consisting of: KR, KK, RK, RR, RQ, FR, RL, KL, HK, LK, QK, and KV; and the dipeptide X8-X9 is selected from the group consisting of: LA, LL, AL, AA, LC, LV, QA, KA, LS, LI, LY, and RA.
43. The fusion protein according to Claim 34, wherein said protein expression enhancing polypeptide comprises one of the following amino acid sequences:
44. The fusion protein according to Claim 34, wherein the target protein binding domain is an antibody or an antigen-binding fragment thereof, an antibody binding protein, a ligand binding domain of a receptor protein, a protein ligand of a receptor protein, a protein antigen that is bound by an antibody or an antigen-binding fragment thereof, or a PDZ
domain.
domain.
45 The fusion protein according to Claim 44, wherein the target protein binding domain is an antibody binding protein.
46. The fusion protein according to Claim 45, wherein the antibody binding protein is an Fc binding protein.
47. The fusion protein according to Claim 46, wherein the Fc binding protein is Protein A or Protein G.
48 The fusion protein according to Claim 45, wherein the antibody binding protein is Protein L.
49 The fusion protein according to Claim 43, wherein said target protein binding domain is a ligand binding domain of a receptor protein, wherein the receptor protein is a cytokine receptor.
50. The fusion protein according to Claim 44, wherein said target protein binding domain is a protein ligand to a receptor protein, wherein the protein ligand is a cytokine.
51. An isolated nucleic acid molecule comprising a nucleic acid sequence encoding a fusion protein according to any one of Claims 34-50.
52. A nucleic acid vector molecule comprising the isolated nucleic acid molecule according to Claim 51.
53 A host cell comprising the nucleic acid vector molecule according to Claim 52.
54. A method of expressing a fusion protein comprising culturing a host cell according to Claim 53 under conditions sufficient to produce the fusion protein.
55. A method of enhancing the expression of a target protein of interest expressed by a host cell comprising transfecting the host cell with an expression vector comprising a structural gene encoding a fusion protein comprising a protein expression enhancing polypeptide linked to the target protein binding domain according to Claim 34, and culturing said transfected host cell under conditions causing the co-expression of said fusion protein encoded by said structural gene and of said target protein of interest.
56. A method of enhancing the expression of a target protein of interest comprising the steps of:
1) constructing a recombinant gene encoding a fusion protein comprising a protein expression enhancing polypeptide according to Claim 1 linked to a target protein binding domain that binds said target protein of interest;
2) inserting the recombinant gene into an expression vector to form a recombinant expression vector wherein said recombinant gene sequence is operably linked to a transcriptional promoter sequence;
3) transfecting said recombinant expression vector into host cells that are compatible with said promoter sequence; and 4) culturing said transfected host cells under conditions that permit co-expression of said fusion protein encoded by said recombinant gene and of said target protein of interest.
1) constructing a recombinant gene encoding a fusion protein comprising a protein expression enhancing polypeptide according to Claim 1 linked to a target protein binding domain that binds said target protein of interest;
2) inserting the recombinant gene into an expression vector to form a recombinant expression vector wherein said recombinant gene sequence is operably linked to a transcriptional promoter sequence;
3) transfecting said recombinant expression vector into host cells that are compatible with said promoter sequence; and 4) culturing said transfected host cells under conditions that permit co-expression of said fusion protein encoded by said recombinant gene and of said target protein of interest.
57. A method of restoring a secreted protein function in cells of a mammalian subject that are deficient in the secretion of a native secreted protein that provides said secreted protein function comprising inserting into cells of the subject an exogenous nucleic acid molecule encoding a fusion protein according to Claim 34 comprising a protein expression enhancing polypeptide linked to a target protein binding domain that binds the native secreted protein, wherein expression of the fusion protein and the native secreted protein in the cells enhances secretion of said native protein to provide said protein function to the cells of the subject.
58. The method according to Claim 57, wherein the subject has a disease associated with the deficient secretion of the native protein in the subject.
59. The method according to Claim 58, wherein said disease is selected from the group consisting of a prion-associated disease, Alzheimer's disease, Parkinson's disease, Huntington's disease, cystic fibrosis (CF), and .alpha.1 -antitrypsin (AAT) deficiency.
60. The method according to Claim 59, wherein the subject is a human subject deficient in the secretion of cystic fibrosis transmembrane conductance regulator protein and the disease is cystic fibrosis.
61. The method according to Claim 59, wherein the subject is a human subject deficient in secretion of AAT and the disease is AAT deficiency.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA3138788A CA3138788A1 (en) | 2012-12-05 | 2013-12-05 | Protein expression enhancing polypeptides |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261733743P | 2012-12-05 | 2012-12-05 | |
US201261733884P | 2012-12-05 | 2012-12-05 | |
US61/733,884 | 2012-12-05 | ||
US61/733,743 | 2012-12-05 | ||
PCT/US2013/073442 WO2014089375A1 (en) | 2012-12-05 | 2013-12-05 | Protein expression enhancing polypeptides |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA3138788A Division CA3138788A1 (en) | 2012-12-05 | 2013-12-05 | Protein expression enhancing polypeptides |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2893359A1 true CA2893359A1 (en) | 2014-06-12 |
CA2893359C CA2893359C (en) | 2021-12-28 |
Family
ID=50884014
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2893359A Active CA2893359C (en) | 2012-12-05 | 2013-12-05 | Protein expression enhancing polypeptides |
CA3138788A Pending CA3138788A1 (en) | 2012-12-05 | 2013-12-05 | Protein expression enhancing polypeptides |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA3138788A Pending CA3138788A1 (en) | 2012-12-05 | 2013-12-05 | Protein expression enhancing polypeptides |
Country Status (8)
Country | Link |
---|---|
US (2) | US9758807B2 (en) |
EP (1) | EP2929045B1 (en) |
JP (2) | JP6345688B2 (en) |
KR (2) | KR20150093768A (en) |
CN (1) | CN104968795B (en) |
AU (2) | AU2013355120B2 (en) |
CA (2) | CA2893359C (en) |
WO (1) | WO2014089375A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106478773A (en) * | 2015-08-25 | 2017-03-08 | 三生国健药业(上海)股份有限公司 | A kind of novel signal peptide of synthetic |
CN106478774A (en) * | 2015-08-25 | 2017-03-08 | 三生国健药业(上海)股份有限公司 | A kind of signal peptide for protein expression |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ744257A (en) | 2011-06-28 | 2022-10-28 | Inhibrx Inc | Serpin fusion polypeptides and methods of use thereof |
US10400029B2 (en) | 2011-06-28 | 2019-09-03 | Inhibrx, Lp | Serpin fusion polypeptides and methods of use thereof |
BR112017008525A2 (en) * | 2014-10-27 | 2018-01-30 | Inhibrx Lp | isolated fusion protein, and methods for treating or alleviating a symptom of a disease or disorder, for treating or alleviating an inflammation or symptom of an inflammatory disease or disorder, and for reducing the risk of infection in an individual. |
EP3356543A4 (en) | 2015-09-28 | 2019-05-29 | The Trustees of Columbia University in the City of New York | Modified bacterial protein expression system |
US11390899B2 (en) * | 2016-09-26 | 2022-07-19 | SOLA Biosciences, LLC | Cell-associated secretion-enhancing fusion proteins |
KR102622188B1 (en) | 2016-10-07 | 2024-01-05 | 엔터롬 에스.에이. | Immunogenic Compounds for Cancer Treatment |
EP3522917A2 (en) | 2016-10-07 | 2019-08-14 | Enterome S.A. | Microbiota sequence variants of tumor-related antigenic epitopes |
US11478538B2 (en) | 2016-10-07 | 2022-10-25 | Enterome S.A. | Immunogenic compounds for cancer therapy |
US10717994B2 (en) * | 2016-12-15 | 2020-07-21 | Agricultural Technology Research Institute | Recombinant polypeptide for enhancing cell transduction efficiency of a target agent |
US20220160827A1 (en) * | 2017-05-16 | 2022-05-26 | Translate Bio, Inc. | TREATMENT OF CYSTIC FIBROSIS BY DELIVERY OF CODON-OPTIMIZED mRNA ENCODING CFTR |
KR20200131279A (en) * | 2018-03-14 | 2020-11-23 | 시애틀 칠드런즈 호스피탈 디/비/에이 시애틀 칠드런즈 리서치 인스티튜트 | IL-13 receptor alpha 2 (IL13RA2) chimeric antigen receptor for tumor specific T cell immunotherapy |
BR112020020780A2 (en) | 2018-04-11 | 2021-03-02 | Enterome S.A. | antigenic peptides for cancer prevention and treatment |
US20210106652A1 (en) * | 2018-04-11 | 2021-04-15 | Enterome S.A. | Immunogenic Compounds For Treatment Of Fibrosis, Autoimmune Diseases And Inflammation |
CN109913478A (en) * | 2019-04-09 | 2019-06-21 | 贵州大学 | A kind of sorghum E3 ubiquitin ligase SbBAG4 gene and its recombinant vector and expression |
WO2021222168A2 (en) * | 2020-04-28 | 2021-11-04 | Sola Biosciences Llc | Compositions and methods for the treatment of tdp-43 proteinopathies |
CA3183251A1 (en) * | 2020-06-05 | 2021-12-09 | Sola Biosciences Llc | Compositions and methods for the treatment of synucleinopathies |
CN112028972B (en) * | 2020-08-27 | 2021-05-11 | 北京百普赛斯生物科技股份有限公司 | Signal peptide for improving secretion expression of recombinant protein of mammalian cell and application thereof |
CN113402582B (en) * | 2021-06-19 | 2023-03-17 | 江西农业大学 | ANK tripeptide and application thereof |
WO2023060248A1 (en) * | 2021-10-08 | 2023-04-13 | Sola Biosciences Llc | Compositions and methods for the treatment of p53-mediated cancers |
WO2023081861A1 (en) * | 2021-11-04 | 2023-05-11 | University Of Virginia Patent Foundation | Enhanced expression via autotransporters |
CN114085873A (en) * | 2021-11-16 | 2022-02-25 | 珠海中科先进技术研究院有限公司 | Cancer cell state identification gene circuit group and preparation method thereof |
WO2024125530A1 (en) * | 2022-12-12 | 2024-06-20 | 苏州荷光科汇生物科技有限公司 | Aav vector for infecting retina, adalimumab, and use thereof |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001036440A1 (en) | 1999-11-19 | 2001-05-25 | Human Genome Sciences, Inc. | 23 human secreted proteins |
US6747137B1 (en) * | 1998-02-13 | 2004-06-08 | Genome Therapeutics Corporation | Nucleic acid sequences relating to Candida albicans for diagnostics and therapeutics |
CA2344993C (en) * | 1998-10-02 | 2012-11-13 | Hansjorg Reimann | Method for the production of (poly)peptides by using truncated variants of the sv40 large t antigen with an intact n terminus |
US5950282A (en) * | 1998-10-05 | 1999-09-14 | Pinto; Akiva | Textile chute feed |
US20090087878A9 (en) * | 1999-05-06 | 2009-04-02 | La Rosa Thomas J | Nucleic acid molecules associated with plants |
EP1077263A1 (en) | 1999-07-29 | 2001-02-21 | F.Hoffmann-La Roche Ag | Process for producing natural folded and secreted proteins by co-secretion of chaperones |
CA2343602A1 (en) | 2000-04-18 | 2001-10-18 | Genset | Est's and encoded human proteins |
US7834146B2 (en) * | 2000-05-08 | 2010-11-16 | Monsanto Technology Llc | Recombinant polypeptides associated with plants |
WO2002019965A2 (en) | 2000-09-07 | 2002-03-14 | Science & Technology Corporation @ Unm | Heat shock response and virus replication |
US7445904B2 (en) | 2002-09-26 | 2008-11-04 | Suedhof Thomas C | Cysteine string protein and its role in neurodegenerative diseases |
GB0512707D0 (en) * | 2005-06-22 | 2005-07-27 | Delta Biotechnology Ltd | Gene expression technique |
US7939711B2 (en) | 2006-09-11 | 2011-05-10 | The Chinese University Of Hong Kong | Abiotic stress tolerance conferred by J-domain containing proteins |
JP2008161185A (en) | 2006-12-04 | 2008-07-17 | Locomogene Inc | Decomposition promotion technology of misfolded protein with endoplasmic reticulum reductase |
TWI328040B (en) | 2007-05-04 | 2010-08-01 | Stresspro Biomedicine Inc | Expression system of recombinant proteins with enhanced yield and immunogenecity |
CN101307310B (en) * | 2007-05-15 | 2012-08-08 | 康泰生医科技股份有限公司 | Expression system with recombination protein for increasing yield and immunogenicity |
WO2012087835A2 (en) | 2010-12-22 | 2012-06-28 | Boston Biomedical Research Institute | Compositions and methods for enhancing protein folding |
-
2013
- 2013-12-05 AU AU2013355120A patent/AU2013355120B2/en active Active
- 2013-12-05 KR KR1020157017990A patent/KR20150093768A/en active Search and Examination
- 2013-12-05 EP EP13861465.6A patent/EP2929045B1/en active Active
- 2013-12-05 KR KR1020187012410A patent/KR20180049238A/en not_active Application Discontinuation
- 2013-12-05 CA CA2893359A patent/CA2893359C/en active Active
- 2013-12-05 JP JP2015545857A patent/JP6345688B2/en active Active
- 2013-12-05 US US14/649,187 patent/US9758807B2/en active Active
- 2013-12-05 CA CA3138788A patent/CA3138788A1/en active Pending
- 2013-12-05 WO PCT/US2013/073442 patent/WO2014089375A1/en active Application Filing
- 2013-12-05 CN CN201380072060.8A patent/CN104968795B/en active Active
-
2017
- 2017-01-24 JP JP2017009961A patent/JP6688237B2/en active Active
- 2017-09-12 US US15/701,889 patent/US20180087081A1/en not_active Abandoned
-
2018
- 2018-02-09 AU AU2018200971A patent/AU2018200971A1/en not_active Abandoned
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106478773A (en) * | 2015-08-25 | 2017-03-08 | 三生国健药业(上海)股份有限公司 | A kind of novel signal peptide of synthetic |
CN106478774A (en) * | 2015-08-25 | 2017-03-08 | 三生国健药业(上海)股份有限公司 | A kind of signal peptide for protein expression |
CN106478773B (en) * | 2015-08-25 | 2021-09-14 | 三生国健药业(上海)股份有限公司 | Novel artificially synthesized signal peptide |
CN106478774B (en) * | 2015-08-25 | 2021-09-14 | 三生国健药业(上海)股份有限公司 | Signal peptide for protein expression |
Also Published As
Publication number | Publication date |
---|---|
US20150299756A1 (en) | 2015-10-22 |
CA3138788A1 (en) | 2014-06-12 |
AU2018200971A1 (en) | 2018-03-01 |
CA2893359C (en) | 2021-12-28 |
JP2016500371A (en) | 2016-01-12 |
EP2929045A4 (en) | 2016-06-01 |
CN104968795B (en) | 2021-07-20 |
CN104968795A (en) | 2015-10-07 |
JP6688237B2 (en) | 2020-04-28 |
AU2013355120A1 (en) | 2015-06-04 |
EP2929045A1 (en) | 2015-10-14 |
KR20150093768A (en) | 2015-08-18 |
KR20180049238A (en) | 2018-05-10 |
JP2017113006A (en) | 2017-06-29 |
WO2014089375A1 (en) | 2014-06-12 |
US9758807B2 (en) | 2017-09-12 |
US20180087081A1 (en) | 2018-03-29 |
AU2013355120B2 (en) | 2017-11-09 |
JP6345688B2 (en) | 2018-06-20 |
EP2929045B1 (en) | 2020-12-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2893359C (en) | Protein expression enhancing polypeptides | |
JP6995151B2 (en) | synTac polypeptide and its use | |
JP7481852B2 (en) | Methods for producing immune ligand/payload complexes | |
JP7015244B2 (en) | Protease-activated T cell bispecific molecule | |
JP6498601B2 (en) | Multivalent heteromultimeric scaffold designs and constructs | |
CA2339331C (en) | Expression and export of angiogenesis inhibitors as immunofusins | |
JP6618463B2 (en) | Trimeric antigen-binding molecule | |
US11390899B2 (en) | Cell-associated secretion-enhancing fusion proteins | |
US20230002466A1 (en) | Engineered interleukin-2 receptor beta agonists | |
JP2020039359A (en) | Genetically engineered growth factor variants | |
US20200399588A1 (en) | Wnt compositions and methods of process from serum-free culturing conditions | |
KR102201154B1 (en) | Method for preparing polyglutamate-TAT-Cre fusion protein |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |
Effective date: 20150529 |